<SEC-DOCUMENT>0001564590-21-025109.txt : 20210506
<SEC-HEADER>0001564590-21-025109.hdr.sgml : 20210506
<ACCEPTANCE-DATETIME>20210506170921
ACCESSION NUMBER:		0001564590-21-025109
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		54
CONFORMED PERIOD OF REPORT:	20210331
FILED AS OF DATE:		20210506
DATE AS OF CHANGE:		20210506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oncternal Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001260990
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				621715807
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50549
		FILM NUMBER:		21898878

	BUSINESS ADDRESS:	
		STREET 1:		12230 EL CAMINO REAL
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		(858) 434-1113

	MAIL ADDRESS:	
		STREET 1:		12230 EL CAMINO REAL
		STREET 2:		SUITE 300
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GTX INC /DE/
		DATE OF NAME CHANGE:	20030822
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>onct-10q_20210331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml  version="1.0" encoding="utf-8"?>
<!-- DFIN ActiveDisclosure(SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-06T02:54:59.2100383+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 6f376e511213405db71fc059864ab73e -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:onct="http://www.oncternal.com/20210331" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html" />
<title>
onct-10q_20210331.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body><div style="display:none">
	<ix:header>
		<ix:hidden>
			<ix:nonNumeric id="F_000001" name="dei:EntityCentralIndexKey" contextRef="C_0001260990_20210101_20210331">0001260990</ix:nonNumeric>
			<ix:nonNumeric id="F_000004" name="dei:AmendmentFlag" contextRef="C_0001260990_20210101_20210331">false</ix:nonNumeric>
			<ix:nonNumeric id="F_000006" name="dei:DocumentFiscalPeriodFocus" contextRef="C_0001260990_20210101_20210331">Q1</ix:nonNumeric>
			<ix:nonNumeric id="F_000008" name="dei:CurrentFiscalYearEndDate" contextRef="C_0001260990_20210101_20210331">--12-31</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000257" name="onct:CollaborativeArrangementPotentialMilestonePayments" contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210331" decimals="-6">0</ix:nonFraction>
			<ix:nonNumeric id="F_000276" name="onct:ResearchAgreementTerm" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20210101_20210331">P5Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000363" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150701_20150731">P4Y</ix:nonNumeric>
			<ix:nonNumeric id="F_000365" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenPlanMember_20150701_20150731">P4Y</ix:nonNumeric>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000053" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001260990_20210331" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000054" name="us-gaap:CommitmentsAndContingencies" contextRef="C_0001260990_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000055" name="us-gaap:PreferredStockValue" contextRef="C_0001260990_20210331" xsi:nil="true"></ix:nonFraction>
			<ix:nonFraction unitRef="U_iso4217USD" id="F_000056" name="us-gaap:PreferredStockValue" contextRef="C_0001260990_20201231" xsi:nil="true"></ix:nonFraction>
			<ix:nonNumeric id="F_000337" name="onct:ClassOfWarrantWeightedAverageRemainingContractualTerm" contextRef="C_0001260990_20200101_20201231">P4Y4M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000338" name="onct:WarrantWeightedAverageRemainingContractualTermExercised" contextRef="C_0001260990_20210101_20210331">P4Y7M2D</ix:nonNumeric>
			<ix:nonNumeric id="F_000339" name="onct:ClassOfWarrantWeightedAverageRemainingContractualTerm" contextRef="C_0001260990_20210101_20210331">P4Y0M26D</ix:nonNumeric>
			<ix:nonNumeric id="F_000350" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20210331">P8Y10M25D</ix:nonNumeric>
			<ix:nonNumeric id="F_000351" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20210331">P8Y10M25D</ix:nonNumeric>
			<ix:nonNumeric id="F_000352" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20210331">P7Y3M19D</ix:nonNumeric>
			<ix:nonNumeric id="F_000383" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001260990_20210101_20210331">P6Y4M24D</ix:nonNumeric>
			<ix:nonNumeric id="F_000384" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="C_0001260990_20200101_20200331">P5Y4M24D</ix:nonNumeric>
		</ix:hidden>
		<ix:references>
			<link:schemaRef xlink:type="simple" xlink:href="onct-20210331.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef>
		</ix:references>
		<ix:resources>
			<xbrli:context id="C_0001260990_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlishares">
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001260990_20210429">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-04-29</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD">
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001260990_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_iso4217USD_xbrlishares">
				<xbrli:divide>
					<xbrli:unitNumerator>
						<xbrli:measure>iso4217:USD</xbrli:measure>
					</xbrli:unitNumerator>
					<xbrli:unitDenominator>
						<xbrli:measure>xbrli:shares</xbrli:measure>
					</xbrli:unitDenominator>
				</xbrli:divide>
			</xbrli:unit>
			<xbrli:context id="C_0001260990_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_onctsegment">
				<xbrli:measure>onct:segment</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockSubjectToRepurchaseMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockSubjectToRepurchaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockSubjectToRepurchaseMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockSubjectToRepurchaseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_utrsqft">
				<xbrli:measure>utr:sqft</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-05-22</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190423_20190522">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-04-23</xbrli:startDate>
					<xbrli:endDate>2019-05-22</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210317_20210317">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-03-17</xbrli:startDate>
					<xbrli:endDate>2021-03-17</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:unit id="U_xbrlipure">
				<xbrli:measure>xbrli:pure</xbrli:measure>
			</xbrli:unit>
			<xbrli:context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_onctShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onct:ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_onctShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onct:ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20150101_20151231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-01-01</xbrli:startDate>
					<xbrli:endDate>2015-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20151231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20141231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:MDAndersonCancerCenterMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2014-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:MDAndersonCancerCenterMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:MDAndersonCancerCenterMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2016-05-01</xbrli:startDate>
					<xbrli:endDate>2016-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20170101_20171231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-01-01</xbrli:startDate>
					<xbrli:endDate>2017-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMinimumMember_20160531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMaximumMember_20160531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2016-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ResearchAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ResearchAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctRegentsLicenseAgreementMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:RegentsLicenseAgreementMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:LicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfTennesseeResearchFoundationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:LicenseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfTennesseeResearchFoundationMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20170801_20170831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-08-01</xbrli:startDate>
					<xbrli:endDate>2017-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-10-01</xbrli:startDate>
					<xbrli:endDate>2017-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2017-10-01</xbrli:startDate>
					<xbrli:endDate>2017-10-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-05-01</xbrli:startDate>
					<xbrli:endDate>2020-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-05-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-05-01</xbrli:startDate>
					<xbrli:endDate>2020-05-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-01</xbrli:startDate>
					<xbrli:endDate>2020-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-01</xbrli:startDate>
					<xbrli:endDate>2020-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-07-01</xbrli:startDate>
					<xbrli:endDate>2020-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-01</xbrli:startDate>
					<xbrli:endDate>2020-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-08-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-08-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-08-01</xbrli:startDate>
					<xbrli:endDate>2020-08-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-11-01</xbrli:startDate>
					<xbrli:endDate>2020-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-11-30</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-11-01</xbrli:startDate>
					<xbrli:endDate>2020-11-30</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2020-12-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-12-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_20200101_20201231">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-12-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2019-06-07</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607_20190607">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2019-06-07</xbrli:startDate>
					<xbrli:endDate>2019-06-07</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:EquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:EquityIncentivePlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandThirteenPlanMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandThirteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctGTxStockOptionPlansMember_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:GTxStockOptionPlansMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-03-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_srtConsolidatedEntitiesAxis_onctPrivateOncternalMember_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
						<xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">onct:PrivateOncternalMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2015-07-31</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150701_20150731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-07-01</xbrli:startDate>
					<xbrli:endDate>2015-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenPlanMember_20150701_20150731">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2015-07-01</xbrli:startDate>
					<xbrli:endDate>2015-07-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctInducementPlanMember_20210211">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:InducementPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:instant>2021-02-11</xbrli:instant>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenAndTwoThousandFifteenPlanMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20210331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2021-01-01</xbrli:startDate>
					<xbrli:endDate>2021-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
			<xbrli:context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20200331">
				<xbrli:entity>
					<xbrli:identifier scheme="http://www.sec.gov/CIK">0001260990</xbrli:identifier>
					<xbrli:segment>
						<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
					</xbrli:segment>
				</xbrli:entity>
				<xbrli:period>
					<xbrli:startDate>2020-01-01</xbrli:startDate>
					<xbrli:endDate>2020-03-31</xbrli:endDate>
				</xbrli:period>
			</xbrli:context>
		</ix:resources>
	</ix:header>
</div>

<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&#160;</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">WASHINGTON, D.C. 20549</p>
<p style="margin-bottom:6pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40.04%;margin-right:40.04%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM&#160;<ix:nonNumeric id="F_000002" name="dei:DocumentType" contextRef="C_0001260990_20210101_20210331">10-Q</ix:nonNumeric></p>
<p style="margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40.04%;margin-right:40.04%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-size:9pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:9pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000028" name="dei:DocumentQuarterlyReport" contextRef="C_0001260990_20210101_20210331" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934<span style="font-weight:normal;"> </span></p></td></tr></table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FOR THE QUARTERLY PERIOD ENDED <ix:nonNumeric id="F_000003" name="dei:DocumentPeriodEndDate" contextRef="C_0001260990_20210101_20210331" format="ixt:datemonthdayyearen">MARCH 31, <ix:nonNumeric id="F_000005" name="dei:DocumentFiscalYearFocus" contextRef="C_0001260990_20210101_20210331">2021</ix:nonNumeric></ix:nonNumeric></p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">or</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-size:9pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:9pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000029" name="dei:DocumentTransitionReport" contextRef="C_0001260990_20210101_20210331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:9pt;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</p></td></tr></table></div>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number <ix:nonNumeric id="F_000015" name="dei:EntityFileNumber" contextRef="C_0001260990_20210101_20210331">000-50549</ix:nonNumeric></p>
<p style="margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40.04%;margin-right:40.04%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000000" name="dei:EntityRegistrantName" contextRef="C_0001260990_20210101_20210331">Oncternal Therapeutics, Inc.</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p>
<p style="margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40.04%;margin-right:40.04%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000027" name="dei:EntityIncorporationStateCountryCode" contextRef="C_0001260990_20210101_20210331" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td valign="bottom" style="width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="width:49.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000016" name="dei:EntityTaxIdentificationNumber" contextRef="C_0001260990_20210101_20210331">62-1715807</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="bottom" style="width:49.5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom" style="width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="width:49.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000017" name="dei:EntityAddressAddressLine1" contextRef="C_0001260990_20210101_20210331">12230 El Camino Real</ix:nonNumeric>, <ix:nonNumeric id="F_000018" name="dei:EntityAddressAddressLine2" contextRef="C_0001260990_20210101_20210331">Suite 300</ix:nonNumeric><br /><ix:nonNumeric id="F_000019" name="dei:EntityAddressCityOrTown" contextRef="C_0001260990_20210101_20210331">San Diego</ix:nonNumeric>, <ix:nonNumeric id="F_000020" name="dei:EntityAddressStateOrProvince" contextRef="C_0001260990_20210101_20210331">CA</ix:nonNumeric> <ix:nonNumeric id="F_000021" name="dei:EntityAddressPostalZipCode" contextRef="C_0001260990_20210101_20210331">92130</ix:nonNumeric><br />(<ix:nonNumeric id="F_000022" name="dei:CityAreaCode" contextRef="C_0001260990_20210101_20210331">858</ix:nonNumeric>)&#160;<ix:nonNumeric id="F_000023" name="dei:LocalPhoneNumber" contextRef="C_0001260990_20210101_20210331">434-1113</ix:nonNumeric></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</p>
<p style="margin-bottom:0pt;text-align:center;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-left:40.04%;margin-right:40.04%;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="text-align:center;margin-bottom:4pt;margin-top:4pt;text-indent:5.34%;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="width:33.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-top:4pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom" style="width:33.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom" style="width:33.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top" style="width:33.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000025" name="dei:Security12bTitle" contextRef="C_0001260990_20210101_20210331">Common Stock, $0.001 par value</ix:nonNumeric></p></td>
<td valign="bottom" style="width:33.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000007" name="dei:TradingSymbol" contextRef="C_0001260990_20210101_20210331">ONCT</ix:nonNumeric></p></td>
<td valign="bottom" style="width:33.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <ix:nonNumeric id="F_000026" name="dei:SecurityExchangeName" contextRef="C_0001260990_20210101_20210331" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Capital Market</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: None</p>
<p style="text-align:center;border-bottom:Solid 0.75pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;margin-left:40.04%;margin-right:40.04%;text-indent:0%;color:#000000;font-size:3pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000012" name="dei:EntityCurrentReportingStatus" contextRef="C_0001260990_20210101_20210331">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T <span style="color:#000000;">(&#167;232.405 of this chapter) </span>during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric id="F_000024" name="dei:EntityInteractiveDataCurrent" contextRef="C_0001260990_20210101_20210331">Yes</ix:nonNumeric>&#160;&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span>&#160;&#160;&#160;&#160;No&#160;<span style="font-family:Segoe UI Symbol;">&#9744;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large accelerated filer</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated filer</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000009" name="dei:EntityFilerCategory" contextRef="C_0001260990_20210101_20210331" format="ixt-sec:entityfilercategoryen">Non-accelerated filer</ix:nonNumeric></p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller reporting company</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000010" name="dei:EntitySmallBusiness" contextRef="C_0001260990_20210101_20210331" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Segoe UI Symbol;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:52.46%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:20.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:3.18%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:Segoe UI Symbol;color:#000000;"><ix:nonNumeric id="F_000011" name="dei:EntityEmergingGrowthCompany" contextRef="C_0001260990_20210101_20210331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;&#160;&#160;Yes&#160;<span style="font-family:Segoe UI Symbol;"><ix:nonNumeric id="F_000013" name="dei:EntityShellCompany" contextRef="C_0001260990_20210101_20210331" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span>&#160;&#160;&#160;&#160;No&#160;<span style="font-family:Segoe UI Symbol;">&#9746;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of April 29, 2021, the registrant had <ix:nonFraction unitRef="U_xbrlishares" id="F_000014" name="dei:EntityCommonStockSharesOutstanding" contextRef="C_0001260990_20210429" decimals="INF" format="ixt:numdotdecimal">49,368,545</ix:nonFraction> shares of common stock outstanding.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:2pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics,&#160;Inc.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">FORM&#160;10-Q</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td style="width:10.75%;"></td>
<td style="width:80.52%;"></td>
<td style="width:8.73%;"></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I_FINANCIAL_INFORMATION"><span style="text-decoration:underline;">PART I - FINANCIAL INFORMATION</span></a></p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1.</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_FINANCIAL_STATEMENTS"><span style="text-decoration:underline;">Condensed Consolidated Financial Statements</span></a></p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_BALANCE_SHEETS"><span style="text-decoration:underline;">Condensed Consolidated Balance Sheets</span></a></p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
</tr>
<tr>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#StatementOperation"><span style="text-decoration:underline;">Condensed Consolidated Statements of Operations</span></a></p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONDENSED_CONSOLIDATED_STATEME"><span style="text-decoration:underline;">Condensed Consolidated Statements of Cash Flows</span></a></p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#UNAUDITED_CONDENSED_CONSOLIDATED_STATEME"><span style="text-decoration:underline;">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></a></p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
</tr>
<tr>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA"><span style="text-decoration:underline;">Notes to Condensed Consolidated Financial Statements</span></a></p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
</tr>
<tr>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ONCTERNAL_MANAGEMENTS_DISCUSSION_ANALYSI"><span style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p></td>
</tr>
<tr>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU"><span style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_CONTROLS_PROCEDURES"><span style="text-decoration:underline;">Controls and Procedures</span></a></p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
</tr>
<tr>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IIOR_INFORMATION"><span style="text-decoration:underline;">PART II - OTHER INFORMATION</span></a></p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1.</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_LEGAL_PROCEEDINGS"><span style="text-decoration:underline;">Legal Proceedings</span></a></p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 1A.</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><span style="text-decoration:underline;">Risk Factors</span></a></p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 2.</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT"><span style="text-decoration:underline;">Unregistered Sales of Equity Securities</span></a></p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 3.</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES"><span style="text-decoration:underline;">Defaults Upon Senior Securities</span></a></p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 4.</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><span style="text-decoration:underline;">Mine Safety Disclosures</span></a></p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 5.</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5"><span style="text-decoration:underline;">Other Information</span></a></p></td>
<td valign="top" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 6.</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_EXHIBITS"><span style="text-decoration:underline;">Exhibits</span></a></p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td colspan="2" valign="bottom" style="white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><span style="text-decoration:underline;">Signatures</span></a></p></td>
<td valign="bottom" style="white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_I_FINANCIAL_INFORMATION">PART&#160;I - FINANCIAL INFORMATION</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_1_FINANCIAL_STATEMENTS">Item 1.&#160;&#160;Financial Statements</p>
<p style="text-align:center;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_BALANCE_SHEETS">Condensed Consolidated Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except par value)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000030" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001260990_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">111,211</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000031" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">116,737</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid and other</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000032" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001260990_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,873</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000033" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,266</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000034" name="us-gaap:AssetsCurrent" contextRef="C_0001260990_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">113,084</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000035" name="us-gaap:AssetsCurrent" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">118,003</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Right-of-use asset</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000036" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001260990_20210331" decimals="-3" scale="3">204</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000037" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="C_0001260990_20201231" decimals="-3" scale="3">40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000038" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001260990_20210331" decimals="-3" scale="3">769</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000039" name="us-gaap:OtherAssetsNoncurrent" contextRef="C_0001260990_20201231" decimals="-3" scale="3">766</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000040" name="us-gaap:Assets" contextRef="C_0001260990_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">114,057</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000041" name="us-gaap:Assets" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">118,809</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities and Stockholders&#8217; Equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000042" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001260990_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,892</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000043" name="us-gaap:AccountsPayableCurrent" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,143</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000044" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001260990_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,773</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000045" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,042</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred grant revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000046" name="us-gaap:DeferredRevenue" contextRef="C_0001260990_20210331" decimals="-3" scale="3">885</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000047" name="us-gaap:DeferredRevenue" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,633</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease, current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000048" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001260990_20210331" decimals="-3" scale="3">173</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000049" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001260990_20201231" decimals="-3" scale="3">40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000050" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001260990_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">5,723</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000051" name="us-gaap:LiabilitiesCurrent" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">5,858</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease, net of current</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000052" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001260990_20210331" decimals="-3" scale="3">31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 3)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000053">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000054">&#160;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000067" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001260990_20210331" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000068" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="C_0001260990_20201231" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value, authorized shares &#8211; <ix:nonFraction unitRef="U_xbrlishares" id="F_000069" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001260990_20210331" decimals="INF" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000070" name="us-gaap:PreferredStockSharesAuthorized" contextRef="C_0001260990_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3">5,000</ix:nonFraction></ix:nonFraction>&#59; issued and outstanding shares &#8211; <ix:nonFraction unitRef="U_xbrlishares" id="F_000071" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001260990_20210331" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000072" name="us-gaap:PreferredStockSharesIssued" contextRef="C_0001260990_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000073" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001260990_20210331" decimals="INF" format="ixt-sec:numwordsen" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000074" name="us-gaap:PreferredStockSharesOutstanding" contextRef="C_0001260990_20201231" decimals="INF" format="ixt-sec:numwordsen" scale="3">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000055">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000056">&#8212;</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000075" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001260990_20210331" decimals="INF"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000076" name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="C_0001260990_20201231" decimals="INF">0.001</ix:nonFraction></ix:nonFraction> par value&#59; authorized shares &#8211; <ix:nonFraction unitRef="U_xbrlishares" id="F_000077" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001260990_20210331" decimals="INF" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000078" name="us-gaap:CommonStockSharesAuthorized" contextRef="C_0001260990_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3">60,000</ix:nonFraction></ix:nonFraction>&#59; issued and outstanding shares &#8211; <ix:nonFraction unitRef="U_xbrlishares" id="F_000079" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001260990_20210331" decimals="INF" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000081" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001260990_20210331" decimals="INF" format="ixt:numdotdecimal" scale="3">49,366</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="U_xbrlishares" id="F_000080" name="us-gaap:CommonStockSharesIssued" contextRef="C_0001260990_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3"><ix:nonFraction unitRef="U_xbrlishares" id="F_000082" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001260990_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3">48,802</ix:nonFraction></ix:nonFraction> at March 31, 2021 and December 31, 2020, respectively</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000057" name="us-gaap:CommonStockValue" contextRef="C_0001260990_20210331" decimals="-3" scale="3">49</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000058" name="us-gaap:CommonStockValue" contextRef="C_0001260990_20201231" decimals="-3" scale="3">49</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000059" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001260990_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">196,999</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000060" name="us-gaap:AdditionalPaidInCapital" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">195,699</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000061" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001260990_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">88,745</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000062" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001260990_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">82,797</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000063" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">108,303</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000064" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">112,951</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders&#8217; equity</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000065" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001260990_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">114,057</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000066" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">118,809</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always" />

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="StatementOperation">Condensed Consolidated Statements of Operations</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited&#59; in thousands, except per share data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="8" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000083" name="us-gaap:Revenues" contextRef="C_0001260990_20210101_20210331" decimals="-3" scale="3">748</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000084" name="us-gaap:Revenues" contextRef="C_0001260990_20200101_20200331" decimals="-3" scale="3">578</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000085" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="C_0001260990_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">3,913</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000086" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="C_0001260990_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,696</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000087" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001260990_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,794</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000088" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001260990_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,633</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000089" name="us-gaap:OperatingExpenses" contextRef="C_0001260990_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">6,707</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000090" name="us-gaap:OperatingExpenses" contextRef="C_0001260990_20200101_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">5,329</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000091" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001260990_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">5,959</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000092" name="us-gaap:OperatingIncomeLoss" contextRef="C_0001260990_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,751</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000093" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001260990_20210101_20210331" decimals="-3" scale="3">11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000094" name="us-gaap:InvestmentIncomeInterest" contextRef="C_0001260990_20200101_20200331" decimals="-3" scale="3">13</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000095" name="us-gaap:NetIncomeLoss" contextRef="C_0001260990_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">5,948</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000096" name="us-gaap:NetIncomeLoss" contextRef="C_0001260990_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,738</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000097" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001260990_20210101_20210331" decimals="2" sign="-">0.12</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000098" name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="C_0001260990_20200101_20200331" decimals="2" sign="-">0.31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares outstanding, basic and diluted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000099" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001260990_20210101_20210331" decimals="0" format="ixt:numdotdecimal">49,094</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000100" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="C_0001260990_20200101_20200331" decimals="0" format="ixt:numdotdecimal">15,355</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always" />

<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="CONDENSED_CONSOLIDATED_STATEME">Condensed Consolidated Statements of Cash Flows</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited&#59; in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from operating activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000101" name="us-gaap:ProfitLoss" contextRef="C_0001260990_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">5,948</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000102" name="us-gaap:ProfitLoss" contextRef="C_0001260990_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,738</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000103" name="us-gaap:ShareBasedCompensation" contextRef="C_0001260990_20210101_20210331" decimals="-3" scale="3">838</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000104" name="us-gaap:ShareBasedCompensation" contextRef="C_0001260990_20200101_20200331" decimals="-3" scale="3">399</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Noncash lease expense</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000105" name="onct:NoncashLeaseExpense" contextRef="C_0001260990_20210101_20210331" decimals="-3" scale="3">40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000106" name="onct:NoncashLeaseExpense" contextRef="C_0001260990_20200101_20200331" decimals="-3" scale="3">36</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid and other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000107" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001260990_20210101_20210331" decimals="-3" scale="3">609</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000108" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="C_0001260990_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">90</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000109" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001260990_20210101_20210331" decimals="-3" scale="3">749</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000110" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="C_0001260990_20200101_20200331" decimals="-3" scale="3">336</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000111" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001260990_20210101_20210331" decimals="-3" sign="-" scale="3">267</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000112" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="C_0001260990_20200101_20200331" decimals="-3" scale="3">455</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in lease liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000113" name="onct:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_0001260990_20210101_20210331" decimals="-3" sign="-" scale="3">40</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000114" name="onct:IncreaseDecreaseInOperatingLeaseLiability" contextRef="C_0001260990_20200101_20200331" decimals="-3" sign="-" scale="3">36</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred grant revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000115" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="C_0001260990_20210101_20210331" decimals="-3" sign="-" scale="3">748</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000116" name="us-gaap:IncreaseDecreaseInDeferredRevenue" contextRef="C_0001260990_20200101_20200331" decimals="-3" sign="-" scale="3">578</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000117" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001260990_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">5,985</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000118" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="C_0001260990_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,036</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by investing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cash flows from financing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000119" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001260990_20210101_20210331" decimals="-3" scale="3">358</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000120" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="C_0001260990_20200101_20200331" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of common stock warrants</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000121" name="us-gaap:ProceedsFromWarrantExercises" contextRef="C_0001260990_20210101_20210331" decimals="-3" scale="3">101</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000122" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001260990_20210101_20210331" decimals="-3" scale="3">459</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000123" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="C_0001260990_20200101_20200331" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Net decrease in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000124" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001260990_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">5,526</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000125" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="C_0001260990_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,032</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at beginning of period</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000126" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">116,737</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000127" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">20,051</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:67.02%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at end of period</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000128" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001260990_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">111,211</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000129" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="C_0001260990_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">16,019</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of non-cash investing and financing activities:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cashless exercise of warrants</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000130" name="onct:CashlessExerciseOfWarrants" contextRef="C_0001260990_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,836</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment of 2019 bonus awards with stock options in lieu of cash</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000131" name="us-gaap:StockIssued1" contextRef="C_0001260990_20200101_20200331" decimals="-3" scale="3">415</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:67.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred financing costs included in accounts payable and accrued liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000132" name="us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" contextRef="C_0001260990_20200101_20200331" decimals="-3" scale="3">179</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="UNAUDITED_CONDENSED_CONSOLIDATED_STATEME">Condensed Consolidated Statements of Stockholders' Equity</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited&#59; in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.14%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31, 2021</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000133" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" format="ixt:numdotdecimal" scale="3">48,802</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000134" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" scale="3">49</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000135" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">195,699</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000136" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">82,797</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000137" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">112,951</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options for cash</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000138" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="INF" scale="3">88</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000139" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" scale="3">358</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000140" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001260990_20210101_20210331" decimals="-3" scale="3">358</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of warrants for cash</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000141" name="onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="INF" scale="3">17</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000142" name="onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" scale="3">101</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000143" name="onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" contextRef="C_0001260990_20210101_20210331" decimals="-3" scale="3">101</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cashless exercise of warrants</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000144" name="onct:ExerciseOfCashlessWarrantShares" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331" decimals="INF" scale="3">459</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting related to unvested share liability</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000145" name="onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000146" name="onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" contextRef="C_0001260990_20210101_20210331" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000147" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331" decimals="-3" scale="3">838</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000148" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001260990_20210101_20210331" decimals="-3" scale="3">838</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000149" name="us-gaap:NetIncomeLoss" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">5,948</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000150" name="us-gaap:NetIncomeLoss" contextRef="C_0001260990_20210101_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">5,948</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2021</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000151" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="INF" format="ixt:numdotdecimal" scale="3">49,366</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000152" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331" decimals="-3" scale="3">49</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000153" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">196,999</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000154" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">88,745</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000155" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">108,303</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="18" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.14%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March 31, 2020</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2019</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000156" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" format="ixt:numdotdecimal" scale="3">15,387</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000157" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" scale="3">15</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000158" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">79,869</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000159" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">65,572</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000160" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_20191231" decimals="-3" format="ixt:numdotdecimal" scale="3">14,312</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise of stock options for cash</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000161" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331" decimals="INF" scale="3">5</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000162" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000163" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="C_0001260990_20200101_20200331" decimals="-3" scale="3">4</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting related to unvested share liability</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000164" name="onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000165" name="onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" contextRef="C_0001260990_20200101_20200331" decimals="-3" scale="3">3</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000166" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331" decimals="-3" scale="3">399</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000167" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="C_0001260990_20200101_20200331" decimals="-3" scale="3">399</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of 2019 bonus award with stock options in lieu of cash</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000168" name="onct:IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331" decimals="-3" scale="3">415</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000169" name="onct:IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" contextRef="C_0001260990_20200101_20200331" decimals="-3" scale="3">415</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000170" name="us-gaap:NetIncomeLoss" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,738</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000171" name="us-gaap:NetIncomeLoss" contextRef="C_0001260990_20200101_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">4,738</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2020</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000172" name="us-gaap:CommonStockSharesOutstanding" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331" decimals="INF" format="ixt:numdotdecimal" scale="3">15,392</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000173" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331" decimals="-3" scale="3">15</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000174" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">80,690</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000175" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" scale="3">70,310</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000176" name="us-gaap:StockholdersEquity" contextRef="C_0001260990_20200331" decimals="-3" format="ixt:numdotdecimal" scale="3">10,395</ix:nonFraction></p></td>
<td valign="middle" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">See accompanying notes.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="NOTES_TO_CONDENSED_CONSOLIDATED_FINANCIA">Notes to Condensed Consolidated Financial Statements</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Unaudited)</p><ix:nonNumeric id="F_000177" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true" continuedAt="F_000177_dcnt_f238b879-e292-44b6-8b83-1b0367db21a6">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Description of Business</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc. (&#8220;Oncternal&#8221; or the &#8220;Company&#8221;), formerly known as GTx, Inc., was incorporated in Tennessee in September 1997 and reincorporated in Delaware in 2003 and is based in San Diego, California.  Oncternal is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The Company&#8217;s clinical pipeline includes cirmtuzumab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and TK216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1.</p><ix:nonNumeric id="F_000183" name="us-gaap:BusinessCombinationsPolicy" contextRef="C_0001260990_20210101_20210331" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Merger</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 7, 2019, the Company, then operating as GTx, Inc. (&#8220;GTx&#8221;), completed the merger contemplated by its Agreement and Plan of Merger and Reorganization, as amended (the &#8220;Merger Agreement&#8221;), with privately-held Oncternal Therapeutics, Inc. (&#8220;Private Oncternal&#8221;) and Grizzly Merger Sub, Inc., a wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;), dated March 6, 2019. Under the Merger Agreement, Merger Sub merged with and into Private Oncternal, with Private Oncternal surviving as a wholly-owned subsidiary of the Company (the &#8220;Merger&#8221;). GTx changed its name to Oncternal Therapeutics, Inc., and Private Oncternal, which remains as a wholly-owned subsidiary of the Company, changed its name to Oncternal Oncology, Inc. On June 10, 2019, the Company&#8217;s common stock began trading on The Nasdaq Capital Market under the ticker symbol &#8220;ONCT.&#8221;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as otherwise indicated, references herein to &#8220;Oncternal,&#8221;and &#8220;the Company,&#8221; refer to Oncternal Therapeutics, Inc. on a post-Merger basis, and the term &#8220;Private Oncternal&#8221; refers to the business of privately-held Oncternal Therapeutics, Inc., prior to completion of the Merger.&#160;&#160;References to GTx refer to GTx, Inc. prior to completion of the Merger.&#160;&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000184" name="us-gaap:ConsolidationPolicyTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oncternal Oncology, Inc. and Oncternal, Inc. All intercompany accounts and transactions have been eliminated in the preparation of the condensed consolidated financial statements.</p></ix:nonNumeric><ix:nonNumeric id="F_000185" name="onct:LiquidityAndGoingConcernPolicyTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true" continuedAt="F_000185_dcnt_1e235931-23c3-42fc-bf3e-d773206b8d1c">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Going Concern</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows Accounting Standards Codification (ASC) <span style="font-style:italic;">Topic 205-40, Presentation of Financial Statements&#8212;Going Concern</span>, which requires that management evaluate whether there are relevant conditions and events that in the aggregate raise substantial doubt about the entity&#8217;s ability to continue as a going concern and to meet its obligations as they become due within one year after the date that the financial statements are issued.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.&#160;&#160;As of March 31, 2021, the Company had $<ix:nonFraction unitRef="U_iso4217USD" id="F_000209" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="C_0001260990_20210331" decimals="-5" scale="6">111.2</ix:nonFraction> million in cash and cash equivalents. The Company believes it has sufficient cash to fund its projected operating requirements for at least twelve months from the filing date of this Quarterly Report. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.&#160;&#160;The Company has experienced net losses and negative cash flows from operating activities since its inception and has an accumulated deficit of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000208" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="C_0001260990_20210331" decimals="-5" sign="-" scale="6">88.7</ix:nonFraction> million as of March 31, 2021. The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.&#160;</p></ix:nonNumeric></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000177_dcnt_f238b879-e292-44b6-8b83-1b0367db21a6" continuedAt="F_000177_dcnt_1532a2e2-8289-404e-a8b2-10d771a95e35"><ix:continuation id="F_000185_dcnt_1e235931-23c3-42fc-bf3e-d773206b8d1c">
</ix:continuation><ix:nonNumeric id="F_000186" name="onct:UnauditedInterimFinancialInformationPolicyTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unaudited condensed consolidated financial statements at March&#160;31, 2021, and for the three months ended March&#160;31, 2021 and 2020, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). These unaudited condensed consolidated financial statements have been prepared on the same basis as the audited, consolidated financial statements and include all adjustments, consisting of only normal recurring accruals, which in the opinion of management are necessary to present fairly the Company&#8217;s financial position as of the interim date and results of operations for the interim periods presented. Interim results are not necessarily indicative of results for a full year or future periods. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements for the year ended December 31, 2020, filed with the SEC on its Annual Report on Form 10-K/A for the year ended December 31, 2020, filed with the SEC on March 12, 2021. The results presented in these unaudited condensed consolidated financial statements are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.</p></ix:nonNumeric><ix:nonNumeric id="F_000187" name="us-gaap:UseOfEstimates" contextRef="C_0001260990_20210101_20210331" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company&#8217;s condensed consolidated financial statements and accompanying notes requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities. Significant estimates consist of those used to determine the fair value of the Company&#8217;s stock-based awards and those used to determine grant revenue and accruals for research and development costs. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p></ix:nonNumeric><ix:nonNumeric id="F_000188" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market accounts.</p></ix:nonNumeric><ix:nonNumeric id="F_000189" name="onct:ConcentrationRiskCreditRiskPolicyTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p></ix:nonNumeric><ix:nonNumeric id="F_000190" name="onct:PatentCostsPolicyTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent Costs</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</p></ix:nonNumeric><ix:nonNumeric id="F_000191" name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="C_0001260990_20210101_20210331" escape="true" continuedAt="F_000191_dcnt_aaf00f24-8913-4c00-8160-f0e3a5f856d0">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses and Accruals</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of costs incurred for the Company&#8217;s own and for sponsored and collaborative research and development activities. Research and development costs are expensed as incurred and include manufacturing process development costs, manufacturing costs, costs associated with preclinical studies and clinical trials, regulatory and medical affairs activities, quality assurance activities, salaries and benefits, including stock-based compensation, fees paid to third-party consultants, license fees and overhead.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:4.17%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying consolidated balance sheets as prepaid expenses and other assets or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities and all clinical trial expenses are included in research and development expenses. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. As of March 31, 2021, the Company&#8217;s clinical trial accrual balance of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000210" name="onct:AccruedClinicalTrials" contextRef="C_0001260990_20210331" decimals="-5" scale="6">1.1</ix:nonFraction>&#160;million is included in accrued liabilities and other liabilities.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000177_dcnt_1532a2e2-8289-404e-a8b2-10d771a95e35" continuedAt="F_000177_dcnt_22990544-b9f7-4312-880e-293ec515449f"><ix:continuation id="F_000191_dcnt_aaf00f24-8913-4c00-8160-f0e3a5f856d0">
</ix:continuation><ix:nonNumeric id="F_000192" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="C_0001260990_20210101_20210331" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1: Observable inputs such as quoted prices in active markets.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company&#8217;s current financial assets and liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company has no current financial assets or liabilities measured at fair value on a recurring basis and no transfers between levels have occurred during the periods presented.</p></ix:nonNumeric><ix:nonNumeric id="F_000193" name="us-gaap:RevenueRecognitionPolicyTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently generates revenue from the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) pursuant to a research subaward agreement (see Note 4), which provides the Company with payments in return for certain research and development activities over a contractually defined period. Revenue from such subaward is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the subaward agreement have been met.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The subaward agreement is on a best-effort basis and does not require scientific achievement as a performance obligation. All fees received under the agreement are non-refundable. The costs associated with the agreement are expensed as incurred and reflected as a component of research and development expense in the accompanying condensed consolidated statements of operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Funds received from the subaward agreement are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the subaward are part of the Company&#8217;s development programs. In those instances where the Company first receives consideration in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company records a grant receivable. At March 31, 2021, and December 31, 2020, the Company had deferred grant revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000211" name="us-gaap:DeferredRevenue" contextRef="C_0001260990_20210331" decimals="-5" scale="6">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000212" name="us-gaap:DeferredRevenue" contextRef="C_0001260990_20201231" decimals="-5" scale="6">1.6</ix:nonFraction> million, respectively.</p></ix:nonNumeric><ix:nonNumeric id="F_000194" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="C_0001260990_20210101_20210331" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense represents the fair value of equity awards, on the grant date, recognized in the period using the Black-Scholes option pricing model. The Company recognizes expense for awards with graded vesting schedules over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is deemed probable. The Company recognizes forfeitures for all awards as such forfeitures occur.</p></ix:nonNumeric><ix:nonNumeric id="F_000195" name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true" continuedAt="F_000195_dcnt_9988e32c-44eb-43d7-a7a1-174d1aaa2bcd">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</p></ix:nonNumeric></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000177_dcnt_22990544-b9f7-4312-880e-293ec515449f"><ix:continuation id="F_000195_dcnt_9988e32c-44eb-43d7-a7a1-174d1aaa2bcd">
</ix:continuation><ix:nonNumeric id="F_000196" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in <ix:nonFraction unitRef="U_onctsegment" id="F_000213" name="us-gaap:NumberOfOperatingSegments" contextRef="C_0001260990_20210101_20210331" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction> operating segment in the United States.</p></ix:nonNumeric><ix:nonNumeric id="F_000197" name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities and adjusted for the weighted-average number of common shares outstanding that are subject to repurchase. The Company has excluded weighted-average shares subject to repurchase of <ix:nonFraction unitRef="U_xbrlishares" id="F_000214" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" contextRef="C_0001260990_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">13,000</ix:nonFraction> shares and <ix:nonFraction unitRef="U_xbrlishares" id="F_000215" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" contextRef="C_0001260990_20200101_20200331" decimals="INF" format="ixt:numdotdecimal">32,000</ix:nonFraction> shares from the weighted-average number of common shares outstanding for the three months ended March 31, 2021 and 2020, respectively. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.</p><ix:nonNumeric id="F_000199" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares&#59; in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000216" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">4,278</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000217" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20200101_20200331" decimals="INF">841</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000218" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">4,069</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000219" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20200331" decimals="INF" format="ixt:numdotdecimal">2,168</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000220" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockSubjectToRepurchaseMember_20210101_20210331" decimals="INF">10</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000221" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockSubjectToRepurchaseMember_20200101_20200331" decimals="INF">30</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000222" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">8,357</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000223" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="C_0001260990_20200101_20200331" decimals="INF" format="ixt:numdotdecimal">3,039</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric><ix:nonNumeric id="F_000198" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the FASB issued ASU 2020-06, <span style="font-style:italic;">Debt&#8212;Debt with Conversion and Other Options</span> (Subtopic 470-20) and <span style="font-style:italic;">Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity</span> (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company adopted this standard effective January 1, 2021, and the adoption had no impact on the consolidated financial statements.</p></ix:nonNumeric></ix:continuation><ix:nonNumeric id="F_000178" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Balance Sheet Details</p></td></tr></table></div><ix:nonNumeric id="F_000200" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000224" name="onct:AccruedResearchAndDevelopmentExpenses" contextRef="C_0001260990_20210331" decimals="-3" scale="3">605</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000225" name="onct:AccruedResearchAndDevelopmentExpenses" contextRef="C_0001260990_20201231" decimals="-3" scale="3">412</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000226" name="onct:AccruedClinicalTrials" contextRef="C_0001260990_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">1,138</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000227" name="onct:AccruedClinicalTrials" contextRef="C_0001260990_20201231" decimals="-3" scale="3">980</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal fees</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000228" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001260990_20210331" decimals="-3" scale="3">308</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000229" name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="C_0001260990_20201231" decimals="-3" scale="3">77</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000230" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001260990_20210331" decimals="-3" scale="3">699</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000231" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">1,528</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000232" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001260990_20210331" decimals="-3" scale="3">23</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000233" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="C_0001260990_20201231" decimals="-3" scale="3">45</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000234" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001260990_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,773</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000235" name="us-gaap:AccruedLiabilitiesCurrent" contextRef="C_0001260990_20201231" decimals="-3" format="ixt:numdotdecimal" scale="3">3,042</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000179" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true" continuedAt="F_000179_dcnt_0bd5dfb6-9de4-4d6c-b62c-9fabf00a7a12">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments, Contingencies and Related Party Transactions</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Lease</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000236" name="us-gaap:LeaseAndRentalExpense" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210101_20210331" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_iso4217USD" id="F_000237" name="us-gaap:LeaseAndRentalExpense" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20200101_20200331" decimals="0" format="ixt:numdotdecimal">41,000</ix:nonFraction></ix:nonFraction> for <span style="color:#000000;">each of </span>the three months ended March&#160;31, 2021 and 2020. </p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000179_dcnt_0bd5dfb6-9de4-4d6c-b62c-9fabf00a7a12">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 22, 2019, the Company entered into a sublease agreement for office space of <ix:nonFraction unitRef="U_utrsqft" id="F_000238" name="us-gaap:NetRentableArea" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522" decimals="0" format="ixt:numdotdecimal">4,677</ix:nonFraction> square feet in San Diego, California which expired on <ix:nonNumeric id="F_000239" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190423_20190522" format="ixt:datemonthdayyearen">March 31, 2021</ix:nonNumeric>. On March 17, 2021, the Company entered into a lease directly with the landlord for the same facility (the &#8220;San Diego Lease&#8221;) which expires on <ix:nonNumeric id="F_000240" name="us-gaap:LeaseExpirationDate1" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210317_20210317" format="ixt:datemonthdayyearen">May 31, 2022</ix:nonNumeric>. Base rent under the San Diego Lease is approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000241" name="onct:AnnualBaseRent" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190423_20190522" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction unitRef="U_iso4217USD" id="F_000242" name="onct:AnnualBaseRent" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210317_20210317" decimals="0" format="ixt:numdotdecimal">184,000</ix:nonFraction></ix:nonFraction> annually and the monthly rent expense is being recognized on a straight-line basis over the term of the lease. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The San Diego Lease is included in the accompanying condensed consolidated balance sheet at the present value of the lease payments. As the San Diego Lease does not have an implicit interest rate, the present value reflects a <ix:nonFraction unitRef="U_xbrlipure" id="F_000243" name="us-gaap:LesseeOperatingLeaseDiscountRate" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210331" decimals="3" scale="-2">10.0</ix:nonFraction>% discount rate which is the estimated rate of interest that the Company would have to pay in order to borrow an amount equal to the lease payments on a collateralized basis over a similar term and in a similar economic environment. The Company recognized a net operating lease right-of-use asset and an aggregate lease liability of $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000244" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210331" decimals="0" format="ixt:numdotdecimal">204,000</ix:nonFraction></span> as of March&#160;31, 2021, in the accompanying condensed consolidated balance sheets. The weighted average remaining lease term was <ix:nonNumeric id="F_000245" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210331" format="ixt-sec:duryear">1.2</ix:nonNumeric> years.</p><ix:nonNumeric id="F_000201" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of the lease liability due under this lease agreement as of March&#160;31, 2021, are as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity of lease liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000246" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="C_0001260990_20210331" decimals="-3" scale="3">138</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000247" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="C_0001260990_20210331" decimals="-3" scale="3">77</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000248" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="C_0001260990_20210331" decimals="-3" scale="3">215</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000249" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="C_0001260990_20210331" decimals="-3" scale="3">11</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000250" name="us-gaap:OperatingLeaseLiability" contextRef="C_0001260990_20210331" decimals="-3" scale="3">204</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.26%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less current portion of lease liability</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_iso4217USD" id="F_000251" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="C_0001260990_20210331" decimals="-3" scale="3">173</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.26%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000252" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="C_0001260990_20210331" decimals="-3" scale="3">31</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Related Party Transactions<span style="font-weight:normal;font-style:normal;">&#160;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective in September 2019, the Company and Shanghai Pharmaceutical (USA) Inc. (&#8220;SPH USA&#8221;), the Company&#8217;s largest stockholder and an affiliate of two of the Company&#8217;s directors entered into a Materials and Supply and Services Agreement (&#8220;SPH USA Services Agreement&#8221;). Pursuant to the SPH USA Services Agreement, the Company and SPH USA will execute various statements of work for the transfer to SPH USA of key reagents and other materials, and for the supply of certain services by the Company to SPH USA, as contemplated under and in furtherance of a license and distribution agreement between the parties (see Note 4). The Company recorded amounts receivable from SPH USA related to statements of work totaling $<ix:nonFraction unitRef="U_iso4217USD" id="F_000253" name="us-gaap:AccountsReceivableRelatedParties" contextRef="C_0001260990_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_onctShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_20210331" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000254" name="us-gaap:AccountsReceivableRelatedParties" contextRef="C_0001260990_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_onctShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_20201231" decimals="-5" scale="6">0.3</ix:nonFraction></ix:nonFraction> million as of March 31, 2021 and December 31, 2020. The Company has an agreement with SPH USA for certain rights to the greater China area (see Note 4).</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the securities purchase agreements and underwritten offerings described in Note 5, other investors included individuals or entities affiliated with David F. Hale, SPH USA, Daniel L. Kisner, Hazel M. Aker, and Michael G. Carter.</p></ix:continuation><ix:nonNumeric id="F_000180" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true" continuedAt="F_000180_dcnt_5e21bcca-e266-4d1b-a686-3b3bad565c37">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">License, Collaboration and Research Subaward Agreements</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Georgetown University (&#8220;Georgetown&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2014, the Company entered into an Exclusive License Agreement (the &#8220;Georgetown License Agreement&#8221;) with Georgetown, pursuant to which the Company: (i) licensed the exclusive worldwide right to patents and technologies for the development and commercialization of certain product candidates targeting EWS-FLI1 as an anti-tumor therapy for therapeutic, diagnostics, or research tool purposes, (ii) is solely responsible for all development and commercialization activities and costs, and (iii) is responsible for all costs related to the filing, prosecution and maintenance of the licensed patent rights.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Georgetown License Agreement, commencing in 2015, the Company: (i) shall pay and has paid an annual license maintenance fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000255" name="onct:LicenseMaintenanceFeeToBePaidAndPaymentMade" contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20150101_20151231" decimals="0" format="ixt:numdotdecimal">10,000</ix:nonFraction> until the first commercial sale occurs, (ii) is required to make up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000256" name="onct:CollaborativeArrangementPotentialMilestonePayments" contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20151231" decimals="INF" scale="6">0.2</ix:nonFraction> million in aggregate milestone payments upon the achievement of certain regulatory milestones, and (iii) will be required to pay low single digit royalties based on annual net product sales. The Company accounted for the licensed technology as an asset acquisition because it did not meet the definition of a business. All milestone payments under the Georgetown License Agreement will be recognized as research and development expense upon completion of the required events, as the triggering events are not considered to be probable until they are achieved. As of March&#160;31, 2021, the Company had <span style="color:#000000;">not</span> triggered or made any milestone payments under the Georgetown License Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Georgetown License Agreement may be terminated by either party upon material breach or may be terminated by the Company as to one or more countries with <ix:nonNumeric id="F_000258" name="onct:NumberOfDaysInWrittenNoticeOfTermination" contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210101_20210331" format="ixt-sec:durday">90</ix:nonNumeric> days written notice of termination. The term of the Georgetown License Agreement will continue until the expiration of the last valid claim within the patent rights covering the product. Georgetown may terminate the agreement in the event: (i) the Company fails to pay any amount and fails to cure such failure within <ix:nonNumeric id="F_000259" name="onct:NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210101_20210331" format="ixt-sec:durday">30</ix:nonNumeric> days after receipt of notice, (ii) the Company defaults in its obligation to obtain and maintain insurance and fails to remedy such breach within <ix:nonNumeric id="F_000260" name="onct:NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210101_20210331" format="ixt-sec:durday">60</ix:nonNumeric> days after receipt of notice, or (iii) the Company declares insolvency or bankruptcy. The Company may terminate the Georgetown License Agreement at any time upon at least <ix:nonNumeric id="F_000261" name="onct:MinimumPeriodOfWrittenNoticeToTerminateAgreement" contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210101_20210331" format="ixt-sec:durday">60</ix:nonNumeric> days&#8217; written notice.&#160;&#160;&#160;&#160;&#160;&#160;</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000180_dcnt_5e21bcca-e266-4d1b-a686-3b3bad565c37" continuedAt="F_000180_dcnt_6f5f5f6f-5b5a-4ba1-a062-6794e467912b">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The University of Texas MD Anderson Cancer Center (&#8220;MD Anderson&#8221;)</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2014, the Company entered into a collaboration agreement (as amended, the &#8220;Collaboration&#8221;) with MD Anderson, which provides for the conduct of preclinical and clinical research for TK216 in exchange for certain program payments. If MD Anderson successfully completes all the requirements of the Collaboration in full and the program is successfully commercialized, the Company will be required to pay aggregate milestone payments of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000262" name="onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments" contextRef="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20141231" decimals="-5" scale="6">1.0</ix:nonFraction> million based on net product sales. In July 2020, the Company entered into a research agreement with MD Anderson for certain services up to an aggregate cost of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000264" name="us-gaap:EquityMethodInvestmentAggregateCost" contextRef="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20200731" decimals="-3" format="ixt:numdotdecimal" scale="3">293,000</ix:nonFraction>. The <span style="color:#000000;">Company</span> recorded research and development expense <span style="color:#000000;">of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000263" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20210101_20210331" decimals="-5" scale="6">0.1</ix:nonFraction> million and a nominal amount </span>for each of the three months ended March&#160;31, 2021 and 2020, respectively.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Agreements with the Regents of the University of California (the &#8220;Regents&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, and as amended and restated in August 2018, and as amended in March and May 2019, the Company entered into a license agreement (as amended, the &#8220;Regents License Agreement&#8221;) for the development, manufacturing and distribution rights related to the development and commercialization of ROR1 related naked antibodies, antibody fragments or synthetic antibodies, and genetically engineered cellular therapy. The Regents License Agreement provides for the following: (i) in May 2016, an upfront license fee of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000265" name="onct:UpfrontLicenseFeesPaid" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531" decimals="-5" scale="6">0.5</ix:nonFraction> million was paid and <ix:nonFraction unitRef="U_xbrlishares" id="F_000266" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531" decimals="INF" format="ixt:numdotdecimal">107,108</ix:nonFraction> shares of common stock were issued, (ii) $<ix:nonFraction unitRef="U_iso4217USD" id="F_000267" name="onct:AnnualLicenseMaintenanceFees" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20170101_20171231" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction> in annual license maintenance fees commencing in 2017, (iii) reimbursement of certain annual patent costs, (iv) certain development and regulatory milestones aggregating from $<ix:nonFraction unitRef="U_iso4217USD" id="F_000268" name="onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMinimumMember_20160531" decimals="INF" scale="6">10.0</ix:nonFraction> million to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000269" name="onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMaximumMember_20160531" decimals="INF" scale="6">12.5</ix:nonFraction> million, on a per product basis, (v) certain worldwide sales milestones based on achievement of tiered revenue levels aggregating $<ix:nonFraction unitRef="U_iso4217USD" id="F_000270" name="onct:SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531" decimals="-5" scale="6">75.0</ix:nonFraction> million, (vi) low single-digit royalties, including potential future minimum annual royalties, on net sales of each target, and (vii) minimum diligence to advance licensed assets consisting of at least $<ix:nonFraction unitRef="U_iso4217USD" id="F_000271" name="onct:AdvanceLicensedAssets" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMinimumMember_20160531" decimals="INF" scale="6">1.0</ix:nonFraction> million in development spend annually through 2021. Under the Regents License Agreement, the Company recorded:&#160;<span style="color:#000000;">(i) $<ix:nonFraction unitRef="U_iso4217USD" id="F_000274" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20210101_20210331" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction> and <ix:nonFraction unitRef="U_iso4217USD" id="F_000275" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20200101_20200331" decimals="0" format="ixt-sec:numwordsen">none</ix:nonFraction> in license maintenance fees as research and development expense for each of the three months ended March 31, 2021 and 2020, (ii) $<ix:nonFraction unitRef="U_iso4217USD" id="F_000272" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20210101_20210331" decimals="-5" scale="6">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000273" name="us-gaap:GeneralAndAdministrativeExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20200101_20200331" decimals="0" format="ixt:numdotdecimal">25,000</ix:nonFraction> in patent costs as general and administrative expense for the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021, the Company believes it has met its obligations under the Regents License Agreement.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2016, and as modified by the amended and restated Regents License Agreement in August 2018, the Company entered into a Research Agreement (the &#8220;Research Agreement&#8221;) with the Regents for further research on a ROR1 therapeutic development program. Under this <span style="-sec-ix-hidden:F_000276">five-year</span> agreement, the Regents will have an aggregate budget of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000277" name="onct:ResearchAgreementResearchFundingAmount" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20210101_20210331" decimals="-5" scale="6">3.6</ix:nonFraction> million, with $<ix:nonFraction unitRef="U_iso4217USD" id="F_000278" name="onct:ResearchAgreementResearchFundingAmountPayable" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20210101_20210331" decimals="0" format="ixt:numdotdecimal">125,000</ix:nonFraction> payable quarterly. The Company recorded $<ix:nonFraction unitRef="U_iso4217USD" id="F_000279" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20210101_20210331" decimals="-5" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000280" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20200101_20200331" decimals="-5" scale="6">0.1</ix:nonFraction></ix:nonFraction> million in research and development expense under this agreement&#160;for each of the three months ended March 2021 and 2020, respectively. Such costs are includable as part of the Company&#8217;s annual diligence obligations under the Regents License Agreement. The Regents License Agreement will expire upon the later of the expiration date of the longest-lived patent rights or the fifteenth anniversary of the first commercial sale of a licensed product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Regents may terminate the Regents License Agreement if: (i) a material breach by the Company is not cured within a reasonable time, (ii) the Company files a claim asserting the Regents licensed patent rights are invalid or unenforceable and (iii) the Company files for bankruptcy. The Company may terminate the agreement at any time upon at least <ix:nonNumeric id="F_000281" name="onct:NumberOfDaysInWrittenNoticeOfTermination" contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctRegentsLicenseAgreementMember_20210101_20210331" format="ixt-sec:durday">60</ix:nonNumeric> days&#8217; written notice.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The University of Tennessee Research Foundation (&#8220;UTRF&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2015, the Company and UTRF entered into a license agreement (the &#8220;SARD License Agreement&#8221;) pursuant to which the Company was granted exclusive worldwide rights in all existing selective androgen receptor degrader (&#8220;SARD&#8221;) technologies owned or controlled by UTRF, including all improvements thereto.&#160; Under the SARD License Agreement, the Company is obligated to employ active, diligent efforts to conduct preclinical research and development activities for the SARD program to advance one or more lead compounds into clinical development.&#160; The Company is also obligated to pay UTRF annual license maintenance fees, low single-digit royalties on net sales of products and additional royalties on sublicense revenues, depending on the state of development of a clinical product candidate at the time it is sublicensed. The Company recorded research and development expense under this agreement of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000282" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20210101_20210331" decimals="0" format="ixt:numdotdecimal">35,000</ix:nonFraction> and <span style="color:#000000;">$<ix:nonFraction unitRef="U_iso4217USD" id="F_000283" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20200101_20200331" decimals="-5" scale="6">0.1</ix:nonFraction> million</span> for each of the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021, the Company believes it has met its obligations under the SARD License Agreement.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) Awards</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2017, <span style="color:#000000;">and as amended and restated in December 2020,</span> CIRM awarded an $<ix:nonFraction unitRef="U_iso4217USD" id="F_000284" name="onct:ResearchAndDevelopmentGrants" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20170801_20170831" decimals="-5" scale="6">18.3</ix:nonFraction> million grant to<span style="color:#000000;"> researchers at UC San Diego</span> to advance the Company&#8217;s Phase 1/2 clinical trial evaluating cirmtuzumab in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma. The Company: (i) is conducting this study in collaboration with UC San Diego, (ii) estimates it will receive approximately $<ix:nonFraction unitRef="U_iso4217USD" id="F_000285" name="onct:DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20170801_20170831" decimals="-5" scale="6">14.0</ix:nonFraction> million in development milestones under research subaward agreements during the award project period, estimated to be from October 1, 2017 to March 31, 2022, (iii) is committed to certain co-funding requirements, (iv) received <span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000286" name="onct:SubawardPaymentsReceived" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20210101_20210331" decimals="-6" format="ixt-sec:numwordsen" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000287" name="onct:SubawardPaymentsReceived" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20200331" decimals="-6" format="ixt-sec:numwordsen" scale="6">no</ix:nonFraction></ix:nonFraction></span> subaward payments in the three months ended March 31, 2021 and 2020, and (v) is required to provide UC San Diego progress and financial update reports throughout the award period. The subaward does not bear a royalty payment commitment, nor is the subaward otherwise refundable. For the three months ended March 31, 2021 and 2020, the Company recorded revenue of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000288" name="us-gaap:Revenues" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20210101_20210331" decimals="-5" scale="6">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000289" name="us-gaap:Revenues" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20200331" decimals="-5" scale="6">0.6</ix:nonFraction> million, respectively. Related qualifying subaward costs for the three months ended March 31, 2021 and 2020 were $<ix:nonFraction unitRef="U_iso4217USD" id="F_000290" name="onct:RelatedQualifyingSubawardCosts" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20210101_20210331" decimals="-5" scale="6">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="U_iso4217USD" id="F_000291" name="onct:RelatedQualifyingSubawardCosts" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20200331" decimals="-5" scale="6">1.3</ix:nonFraction> million, respectively. As of March 31,2021, the Company believes it has met its obligations under the CIRM award and UC San Diego subawards.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000180_dcnt_6f5f5f6f-5b5a-4ba1-a062-6794e467912b">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2017, CIRM awarded a $<ix:nonFraction unitRef="U_iso4217USD" id="F_000292" name="onct:ResearchAndDevelopmentGrants" contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031" decimals="-5" scale="6">5.8</ix:nonFraction> million grant to the researchers at UC San Diego to develop a novel anti-cancer stem cell targeted therapy for patients with advanced solid and hematological malignancies. In connection with such CIRM award, the Company agreed to provide up to $<ix:nonFraction unitRef="U_iso4217USD" id="F_000293" name="onct:AmountAgreedToBeProvidedInContingencyFunds" contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031" decimals="INF" scale="6">1.0</ix:nonFraction> million in contingency funds if required during the grant period, which expired in April 2020. The Company recorded <ix:nonFraction unitRef="U_iso4217USD" id="F_000295" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_20210101_20210331" decimals="-6" format="ixt-sec:numwordsen" scale="6"><ix:nonFraction unitRef="U_iso4217USD" id="F_000296" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="C_0001260990_20200101_20200331" decimals="-6" format="ixt-sec:numwordsen" scale="6">no</ix:nonFraction></ix:nonFraction> research and development expense, and <ix:nonFraction unitRef="U_iso4217USD" id="F_000294" name="onct:AmountAgreedToBeProvidedInContingencyFunds" contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20200331" decimals="-6" format="ixt-sec:numwordsen" scale="6">no</ix:nonFraction> contingency funds have been provided under such CIRM award for each of the three months ended March 31, 2021 and 2020.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical Trial and Supply Agreement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, the Company entered into a Clinical Trial and Supply Agreement with Pharmacyclics, LLC, an AbbVie Company (&#8220;Pharmacyclics&#8221;) to supply ibrutinib for the Company&#8217;s Phase 1/2 clinical trial evaluating cirmtuzumab in combination with ibrutinib, which agreement was amended in August 2019. Such agreement does not bear any upfront costs, inventory purchase costs, milestone or royalty payment commitments or other financial obligations.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">SPH USA, a Related Party</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License and Development Agreement (&#8220;LDA&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018<span style="color:#000000;">, and as amended in August 2020</span>, the Company entered into the LDA with SPH USA for: (i) the territory of the People&#8217;s Republic of China, Hong Kong, Macau, and Taiwan (&#8220;Greater China&#8221;), and (ii) rights to manufacture, develop, market, distribute and sell all of the Company&#8217;s product candidates under the Georgetown License Agreement and the Regents License Agreement (exclusive to Greater China only). Under the LDA, SPH USA is solely responsible for: (a) all preclinical and clinical development activities required in order to obtain regulatory approval in Greater China for such product candidates, (b) any third-party license milestone or royalty payments owed under the Georgetown License Agreement and the Regents License Agreement, and (c) paying the Company a low single digit royalty on net sales in the territory.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The LDA will expire upon the expiration of the last royalty term for the last licensed product. The LDA may be terminated by: (i) SPH USA on a country by country or product by product basis with 180 days written notice, (ii) either party upon material breach that is not cured within 90 days, and (iii) either party in the event the other party declares insolvency or bankruptcy.</p></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:9pt;">&#160;</p><ix:nonNumeric id="F_000181" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true" continuedAt="F_000181_dcnt_d453291c-6166-4b35-9f51-38937a8b2619">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;text-indent:-4.17%;font-size:9pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stockholders&#8217; Equity</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Securities Purchase <span style="color:#000000;">Agreements and Underwritten Offering</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, the Company entered into a Securities Purchase Agreement (the &#8220;May Purchase Agreement&#8221;) with several institutional and individual investors (including an entity affiliated with David F. Hale, the chairman of the Company&#8217;s board of directors) for the concurrent sale of: (i) <ix:nonFraction unitRef="U_xbrlishares" id="F_000297" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531" decimals="INF" format="ixt:numdotdecimal">1,943,636</ix:nonFraction> shares of the Company&#8217;s common stock in a registered direct offering, resulting in net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000298" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531" decimals="-5" scale="6">4.4</ix:nonFraction> million, after deducting the placement agent&#8217;s cash commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the warrants, and (ii) unregistered warrants to purchase up to an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000299" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531" decimals="INF" format="ixt:numdotdecimal">971,818</ix:nonFraction> shares of common stock. The combined purchase price for one share and one warrant to purchase half of a share of common stock was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000300" name="onct:CombinedPurchasePriceOfShareAndWarrantPerUnit" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531" decimals="4">2.5725</ix:nonFraction>. <span style="color:#000000;">In addition, the Company issued warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000301" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531" decimals="INF" format="ixt:numdotdecimal">116,618</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000302" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531" decimals="4">3.2156</ix:nonFraction> per share to the placement agent, H.C. Wainwright &#38; Co., LLC (&#8220;Wainwright&#8221; or the &#8220;placement agent&#8221;) as part of its compensation, which warrants were immediately exercisable and expire on <ix:nonNumeric id="F_000303" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531" format="ixt:datemonthdayyearen">May 21, 2025</ix:nonNumeric>.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company entered into a Securities Purchase Agreement (the &#8220;July Purchase Agreement&#8221;) with several institutional and individual investors for the concurrent sale of: (i) <ix:nonFraction unitRef="U_xbrlishares" id="F_000304" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731" decimals="INF" format="ixt:numdotdecimal">2,581,867</ix:nonFraction> shares of the Company&#8217;s common stock in a registered direct offering, resulting in net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000305" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731" decimals="-5" scale="6">5.7</ix:nonFraction> million, after deducting the placement agent&#8217;s cash commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the warrants, and (ii) unregistered warrants to purchase up to an aggregate of <ix:nonFraction unitRef="U_xbrlishares" id="F_000306" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731" decimals="INF" format="ixt:numdotdecimal">1,290,933</ix:nonFraction> shares of common stock.&#160;The combined purchase price for one share and one warrant to purchase half of a share of common stock was $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000307" name="onct:CombinedPurchasePriceOfShareAndWarrantPerUnit" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731" decimals="4">2.3825</ix:nonFraction>. The warrants issued to investors were, subject to certain ownership limitations, immediately exercisable at an exercise price equal to $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000308" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731" decimals="2">2.32</ix:nonFraction> per share and expire on <ix:nonNumeric id="F_000309" name="onct:CommonStockWarrantsExpirationDate" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731" format="ixt:datemonthdayyearen">January 21, 2026</ix:nonNumeric>. In addition, the Company issued warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000310" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731" decimals="INF" format="ixt:numdotdecimal">154,912</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000311" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731" decimals="4">2.9781</ix:nonFraction> per share to the placement agent as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on <ix:nonNumeric id="F_000312" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731" format="ixt:datemonthdayyearen">July 21, 2025</ix:nonNumeric>. Other investors participating in the July Purchase Agreement included an entity affiliated with SPH USA, the Company&#8217;s largest stockholder, Daniel L. Kisner, a member of the Company&#8217;s board of directors, and Hazel M. Aker, the Company&#8217;s then General Counsel.</p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000181_dcnt_d453291c-6166-4b35-9f51-38937a8b2619" continuedAt="F_000181_dcnt_6244fc99-6ca9-44c0-8b60-a23ff12051c8">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020, the Company </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">entered into</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> an underwriting agreement</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (as amended and restated, the &#8220;</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">w</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">riting Agreement&#8221;) with Wainwright</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the sale of </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000313" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831" decimals="INF" format="ixt:numdotdecimal">2,428,886</ix:nonFraction></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of the Company&#8217;s common stock at a price </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the public </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000316" name="onct:CombinedPurchasePriceOfShareAndWarrantPerUnit" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831" decimals="2">2.10</ix:nonFraction></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per share, resulting in net proceeds of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000314" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831" decimals="-5" scale="6">4.4</ix:nonFraction></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million, after deducting the </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">underwriter&#8217;s discounts,</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commissions</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and other offering expenses.&#160; In addition, the Company issued warrants to purchase </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000315" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831" decimals="INF" format="ixt:numdotdecimal">145,733</ix:nonFraction></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of common stock at an exercise price of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000317" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831" decimals="3">2.625</ix:nonFraction></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per share to </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wainwright</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as part of its compensation</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">warrants were immediately exercisable upon issuance and terminate on </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonNumeric id="F_000318" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831" format="ixt:datemonthdayyearen">August 27, 2025</ix:nonNumeric></span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> i</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nvestor</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> participating</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the transaction included Michael G. Carter, a member of the Company&#8217;s board of directors.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, the Company entered into an underwriting agreement (as amended and restated, the &#8220;November Underwriting Agreement&#8221;) with Wainwright for the sale of <ix:nonFraction unitRef="U_xbrlishares" id="F_000319" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130" decimals="INF" format="ixt:numdotdecimal">7,258,065</ix:nonFraction> shares of the Company&#8217;s common stock at a price to the public of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000322" name="onct:CombinedPurchasePriceOfShareAndWarrantPerUnit" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130" decimals="2">3.10</ix:nonFraction> per share, resulting in net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000320" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130" decimals="-5" scale="6">20.4</ix:nonFraction> million, after deducting the underwriter&#8217;s discounts, commissions and other offering expenses. In addition, the Company issued warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000321" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130" decimals="INF" format="ixt:numdotdecimal">435,484</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000323" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130" decimals="3">3.875</ix:nonFraction> per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on <ix:nonNumeric id="F_000324" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130" format="ixt:datemonthdayyearen">November 17, 2025</ix:nonNumeric>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the Company entered into an underwriting agreement (as amended and restated, the &#8220;December Underwriting Agreement&#8221;) with Wainwright for the sale of <ix:nonFraction unitRef="U_xbrlishares" id="F_000325" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231" decimals="INF" format="ixt:numdotdecimal">19,161,667</ix:nonFraction> shares of the Company&#8217;s common stock at a price to the public of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000328" name="onct:CombinedPurchasePriceOfShareAndWarrantPerUnit" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231" decimals="2">4.50</ix:nonFraction> per share, resulting in net proceeds of $<ix:nonFraction unitRef="U_iso4217USD" id="F_000326" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231" decimals="-5" scale="6">79.0</ix:nonFraction> million, after deducting the underwriter&#8217;s discounts, commissions and other offering expenses In addition, the Company issued warrants to purchase <ix:nonFraction unitRef="U_xbrlishares" id="F_000327" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231" decimals="INF" format="ixt:numdotdecimal">1,149,700</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000329" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231" decimals="3">5.625</ix:nonFraction> per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on <ix:nonNumeric id="F_000330" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231" format="ixt:datemonthdayyearen">December 9, 2025</ix:nonNumeric>. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the May Purchase Agreement and July Purchase Agreement, the Company also agreed, on a best-efforts basis, to: (i) maintain its listing on The Nasdaq Capital Market to provide for the resale of the shares of common stock issuable upon the exercise of the warrants, and (ii) not enter into any agreement for the issuance of any shares of common stock involving a variable rate transaction before July 21, 2021, <span style="color:#000000;">other than pursuant to a new at-the-market offering facility with the placement </span>agent. Variable rate&#160;transaction means a transaction in which the Company issues or sells, or agrees to issue or sell, common stock or convertible securities in which the applicable sale, conversion, exercise or exchange price or&#160;rate&#160;may directly or indirectly effectively be reduced. The<span style="color:#000000;"> Company does not currently have an active at-the-market offering facility. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock Warrants</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-size:6pt;">&#160;</p><ix:nonNumeric id="F_000202" name="onct:ScheduleOfWarrantActivityTableTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of warrant activity and changes in warrants outstanding is presented below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.56%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares Underlying Warrants</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Exercise Price Per Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Remaining Contractual Term (in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000331" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_20201231" decimals="INF" format="ixt:numdotdecimal">5,031,841</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000334" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_20201231" decimals="INF">9.25</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000337">4.40</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.56%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000332" name="onct:ExerciseOfWarrants" contextRef="C_0001260990_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">754,255</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000335" name="onct:WarrantExercisedPricePerShare" contextRef="C_0001260990_20210101_20210331" decimals="INF">2.57</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000338">4.59</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.56%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000333" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="C_0001260990_20210331" decimals="INF" format="ixt:numdotdecimal">4,277,586</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000336" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="C_0001260990_20210331" decimals="INF">10.42</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000339">4.07</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, all warrants met the criteria for classification in stockholders&#8217; equity.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.67%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Equity Incentive Plans</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contemporaneous with the Merger closing: (i) Private Oncternal&#8217;s 2015 Equity Incentive Plan, as amended (the &#8220;2015 Plan&#8221;) was assumed by the Company, and (ii) the Company adopted the 2019 Incentive Award Plan (&#8220;2019 Plan&#8221;) under which the sum of: (a) <ix:nonFraction unitRef="U_xbrlishares" id="F_000340" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607" decimals="INF" format="ixt:numdotdecimal">1,678,571</ix:nonFraction>&#160;shares of common stock, (b)&#160; up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000341" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607" decimals="INF" format="ixt:numdotdecimal">275,579</ix:nonFraction> shares of common stock which were subject to outstanding awards under the GTx 2013 Equity Incentive Plan (the &#8220;2013 Plan&#8221;) as of June 7, 2019, that upon cancellation will become available for issuance under the 2019 Plan, and (c)&#160;an annual increase on the first day of each calendar year beginning January&#160;1, 2020, and ending on and including January&#160;1, 2029, equal to the lesser of (A) <ix:nonFraction unitRef="U_xbrlipure" id="F_000342" name="onct:SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607_20190607" decimals="2" scale="-2">5</ix:nonFraction>% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (B)&#160;such smaller number of shares of common stock as is determined by the Board, are reserved for issuance. At March 31, 2021, <ix:nonFraction unitRef="U_xbrlishares" id="F_000343" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember_20210331" decimals="INF" format="ixt:numdotdecimal">2,143,999</ix:nonFraction> shares remain available for future issuance under the 2019 Plan and Inducement Plan.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000181_dcnt_6244fc99-6ca9-44c0-8b60-a23ff12051c8" continuedAt="F_000181_dcnt_71b0217f-5f9c-4f81-94f9-f30bb4cad642">
<ix:nonNumeric id="F_000203" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.66%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000344" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210331" decimals="INF" format="ixt:numdotdecimal">3,977,826</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000347" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210331" decimals="INF">5.46</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000350">8.90</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000353" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">11,378,589</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000345" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210331" decimals="INF" format="ixt:numdotdecimal">3,977,826</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000348" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210331" decimals="INF">5.46</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000351">8.90</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000354" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">11,378,589</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000346" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210331" decimals="INF" format="ixt:numdotdecimal">1,075,315</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000349" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210331" decimals="INF">3.51</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000352">7.30</span></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000355" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">5,170,595</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p></ix:nonNumeric>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, under the 2013 Plan, there were: (i) <span style="color:#000000;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000356" name="onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandThirteenPlanMember_20210331" decimals="INF" format="ixt:numdotdecimal">87,133</ix:nonFraction></span> outstanding and fully vested and exercisable options with a weighted average exercise price of $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000357" name="onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" contextRef="C_0001260990_20210331" decimals="2">62.48</ix:nonFraction></span> per share that expire in the second quarter of 2021, and (ii) <span style="color:#000000;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000358" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">24,282</ix:nonFraction></span> options cancelled during the three months ended March 31, 2021 were added to the 2019 Plan. As of March 31, 2021, the remaining former GTx stock option plans had an aggregate of <span style="color:#000000;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000359" name="onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" contextRef="C_0001260990_us-gaapPlanNameAxis_onctGTxStockOptionPlansMember_20210331" decimals="INF" format="ixt:numdotdecimal">4,582</ix:nonFraction></span> outstanding and fully vested and exercisable options with a weighted average exercise price of $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000360" name="onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" contextRef="C_0001260990_us-gaapPlanNameAxis_onctGTxStockOptionPlansMember_20210331" decimals="2">270.00</ix:nonFraction></span> per share that expire in the second quarter of 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2015, Private Oncternal adopted the 2015 Plan which provided for the issuance of up to <ix:nonFraction unitRef="U_xbrlishares" id="F_000361" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001260990_srtConsolidatedEntitiesAxis_onctPrivateOncternalMember_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150731" decimals="INF" format="ixt:numdotdecimal">631,120</ix:nonFraction> shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants.&#160;&#160;In general, the options issued under the 2015 Plan expire <ix:nonNumeric id="F_000362" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150701_20150731" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> from the date of grant and vest over a <span style="-sec-ix-hidden:F_000363">four-year</span> period. Certain grants vest based on the achievement of development or regulatory milestones. No further awards will be made under the 2015 Plan, which was terminated as to new grants in June 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2019 Plan provides for the issuance of shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants.&#160;&#160;In general, the options issued under the 2019 Plan expire <ix:nonNumeric id="F_000364" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenPlanMember_20150701_20150731" format="ixt-sec:durwordsen">ten years</ix:nonNumeric> from the date of grant and vest over a <span style="-sec-ix-hidden:F_000365">four-year</span> period. Certain grants vest based on the achievement of development or regulatory milestones. The 2019 Plan allows for the early exercise of all stock option grants if authorized by the board of directors at the time of grant. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 11, 2021, the Company&#8217;s board of directors adopted the 2021 Employment Inducement Incentive Award Plan (the &#8220;Inducement Plan&#8221;) and initially reserved <ix:nonFraction unitRef="U_xbrlishares" id="F_000366" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001260990_us-gaapPlanNameAxis_onctInducementPlanMember_20210211" decimals="INF" format="ixt:numdotdecimal">700,000</ix:nonFraction> shares of common stock for issuance. The Inducement Plan is a non-shareholder approved stock plan adopted pursuant to the &#8220;inducement exception&#8221; provided under Nasdaq listing rules. The Inducement Plan will be used exclusively for the issuance of non-statutory stock options to certain new hires who satisfied the requirements to be granted inducement grants under Nasdaq rules as an inducement material to the individual&#8217;s entry into employment with the Company. The terms of the Inducement Plan are substantially similar to the terms of our 2019 Plan. </p><ix:nonNumeric id="F_000204" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the Company&#8217;s stock option activity under the 2019 Plan, Inducement Plan and 2015 Plan is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000367" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001260990_20201231" decimals="INF" format="ixt:numdotdecimal">2,107,625</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000372" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001260990_20201231" decimals="2">4.08</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000368" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="C_0001260990_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">2,127,000</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000373" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="C_0001260990_20210101_20210331" decimals="2">6.78</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000369" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="C_0001260990_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">168,750</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000374" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="C_0001260990_20210101_20210331" decimals="2">5.47</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(<ix:nonFraction unitRef="U_xbrlishares" id="F_000370" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="C_0001260990_20210101_20210331" decimals="INF" format="ixt:numdotdecimal">88,049</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000375" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="C_0001260990_20210101_20210331" decimals="2">4.06</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2021</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000371" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="C_0001260990_20210331" decimals="INF" format="ixt:numdotdecimal">3,977,826</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000376" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="C_0001260990_20210331" decimals="2">5.46</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information about the Company&#8217;s outstanding stock options under the 2019 Plan and 2015 Plan is as follows (in thousands, except share and per share data and expected term):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average grant date fair value per share of option grants for the three months ended March 31, 2021 was $<span style="color:#000000;"><ix:nonFraction unitRef="U_iso4217USD_xbrlishares" id="F_000377" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20210101_20210331" decimals="2">5.06</ix:nonFraction></span> per share.&#160;&#160;The aggregate intrinsic value of stock options exercised during the three months ended March 31, 2021 was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000378" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20210101_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">365,000</ix:nonFraction>. The intrinsic value is calculated as the difference between the fair value of the Company&#8217;s common stock at the time of the option exercise and the exercise price of that stock option.</p></ix:continuation>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000181_dcnt_71b0217f-5f9c-4f81-94f9-f30bb4cad642">

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense</p><ix:nonNumeric id="F_000205" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="C_0001260990_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants, were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000379" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001260990_20210101_20210331" decimals="3" scale="-2">0.6</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000380" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="C_0001260990_20200101_20200331" decimals="3" scale="-2">1.0</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000381" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001260990_20210101_20210331" decimals="3" scale="-2">89.9</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlipure" id="F_000382" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="C_0001260990_20200101_20200331" decimals="3" scale="-2">89.4</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000383">6.4</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000384">5.4</span></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.17%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility. <span style="font-style:normal;">Prior to the Merger, Private Oncternal did not have a trading history for its common stock.&#160;&#160;Accordingly, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the life sciences industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected term. <span style="font-style:normal;">The expected term represents the period of time that options are expected to be outstanding. Because Private Oncternal did not have historical exercise behavior, it determined the expected life assumption using the simplified method for employees, which is an average of the contractual term of the option and its vesting period. The expected term for nonemployee options is generally the remaining contractual term.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate. <span style="font-style:normal;">The risk-free interest rate is based on the implied yield on the U.S. Treasury securities with a maturity date similar to the expected term of the associated stock option award.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected dividend yield. <span style="font-style:normal;">The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero.</span></p><ix:nonNumeric id="F_000206" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense recognized for all equity awards has been reported in the condensed consolidated statements of operations as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000385" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331" decimals="-3" scale="3">473</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000386" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20200331" decimals="-3" scale="3">139</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000387" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20210331" decimals="-3" scale="3">365</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000388" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20200331" decimals="-3" scale="3">260</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000389" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001260990_20210101_20210331" decimals="-3" scale="3">838</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_iso4217USD" id="F_000390" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_0001260990_20200101_20200331" decimals="-3" scale="3">399</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, the total compensation cost related to non-vested awards not yet recognized was $<ix:nonFraction unitRef="U_iso4217USD" id="F_000391" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="C_0001260990_20210331" decimals="-5" scale="6">12.4</ix:nonFraction> million and the weighted-average period over which it is expected to be recognized was <ix:nonNumeric id="F_000392" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="C_0001260990_20210101_20210331" format="ixt-sec:duryear">3.6</ix:nonNumeric> years. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock Reserved for Future Issuance</p><ix:nonNumeric id="F_000207" name="us-gaap:ScheduleOfStockByClassTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for future issuance is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000393" name="onct:CommonStockWarrantsReservedForFutureIssuance" contextRef="C_0001260990_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,278</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options issued and outstanding</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000394" name="onct:CommonStockOptionsIssuedAndOutstandingForFutureIssuance" contextRef="C_0001260990_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">4,069</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock available for issuance under the Inducement Plan and 2019 Plan</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000395" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">2,144</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><ix:nonFraction unitRef="U_xbrlishares" id="F_000396" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="C_0001260990_20210331" decimals="-3" format="ixt:numdotdecimal" scale="3">10,491</ix:nonFraction></p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div></ix:nonNumeric></ix:continuation>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><ix:nonNumeric id="F_000182" name="onct:COVID19PandemicAndCARESActDisclosureTextBlock" contextRef="C_0001260990_20210101_20210331" escape="true" continuedAt="F_000182_dcnt_59775b80-34a9-46e9-be37-da003a93557e">
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6</span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">COVID-19 Pandemic and CARES Act</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A novel strain of coronavirus (SAR-CoV-2) causing a severe respiratory disease (&#8220;COVID-19&#8221;), was declared a global pandemic by the World Health Organization in March 2020. COVID-19 has presented substantial public health and economic challenges and is affecting economies, financial markets and business operations around the world. International and U.S. governmental authorities in impacted regions have taken actions in an effort to slow the spread of COVID-19, including issuing varying forms of &#8220;stay-at-home&#8221; orders, and restricting business functions outside of one&#8217;s home. In response, the Company has put restrictions on employee travel and working from its executive offices with many employees continuing their work remotely. While the Company is currently continuing the clinical trials it has underway in sites across the U.S., COVID-19 precautions have directly or indirectly impacted the timeline for some of its clinical trials. Additionally, the Company&#8217;s expectations for the timing of first-in-human dosing of its ROR1 CAR-T therapy has been delayed to the first half of 2022. The Company considered the impacts of COVID-19 on the assumptions and estimates used to prepare its condensed consolidated financial statements and determined that there were no material adverse impacts on the Company&#8217;s results of operations and financial position at March 31, 2021. The full extent to which the COVID-19 pandemic will continue to directly or indirectly impact the Company&#8217;s business results of operations and financial condition, will depend on future development that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, the success or failure of vaccination programs, the emergence of new variants of COVID-19, as well as the economic impact on local, regional, national and international markets.&#160; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the COVID-19 pandemic, the CARES Act was signed into law on March 27, 2020.&#160; The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#8217;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property, and authorized the Paycheck Protection Program. The CARES Act had no material impact on the Company&#8217;s income tax provision for the three months ended March&#160;31, 2021.&#160;&#160;<span style="color:#000000;">The Company continues to monitor changes and revisions to the CARES Act and its impact on the Company&#8217;s condensed consolidated financial position, results of operations and cash flows.</span></p></ix:nonNumeric>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always" /><ix:continuation id="F_000182_dcnt_59775b80-34a9-46e9-be37-da003a93557e">
</ix:continuation>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ONCTERNAL_MANAGEMENTS_DISCUSSION_ANALYSI">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with: (i)&#160;our unaudited condensed consolidated financial statements and related notes thereto included elsewhere in this Quarterly Report on Form 10-Q for the period ended March 31, 2021, and (ii) our audited financial statements and notes thereto for the year ended December 31, 2020 and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in in our 2020 Annual Report on Form 10-K/A for the year ended December 31, 2020.&#160;&#160;Except as otherwise indicated herein or as the context otherwise requires, references in this Quarterly Report to &#8220;Oncternal&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Oncternal Therapeutics, Inc., a Delaware corporation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cautionary Note Regarding Forward-Looking Statements </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Quarterly Report contains <span style="color:#000000;">forward-looking statements</span> within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;)<span style="color:#000000;">. </span>All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, business strategies and plans, prospective products, product approvals, research and development costs, the expected impact of COVID-19, timing and likelihood of success, plans and objectives of management for future operations and future results of anticipated products, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; or the negative of these terms or other comparable terminology. These forward-looking statements are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of risks, uncertainties and assumptions<span style="color:#000000;">, including those </span>described in <span style="color:#000000;">our Annual Report on Form 10-K/A, filed with the SEC on March 12, 2021, and in</span> Part II, Item 1A,<span style="color:#000000;"> &#8220;Risk </span>Factors&#8221; of this Quarterly Report. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and <span style="color:#000000;">actual results could differ materially from those </span>projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for cancers with critical unmet medical need. Our development efforts are focused on promising, yet untapped, biological pathways implicated in cancer generation or progression. Our pipeline includes cirmtuzumab, an investigational humanized monoclonal antibody that is designed to inhibit Receptor tyrosine kinase-like Orphan Receptor 1, or ROR1, a growth factor receptor that is widely expressed on many tumors and that activates pathways leading to increased tumor proliferation, invasiveness and drug resistance. Cirmtuzumab is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib (Imbruvica<sup style="font-size:85%;line-height:120%;vertical-align:top">&#174;</sup>) (Cirmtuzumab and Ibrutinib targeting ROR1 for Leukemia and Lymphoma, or CIRLL), for the treatment of patients with B-cell lymphoid malignancies, including <span style="color:#000000;">mantle cell lymphoma, or </span>MCL, <span style="color:#000000;">and chronic lymphocytic leukemia, or </span>CLL, and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer. <span style="color:#000000;">We are also supporting an investigator-sponsored Phase 2 clinical trial of cirmtuzumab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL, which is currently enrolling patients. </span>We are developing a chimeric antigen receptor T cell, or CAR-T, therapy candidate that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. In addition, we are developing TK216, an investigational small molecule that is designed to inhibit the ETS, or E26 Transformation Specific, family of oncoproteins, which have been shown in preclinical studies to alter gene transcription and RNA processing and lead to increased cell proliferation and invasion. TK216 is being evaluated in a Phase 1/2 clinical trial as a single agent and in combination with vincristine in patients with relapsed or refractory Ewing sarcoma, a rare pediatric cancer. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <span style="color:#000000;">U.S. Food and Drug Administration, or </span>FDA, has granted orphan drug designations for cirmtuzumab for the treatment of MCL and for the treatment of CLL/small lymphocytic lymphoma, and has granted rare pediatric disease designation, as well as orphan drug and fast track designations for TK216 for the treatment of Ewing Sarcoma.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.13%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our clinical strategy for cirmtuzumab prioritizes development in MCL, based on encouraging interim clinical results from the CIRLL Phase 1/2 clinical trial that were presented at the American Society Clinical of Oncology 2020 Annual Meeting in May. The CIRLL study target enrollment for patients with relapsed/refractory MCL in the Phase 2 expansion cohort is at least 20 patients to allow for the enrollment of patients with a broader range of prior BTK inhibitor treatments.&#160;&#160;The total enrollment of CLL patients in the randomized Phase 2 CLL cohort of the CIRLL study is 28 patients, which was reached in 2020. In September 2020, we met with the FDA and are in dialogue with the FDA regarding potential accelerated approval pathways for cirmtuzumab plus ibrutinib in patients with relapsed/refractory MCL. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always" />

<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.13%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the inception of privately-held Oncternal Therapeutics, Inc. in 2013, we have devoted most of our resources to organizing and staffing, business planning, raising capital, acquiring product candidates and securing related intellectual property rights and advancing our cirmtuzumab and TK216 clinical development programs.&#160;&#160;Under research subaward agreements between us and UC San Diego, we are eligible to receive approximately $14.0 million in development milestones during the award project period, estimated to be from October 1, 2017 to March 31, 2022.&#160;&#160;Through March 31, 2021, we have funded our operations primarily through: (i) gross proceeds of $125.0 million from the issuance of common stock, (ii) gross proceeds of $49.0 million from the issuance of convertible preferred stock, (iii) receipt of $11.6 million in subaward grant payments received from UC San Diego, and (iv) cash proceeds of $18.3 million received in connection with the closing of the merger with GTx, Inc. in June 2019, or the GTx Merger.&#160;&#160;As of March 31, 2021, we had cash and cash equivalents of $111.2 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred net losses in each year since inception.&#160;&#160;Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates.&#160;&#160;Our net loss was $5.9 million for the three months ended March 31, 2021.&#160;&#160;As of March 31, 2021, we had an accumulated deficit of $88.7 million.&#160;&#160;Substantially all of our net losses have resulted from costs incurred in connection with: (i) advancing our research and development programs, (ii) general and administrative costs associated with our operations, including the costs associated with operating as a public company, and (iii) in-process research and development costs associated with the GTX Merger.&#160;&#160;We expect to continue to incur significant and increasing operating losses for at least the next several years.&#160;&#160;We expect that our expenses and capital funding requirements will increase substantially in connection with our ongoing activities, particularly if and as we:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>advance cirmtuzumab through clinical development in multiple indications, initially focused on MCL&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>generate clinical proof-of-concept data with TK216 in Ewing sarcoma, an orphan pediatric cancer indication&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>advance our ROR1-targeting CAR-T therapy candidate to clinical development, initially in hematological cancers and then in solid tumors&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>respond to the impacts of the COVID-19 pandemic, which has slowed enrollment into our clinical trials&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>evaluate cirmtuzumab in additional ROR1-positive solid tumors&#59; </p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>evaluate TK216 in additional tumors with ETS fusion proteins or overexpression&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>continue to develop additional product candidates&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>acquire or in&#8209;license other product candidates and technologies&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>maintain, expand and protect our intellectual property portfolio&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>establish a commercial manufacturing source and secure supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain regulatory approval&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>seek regulatory approvals for any product candidates that successfully complete clinical trials&#59;</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain regulatory approval&#59; and</p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;"></span>add operational, financial and management information systems and personnel, including personnel to support our planned product development and future commercialization efforts, as well as to support our transition to a public reporting company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will not generate product sales revenue unless and until we successfully complete clinical development and obtain regulatory approval for our product candidates. If we obtain regulatory approval for any of our product candidates and do not enter into a commercialization partnership, we expect to incur significant expenses related to developing our internal commercialization capability to support product sales, marketing and distribution.&#160;&#160;In addition, we expect to incur additional costs associated with operating as a public company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result, we believe we will need substantial additional funding to support our continuing operations and pursue our business strategy. Until such time as we can generate significant product sales revenue, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, government funding, or other sources, including potentially collaborations, licenses and other similar arrangements.&#160;&#160;We may not be able to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all.&#160;&#160;If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, reduce or eliminate the development and commercialization of one or more of our product candidates or delay our pursuit of potential in licenses or acquisitions.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">are able to</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> generate product sales, we may not become profitable.&#160;&#160;If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements for at least the next twelve months.&#160;&#160;We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. Beyond that point, we will need to raise additional capital to finance our operations, which cannot be assured.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Business Update Regarding COVID-19</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 worldwide pandemic has presented substantial public health and economic challenges and is affecting economies, financial markets and business operations around the world. International and U.S. governmental authorities in impacted regions have taken actions in an effort to slow the spread of COVID-19, including issuing and modifying varying forms of &#8220;stay-at-home&#8221; orders, and restricting business functions outside of one&#8217;s home. In response, we have put restrictions on employee travel and working from our executive offices, with many employees continuing their work remotely. To date, we have been able to continue to supply cirmtuzumab and TK216 clinical trial sites for patients enrolled in our ongoing clinical trials and do not currently anticipate any interruptions in the supply of cirmtuzumab or TK216. While we are continuing the clinical trials we have underway in sites across the U.S., COVID-19 precautions have directly or indirectly impacted the timeline for some of our clinical trials. For our existing patients, we are actively working with all of our clinical trial sites to minimize disruptions and address concerns on an individual site or patient basis in order to allow participating patients to continue to receive treatment at home or in alternative healthcare settings while minimizing their potential exposure to the virus that causes COVID-19. If restrictions related to the COVID-19 outbreak continue or if additional clinical trial sites pause patient enrollment or treatments, our clinical trial milestones would be negatively impacted.&#160; Additionally, our expectations for the timing of first-in-human dosing of our ROR1 CAR-T therapy has been delayed to the first half of 2022. Any delays in the completion of our clinical trials and any disruption in our supply chain could have a material adverse effect on our business, results of operations and financial condition. The full extent to which the COVID-19 pandemic will continue to directly or indirectly impact our business, results of operations and financial condition, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, the success or failure of vaccination programs, the emergence of new variants of COVID-19, as well as the economic impact on local, regional, national and international markets.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Components of Results of Operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Grant Revenue</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not and do not expect to generate any product sales revenue in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate product sales revenue in the future. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates. Our total revenue to date has been derived from a California Institute for Regenerative Medicine, or CIRM, grant subaward with UC San Diego.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2017, CIRM awarded an $18.3 million grant to researchers at UC San Diego to advance our Phase 1/2 clinical trial evaluating cirmtuzumab in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including MCL and CLL. We are conducting this study in collaboration with UC San Diego and estimate we will receive approximately $14.0 million in development milestones under research subaward agreements during the award project period, estimated to be from October 1, 2017 to March 31, 2022. In addition, we are committed to certain co-funding requirements and are required to provide UC San Diego progress and financial update reports throughout the award project period. We received no subaward payments in the three months ended March&#160;31, 2021 and 2020, respectively. As of&#160;March 31, 2021: (i) the remaining estimated subaward funds available total $2.8 million, and (ii) we believe we have met our obligations under the CIRM award and UC San Diego subawards.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Operating Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist primarily of costs incurred for the preclinical and clinical development of our lead product candidate, cirmtuzumab, as well as TK216, which include:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">expenses under agreements with consultants, third-party contract organizations, and investigative clinical trial sites that conduct research and development activities on our behalf&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">costs related to the development and manufacture of preclinical study and clinical trial material&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">salaries and employee-related costs, including stock-based compensation&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">costs incurred under our collaboration and third-party licensing agreements&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">laboratory and vendor expenses related to the execution of preclinical and clinical trials.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We accrue all research and development costs in the period for which they are incurred. Costs for certain development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors, collaborators and third-party service providers. Advance payments for goods or services to be received in future periods for use in research and development activities are deferred and then expensed as the related goods are delivered and as services are performed. Any unearned advances would be refunded when known.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect our research and development expenses to increase substantially for the foreseeable future as we: (i) invest in additional operational personnel to support our planned product development efforts, and (ii) continue to invest in developing our product candidates preclinically, advance them into later stages of clinical development, and as we begin to conduct larger clinical trials. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our direct research and development expenses are tracked by product candidate and consist primarily of external costs, such as fees paid under third-party license agreements and to outside consultants, contract research organizations, or CROs, contract manufacturing organizations and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. We do not allocate employee costs and costs associated with our discovery efforts, laboratory supplies and facilities, including other indirect costs, to specific product candidates because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to conduct our research as well as for managing our preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple programs and, therefore, we do not track our costs by product candidate unless we can include them as subaward costs.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot determine with certainty the timing of initiation, the duration or the completion costs of current or future preclinical studies and clinical trials of our product candidates due to the inherently unpredictable nature of preclinical and clinical development, including any potential expanded dosing beyond the original protocols based in part on ongoing clinical success and the potential effects of the COVID-19 pandemic. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments and our ongoing assessments of each product candidate&#8217;s commercial potential. We will need to raise substantial additional capital in the future. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of personnel-related costs, insurance costs, facility costs and professional fees for legal, patent, consulting, investor and public relations, accounting and audit services. Personnel-related costs consist of salaries, benefits and stock-based compensation. We expect our general and administrative expenses will increase substantially as we: (i) incur additional costs associated with being a public company, including audit, legal, regulatory, and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations costs, (ii) hire additional personnel, and (iii) protect our intellectual property.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Interest Income </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income consists of interest earned on our cash equivalents, which consist of money market funds. Our interest income has not been significant due to low interest earned on invested balances.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Comparison of Three Months Ended March&#160;31, 2021 and 2020 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the three months ended March 31, 2021 and 2020:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="10" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant revenue</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">748</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">578</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">170</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,913</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,696</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,217</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,794</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,633</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">161</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,707</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,329</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,378</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,959</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,751</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,208</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income (expense):</p></td>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total other income (expense)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,948</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,738</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,210</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Grant Revenue</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grant revenue <span style="color:#000000;">was $0.8 million and $0.6 million</span> for the three months ended March 31, 2021 and 2020<span style="color:#000000;">, respectively</span>. The <span style="color:#000000;">increase of $0.2 million</span> was driven primarily by <span style="color:#000000;">higher</span> research and development subaward costs in 2021 as compared to 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our research and development expenses for the periods indicated:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Increase/</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Decrease)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cirmtuzumab</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,646</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,360</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">286</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TK216</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">572</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">350</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unallocated research and development expenses</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,695</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">986</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">709</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.54%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,913</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,696</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,217</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses for the three months ended March 31, 2021 and 2020 were $3.9 million and $2.7 million, respectively, <span style="color:#000000;">an increase</span> of $1.2 million. The <span style="color:#000000;">increase</span> was due to a <span style="color:#000000;">$0.5 million change</span> in <span style="color:#000000;">total</span> direct product candidate costs, and a $0.7 million <span style="color:#000000;">increase</span> in unallocated expenses.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct expenses for cirmtuzumab increased $0.3 million for the three months ended March 31, 2021, compared to the three months ended March 31, 2020, primarily due to an increase in MCL patients enrolled in the clinical trial.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Direct expenses for TK216 increased $0.2 million for the three months ended March 31, 2021, compared to the three months ended March 31, 2020,<span style="color:#000000;"> primarily</span> due to an increase in clinical trial costs related to our ongoing Phase 1/2 clinical trial of TK216 in refractory Ewing sarcoma.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unallocated expenses increased $0.7 million for three months ended March 31, 2021, compared to the three months ended March 31, 2020, primarily due to higher personnel costs.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses for the three months ended March 31, 2021 and 2020 were $2.8 million and $2.6 million, respectively, an increase of $0.2 million. The increase is primarily due to a $0.3 million increase in legal, personnel and director&#8217;s and officer&#8217;s insurance costs, that were partially offset by a $0.1 million decrease in professional and other public company expenses.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always" />
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred losses and negative cash flows from operations since inception. As of March 31, 2021, we had an accumulated deficit of $88.7 million and anticipate that we will continue to incur net losses for the foreseeable future. As of March 31, 2021, we had $111.2 million in cash and cash equivalents. We believe we have sufficient cash to fund our projected operating requirements for at least twelve months from the filing date of this Quarterly Report.&#160;&#160;We expect our operating expenses to continue to be substantial for the foreseeable future and, as a result, we will need additional capital to fund our operations, which we may obtain through one or more public or private equity or debt financings, or other sources such as potential collaboration arrangements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Cash Flows</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our sources and uses of cash for each of the periods presented:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in):</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,985</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,036</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">459</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net decrease in cash and cash equivalents</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,526</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,032</p></td>
<td valign="bottom" style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating activities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March&#160;31, 2021, net cash used in operating activities was $6.0 million, resulting from our net loss of $5.9 million, which included non-cash charges of $0.8 million related to stock-based compensation expense, offset by a $0.9 million change in our operating assets and liabilities. The $0.9 million change in operating assets and liabilities primarily consisted of a $0.6 million decrease in prepaid and other assets, a $0.7 million <span style="color:#000000;">decrease</span> in deferred revenue, and a $0.4 million increase in accounts payable and accrued expenses.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investing activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by investing activities was zero for each of the three months ended March 31, 2021 and 2020. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:normal;font-style:italic;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Financing activities</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities was $0.5 million for the three months ended March 31, 2021, which resulted from net proceeds of $0.4 million received from the exercise of warrants and $0.1 million received from the exercise of common stock options. Net cash provided by financing activities was nominal for the three months ended March 31, 2020. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Funding Requirements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect that our existing cash and cash equivalents will be sufficient to fund our operations into 2023. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. We have based this estimate on plans that may change as circumstances evolve and assumptions that may prove to be wrong, and we could use our capital resources sooner than we expect. Additionally, the process of testing product candidates in clinical trials is costly, and the timing of progress, potential amendments, or changes in protocols for our existing studies beyond our planned study protocols based in part on our clinical progress, and expenses in these trials is uncertain.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future capital requirements will depend on many factors, including:</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the type, number, scope, progress, expansions, results, costs and timing of, our preclinical studies and clinical trials of our product candidates which we are pursuing or may choose to pursue in the future&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs incurred as a result of the COVID-19 pandemic, including clinical trial delays&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs and timing of manufacturing for our product candidates, including commercial manufacturing if any product candidate is approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the future potential costs of obtaining ibrutinib, for which we currently obtain supply at no cost under our clinical supply agreement with Pharmacyclics LLC, and vincristine to conduct our clinical trials of cirmtuzumab and TK216, respectively&#59; </span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs, timing and outcome of regulatory review of our product candidates&#59;</span></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs associated with hiring additional personnel and consultants as our preclinical and clinical activities increase&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the costs and timing of establishing or securing sales and marketing capabilities if any product candidate is approved&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">our ability to achieve sufficient market acceptance, adequate coverage and reimbursement from third-party payors and adequate market share and revenue for any approved products&#59;</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements&#59; and</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.17%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><span style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></span><span style="font-size:10pt;font-family:'Times New Roman'">&#8226;</span></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><span style="Background-color:#auto;text-decoration:none;"></span><span style="color:#000000;">costs associated with any products or technologies that we may in-license or acquire.</span></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial product revenues to support our cost structure, we expect to finance our losses from operations and capital funding needs through a combination of equity offerings, debt financings, government funding and other sources, including potentially collaborations, licenses and other similar arrangements. To the extent we raise additional capital through the sale of debt or equity securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, licenses and other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through debt or equity financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates by ourselves. There can be no assurance that we will be able to obtain any sources of financing on acceptable terms, or at all.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Obligations and Commitments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are party to a number of license agreements, pursuant to which we have payment obligations that are contingent upon future events such as our achievement of specified development, regulatory and commercial milestones and are required to make royalty payments in connection with the sale of products developed under those agreements. As of March 31, 2021, we were unable to estimate the timing or likelihood of achieving the milestones or making future product sales.&#160;&#160;See Note 4 to our condensed consolidated financial statements included elsewhere in this Quarterly Report for a description of these agreements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We enter into contracts in the normal course of business with clinical trial sites and clinical supply manufacturers and with vendors for preclinical studies, research supplies and other services and products for operating purposes. These contracts generally provide for termination after a notice period.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:10pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of the financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our estimates are based on our historical experience, trends and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consider our critical accounting policies and estimates to be related to research and development expenses and accruals, and revenue recognition. There have been no material changes to our critical accounting policies and estimates during the three months ended March 31, 2021, from those disclosed in &#8220;Oncternal&#8217;s Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#8211; Critical Accounting Policies,&#8221; included in the Annual Report on Form 10-K/A. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always" />

<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_3_QUANTITATIVE_QUALITATIVE_DISCLOSU">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a smaller reporting company, as defined by Rule 12b-2 of the Exchange Act, and are not required to provide the information required under this item.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_4_CONTROLS_PROCEDURES">ITEM 4. CONTROLS AND PROCEDURES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain &#8220;disclosure controls and procedures&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act that are designed to ensure that information required to be disclosed in the reports we file and submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies judgment in evaluating the benefits of possible controls and procedures relative to their costs.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, who serve as our principal executive officer and principal financial officer, respectively, has evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2021. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of such date.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Inherent Limitations of Disclosure Controls and Internal Control over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.13%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of their inherent limitations, our disclosure controls and procedures and our internal control over financial reporting may not prevent material errors or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. The effectiveness of our disclosure controls and procedures and our internal control over financial reporting is subject to risks, including that the controls may become inadequate because of changes in conditions or that the degree of compliance with our policies or procedures may deteriorate.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="PART_IIOR_INFORMATION">PART II &#8212; OTHER INFORMATION</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;" id="ITEM_1_LEGAL_PROCEEDINGS">Item 1. Legal Proceedings</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM1">From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;" id="ITEM_1A_RISK_FACTORS">Item 1A. Risk Factors<span style="text-transform:none;"> </span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">An investment in our securities involves a high degree of risk. You should carefully consider the specific factors discussed below, as well as all other information included in this Quarterly Report on Form 10-Q, including our financial statements, the notes thereto and the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; If any of the following risks actually occurs, our business, financial condition, operating results, prospects and ability to accomplish our strategic objectives could be materially harmed. As a result, the trading price of our common stock could decline and you could lose all or part of your investment. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations. The occurrence of any of these known or unknown risks might cause you to lose all or part of your investment in our securities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been no material changes to the risk factors included in &#8220;Item 1A. Risk Factors&#8221; of our Annual Report on Form 10-K/A for the year ended December&#160;31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;" id="ITEM_2_UNREGISTERED_SALES_EQUITY_SECURIT">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;" id="ITEM_3_DEFAULTS_UPON_SENIOR_SECURITIES">Item 3. Defaults Upon Senior Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;" id="ITEM_4_MINE_SAFETY_DISCLOSURES">Item 4. Mine Safety Disclosures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-size:10pt;font-style:normal;font-variant: normal;" id="ITEM_5">ITEM 5. OTHER INFORMATION</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="ITEM_6_EXHIBITS">Item 6. Exhibits.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT INDEX</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:99.86%;">
<tr>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="4" valign="bottom" style="padding-left:3pt;padding-Right:3pt;padding-Top:0pt;padding-Bottom:0pt;width:39.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr style="height:3.6pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Exhibit</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Filing</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Herewith</p></td>
</tr>
<tr style="height:3.6pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000095013405014821/f11069orexv4w1.htm"><span style="text-decoration:underline;">Restated Certificate of Incorporation of the Registrant</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-3</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-127175</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 4, 2005</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000095012311046639/c16700exv3w2.htm"><span style="text-decoration:underline;">Certificate of Amendment of Restated Certificate of Incorporation of the Registrant</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 6, 2011</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000110465914037092/a14-12275_1ex3d3.htm"><span style="text-decoration:underline;">Certificate of Amendment of Restated Certificate of Incorporation of the Registrant</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 9, 2014</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000110465915036849/a15-7744_1ex3d4.htm"><span style="text-decoration:underline;">Certificate of Amendment of Restated Certificate of Incorporation of the Registrant</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 11, 2015</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.4</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.5</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000110465916160637/a16-22576_1ex3d1.htm"><span style="text-decoration:underline;">Certificate of Amendment of Restated Certificate of Incorporation of the Registrant</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 5, 2016</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.6</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519168683/d759374dex31.htm"><span style="text-decoration:underline;">Certificate of Amendment of Restated Certificate of Incorporation of the Registrant</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 10, 2019</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.7</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519168683/d759374dex32.htm"><span style="text-decoration:underline;">Certificate of Amendment of Restated Certificate of Incorporation of the Registrant</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 10, 2019</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.8</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519168683/d759374dex33.htm"><span style="text-decoration:underline;">Amended and Restated Bylaws of the Registrant</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 10, 2019</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459019031056/onct-ex42_392.htm"><span style="text-decoration:underline;">Specimen of Common Stock Certificate</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 9, 2019</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000110465917063137/a17-24206_1ex4d9.htm"><span style="text-decoration:underline;">Form of Common Stock Warrant, issued by Registrant pursuant to the Purchase Agreement, dated September 25, 2017, between t</span><span style="text-decoration:underline;">he </span><span style="text-decoration:underline;">Registrant and the purchasers identified in Exhibit A therein</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-3</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-221040</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October 20, 2017</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312519099541/d722331dex411.htm"><span style="text-decoration:underline;">Form of Warrant to purchase shares of Series B-2 Preferred Stock of the Registrant</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-4</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-230758</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 8, 2019</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459019031056/onct-ex41_414.htm"><span style="text-decoration:underline;">Form of Amendment to Warrant to Purchase shares of Series B-2 Preferred Stock of the Registrant</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10-Q</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 9, 2019</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459020026567/onct-ex41_7.htm"><span style="text-decoration:underline;">Form of Common Stock Warrant, issued by the Registrant pursuant to the Securities Purchase Agreement, dated May 19, 2020, between the Registrant the purchasers signatory thereto</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 21, 2020</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312520196296/d68015dex41.htm"><span style="text-decoration:underline;">Form of Placement Agent Warrant, issued by the Registrant pursuant to the Securities Purchase Agreement, dated May 19, 2020, between the Registrant and the purchasers signatory thereto</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 21, 2020</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312520196296/d68015dex41.htm"><span style="text-decoration:underline;">Form of Common Stock Warrant, issued by the Registrant pursuant to the Securities Purchase Agreement, dated July 17, 2020, between the Registrant and the purchasers signatory thereto</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 21, 2020</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr style="height:2.7pt;">
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.8</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312520196296/d68015dex42.htm"><span style="text-decoration:underline;">Form of Placement Agent Warrant, issued by the Registrant pursuant to the Securities Purchase Agreement, dated July 17, 2020, between the Registrant and the purchasers signatory thereto</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 21, 2020</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:99.86%;">
<tr>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="4" valign="bottom" style="padding-left:3pt;padding-Right:3pt;padding-Top:0pt;padding-Bottom:0pt;width:39.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr style="height:3.6pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Exhibit</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Filing</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Herewith</p></td>
</tr>
<tr style="height:3.6pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr style="height:2.15pt;">
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1260990/000119312520236278/d32449d8k.htm"><span style="text-decoration:underline;">Form of Underwriter Warrant, issued by Registrant pursuant to the Amended and Restated Underwriting Agreement, dated August 27, 2020, between the Registrant and H.C. Wainwright &#38; Co., LLC</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 31, 2020</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.10</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312520298237/d76696dex41.htm"><span style="text-decoration:underline;">Form of Underwriter Warrant, issued by the Registrant pursuant to the Amended and Restated Underwriting Agreement, dated November 17, 2020, between the Registrant and HCW</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November 19, 2020</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.11</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000119312520315323/d67428dex41.htm"><span style="text-decoration:underline;">Form of Underwriter Warrant, issued by the Registrant pursuant to the Amended and Restated Underwriting Agreement, dated December 9, 2020, between the Registrant and HCW</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 11, 2020</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:5pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex101_249.htm"><span style="text-decoration:underline;">Office Lease between Cognac Del Mar Owner II LLC and Registrant dated March 17, 2021</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex102_247.htm"><span style="text-decoration:underline;">Non-Employee Director Compensation Policy, as amended and restated, effective March 18, 2021#</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex103_248.htm"><span style="text-decoration:underline;">Employment Transition Agreement between Frank Hsu, M.D. and Registrant, dated February 24, 2021#</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459021006178/onct-ex101_8.htm"><span style="text-decoration:underline;">Oncternal Therapeutics, Inc. 2021 Employment Inducement Incentive Award Plan#</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">000-50549</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 17, 2021</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.5</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1260990/000156459021014606/onct-ex104_89.htm"><span style="text-decoration:underline;">Form of Stock Option Grant Notice and Stock Option Agreement under the Oncternal Therapeutics, Inc. 2021 Employment Inducement Incentive Award Plan#</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-8</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-254581</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 22, 2021</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex311_8.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex312_9.htm"><span style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1*</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex321_7.htm"><span style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.2*</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="onct-ex322_6.htm"><span style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Schema Document</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:99.86%;">
<tr>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
<td colspan="4" valign="bottom" style="padding-left:3pt;padding-Right:3pt;padding-Top:0pt;padding-Bottom:0pt;width:39.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Incorporated by Reference</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&#160;</p></td>
</tr>
<tr style="height:3.6pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Exhibit</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">File Number</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of Filing</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Filed</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Herewith</p></td>
</tr>
<tr style="height:3.6pt;">
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
</tr>
<tr>
<td valign="top" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p></td>
<td valign="top" style="width:0.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:44.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:5.8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:11.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:15.28%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:2pt;padding-Top:0pt;padding-Bottom:0pt;width:7.06%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&#160;</p></td>
<td valign="bottom" style="padding-left:3pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:7.74%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:86.56%;text-indent:0%;font-size:6pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">These <span style="color:#000000;">certifications are being furnished solely to accompany this quarterly report pursuant to 18 U.S.C. Section&#160;1350, and are not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934 and are not subject to the liability of that section. These certifications are not to be incorporated by reference into any filing of Oncternal Therapeutics, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></p></td></tr></table></div>
<div style="align:left;">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">#</span></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;color:#000000;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:8pt;">Management compensatory plan or arrangement.</p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always" />
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;" id="SIGNATURES">SIGNATURES</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" style="margin:auto;border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company Name</p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 6, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;James B. Breitmeyer</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Name<span style="font-weight:normal;">: James B. Breitmeyer</span></p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Title<span style="font-weight:normal;">:&#160;&#160;President and Chief Executive Officer</span></p></td>
</tr>
<tr>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: May 6, 2021</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Richard G. Vincent</p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="middle" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Name<span style="font-weight:normal;">: Richard G. Vincent</span></p></td>
</tr>
<tr>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Title<span style="font-weight:normal;">:&#160;&#160; Chief Financial Officer</span></p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;">&#160;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>onct-ex101_249.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex101_249.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 10.1</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OFFICE LEASE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">by and between<br /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COGNAC DEL MAR OWNER II LLC,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">a Delaware limited liability company<br /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(&#8220;<font style="text-decoration:underline;">Landlord</font>&#8221;)<br /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ONCTERNAL THERAPEUTICS, INC.,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">a Delaware corporation<font style="color:#000000;"><br /></font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(&#8220;<font style="text-decoration:underline;">Tenant</font>&#8221;)<br /></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">Office lease</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS OFFICE LEASE (&#8220;<font style="text-decoration:underline;">Lease</font>&#8221;) is made between <font style="font-weight:bold;">COGNAC DEL MAR OWNER II LLC</font>, a Delaware limited liability company (&#8220;<font style="text-decoration:underline;">Landlord</font>&#8221;), and the Tenant described in <font style="font-style:italic;">Item 1</font> of the Basic Lease Provisions.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc162863176"></a><a name="_Toc515875069"></a>LEASE OF PREMISES</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord hereby leases to Tenant and Tenant hereby leases from Landlord, subject to all of the terms and conditions set forth herein, those certain premises (the &#8220;<font style="text-decoration:underline;">Premises</font>&#8221;) described in <font style="font-style:italic;">Item&#160;3</font> of the Basic Lease Provisions and as shown in the drawing attached hereto as <font style="font-style:italic;text-decoration:underline;">Exhibit&#160;A-1</font>.&nbsp;&nbsp;The Premises are located in the Building described in <font style="font-style:italic;">Item&#160;2</font> of the Basic Lease Provisions.&nbsp;&nbsp;The Building is located on that certain land (the &#8220;<font style="text-decoration:underline;">Land</font>&#8221;), which is a part of a larger tract of land owned by Landlord, all of which is improved with landscaping, parking facilities and other improvements, fixtures and common areas and appurtenances now or hereafter placed, constructed or erected on the Land, including both buildings located at 12220 &#8211; 12230 El Camino Real, San Diego, California (sometimes referred to herein as the &#8220;<font style="text-decoration:underline;">Project</font>&#8221;), as shown on the site plan attached as <font style="font-style:italic;text-decoration:underline;">Exhibit A-2</font> to this Lease.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc162863177"></a><a name="_Toc515875070"></a>BASIC LEASE PROVISIONS<br /></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tenant:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc., <font style="color:#000000;">a Delaware corporation </font>(&#8220;<font style="text-decoration:underline;">Tenant</font>&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Building:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive Center Del Mar</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12230 El Camino Real</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Diego, California&nbsp;&nbsp;92130</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Premises:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suite(s): 300</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rentable Area:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,677 square feet</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Usable Area:</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,995 square feet</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rentable Area of the Building:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,293 square feet</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rentable Area of the Project:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115,561 square feet (subject to <font style="text-decoration:underline;">Paragraph&#160;18</font>)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)&nbsp;&nbsp;Tenant&#8217;s Proportionate Share for the Building:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.1633<font style="color:#000000;">%</font> (4,677 rsf / 57,293 rsf)&nbsp;&nbsp; (See <font style="text-decoration:underline;">Paragraph&#160;3</font>)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)&nbsp;&nbsp;Tenant&#8217;s Proportionate Share for the Project:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.0472<font style="color:#000000;">%</font> (4,677 rsf/ 115,561 rsf) (See <font style="text-decoration:underline;">Paragraph&#160;3</font>)</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basic Annual Rent:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(See <font style="text-decoration:underline;">Paragraph&#160;2</font>)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:-2.45pt;;margin-right:7.69%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">*</font><font style="text-decoration:underline;color:#000000;">Months 1 - 14</font><font style="text-decoration:underline;">, inclusive</font>:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:-2.45pt;;margin-right:7.69%;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Monthly Installment:</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:7.69%;text-indent:-2.45pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;margin-right:7.69%;text-indent:-2.45pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Annual Amount:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$15,336.14<font style="color:#000000;"> (approx. </font>$3.28<font style="color:#000000;">/sq. ft. of Rentable Area/month)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$184,033.78</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:50%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Each reference to a month in the table above shall refer to a full calendar month (e.g. January 1<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup> through January 31<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup>, February 1<sup style="font-size:85%;line-height:120%;vertical-align:top">st</sup> through February 29<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>, etc.) following the Commencement Date.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Installment Payable Upon Execution:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$15,336.14</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Security Deposit Payable Upon Execution:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$15,336.14 <font style="color:#000000;">(See </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;2(c)</font><font style="color:#000000;">)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Base Year for Operating Costs:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021&nbsp;&nbsp;(See <font style="text-decoration:underline;">Paragraph&#160;3</font>)</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Initial Term:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fourteen (14) full calendar months <font style="color:#000000;">(See </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;1</font><font style="color:#000000;">)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commencement Date:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April 1, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Termination Date:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May 31, 2022</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Broker(s)<font style="font-weight:normal;"> (See </font><font style="text-decoration:underline;font-weight:normal;">Paragraph&#160;19(k)</font><font style="font-weight:normal;">):</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Broker:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cushman &amp; Wakefield</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tenant&#8217;s Broker:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Re:Align</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Parking Spaces:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Four (4)<font style="color:#000000;"> unreserved parking spaces per one thousand (1,000) square feet of Usable Area in the Premises, available to Tenant at the then-current rate generally offered to patrons of the Building, as such rate may change from time-to-time.&nbsp;&nbsp;(See </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;18</font><font style="color:#000000;">)</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Addresses for Notices:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">To:<font style="text-decoration:underline;">TENANT</font>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">To:<font style="text-decoration:underline;">LANDLORD</font>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Premises</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cognac Del Mar Owner II LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c/o PGIM Real Estate</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101 California Street, 40<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> Floor</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Francisco, CA&nbsp;&nbsp;94111</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: PRISA II Asset Manager</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">With a copy to:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cognac Del Mar Owner II LLC </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c/o PGIM Real Estate</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7 Giralda Farms</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Madison, NJ&nbsp;&nbsp;07940</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Legal</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">And</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cognac Del Mar Owner II LLC </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c/o Unire Real Estate Group, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">675 Placentia Avenue, Suite 200</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brea, CA 92821</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attn: Mark Harryman</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Place of Payment:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All payments payable under this Lease shall be sent to Landlord at P.O. Box 100398, Pasadena, CA&nbsp;&nbsp;91189--0398 (or to such other address that Landlord may later designate in writing).</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Guarantor:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date of this Lease:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The date executed by Landlord on the signature page of this Lease.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Construction Allowance:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:14.4pt;;text-indent:-14.4pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.</p></td>
<td valign="top"  style="width:40%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The &#8220;State&#8221; is the State of California.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Lease consists of the foregoing introductory paragraphs and Basic Lease Provisions, the provisions of the Standard Lease Provisions (the &#8220;<font style="text-decoration:underline;">Standard Lease Provisions</font>&#8221;) (consisting of <font style="text-decoration:underline;">Paragraphs&#160;1</font> through <font style="text-decoration:underline;">Paragraph&#160;19</font> which follow) and <font style="font-style:italic;text-decoration:underline;">Exhibits&#160;A-1</font><font style="font-style:italic;"> </font>through <font style="font-style:italic;text-decoration:underline;">Exhibit&#160;A-2</font><font style="font-style:italic;"> </font>and<font style="font-style:italic;"> </font><font style="font-style:italic;text-decoration:underline;">Exhibits&#160;B</font><font style="font-style:italic;"> </font>through<font style="font-style:italic;"> </font><font style="font-style:italic;text-decoration:underline;">Exhibit&#160;G</font><font style="font-style:italic;">,</font> all of which are incorporated herein by this reference.&nbsp;&nbsp;In the event of any conflict between the provisions of the Basic Lease Provisions and the provisions of the Standard Lease Provisions, the Standard Lease Provisions shall control.</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc162863178"></a><a name="_Toc515875071"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">STANDARD LEASE PROVISIONS</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Toc162863179"></a><a name="_Toc3448448"></a><a name="_Toc3555440"></a><a name="_Toc515875072"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">TERM</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Initial Term of this Lease and the Rent (defined below) shall commence </font>on the date set forth in <font style="font-style:italic;">Item 10</font> of the Basic Lease Provisions <font style="color:#000000;">(the &#8220;</font><font style="text-decoration:underline;color:#000000;">Commencement Date</font><font style="color:#000000;">&#8221;) and the Initial Term shall end on the last day of the fourteenth (14th) full calendar month after the Commencement Date (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Termination Date</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;Unless earlier terminated in accordance with the provisions hereof, the Initial Term of this Lease shall be the period shown in </font><font style="font-style:italic;color:#000000;">Item&#160;9</font><font style="color:#000000;"> of the Basic Lease Provisions.&nbsp;&nbsp;As used herein, &#8220;</font><font style="text-decoration:underline;color:#000000;">Lease Term</font><font style="color:#000000;">&#8221; shall mean the Initial Term referred to in </font><font style="font-style:italic;color:#000000;">Item&#160;9</font><font style="color:#000000;"> of the Basic Lease Provisions, together with any extension of the Lease Term hereof exercised or entered in accordance with the terms and conditions expressly set forth herein.&nbsp;&nbsp;This Lease shall be a binding contractual obligation effective upon execution hereof by Landlord and Tenant, notwithstanding the later commencement of the Initial Term of this Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Premises will be delivered to Tenant on the Commencement Date.&nbsp;&nbsp;If the Commencement Date is delayed or otherwise does not occur on the date, set forth in </font><font style="font-style:italic;color:#000000;">Item&#160;10</font><font style="color:#000000;"> of the Basic Lease Provisions, this Lease shall not be void or voidable, nor shall Landlord be liable to Tenant for any loss or damage resulting therefrom.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Toc162863180"></a><a name="_Toc3448449"></a><a name="_Toc3555441"></a><a name="_Toc515875073"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">BASIC ANNUAL RENT AND SECURITY DEPOSIT</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant agrees to pay during each partial or whole calendar month of the Lease Term as Basic Annual Rent (&#8220;</font><font style="text-decoration:underline;color:#000000;">Basic Annual Rent</font><font style="color:#000000;">&#8221;) for the Premises the sums shown for such periods in </font><font style="font-style:italic;color:#000000;">Item&#160;5</font><font style="color:#000000;"> of the Basic Lease Provisions.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Except as expressly provided to the contrary herein, Basic Annual Rent shall be payable in consecutive monthly installments, in advance, without demand, deduction or offset, commencing on the Commencement Date and continuing on the first day of each calendar month thereafter until the expiration of the Lease Term.&nbsp;&nbsp;The first full monthly installment of Basic Annual Rent (as set forth in </font><font style="font-style:italic;text-decoration:underline;color:#000000;">Item 6</font><font style="color:#000000;"> of the Basic Lease Provisions</font><font style="font-style:italic;color:#000000;">) </font><font style="color:#000000;">shall be payable upon Tenant&#8217;s execution of this Lease.&nbsp;&nbsp;The obligation of Tenant to pay Rent and other sums to Landlord and the obligations of Landlord under this Lease are independent obligations.&nbsp;&nbsp;If the Commencement Date is a day other than the first day of a calendar month, or the Lease Term expires on a day other than the last day of a calendar month, then the Rent for such partial month shall be calculated on a per diem basis.&nbsp;&nbsp;In the event Landlord delivers possession of the Premises to Tenant prior to the Commencement Date, Tenant agrees it shall be bound by and subject to all terms, covenants, conditions and obligations of this Lease during the period between the date possession is delivered and the Commencement Date, other than the payment of Basic Annual Rent, in the same manner as if delivery had occurred on the Commencement Date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Simultaneously with the execution of this Lease, Tenant has paid or will pay Landlord the security deposit (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Security Deposit</font><font style="color:#000000;">&#8221;) set forth in </font><font style="font-style:italic;color:#000000;">Item&#160;7</font><font style="color:#000000;"> of the Basic Lease Provisions as security for the performance of the provisions hereof by Tenant.&nbsp;&nbsp;Landlord shall not be required to keep the Security Deposit separate from its general funds and Tenant shall not be entitled to interest thereon.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If Tenant defaults with respect to any provision of this Lease, including, without limitation, the provisions relating to the payment of Rent or the cleaning of the Premises upon the termination of this Lease, or amounts which Landlord may be entitled to recover pursuant to the provisions of Section 1951.2 of the California Civil Code, Landlord may, but shall not be required to, use, apply or retain all or any part of the Security Deposit (i)&#160;for the payment of any Rent or any other sum in default, (ii)&#160;for the payment of any other amount which Landlord may spend or become obligated to spend by reason of Tenant&#8217;s default hereunder, or (iii)&#160;to compensate Landlord for any other loss or damage which Landlord may suffer by reason of Tenant&#8217;s default hereunder, including, without limitation, costs and reasonable attorneys&#8217; fees incurred by Landlord to recover possession of the Premises following a default by Tenant hereunder.&nbsp;&nbsp;If any portion of the Security Deposit is so used or applied, Tenant shall, upon demand therefor, deposit cash with Landlord in an amount sufficient to restore the Security Deposit to the appropriate amount, as determined hereunder.&nbsp;&nbsp;If Tenant shall fully perform every provision of this Lease to be performed by it (including compliance with <font style="text-decoration:underline;">Paragraph 5(c)</font> concerning the surrender condition of the Premises),, the Security Deposit or any balance thereof shall be returned to Tenant (or, at Landlord&#8217;s option, to the last assignee of Tenant&#8217;s interest hereunder) within sixty&#160;(60) days following the expiration of the Lease Term; provided, however, that Landlord may retain the Security Deposit until such time as any amount due from Tenant in accordance with <font style="text-decoration:underline;">Paragraph&#160;3</font> below has been </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determined and paid to Landlord in full.&nbsp;&nbsp;Tenant hereby waives the provisions of Section 1950.7 of the California Civil Code.&nbsp;&nbsp;Tenant also waives all provisions of law, now or hereafter in force, which provide that Landlord may claim from a security deposit only those sums reasonably necessary to remedy defaults in the payment of rent, to repair damage caused by Tenant or to clean the Premises, it being agreed that Landlord may, in addition, claim those sums reasonably necessary to compensate Landlord for any other loss or damage, foreseeable or unforeseeable, caused by the act or omission of Tenant or any Tenant Parties (as defined in </font><font style="text-decoration:underline;">Paragraph 6(g)(</font><font style="text-decoration:underline;">i</font><font style="text-decoration:underline;">) </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">below).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The parties agree that for all purposes hereunder the Premises and the Building shall be stipulated to contain the number of square feet of Rentable Area and the number of square feet of Usable Area described in </font><font style="font-style:italic;color:#000000;">Item&#160;3</font><font style="color:#000000;"> of the Basic Lease Provisions, based upon the Standard Method for Measuring Floor Area in Office Buildings (ANSI/BOMA Z65.1, 1996).&nbsp;&nbsp;Tenant has inspected the Premises and is fully familiar with the scope and size thereof.&nbsp;&nbsp;Tenant agrees to pay the full Basic Annual Rent and Additional Rent (defined below) set forth in this Lease in consideration for the use and occupancy of said space, regardless of the actual number of square feet contained therein, and Tenant shall have no right to terminate this Lease or receive any adjustment or rebate of any Basic Annual Rent or Additional Rent payable hereunder if the amount set forth in </font><font style="font-style:italic;text-decoration:underline;color:#000000;">Item&#160;3</font><font style="color:#000000;"> is incorrect.&nbsp;&nbsp;Notwithstanding the foregoing, at Landlord&#8217;s election, Landlord&#8217;s space planner may verify the exact number of square feet of Rentable Area in the Premises.&nbsp;&nbsp;In the event Landlord&#8217;s space planner determines that there is a variation from the number of square feet specified in </font><font style="font-style:italic;color:#000000;">Item&#160;3</font><font style="color:#000000;"> of the Basic Lease Provisions, Landlord and Tenant shall execute an amendment to this Lease for the purpose of making appropriate adjustments to the Basic Annual Rent, the Security Deposit, Tenant&#8217;s Proportionate Share and such other provisions hereof as shall be appropriate under the circumstances.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Toc162863181"></a><a name="_Toc3448450"></a><a name="_Toc3555442"></a><a name="_Toc515875074"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">ADDITIONAL RENT</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If Operating Costs (defined below) for the Project for any calendar year during the Lease Term exceed Base Operating Costs (defined below), Tenant shall pay to Landlord as Additional Rent an amount equal to Tenant&#8217;s Proportionate Share (defined below) of such excess.&nbsp;&nbsp;</font><font style="text-decoration:none;color:#auto;">Tenant shall also pay to Landlord as Additional Rent an amount equal to Tenant&#8217;s Proportionate Share of Electricity Utility Charges (defined below) for the Project.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_DV_M28"></a><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="text-decoration:underline;color:#000000;">Tenant&#8217;s Proportionate Share</font><font style="color:#000000;">&#8221; is, subject to the provisions of </font><font style="text-decoration:underline;color:#000000;">Paragraph 18</font><font style="color:#000000;">, the percentage number described in </font><font style="text-decoration:underline;font-style:italic;color:#000000;">Item 4</font><font style="color:#000000;"><a name="_DV_M28"></a> of the Basic Lease Provisions.&nbsp;&nbsp;Tenant&#8217;s Proportionate Share represents a fraction, the numerator of which is the number of square feet of Rentable Area in the Premises and the denominator of which is the number of square feet of Rentable Area in the Building or Project, as applicable.&nbsp;&nbsp;To the extent the applicable Operating Costs or Electricity Utility Charges are attributed by Landlord solely to the Building (rather than to the entire Project), then Tenant&#8217;s Proportionate Share,</font><font style="font-size:11pt;font-family:Calibri;color:#000000;"> </font><font style="color:#000000;">with respect to such Operating Costs or Electricity Utility Charges, shall, at Landlord&#8217;s election, be a fraction, the numerator of which is the number of square feet of Rentable Area in the Premises and the denominator of which is the number of square feet of Rentable Area in the Building</font><font style="text-decoration:none;color:#000000;">.</font><font style="color:#000000;"> To the extent the applicable Operating Costs or Electricity Utility Charges are attributed by Landlord to the entire Project, then Tenant&#8217;s Proportionate Share,</font><font style="font-size:11pt;font-family:Calibri;color:#000000;"> </font><font style="color:#000000;">with respect to such Operating Costs or Electricity Utility Charges, shall, at Landlord&#8217;s election, be a fraction, the numerator of which is the number of square feet of Rentable Area in the Premises and the denominator of which is the number of square feet of Rentable Area in the Project, as determined by Landlord pursuant to </font><font style="text-decoration:underline;color:#000000;">Paragraph 18</font><font style="text-decoration:none;color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="text-decoration:underline;color:#000000;">Electricity Utility Charges</font><font style="color:#000000;">&#8221; means the cost of electricity serving the Premises and the Project, together with the costs (amortized on a straight line basis over the useful life) incurred by Landlord for capital improvements, capital replacements, capital equipment and capital tools reasonably intended by Landlord to produce a reduction in energy consumption and/or effect other economies in the operation of the Project.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_DV_C21"></a><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="text-decoration:underline;color:#000000;">Base Operating Costs</font><font style="color:#000000;"><a name="_DV_C21"></a>&#8221; means all Operating Costs incurred or payable by Landlord during the calendar year specified as Tenant&#8217;s Base Year for Operating Costs in </font><font style="font-style:italic;text-decoration:underline;color:#000000;">Item 8</font><font style="color:#000000;"> of the Basic Lease Provisions.&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="text-decoration:underline;color:#000000;">Operating Costs</font><font style="color:#000000;">&#8221; means all costs, expenses and obligations incurred or payable by Landlord in connection with the operation, ownership, management, repair or maintenance of the Building and the Project during or allocable to the Lease Term, including without limitation, the following:</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_DV_C31"></a><font style="text-decoration:none;Background-color:#auto;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The cost of services provided to the Premises, the Building or the Project, including, without limitation:</font><font style="font-family:Arial;color:#000000;"> (</font><font style="color:#000000;">except to the extent paid by Tenant as part of Electricity Utility Charges) water and sewer charges and the costs of electricity, heating, ventilating, air conditioning and other utilities, and utilities surcharges and any other costs, levies or assessments resulting from statutes or regulations promulgated by any government authority in connection with the use or occupancy of the Project or the parking facilities serving the Project;&nbsp;&nbsp;supplies, equipment, tools, materials, service contracts, window cleaning, maintenance and repair of sidewalks and Building exterior and services areas, gardening and landscaping; except to the extent paid by Tenant as part of Electricity Utility Charges, waste disposal and janitorial services; the cost of compensation, including employment, welfare and social security taxes, paid vacation days, disability, pension, medical and other fringe benefits of all persons (including independent contractors) who perform services connected with the operation, maintenance, repair or replacement of the Project; any association assessments, costs, dues and/or expenses relating to the Project, personal property taxes on and maintenance and repair of equipment and other personal property used in connection with the operation, maintenance or repair of the Project; repair and replacement of window coverings provided by Landlord in the premises of tenants in the Project; such reasonable auditors&#8217; fees and legal fees as are incurred in connection with the operation, maintenance or repair of the Project; administration fees; a property management fee and rent for the property management office (which fee and rent may be imputed if Landlord has internalized management or otherwise acts as its own property manager, or does not charge its third-party property manager rent); the maintenance of any easements or ground leases benefiting the Project, whether by Landlord or by an independent contractor; costs allocated by agreements between the owners of the Building or Project; a reasonable allowance for depreciation of personal property used in the operation, maintenance or repair of the Project; license, permit and inspection fees; all costs and expenses required by any governmental or quasi-governmental authority or by applicable law, for any reason, including capital improvements, whether capitalized or not, and the cost of any capital improvements made to the Project by Landlord that improve life-safety systems, reduce operating expenses or are reasonably intended to maintain the Building&#8217;s status as a Class A property, and the costs to replace items which Landlord would be obligated to maintain under the Lease (such costs to be amortized over such reasonable periods as Landlord shall reasonably determine together with interest thereon at the rate of ten percent&#160;(10%) per annum or such other rate as may have been paid by Landlord on funds borrowed for the purpose of funding such improvements); the cost of air conditioning, heating, ventilating, plumbing, elevator maintenance and repair (to include the replacement of components) and other mechanical and electrical systems repair and maintenance; sign maintenance; and Common Area (defined below) repair, resurfacing, operation and maintenance; the reasonable cost for temporary lobby displays and events commensurate with the operation of a similar class building,&nbsp;&nbsp;the cost of providing security services, if any, deemed appropriate by Landlord; Taxes (as defined below); and all costs and expenses for insurance for the Project, including, but not limited to, public liability, fire, property damage, wind, hurricane, earthquake, terrorism, flood, rental loss, rent continuation, boiler machinery, business interruption, contractual indemnification and All Risk, Causes of Loss&#160;</font><font style="color:#000000;"><a name="_DV_C31"></a>&#8209;&#160;Special Form coverage insurance for up to the full replacement cost of the Project and such other insurance as is customarily carried by operators of other similar class office buildings in the city in which the Project is located, to the extent carried by Landlord in its discretion, and the deductible portion of any insured loss otherwise covered by such insurance</font><font style="color:#000000;">.</font><font style="color:#000000;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_DV_M30"></a><a name="_DV_M31"></a><a name="_DV_C32"></a><a name="_DV_M33"></a><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">&#8220;</font><font style="text-decoration:underline;color:#000000;">Taxes</font><font style="color:#000000;"><a name="_DV_M30"></a>&#8221; means any and all forms<a name="_DV_M31"></a> of assessment, license fee, license tax, business license fee, commercial rental tax, levy, charge, improvement bond, tax, water and sewer rents and charges, utilities and communications taxes and charges or similar or dissimilar imposition imposed by any authority having the direct power to tax, including any city, county, state or federal government, or any school, agricultural, lighting, drainage or other improvement or special assessment district thereof, or any other governmental charge, general and special, ordinary and extraordinary, foreseen and unforeseen, which may be assessed <a name="_DV_C32"></a> against any legal or equitable interest of Landlord in the Premises, Building, Common Areas or Project<a name="_DV_M33"></a>. Taxes shall also include, without limitation:&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_DV_M35"></a><font style="Background-color:#auto;text-decoration:none;">(A)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any tax on Landlord&#8217;s &#8220;right&#8221; to rent or &#8220;right&#8221; to other income from the Premises or as against Landlord&#8217;s business of leasing the <a name="_DV_M35"></a>Premises; </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_DV_M36"></a><font style="text-decoration:none;Background-color:#auto;">(B)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_DV_M36"></a>any assessment, tax, fee, levy or charge in substitution, partially or totally, of any assessment, tax, fee, levy or charge previously included within the definition of real property tax, it being acknowledged by Tenant and Landlord that Proposition 13 was adopted by the voters of the State of California in the June, 1978 election and that assessments, taxes, fees, levies and charges may be imposed by governmental agencies for such services as fire protection, street, sidewalk and road maintenance, refuse removal and for other governmental services formerly provided without charge to property owners or occupants.&nbsp;&nbsp;It is the intention of Tenant and Landlord that all such new and increased assessments, taxes, fees, levies and charges be included within the definition of &#8220;</font><font style="color:#000000;">Taxes&#8221; for the purposes of this </font><font style="color:#000000;">Lease;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_DV_M37"></a><font style="Background-color:#auto;text-decoration:none;">(C)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any assessment, tax, fee, levy or charge allocable to or measured by the area of the Premises or other premises in the Building or the rent payable by Tenant hereunder or other tenants of the Project, including, without limitation, any gross receipts tax or excise tax levied by state, city or federal government, or any political subdivision thereof, with respect to the receipt of such rent, or upon or with respect to the possession, leasing, operation, management, maintenance, alteration, repair, use or occupancy by Tenant of the Premises, or any portion thereof but not on Landlord&#8217;s other operations;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_DV_M38"></a><font style="Background-color:#auto;text-decoration:none;">(D)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any assessment, tax, fee, levy or charge upon this transaction or any document to which Tenant is a party, creating or transferring an interest or an estate in the Premises; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_DV_M39"></a><a name="_DV_M40"></a><font style="Background-color:#auto;text-decoration:none;">(E)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any assessment, tax, fee, levy<a name="_DV_M40"></a> or charge by any governmental agency related to any transportation plan, fund or system (including assessment districts) instituted within the geographic area of which the Project is a part; and/or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_DV_M41"></a><font style="Background-color:#auto;text-decoration:none;">(F)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_DV_M41"></a>any costs and expenses (including, without limitation, reasonable attorneys&#8217; fees) incurred in attempting to protest, reduce or minimize Taxes.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding anything herein to the contrary, the following items shall be excluded from Operating Costs and Taxes:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(A)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">interest, principal, points and fees on debt or amortization payments on any mortgages or deeds of trust or any other debt for borrowed money, unless such costs are directly attributable to Tenant&#8217;s, its agents&#8217; or employees&#8217; activities in, on or about the Project, or as a result of a Tenant&#8217;s breach or default under this Lease;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(B)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">leasing commissions, attorneys&#8217; fees, costs and disbursements and other expenses incurred in connection with leasing, renovating or improving vacant premises (including permit, license and inspection fees) in the Project for lease by specific tenants or prospective tenants of the Project;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(C)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">legal fees or other expenses incurred in connection with disputes with other tenants in the Project;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(D)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">advertising and promotional expenditures except for (i) the Building directory and interior signs identifying any retail use tenants and signage for various equipment room and Common Areas, and (ii) costs of signs in, on, or outside the Building identifying the owner or any tenant of the Building;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(E)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">all items and services for which Tenant or other tenants reimburse Landlord outside of Operating Costs;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(F)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">costs of repairs, replacements, or other work occasioned by fire, windstorm or other casualty to the extent that Landlord is actually reimbursed by insurance proceeds (however any deductible Landlord is required to pay with respect to any of the foregoing shall be included in Operating Costs);</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(G)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">penalties and interest due to a violation of Law by Landlord relating to the Building (but this provision does not relieve Tenant of liability for penalties or interest incurred due to violations of Law by Tenant</font><font style="color:#000000;">);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(H)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">cost of correcting defects in the design, construction or equipment of the Building or the Project (except the conditions resulting from ordinary wear and tear and use, which shall not be deemed defects for purposes of this category); </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(I)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">except for the costs of capital improvements expressly set forth in this </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;3(e)(i)</font><font style="color:#000000;"> above, the cost of any item that, under generally accepted accounting principles, are properly classified as capital expenses; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(J)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Landlord&#8217;s charitable or political contributions; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(K)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">costs (including permit, license and inspection fees) incurred in renovating or otherwise improving or decorating, painting or redecorating Rentable Area;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(L)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> any cost representing an amount paid to an employee or affiliate of Landlord that is in excess of the commercially reasonable range of amounts that are customarily paid for such product or service in arm&#8217;s-length transactions to third-parties of comparable skill, competence, stature, and reputation; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(M)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Landlord&#8217;s general corporate overhead expenses for services related solely to the corporate legal and tax filings of the Landlord entity and not related to the Building or Project or the operation or management thereof or the revenues or services generated or related thereto (e.g. the fees paid to Landlord&#8217;s property manager shall be expressly includable within Operating Costs); </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(N)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">salaries or other compensation paid to employees of Landlord above the grade of senior property manager (however compensation paid to the property manager, whether an employee or agent of Landlord shall be expressly included), and the salary and compensation of the senior property manager shall be prorated over the portfolio of buildings being managed by an asset manager;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(O)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Landlord&#8217;s costs of any services sold to tenants for which Landlord is actually reimbursed by such tenants as a separate, additional charge or rental over and above the Basic Annual Rent and Operating Costs payable under the lease with such tenant or other occupant; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(P)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">late fees, interest, penalties or charges incurred by Landlord due to Landlord&#8217;s negligent late payment of expenses and Taxes, except to the extent attributable to Tenant&#8217;s actions or inactions; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(Q)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">costs incurred:&nbsp;&nbsp;(i)&#160;to comply with applicable Laws with respect to any Hazardous Materials that were in existence in, on, under or about the Project (or any portion thereof) prior to the Date of this Lease and not caused by Tenant or Tenant Parties (defined herein), and were of such a nature that a federal, state or municipal governmental or quasi-governmental authority, if it had then had knowledge of the presence of such Hazardous Materials, in the state, and under the conditions that they then existed in, on, under or about the Project, would have then required the removal, remediation or other action with respect thereto; and/or (ii)&#160;with respect to Hazardous Materials that are disposed of or otherwise introduced into, on, under or about the Project after the Date of this Lease by Landlord or Landlord's agents, employees, contractors or licensees (including any other tenants of the Building) and are of such a nature, at time of disposition or introduction, that a federal, state or municipal governmental or quasi-governmental authority, if it had then had knowledge of the presence of such Hazardous Materials, in the state, and under the conditions, that they then existed in, on, under or about the Project, would have then required the removal, remediation or other action with respect thereto;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(R)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">costs for acquisition of (as contrasted with the maintenance or rental of) sculptures, paintings, or other objects of art; and</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:15.38%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(S)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any depreciation or amortization of the Project except as expressly permitted herein.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_DV_C51"></a><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Operating Costs and Electricity Utility Charges for any calendar year during which actual occupancy of the Project is less than ninety&#8209;five percent&#160;(95%) of the Rentable Area of the Project shall be appropriately adjusted to reflect ninety<a name="_DV_C51"></a>&#8209;five percent&#160;(95%) occupancy of the existing Rentable Area of the Project during such period.&nbsp;&nbsp;In determining Operating Costs and Electricity Utility Charges, if any services or utilities are separately charged to tenants of the Project or others, Operating Costs or Electricity Utility Charges, as applicable, shall be adjusted by Landlord to reflect the amount of expense which would have been incurred for such services or utilities on a full time basis for normal Project operating hours.&nbsp;&nbsp;Operating Costs </font><font style="text-decoration:none;color:#auto;">for the Base Year </font><font style="color:#000000;">(as defined in </font><font style="font-style:italic;color:#000000;">Item 8</font><font style="color:#000000;"> of the Basic Lease Provisions) shall not include (i) Operating Costs attributable to temporary market-wide labor-rate increases and/or utility rate increases due to extraordinary circumstances, including, but not limited to Force Majeure, conservation surcharges, boycotts, embargoes, or other shortages, (ii) one-time special assessments, charges, costs or fees or extraordinary charges or costs incurred in the Base Year only, or (iii) amortization of any capital items including, but not limited to, capital improvements, capital repairs and capital replacements (including such amortized costs where the actual improvement, repair or replacement was made in prior years).&nbsp;&nbsp;In addition, if in any calendar year subsequent to the Base Year, the amount of Operating Costs decreases due to a reduction in the cost of providing utilities, security and/or other services to the Project for any reason, including without limitation, because of deregulation of the utility industry and/or reduction in rates achieved in contracts with utilities and/or service providers, then for purposes of the calendar year in which such decrease in Operating Costs occurred and all subsequent calendar years, the Operating Costs for the Base Year shall be decreased by an amount equal to such decrease.&nbsp;&nbsp;In the event (i)&#160;the Commencement Date shall be a date other than January&#160;1, (ii)&#160;the date fixed for the expiration of the Lease Term shall be a date other than December&#160;31, (iii)&#160;of any early termination of this Lease, or (iv)&#160;of any increase or decrease in the size of the Premises, then in each such event, an appropriate adjustment in the application of this </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;3</font><font style="color:#000000;"> shall, subject to the provisions of this Lease, be made to reflect such event on a basis determined by Landlord to be consistent with the principles underlying the provisions of this </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;3</font><font style="color:#000000;">. In addition, Landlord shall have the right, from time to time, to equitably allocate and prorate some or all of the Operating Costs or Electricity Utility Charges among different tenants and/or different buildings of the Project and/or on a building-by-building basis (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Cost Pools</font><font style="color:#000000;">&#8221;), adjusting Tenant&#8217;s Proportionate Share as to each of the separately allocated costs based on the ratio of the Rentable Area of the Premises to the Rentable Area of all of the premises to which such costs are allocated.&nbsp;&nbsp;Such Cost Pools may include, without limitation, the office space tenants and retail space tenants of the buildings in the Project.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_DV_C54"></a><a name="_DV_M71"></a><a name="_DV_C55"></a><a name="_DV_M72"></a><a name="_DV_C56"></a><a name="_DV_M73"></a><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_DV_C54"></a>Prior to the commencement of each calendar year of the Lease Term following the Commencement Date, Landlord shall have the right to give to Tenant a written estimate of Tenant&#8217;s Proportionate Share of </font><font style="text-decoration:none;color:#auto;">(i<a name="_DV_M71"></a>) </font><font style="color:#000000;"><a name="_DV_C55"></a>the Operating Costs for the Project for the ensuing year over the Base Operating Costs</font><font style="text-decoration:none;color:#auto;"><a name="_DV_M72"></a> and (ii) the Electricity Utility Charges for the Project for the ensuing year</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant shall pay such estimated amount to Landlord in equal monthly installments, in advance on the first day of each month.&nbsp;&nbsp;Within a reasonable period after the end of each calendar year, Landlord shall furnish Tenant a statement (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Year End Statement</font><font style="color:#000000;">&#8221;) <a name="_DV_C56"></a>indicating in reasonable detail the excess of Operating Costs over Base Operating Costs,</font><font style="text-decoration:none;color:#auto;"> <a name="_DV_M73"></a>and the total Electricity Utility Charges </font><font style="color:#000000;">for such period and the parties shall, within thirty (30) days thereafter, make any payment or allowance necessary to adjust Tenant&#8217;s estimated payments to Tenant&#8217;s actual share of such excess as indicated the Year End Statement.&nbsp;&nbsp;Any payment due Landlord shall be payable by Tenant on demand from Landlord.&nbsp;&nbsp;Any amount due Tenant shall be credited against installments next becoming due under this </font><font style="text-decoration:underline;color:#000000;">Paragraph 3(f)</font><font style="color:#000000;"> or refunded to Tenant, if requested by Tenant.&nbsp;&nbsp;In no event shall Landlord be liable for &#8206;damages to Tenant based upon any incorrect or disputed Year End Statement, &#8206;nor shall Tenant have any right to terminate this Lease by reason of any incorrect or disputed &#8206;excess Operating Costs.&nbsp;&nbsp;The sole remedy of Tenant regarding any excess Operating Costs dispute shall be refund of any charge which exceeds the &#8206;amount allowed by this Lease.&nbsp;&nbsp; Tenant may, at its sole expense conduct or require a non-binding audit to be conducted of the Year End Statement, provided that (a)&#160;not more than one such audit may be conducted during any calendar year, (b)&#160;the records for each calendar year may be audited only once, (c)&#160;such audit must be commenced within sixty (60) days following Tenant's receipt of the Year End Statement, (d)&#160;such audit must be completed within one hundred twenty (120) days following Tenant's receipt of the Year End Statement (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Review Period</font><font style="color:#000000;">&#8221;), and (e) any audit must be conducted by a nationally recognized or regionally recognized accounting firm that (i) is not paid on a contingency fee basis and has at least seven (7) years of experience reviewing financial operating records of comparable buildings, (ii)&#160;is acceptable to Landlord in its reasonable discretion, (iii) together with Tenant, executes Landlord&#8217;s standard form audit confidentiality agreement, (iv) has not represented, and agrees not to represent, any other tenant of the Project in </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">connection with an audit of the Project, (v) agrees to impartially represent Landlord and Tenant in conducting the audit, and (vi) agrees to promptly provide Landlord with a copy of its audit report.&nbsp;&nbsp;If Tenant fails to commence or complete such </font><font style="color:#000000;">non-binding </font><font style="color:#000000;">audit within such time frames, it shall be deemed conclusively that the Year End Statement is correct.&nbsp;&nbsp;For purposes of any </font><font style="color:#000000;">non-binding </font><font style="color:#000000;">audit</font><font style="color:#000000;"> performed by Tenant</font><font style="color:#000000;">, Tenant shall provide Landlord with fifteen (15) days&#8217; prior written notice of its request to inspect Landlord&#8217;s books and such </font><font style="color:#000000;">non-binding </font><font style="color:#000000;">audit shall be conducted at the offices of Landlord or Landlord's managing agent during ordinary business hours, provided that any such audit must be conducted so as not to interfere with Landlord's business operations and must be reasonable as to scope and time.</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="color:#000000;">The payment of Rent may never be contingent upon the</font><font style="color:#000000;"> performance of such non-binding audit.&nbsp;&nbsp;If, </font><font style="color:#000000;">within thirty (30) days after the Review Period, Tenant notifies Landlord in writing that Tenant</font><font style="color:#000000;">&#8217;s non-binding audit has revealed a material error set forth in the Year End Statement and Landlord disputes the results of Tenant&#8217;s non-binding audit</font><font style="color:#000000;">, </font><font style="color:#000000;">then </font><font style="color:#000000;">a certification as to the proper amount shall be made</font><font style="color:#000000;"> pursuant to a binding audit</font><font style="color:#000000;">, at Tenant&#8217;s expense (except as provided hereinbelow), </font><font style="color:#000000;">performed </font><font style="color:#000000;">by an independent certified public accountant </font><font style="color:#000000;">reasonably </font><font style="color:#000000;">selected by Landlord, who meets the qualifications set forth hereinabove.&nbsp;&nbsp;Such certification by the independent certified public accountant shall be binding upon Landlord and Tenant.</font><font style="color:#000000;">&nbsp;&nbsp;</font><font style="color:#000000;">If</font><font style="color:#000000;">, pursuant to the binding audit,</font><font style="color:#000000;"> Operating Costs</font><font style="color:#000000;"> or Taxes</font><font style="color:#000000;"> are determined to have been overstated or understated by Landlord </font><font style="color:#000000;">in the Year End Statement </font><font style="color:#000000;">for any calendar year, then </font><font style="color:#000000;">Landlord shall provide to Tenant the appropriate credit (or, if the Lease Term has expired, the appropriate refund) or Tenant shall immediately make the appropriate payment to Landlord, as</font><font style="color:#000000;"> is applicable, and if Operating Costs </font><font style="color:#000000;">or Taxes </font><font style="color:#000000;">are determined to have been overstated </font><font style="color:#000000;">in the Year End Statement </font><font style="color:#000000;">by Landlord for any calendar year by in excess of five percent (5%), then Landlord shall pay the cost of the </font><font style="color:#000000;">independent certified public accountant that performed the binding audit</font><font style="color:#000000;"> described above up to a maximum amount of $2,500.&nbsp;&nbsp;Landlord may adjust Operating Costs</font><font style="color:#000000;"> or Taxes</font><font style="color:#000000;"> and submit a corrected Year End Statement to account for Operating Costs </font><font style="color:#000000;">or Taxes </font><font style="color:#000000;">that were first billed to Landlord after the date that is ten (10) business days before the date on which the Year End Statement was furnished.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">All capital levies or other taxes assessed or imposed on Landlord upon the rents payable to Landlord under this Lease and any excise, transaction, sales, gross receipts, or privilege tax, assessment, levy or charge measured by or based, in whole or in part, upon such rents from the Premises and/or the Project or any portion thereof shall be paid by Tenant to Landlord monthly in estimated installments or upon demand, at the option of Landlord, as Additional Rent to be allocated to monthly Operating Costs.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant shall pay before delinquency all taxes and assessments (i)&#160;levied against any personal property, tenant improvements or trade fixtures of Tenant in or about the Premises, (ii)&#160;based upon this Lease or any document to which Tenant is a party creating or transferring an interest in this Lease or an estate in all or any portion of the Premises, and (iii)&#160;levied for any business, professional, or occupational license fees.&nbsp;&nbsp;If any such taxes or assessments are levied against Landlord or Landlord&#8217;s property or if the assessed value of the Project is increased by the inclusion therein of a value placed upon such personal property or trade fixtures, Tenant shall upon demand reimburse Landlord for the taxes and assessments so levied against Landlord, or such taxes, levies and assessments resulting from such increase in assessed value.&nbsp;&nbsp;To the extent that any such taxes are not separately assessed or billed to Tenant, Tenant shall pay the amount thereof as invoiced to Tenant by Landlord.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_DV_M77"></a><a name="_DV_C60"></a><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Any delay or failure of Landlord in (i)&#160;delivering any estimate or statement described in this </font><font style="text-decoration:underline;color:#000000;">Paragraph 3</font><font style="color:#000000;"><a name="_DV_M77"></a><a name="_DV_C60"></a>, or (ii) computing or billing Tenant&#8217;s Proportionate Share of excess Operating Costs</font><font style="text-decoration:none;color:#auto;"> </font><font style="color:#000000;">or Tenant&#8217;s Proportionate Share of Electricity Utility Charges shall not constitute a waiver of its right to require an increase in Rent, or in any way impair, the continuing obligations of Tenant under this </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;3</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_DV_C69"></a><a name="_DV_M85"></a><a name="_DV_M86"></a><font style="Background-color:#auto;text-decoration:none;">(k)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_DV_C69"></a>Even though the Lease Term has expired and Tenant has vacated the Premises, when the final determination is made of Tenant&#8217;s Proportionate Share of excess <a name="_DV_M85"></a>Operating Costs and Tenant&#8217;s Proportionate Share of Electricity Utility Charges <a name="_DV_M86"></a>for the year in which this Lease terminates, Tenant shall immediately pay any increase due over the estimated Operating Costs and/or Electricity Utility Charges paid, and conversely, any overpayment made by Tenant shall be promptly refunded to Tenant by Landlord.&nbsp;&nbsp;The provisions of this </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;3</font><font style="color:#000000;"> shall survive any termination or expiration of this Lease. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(l)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant shall pay all sales and use tax levied or assessed against all Basic Annual Rent, Tenant&#8217;s Proportionate Share of Operating Costs and Electricity Utility Charges, and any other payments due under this Lease simultaneously with each installment of Basic Annual Rent, Tenant&#8217;s Proportionate Share of Operating Costs and Electricity Utility Charges and any other payment required hereunder.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(m)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">All Operating Costs and any other sums payable by Tenant to Landlord under this Lease (except Basic Annual Rent) shall be &#8220;</font><font style="text-decoration:underline;color:#000000;">Additional Rent</font><font style="color:#000000;">.&#8221;&nbsp;&nbsp;The Basic Annual Rent, as adjusted pursuant to </font><font style="text-decoration:underline;color:#000000;">Paragraphs 2, 3 and 7</font><font style="color:#000000;">, and other Additional Rent, are sometimes collectively referred to as, and shall constitute, &#8220;</font><font style="text-decoration:underline;color:#000000;">Rent</font><font style="color:#000000;">&#8221;.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Toc162863182"></a><a name="_Toc3448451"></a><a name="_Toc3555443"></a><a name="_Toc515875075"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">IMPROVEMENTS AND ALTERATIONS</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Landlord hereby delivers to Tenant, and Tenant hereby accepts from Landlord, the Premises in its existing &#8220;AS-IS&#8221;, &#8220;WHERE-IS&#8221; and &#8220;WITH ALL FAULTS&#8221; condition, and Tenant acknowledges that Landlord shall have no obligation to refurbish or otherwise improve the Premises after the Date of this Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Any alterations, additions, or improvements made by or on behalf of Tenant to the Premises (&#8220;</font><font style="text-decoration:underline;color:#000000;">Alterations</font><font style="color:#000000;">&#8221;) shall be subject to Landlord&#8217;s prior written consent.&nbsp;&nbsp;Tenant shall cause, at its sole cost and expense, all Alterations to comply with insurance requirements and with Laws and shall construct, at its sole cost and expense, any alteration or modification required by Laws as a result of any Alterations.&nbsp;&nbsp;All Alterations shall be constructed at Tenant&#8217;s sole cost and expense and in a good and workmanlike manner by contractors reasonably acceptable to Landlord and only good grades of materials shall be used.&nbsp;&nbsp;All plans and specifications for any Alterations shall be submitted to Landlord for its approval.&nbsp;&nbsp;Landlord may monitor construction of the Alterations.&nbsp;&nbsp;Landlord&#8217;s right to review plans and specifications and to monitor construction shall be solely for its own benefit, and Landlord shall have no duty to see that such plans and specifications or construction comply with applicable Laws.&nbsp;&nbsp;Without limiting the other grounds upon which Landlord may refuse to approve any contractor or subcontractor, Landlord may take into account the desirability of maintaining harmonious labor relations at the Project.&nbsp;&nbsp;Landlord may also require that all life safety related work and all mechanical, electrical, plumbing and roof related work be performed by contractors designated by Landlord.&nbsp;&nbsp;Landlord shall have the right, in its sole discretion, to instruct Tenant to remove any improvements or Alterations from the Premises at the expiration or earlier termination of the Lease.&nbsp;&nbsp;If, upon the termination of this Lease, Landlord requires Tenant to remove any or all of such Alterations from the Premises, then Tenant, at Tenant&#8217;s sole cost and expense, shall promptly remove such Alterations and improvements and Tenant shall repair and restore the Premises to its original condition as of the Commencement Date, reasonable wear and tear excepted.&nbsp;&nbsp;Any Alterations remaining in the Premises following the expiration of the Lease Term or following the surrender of the Premises from Tenant to Landlord, shall become the property of Landlord unless Landlord notifies Tenant otherwise.&nbsp;&nbsp;Tenant shall provide Landlord with the identities and mailing addresses of all persons performing work or supplying materials, prior to beginning such construction, and Landlord may post on and about the Premises and record any notices of non-responsibility pursuant to applicable law.&nbsp;&nbsp;Tenant shall assure payment for the completion of all work free and clear of liens and shall provide certificates of insurance for worker&#8217;s compensation and other coverage in amounts and from an insurance company reasonably satisfactory to Landlord protecting Landlord against liability for bodily injury or property damage during construction.&nbsp;&nbsp;Upon completion of any Alterations and upon Landlord&#8217;s reasonable request, Tenant shall deliver to Landlord sworn statements setting forth the names of all contractors and subcontractors who did work on the Alterations and final lien waivers from all such contractors and subcontractors.&nbsp;&nbsp;Tenant shall pay to Landlord, as Additional Rent, the reasonable costs of Landlord&#8217;s engineers and other consultants (but not Landlord&#8217;s on-site management personnel) for review of all plans, specifications and working drawings for the Alterations and for the incorporation of such Alterations in the Landlord&#8217;s master Building drawings, within ten (10) business days after Tenant&#8217;s receipt of invoices either from Landlord or such consultants together with (in any event) an administrative charge of ten percent (10%) of the actual costs of such work.&nbsp;&nbsp;In addition to such costs, Tenant shall pay to Landlord, within ten (10) business days after completion of any Alterations, the actual, reasonable costs incurred by Landlord for services rendered by Landlord&#8217;s management personnel and engineers to coordinate and/or supervise any of the Alterations to the extent such services are provided in excess of or after the normal on-site hours of such engineers and management personnel.&nbsp;&nbsp;Together with Tenant&#8217;s request for approval of any Alterations and the plans and specifications submitted to Landlord therefor, Tenant may expressly request in writing (in bold upper case letters (in 16 point font or larger) that Landlord specify whether the Alterations (or portions thereof) must be removed from the Premises upon the expiration or earlier termination of the Lease Term (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Removal Request</font><font style="color:#000000;">&#8221;), in which case Landlord shall specify such Alterations (or portions thereof) together with Landlord&#8217;s written approval thereof (if such approval is granted in accordance with the terms hereof).&nbsp;&nbsp;If Tenant delivers a Removal Request to Landlord with the information regarding the Alterations required herein, and Landlord delivers to Tenant written approval of such Alterations, and together with such approval Landlord specifies that such Alterations (or any portions thereof) are not required to be removed upon the expiration or earlier termination of this Lease, then Tenant shall not be required to remove such Alterations.&nbsp;&nbsp;Notwithstanding the foregoing, Landlord </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">shall have the right, in its sole discretion, to instruct Tenant to remove from the Premises those Alterations </font><font style="color:#000000;">that</font><font style="color:#000000;"> (</font><font style="color:#000000;">i</font><font style="color:#000000;">)&#160;were not approved</font><font style="color:#000000;"> in writing and</font><font style="color:#000000;"> in advance by Landlord, (ii)&#160;were not built in conformance with the plans and specifications approved</font><font style="color:#000000;"> in writing </font><font style="color:#000000;">by Landlord, or (iii)&#160;Landlord specified during its review of </font><font style="color:#000000;">the applicable </font><font style="color:#000000;">plans and specifications would need to be removed by Tenant upon the expiration </font><font style="color:#000000;">or earlier termination </font><font style="color:#000000;">of this Lease.</font><font style="color:#000000;"> However, Tenant will have no obligation to remove, replace or modify any tenant improvements existing as of the Date of this Lease nor will Tenant be obligated to restore the Premises to a condition pre-existing the Date of this Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant shall keep the Premises, the Building and the Project free from any and all liens arising out of any Alterations, work performed, materials furnished, or obligations incurred by or for Tenant.&nbsp;&nbsp;In the event that Tenant shall not, within ten&#160;(10) days following the imposition of any such lien, cause the same to be released of record by payment or posting of a bond in a form and issued by a surety acceptable to Landlord, Landlord shall have the right, but not the obligation, to cause such lien to be released by such means as it shall deem proper (including payment of or defense against the claim giving rise to such lien); in such case, Tenant shall reimburse Landlord for all amounts so paid by Landlord in connection therewith, together with all of Landlord&#8217;s costs and expenses, with interest thereon at the Default Rate (defined below) and Tenant shall indemnify and defend each and all of the Landlord Indemnitees (defined below) against any damages, losses or costs arising out of any such claim.&nbsp;&nbsp;Tenant&#8217;s indemnification of Landlord contained in this Paragraph shall survive the expiration or earlier termination of this Lease.&nbsp;&nbsp;Such rights of Landlord shall be in addition to all other remedies provided herein or by law.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">NOTICE IS HEREBY GIVEN THAT LANDLORD SHALL NOT BE LIABLE FOR ANY LABOR, SERVICES OR MATERIALS FURNISHED OR TO BE FURNISHED TO TENANT, OR TO ANYONE HOLDING THE PREMISES THROUGH OR UNDER TENANT, AND THAT NO MECHANICS&#8217; OR OTHER LIENS FOR ANY SUCH LABOR, SERVICES OR MATERIALS SHALL ATTACH TO OR AFFECT THE INTEREST OF LANDLORD IN THE PREMISES.&nbsp;&nbsp;</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Toc162863183"></a><a name="_Toc3448452"></a><a name="_Toc3555444"></a><a name="_Toc515875076"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">REPAIRS</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Landlord shall keep the Common Areas of the Building and the Project in a clean and neat condition.&nbsp;&nbsp;Subject to </font><font style="text-decoration:underline;color:#000000;">subparagraph&#160;(b)</font><font style="color:#000000;"> below, Landlord shall make all necessary repairs, within a reasonable period following receipt of notice of the need therefor from Tenant, to the exterior walls, exterior doors, exterior locks on exterior doors and windows of the Building, and to the Common Areas and to public corridors and other public areas of the Project not constituting a portion of any tenant&#8217;s premises and shall use reasonable efforts to keep all Building standard equipment used by Tenant in common with other tenants in good condition and repair and to replace same at the end of such equipment&#8217;s normal and useful life, reasonable wear and tear and casualty loss excepted.&nbsp;&nbsp;Except as expressly provided in </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;9</font><font style="color:#000000;"> of this Lease, there shall be no abatement of Rent and no liability of Landlord by reason of any injury to or interference with Tenant&#8217;s business arising from the making of any repairs, alterations or improvements in or to any portion of the Premises, the Building or the Project.&nbsp;&nbsp;Tenant waives the right to make repairs at Landlord&#8217;s expense under any law, statute or ordinance now or hereafter in effect (including the provisions of California Civil Code Section 1942 and any successive sections or statutes of a similar nature).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant, at its expense, (i)&#160;shall keep the Premises and all fixtures and equipment contained therein in a safe, clean and neat condition, and (ii)&#160;shall bear the cost of maintenance and repair, by contractors selected by Landlord, of all facilities which are not expressly required to be maintained or repaired by Landlord and which are located in the Premises, including, without limitation, lavatory, shower, toilet, wash basin and kitchen facilities and supplemental heating and air conditioning systems (including all plumbing connected to said facilities or systems installed by or on behalf of Tenant or existing in the Premises at the time of Landlord&#8217;s delivery of the Premises to Tenant).&nbsp;&nbsp;Tenant shall make all repairs to the Premises not required to be made by Landlord under </font><font style="text-decoration:underline;color:#000000;">subparagraph&#160;(a)</font><font style="color:#000000;"> above with replacements of any materials to be made by use of materials of equal or better quality.&nbsp;&nbsp;Tenant shall do all decorating, remodeling, alteration and painting required by Tenant during the Lease Term.&nbsp;&nbsp;Tenant shall pay for the cost of any repairs to the Premises, the Building or the Project made necessary by any negligence or willful misconduct of Tenant or any of its assignees, subtenants, employees or their respective agents, representatives, contractors, or other persons permitted in or invited to the Premises or the Project by Tenant.&nbsp;&nbsp;If Tenant fails to make such repairs or replacements within fifteen&#160;(15) days after written notice from Landlord, Landlord may at its option </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">make such repairs or replacements, and Tenant shall upon demand pay Landlord for the cost thereof, together with an administration fee equal to fifteen percent&#160;(15%) of such costs.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Upon the expiration or earlier termination of this Lease, Tenant shall surrender the Premises in a safe, clean and neat condition, normal wear and tear excepted.&nbsp;&nbsp;Prior to the expiration or earlier termination of this Lease, Tenant shall remove from the Premises (i) all trade fixtures, furnishings and other personal property of Tenant, except as otherwise set forth in </font><font style="text-decoration:underline;color:#000000;">Paragraph 4(b)</font><font style="color:#000000;"> of this Lease, and (ii) all computer and phone cabling and wiring from the Premises, and Tenant shall repair all damage caused by such removal, and shall restore the Premises to its original condition, reasonable wear and tear excepted.&nbsp;&nbsp;In addition to all other rights Landlord may have, in the event Tenant does not so remove any such fixtures, furnishings or personal property, Tenant shall be deemed to have abandoned the same, in which case Landlord may store or dispose of the same at Tenant&#8217;s expense, appropriate the same for itself, and/or sell the same in its discretion.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">6.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Toc162863184"></a><a name="_Toc3448453"></a><a name="_Toc3555445"></a><a name="_Toc515875077"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">USE OF PREMISES</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant shall use the Premises only for general office uses and shall not use the Premises or permit the Premises to be used for any other purpose.&nbsp;&nbsp;Landlord shall have the right to deny its consent to any change in the permitted use of the Premises in its sole and absolute discretion.&nbsp;&nbsp;Tenant shall not at any time use or occupy the Premises, or suffer or permit anyone to use or occupy the Premises, or permit anything to be done in the Premises, in any manner that:&nbsp;&nbsp;(i)&#160;violates the certificate of occupancy for the Premises or for the Building, (ii) involves the operation of any division, agency or bureau of the United States, of any state or local government, of any foreign government, or of any subdivision thereof, (iii) involves gambling in any form, or the use of lottery, gaming or arcade devices, (iv)&#160;involves the sale, rental or viewing of pornographic, obscene or &#8220;adult materials,&#8221; or involves adult entertainment of any kind, (v)&#160;otherwise impairs the character, reputation or appearance of the Building as a first-class Building; (vi)&#160;impairs the proper and economic maintenance, operation and repair of the Building and/or its equipment, facilities or systems; (vii)&#160;annoys or inconveniences other tenants or occupants of the Building; or (viii)&#160;causes any labor dispute in or adjacent to the Building.&nbsp;&nbsp;Tenant shall not at any time keep pets or animals of any kind on the Premises.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant shall not at any time use or occupy the Premises, or permit any act or omission in or about the Premises in violation of any covenant of record, law, statute, building or zoning code, ordinance, or governmental order, condition of approval, rule or regulation (including, but not limited to, Title III of the Americans With Disabilities Act of 1990), as well as the same may be amended and supplemented from time to time (collectively, &#8220;</font><font style="text-decoration:underline;color:#000000;">Law</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;color:#000000;">Laws</font><font style="color:#000000;">&#8221;) and Tenant shall, upon written notice from Landlord, discontinue any use of the Premises which is declared by any governmental authority to be a violation of Law.&nbsp;&nbsp;If any Law shall, by reason of the nature of Tenant&#8217;s use or occupancy of the Premises, impose any duty upon Tenant or Landlord with respect to (i)&#160;modification or other maintenance of the Premises, the Building or the Project, or (ii)&#160;the use, alteration or occupancy thereof, Tenant shall comply with such Law at Tenant&#8217;s sole cost and expense.&nbsp;&nbsp;This Lease shall be subject to and Tenant shall comply with all financing documents encumbering the Building or the Project at any time and all covenants, conditions and restrictions affecting the Premises, the Building or the Project at any time, including, but not limited to, Tenant&#8217;s execution of any subordination agreements requested by a mortgagee (which for purposes of this Lease includes any lender or grantee under a deed of trust) of the Premises, the Building or the Project.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant shall not at any time use or occupy the Premises in violation of the certificates of occupancy issued for or restrictive covenants pertaining to the Building or the Premises, and in the event that any architectural control committee or department of the State or the city or county in which the Project is located shall at any time contend or declare that the Premises are used or occupied in violation of such certificate or certificates of occupancy or restrictive covenants, Tenant shall, upon five&#160;(5) days&#8217; notice from Landlord or any such governmental agency, immediately discontinue such use of the Premises (and otherwise remedy such violation).&nbsp;&nbsp;The failure by Tenant to discontinue such use shall be considered a default under this Lease and Landlord shall have the right to exercise any and all rights and remedies provided herein or by Law.&nbsp;&nbsp;Any statement in this Lease of the nature of the business to be conducted by Tenant in the Premises shall not be deemed or construed to constitute a representation or guaranty by Landlord that such business is or will continue to be lawful or permissible under any certificate of occupancy issued for the Building or the Premises, or otherwise permitted by Law.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant shall not do or permit to be done anything which may invalidate or increase the cost of any fire, All Risk, Causes of Loss &#8211; Special Form or other insurance policy covering the Building, the Project and/or property located therein and shall comply with all rules, orders, regulations and requirements of the appropriate fire codes and ordinances or any other organization performing a similar function.&nbsp;&nbsp;In addition to all other remedies of Landlord, Landlord may require Tenant, promptly upon demand, to reimburse Landlord for the full amount of any additional premiums charged for such policy or policies by reason of Tenant&#8217;s failure to comply with the provisions of this </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;6</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant shall not in any way interfere with the rights or quiet enjoyment of other tenants or occupants of the Premises, the Building or the Project.&nbsp;&nbsp;Tenant shall not use or allow the Premises to be used for any improper, immoral, unlawful or objectionable purpose, nor shall Tenant cause, maintain, or permit any nuisance in, on or about the Premises, the Building or the Project.&nbsp;&nbsp;Tenant shall not place weight upon any portion of the Premises exceeding the structural floor load (per square foot of area) which such area was designated (and is permitted by Law) to carry or otherwise use any Building system in excess of its capacity or in any other manner which may damage such system or the Building.&nbsp;&nbsp;Tenant shall not create within the Premises a working environment with a density of greater than five (5) persons per 1,000 square feet of Rentable Area.&nbsp;&nbsp;Business machines and mechanical equipment shall be placed and maintained by Tenant, at Tenant&#8217;s expense, in locations and in settings sufficient in Landlord&#8217;s reasonable judgment to absorb and prevent vibration, noise and annoyance.&nbsp;&nbsp;Tenant shall not commit or suffer to be committed any waste in, on, upon or about the Premises, the Building or the Project.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant shall take all reasonable steps necessary to adequately secure the Premises from unlawful intrusion, theft, fire and other hazards, and shall keep and maintain any and all security devices in or on the Premises in good working order, including, but not limited to, exterior door locks for the Premises and smoke detectors and burglar alarms located within the Premises and shall cooperate with Landlord and other tenants in the Project with respect to access control and other safety matters.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">As used herein, the term &#8220;</font><font style="text-decoration:underline;color:#000000;">Hazardous Material</font><font style="color:#000000;">&#8221; means any hazardous or toxic substance, material or waste which is or becomes regulated by any local governmental authority, the State or the United States Government, including, without limitation, any material or substance which is (A)&#160;defined or listed as a &#8220;</font><font style="text-decoration:underline;color:#000000;">hazardous waste</font><font style="color:#000000;">,&#8221; &#8220;</font><font style="text-decoration:underline;color:#000000;">pollutant</font><font style="color:#000000;">,&#8221; &#8220;</font><font style="text-decoration:underline;color:#000000;">extremely hazardous waste</font><font style="color:#000000;">,&#8221; &#8220;</font><font style="text-decoration:underline;color:#000000;">restricted hazardous waste</font><font style="color:#000000;">,&#8221; &#8220;</font><font style="text-decoration:underline;color:#000000;">hazardous substance</font><font style="color:#000000;">&#8221; or &#8220;</font><font style="text-decoration:underline;color:#000000;">hazardous material</font><font style="color:#000000;">&#8221; under any applicable federal, state or local Law or administrative code promulgated thereunder, (B)&#160;petroleum, or (C)&#160;asbestos.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant agrees that all operations or activities upon, or any use or occupancy of the Premises, or any portion thereof, by Tenant, its assignees, subtenants, and their respective agents, servants, employees, invitees, representatives and contractors (collectively referred to herein as &#8220;</font><font style="text-decoration:underline;color:#000000;">Tenant Parties</font><font style="color:#000000;">&#8221;), throughout the Lease Term, shall be in all respects in compliance with all federal, state and local Laws then governing or in any way relating to the generation, handling, manufacturing, treatment, storage, use, transportation, release, spillage, leakage, dumping, discharge or disposal of any Hazardous Materials.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant agrees to indemnify, defend and hold Landlord and the Landlord Indemnitees (defined below)</font><font style="font-weight:bold;font-style:italic;color:#000000;"> </font><font style="color:#000000;">harmless for, from and against any and all claims, actions, administrative proceedings (including informal proceedings), judgments, damages, punitive damages, penalties, fines, costs, liabilities, interest or losses, including reasonable attorneys&#8217; fees and expenses, court costs, consultant fees, and expert fees, together with all other costs and expenses of any kind or nature that arise during or after the Lease Term directly or indirectly from or in connection with the presence, suspected presence, or release of any Hazardous Material in or into the air, soil, surface water or groundwater at, on, about, under or within the Premises, or any portion thereof caused by Tenant or Tenant Parties.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In the event any investigation or monitoring of site conditions or any clean-up, containment, restoration, removal or other remedial work (collectively, the &#8220;</font><font style="text-decoration:underline;color:#000000;">Remedial Work</font><font style="color:#000000;">&#8221;) is required under any applicable federal, state or local Law, by any judicial order, or by any governmental entity as the result of operations or activities upon, or any use or occupancy of any portion of the Premises by Tenant or Tenant Parties, Landlord shall perform or cause to be performed the Remedial Work in compliance with such Law or order at Tenant&#8217;s sole cost and expense.&nbsp;&nbsp;All Remedial Work shall be performed by one or more </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">contractors, </font><font style="color:#000000;">selected</font><font style="color:#000000;"> and approved by Landlord, and under the supervision of a consulting engineer, selected by Tenant and approved in advance in writing by Landlord.&nbsp;&nbsp;All costs and expenses of such Remedial Work shall be paid by Tenant, including, without limitation, the charges of such contractor(s), the consulting engineer, any costs, fees, penalties or fines imposed by any governmental entity inspecting or certifying the Remedial Work, and Landlord&#8217;s reasonable attorneys&#8217; fees and costs incurred in connection with monitoring or review of such Remedial Work.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Each of the covenants and agreements of Tenant set forth in this </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;6(g)</font><font style="color:#000000;"> shall survive the expiration or earlier termination of this Lease.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">7.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Toc162863185"></a><a name="_Toc3448454"></a><a name="_Toc3555446"></a><a name="_Toc515875078"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">UTILITIES AND SERVICES</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Provided that Tenant is not in default hereunder, Landlord shall furnish, or cause to be furnished to the Premises, the utilities and services described in </font><font style="font-style:italic;text-decoration:underline;color:#000000;">Exhibit&#160;C</font><font style="color:#000000;"> attached hereto, subject to the conditions and in accordance with the standards set forth therein and in this Lease; however, Landlord may, in its sole discretion, require that Tenant, at its sole cost and expense, obtain the electricity to be consumed at the Premises by contracting directly with utility providers, at its expense (with payments to be made by Tenant directly to Tenant&#8217;s electricity provider), in an amount to accommodate seasonal changes to permit comfortable operation of the Premises and to prevent damage to the Premises, which electrical consumption may be separately metered by Landlord.&nbsp;&nbsp;If a separate meter is not installed at Tenant's cost, such excess cost will be established by an estimate agreed upon by Landlord and Tenant, and if the parties fail to agree, as established by an independent licensed engineer. Said estimates to be reviewed and adjusted quarterly.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant agrees to cooperate fully at all times with Landlord and to comply with all regulations and requirements which Landlord may from time to time prescribe for the use of the utilities and services described herein and in </font><font style="font-style:italic;text-decoration:underline;color:#000000;">Exhibit&#160;C</font><font style="color:#000000;">.&nbsp;&nbsp;Landlord shall not be liable to Tenant for the failure of any other tenant, or its assignees, subtenants, employees, or their respective invitees, licensees, agents or other representatives to comply with such regulations and requirements.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If Tenant requires utilities or services in quantities greater than or at times other than that generally furnished by Landlord pursuant to </font><font style="font-style:italic;text-decoration:underline;color:#000000;">Exhibit&#160;C</font><font style="color:#000000;">, Tenant shall pay to Landlord, upon receipt of a written statement therefor, Landlord&#8217;s charge for such use.&nbsp;&nbsp;In the event that Tenant shall require additional electric current, water or gas for use in the Premises and if, in Landlord&#8217;s judgment, such excess requirements cannot be furnished unless additional risers, conduits, feeders, switchboards and/or appurtenances are installed in the Building, subject to the conditions stated below, Landlord may proceed to install the same at the sole cost of Tenant, payable upon demand in advance.&nbsp;&nbsp;The installation of such facilities shall be conditioned upon Landlord&#8217;s consent, and a determination that the installation and use thereof (i)&#160;shall be permitted by applicable Law and insurance regulations, (ii)&#160;shall not cause permanent damage or injury to the Building or adversely affect the value of the Building or the Project, and (iii)&#160;shall not cause or create a dangerous or hazardous condition or interfere with or disturb other tenants in the Building.&nbsp;&nbsp;Subject to the foregoing, Landlord shall, upon reasonable prior notice by Tenant, furnish to the Premises additional elevator, heating, air conditioning and/or cleaning services upon such reasonable terms and conditions as shall be determined by Landlord, including payment of Landlord&#8217;s charge therefor.&nbsp;&nbsp;In the case of any additional utilities or services to be provided hereunder, Landlord may require additional switch and metering systems to be installed so as to measure the amount of such additional utilities or services.&nbsp;&nbsp;The cost of installation, maintenance and repair thereof shall be paid by Tenant upon demand.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Landlord shall not be liable for, and Tenant shall not be entitled to, any damages, abatement or reduction of Rent, or other liability by reason of any failure to furnish any services or utilities described herein or in </font><font style="font-style:italic;text-decoration:underline;color:#000000;">Exhibit&#160;C</font><font style="color:#000000;"> for any reason (other than Landlord&#8217;s gross negligence or willful misconduct), including, without limitation, when caused by accident, breakage, water leakage, flooding, repairs, Alterations or other improvements to the Project, strikes, lockouts or other labor disturbances or labor disputes of any character, governmental regulation, moratorium or other governmental action, inability to obtain electricity, water or fuel, or any other cause beyond Landlord&#8217;s control.&nbsp;&nbsp;Tenant shall be required to cooperate with the energy conservation efforts of governmental agencies or utility suppliers or those implemented by Landlord.&nbsp;&nbsp;No such failure, stoppage or interruption of any such utility or service shall be construed as an eviction of Tenant, nor shall the same relieve Tenant from any obligation to perform any </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">covenant or agreement under this Lease.&nbsp;&nbsp;In the event of any failure, </font><font style="color:#000000;">stoppage</font><font style="color:#000000;"> or interruption thereof, Landlord shall use reasonable efforts to attempt to restore all services promptly.&nbsp;&nbsp;No representation is made by Landlord with respect to the adequacy or fitness of the Building&#8217;s ventilating, air conditioning or other systems to maintain temperatures as may be required for the operation of any computer, data processing or other special equipment of Tenant.&nbsp;&nbsp;Tenant hereby waives the provisions of California Civil Code Section 1932(1) or any other applicable existing or future law, ordinance or governmental regulation permitting the termination of this Lease due to an interruption, </font><font style="color:#000000;">failure</font><font style="color:#000000;"> or inability to provide any services.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Landlord reserves the right from time to time to make reasonable and nondiscriminatory modifications to the above standards (including, without limitation, those described in </font><font style="font-style:italic;text-decoration:underline;color:#000000;">Exhibit&#160;C</font><font style="color:#000000;">) for utilities and services.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant shall not use the Premises in any manner that will cause the Building or any part thereof not to conform with Landlord&#8217;s operations and maintenance practices for the Building, whether incorporated into the Rules and Regulations, separate written sustainability policies or otherwise implemented by Landlord, as they may be revised from time to time, addressing energy efficiency; water efficiency; recycling, composting, and waste management; indoor air quality; chemical use; and other best practices adopted by Landlord in connection with the certification of the Building issued pursuant to the applicable Green Building Standard, as hereinafter defined (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Landlord&#8217;s Sustainability Practices</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;All Alterations, additions or improvements to the Premises, to the extent permitted in this Lease, shall be in accordance with Rules and Regulations in effect with respect thereto and the requirements of Landlord&#8217;s Sustainability Practices, including the applicable Green Building Standard concerning the environmental compliance of the Building, as the same may change from time to time, and with plans and specifications meeting the requirements set forth in the Rules and Regulations and approved in advance by Landlord.&nbsp;&nbsp;Tenant acknowledges that the Building is or may be in the future be certified or rated pursuant to the U.S. EPA&#8217;s Energy Star &#174; Portfolio Manager, the Green Building Initiative&#8217;s Green Globes&#8482; building rating system, the U.S. Green Building Council&#8217;s Leadership in Energy and Environmental Design (LEED&#174;) building rating system, the ASHRAE Building Energy Quotient (BEQ), or operated to meet another standard for high performance buildings adopted by Landlord (collectively, the &#8220;</font><font style="text-decoration:underline;color:#000000;">Green Building Standard</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;In addition, as contemplated by Nonresidential Building Energy Use Disclosure Program (AB 1103) Landlord may collect and maintain records regarding energy and utilities usage at the Project.&nbsp;&nbsp;As and when requested by Landlord during the Term, to the extent reasonably available to Tenant, Tenant shall provide Landlord (in the format requested by Landlord and reasonably necessary or desirable to comply with the requirements of the applicable Green Building Standard or any commissioning or retro-commissioning of the Building&#8217;s systems or the Nonresidential Building Energy Use Disclosure Program) with data concerning Tenant&#8217;s energy consumption, water consumption, and the operation of the Building&#8217;s systems.&nbsp;&nbsp;Such data may include, without limitation, Tenant&#8217;s operating hours, the number of on-site personnel, the types of equipment used at the Building (including computer equipment, if applicable), office supply purchases, light bulb purchases, cleaning product materials (both chemicals and paper products), as applicable, and energy use and cost.&nbsp;&nbsp;Landlord may post such information to its account with the EPA&#8217;s ENERGY STAR&#174; program Portfolio Manager and disclose such information to the California Energy Commission, lenders, its constituents, consultants and advisors and prospective purchasers, investors and lenders.&nbsp;&nbsp;Landlord shall have no liability to Tenant if, once obtained, any such Green Building Standard rating or certification lapses and is not reinstated by Landlord.&nbsp;&nbsp;In addition, Landlord shall not be required to treat the information collected by Landlord pursuant to this paragraph as confidential and shall have no liability to Tenant on account of the disclosure of such information.&nbsp;&nbsp;Tenant shall continually during the Term maintain the Premises in accordance with all present and future laws, Landlord&#8217;s Sustainability Practices and the standards recommended by the Board of Fire Underwriters applicable to any work, installation, occupancy, use or manner of use by Tenant of the Premises or any part thereof, and shall, at Tenant's expense, obtain all permits, licenses and the like required by applicable law.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">8.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Toc162863186"></a><a name="_Toc3448455"></a><a name="_Toc3555447"></a><a name="_Toc515875079"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">NON-LIABILITY AND INDEMNIFICATION OF LANDLORD; INSURANCE</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Landlord shall not be liable for any injury, loss or damage suffered by Tenant or to any person or property occurring or incurred in or about the Premises, the Building or the Project from any cause, EVEN IF SUCH LIABILITIES ARE CAUSED SOLELY OR IN PART BY THE NEGLIGENCE OF ANY LANDLORD INDEMNITEE (DEFINED BELOW), BUT NOT TO THE EXTENT SUCH LIABILITIES ARE CAUSED BY THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF ANY SUCH LANDLORD INDEMNITEE (DEFINED </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">BELOW).&nbsp;&nbsp;Without limiting the foregoing, neither Landlord nor any of the Landlord Indemnitees shall be liable for and there shall be no abatement of Rent (except in the event of a casualty loss or a condemnation as set forth in </font><font style="text-decoration:underline;color:#000000;">Paragraphs&#160;9 and 10</font><font style="color:#000000;"> of this Lease) for (</font><font style="color:#000000;">i</font><font style="color:#000000;">)&#160;any damage to Tenant&#8217;s property stored with or entrusted to Landlord or the Landlord Indemnitees, (ii)&#160;loss of or damage to any property by theft or any other wrongful or illegal act, or (iii)&#160;any injury or damage to persons or property resulting from fire, explosion, falling plaster, steam, gas, electricity, water or rain which may leak from any part of the Building or the Project or from the pipes, appliances, appurtenances or plumbing works therein or from the roof, street or sub-surface or from any other place or resulting from dampness or any other cause whatsoever or from the acts or omissions of other tenants, occupants or other visitors to the Building or the Project or from any other cause whatsoever, (iv)&#160;any diminution or shutting off of light, air or view by any structure which may be erected on lands adjacent to the Building, whether within or outside of the Project, or (v)&#160;any latent or other defect in the Premises, the Building or the Project.&nbsp;&nbsp;Tenant shall give prompt notice to Landlord in the event of (1)&#160;the occurrence of a fire or accident in the Premises or in the Building, or (2)&#160;the discovery of a defect therein or in the fixtures or equipment thereof.&nbsp;&nbsp;This </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;8(a)</font><font style="color:#000000;"> shall survive the expiration or earlier termination of this Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant hereby agrees to indemnify, protect, defend and hold harmless Landlord and its designated property management company, the Designated Landlord Parties, and their respective partners, members, affiliates and subsidiaries, and all of their respective officers, directors, shareholders, employees, servants, partners, representatives, insurers and agents (collectively, &#8220;</font><font style="text-decoration:underline;color:#000000;">Landlord Indemnitees</font><font style="color:#000000;">&#8221;) for, from and against all liabilities, claims, fines, penalties, costs, damages or injuries to persons, damages to property, losses, liens, causes of action, suits, judgments and expenses (including court costs, attorneys&#8217; fees, expert witness fees and costs of investigation), of any nature, kind or description of any person or entity, directly or indirectly arising out of, caused by, or resulting from (in whole or part) (1) Tenant&#8217;s construction of or use, occupancy or enjoyment of the Premises, (2) any activity, work or other things done, permitted or suffered by Tenant and its agents and employees in or about the Premises, (3) any breach or default in the performance of any of Tenant&#8217;s obligations under this Lease, (4) any act, omission, negligence or willful misconduct of Tenant or any of its agents, contractors, employees, business invitees or licensees, or (5) any damage to Tenant&#8217;s property, or the property of Tenant&#8217;s agents, employees, contractors, business invitees or licensees, located in or about the Premises (collectively, &#8220;</font><font style="text-decoration:underline;color:#000000;">Liabilities</font><font style="color:#000000;">&#8221;); EVEN IF SUCH LIABILITIES ARE CAUSED SOLELY OR IN PART BY THE NEGLIGENCE OF ANY LANDLORD INDEMNITEE, BUT NOT TO THE EXTENT SUCH LIABILITIES ARE CAUSED BY THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF ANY SUCH LANDLORD INDEMNITEE.&nbsp;&nbsp;This </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;8(b)</font><font style="color:#000000;"> shall survive the expiration or earlier termination of this Lease.&nbsp;&nbsp;Tenant hereby waives the provisions of any present or future law &#8206;that limits or eliminates the liability of an employer regarding claims for indemnity and/or &#8206;contribution by Landlord in the event of injury or death of an &#8206;employee.&nbsp;&nbsp;This </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;8(b)</font><font style="color:#000000;"> shall survive the expiration or earlier termination of this Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant shall promptly advise Landlord in writing of any action, administrative or legal proceeding or investigation as to which this indemnification may apply, and Tenant, at Tenant&#8217;s expense, shall assume on behalf of each and every Landlord Indemnitee and conduct with due diligence and in good faith the defense thereof with counsel reasonably satisfactory to Landlord; provided, however, that any Landlord Indemnitee shall have the right, at its option, to be represented therein by advisory counsel of its own selection and at its own expense.&nbsp;&nbsp;In the event of failure by Tenant to fully perform in accordance with this Paragraph, Landlord, at its option, and without relieving Tenant of its obligations hereunder, may so perform, but all costs and expenses so incurred by Landlord in that event shall be reimbursed by Tenant to Landlord, together with interest on the same from the date any such expense was paid by Landlord until reimbursed by Tenant, at the rate of interest provided to be paid on judgments, by the law of the jurisdiction to which the interpretation of this Lease is subject.&nbsp;&nbsp;The indemnification provided in </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;8(b)</font><font style="color:#000000;"> shall not be limited to damages, compensation or benefits payable under insurance policies, workers&#8217; compensation acts, disability benefit acts or other employees&#8217; benefit acts.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Insurance</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant at all times during the Lease Term shall, at its own expense, keep in full force and effect (A)&#160;commercial general liability insurance providing coverage on an occurrence form against bodily injury and disease, including death resulting therefrom, bodily injury and property damage, and premises operations, products/completed operations hazard and contractual coverage (including for the performance of its indemnity obligations set forth in this </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;8</font><font style="color:#000000;"> and in </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;6(g)(ii)</font><font style="color:#000000;"> of this Lease), to a </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">combined single limit of $1,000,000 to one or more than one person as the result of any one accident or occurrence, $2,000,000 General Aggregate and $2,000,000 Completed Operations Aggregate, with a deductible or self-insured retention under such policy not to exceed $10,000.00, (B)&#160;worker&#8217;s compensation insurance to the statutory limit, if any, and employer&#8217;s liability insurance to the limit of $1,000,000 per occurrence, (C)&#160;All Risk or Causes of Loss &#8211; Special Form property insurance, including fire and extended coverage, earthquake, sprinkler leakage, theft, vandalism, malicious mischief, glass breakage, and flood coverage, covering full replacement value of all of Tenant&#8217;s personal property, trade fixtures and improvements in the Premises, with a maximum deductible of $25,000.00, (D) Business Interruption Insurance/Loss of Rents for all perils required to be covered by the property insurance set forth in </font><font style="text-decoration:underline;color:#000000;">clause&#160;(C)</font><font style="color:#000000;"> herein above on an actual loss sustained basis in an amount equal to one hundred percent (100%) of the projected gross revenue from the Premises (less non-continuing expenses) for a minimum period of restoration of eighteen (18) months plus an extended period of indemnity endorsement of at least twelve (12) months, (E) Equipment Breakdown (also known as boiler and machinery) Insurance, if applicable, on terms consistent with the property insurance set forth in </font><font style="text-decoration:underline;color:#000000;">clause (C)</font><font style="color:#000000;"> herein above, (F) Business Automobile Liability Insurance for all owned, hired, and non-owned in an amount of not less than $1,000,000 combined single limit each accident, and (G)&#160;Umbrella / Excess Liability Insurance in an amount of not less than $5,000,000.00.&nbsp;&nbsp;Landlord (Cognac Del Mar Owner II LLC), Landlord&#8217;s agent, Landlord&#8217;s property manager, mortgagee, and Designated Landlord Parties (defined below) shall be named additional insureds on each of said policies (excluding the worker&#8217;s compensation policy) and said policies shall be issued by an insurance company or companies authorized to do business in California and which have policyholder ratings not lower than &#8220;A-&#8221; and financial ratings not lower than &#8220;VIII&#8221; in Best&#8217;s Insurance Guide (latest edition in effect as of the Date of Lease and subsequently in effect as of the date of renewal of the required policies).&nbsp;&nbsp;EACH OF SAID POLICIES SHALL ALSO INCLUDE A WAIVER OF SUBROGATION PROVISION OR ENDORSEMENT IN FAVOR OF LANDLORD, AND AN ENDORSEMENT PROVIDING THAT LANDLORD SHALL RECEIVE THIRTY&#160;(30) DAYS PRIOR WRITTEN NOTICE OF ANY CANCELLATION OF, NONRENEWAL OF, REDUCTION OF COVERAGE OR MATERIAL CHANGE IN COVERAGE ON SAID POLICIES.&nbsp;&nbsp;Tenant hereby waives its right of recovery against any Landlord Indemnitee of any amounts paid by Tenant or on Tenant&#8217;s behalf to satisfy applicable worker&#8217;s compensation laws.&nbsp;&nbsp;The policies or duly executed certificates showing the material terms for the same, together with satisfactory evidence of the payment of the premiums therefor, shall be deposited with Landlord on the date Tenant first occupies the Premises and upon renewals of such policies not less than fifteen&#160;(15) days prior to the expiration of the term of such coverage.&nbsp;&nbsp;If certificates are supplied rather than the policies themselves, Tenant shall allow Landlord, at all reasonable times, to inspect the policies of insurance required herein.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">It is expressly understood and agreed that the coverages required represent Landlord&#8217;s minimum requirements and such are not to be construed to void or limit Tenant&#8217;s obligations contained in this Lease, including without limitation Tenant&#8217;s indemnity obligations hereunder.&nbsp;&nbsp;Neither shall (A)&#160;the insolvency, bankruptcy or failure of any insurance company carrying Tenant, (B)&#160;the failure of any insurance company to pay claims occurring nor (C)&#160;any exclusion from or insufficiency of coverage be held to affect, negate or waive any of Tenant&#8217;s indemnity obligations under this </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;8</font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;6(g)(ii)</font><font style="color:#000000;"> or any other provision of this Lease.&nbsp;&nbsp;With respect to insurance coverages, except worker&#8217;s compensation, maintained hereunder by Tenant and insurance coverages separately obtained by Landlord, all insurance coverages afforded by policies of insurance maintained by Tenant shall be primary insurance as such coverages apply to Landlord, and such insurance coverages separately maintained by Landlord shall be excess, and Tenant shall have its insurance policies so endorsed.&nbsp;&nbsp;The amount of liability insurance under insurance policies maintained by Tenant shall not be reduced by the existence of insurance coverage under policies separately maintained by Landlord.&nbsp;&nbsp;Tenant shall be solely responsible for any premiums, assessments, penalties, deductible assumptions, retentions, audits, retrospective adjustments or any other kind of payment due under its policies.&nbsp;&nbsp;Landlord reserves the right to require additional coverage and increase limits as industry standards change.&nbsp;&nbsp;Should Tenant engage the services of a contractor, Tenant will make certain that such contractor will carry the insurance required under the applicable provisions of this Lease.&nbsp;&nbsp;Tenant shall also make certain that all specific entities required are listed in the Tenant&#8217;s agreement with the contractor as additional insureds.&nbsp;&nbsp;The &#8220;Designated Landlord Parties&#8221; shall include The Prudential Insurance Company of America; PGIM, Inc.; PRISA II LHC, LLC; and any designated affiliates of the foregoing, and any other legal or d/b/a name under which the foregoing entities do business from time-to-time.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant&#8217;s occupancy of the Premises without delivering the certificates of insurance shall not constitute a waiver of Tenant&#8217;s obligations to provide the required coverages.&nbsp;&nbsp;If Tenant provides to Landlord a certificate that does not evidence the coverages required herein, or that is faulty in any respect, such shall not constitute a waiver of Tenant&#8217;s obligations to provide the proper insurance.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Throughout the Lease Term, Landlord agrees to maintain (i)&#160;fire and extended coverage insurance, and, at Landlord&#8217;s option earthquake damage coverage terrorism coverage, wind and hurricane coverage, and such additional property insurance coverage as Landlord deems appropriate, on the insurable portions of Building and the remainder of the Project in an amount not less than the fair replacement value thereof, subject to reasonable deductibles (ii)&#160;boiler and machinery insurance amounts and with deductibles that would be considered standard for similar class office buildings owned by similar institutional landlords in the Del Mar Heights/Torrey Hills submarket of San Diego, California and (iii)&#160;commercial general liability insurance with a combined single limit coverage of at least $1,000,000.00 per occurrence.&nbsp;&nbsp;All such insurance shall be obtained from insurers Landlord reasonably believes to be financially responsible in light of the risks being insured.&nbsp;&nbsp;The premiums for any such insurance shall be a part of Operating Costs.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Mutual Waivers of Recovery</font><font style="color:#000000;">.&nbsp;&nbsp;Landlord, Tenant, and all parties claiming under them, each mutually release and discharge each other from responsibility for that portion of any loss or damage paid or reimbursed by an insurer of Landlord or Tenant under any fire, extended coverage or other property insurance policy maintained by Tenant with respect to its Premises or by Landlord with respect to the Building or the Project (or which would have been paid had the insurance required to be maintained hereunder been in full force and effect), no matter how caused, including negligence, and each waives any right of recovery from the other including, but not limited to, claims for contribution or indemnity, which might otherwise exist on account thereof.&nbsp;&nbsp;Any fire, extended coverage or property insurance policy maintained by Tenant with respect to the Premises, or Landlord with respect to the Building or the Project, shall contain, in the case of Tenant&#8217;s policies, a waiver of subrogation provision or endorsement in favor of Landlord, and in the case of Landlord&#8217;s policies, a waiver of subrogation provision or endorsement in favor of Tenant, or, in the event that such insurers cannot or shall not include or attach such waiver of subrogation provision or endorsement, Tenant and Landlord shall obtain the approval and consent of their respective insurers, in writing, to the terms of this Lease.&nbsp;&nbsp;Tenant agrees to indemnify, protect, defend and hold harmless each and all of the Landlord Indemnitees from and against any claim, suit or cause of action asserted or brought by Tenant&#8217;s insurers for, on behalf of, or in the name of Tenant, including, but not limited to, claims for contribution, indemnity or subrogation, brought in contravention of this paragraph.&nbsp;&nbsp;The mutual releases, discharges and waivers contained in this provision shall apply EVEN IF THE LOSS OR DAMAGE TO WHICH THIS PROVISION APPLIES IS CAUSED SOLELY OR IN PART BY THE NEGLIGENCE OF LANDLORD OR TENANT.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Business Interruption</font><font style="color:#000000;">.&nbsp;&nbsp;Landlord shall not be responsible for, and Tenant releases and discharges Landlord from, and Tenant further waives any right of recovery from Landlord for, any loss for or from business interruption or loss of use of the Premises suffered by Tenant in connection with Tenant&#8217;s use or occupancy of the Premises, EVEN IF SUCH LOSS IS CAUSED SOLELY OR IN PART BY THE NEGLIGENCE OF LANDLORD.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Adjustment of Claims</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant shall cooperate with Landlord and Landlord&#8217;s insurers in the adjustment of any insurance claim pertaining to the Building or the Project or Landlord&#8217;s use thereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Increase in Landlord&#8217;s Insurance Costs</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant agrees to pay to Landlord any increase in premiums for Landlord&#8217;s insurance policies resulting from Tenant&#8217;s use or occupancy of the Premises.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Failure to Maintain Insurance</font><font style="color:#000000;">.&nbsp;&nbsp;Any failure of Tenant to obtain and maintain the insurance policies and coverages required hereunder or failure by Tenant to meet any of the insurance requirements of this Lease shall constitute an event of default hereunder, and such failure shall entitle Landlord to pursue, exercise or obtain any of the remedies provided for in </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;12(b)</font><font style="color:#000000;">, and Tenant shall be solely responsible for any loss suffered by Landlord as a result of such failure.&nbsp;&nbsp;In addition, in the event of failure by Tenant to maintain the insurance policies and coverages required by this Lease or to meet any of the insurance requirements of this Lease, Landlord, at its option, and without relieving Tenant of its obligations hereunder, may obtain said insurance policies and coverages or perform any other insurance obligation of Tenant, but all costs and expenses incurred by Landlord in obtaining such insurance or performing Tenant&#8217;s insurance obligations shall be reimbursed by Tenant to Landlord, together with interest on same at the Default Rate (as defined below) from the date any such cost or expense was paid by Landlord until reimbursed by Tenant.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">9.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Toc162863187"></a><a name="_Toc3448456"></a><a name="_Toc3555448"></a><a name="_Toc515875080"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">FIRE OR CASUALTY</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Subject to the provisions of this </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;9</font><font style="color:#000000;">, in the event the Premises, or access thereto, is wholly or partially destroyed by fire or other casualty, Landlord shall (to the extent permitted by Law and covenants, conditions and restrictions then applicable to the Project) rebuild, repair or restore the Premises and access thereto to substantially the same condition as existing immediately prior to such destruction and this Lease shall continue in full force and effect.&nbsp;&nbsp;Notwithstanding the foregoing, (i)&#160;Landlord&#8217;s obligation to rebuild, repair or restore the Premises shall not apply to any personal property, equipment, trade fixtures, Alterations, or other items installed or contained in the Premises (which shall be Tenant&#8217;s obligation to restore), (ii)&#160;Landlord shall have no obligation whatsoever to rebuild, repair or restore the Premises with respect to any damage or destruction occurring during the last twelve&#160;(12) months of the Lease Term or any extension of the Lease Term, and (iii) Landlord shall have no duty to rebuild, repair or restore if the damage is due to an uninsurable casualty, or if insurance proceeds are insufficient to pay for such rebuilding, repair or restoration, or if the holder of any mortgage, deed of trust or similar instrument applies proceeds of insurance to reduce its loan balance and the remaining proceeds, if any, available to Landlord are not sufficient to pay for such rebuilding, repair or restoration.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Landlord may elect to terminate this Lease in any of the following cases of damage or destruction to the Premises, the Building or the Project:&nbsp;&nbsp;(i)&#160;where the cost of rebuilding, repairing and restoring (collectively, &#8220;</font><font style="text-decoration:underline;color:#000000;">Restoration</font><font style="color:#000000;">&#8221;) of the Building or the Project, would, regardless of the lack of damage to the Premises or access thereto, in the reasonable opinion of Landlord, exceed twenty percent&#160;(20%) of the then replacement cost of the Building; (ii)&#160;where, in the case of any damage or destruction to any portion of the Building or the Project by uninsured casualty, the cost of Restoration of the Building or the Project, in the reasonable opinion of Landlord, exceeds $500,000; or (iii)&#160;where, in the case of any damage or destruction to the Premises or access thereto by uninsured casualty, the cost of Restoration of the Premises or access thereto, in the reasonable opinion of Landlord, exceeds twenty percent&#160;(20%) of the replacement cost of the Premises; or (iv)&#160;where the holder of any mortgage on the Building shall require that the insurance proceeds or any portion thereof be used to retire all or a portion of the mortgage debt; or (v) if Landlord has not obtained appropriate zoning approvals for reconstruction of the Project, Building or Premises.&nbsp;&nbsp;Any such termination shall be made by thirty&#160;(30) days&#8217; prior written notice to Tenant given within ninety&#160;(90) days of the date of such damage or destruction.&nbsp;&nbsp;If this Lease is not terminated by Landlord and as the result of any damage or destruction, the Premises, or a portion thereof, are rendered untenantable, the Basic Annual Rent shall abate reasonably during the period of Restoration (based upon the extent to which such damage and Restoration materially interfere with Tenant&#8217;s business in the Premises and provided that there shall be no abatement of Basic Annual Rent to the extent the damage or destruction was caused by the negligence or willful misconduct of Tenant or its employees, agents, contractors, or invitees); provided however, Tenant shall have the right to terminate this Lease if more than fifty percent (50%) of the Premises are rendered untenantable for a period of twelve (12) months after the date of damage or destruction by delivering written notice to Landlord of its intent to terminate this Lease after such twelve (12) month period but prior to the substantial completion of the Restoration of the Building.&nbsp;&nbsp;This Lease shall be considered an express agreement governing any case of damage to or destruction of the Premises, the Building or the Project.&nbsp;&nbsp;This Lease sets forth the terms and conditions upon which this Lease may terminate in the event of any damage or destruction.&nbsp;&nbsp;Accordingly, the parties hereby waive the provisions of California Civil Code Section 1932, Subsection 2, and Section 1933, Subsection 4 (and any existing or future statutes which provision(s) permit the parties to terminate this Lease as a result of any damage or destruction).&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">10.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Toc162863188"></a><a name="_Toc3448457"></a><a name="_Toc3555449"></a><a name="_Toc515875081"></a><font style="text-decoration:none;Background-color:#auto;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">EMINENT DOMAIN</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event the whole of the Premises, the Building or the Project shall be taken under the power of eminent domain, or sold to prevent the exercise thereof (collectively, a &#8220;<font style="text-decoration:underline;">Taking</font>&#8221;), this Lease shall automatically terminate as of the date of such Taking.&nbsp;&nbsp;In the event a Taking of a portion of the Project, the Building or the Premises shall, in the reasonable opinion of Landlord, substantially interfere with Landlord&#8217;s operation thereof, Landlord may terminate this Lease upon thirty&#160;(30) days&#8217; written notice to Tenant given at any time within sixty&#160;(60) days following the date of such Taking.&nbsp;&nbsp;For purposes of this Lease, the date of Taking shall be the earlier of the date of transfer of title resulting from such Taking or the date of transfer of possession resulting from such Taking.&nbsp;&nbsp;In the event that a portion of the Premises is so taken and this Lease is not terminated, Landlord shall, to the extent of proceeds paid to Landlord as a result of the Taking, with reasonable diligence, use commercially reasonable efforts to proceed to restore (to the extent permitted by Law and covenants, conditions and restrictions then applicable to the Project) the Premises (other than Tenant&#8217;s personal property and fixtures, and above-standard tenant improvements) to a complete, functioning unit.&nbsp;&nbsp;In such case, the Basic Annual Rent shall be reduced proportionately based on the portion of the Premises so taken.&nbsp;&nbsp;If all or any portion of the Premises is the subject of a temporary Taking, this Lease shall remain in full force and effect and Tenant shall continue to perform each of its obligations under this Lease; in such case, Tenant shall be entitled to receive the entire award allocable to the temporary Taking of the Premises.&nbsp;&nbsp;Except as provided herein, Tenant shall not assert any claim against Landlord or the condemning authority for, and hereby assigns to Landlord, any compensation in connection with any such Taking, and Landlord shall be entitled to receive the entire amount of any award therefor, without deduction for any estate or interest of Tenant.&nbsp;&nbsp;Nothing contained in this <font style="text-decoration:underline;">Paragraph&#160;10</font> shall be deemed to give Landlord any interest in, or prevent Tenant from making a separate claim for, any award against the condemning authority for the Taking of Tenant&#8217;s personal property or for relocation or moving expenses recoverable by Tenant from the condemning authority.&nbsp;&nbsp;This <font style="text-decoration:underline;">Paragraph&#160;10</font> shall be Tenant&#8217;s sole and exclusive remedy in the event of a Taking.&nbsp;&nbsp;This Lease sets forth the terms and conditions upon which this Lease may terminate in the event of a Taking.&nbsp;&nbsp;Accordingly, the parties waive the provisions of the California Code of Civil Procedure Section 1265.130 and any existing or future statutes which provision(s) permit the parties to terminate this Lease as a result of a Taking.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">11.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Toc162863189"></a><a name="_Toc3448458"></a><a name="_Toc3555450"></a><a name="_Toc515875082"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">ASSIGNMENT AND SUBLETTING</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant shall not directly or indirectly, voluntarily or involuntarily, by operation of law or otherwise, assign, sublet, mortgage, hypothecate or otherwise encumber all or any portion of its interest in this Lease or in the Premises or grant any license in or suffer any person other than Tenant or its employees to use or occupy the Premises or any part thereof without obtaining the prior written consent of Landlord, which consent shall not be unreasonably withheld.&nbsp;&nbsp;Any such attempted assignment, subletting, license, mortgage, hypothecation, other encumbrance or other use or occupancy without the consent of Landlord shall be null and void and of no effect.&nbsp;&nbsp;Any mortgage, hypothecation or encumbrance of all or any portion of Tenant&#8217;s interest in this Lease or in the Premises and any grant of a license or sufferance of any person other than Tenant or its employees to use or occupy the Premises or any part thereof shall be deemed to be an &#8220;assignment&#8221; of this Lease.&nbsp;&nbsp;In addition, as used in this </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;11</font><font style="color:#000000;">, the term &#8220;Tenant&#8221; shall also mean any entity that has guaranteed Tenant&#8217;s obligations under this Lease, and the restrictions applicable to Tenant contained herein shall also be applicable to such guarantor.&nbsp;&nbsp;Landlord&#8217;s agreement to not unreasonably withhold its consent shall only apply to the first assignment or sublease under the Lease. Notwithstanding the foregoing, Tenant may assign its entire interest under this Lease to a Tenant Affiliate (defined below) or to a successor to Tenant by purchase, merger, consolidation or reorganization without the consent of Landlord, provided that all of the following conditions are satisfied in Landlord&#8217;s reasonable discretion (a &#8220;</font><font style="text-decoration:underline;color:#000000;">Permitted Transfer</font><font style="color:#000000;">&#8221;; such successor to a Permitted Transfer, a &#8220;</font><font style="text-decoration:underline;color:#000000;">Permitted Transferee</font><font style="color:#000000;">&#8221;):&nbsp;&nbsp;(1)&#160;the transfer is for a good faith business purpose and not for the avoidance of liability under this Lease; (2) no uncured event of default exists under this Lease; (3) if not a Tenant Affiliate, Tenant&#8217;s successor shall own more than fifty percent (50%) of the assets of Tenant; (4) Tenant&#8217;s successor shall have a Tangible Net Worth which is at least equal to the greater of Tenant&#8217;s and Guarantor&#8217;s&nbsp;&nbsp;aggregate Tangible Net Worth at the Date of this Lease or Tenant&#8217;s and Guarantor&#8217;s&nbsp;&nbsp;aggregate Tangible Net Worth as of the day prior to the proposed assignment; (5) no portion of the Building or Premises would become subject to additional or different Laws as a consequence of the proposed assignment; (6) Tenant&#8217;s successor&#8217;s use of the Premises shall be solely for the use permitted under this Lease and shall not conflict with any exclusive usage rights granted to any other tenant in the Building or Project; (7) neither the transfer nor any consideration payable to Landlord in connection therewith adversely affects any pension fund or ERISA qualification tests applicable to </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Landlord; (8) Tenant&#8217;s successor </font><font style="color:#000000;">is not</font><font style="color:#000000;"> in litigation with Landlord; and (9) Tenant shall give Landlord thirty (30) days of advance written notice of the proposed assignment, along with all applicable documentation and other information necessary for Landlord to determine that the requirements of this paragraph have been satisfied, including if applicable, the qualification of such proposed assignee as a Tenant Affiliate (if to a Tenant Affiliate, such Tenant Affiliate shall remain a Tenant Affiliate throughout the Term and if such Tenant Affiliate shall cease to be a Tenant Affiliate, such change in affiliation shall be deemed a transfer hereunder requiring Landlord&#8217;s prior written consent).&nbsp;&nbsp;The term &#8220;</font><font style="text-decoration:underline;color:#000000;">Tenant Affiliate</font><font style="color:#000000;">&#8221; means any person or entity controlling, controlled by or under common control with Tenant.&nbsp;&nbsp;The term &#8220;controlled by&#8221; or &#8220;commonly controlled with&#8221; shall mean the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of such controlled person or entity, or the ownership, directly or indirectly, of at least fifty-one percent&#160;(51%) of the voting securities of, or possession of the right to vote, in the ordinary direction of its affairs, at least fifty-one percent&#160;(51%) of the voting interest in, any person or entity.</font><font style="color:#000000;"> &#8220;Tangible Net Worth&#8221; shall be defined as the physical worth of an entity, by adding together such entity&#8217;s total physical, tangible assets, determined in accordance with generally accepted accounting principles (after deducting proper reserves), and subtracting the value of all liabilities and intangible assets (including goodwill, patents, trademarks, licenses, treasury stock, copyrights or any write-up in the book value of any assets). If requested by Landlord, a Tenant Affiliate or successor shall sign a commercially reasonable form of assumption agreement</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No assignment or subletting shall relieve Tenant of its obligation to pay the Rent and to perform all of the other obligations to be performed by Tenant hereunder.&nbsp;&nbsp;The acceptance of Rent by Landlord from any other person shall not be deemed to be a waiver by Landlord of any provision of this Lease or to be a consent to any subletting or assignment.&nbsp;&nbsp;Consent by Landlord to one subletting or assignment shall not be deemed to constitute a consent to any other or subsequent attempted subletting or assignment.&nbsp;&nbsp;If Tenant desires at any time to assign this Lease or to sublet the Premises or any portion thereof, it shall first notify Landlord of its desire to do so and shall submit in writing to Landlord all pertinent information relating to the proposed assignee or sublessee, all pertinent information relating to the proposed assignment or sublease, and all such financial information as Landlord may reasonably request concerning Tenant and the proposed assignee or subtenant.&nbsp;&nbsp;Any assignment or sublease shall be expressly subject to the terms and conditions of this Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In the event that Tenant proposes to sublease more than twenty-five percent (25%) of the Premises or assign the Lease, in each case to a party that is not a Permitted Transferee, then at any time within thirty&#160;(30) days after Landlord&#8217;s receipt of the information specified in </font><font style="text-decoration:underline;color:#000000;">subparagraph&#160;(b)</font><font style="color:#000000;"> above, Landlord may by written notice to Tenant elect to terminate this Lease as to the portion of the Premises so proposed to be subleased or assigned (which may include all of the Premises), with a proportionate abatement in the Rent payable hereunder; however, in the event Landlord elects to terminate this Lease (or as to the portion of the Premises so proposed to be subleased), then Tenant may, within five (5) business days of Landlord&#8217;s election, rescind its request to sublease or assign the Lease as so proposed and, in such case, Landlord&#8217;s election to terminate this Lease shall be rendered null and void and the Lease shall continue in full force and effect.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant acknowledges that it shall be reasonable for Landlord to withhold its consent to a proposed assignment or sublease in any of the following instances:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The assignee or sublessee (or any affiliate of the assignee or sublessee) is not, in Landlord&#8217;s reasonable opinion, sufficiently creditworthy to perform the obligations such assignee or sublessee will have under this Lease;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The intended use of the Premises by the assignee or sublessee is not for general office use;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The intended use of the Premises by the assignee or sublessee would materially increase the pedestrian or vehicular traffic to the Premises or the Building;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Occupancy of the Premises by the assignee or sublessee would, in the good faith judgment of Landlord, violate any agreement binding upon Landlord, the Building or the Project with regard to the identity of tenants, usage in the Building, or similar matters;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(v)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The assignee or sublessee (or any affiliate of the assignee or sublessee) is then negotiating with Landlord or has negotiated with Landlord within the previous six (6) months, or is a current tenant or subtenant within the Building or </font><font style="color:#000000;">Project;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(vi)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The identity or business reputation of the assignee or sublessee will, in the good faith judgment of Landlord, tend to damage the goodwill or reputation of the Building or Project;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(vii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the proposed sublease would result in more than two subleases of portions of the Premises being in effect at any one time during the Lease Term;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(viii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the net effective rent payable by the assignee or sublessee (adjusted on a square foot of Rentable Area basis) is less than the net effective rent then being quoted by Landlord for new leases in the Building for comparable size space for a comparable period of time; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ix)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In the case of a sublease, the subtenant has not acknowledged that the Lease controls over any inconsistent provision in the sublease; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(x)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The assignee or sublessee violates the provisions set forth in </font><font style="text-decoration:underline;color:#000000;">Paragraph 19(bb) (Compliance)</font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">19(cc) (ERISA)</font><font style="color:#000000;"> of this Lease or fails to make the representations set forth therein.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing criteria shall not exclude any other reasonable basis for Landlord to refuse its consent to such assignment or sublease.&nbsp;&nbsp;The grant of any consent or approval required from Landlord under this Lease shall be proved only by proof of a written document signed and delivered by Landlord expressly setting forth such consent or approval.&nbsp;&nbsp;Notwithstanding any contrary provision of this Lease, if Tenant or any proposed assignee or sublessee claims that Landlord has unreasonably withheld its consent to a proposed assignment or sublease or otherwise has breached its obligations under this <font style="text-decoration:underline;">Paragraph&#160;11</font>, their sole remedy shall be to seek a declaratory judgment and/or injunctive relief without any monetary damages, and, with respect thereto, Tenant, on behalf of itself and, to the extent permitted by law, such proposed assignee/sublessee, hereby waives all other remedies against Landlord, including, without limitation, the right to seek monetary damages or to terminate this Lease.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding any assignment or subletting, Tenant and any guarantor or surety of Tenant&#8217;s obligations under this Lease shall at all times during the Initial Term and any subsequent renewals or extensions remain fully responsible and liable for the payment of the rent and for compliance with all of Tenant&#8217;s other obligations under this Lease.&nbsp;&nbsp;In the event that the Rent due and payable by a sublessee or assignee (or a combination of the rental payable under such sublease or assignment, plus any bonus or other consideration therefor or incident thereto) exceeds the Rent payable under this Lease, then Tenant shall be bound and obligated to pay Landlord, as Additional Rent hereunder, all such excess Rent and other excess consideration within ten&#160;(10) days following receipt thereof by Tenant.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If this Lease is assigned or if the Premises is subleased (whether in whole or in part), or in the event of the mortgage, pledge, or hypothecation of Tenant&#8217;s leasehold interest, or grant of any concession or license within the Premises, or if the Premises are occupied in whole or in part by anyone other than Tenant, then upon a default by Tenant hereunder Landlord may collect Rent from the assignee, sublessee, mortgagee, pledgee, party to whom the leasehold interest was hypothecated, concessionee or licensee or other occupant and, except to the extent set forth in the preceding paragraph, apply the amount collected to the next Rent payable hereunder; and all such Rent collected by Tenant shall be held in deposit for Landlord and immediately forwarded to Landlord.&nbsp;&nbsp;No such transaction or collection of Rent or application thereof by Landlord, however, shall be deemed a waiver of these provisions or a release of Tenant from the further performance by Tenant of its covenants, duties, or obligations hereunder.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If Tenant effects an assignment or sublease or requests the consent of Landlord to any proposed assignment or sublease, then, simultaneously with the same, Tenant shall pay Landlord a non-refundable administrative fee of Two Thousand Dollars ($2,000.00), plus, upon Landlord&#8217;s request therefor, any reasonable attorneys&#8217; and paralegal fees and costs incurred by Landlord in connection with such assignment or sublease or request for consent.&nbsp;&nbsp;Acceptance of the Two Thousand Dollar ($2,000.00) administrative fee and/or reimbursement of Landlord&#8217;s attorneys&#8217; and paralegal fees shall in no event obligate Landlord to consent to any proposed assignment or sublease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding any provision of this Lease to the contrary, in the event this Lease is assigned to any person or entity pursuant to the provisions of the Bankruptcy Code, any and all monies or other consideration payable or otherwise to be delivered in connection with such assignment shall be paid or delivered to Landlord, shall be and remain the exclusive property of Landlord and shall not constitute the property of Tenant or Tenant&#8217;s estate within the meaning of the Bankruptcy Code.&nbsp;&nbsp;All such money and other consideration not paid or delivered to Landlord shall be held in trust for the benefit of Landlord and shall be promptly paid or delivered to Landlord.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding anything in this Lease to the contrary, no assignment, sublease or other transfer of this Lease or the Premises by Tenant (with or without the consent of Landlord), nor any consideration payable to Landlord in connection therewith, may adversely affect any pension fund or ERISA qualification tests applicable to Landlord, including the covenants set forth in </font><font style="text-decoration:underline;color:#000000;">Paragraphs 19(bb)</font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">(cc)</font><font style="color:#000000;"> of this Lease, and any assignment, sublease or other transfer that adversely affects such qualification tests shall be void and of no effect.&nbsp;&nbsp;Upon any assignment, sublease or other transfer of this Lease or the Premises by Tenant, the applicable assignee, sublessee or transferee, shall automatically be deemed to have remade the representations set forth in </font><font style="text-decoration:underline;color:#000000;">Paragraphs 19(bb)</font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">(cc)</font><font style="color:#000000;"> of this Lease and, upon Landlord&#8217;s prior written request, shall expressly remake such representations in writing to Landlord.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">12.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Toc162863190"></a><a name="_Toc3448459"></a><a name="_Toc3555451"></a><a name="_Toc515875083"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">DEFAULT</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Events of Default</font><font style="color:#000000;">.&nbsp;&nbsp;The occurrence of any one or more of the following events shall constitute an &#8220;event of default&#8221; or &#8220;default&#8221; (herein so called) under this Lease by Tenant: (i)&#160;the failure by Tenant to make any payment of Rent or any other payment required to be made by Tenant hereunder within five&#160;(5) days after Landlord notifies Tenant of such nonpayment; provided, however, Landlord shall only be obligated to provide such written notice to Tenant one&#160;(1) time within any consecutive twelve&#160;(12) month period and in the event Tenant fails to timely pay Rent or any other sums for a second</font><font style="font-weight:bold;font-style:italic;color:#000000;"> </font><font style="color:#000000;">time during any consecutive twelve&#160;(12) month period, then Tenant shall be in default for such late payment and Landlord shall have no obligation or duty to provide notice of such non-payment to Tenant prior to declaring an event of default under this Lease; (ii)&#160;the failure by Tenant to observe or perform any of the express or implied covenants or provisions of this Lease to be observed or performed by Tenant, other than monetary failures as specified in clause&#160;(i) of this paragraph above</font><font style="font-size:11pt;font-family:Calibri;color:#000000;"> </font><font style="color:#000000;">and the other events specified in clauses (iii) through (xii) of this paragraph below, where such failure shall continue for a period of thirty (30) days after written notice thereof from Landlord to Tenant, provided, however, that if more than thirty (30) days are reasonably required to cure any such failure, then Tenant shall have the additional time reasonably required to cure such failure, before an event of default shall be deemed to have occurred, so long as Tenant commences to cure such failure within said thirty (30) day period and diligently prosecutes such cure in good faith until completion within the period reasonably required to perform the same, which in no event shall exceed sixty (60) days after Tenant&#8217;s receipt of Landlord&#8217;s notice of such failure, and provided further that if the same such failure occurs more than two&#160;(2) times during any consecutive twelve&#160;(12) month period, then an event of default shall be deemed to have occurred upon the third and all subsequent such failures, without notice from Landlord); (iii)&#160;the making by Tenant or any guarantor hereof of any general assignment for the benefit of creditors; (iv)&#160;the filing by or against Tenant or any guarantor hereof of a petition to have Tenant or any guarantor hereof adjudged a bankrupt or a petition for reorganization or arrangement under any law relating to bankruptcy (unless, in the case of a petition filed against Tenant or any guarantor hereof, the same is dismissed within sixty&#160;(60) days); (v)&#160;the appointment of a trustee or receiver to take possession of substantially all of Tenant&#8217;s assets located at the Premises or of Tenant&#8217;s interest in this Lease or of substantially all of guarantor&#8217;s assets, where possession is not restored to Tenant or guarantor within sixty&#160;(60) days; (vi)&#160;the attachment, execution or other judicial seizure of substantially all of Tenant&#8217;s assets located at the Premises or of substantially all of guarantor&#8217;s assets or of Tenant&#8217;s interest in this Lease where such seizure is not discharged within sixty (60) days; (vii)&#160;any material representation or warranty made by Tenant or guarantor in this Lease or any other document delivered in connection with the execution and delivery of this Lease or pursuant to this Lease proves to be incorrect in any material </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">respect; (viii)&#160;Tenant or guarantor shall be liquidated or dissolved or shall begin proceedings towards its liquidation or dissolution; (ix) the failure to deposit or restore the Security Deposit as required pursuant to </font><font style="text-decoration:underline;color:#000000;">Paragraph 2(c)</font><font style="color:#000000;"> of this Lease; (x) any assignment, subletting, license, mortgage, hypothecation, other encumbrance or other use or occupancy prohibited by the provisions of </font><font style="text-decoration:underline;color:#000000;">Paragraph 11</font><font style="color:#000000;"> of this Lease; or (xi)&#160;the vacation or abandonment of the Premises by Tenant.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any notice sent by Landlord to Tenant pursuant to this <font style="text-decoration:underline;">Paragraph 12(a)</font> shall be in lieu of, and not in addition to, any notice required under any applicable law and Tenant hereby waives the service of any demand for payment of Rent or for possession and waives the service of any other notice or demand prescribed by any Laws, including, without limitation, California Code of Civil Procedure Section 1161.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Landlord&#8217;s Remedies; Termination</font><font style="color:#000000;">.&nbsp;&nbsp;In the event of any event of default by Tenant, in addition to any other remedies available to Landlord under this Lease, at law or in equity, Landlord shall have the immediate option to terminate this Lease and all rights of Tenant hereunder and Landlord shall have all the rights and remedies of a Landlord provided by Section 1951.2 of the California Civil Code.&nbsp;&nbsp;In the event that Landlord shall elect to so terminate this Lease, then Landlord may recover from Tenant:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the worth at the time of award of any unpaid rent which had been earned at the time of such termination; plus</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the worth at the time of the award of the amount by which the unpaid rent which would have been earned after termination until the time of award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided; plus</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">the worth at the time of award of the amount by which the unpaid rent for the balance of the term after the time of award exceeds the amount of such rental loss that Tenant proves could be reasonably avoided; plus</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">any other amount necessary to compensate Landlord for all the detriment proximately caused by Tenant&#8217;s failure to perform its obligations under this Lease or which, in the ordinary course of things, would be likely to result therefrom including, but not limited to: unamortized Tenant Improvement&nbsp;&nbsp;costs and any free or abated Rent; attorneys&#8217; fees; brokers&#8217; commissions; the costs of refurbishment, alterations, renovation and repair of the Premises; and removal (including the repair of any damage caused by such removal) and storage (or disposal) of Tenant&#8217;s personal property, equipment, fixtures, and any other items which Tenant is required under this Lease to remove but does not remove.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As used in subparagraphs (i) and (ii) of <font style="text-decoration:underline;">Paragraph 12(b)</font> above, the &#8220;worth at the time of award &#8220; is computed by allowing interest at the Default Rate (as defined below).&nbsp;&nbsp;As used in subparagraph (iii) of <font style="text-decoration:underline;">Paragraph 12(b)</font> above, the &#8220;worth at the time of award&#8221; is computed by discounting such amount at the discount rate of the Federal Reserve Bank of San Francisco at the time of award plus one percent (1%).&nbsp;&nbsp;The term &#8220;Default Rate&#8221; as used in this Lease shall mean the lesser of (A) the rate announced from time to time by Wells Fargo Bank or, if Wells Fargo bank ceases to exist or ceases to publish such rate, then the rate announced from time to time by the largest (as measured by deposits) chartered bank operating in California, as its &#8220;prime rate&#8221; or &#8220;reference rate&#8221;, plus six percent (6%), or (B) the maximum rate of interest permitted by applicable Law. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Landlord&#8217;s Remedies; Re-Entry Rights</font><font style="color:#000000;">.&nbsp;&nbsp;In the event of any event of default by Tenant, in addition to any other remedies available to Landlord under this Lease, at law or in equity, Landlord shall also have the right, to the extent permitted by applicable Law, with or without terminating this Lease, to re-enter the Premises and remove all persons and property from the Premises; such property may be removed, stored and/or disposed of pursuant to </font><font style="text-decoration:underline;color:#000000;">Paragraph 5(c)</font><font style="color:#000000;"> of this Lease or any other procedures permitted by applicable Law.&nbsp;&nbsp;No re-entry or taking possession of the Premises by Landlord pursuant to this </font><font style="text-decoration:underline;color:#000000;">Paragraph 12(c)</font><font style="color:#000000;">, and no acceptance of surrender of the Premises or other action on Landlord&#8217;s part, shall be construed as an election to terminate this Lease unless a written notice of such intention be given to Tenant or unless the termination thereof be decreed by a court of competent jurisdiction.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Continuation of Lease</font><font style="color:#000000;">.&nbsp;&nbsp;Landlord shall have the remedy described in California Civil Code Section 1951.4 (lessor may continue lease in effect after lessee&#8217;s breach and abandonment and recover rent as it becomes due, if lessee has the right to sublet or assign, subject only to reasonable limitations).&nbsp;&nbsp;Accordingly, if Landlord does not elect to terminate this Lease on account of any event of default by Tenant, Landlord may, from time to time, without terminating this Lease, enforce all of its rights and remedies under this Lease, including the right to recover all rent as it becomes due.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Landlord&#8217;s Right to Perform</font><font style="color:#000000;">.&nbsp;&nbsp;Except as specifically provided otherwise in this Lease, all covenants and agreements by Tenant under this Lease shall be performed by Tenant at Tenant&#8217;s sole cost and expense and without any abatement or offset of Rent.&nbsp;&nbsp;If Tenant shall fail to pay any sum of money (other than Basic Annual Rent) or perform any other act on its part to be paid or performed hereunder and such failure shall continue for three (3) days with respect to monetary obligations (or ten (10) days with respect to non-monetary obligations, except in case of emergencies, in which such case, such shorter period of time as is reasonable under the circumstances) after Tenant&#8217;s receipt of written notice thereof from Landlord, Landlord may, without waiving or releasing Tenant from any of Tenant&#8217;s obligations, make such payment or perform such other act on behalf of Tenant.&nbsp;&nbsp;All sums so paid by Landlord and all necessary incidental costs incurred by Landlord in performing such other acts shall be payable by Tenant to Landlord within five (5) days after demand therefor as Additional Rent.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Interest</font><font style="color:#000000;">.&nbsp;&nbsp;If any monthly installment of Rent or Operating Costs or Electricity Utility Charges, or any other amount payable by Tenant hereunder is not received by Landlord by the date when due, it shall bear interest at the Default Rate from the date due until paid.&nbsp;&nbsp;All interest, and any late charges imposed pursuant to </font><font style="text-decoration:underline;color:#000000;">Paragraph 12(g)</font><font style="color:#000000;"> below, shall be considered Additional Rent due from Tenant to Landlord under the terms of this Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Late Charges</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant acknowledges that, in addition to interest costs, the late payments by Tenant to Landlord of any monthly installment of Basic Annual Rent, Additional Rent or other sums due under this Lease will cause Landlord to incur costs not contemplated by this Lease, the exact amount of such costs being extremely difficult and impractical to fix.&nbsp;&nbsp;Such other costs include, without limitation, processing, administrative and accounting charges and late charges that may be imposed on Landlord by the terms of any mortgage, deed of trust or related loan documents encumbering the Premises, the Building or the Project.&nbsp;&nbsp;Accordingly, if any monthly installment of Basic Annual Rent, Additional Rent or any other amount payable by Tenant hereunder is not received by Landlord by the due date thereof, Tenant shall pay to Landlord an additional sum of five percent (5%) of the overdue amount as a late charge, but in no event more than the maximum late charge allowed by law.&nbsp;&nbsp;The parties agree that such late charge represents a fair and reasonable estimate of the costs that Landlord will incur by reason of any late payment as hereinabove referred to by Tenant, and the payment of late charges and interest are distinct and separate in that the payment of interest is to compensate Landlord for the use of Landlord&#8217;s money by Tenant, while the payment of late charges is to compensate Landlord for Landlord&#8217;s processing, administrative and other costs incurred by Landlord as a result of Tenant&#8217;s delinquent payments.&nbsp;&nbsp;Acceptance of a late charge or interest shall not constitute a waiver of Tenant&#8217;s default with respect to the overdue amount or prevent Landlord from exercising any of the other rights and remedies available to Landlord under this Lease or at law or in equity now or hereafter in effect.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Rights and Remedies Cumulative</font><font style="color:#000000;">.&nbsp;&nbsp;All rights, options and remedies of Landlord contained in this </font><font style="text-decoration:underline;color:#000000;">Paragraph 12</font><font style="color:#000000;"> and elsewhere in this Lease shall be construed and held to be cumulative, and no one of them shall be exclusive of the other, and Landlord shall have the right to pursue any one or all of such remedies or any other remedy or relief which may be provided by Law or in equity, whether or not stated in this Lease.&nbsp;&nbsp;Nothing in this </font><font style="text-decoration:underline;color:#000000;">Paragraph 12</font><font style="color:#000000;"> shall be deemed to limit or otherwise affect Tenant&#8217;s indemnification of Landlord pursuant to any provision of this Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Tenant&#8217;s Waiver of Redemption</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant hereby waives and surrenders for itself and all those claiming under it, including creditors of all kinds, (i) any right and privilege which it or any of them may have under any present or future law to redeem any of the Premises or to have a continuance of this Lease after termination of this Lease or of Tenant&#8217;s right of occupancy or possession pursuant to any court order or any provision hereof, and (ii) the benefits of any present or future law which exempts property from liability for debt or for distress for rent.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(j)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Costs Upon Default and Litigation</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant shall pay to Landlord and its mortgagees as Additional Rent all the expenses incurred by Landlord or its mortgagees in connection with any breach or default by Tenant hereunder or the exercise of any remedy by reason of any breach or default by Tenant hereunder, including reasonable attorneys&#8217; fees and expenses.&nbsp;&nbsp;If Landlord or its mortgagees shall be made a party to any litigation commenced against Tenant or any litigation pertaining to this Lease or the Premises, at the option of Landlord and/or its mortgagees, Tenant, at its expense, shall provide Landlord and/or its mortgagees with counsel approved by Landlord and/or its mortgagees and shall pay all costs incurred or paid by Landlord and/or its mortgagees in connection with such litigation.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">13.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Toc162863191"></a><a name="_Toc3448460"></a><a name="_Toc3555452"></a><a name="_Toc515875084"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">ACCESS; CONSTRUCTION</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord reserves from the leasehold estate hereunder, in addition to all other rights reserved by Landlord under this Lease, the right to use the roof and exterior walls of the Premises and the area beneath, adjacent to and above the Premises, together with the right to install, use, maintain, repair, replace and relocate equipment, machinery, meters, pipes, ducts, plumbing, conduits and wiring through the Premises, which serve other portions of the Building or the Project in a manner and in locations which do not unreasonably interfere with Tenant&#8217;s use of the Premises.&nbsp;&nbsp;In addition, Landlord shall have free access to any and all mechanical installations of Landlord or Tenant, including, without limitation, machine rooms, telephone rooms and electrical closets.&nbsp;&nbsp;Tenant agrees that there shall be no construction of partitions or other obstructions which materially interfere with or which threaten to materially interfere with Landlord&#8217;s free access thereto, or materially interfere with the moving of Landlord&#8217;s equipment to or from the enclosures containing said installations.&nbsp;&nbsp;Upon at least twenty-four&#160;(24) hours&#8217; prior notice (&#8220;<font style="text-decoration:underline;">Entry Notice</font>&#8221;) (except in the event of an emergency, when no Entry Notice shall be necessary), Landlord reserves and shall at any time and all times have the right to enter the Premises to inspect the same, to supply janitorial service and any other service to be provided by Landlord to Tenant hereunder, to exhibit the Premises to prospective purchasers, lenders or tenants, to post notices of non-responsibility, to alter, improve, restore, rebuild or repair the Premises or any other portion of the Building, or to do any other act permitted or contemplated to be done by Landlord hereunder, all without being deemed guilty of an eviction of Tenant and without liability for abatement of Rent or otherwise.&nbsp;&nbsp;For such purposes, Landlord may also erect scaffolding and other necessary structures where reasonably required by the character of the work to be performed.&nbsp;&nbsp;Landlord shall conduct all such inspections and/or improvements, alterations and repairs so as to minimize, to the extent reasonably practical and without additional expense to Landlord, any interruption of or interference with the business of Tenant. To the extent any of Landlord&#8217;s representatives or contractors enter the Premises pursuant to an Entry Notice (i.e. not an emergency situation), then Tenant shall have the right to have a representative of Tenant present to accompany such entry into the Premises by Landlord&#8217;s representatives or contractors; however, if a representative of Tenant fails to meet Landlord&#8217;s representatives or contractors at the Premises at the time specified in the Entry Notice, then Landlord&#8217;s representatives or contractors shall nonetheless have the right to enter the Premises at the time specified in the Entry Notice in accordance with Landlord&#8217;s rights specified in this paragraph.&nbsp;&nbsp;Notwithstanding anything herein to the contrary, an Entry Notice shall not be required for entry into the Premises by Landlord or its agents, representatives or contractors to provide ongoing, routine services for which a planned schedule has already been delivered in writing to Tenant, such as regular janitorial services.  Tenant hereby waives any claim for damages for any injury or inconvenience to or interference with Tenant&#8217;s business, any loss of occupancy or quiet enjoyment of the Premises, and any other loss occasioned thereby.&nbsp;&nbsp;For each of such purposes, Landlord shall at all times have and retain a key with which to unlock all of the doors in, upon and about the Premises (excluding Tenant&#8217;s vaults and safes, access to which shall be provided by Tenant upon Landlord&#8217;s reasonable request).&nbsp;&nbsp;Landlord shall have the right to use any and all means which Landlord may deem proper in an emergency in order to obtain entry to the Premises or any portion thereof, and Landlord shall have the right, at any time during the Lease Term, to provide whatever access control measures it deems reasonably necessary to the Project, without any interruption or abatement in the payment of Rent by Tenant.&nbsp;&nbsp;Any entry into the Premises obtained by Landlord by any of such means shall not under any circumstances be construed to be a forcible or unlawful entry into, or a detainer of, the Premises, or any eviction of Tenant from the Premises or any portion thereof.&nbsp;&nbsp;No provision of this Lease shall be construed as obligating Landlord to perform any repairs, Alterations or decorations to the Premises or the Project except as otherwise expressly agreed to be performed by Landlord pursuant to the provisions of this Lease.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">14.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Toc162863192"></a><a name="_Toc515875085"></a><font style="text-decoration:none;Background-color:#auto;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">BANKRUPTCY</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If at any time on or before the Commencement Date there shall be filed by or against Tenant in any court, tribunal, administrative agency or any other forum having jurisdiction, pursuant to any applicable law, either of the United States or of any state, a petition in bankruptcy or insolvency or for reorganization or for the appointment of a receiver, trustee or conservator of all or a portion of Tenant&#8217;s property, or if Tenant makes an assignment for the benefit of creditors, this Lease shall </font><font style="text-decoration:underline;color:#000000;">ipso facto</font><font style="color:#000000;"> be canceled and terminated and in such event neither Tenant nor any person claiming through or under Tenant or by virtue of any applicable law or by an order of any court, tribunal, administrative agency or any other forum having jurisdiction, shall be entitled to possession of the Premises and Landlord, in addition to the other rights and remedies given by </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;12</font><font style="color:#000000;"> hereof or by virtue of any other provision contained in this Lease or by virtue of any applicable law, may retain as damages any Rent, Security Deposit or moneys received by it from Tenant or others on behalf of Tenant.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If, after the Commencement Date, or if at any time during the Lease Term, there shall be filed against Tenant in any court, tribunal, administrative agency or any other forum having jurisdiction, pursuant to any applicable law, either of the United States or of any state, a petition in bankruptcy or insolvency or for reorganization or for the appointment of a receiver, trustee or conservator of all or a portion of Tenant&#8217;s property, and the same is not dismissed after sixty&#160;(60) calendar days, or if Tenant makes an assignment for the benefit of creditors, this Lease, at the option of Landlord exercised within a reasonable time after notice of the happening of any one or more of such events, may be canceled and terminated and in such event neither Tenant nor any person claiming through or under Tenant or by virtue of any statute or of an order of any court shall be entitled to possession or to remain in possession of the Premises, but shall forthwith quit and surrender the Premises, and Landlord, in addition to the other rights and remedies granted by </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;12</font><font style="color:#000000;"> hereof or by virtue of any other provision contained in this Lease or by virtue of any applicable law, may retain as damages any Rent, Security Deposit or moneys received by it from Tenant or others on behalf of Tenant.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In the event of the occurrence of any of those events specified in this </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;14</font><font style="color:#000000;">, if Landlord shall not choose to exercise, or by applicable law, shall not be able to exercise, its rights hereunder to terminate this Lease upon the occurrence of such events, then, in addition to any other rights of Landlord hereunder or by virtue of applicable law, (i)&#160;Landlord shall not be obligated to provide Tenant with any of the utilities or services specified in </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;7</font><font style="color:#000000;">, unless Landlord has received compensation in advance for such utilities or services, and the parties agree that Landlord&#8217;s reasonable estimate of the compensation required with respect to such services shall control, and (ii)&#160;neither Tenant, as debtor-in-possession, nor any trustee or other person (hereinafter collectively referred to as the &#8220;</font><font style="text-decoration:underline;color:#000000;">Assuming Tenant</font><font style="color:#000000;">&#8221;) shall be entitled to assume this Lease unless on or before the date of such assumption, the Assuming Tenant (x)&#160;cures, or provides adequate assurance that the latter will promptly cure, any existing default under this Lease, (y)&#160;compensates, or provides adequate assurance that the Assuming Tenant will promptly compensate Landlord for any pecuniary loss (including, without limitation, attorneys&#8217; fees and disbursements) resulting from such default, and (z)&#160;provides adequate assurance of future performance under this Lease, it being covenanted and agreed by the parties that, for such purposes, any cure or compensation shall be effected by the immediate payment of any monetary default or any required compensation, or the immediate correction or bonding of any nonmonetary default.&nbsp;&nbsp;For purposes of this Lease, (1)&#160;any &#8220;adequate assurance&#8221; of such cure or compensation shall be effected by the establishment of an escrow fund for the amount at issue or by the issuance of a bond, and (2)&#160;&#8220;adequate assurance&#8221; of future performance shall be effected by the establishment of an escrow fund for the amount at issue or by the issuance of a bond.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">15.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">[INTENTIONALLY OMITTED]</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">16.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Toc3448462"></a><a name="_Toc3448622"></a><a name="_Toc3448721"></a><a name="_Toc3448760"></a><a name="_Toc3448812"></a><a name="_Toc3448463"></a><a name="_Toc3448623"></a><a name="_Toc3448722"></a><a name="_Toc3448761"></a><a name="_Toc3448813"></a><a name="_Toc3448464"></a><a name="_Toc3448814"></a><a name="_Toc3448815"></a><a name="_Toc162863194"></a><a name="_Toc3448466"></a><a name="_Toc3555455"></a><a name="_Toc515875087"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">SUBORDINATION; ATTORNMENT; ESTOPPEL CERTIFICATES</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant agrees that this Lease and the rights of Tenant hereunder shall be subject and subordinate to any and all deeds to secure debt, deeds of trust, security interests, mortgages, master leases, ground leases or other security documents and any and all modifications, renewals, extensions, consolidations and replacements thereof (collectively, &#8220;</font><font style="text-decoration:underline;color:#000000;">Security Documents</font><font style="color:#000000;">&#8221;) which now or hereafter constitute a lien upon or affect the Project, the Building or the Premises.&nbsp;&nbsp;Such subordination shall be effective without the necessity of the execution by Tenant of any additional document for the purpose of evidencing or effecting such subordination.&nbsp;&nbsp;In addition, Landlord shall have </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">the right to subordinate or cause to be subordinated any such Security Documents to this Lease and in such case, in the event of the termination or transfer of Landlord&#8217;s estate or interest in the Project by reason of any termination or foreclosure of any such Security Documents, Tenant shall, notwithstanding such subordination, attorn to and become the Tenant of the successor-in-interest to Landlord at the option of such successor-in-interest.&nbsp;&nbsp;Furthermore, Tenant shall within ten&#160;(10) days of demand therefor execute any instruments or other documents which may be required by Landlord or the holder of any Security Document and specifically shall execute, acknowledge and deliver within ten&#160;(10) days of demand therefor a subordination of lease or subordination of deed of trust or mortgage, in the form required by the holder of the Security Document requesting the document; the failure to do so by Tenant within such time period shall be a material default hereunder; provided, however, the new landlord or the holder of any Security Document shall agree that Tenant&#8217;s quiet enjoyment of the Premises shall not be disturbed as long as Tenant is not in default under this Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If any proceeding is brought for default under any ground or master lease to which this Lease is subject or in the event of foreclosure or the exercise of the power of sale under any mortgage, deed of trust or other Security Document made by Landlord covering the Premises, at the election of such ground lessor, master lessor or purchaser at foreclosure, Tenant shall attorn to and recognize the same as Landlord under this Lease, provided such successor expressly agrees in writing to be bound to all future obligations by the terms of this Lease, and if so requested, Tenant shall enter into a new lease with that successor on the same terms and conditions as are contained in this Lease (for the unexpired Lease Term then remaining).&nbsp;&nbsp;However, in the event of attornment, no successor shall be:&nbsp;&nbsp;(i) liable for any act or omission of Landlord prior to the date such successor becomes Landlord under this Lease; (ii) subject to any defense, claim, counterclaim, set-off or offsets which Tenant may have against Landlord prior to the date such successor becomes Landlord under this Lease; (iii) bound by any prepayment of Rent to Landlord made more than one month prior to its due date; (iv) bound by any obligation to make any payment to Tenant which was required to be made prior to the time such successor becomes Landlord under this Lease; (v) bound by any modification, amendment or renewal, or termination of this Lease made without such successor&#8217;s consent; (vi) liable for the repayment of the Security Deposit, unless the Security Deposit actually is paid to such successor; or (vii)&#160;obligated to perform any improvements to the Project, Building or Premises, provide monies for improvements to the Premises or to expend monies in excess of insurance proceeds or condemnation awards to restore the Premises, Building or Project after a casualty or condemnation, other than the express ongoing obligations of repair or maintenance of Landlord under this Lease that arise after such successor becomes Landlord under this Lease.&nbsp;&nbsp;Tenant hereby waives its rights under any current or future law which gives or purports to give Tenant any right to terminate or otherwise adversely affect this Lease and the obligations of Tenant hereunder in the event of any such foreclosure proceeding or sale.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In addition to any statutory lien for Rent in Landlord&#8217;s favor, Landlord (the secured party for purposes hereof) shall have and Tenant (the debtor for purposes hereof) hereby grants to Landlord, an express contract lien and a continuing security interest to secure the payment of all Rent due hereunder from Tenant, upon all goods, wares, equipment, fixtures, furniture, inventory and other personal property of Tenant (and any transferees or other occupants of the Premises) presently or hereafter situated on the Premises and upon all proceeds of any insurance which may accrue to Tenant by reason of damage or destruction of any such property.&nbsp;&nbsp;In the event of a default under this Lease, Landlord shall have, in addition to any other remedies provided herein or by law, all rights and remedies under the Uniform Commercial Code of the state in which the Premises is located, including without limitation the right to sell the property described in this paragraph at public or private sale upon ten (10) days&#8217; notice to Tenant, which notice Tenant hereby agrees is adequate and reasonable.&nbsp;&nbsp;Tenant hereby agrees to execute such other instruments necessary or desirable in Landlord&#8217;s discretion to perfect the security interest hereby created.&nbsp;&nbsp;Any statutory lien for Rent is not hereby waived, the express contractual lien herein granted being in addition and supplementary thereto.&nbsp;&nbsp;Landlord and Tenant agree that this Lease and the security interest granted herein serve as a financing statement, and a copy or photographic or other reproduction of this paragraph of this Lease may be filed of record by Landlord and have the same force and effect as the original.&nbsp;&nbsp;Tenant warrants and represents that the collateral subject to the security interest granted herein is not purchased or used by Tenant for personal, family or household purposes.&nbsp;&nbsp;Tenant further warrants and represents to Landlord that the lien granted herein constitutes a first and superior lien and that Tenant will not allow the placing of any other lien upon any of the property described in this paragraph without the prior written consent of Landlord.&nbsp;&nbsp;Notwithstanding the provisions of this </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;16(c)</font><font style="color:#000000;"> to the contrary, if Tenant desires to obtain a loan secured by Tenant&#8217;s personal property in the Premises and requests that Landlord execute a lien waiver in connection therewith, Landlord may, in its sole discretion, based upon Landlord&#8217;s review of Tenant&#8217;s financial </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">condition, agree to subordinate its lien rights to the rights of Tenant&#8217;s lender pursuant to a lien subordination on Landlord&#8217;s standard form, provided that Tenant delivers such request in writing to Landlord together with a non-refundable processing fee in the amount of Five Hundred Dollars&#160;($500.00).&nbsp;&nbsp;Tenant shall reimburse Landlord, upon demand, for all reasonable out-of-pocket expenses incurred by Landlord, including, without limitation, attorneys&#8217; fees, in connection with negotiating and entering into such lien subordination agreement.&nbsp;&nbsp;Nothing in this </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;16(c)</font><font style="color:#000000;"> shall permit Tenant to encumber its leasehold interest in the Premises.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant shall, upon not less than ten (10) days&#8217; prior notice by Landlord, execute, acknowledge and deliver to Landlord a statement in writing certifying to those facts for which certification has been requested by Landlord or any current or prospective purchaser, holder of any Security Document, ground lessor or master lessor, including, but without limitation, that (i)&#160;this Lease is unmodified and in full force and effect (or if there have been modifications, that the same is in full force and effect as modified and stating the modifications), (ii)&#160;the dates to which the Basic Annual Rent, Additional Rent and other charges hereunder have been paid, if any, and (iii)&#160;whether Landlord is in default in the performance of any covenant, agreement or condition contained in this Lease and, if so, specifying each such default of which Tenant may have knowledge.&nbsp;&nbsp;The form of the statement attached hereto as </font><font style="font-style:italic;text-decoration:underline;color:#000000;">Exhibit&#160;E</font><font style="color:#000000;"> is hereby approved by Tenant for use pursuant to this </font><font style="text-decoration:underline;color:#000000;">subparagraph&#160;(d)</font><font style="color:#000000;">; however, at Landlord&#8217;s option, Landlord shall have the right to use other forms for such purpose.&nbsp;&nbsp;Tenant&#8217;s failure to execute and deliver such statement within such time shall, at the option of Landlord, constitute a material default under this Lease and, in any event, shall be conclusive upon Tenant that this Lease is in full force and effect without modification except as may be represented by Landlord in any such certificate prepared by Landlord and delivered to Tenant for execution.&nbsp;&nbsp;Any statement delivered pursuant to this </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;16</font><font style="color:#000000;"> may be relied upon by any prospective purchaser of the fee of the Building or the Project or any mortgagee, ground lessor or other like encumbrancer thereof or any assignee of any such encumbrance upon the Building or the Project.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">17.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Toc162863195"></a><a name="_Toc3448467"></a><a name="_Toc3555456"></a><a name="_Toc515875088"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">SALE BY LANDLORD; TENANT&#8217;S REMEDIES; NONRECOURSE LIABILITY</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">In the event of a sale or conveyance by Landlord of the Building or the Project, Landlord shall be released from any and all liability under this Lease.&nbsp;&nbsp;If the Security Deposit has been deposited by Tenant to Landlord prior to such sale or conveyance, Landlord shall transfer the Security Deposit (or any remaining balance at such time) to the purchaser, and upon delivery to Tenant of notice thereof, Landlord shall be discharged from any further liability in reference thereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Landlord shall not be in default of any obligation of Landlord hereunder unless Landlord fails to perform any of its obligations under this Lease within thirty&#160;(30) days after receipt of written notice of such failure from Tenant; provided, however, that if the nature of Landlord&#8217;s obligation is such that more than thirty&#160;(30) days are required for its performance, Landlord shall not be in default if Landlord commences to cure such default within the thirty (30) day period and thereafter diligently prosecutes the same to completion.&nbsp;&nbsp;All obligations of Landlord under this Lease will be binding upon Landlord only during the period of its ownership of the Project and not thereafter.&nbsp;&nbsp;All obligations of Landlord hereunder shall be construed as covenants, not conditions; and, except as may be otherwise expressly provided in this Lease, Tenant may not terminate this Lease for breach of Landlord&#8217;s obligations hereunder.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="El2d32O"></a><a name="El2n32O"></a><a name="El2e32O"></a><a name="El2j32O"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding anything contained in this Lease to the contrary, the obligations of Landlord under this Lease (including any actual or alleged breach or default by Landlord) do not constitute personal obligations of the individual partners, directors, officers, trustees, members or shareholders of Landlord or Landlord&#8217;s members or partners, and Tenant shall not seek recourse against the individual partners, directors, officers, trustees, members or shareholders of Landlord or against Landlord&#8217;s members or partners or against any other persons or entities having any interest in Landlord, or against any of their personal assets for satisfaction of any liability with respect to this Lease.&nbsp;&nbsp;Any liability of Landlord for a default by Landlord under this Lease, or a breach by Landlord of any of its obligations under the Lease, shall be limited solely to its interest in the Project, and in no event shall any personal liability be asserted against Landlord and/or any Landlord Indemnitee in connection with this Lease nor shall any recourse be had to any other property or assets of Landlord, its partners, directors, officers, trustees, members, shareholders or any other persons or entities having any interest in Landlord.&nbsp;&nbsp;Tenant&#8217;s sole and exclusive remedy for a default or breach of this Lease by Landlord shall be either (i<a name="El2d32O"></a>)&#160;an action for damages, or (ii)&#160;an action for injunctive relief; Tenant hereby waiving and agreeing that Tenant shall have no offset rights or right to terminate this Lease on account of any breach or default by Landlord under this Lease.&nbsp;&nbsp;Under no circumstances whatsoever shall Landlord </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;"><a name="El2n32O"></a>ever be liable </font><font style="color:#000000;">for </font><font style="color:#000000;"><a name="El2e32O"></a>punitive, consequential or special damages or loss of profits under this </font><font style="color:#000000;">Lease </font><font style="color:#000000;"><a name="El2j32O"></a>and </font><font style="color:#000000;">Tenant </font><font style="color:#000000;">waives any rights it may have to such damages under this Lease in the event of a breach or default by Landlord under this Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">As a condition to the effectiveness of any notice of default given by Tenant to Landlord, Tenant shall also concurrently give such notice under the provisions of </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;17(b)</font><font style="color:#000000;"> to each beneficiary under a Security Document encumbering the Project of whom Tenant has received written notice (such notice to specify the address of the beneficiary).&nbsp;&nbsp;In the event Landlord shall fail to cure any breach or default within the time period specified in </font><font style="text-decoration:underline;color:#000000;">subparagraph&#160;(b)</font><font style="color:#000000;">, then prior to the pursuit of any remedy therefor by Tenant, each such beneficiary shall have an additional thirty&#160;(30) days within which to cure such default, or if such default cannot reasonably be cured within such period, then each such beneficiary shall have such additional time as shall be necessary to cure such default (including, without limitation, time necessary to obtain possession of the Project if possession is necessary to cure such default), provided that within such thirty&#160;(30) day period, such beneficiary has commenced and is diligently pursuing the remedies available to it which are necessary to cure such default (including, without limitation, as appropriate, commencement of foreclosure proceedings).</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">18.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Toc162863196"></a><a name="_Toc3448468"></a><a name="_Toc3555457"></a><a name="_Toc515875089"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">PARKING; COMMON AREAS</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant shall have the right to the nonexclusive use of the number of parking spaces located in the parking areas of the Project specified in </font><font style="font-style:italic;color:#000000;">Item&#160;13</font><font style="color:#000000;"> of the Basic Lease Provisions for the parking of operational motor vehicles used by Tenant, its officers and employees only on an unreserved basis and in common with the other occupants of the Building and permitted users of the Project, unless otherwise designated by Landlord.&nbsp;&nbsp;Landlord reserves the right, at any time upon written notice to Tenant, to designate the location of Tenant&#8217;s parking spaces as determined by Landlord in its reasonable discretion.&nbsp;&nbsp;The use of such spaces shall be subject to the rules and regulations adopted by Landlord from time to time for the use of the parking areas.&nbsp;&nbsp;Landlord further reserves the right to make such changes to the parking system as Landlord may deem necessary or reasonable from time to time; i.e., Landlord may provide for one or a combination of parking systems, including, without limitation, self-parking, single or double stall parking spaces, and valet assisted parking.&nbsp;&nbsp;Except as otherwise expressly agreed to in this Lease, Tenant agrees that Tenant, its officers and employees shall not be entitled to park in any reserved or specially assigned areas designated by Landlord from time to time in the Project&#8217;s parking areas.&nbsp;&nbsp;Landlord may require execution of an agreement with respect to the use of such parking areas by Tenant and/or its officers and employees in form satisfactory to Landlord as a condition of any such use by Tenant, its officers and employees.&nbsp;&nbsp;A default by Tenant, its officers or employees in the payment of such charges, the compliance with such rules and regulations, or the performance of such agreement(s) shall constitute a material default by Tenant hereunder.&nbsp;&nbsp;Tenant shall not permit or allow any vehicles that belong to or are controlled by Tenant or Tenant&#8217;s officers, employees, suppliers, shippers, customers or invitees to be loaded, unloaded or parked in areas other than those designated by Landlord for such activities.&nbsp;&nbsp;If Tenant permits or allows any of the prohibited activities described in this Paragraph, then Landlord shall have the right, without notice, in addition to such other rights and remedies that it may have, to remove or tow away the vehicle involved and charge the cost to Tenant, which cost shall be immediately payable upon demand by Landlord.&nbsp;&nbsp;Tenant hereby waives any and all rights to install or to require Landlord to make available any electric vehicle charging station(s), whether such rights are granted by or under any present or future Laws.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Subject to </font><font style="text-decoration:underline;color:#000000;">subparagraph&#160;(c)</font><font style="color:#000000;"> below and the remaining provisions of this Lease, Tenant shall have the nonexclusive right, in common with others, to the use of such entrances, lobbies, restrooms, elevators, ramps, drives, stairs, and similar access ways and service ways and other common areas and facilities in and adjacent to the Building and the Project as are designated from time to time by Landlord for the general nonexclusive use of Landlord, Tenant and the other tenants of the Project and their respective employees, agents, representatives, licensees and invitees (&#8220;</font><font style="text-decoration:underline;color:#000000;">Common Areas</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;The use of such Common Areas shall be subject to the rules and regulations contained herein and the provisions of any covenants, conditions and restrictions affecting the Building or the Project.&nbsp;&nbsp;Tenant shall keep all of the Common Areas free and clear of any obstructions created or permitted by Tenant or resulting from Tenant&#8217;s operations, and shall use the Common Areas only for normal activities, ingress and egress by Tenant and its employees, agents, representatives, licensees and invitees to and from the Premises, the Building or the Project.&nbsp;&nbsp;If, in the reasonable opinion of Landlord, unauthorized persons are using the Common Areas by reason of the presence of Tenant in the Premises, Tenant, upon demand of Landlord, shall correct such situation by appropriate action or proceedings against all such unauthorized persons.&nbsp;&nbsp;Nothing herein shall affect the rights of Landlord at any time to remove any such unauthorized persons from said areas or to prevent the use of any of said areas by unauthorized </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">persons.&nbsp;&nbsp;Landlord reserves the right to make such changes, alterations, additions, deletions, improvements, repairs or replacements in or to the Building, the Project (including the Premises, in accordance with </font><font style="text-decoration:underline;color:#000000;">Paragraph 13</font><font style="color:#000000;">) and the Common Areas as Landlord may reasonably deem necessary or desirable, including, without limitation, constructing new buildings and making changes in the location, size, shape and number of driveways, entrances, parking spaces, parking areas, loading areas, landscaped areas and walkways; provided, however, that there shall be no unreasonable permanent obstruction of access to or use of the Premises resulting therefrom.&nbsp;&nbsp;In the event that the Project is not completed on the date of execution of this Lease, Landlord shall have the sole judgment and discretion to determine the architecture, design, appearance, construction, workmanship, materials and equipment with respect to construction of the Project.&nbsp;&nbsp;Notwithstanding any provision of this Lease to the contrary, the Common Areas shall not in any event be deemed to be a portion of or included within the Premises leased to Tenant and the Premises shall not be deemed to be a portion of the Common Areas.&nbsp;&nbsp;This Lease is granted subject to the terms hereof, the rights and interests of third parties under existing liens, ground leases, easements and encumbrances affecting such property, all zoning regulations, rules, ordinances, building restrictions and other laws and regulations now in effect or hereafter adopted by any governmental authority having jurisdiction over the Project or any part thereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_DV_M215"></a><a name="_DV_M216"></a><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Notwithstanding any provision of this Lease to the contrary, Landlord specifically reserves the right to redefine the term &#8220;</font><font style="text-decoration:none;color:#000000;">Project</font><font style="color:#000000;"><a name="_DV_M215"></a>&#8221; for purposes of allocating and calculating <a name="_DV_M216"></a>Operating Costs and Electricity Utility Charges so as to include or exclude areas as Landlord shall from time to time determine or specify (and any such determination or specification shall be without prejudice to Landlord&#8217;s right to revise thereafter such determination or specification).&nbsp;&nbsp;In addition, Landlord shall have the right to contract or otherwise arrange for amenities, services or utilities (the cost of which is included within Operating Costs or Electricity Utility Charges) to be on a common or shared basis to both the Project (i.e., the area with respect to which Operating Costs or Electricity Utility Charges are determined) and adjacent areas not included within the Project, so long as the basis on which the cost of such amenities, services or utilities is allocated to the Project is determined on an arms-length basis or some other basis reasonably determined by Landlord.&nbsp;&nbsp;In the case where the definition of the Project is revised for purposes of the allocation or determination of Operating Costs or Electricity Utility Charges, Tenant&#8217;s Proportionate Share shall be appropriately revised to equal the percentage share of all Rentable Area contained within the Project (as then defined) represented by the Premises.&nbsp;&nbsp;The Rentable Area of the Project is subject to adjustment by Landlord from time to time to reflect any re-measurement thereof by Landlord&#8217;s architect, at Landlord&#8217;s request, and/or as a result of any additions or deletions to any of the buildings in the Project as designated by Landlord.&nbsp;&nbsp;Landlord shall have the sole right to determine which portions of the Project and other areas, if any, shall be served by common management, operation, maintenance and repair.&nbsp;&nbsp;Landlord shall also have the right, in its sole discretion, to allocate and prorate any portion or portions of the Operating Costs and/or Electricity Utility Charges on a building-by-building basis, on an aggregate basis of all buildings in the Project, or any other reasonable manner, and if allocated on a Building basis, then Tenant&#8217;s Proportionate Share shall, as to the portion of the Operating Costs and/or Electricity Utility Charges so allocated, be based on the ratio of the Rentable Area of the Premises to the Rentable Area of the Building. Landlord shall have the exclusive rights to the airspace above and around, and the subsurface below, the Premises and other portions of the Building and Project.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:bold;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">19.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><a name="_Toc162863197"></a><a name="_Toc3448469"></a><a name="_Toc3555458"></a><a name="_Toc515875090"></a><font style="Background-color:#auto;text-decoration:none;"></font><font style="font-weight:normal;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">MISCELLANEOUS</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Attorneys&#8217; Fees</font><font style="color:#000000;">.&nbsp;&nbsp;In the event of any legal action or proceeding brought by either party against the other arising out of this Lease, the prevailing party shall be entitled to recover reasonable attorneys&#8217; fees and costs (including, without limitation, court costs and expert witness fees) incurred in such action.&nbsp;&nbsp;Such amounts shall be included in any judgment rendered in any such action or proceeding.&nbsp;&nbsp;This provision shall survive any termination or expiration of the Lease.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(b)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Waiver</font><font style="color:#000000;">.&nbsp;&nbsp;No waiver by Landlord of any provision of this Lease or of any breach by Tenant hereunder shall be deemed to be a waiver of any other provision hereof, or of any subsequent breach by Tenant.&nbsp;&nbsp;Landlord&#8217;s consent to or approval of any act by Tenant requiring Landlord&#8217;s consent or approval under this Lease shall not be deemed to render unnecessary the obtaining of Landlord&#8217;s consent to or approval of any subsequent act of Tenant.&nbsp;&nbsp;No act or thing done by Landlord or Landlord&#8217;s agents during the Lease Term shall be deemed an acceptance of a surrender of the Premises, unless in writing signed by Landlord.&nbsp;&nbsp;The delivery of the keys to any employee or agent of Landlord shall not operate as a termination of the Lease or a surrender of the Premises.&nbsp;&nbsp;The acceptance of any Rent by Landlord following a breach of this Lease by Tenant shall not constitute a waiver by Landlord of such breach or any other breach unless such waiver is expressly stated in a writing signed by Landlord.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Notices</font><font style="color:#000000;">.&nbsp;&nbsp;Any notice, demand, request, consent, approval, disapproval, certificate or other communication (&#8220;</font><font style="text-decoration:underline;color:#000000;">Notice</font><font style="color:#000000;">&#8221;) required or desired to be given under this Lease shall be in writing and given by certified mail, return receipt requested, by personal delivery or by Federal Express or a similar nationwide overnight delivery service providing a receipt for delivery.&nbsp;&nbsp;Notices may not be given by facsimile or electronic mail (unless expressly agreed by the parties).&nbsp;&nbsp;The date of giving any Notice shall be deemed to be the date upon which delivery is actually made by one of the methods described in this </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;19(c)</font><font style="color:#000000;"> (or attempted if said delivery is refused or rejected).&nbsp;&nbsp;If a Notice is received on a Saturday, Sunday or legal holiday, it shall be deemed received on the next business day.&nbsp;&nbsp;All notices, demands, requests, consents, approvals, disapprovals certificates or other communications shall be addressed at the address specified in </font><font style="font-style:italic;text-decoration:underline;color:#000000;">Item&#160;14</font><font style="color:#000000;"> of the Basic Lease Provisions or to such other addresses as may be specified by written notice from Landlord to Tenant and if to Tenant, at the Premises.&nbsp;&nbsp;Either party may change its address by giving reasonable advance written Notice of its new address in accordance with the methods described in this Paragraph; provided, however, no Notice of either party&#8217;s change of address shall be effective until fifteen&#160;(15) days after the addressee&#8217;s actual receipt thereof. For the purpose of this Lease, Landlord&#8217;s counsel may provide Notices to Tenant on behalf of Landlord and such Notices shall be binding on Tenant as if such Notices have been provided directly by Landlord.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Access Control</font><font style="color:#000000;">.&nbsp;&nbsp;Landlord shall be the sole determinant of the type and amount of any access control or courtesy guard services to be provided to the Project, if any.&nbsp;&nbsp;IN ALL EVENTS, LANDLORD SHALL NOT BE LIABLE TO TENANT, AND TENANT HEREBY WAIVES ANY CLAIM AGAINST LANDLORD, FOR (I)&#160;ANY UNAUTHORIZED OR CRIMINAL ENTRY OF THIRD PARTIES INTO THE PREMISES, THE BUILDING OR THE PROJECT, (II)&#160;ANY DAMAGE TO PERSONS, OR (III)&#160;ANY LOSS OF PROPERTY IN AND ABOUT THE PREMISES, THE BUILDING OR THE PROJECT, BY OR FROM ANY UNAUTHORIZED OR CRIMINAL ACTS OF THIRD PARTIES, REGARDLESS OF ANY ACTION, INACTION, FAILURE, BREAKDOWN, MALFUNCTION AND/OR INSUFFICIENCY OF THE ACCESS CONTROL OR COURTESY GUARD SERVICES PROVIDED BY LANDLORD, IF ANY.&nbsp;&nbsp;Tenant shall provide such supplemental security services and shall install within the Premises such supplemental security equipment, systems and procedures as may reasonably be required for the protection of its employees and invitees, provided that Tenant shall coordinate such services and equipment with any security provided by Landlord.&nbsp;&nbsp;The determination of the extent to which such supplemental security equipment, systems and procedures are reasonably required shall be made in the sole judgment, and shall be the sole responsibility, of Tenant.&nbsp;&nbsp;Tenant acknowledges that it has neither received nor relied upon any representation or warranty made by or on behalf of Landlord with respect to the safety or security of the Premises or the Project or any part thereof or the extent or effectiveness of any security measures or procedures now or hereafter provided by Landlord, and further acknowledges that Tenant has made its own independent determinations with respect to all such matters.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Storage</font><font style="color:#000000;">.&nbsp;&nbsp;Any storage space at any time leased to Tenant hereunder shall be used exclusively for storage.&nbsp;&nbsp;Notwithstanding any other provision of this Lease to the contrary, (i)&#160;Landlord shall have no obligation to provide heating, cleaning, water or air conditioning therefor, and (ii)&#160;Landlord shall be obligated to provide to such storage space only such electricity as will, in Landlord&#8217;s judgment, be adequate to light said space as storage space.&nbsp;&nbsp;Landlord may require execution of an agreement with respect to the use of any storage areas by Tenant and/or its officers and employees in form satisfactory to Landlord as a condition of any such use by Tenant, its officers and employees.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Holding Over</font><font style="color:#000000;">.&nbsp;&nbsp;If Tenant retains possession of the Premises after the termination or expiration of the Lease Term without prior written approval of Landlord, then Tenant shall, at Landlord&#8217;s election, become a tenant </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">at sufferance (and not a tenant at will), such possession shall be subject to immediate termination by Landlord at any time, and all of the other terms and provisions of this Lease (excluding any expansion or renewal option or other similar right or option) shall be applicable during such holdover period, except that Tenant shall pay Landlord from time to time, upon demand, as Basic Annual Rent for the holdover period, an amount equal to </font><font style="color:#000000;">one hundred fifty percent (150%) of </font><font style="color:#000000;">the Basic Annual Rent in effect on the termination date, computed on a monthly basis for each month or part thereof during such holding over.&nbsp;&nbsp;All other payments (including payments of Additional Rent) shall continue under the terms of this Lease.&nbsp;&nbsp;In addition, Tenant shall be liable for all damages incurred by Landlord </font><font style="color:#000000;">as a result of</font><font style="color:#000000;"> such holding over, including, without limitation, any claim made by any succeeding tenant based thereon.&nbsp;&nbsp;No holding over by Tenant, whether with or without consent of Landlord, shall operate to extend this Lease except as otherwise expressly provided, and this Paragraph shall not be construed as consent for Tenant to retain possession of the Premises.&nbsp;&nbsp;The provisions of this </font><font style="text-decoration:underline;color:#000000;">Paragraph 19(f)</font><font style="color:#000000;"> shall not be deemed to limit or constitute a waiver of any other rights or remedies of Landlord provided herein or at law.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Condition of Premises</font><font style="color:#000000;">.&nbsp;&nbsp;EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS LEASE, LANDLORD HEREBY DISCLAIMS ANY EXPRESS OR IMPLIED REPRESENTATION OR WARRANTY THAT THE PREMISES ARE SUITABLE FOR TENANT&#8217;S INTENDED PURPOSE OR USE, WHICH DISCLAIMER IS HEREBY ACKNOWLEDGED BY TENANT.&nbsp;&nbsp;THE TAKING OF POSSESSION BY TENANT SHALL BE CONCLUSIVE EVIDENCE THAT TENANT:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">ACCEPTS THE PREMISES, THE BUILDING AND LEASEHOLD IMPROVEMENTS AS SUITABLE FOR THE PURPOSES FOR WHICH THE PREMISES WERE LEASED;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">ACCEPTS THE PREMISES AND PROJECT AS BEING IN GOOD AND SATISFACTORY CONDITION;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">WAIVES ANY DEFECTS IN THE PREMISES AND ITS APPURTENANCES EXISTING NOW OR IN THE FUTURE, EXCEPT THAT TENANT&#8217;S TAKING OF POSSESSION SHALL NOT BE DEEMED TO WAIVE LANDLORD&#8217;S COMPLETION OF MINOR FINISH WORK ITEMS THAT DO NOT INTERFERE WITH TENANT&#8217;S OCCUPANCY OF THE PREMISES; AND</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">WAIVES ALL CLAIMS BASED ON ANY IMPLIED WARRANTY OF SUITABILITY OR HABITABILITY.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(h)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Quiet Possession</font><font style="color:#000000;">.&nbsp;&nbsp;Upon Tenant&#8217;s paying the Rent reserved hereunder and observing and performing all of the covenants, conditions and provisions on Tenant&#8217;s part to be observed and performed hereunder, Tenant shall have quiet possession of the Premises for the Lease Term hereof without hindrance or ejection by any person lawfully claiming under Landlord, subject to the provisions of this Lease and to the provisions of any (i)&#160;covenants, conditions and restrictions, (ii)&#160;master lease, or (iii)&#160;Security Documents to which this Lease is subordinate or may be subordinated.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Matters of Record</font><font style="color:#000000;">.&nbsp;&nbsp;Except as otherwise provided herein, this Lease and Tenant&#8217;s rights hereunder are subject and subordinate to all matters affecting Landlord&#8217;s title to the Project recorded in the Real Property Records of the County in which the Project is located, prior to and subsequent to the date hereof, including, without limitation, all covenants, conditions and restrictions.&nbsp;&nbsp;Tenant agrees for itself and all persons in possession or holding under it that it will comply with and not violate any such covenants, conditions and restrictions or other matters of record.&nbsp;&nbsp;Landlord reserves the right, from time to time, to grant such easements, rights and dedications as Landlord deems necessary or desirable, and to cause the recordation of parcel maps and covenants, conditions and restrictions affecting the Premises, the Building or the Project, as long as such easements, rights, dedications, maps, and covenants, conditions and restrictions do not materially interfere with the use of the Premises by Tenant.&nbsp;&nbsp;At Landlord&#8217;s request, Tenant shall join in the execution of any of the aforementioned documents.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(j)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Successors and Assigns</font><font style="color:#000000;">.&nbsp;&nbsp;Except as otherwise provided in this Lease, all of the covenants, conditions and provisions of this Lease shall be binding upon and shall inure to the benefit of the parties hereto and their respective heirs, personal representatives, successors and assigns.&nbsp;&nbsp;Tenant shall attorn to each purchaser, successor or assignee of Landlord upon the terms and condition hereof.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(k)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Brokers</font><font style="color:#000000;">.&nbsp;&nbsp;Landlord has entered into an agreement with Landlord&#8217;s Broker specified in </font><font style="font-style:italic;color:#000000;">Item&#160;12</font><font style="color:#000000;"> of the Basic Lease Provision as representing Landlord, and Landlord shall pay any commissions or fees that are payable to Landlord&#8217;s Broker with respect to this Lease in accordance with the provisions of a separate commission contract.&nbsp;&nbsp;Landlord shall have no further or separate obligation for payment of commissions or fees to any other real estate broker, finder or intermediary.&nbsp;&nbsp;Tenant represents that it has not had any dealings with any real estate broker, </font><font style="color:#000000;">finder</font><font style="color:#000000;"> or intermediary with respect to this Lease, other than Landlord&#8217;s Broker and Tenant&#8217;s Broker specified in </font><font style="font-style:italic;color:#000000;">Item&#160;12</font><font style="color:#000000;"> of the Basic Lease Provision as representing Tenant.&nbsp;&nbsp;Any commissions or fees payable to Tenant&#8217;s Broker with respect to this Lease shall be paid exclusively by Landlord&#8217;s Broker.&nbsp;&nbsp;Each party represents and warrants to the other, that, to its knowledge, no other broker, agent or finder (a) negotiated or was instrumental in negotiating or consummating this Lease on its behalf, and (b) is or might be entitled to a commission or compensation in connection with this Lease.&nbsp;&nbsp;Tenant shall indemnify, protect, defend (by counsel reasonably approved in writing by Landlord) and hold Landlord harmless from and against any and all claims, judgments, suits, causes of action, damages, losses, liabilities and expenses (including attorneys&#8217; fees and court costs) resulting from any breach by Tenant of the foregoing representation, including, without limitation, any claims that may be asserted against Landlord by any broker, agent or finder undisclosed by Tenant herein.&nbsp;&nbsp;Landlord shall indemnify, protect, defend (by counsel reasonably approved in writing by Tenant) and hold Tenant harmless from and against any and all claims, judgments, suits, causes of action, damages, losses, liabilities and expenses (including attorneys&#8217; fees and court costs) resulting from any breach by Landlord of the foregoing representation, including, without limitation, any claims that may be asserted against Tenant by any broker, agent or finder undisclosed by Landlord herein.&nbsp;&nbsp;The foregoing indemnities shall survive the expiration or earlier termination of this Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(l)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Project or Building Name and Signage</font><font style="color:#000000;">.&nbsp;&nbsp;Landlord shall have the right at any time to change the name of the Project or Building and to install, affix and maintain any and all signs on the exterior and on the interior of the Project or Building as Landlord may, in Landlord&#8217;s sole discretion, desire.&nbsp;&nbsp;Tenant shall not use the name of the Project or Building or use pictures or illustrations of the Project or Building in advertising or other publicity or for any purpose other than as the address of the business to be conducted by Tenant in the Premises, without the prior written consent of Landlord.&nbsp;&nbsp;Additionally, Landlord shall have the exclusive right at all times during the Lease Term to change, modify, add to or otherwise alter the name, number, or designation of the Building and/or the Project, and Landlord shall not be liable for claims or damages of any kind which may be attributed thereto or result therefrom.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(m)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Examination and Submission of Lease</font><font style="color:#000000;">.&nbsp;&nbsp;Submission of this instrument for examination or signature by Tenant does not constitute a reservation of or option for lease, and it is not effective as a lease or otherwise until full execution by and delivery to both Landlord and Tenant.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(n)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Time</font><font style="color:#000000;">.&nbsp;&nbsp;Time is of the essence of this Lease and each and all of its provisions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(o)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Defined Terms and Marginal Headings</font><font style="color:#000000;">.&nbsp;&nbsp;The words &#8220;Landlord&#8221; and &#8220;Tenant&#8221; as used herein shall include the plural as well as the singular and for purposes of </font><font style="text-decoration:underline;color:#000000;">Paragraphs&#160;5,&#160;7,&#160;13 and&#160;18</font><font style="color:#000000;">, the term Landlord shall include Landlord, its employees, contractors and agents.&nbsp;&nbsp;The marginal headings and titles to the paragraphs of this Lease are not a part of this Lease and shall have no effect upon the construction or interpretation of any part hereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(p)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Conflict of Laws; Prior Agreements; Separability</font><font style="color:#000000;">.&nbsp;&nbsp;This Lease shall be governed by and construed pursuant to the laws of the State of California.&nbsp;&nbsp;This Lease contains all of the agreements of the parties hereto with respect to any matter covered or mentioned in this Lease.&nbsp;&nbsp;No prior agreement, understanding or representation pertaining to any such matter shall be effective for any purpose.&nbsp;&nbsp;No provision of this Lease may be amended or added to except by an agreement in writing signed by the parties hereto or their respective successors in interest.&nbsp;&nbsp;The illegality, invalidity or unenforceability of any provision of this Lease shall in no way impair or invalidate any other provision of this Lease, and such remaining provisions shall remain in full force and effect.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(q)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Authority</font><font style="color:#000000;">.&nbsp;&nbsp;If Tenant is a corporation or limited liability company, each individual executing this Lease on behalf of Tenant hereby covenants and warrants that Tenant is a duly authorized and existing corporation or limited liability company, that Tenant has and is qualified to do business in the State, that the corporation or limited liability company has full right and authority to enter into this Lease, and that each person signing on behalf of the corporation is authorized to do so.&nbsp;&nbsp;If Tenant is a partnership or trust, each individual executing this Lease on behalf of Tenant hereby covenants and warrants that he is duly authorized to execute and deliver this Lease on behalf of Tenant in accordance with the terms of such entity&#8217;s partnership or trust agreement.&nbsp;&nbsp;Tenant shall provide Landlord on demand with such evidence of such authority as Landlord shall reasonably request, including, without limitation, resolutions, </font><font style="color:#000000;">certificates</font><font style="color:#000000;"> and opinions of counsel.&nbsp;&nbsp;This Lease shall not be construed to create a partnership, joint venture or similar relationship or arrangement between Landlord and Tenant hereunder.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(r)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Joint and Several Liability</font><font style="color:#000000;">.&nbsp;&nbsp;If two or more individuals, corporations, partnerships or other business associations (or any combination of two or more thereof) shall sign this Lease as Tenant, the liability of each such individual, corporation, partnership or other business association to pay Rent and perform all other obligations hereunder shall be deemed to be joint and several, and all notices, payments and agreements given or made by, with or to any one of such individuals, corporations, partnerships or other business associations shall be deemed to have been given or made by, with or to all of them.&nbsp;&nbsp;In like manner, if Tenant shall be a partnership or other business association, the members of which are, by virtue of statute or federal law, subject to personal liability, then the liability of each such member shall be joint and several.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(s)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Rental Allocation</font><font style="color:#000000;">.&nbsp;&nbsp;For purposes of Section&#160;467 of the Internal Revenue Code of&#160;1986, as amended from time to time, Landlord and Tenant hereby agree to allocate all Rent to the period in which payment is due, or if later, the period in which Rent is paid.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(t)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Rules and Regulations</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant agrees to comply with all rules and regulations of the Building and the Project imposed by Landlord as set forth on </font><font style="font-style:italic;text-decoration:underline;color:#000000;">Exhibit&#160;D</font><font style="color:#000000;"> attached hereto, as the same may be changed from time to time upon reasonable notice to Tenant.&nbsp;&nbsp;Landlord shall not be liable to Tenant for the failure of any other tenant or any of its assignees, subtenants, or their respective agents, employees, representatives, invitees or licensees to conform to such rules and regulations.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(u)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Joint Product</font><font style="color:#000000;">.&nbsp;&nbsp;This Lease is the result of arms-length negotiations between Landlord and Tenant and their respective attorneys.&nbsp;&nbsp;Accordingly, neither party shall be deemed to be the author of this Lease and this Lease shall not be construed against either party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(v)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Financial Statements</font><font style="color:#000000;">.&nbsp;&nbsp;Upon Landlord&#8217;s written request, Tenant shall promptly furnish Landlord, from time to time, with the most current audited financial statements prepared in accordance with generally accepted accounting principles, certified by Tenant and an independent auditor to be true and correct, reflecting Tenant&#8217;s then current financial condition.&nbsp;&nbsp;Tenant hereby represents and warrants that financial statements and other information furnished by Tenant to Landlord are true, accurate and complete, and such representation and warranty shall survive the execution and termination of this Lease and is material consideration relied upon by Landlord in executing this Lease.&nbsp;&nbsp;Any false, misleading or inaccurate statement made by Tenant therein shall constitute a material breach and an event of default hereunder.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(w)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Force Majeure</font><font style="color:#000000;">.&nbsp;&nbsp;Any prevention, delay or stoppage due to strikes, lockouts, labor disputes, acts of God, acts of war, terrorism, terrorist activities, inability to obtain services, labor, or materials or reasonable substitutes therefore, governmental actions, civil commotions, fire, flood, earthquake or other casualty, and other causes beyond the reasonable control of the party obligated to perform, except with respect to the obligations imposed with regard to Rent and other charges to be paid by Tenant pursuant to this Lease and except as to Tenant&#8217;s obligations under </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;6</font><font style="color:#000000;"> and </font><font style="text-decoration:underline;color:#000000;">Paragraph 8</font><font style="color:#000000;"> of this Lease and </font><font style="text-decoration:underline;color:#000000;">Paragraph&#160;19(f)</font><font style="color:#000000;"> of this Lease (collectively, a &#8220;</font><font style="text-decoration:underline;color:#000000;">Force Majeure</font><font style="color:#000000;">&#8221;), notwithstanding anything to the contrary contained in this Lease, shall excuse the performance of such party for a period equal to any such prevention, delay or stoppage and, therefore, if this Lease specifies a time period for performance of an obligation of either party, that time period shall be extended by the period of any delay in such party&#8217;s performance caused by a Force Majeure.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(x)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;">Union Contracts.</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Following notice from Landlord of any union contracts affecting the Land or the Project, Tenant agrees that the exercise of its rights pursuant to the provisions of </font><font style="text-decoration:underline;">Paragraph 4</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of this Lease or any other provisions of this Lease or the Exhibits hereto shall not be done in a manner which would violate such union contracts, nor create any lawful work stoppage, picketing, labor disruption or dispute or any interference with the business of Landlord or any tenant or occupant of the Project.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(y)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Office and Communication Services</font><font style="color:#000000;">.&nbsp;&nbsp;Landlord has advised Tenant that certain office and communications services may be offered to tenants of the Building by a concessionaire under contract with Landlord (&#8220;</font><font style="text-decoration:underline;color:#000000;">Provider</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;Tenant shall be permitted to contract with Provider for the provision of any or all of such services on such terms and conditions as Tenant and Provider may agree.&nbsp;&nbsp;Tenant acknowledges and agrees that:&nbsp;&nbsp;(i)&#160;Landlord has made no warranty or representation to Tenant with respect to the availability of any such services, or the quality, reliability or suitability thereof; (ii)&#160;the Provider is not acting as the agent or representative of Landlord in the provision of such services, and Landlord shall have no liability or responsibility for any failure or inadequacy of such services, or any equipment or facilities used in the furnishing thereof, or any act or omission of Provider, or its agents, employees, representatives, officers or contractors; (iii)&#160;Landlord shall have no responsibility or liability for the installation, alteration, repair, maintenance, furnishing, operation, adjustment or removal of any such services, equipment or facilities; and (iv)&#160;any contract or other agreement between Tenant and Provider shall be independent of this Lease, the obligations of Tenant hereunder, and the rights of Landlord hereunder, and, without limiting the foregoing, no default or failure of Provider with respect to any such services, equipment or facilities, or under any contract or agreement relating thereto, shall have any effect on this Lease or give to Tenant any offset or defense to the full and timely performance of its obligations hereunder, or entitle Tenant to any abatement of Basic Annual Rent or Additional Rent or any other payment required to be made by Tenant hereunder, or constitute any accrual or constructive eviction of Tenant, or otherwise give rise to any other claim of any nature against Landlord.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(z)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Counterparts</font><font style="color:#000000;">.&nbsp;&nbsp;This Lease may be executed in several counterparts, each of which shall be deemed an original, and all of which shall constitute but one and the same instrument. To facilitate execution of this Lease, the parties may execute and exchange counterparts of this Lease via attachment to electronic mail (*.pdf or similar file types).&nbsp;&nbsp;The parties further agree that counterparts of this Lease may be signed electronically via Adobe Sign, DocuSign protocol or other electronic platform.&nbsp;&nbsp;All such signatures may be used in the place of original "wet ink" signatures to this Lease and shall have the same legal effect as the physical delivery of an original signature.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(aa)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Waiver of Jury Trial</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="font-weight:bold;color:#000000;">LANDLORD AND TENANT WAIVE THEIR RESPECTIVE RIGHTS TO TRIAL BY JURY OF ANY CONTRACT OR TORT CLAIM, COUNTERCLAIM, CROSS-COMPLAINT, OR CAUSE OF ACTION IN ANY ACTION, PROCEEDING, OR HEARING BROUGHT BY EITHER PARTY AGAINST THE OTHER ON ANY MATTER ARISING OUT OF OR IN ANY WAY CONNECTED WITH THIS LEASE, THE RELATIONSHIP OF LANDLORD AND TENANT, OR TENANT&#8217;S USE OR OCCUPANCY OF THE LEASED PREMISES, INCLUDING WITHOUT LIMITATION ANY CLAIM OF INJURY OR DAMAGE OR THE ENFORCEMENT OF ANY REMEDY UNDER ANY CURRENT OR FUTURE LAW, STATUTE, REGULATION, CODE, OR ORDINANCE.&nbsp;&nbsp;</font><font style="color:#000000;">Landlord and Tenant agree that this paragraph constitutes a written consent to waiver of trial by jury within the meaning of California Code of Civil Procedure Section&#160;631(a)(2), and Tenant does hereby authorize and empower Landlord to file this paragraph and/or this Lease, as required, with the clerk or judge of any court of competent jurisdiction as a written consent to waiver of jury trial.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref61505299"></a><font style="Background-color:#auto;text-decoration:none;">(bb)</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"><a name="_Ref61505299"></a> </font><font style="text-decoration:underline;color:#000000;">Compliance</font><font style="color:#000000;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">OFAC Compliance</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant certifies, represents, warrants and covenants to Landlord that: (i) it is not, and shall not during the Lease Term become, a person or entity with whom Landlord is restricted from doing business under the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001, H. R. 3162, Public Law 107-56 (commonly known as the &#8220;</font><font style="text-decoration:underline;color:#000000;">USA Patriot Act</font><font style="color:#000000;">&#8221;) and Executive Order Number 13224 on Terrorism Financing, effective September 24, 2001 and regulations promulgated pursuant thereto (collectively, &#8220;</font><font style="text-decoration:underline;color:#000000;">Anti-Terrorism Laws</font><font style="color:#000000;">&#8221;), including, without limitation, persons and entities named on the Office of Foreign Assets Control Specially Designated Nationals and Blocked Persons List (collectively, &#8220;</font><font style="text-decoration:underline;color:#000000;">Prohibited Persons</font><font style="color:#000000;">&#8221;); (ii) to the best of its knowledge, it is not currently engaged in any transactions, provision of services to, or dealings with, or otherwise associated </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">with, any Prohibited Persons, nor otherwise engaged in any activity that would violate Anti-Terrorism Laws in connection with the use or occupancy of the Premises or the Building; and (iii) it will not, during the Lease Term, engage in any transactions, provide services to, deal with, or be otherwise associated with, any Prohibited Persons, nor will it engage in any other activity that would violate Anti-Terrorism Laws in connection with the use or occupancy of the Premises or the Building.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Anti-Corruption Compliance</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant certifies, represents, warrants and covenants to Landlord that it shall not during the Lease Term engage in activities that would violate the provisions of the U.S. Foreign Corrupt Practices Act and the anti-bribery laws of other nations generally. Accordingly, (i) Tenant has not, and shall not, in connection with its performance under this Lease, or in connection with any other business transactions involving Landlord or the Premises, made, promised, or offered to make any payment or transfer of anything of value, directly or indirectly to any US or non-US government official or to an intermediary for payment to any such government official; and, (ii) Tenant has not, and shall not, in connection with its performance under this Lease, or in connection with any other business transactions involving Landlord or the Premises, made, promised, or offered to make any payments or transfers of value that have the purpose or effect of public or commercial bribery, or acceptance of or acquiescence in extortion, kickbacks, or other unlawful or improper means of obtaining business.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Anti-Money Laundering Compliance</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant certifies, represents, warrants and covenants to Landlord that it shall not during the Lease Term engage in activities that would violate the provisions of the US Bank Secrecy Act as amended by the USA Patriot Act (&#8220;</font><font style="text-decoration:underline;color:#000000;">AML Laws</font><font style="color:#000000;">&#8221;).&nbsp;&nbsp;In this regard Tenant will not engage in, facilitate or permit the Premises or the Building to be used in connection with transactions that in any way involve the proceeds of crime under US law or are related to the financing of terrorist activities.&nbsp;&nbsp;Further, Tenant will not use proceeds of crime to pay its obligations under this Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Breach</font><font style="color:#000000;">.&nbsp;&nbsp;If at any time after the date hereof Tenant becomes a Prohibited Person or is accused by The Office of Foreign Assets Control or other Federal Authorities of being associated with a person designated as a Prohibited Person, then it shall notify Landlord within five (5) business days after becoming aware of such designation.&nbsp;&nbsp;If at any time after the date hereof Tenant becomes a Prohibited Person or Tenant otherwise breaches any certification, representation, warranty or covenant set forth in this </font><font style="text-decoration:underline;color:#000000;">Paragraph 19(bb)</font><font style="color:#000000;">, then such event shall constitute an event of default hereunder, entitling Landlord to any and all remedies under this Lease or at law or in equity (including the right to terminate this Lease), without affording Tenant any notice or cure period.&nbsp;&nbsp;Tenant hereby agrees to defend (with counsel reasonably acceptable to Landlord), indemnify, and hold harmless Landlord from and against any and all claims arising from or related to any such breach of the foregoing certifications, representations, warranties and covenants.&nbsp;&nbsp;Tenant&#8217;s indemnification obligations in this </font><font style="text-decoration:underline;color:#000000;">Paragraph 19(bb)</font><font style="color:#000000;"> shall survive the expiration or earlier termination of this Lease.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(cc)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">ERISA</font><font style="color:#000000;">.&#160; Tenant represents, warrants and covenants to Landlord and the Designated Landlord Parties that, as of the date hereof and throughout the Lease Term, Tenant is not, and is not entering into this Lease on behalf of, (i) an employee benefit plan, (ii) a trust holding assets of such a plan or (iii) an entity holding assets of such a plan.&nbsp;&nbsp;Notwithstanding any terms to the contrary in the Lease, in no event may Tenant assign or transfer its interest under this Lease to a third party who is, or is entering into the Lease on behalf of, (i) an employee benefit plan, (ii) a trust holding assets of such a plan or (iii) an entity holding assets of such a plan if such transfer would could cause Landlord to incur any prohibited transaction excise tax penalties or other materially adverse consequences under the Employee Retirement Income Security Act of 1974, as amended, Section 4975 of the Internal Revenue Code of 1986, as amended or similar law.&nbsp;&nbsp;Notwithstanding any provision in this Lease to the contrary, the representations, warranties, covenants and agreements set forth in this Paragraph are intended to inure to the benefit of both Landlord and the Designated Landlord Parties and the Designated Landlord Parties shall be entitled to rely hereon and enforce the provisions of this Paragraph.&nbsp;&nbsp;Tenant acknowledges and agrees that as a condition to the effectiveness of any assignment of, or sublease under, this Lease, and as a requirement and condition of the effectiveness of any consent to assignment or sublease by Landlord pursuant to this Lease, Tenant shall cause the assignee or sublessee to reaffirm, on behalf of such assignee or sublessee, the representations of this Paragraph and </font><font style="text-decoration:underline;color:#000000;">Paragraph 19(bb)</font><font style="color:#000000;"> above, and it shall be reasonable for Landlord to refuse to consent to an assignment of this Lease or sublease of the Premises in the absence of such reaffirmation.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(dd)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Recording</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant shall not record or file this Lease, or any assignment or security document pertaining to this Lease or all or any part of Tenant&#8217;s interest therein without the prior written consent of Landlord, which consent may be subject to such conditions as Landlord shall deem appropriate in its sole discretion.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ee)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Energy Disclosure</font><font style="color:#000000;">.&#160; Tenant acknowledges and agrees that: (a) it has received all disclosures and other documentation or information for the Building required under Section 25402.10 of the California Public Resources Code and its implementing regulations, (b) such disclosure information is for the current occupancy and use of&#160; the Building, (c) the energy profile of the Building will vary depending on future occupancy or use of the Building, (d) the Building has not been proposed for LEED ratings, and (e) Landlord make no claims, representations or warranties regarding the future Energy Star profile of the Building.&#160; Tenant shall reasonably cooperate with Landlord in furnishing any information that may be required in connection with Landlord&#8217;s obligations to furnish energy disclosures as may be required under applicable law, including, without limitation, providing any information that may be required in order to enroll in the US Environmental Protection Agency&#8217;s Energy Star Portfolio Manager.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(ff)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Cannabis</font><font style="color:#000000;">.&nbsp;&nbsp;Tenant agrees that the Premises shall not be used for the use, growing, producing, processing, storing (short or long term), distributing, transporting, or selling of cannabis, cannabis derivatives, or any cannabis containing substances (&#8220;</font><font style="text-decoration:underline;color:#000000;">Cannabis</font><font style="color:#000000;">&#8221;), or any office uses related to the same, nor shall Tenant permit, allow or suffer, any of Tenant&#8217;s officers, employees, agents, servants, licensees, subtenants, concessionaires, contractors and invitees to bring onto the Premises, any Cannabis.&#160; Without limiting the foregoing, the prohibitions in this paragraph shall apply to all Cannabis, whether such Cannabis is legal for any purpose whatsoever under state or federal law or both.&#160; Notwithstanding anything to the contrary, any failure by Tenant to comply with each of the terms, covenants, conditions and provisions of this paragraph shall automatically and without the requirement of any notice be a default that is not subject to cure, and Tenant agrees that upon the occurrence of any such default, Landlord may elect, in its sole discretion, to exercise all of its rights and remedies under this Lease, at law or in equity with respect to such default.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(gg)</font><font style="margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">CASp Disclosure</font><font style="color:#000000;">.&nbsp;&nbsp;As of the Date of this Lease, neither the Building nor the Project has undergone inspection by a Certified Access Specialist (CASp). A CASp can inspect the Premises and determine whether the Premises comply with all of the applicable construction-related accessibility standards under state law.&nbsp;&nbsp;Although state law does not require a CASp inspection of the Premises, Landlord may not prohibit Tenant from obtaining a CASp inspection of the Premises for the occupancy Tenant, if requested by Tenant.&nbsp;&nbsp;The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the Premises.&nbsp;&nbsp;Except as otherwise expressly agreed upon in writing by Landlord, neither Landlord nor the Designated Landlord Parties shall have any obligation for the payment of the CASp fee or the cost of making repairs pursuant thereto, nor shall Landlord or the Designated Landlord Parties have any liability to Tenant arising out of or related to the fact that neither the Project nor the Building has been inspected by a CASp, and Tenant waives all such liability and acknowledges that Tenant shall have no recourse against Landlord or the Project as a result of or in connection therewith.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">[SIGNATURE PAGE TO FOLLOW]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURE PAGE TO OFFICE LEASE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BY AND BETWEEN</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COGNAC DEL MAR OWNER II LLC, AS LANDLORD, AND</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ONCTERNAL THERAPEUTICS, INC., AS TENANT</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, intended to be legally bound hereby, the parties hereto, by their duly authorized representatives, have executed and sealed this Lease with the intention that this Lease constitutes an instrument under seal, and that the parties have executed this Lease to be effective as of the Date of this Lease.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:3.85%;"></td>
<td style="width:6.41%;"></td>
<td style="width:41.46%;"></td>
<td style="width:5.97%;"></td>
<td style="width:42.31%;"></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">&#8220;LANDLORD&#8221;</font></p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">&#8220;TENANT&#8221;</font></p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COGNAC DEL MAR OWNER II LLC,</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ONCTERNAL THERAPEUTICS<font style="font-weight:normal;">,</font></p></td>
</tr>
<tr>
<td colspan="3" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware limited liability company</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware corporation</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="2" valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cognac Del Mar Borrower LLC,</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Richard Vincent</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware limited liability company,</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Richard Vincent</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its sole member</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 17, 2021</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PRISA II LHC, LLC,</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware limited liability company,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">its sole member</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td colspan="3" valign="top"  style=" border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Carly Miller</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td colspan="3" valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Carly Miller</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td colspan="3" valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vice President</p></td>
</tr>
<tr>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style=" border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:</p></td>
<td colspan="3" valign="top"  style=" border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 17, 2021</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739686608.7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\123741849.2&nbsp;&nbsp;Oncternal - Executive Center Del Mar Lease (EDGAR Version)</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT A-1</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">FLOOR PLAN OF THE PREMISES</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Calibri;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gbhcmm0hydxa000001.jpg" title="" alt="" style="width:624px;height:431px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-1 -- 1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739686608.7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\123741849.2&nbsp;&nbsp;Oncternal - Executive Center Del Mar Lease (EDGAR Version)</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT A-2</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">PROJECT SITE PLAN</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-weight:normal;font-style:normal;font-variant: normal;"><img src="gbhcmm0hydxa000002.jpg" title="" alt="" style="width:624px;height:451px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-2 -- 1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739686608.7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\123741849.2&nbsp;&nbsp;Oncternal - Executive Center Del Mar Lease (EDGAR Version)</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT B</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">WORK LETTER</font></p>
<p style="text-align:center;margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Intentionally Omitted]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B-1 -- 1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739686608.7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\123741849.2&nbsp;&nbsp;Oncternal - Executive Center Del Mar Lease (EDGAR Version)</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT C</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">STANDARDS FOR UTILITIES AND SERVICES</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following are the Project Standards for Utilities and Services.&nbsp;&nbsp;Landlord reserves the right to adopt such reasonable, nondiscriminatory modifications and additions hereto as it deems appropriate.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">As long as Tenant is not in default under any of the terms, covenants, conditions, provisions or agreements of this Lease, Landlord shall, subject to the limitations and provisions hereinafter set forth in this </font><font style="font-style:italic;text-decoration:underline;color:#000000;">Exhibit&#160;C</font><font style="color:#000000;">:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Provide automatic passenger elevator facilities on Monday through Friday from 8:00 A.M. to 6:00&#160;P.M. and Saturday from 9:00 A.M. to 1:00 P.M., excepting state and federal holidays (hereinafter referred to as &#8220;</font><font style="text-decoration:underline;color:#000000;">Business Hours</font><font style="color:#000000;">&#8221;), and provide one&#160;(1) automatic passenger elevator at all other times.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Provide to the Premises, during Business Hours (and at other times for an additional charge to be fixed by Landlord), heating, ventilation, and air conditioning (&#8220;</font><font style="text-decoration:underline;color:#000000;">HVAC</font><font style="color:#000000;">&#8221;), when and to the extent, in the judgment of Landlord, any of such services may be required for the comfortable occupancy of the Premises for general office purposes.&nbsp;&nbsp;Landlord shall not be responsible for room temperatures and conditions in the Premises if the lighting and receptacle load for Tenant&#8217;s equipment and fixtures exceed those listed in this </font><font style="text-decoration:underline;color:#000000;">Exhibit C</font><font style="color:#000000;">, if the Premises are used for other than general office purposes or if the Building standard blinds or curtains in the Premises are not closed so as to screen the sun&#8217;s rays.&nbsp;&nbsp;Any after-hours request by Tenant shall be subject to the following: (i) such request must be made at least one (1) business day in advance, (ii)&#160;such request must observe Landlord&#8217;s minimum hours requirement and all requests in excess of such minimum hours requirement shall be increments of one (1) hour, (iii) Tenant shall pay, as additional rent and upon demand, Landlord&#8217;s standard charge for such usage, and (iv) Tenant understands that the Premises may not be separately zoned for HVAC and Tenant shall pay the charge specified in clause (iii) notwithstanding that the provision of after-hours HVAC results in HVAC being provided to other space in the Building or that other tenants of the Building are also paying a charge for after-hours HVAC.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Landlord shall furnish to the Premises twenty-four (24) hours per day, reasonable quantities of electric current as required in Landlord's judgment for normal lighting and fractional horsepower office business machines.&nbsp;&nbsp;Landlord shall also furnish water to the Premises twenty-four (24) hours per day for drinking and lavatory purposes, in such quantities as required in Landlord's judgment for the comfortable and normal use of the Premises.&nbsp;&nbsp;If Tenant requires or consumes water or electrical power in excess of what is considered reasonable or normal by Landlord, Landlord may require Tenant to pay to Landlord, as additional rent, the cost as fairly determined by Landlord incurred for such excess usage. Tenant will not, without the prior written consent of Landlord, use any apparatus, machine or device in the Premises, using current in excess of 110&#160;volts, which will in any way increase the amount of electricity or water usually furnished or supplied for use of the Premises as general office space, nor connect with electric current, except through existing electrical outlets in the Premises, any apparatus or device for the purpose of using electric current in excess of that usually furnished or supplied for use of the Premises as general office space.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Replacement of all standard fluorescent bulbs in all areas and all incandescent bulbs in public areas, rest room areas, and stairwells.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Provide janitorial services to the Premises Monday through Friday (except state and federal holidays), provided the same are used exclusively for the uses permitted under the foregoing Lease, and are kept reasonably in order by Tenant.&nbsp;&nbsp;Tenant shall pay to Landlord the cost of removal of any of Tenant&#8217;s refuse and rubbish, to the extent that the same exceeds the refuse and rubbish which generally would be produced by the use of the Premises for general office purposes.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739686608.7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\123741849.2&nbsp;&nbsp;Oncternal - Executive Center Del Mar Lease (EDGAR Version)</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">2.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No data processing equipment, other special electrical equipment (excluding personal computers utilizing 110&#160;volt electric power), air conditioning or heating units, or plumbing additions shall be installed, nor shall any changes to the Building HVAC, electrical or plumbing systems be made without the prior written consent of Landlord, which consent shall be subject to Landlord&#8217;s sole and absolute discretion.&nbsp;&nbsp;In the case of any such change, Landlord reserves the right to designate and/or approve the contractor to be used.&nbsp;&nbsp;Any permitted installations shall be made under Landlord&#8217;s supervision.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Landlord shall not provide reception outlets or television or radio antennas for television or radio broadcast reception, and Tenant shall not install any such equipment without prior written approval from Landlord.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant agrees to cooperate fully at all times with Landlord, and to abide by all regulations and requirements which Landlord may prescribe for the proper functioning and protection of the Building HVAC, electrical, plumbing and other systems.&nbsp;&nbsp;Tenant shall comply with all Laws, statutes, ordinances and governmental rules and regulations now in force or which may hereafter be enacted or promulgated in connection with Building services furnished to the Premises, including, without limitation, any governmental rule or regulation relating to the heating and cooling of the Building.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C-2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739686608.7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\123741849.2&nbsp;&nbsp;Oncternal - Executive Center Del Mar Lease (EDGAR Version)</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT D</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">BUILDING RULES AND REGULATIONS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The sidewalks, entrances, passages, courts, elevators, vestibules, stairways and corridors of halls shall not be obstructed or used for any purpose other than ingress and egress.&nbsp;&nbsp;The halls, passages, entrances, elevators, stairways, balconies and roof are not for the use of the general public, and the Landlord shall in all cases retain the right to control and prevent access thereto of all persons whose presence, in the judgment of the Landlord, shall be prejudicial to the safety, character, reputation and interests of the Building and its tenants, provided that nothing herein contained shall be construed to prevent such access to persons with whom the Tenant normally deals only for the purpose of conducting its business in the Premises (such as clients, customers, office suppliers and equipment vendors, and the like) unless such persons are engaged in illegal activities.&nbsp;&nbsp;No tenant and no employees of any tenant shall go upon the roof of the Building without the written consent of Landlord.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No awnings or other projections shall be attached to the outside walls of the Building.&nbsp;&nbsp;No curtains, blinds, shades or screens shall be attached to or hung in, or used in connection with, any window or door of the Premises other than Landlord standard window coverings.&nbsp;&nbsp;All electrical ceiling fixtures hung in offices or spaces along the perimeter of the Building must be fluorescent, of a quality, type, design and bulb color approved by Landlord.&nbsp;&nbsp;Neither the interior nor the exterior of any windows shall be coated or otherwise sunscreened without the written consent of Landlord.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No sign, advertisement, notice or handbill shall be exhibited, distributed, painted or affixed by any tenant on, about or from any part of the Premises, the Building or the Project without the prior written consent of the Landlord.&nbsp;&nbsp;If the Landlord shall have given such consent at the time, whether before or after the execution of this Lease, such consent shall in no way operate as a waiver or release of any of the provisions hereof or of this Lease, and shall be deemed to relate only to the particular sign, advertisement or notice so consented to by the Landlord and shall not be construed as dispensing with the necessity of obtaining the specific written consent of the Landlord with respect to each and every such sign, advertisement or notice other than the particular sign, advertisement or notice, as the case may be, so consented to by the Landlord.&nbsp;&nbsp;In the event of the violation of the foregoing by any tenant, Landlord may remove or stop same without any liability, and may charge the expense incurred in such removal or stopping to such tenant.&nbsp;&nbsp;Interior signs on doors and the directory tablet shall be inscribed, painted or affixed for each tenant by the Landlord at the expense of such tenant, and shall be of a size, color and style acceptable to the Landlord.&nbsp;&nbsp;The directory tablet will be provided exclusively for the display of the name and location of tenants only and Landlord reserves the right to exclude any other names therefrom.&nbsp;&nbsp;Nothing may be placed on the exterior of corridor walls or corridor doors other than Landlord&#8217;s standard lettering.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The sashes, sash doors, skylights, windows, and doors that reflect or admit light and air into halls, passageways or other public places in the Building shall not be covered or obstructed by any tenant, nor shall any bottles, parcels or other articles be placed on the window sills.&nbsp;&nbsp;Tenant shall see that the windows, transoms and doors of the Premises are closed and securely locked before leaving the Building and must observe strict care not to leave windows open when it rains.&nbsp;&nbsp;Tenant shall exercise extraordinary care and caution that all water faucets or water apparatus are entirely shut off before Tenant or Tenant&#8217;s employees leave the Building, and that all electricity, gas or air shall likewise be carefully shut off, so as to prevent waste or damage.&nbsp;&nbsp;Tenant shall cooperate with Landlord in obtaining maximum effectiveness of the cooling system by closing window coverings when the sun&#8217;s rays fall directly on the windows of the Premises.&nbsp;&nbsp;Tenant shall not tamper with or change the setting of any thermostats or temperature control valves.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The toilet rooms, water and wash closets and other plumbing fixtures shall not be used for any purpose other than those for which they were considered, and no sweepings, rubbish, rags or other substances shall be thrown therein.&nbsp;&nbsp;All damages resulting from any misuse of the fixtures shall be borne by the tenant who, or whose subtenants, assignees or any of their servants, employees, agents, visitors or licensees shall have caused the same.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No tenant shall mark, paint, drill into, or in any way deface any part of the Premises, the Building or the Project.&nbsp;&nbsp;No boring, cutting or stringing of wires or laying of linoleum or other similar floor coverings shall be permitted, except with the prior written consent of the Landlord and as the Landlord may direct.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D-1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739686608.7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\123741849.2&nbsp;&nbsp;Oncternal - Executive Center Del Mar Lease (EDGAR Version)</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">7.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No bicycles, vehicles, birds or animals of any kind (other than service animals that are required entry to comply with applicable Laws, including the ADA) shall be brought into or kept in or about the Premises, and no cooking shall be done or permitted by any tenant on the Premises, except that the preparation of coffee, tea, hot chocolate and similar items (including those suitable for microwave heating) for tenants and their employees shall be permitted, provided that the power required therefor shall not exceed that amount which can be provided by a 30&#160;amp circuit.&nbsp;&nbsp;No tenant shall cause or permit any unusual or objectionable odors to be produced or permeate the Premises.&nbsp;&nbsp;Smoking or carrying lighted cigars, cigarettes or pipes in the Building is prohibited.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Premises shall not be used for manufacturing or for the storage of merchandise except as such storage may be incidental to Tenant&#8217;s use of the Premises for general office use.&nbsp;&nbsp;No tenant shall occupy or permit any portion of the Premises to be occupied as an office for a public stenographer or typist, or for the manufacture or sale of liquor, narcotics, or tobacco (except by a cigarette vending machine for use by Tenant&#8217;s employees) in any form, or as a medical office, or as a barber or manicure shop, or as an employment bureau, without the express written consent of Landlord.&nbsp;&nbsp;No tenant shall engage or pay any employees on the Premises except those actually working for such tenant on the Premises nor advertise for laborers giving an address at the Premises.&nbsp;&nbsp;The Premises shall not be used for lodging or sleeping or for any immoral or illegal purposes.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No tenant shall make, or permit to be made any unseemly or disturbing noises or disturb or interfere with occupants of this or neighboring buildings or premises or those having business with them, whether by the use of any musical instrument, radio, phonograph, unusual noise, or in any other way.&nbsp;&nbsp;No tenant shall throw anything out of doors, windows or skylights or down the passageways.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No tenant, subtenant or assignee nor any of their servants, employees, agents, visitors or licensees shall at any time bring or keep upon the Premises any flammable, combustible or explosive fluid, chemical or substance.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No additional locks or bolts of any kind shall be placed upon any of the doors or windows by any tenant, nor shall any changes be made in existing locks or the mechanisms thereof.&nbsp;&nbsp;Each tenant must, upon the termination of his tenancy, restore to Landlord all keys of stores, offices, and toilet rooms, either furnished to, or otherwise procured by, such tenant and in the event of the loss of keys so furnished, such tenant shall pay to Landlord the cost of replacing&nbsp;&nbsp;the same or of changing the lock or locks opened by such lost key if Landlord shall deem it necessary to make such changes.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">All removals, or the carrying in or out of any safes, freight, furniture, or bulky matter of any description must take place during the hours which Landlord shall determine from time to time, without the express written consent of Landlord.&nbsp;&nbsp;The moving of safes or other fixtures or bulky matter of any kind must be done upon previous notice to the Project Management Office and under its supervision, and the persons employed by any tenant for such work must be acceptable to the Landlord.&nbsp;&nbsp;Landlord reserves the right to inspect all safes, freight or other bulky articles to be brought into the Building and to exclude from the Building all safes, freight or other bulky articles which violate any of these Rules and Regulations or the Lease of which these Rules and Regulations are a part.&nbsp;&nbsp;Landlord reserves the right to prescribe the weight and position of all safes, which must be placed upon supports approved by Landlord to distribute the weight.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No tenant shall purchase spring water, ice, towel, janitorial maintenance or other similar services from any person or persons not approved by Landlord.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Landlord shall have the right to prohibit any advertising by any tenant which, in Landlord&#8217;s opinion, tends to impair the reputation of the Building or the Project or its desirability as an office location, and upon written notice from Landlord, any tenant shall refrain from or discontinue such advertising.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D-2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739686608.7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\123741849.2&nbsp;&nbsp;Oncternal - Executive Center Del Mar Lease (EDGAR Version)</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">15.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Landlord reserves the right to exclude from the Building between the hours of 6:00&#160;P.M. and 8:00&#160;A.M. and at all hours on Saturday, Sunday and legal holidays all persons who do not present a pass or card key to the Building approved by the Landlord.&nbsp;&nbsp;Each tenant shall be responsible for all persons who enter the Building with or at the invitation of such tenant and shall be liable to Landlord for all acts of such persons.&nbsp;&nbsp;Landlord shall in no case be liable for damages for any error </font><font style="color:#000000;">with regard to</font><font style="color:#000000;"> the admission to or exclusion from the Building of any person.&nbsp;&nbsp;In case of an invasion, mob riot, public excitement or other circumstances rendering such action advisable in Landlord&#8217;s opinion, Landlord reserves the right, without abatement of Rent, to require all persons to vacate the Building and to prevent access to the Building during the continuance of the same for the safety of the tenants, the protection of the Building, and the property in the Building.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">16.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Any persons employed by any tenant to do janitorial work shall, while in the Building and outside of the Premises, be subject to and under the control and direction of the Project Management Office (but not as an agent or servant of said Office or of the Landlord), and such tenant shall be responsible for all acts of such persons.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">17.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">All doors opening onto public corridors shall be kept closed, except when in use for ingress and egress.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">18.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The requirements of Tenant will be attended to only upon application to the Project Management Office.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">19.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Canvassing, soliciting and peddling in the Building are prohibited and each tenant shall report and otherwise cooperate to prevent the same.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">20.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">All office equipment of any electrical or mechanical nature shall be placed by Tenant in the Premises in settings approved by Landlord, to absorb or prevent any vibration, noise or annoyance.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">21.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No air conditioning unit or other similar apparatus shall be installed or used by any tenant without the written consent of Landlord.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">22.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">There shall not be used in any space, or in the public halls of the Building, either by any tenant or others, any hand trucks, except those equipped with rubber tires and rubber side guards.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">23.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No vending machine or machines of any description shall be installed, maintained or operated upon the Premises without the written consent of Landlord.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">24.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The scheduling of tenant move-ins shall be subject to the reasonable discretion of Landlord.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">25.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">If the Tenant desires telephone or telegraph connections, the Landlord will direct electricians as to where and how the wires are to be introduced.&nbsp;&nbsp;No boring or cutting for wires or otherwise shall be made without direction from the Landlord.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">26.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The term &#8220;personal goods or services vendors&#8221; as used herein means persons who periodically enter the Building of which the Premises are a part for the purpose of selling goods or services to a tenant, other than goods or services which are used by the tenant only for the purpose of conducting its business in the Premises.&nbsp;&nbsp;&#8220;Personal goods or services&#8221; include, but are not limited to, drinking water and other beverages, food, barbering services and shoe-shining services.&nbsp;&nbsp;Landlord reserves the right to prohibit personal goods and services vendors from access to the Building except upon Landlord&#8217;s prior written consent and upon such reasonable terms and conditions, including, but not limited to, the payment of a reasonable fee and provision for insurance coverage, as are related to the safety, care and cleanliness of the Building, the preservation of good order thereon, and the relief of any financial or other burden on Landlord or other tenants occasioned by the presence of such vendors or the sale by them of personal goods or services to the tenant or its employees.&nbsp;&nbsp;If necessary for the accomplishment of these purposes, Landlord may exclude a particular vendor entirely or limit the number of vendors who may be present at any one time in the Building.</font></p><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D-3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739686608.7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\123741849.2&nbsp;&nbsp;Oncternal - Executive Center Del Mar Lease (EDGAR Version)</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">27.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Building is a non-smoking building.&nbsp;&nbsp;Smoking (including the use of any e-cigarettes or similar devices) is prohibited at all times within the entire Building, including all leased premises, as well as all public/common areas and parking areas for the Building, including any attached parking garage structure.&nbsp;&nbsp;This prohibition applies during business and non-business hours to restrooms, elevators, elevator lobbies, first floor lobby, stairwells, common hallways, the </font><font style="color:#000000;">lunch room</font><font style="color:#000000;"> and any other public/common area, as well as to all areas within the leased premises by tenants.&nbsp;&nbsp;Smoking is only permitted in the designated smoking area outside the Building and away from the entrances to the Building.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">28.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Building and Project is a weapons free environment.&nbsp;&nbsp;No tenant, owner of a tenant, officer or employee of a tenant, visitor of tenant, contractor or subcontractor of tenant, or any other party shall carry weapons (concealed or not) of any kind in the building, or parking areas.&nbsp;&nbsp;This prohibition applies to all public areas, including without limitation, restrooms, elevators, elevator lobbies, first floor lobby, stairwells, common hallways, all areas within the leased premises of tenants, all surface parking areas and the surrounding land related to the Building.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">PARKING RULES AND REGULATIONS</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the Building Rules and Regulations, the following rules and regulations shall apply with respect to the use of the Building's parking facilities.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Every parker is required to park and lock his/her own vehicle.&nbsp;&nbsp;All responsibility for damage to or loss of vehicles is assumed by the parker and Landlord shall not be responsible for any such damage or loss by water, fire, defective brakes, the act or omissions of others, theft, or for any other cause.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant shall not park or permit its employees to park in any parking areas designated by Landlord as areas for parking by visitors to the Project.&nbsp;&nbsp;Tenant shall not leave vehicles in the parking areas overnight nor park any vehicles in the parking areas other than automobiles, motorcycles, motor driven or non-motor driven bicycles or four wheeled trucks.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Parking stickers or any other device or form of identification supplied by Landlord as a condition of use of the parking facilities shall remain the property of Landlord.&nbsp;&nbsp;Such parking identification device must be displayed as requested and may not be mutilated in any manner.&nbsp;&nbsp;The serial number of the parking identification device may not be obliterated.&nbsp;&nbsp;Devices are not transferable and any device in the possession of an unauthorized holder will be void.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">No overnight or extended term storage of vehicles shall be permitted.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Vehicles must be parked entirely within painted stall lines of a single parking stall.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">All directional signs and arrows must be observed.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The speed limit within all parking areas shall be five (5) miles per hour.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Parking is prohibited:&nbsp;&nbsp;(a)&#160;in areas not striped for parking; (b)&#160;in aisles; (c)&#160;where &#8220;no parking&#8221; signs are posted; (d)&#160;on ramps; (e)&#160;in cross-hatched areas; and (f)&#160;in reserved spaces and in such other areas as may be designated by Landlord or Landlord's parking operator.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Loss or theft of parking identification devices must be reported to the Management Office immediately, and a lost or stolen report must be filed by the Tenant or user of such parking identification device at the time.&nbsp;&nbsp;Landlord has the right to exclude any vehicle from the parking facilities that does not have an identification device.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Any parking identification devices reported lost or stolen found on any unauthorized car will be confiscated and the illegal holder will be subject to prosecution.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D-4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739686608.7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\123741849.2&nbsp;&nbsp;Oncternal - Executive Center Del Mar Lease (EDGAR Version)</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">11.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Washing, waxing, </font><font style="color:#000000;">cleaning</font><font style="color:#000000;"> or servicing of any vehicle in any area not specifically reserved for such purpose is prohibited.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The parking operators, managers or attendants are not authorized to make or allow any exceptions to these rules and regulations.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant's continued right to park in the parking facilities is conditioned upon Tenant abiding by these rules and regulations and those contained in this Lease.&nbsp;&nbsp;Further, if the Lease terminates for any reason whatsoever, Tenant's right to park in the parking facilities shall terminate concurrently therewith.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant agrees to sign a parking agreement with Landlord or Landlord's parking operator within five (5) days of request, which agreement shall provide the manner of payment of monthly parking fees and otherwise be consistent with the Lease and these rules and regulations.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">15.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Landlord reserves the right to refuse the sale or use of monthly stickers or other parking identification devices to any tenant or person who willfully refuse to comply with these rules and regulations and all city, state or federal ordinances, laws or agreements.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">16.</font><font style="font-family:Arial;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Landlord reserves the right to establish and change parking fees, and to modify and/or adopt such other reasonable and non-discriminatory rules and regulations for the parking facilities as it deems necessary for the operation of the parking facilities.&nbsp;&nbsp;Landlord may refuse to permit any person who violates these rules to park in the parking facilities, and any violation of the rules shall subject the vehicle to removal, at such vehicle owner's expense.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D-5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739686608.7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\123741849.2&nbsp;&nbsp;Oncternal - Executive Center Del Mar Lease (EDGAR Version)</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT E</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">FORM ESTOPPEL CERTIFICATE</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The undersigned, ________________________, a _____________ (&#8220;<font style="text-decoration:underline;">Tenant</font>&#8221;), the tenant under that certain Office Lease dated _______________, between Tenant and _____________, a _________, as landlord (&#8220;<font style="text-decoration:underline;">Landlord</font>&#8221;) hereby certifies as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Premises (the &#8220;</font><font style="text-decoration:underline;color:#000000;">Premises</font><font style="color:#000000;">&#8221;) under the Lease is Suite _____, ____________________________.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Lease is in full force and effect and has not been modified or amended in any respect except by amendments dated _________________________&nbsp;&nbsp;(copies of which are attached).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant has accepted, is in sole possession of and is occupying the Premises.&nbsp;&nbsp;Tenant has not subleased all or any part of the Premises, nor has the Lease or Tenant&#8217;s interest in the Premises been assigned, encumbered or transferred in any manner other than:&nbsp;&nbsp;__________________________________________________________________________________________________________________________________________________. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The Commencement Date of the Lease is _______________________________ and the expiration date of the Lease is _____________.&nbsp;&nbsp;There are no options to extend the Lease Term beyond such expiration date other than _________________________.&nbsp;&nbsp;Tenant does not have any option, right of first refusal or other right to purchase all or any part of the property of which the Premises are a part or interest therein.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The present monthly Rent under the Lease is $_____________, consisting of $_________ per month of Basic Annual Rent and $___________ per month of estimated payments of Tenant&#8217;s Proportionate Share of Operating Costs.&nbsp;&nbsp;The sum of $ ___________, representing ___ month&#8217;s Rent has been paid in advance; therefore, Rent under the Lease has been paid through the month of _____________.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant&#8217;s Proportionate Share of Operating Costs is currently ______%.&nbsp;&nbsp;The estimated monthly payments of Tenant&#8217;s Proportionate Share of Operating Costs have been paid through ____________________.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">The security deposit held by Landlord under the Lease is $______________.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="margin-left:36pt;color:#000000;"></font><font style="color:#000000;"> Tenant is entitled to no rent concessions under the Lease other than the following:&nbsp;&nbsp;______________________________________________.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant acknowledges and agrees that any and all improvements or allowances required to be performed or provided by Landlord have been performed or satisfied, except as follows: ____________________________.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Neither Tenant nor the Landlord is in default (or will be in default following the delivery of notice, the passage of time, or both) or claims a default by the other under the Lease, or has any claims, defenses, or rights of offset against payment of Rent under the Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">11.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant acknowledges that Landlord has the right to assign the Lease and the Rent thereunder and to sell, assign, transfer, mortgage or otherwise encumber the Project without the consent of Tenant.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="font-family:Calibri;font-size:11pt;margin-left:36pt;color:#000000;"></font><font style="color:#000000;">Tenant makes this statement for the benefit and protection of ______________ with the understanding that _________________ intends to rely on this statement in connection with ______________.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E-1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739686608.7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\123741849.2&nbsp;&nbsp;Oncternal - Executive Center Del Mar Lease (EDGAR Version)</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, this certificate has been executed and delivered by the authorized officers or representatives of the undersigned as of _______________________.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:50%;">
<tr>
<td colspan="2" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;TENANT&#8221;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:100%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a</p></td>
<td valign="top"  style="width:88.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:88.58%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:88.58%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:88.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:11.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</p></td>
<td valign="top"  style="width:88.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E-2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739686608.7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\123741849.2&nbsp;&nbsp;Oncternal - Executive Center Del Mar Lease (EDGAR Version)</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT F</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Intentionally Omitted]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">F-1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739686608.7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\123741849.2&nbsp;&nbsp;Oncternal - Executive Center Del Mar Lease (EDGAR Version)</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT G</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;text-transform:uppercase;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">AMERICANS WITH DISABILITIES ACT</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant agrees to comply with all requirements of the Americans With Disabilities Act of 1990 (Public Law 101-336 {July&#160;26, 1990}), and any other applicable or related law, code or ordinance applicable to the Premises and the Project, as the same are amended from time to time (collectively, the &#8220;<font style="text-decoration:underline;">Disability Acts</font>&#8221;), to accommodate its employees, invitees and customers.&nbsp;&nbsp;Tenant acknowledges that it shall be wholly responsible for any accommodations or alterations which need to be made to the Premises to cause the same to comply with the Disability Acts.&nbsp;&nbsp;No provision in this Lease should be construed in any manner as permitting, consenting to or authorizing Tenant to violate requirements under any of the Disability Acts and any provision to the Lease which could arguably be construed as authorizing a violation of any of the Disability Acts shall be interpreted in a manner which permits compliance with such Disability Acts. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">G-1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739686608.7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\123741849.2&nbsp;&nbsp;Oncternal - Executive Center Del Mar Lease (EDGAR Version)</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:-7.69%;font-family:Times New Roman;font-size:10pt;"><a name="mpTableOfContents"></a>&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td colspan="2" valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LEASE OF PREMISES</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BASIC LEASE PROVISIONS</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">STANDARD LEASE PROVISIONS</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TERM</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BASIC ANNUAL RENT AND SECURITY DEPOSIT</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADDITIONAL RENT</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IMPROVEMENTS AND ALTERATIONS</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">REPAIRS</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">USE OF PREMISES</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">UTILITIES AND SERVICES</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NON-LIABILITY AND INDEMNIFICATION OF LANDLORD; INSURANCE</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FIRE OR CASUALTY</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">EMINENT DOMAIN</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ASSIGNMENT AND SUBLETTING</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DEFAULT</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ACCESS; CONSTRUCTION</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BANKRUPTCY</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[INTENTIONALLY OMITTED]</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SUBORDINATION; ATTORNMENT; ESTOPPEL CERTIFICATES</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SALE BY LANDLORD; TENANT&#8217;S REMEDIES; NONRECOURSE LIABILITY</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PARKING; COMMON AREAS</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
</tr>
<tr>
<td valign="top"  style="width:5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.</p></td>
<td valign="top"  style="width:90%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MISCELLANEOUS</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">LIST OF EXHIBITS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A-1</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Floor Plan(s)</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A-2</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal Description of the Project</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit B</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Intentionally Omitted]</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit C</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilities and Services</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit D</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Building Rules and Regulations</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit E</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Form Estoppel Certificate</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit F</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Intentionally Omitted]</p></td>
</tr>
<tr>
<td valign="top"  style="width:12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit G</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:87%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ADA</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:-3.85%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-i</a>-</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">739686608.7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">US-DOCS\123741849.2&nbsp;&nbsp;Oncternal - Executive Center Del Mar Lease (EDGAR Version)</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>onct-ex102_247.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex102_247.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 10.2</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;text-transform:uppercase;font-size:11pt;font-style:normal;font-variant: normal;">ONCTERNAL THERAPEUTICS, INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;text-transform:uppercase;font-size:11pt;font-style:normal;font-variant: normal;">NON-EMPLOYEE<font style="text-transform:none;">&#160;DIRECTOR COMPENSATION PROGRAM</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:11pt;font-style:normal;text-transform:none;font-variant: normal;">(Effective Date: March 18, 2021)</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-employee members of the board of directors (the &#8220;<font style="font-weight:bold;font-style:italic;">Board</font>&#8221;) of Oncternal Therapeutics, Inc. (the &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;) shall be eligible to receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this &#8220;<font style="font-weight:bold;font-style:italic;">Program</font>&#8221;) effective from and after March 18, 2021 (the &#8220;<font style="font-weight:bold;font-style:italic;">Effective Date</font>&#8221;).&#160;&#160;The cash and equity compensation described in this Program shall be paid or be made, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any parent or subsidiary of the Company (each, a &#8220;<font style="font-weight:bold;font-style:italic;">Non-Employee Director</font>&#8221;) who may be eligible to receive such cash or equity compensation, unless such Non-Employee Director declines the receipt of such cash or equity compensation by written notice to the Company.&#160;&#160;This Program shall remain in effect&#160;until it is revised or rescinded by further action of the Board.&#160;&#160;This Program may be amended, modified or terminated by the Board at any time in its sole discretion.&#160;The terms and conditions of this Program shall supersede any prior cash and/or equity compensation arrangements between the Company and any of its Non-Employee Directors.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Cash Compensation</font>.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Annual Retainers</font>.&#160;&#160;Each Non-Employee Director shall be eligible to receive an annual retainer of $40,000 for service on the Board.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Additional Annual Retainers</font>.&#160;&#160;In addition, a Non-Employee Director shall receive the following additional annual retainers, as applicable:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Chairperson of the Board</font>.&#160;&#160;A Non-Employee Director serving as Chairperson of the Board shall receive an additional annual retainer of $35,000 for such service.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Audit Committee</font>.&#160;&#160; A Non-Employee Director serving as Chairperson of the Audit Committee shall receive an additional annual retainer of $15,000 for such service.&#160;&#160;Each Non-Employee Director serving as a member of the Audit Committee (other than the Chairperson) shall receive an additional annual retainer of $7,500 for such service.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Compensation Committee</font>.&#160;&#160;A Non-Employee Director serving as Chairperson of the Compensation Committee shall receive an additional annual retainer of $10,000 for such service.&#160;&#160;Each Non-Employee Director serving as a member of the Compensation Committee (other than the Chairperson) shall receive an additional annual retainer of $5,000 for such service.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Nominating and Corporate Governance Committee</font>.&#160;&#160; A Non-Employee Director serving as Chairperson of the Nominating and Corporate Governance Committee shall receive an additional annual retainer of $8,000 for such service.&#160;&#160;Each Non-Employee Director serving as a member of the Nominating and Corporate Governance Committee (other than the Chairperson) shall receive an additional annual retainer of $4,000 for such service.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Science &amp; Technology Committee</font>.&#160;&#160;Each Non-Employee Director serving as a member of the Science &amp; Technology Committee shall receive an additional annual retainer of $8,000 for such service.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Payment of Retainers</font><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;&#160;The annual retainers described in Sections 1(a) and 1(b) shall be earned on a quarterly basis based on a calendar quarter and shall be paid by the Company in arrears not later than the fifteenth day following the end of each calendar quarter.&#160; In the event a Non-Employee Director does not serve as a Non-Employee Director, or in the applicable positions described in Section 1(b), for an entire calendar quarter, the retainer paid to such Non-Employee Director shall be prorated for the portion of such calendar quarter actually served as a Non-Employee Director, or in such position, as applicable.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Equity Compensation</font>.&#160;&#160;Non-Employee Directors shall be granted the equity awards described below.&#160;&#160;The awards described below shall be granted under and shall be subject to the terms and provisions of the Company&#8217;s 2019 Incentive Award Plan or any other applicable Company equity incentive plan then-maintained by the Company (the &#8220;<font style="font-weight:bold;font-style:italic;">Equity Plan</font>&#8221;) and shall be granted subject to the execution and delivery of award agreements, including attached exhibits, in substantially the forms previously approved by the Board, setting forth the vesting schedule applicable to such awards and such other terms as may be required by the Equity Plan.&#160;&#160;All applicable terms of the Equity Plan apply to this Program as if fully set forth herein, and all grants of stock options hereby are subject in all respects to the terms of the Equity Plan.&nbsp;&nbsp;For the avoidance of doubt, the share numbers in this Section 2 shall be subject to adjustment as provided in the Equity Plan.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Initial Awards</font>.&#160;&#160;Each Non-Employee Director who is initially elected or appointed to the Board following the Effective Date shall be automatically granted an option to purchase 50,000 shares of the Company&#8217;s common stock, on the date of such initial election or appointment.&#160;&#160;The awards described in this Section 2(b) shall be referred to as &#8220;<font style="font-weight:bold;font-style:italic;">Initial Awards</font>.&#8221;&#160;&#160;No Non-Employee Director shall be granted more than one (1) Initial Award.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="OLE_LINK1"></a><a name="OLE_LINK2"></a>(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Subsequent Awards</font>.&#160;&#160;A Non-Employee Director who (i) is serving on the Board as of the date of any annual meeting of the Company&#8217;s stockholders and (ii) will continue to serve as a Non-Employee Director immediately following such meeting, shall be automatically granted an option to purchase 25,000 shares of the Company&#8217;s common stock, or with respect to the Non-Employee Director serving as Chairperson of the Board, an option to purchase 37,500 shares of the Company's common stock, on the date of such annual meeting.&#160;&#160;The awards described in this Section 2(c) shall be referred to as &#8220;<font style="font-weight:bold;font-style:italic;">Subsequent Awards</font>.&#8221;&#160;&#160;For the avoidance of doubt, a Non-Employee Director elected for the first time to the Board at an annual meeting of the Company&#8217;s stockholders shall only receive an Initial Award in connection with such election, and shall not receive any Subsequent Award on the date of such meeting as well.&#160;&#160;In the event a Non-Employee Director has not been serving as a member of the Board for twelve (12) months as of the date of any Subsequent Award, the Board may determine to prorate the Subsequent Award to such Non-Employee Director to reflect the number of months served since such initial election through the date of the Subsequent Award.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="OLE_LINK7"></a><a name="OLE_LINK8"></a>(c)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Termination of Employment of Employee Directors</font>.&#160;&#160;Members of the Board who are employees of the Company or any parent or subsidiary of the Company who subsequently terminate their employment with the Company and any parent or subsidiary of the Company and remain on the Board will not receive an Initial Award pursuant to Section 2(b) above, but to the extent that they are otherwise eligible, will be eligible to receive, after termination from employment with the Company and any parent or subsidiary of the Company, Subsequent Awards as described in Section 2(c) above.&#160;&#160;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>(d)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Terms of Awards Granted to Non-Employee Directors</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Purchase Price</font>.&#160;&#160;The per share exercise price of each option granted to a Non-Employee Director shall equal the Fair Market Value (as defined in the Equity Plan) of a share of common stock on the date the option is granted.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Vesting</font><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&#160;&#160;One thirty-sixth of each Initial Award shall vest and become exercisable in substantially equal installments on each monthly anniversary of the date of grant, so that the options subject to each such type of award shall be fully vested on the three-year anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Board through each such vesting date.&#160;One-twelfth of each Subsequent Award shall vest and/or become exercisable in substantially equal installments on each monthly anniversary of the date of grant, so that each Subsequent Award options shall be fully vested on the one-year anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Board through such vesting date.&#160;&#160;Unless otherwise determined by the Board, no portion of an Initial Award or Subsequent Award which is unvested and/or exercisable at the time of a Non-Employee Director&#8217;s termination of service on the Board shall become vested and/or exercisable thereafter.&#160;&#160;</font><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of</font><font style="color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a Non-Employee Director&#8217;s Initial Awards and Subsequent Awards shall vest in full upon the occurrence of a Change in Control (as defined in the Equity Plan).</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Term</font>.&#160;&#160;The term of each stock option granted to a Non-Employee Director shall be ten (10) years from the date the option is granted.&#160;&#160;Upon a Non-Employee Director&#8217;s cessation of service on the Board for any reason, his or her options to purchase shares of the Company&#8217;s common stock granted under this Program shall remain exercisable for twelve (12) months following the cessation of his or her service on the Board (or such longer period as the Board may determine in its discretion on or after the date of grant of such stock options).&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>onct-ex103_248.htm
<DESCRIPTION>EX-10.3
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex103_248.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 10.3</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">EMPLOYMENT TRANSITION AGREEMENT</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Employment Transition Agreement (the &#8220;<font style="font-weight:bold;font-style:italic;">Agreement</font>&#8221;) is entered into by and among Frank Hsu, M.D. (&#8220;<font style="font-weight:bold;font-style:italic;">Executive</font>&#8221;), and Oncternal Therapeutics, Inc. (the &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;) effective as of February 25, 2021 (the &#8220;<font style="font-weight:bold;font-style:italic;">Effective Date</font>&#8221;).</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">Recitals</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Executive is a party to that certain Employment Agreement with the Company dated August 26, 2019 (the &#8220;<font style="font-weight:bold;font-style:italic;">Employment Agreement</font>&#8221;);</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Company desires to continue to employ Executive, and Executive desires to continue employment with the Company, through March 15, 2021 (such date, or any earlier date on which Executive&#8217;s employment with the Company terminates for any reason, the &#8220;<font style="font-weight:bold;font-style:italic;">Transition Date</font>&#8221;), on the terms and conditions set forth in this Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the mutual promises herein contained, the parties agree as follows:</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-weight:bold;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">Agreement</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">1.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Employment Period</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Transition Date</font><font style="color:#000000;">.&nbsp;&nbsp;The Transition Date will occur on March 15, 2021, or such earlier date on which Executive&#8217;s employment with the Company terminates for any reason.&nbsp;&nbsp;The parties acknowledge that the Transition Date will constitute the date of Executive&#8217;s</font><font style="color:#000000;"> &#8220;separation from service&#8221; (as defined in Treasury Regulation Section 1.409A-1(h)). </font><font style="font-weight:bold;color:#000000;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Employment Period</font><font style="color:#000000;">.&nbsp;&nbsp;During the period (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Employment Period</font><font style="color:#000000;">&#8221;) commencing on the Effective Date and ending on the Transition Date, Executive shall continue to be employed by the Company as its Chief Medical Officer.&nbsp;&nbsp;Executive hereby agrees that, effective as of the Transition Date, he shall automatically cease to serve in the position of Chief Medical Officer (and any other titles or officer positions he may hold) of the Company (and any of its affiliates and subsidiaries). Executive shall execute any additional documentation necessary to effectuate the foregoing. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Duties and Responsibilities</font><font style="color:#000000;">.&nbsp;&nbsp;During the Employment Period, Executive will continue to serve the Company as an employee in the role of Chief Medical Officer of the Company.&nbsp;&nbsp;Executive shall be subject to and comply with the policies and procedures generally applicable to employees of the Company to the extent the same are not inconsistent with any term of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Exclusive Services</font><font style="color:#000000;">.&nbsp;&nbsp;During the Employment Period, Executive shall serve and will perform such duties as are customarily associated with his position.&nbsp;&nbsp;Executive agrees to devote his full working time and attention to the business affairs of the Company.&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Compensation During Employment Period</font><font style="color:#000000;">.&nbsp;&nbsp;As compensation for the services to be rendered by Executive to the Company during the Employment Period, Executive shall be paid the compensation and benefits:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(i)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Base Salary</font><font style="color:#000000;">.&nbsp;&nbsp;For the period commencing on the Effective Date and ending on the Transition Date, the Company shall continue to pay to Executive his base salary at the rate of $400,000 per year, payable in accordance with the Company&#8217;s usual pay practices (and in any event no less frequently than monthly). </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(ii)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Annual Bonus</font><font style="color:#000000;">.&nbsp;&nbsp;Executive acknowledges that he has received his annual bonus for 2020 and will not be eligible for any annual bonus for 2021.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iii)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Benefits</font><font style="color:#000000;">.&nbsp;&nbsp;Executive shall be entitled to participate in benefits under the Company&#8217;s benefit plans and arrangements, including, without limitation, any employee benefit plan or arrangement made available in the future by the Company to its senior employees, subject to and on a basis consistent with the terms, conditions and overall administration of such plans and arrangements. The Company shall have the right to amend or delete any such benefit plan or arrangement made available by the Company to its senior employees and not otherwise specifically provided for herein.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(iv)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Expenses</font><font style="color:#000000;">.&nbsp;&nbsp;The Company shall reimburse Executive for reasonable out-of-pocket business expenses incurred in connection with the performance of his duties hereunder, subject to such policies as the Company may from time to time establish, and Executive furnishing the Company with evidence in the form of receipts satisfactory to the Company substantiating the claimed expenditures.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(v)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Paid Time Off</font><font style="color:#000000;">.&nbsp;&nbsp;Executive shall be entitled to such periods of paid time off (&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">PTO</font><font style="color:#000000;">&#8221;) each year as provided from time to time under the Company&#8217;s PTO policy and as otherwise provided for similarly-situated executive employees.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(vi)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Stock Options</font><font style="color:#000000;">.&nbsp;&nbsp;During the Employment Period, Executive&#8217;s stock options granted by the Company shall continue to vest in accordance with the terms of the stock option agreement and the equity plan pursuant to which such stock options were issued.&nbsp;&nbsp;Upon the termination of the Employment Period for any reason, Executive&#8217;s outstanding stock options will cease vesting and any unvested stock options shall terminate.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">At-Will Employment; Termination</font><font style="color:#000000;">.&nbsp;&nbsp;The Company and Executive acknowledge that Executive&#8217;s employment is and shall continue to be at-will, as defined under applicable law, and that Executive&#8217;s employment with the Company may be terminated by either party at any time for any or no reason, with or without notice.&nbsp;&nbsp;If Executive&#8217;s employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, awards or compensation other than as provided in this Agreement.&nbsp;&nbsp;Executive&#8217;s employment under this Agreement shall be terminated immediately on the death of Executive.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Transition Date Matters</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Compensation Through Transition Date</font><font style="color:#000000;">.&nbsp;&nbsp;On the Transition Date, the Company will issue to Executive his final paycheck, reflecting (i) his earned but unpaid base salary through the Transition Date, and (ii) all accrued, unused PTO due Executive through the Transition Date. In addition, as a result of his termination, Executive shall be entitled to receive all benefits, including continuation and conversion rights, provided upon termination of employment under the Company&#8217;s employee benefit plans and policies in accordance with the terms of such plans and policies.&nbsp;&nbsp;The amounts described in this Section 2(a) and Section 2(b) below are referred to as the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Accrued Obligations</font><font style="color:#000000;">.&#8221;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Expense Reimbursements</font><font style="color:#000000;">.&nbsp;&nbsp;The Company, within thirty (30) days after the Transition Date, will reimburse Executive for any and all reasonable and necessary business expenses incurred by Executive in connection with the performance of his job duties prior to the Transition Date, which expenses shall be submitted to the Company with supporting receipts and/or documentation no later than the Transition Date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Benefits</font><font style="color:#000000;">.&nbsp;&nbsp;Executive&#8217;s entitlement to health benefits from the Company, and eligibility to participate in the Company&#8217;s health benefit plans, shall cease on the last day of the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">calendar month during which the </font><font style="color:#000000;">Transition</font><font style="color:#000000;"> </font><font style="color:#000000;">Date occurs, except to the extent Executive elects to and is eligible to receive continued healthcare coverage pursuant to the provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (</font><font style="color:#000000;">&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">COBRA</font><font style="color:#000000;">&#8221;</font><font style="color:#000000;">), for himself and any covered dependents. </font><font style="color:#000000;">Executive</font><font style="color:#000000;">&#8217;</font><font style="color:#000000;">s entitlement to other benefits from the Company, and eligibility to participate in the Company</font><font style="color:#000000;">&#8217;</font><font style="color:#000000;">s other benefit plans and programs, shall cease on the </font><font style="color:#000000;">Transition</font><font style="color:#000000;"> </font><font style="color:#000000;">Date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(d)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Relocation</font><font style="color:#000000;">.&nbsp;&nbsp;Effective February 1, 2021, Executive will not be eligible to receive any further relocation reimbursements or related tax-gross ups under Section 3(h) of the Employment Agreement.&nbsp;&nbsp;In addition, Executive acknowledges that he was provided with temporary housing assistance under Section 3(h)(iv) of the Employment Agreement in excess of $14,000.&nbsp;&nbsp;The Company acknowledges and agrees that it will not require the return or repayment of any such excess temporary housing costs.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Termination Benefits</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Termination Benefits</font>.&nbsp;&nbsp;Upon (i) the expiration of the Employment Period on March 15, 2021, or (ii) any earlier termination of the Employment Period for any reason (other than Executive&#8217;s discharge by the Company for Cause (as defined in the Employment Agreement) or Executive&#8217;s voluntary resignation), and subject to the occurrence of the Release Effective Date (as defined below), Executive&#8217;s compliance with Section 5 and the terms of the Proprietary Information Agreement (as defined below), including Section 5(d) regarding the return of Company property, and the provisions of Section 4, and in addition to the Accrued Obligations, the Company agrees to provide Executive with the following termination benefits, which shall be the sole benefits to which Executive is entitled in connection with his termination of employment (the &#8220;<font style="font-weight:bold;font-style:italic;">Termination Benefits</font>&#8221;):</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Cash Severance</font>.&nbsp;&nbsp;The Company shall pay to Executive a cash termination payment equal to $200,000, which represents Executive&#8217;s base salary for a period of six (6) months, payable in cash in a lump sum within ten (10) days following the Release Effective Date; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">COBRA</font>.&nbsp;&nbsp;For the period beginning on the Transition Date and ending on the date which is six (6) full months following the Transition Date (or, if earlier, (A) the date on which the applicable continuation period under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;<font style="font-weight:bold;font-style:italic;">COBRA</font>&#8221;) expires or (B) the date Executive becomes eligible to receive the equivalent or increased healthcare coverage from a subsequent employer) (such period, the &#8220;<font style="font-weight:bold;font-style:italic;">COBRA Coverage Period</font>&#8221;), if Executive and his eligible dependents who were covered under the Company&#8217;s health insurance plans as of the Transition Date elect to have COBRA coverage and are eligible for such coverage, the Company shall directly pay or reimburse Executive on a monthly basis for an amount equal to (1) the monthly premium Executive is required to pay for continuation coverage pursuant to COBRA for Executive and his eligible dependents who were covered under the Company&#8217;s health plans as of the Transition Date (calculated by reference to the premium as of the Transition Date) less (2) the amount Executive would have had to pay to receive group health coverage for Executive and his covered dependents based on the cost sharing levels in effect on the Transition Date. If any of the Company&#8217;s health benefits are self-funded as of the Transition Date, or if the Company cannot provide the foregoing benefits in a manner that is exempt from Section 409A (as defined below) or that is otherwise compliant with applicable law (including, without limitation, Section 2716 of the Public Health Service Act), instead of providing the payments or reimbursements as set forth above, the Company shall instead pay to Executive the foregoing monthly amount as a taxable monthly payment for the COBRA Coverage Period (or any remaining portion thereof). Executive shall be solely responsible for all matters relating to continuation of coverage pursuant to COBRA, including, without limitation, the election of such coverage and the timely payment of premiums. Executive shall notify the Company immediately; and</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Vesting</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;The vesting and/or exercisability of each of Executive&#8217;s outstanding unvested stock options shall be automatically accelerated on the Release Effective Date as to the number of stock options that would vest over the six (6) month period following the Transition Date had Executive remained continuously employed by the Company during such period.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Release</font>. As a condition to Executive&#8217;s receipt of the Termination Benefits, Executive shall execute and not revoke a general release of all claims in favor of the Company (the &#8220;<font style="font-weight:bold;font-style:italic;">Release</font>&#8221;) in the form attached hereto as <font style="text-decoration:underline;">Exhibit A</font>.&nbsp;&nbsp;The date on which Executive&#8217;s Release becomes effective in accordance with its terms is referred to as the &#8220;<font style="font-weight:bold;font-style:italic;">Release Effective Date</font>.&#8221;&nbsp;&nbsp;In the event Executive&#8217;s Release does not become effective within the fifty-five (55) day period following the Transition Date, Executive shall not be entitled to the aforesaid Termination Benefits.&nbsp;&nbsp;The Termination Benefits set forth above represent full satisfaction of the Company&#8217;s severance obligations to Executive under the Employment Agreement or otherwise.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Exclusive Remedy; No Mitigation</font>. The Termination Benefits shall be the exclusive termination benefits to which Executive is entitled, unless Executive has breached the provisions of this Agreement or the Proprietary Information Agreement, in which case Section 5(e) shall apply. Executive will not be required to mitigate the amount of any payment contemplated by this Agreement, nor will any earnings that Executive may receive from any other source reduce any such payment.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Warranty</font><font style="letter-spacing:-0.1pt;color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">Executive</font><font style="letter-spacing:-0.1pt;color:#000000;"> acknowledges that, other than the compensation set forth in Section 2 above paid to him as provided therein and the Termination Benefits set forth in Section 3 above, he has or will have </font><font style="color:#000000;">received all wages, accrued but unused vacation pay or paid time off, and other compensation or benefits due to him as a result of his employment with and termination from the Company, including any amounts due to him under the Employment Agreement.&nbsp;&nbsp;Executive specifically acknowledges and agrees that the Company does not have any further obligations to Executive for any compensation under the Employment Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:8.65%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Confirmation of Continuing Obligations</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(a)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Proprietary Information and Inventions</font><font style="color:#000000;">.&nbsp;&nbsp;</font><font style="letter-spacing:0.45pt;color:#000000;">Executive </font><font style="color:#000000;">hereby expressly reaffirms his obligations under </font><font style="letter-spacing:0.45pt;color:#000000;">the Proprietary Information and Inventions Agreement (the &#8220;</font><font style="font-weight:bold;font-style:italic;letter-spacing:0.45pt;color:#000000;">Proprietary Information Agreement</font><font style="letter-spacing:0.45pt;color:#000000;">&#8221;)</font><font style="color:#000000;">, a copy of which is attached hereto as </font><font style="text-decoration:underline;color:#000000;">Exhibit B</font><font style="color:#000000;"> and incorporated herein by reference, and agrees that such obligations shall survive the Transition Date.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(b)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;font-size:11pt;color:#000000;">Solicitation of Employees</font><font style="font-size:11pt;color:#000000;">.&nbsp;&nbsp;Executive shall not during the term of Executive&#8217;s employment and for a period of one (1) year following the Transition Date (the &#8220;</font><font style="font-weight:bold;font-style:italic;font-size:11pt;color:#000000;">Restricted Period</font><font style="font-size:11pt;color:#000000;">&#8221;), directly or indirectly, solicit or attempt to solicit any employee of the Company or any of its affiliates to terminate his or her relationship with the Company or its affiliates in order to become an employee or consultant to or for any other person or entity, or otherwise encourage or solicit any employee of the Company or any of its affiliates to leave the Company or such affiliates for any reason or to devote less&nbsp;&nbsp;than all of any such employee&#8217;s efforts to the affairs of the Company.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(c)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;font-size:11pt;color:#000000;">Nondisparagement</font><font style="font-size:11pt;color:#000000;">. Executive shall not disparage the Company, its board of directors, affiliates, or the Company&#8217;s business, and the Company shall not disparage, and shall instruct its then-current members of its board of directors and its executive officers not to disparage, Executive. Nothing contained herein shall preclude any person from enforcing the terms of this Agreement or providing truthful testimony in any judicial or other governmental proceeding when required to do so by legal process.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">(d)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;font-size:11pt;color:#000000;">Return</font><font style="text-decoration:underline;font-size:11pt;letter-spacing:-0.1pt;color:#000000;"> of Property</font><font style="font-size:11pt;letter-spacing:-0.1pt;color:#000000;">.&nbsp;&nbsp;By signing below, Executive represents and warrants that he has returned to the Company </font><font style="font-size:11pt;color:#000000;">all lists, books and records of, or in connection with, the Company&#8217;s business, and all other property belonging to the Company, it being distinctly understood that all such lists, books and records, and other documents, are the property of the Company.&nbsp;&nbsp;Executive further represents and warrants that he has not nor will he copy or transfer any Company information, nor will he maintain any Company information after the Transition Date.&nbsp;&nbsp;Executive&#8217;s compliance with this Section 5(d) shall be a condition to his receipt of the Transition Benefits.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(e)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;font-size:11pt;color:#000000;">Remedy in the Event of Breach</font><font style="font-size:11pt;color:#000000;">.&nbsp;&nbsp;The receipt of the Termination Benefits shall be subject to Executive not violating the provisions of this Agreement or the Proprietary Information Agreement. In the event Executive breaches the provisions of this Agreement or the Proprietary Information Agreement, in addition to all other rights and remedies available to the Company under law or in equity, all continuing payments and benefits to which Executive may otherwise be entitled pursuant to Section 3 shall be immediately suspended, provided that if it is subsequently determined by arbitration or by a court of competent jurisdiction that Executive did not breach such provisions, all suspended amount shall be promptly paid to Executive.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(f)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;font-size:11pt;color:#000000;">Whistleblower Provision</font><font style="font-size:11pt;color:#000000;">.&nbsp;&nbsp;Nothing herein shall be construed to prohibit Executive from communicating directly with, cooperating with, or providing information to, any government regulator, including, but not limited to, the U.S. Securities and Exchange Commission, the U.S. Commodity Futures Trading Commission, or the U.S. Department of Justice. Executive acknowledges that the Company has provided Executive with the following notice of immunity rights in compliance with the requirements of the Defend Trade Secrets Act: (i) Executive shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of proprietary information that is made in confidence to a Federal, State, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, (ii) Executive shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of proprietary information that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal and (iii) if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose the proprietary information to Executive&#8217;s attorney and use the proprietary information in the court proceeding, if Executive files any document containing the proprietary information under seal, and does not disclose the proprietary information, except pursuant to court order.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">(g)</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;font-size:11pt;color:#000000;">Definitions</font><font style="font-size:11pt;color:#000000;">. For purposes of this Section 5, the term &#8220;</font><font style="font-weight:bold;font-style:italic;font-size:11pt;color:#000000;">Company</font><font style="font-size:11pt;color:#000000;">&#8221; means not only Oncternal Therapeutics, Inc., but also any company, partnership or entity which, directly or indirectly, controls, is controlled by or is under common control with Oncternal Therapeutics, Inc.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:8.65%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Cooperation</font><font style="color:#000000;">.&nbsp;&nbsp;Executive will reasonably cooperate, for up to one year following the Transition Date, in connection with any litigation, arbitration, proceedings, government hearing or investigation involving the Company or any other matter that relates to Executive&#8217;s employment period and about which the Executive has knowledge; provided, however, that such cooperation shall be provided at times that are mutually convenient to the Executive and the Company, and the Company shall make good faith efforts to arrange for such cooperation to be provided by the Executive telephonically.&nbsp;&nbsp;The Company will provide Executive with reasonable advanced notice in the event Executive&#8217;s assistance is required.&nbsp;&nbsp;The Company recognizes that Executive&#8217;s ability to cooperate will necessarily be impacted by other personal, professional and work obligations.&nbsp;&nbsp;The Company will reimburse Executive for reasonable expenses incurred in providing such cooperation and will reasonably compensate Executive for his time. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Arbitration</font><font style="color:#000000;">.&nbsp;&nbsp;Any dispute, claim or controversy based on, arising out of or relating to Executive&#8217;s employment or this Agreement shall be settled by final and binding arbitration in San Diego County, California, before a single neutral arbitrator in accordance with the National Rules for the </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">Resolution of Employment Disputes (the &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Rules</font><font style="color:#000000;">&#8221;) of the American Arbitration Association (&#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">AAA</font><font style="color:#000000;">&#8221;), and judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction. The Rules may be found online at www.adr.org. Arbitration may be compelled pursuant to the California Arbitration Act (Code of Civil Procedure &#167;&#167; 1280 et seq.). If the parties are unable to agree upon an arbitrator, one shall be appointed by the AAA in accordance with its Rules. Each party shall pay the fees of its own attorneys, the expenses of its witnesses and all other expenses connected with presenting its case; however, Executive and the Company agree that, to the extent permitted by law, the arbitrator may, in his or her discretion, award reasonable attorneys&#8217; fees to the prevailing party; provided, further, that the prevailing party shall be reimbursed for such fees, costs and expenses within forty-five (45) days following any such award, but in no event later than the last day of Executive&#8217;s taxable year following the taxable year in which the fees, costs and expenses were incurred; provided, further, that the parties&#8217; obligations pursuant to this sentence shall terminate on the tenth (10th) anniversary of the date of Executive&#8217;s termination of employment. Other costs of the arbitration, including the cost of any record or transcripts of the arbitration, AAA&#8217;s administrative fees, the fee of the arbitrator, and all other fees and costs, shall be borne by the Company. This Section 7 is intended to be the exclusive method for resolving any and all claims by the parties against each other for payment of damages under this Agreement or relating to Executive&#8217;s employment; provided, however, that Executive shall retain the right to file administrative charges with or seek relief through any government agency of competent jurisdiction, and to participate in any government investigation, including but not limited to (a) claims for workers&#8217; compensation, state disability insurance or unemployment insurance; (b) claims for unpaid wages or waiting time penalties brought before the California Division of Labor Standards Enforcement; provided, however, that any appeal from an award or from denial of an award of wages and/or waiting time penalties shall be arbitrated pursuant to the terms of this Agreement; and (c) claims for administrative relief from the United States Equal Employment Opportunity Commission and/or the California Department of Fair Employment and Housing (or any similar agency in any applicable jurisdiction other than California); provided, further, that Executive shall not be entitled to obtain any monetary relief through such agencies other than workers&#8217; compensation benefits or unemployment insurance benefits. This Agreement shall not limit either party&#8217;s right to obtain any provisional remedy, including, without limitation, injunctive or similar relief, from any court of competent jurisdiction as may be necessary to protect their rights and interests pending the outcome of arbitration, including without limitation injunctive relief, in any court of competent jurisdiction pursuant to California Code of Civil Procedure &#167;1281.8 or any similar statute of an applicable jurisdiction. Seeking any such relief shall not be deemed to be a waiver of such party&#8217;s right to compel arbitration. Both Executive and the Company expressly waive their right to a jury trial.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;letter-spacing:-0.1pt;color:#000000;">Entire Agreement; Modification</font><font style="letter-spacing:-0.1pt;color:#000000;">.&nbsp;&nbsp;This Agreement, together with the Proprietary Information Agreement and the other agreements referenced herein and therein, constitutes the entire agreement of the Parties in respect of the subject matter contained herein and therein and supersede all prior or simultaneous representations, discussions, negotiations and agreements, whether written or oral, including, without limitation, the </font><font style="color:#000000;">Employment Agreement</font><font style="letter-spacing:-0.1pt;color:#000000;">.&nbsp;&nbsp;</font><font style="color:#000000;">The Employment Agreement shall be superseded entirely by this Agreement and the Employment Agreement shall be terminated and be of no further force or effect.&nbsp;&nbsp;</font><font style="letter-spacing:-0.1pt;color:#000000;">This Agreement may be amended or modified only with the written consent of Executive and an authorized representative of the Company. No oral waiver, amendment or modification will be effective under any circumstances whatsoever</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">9.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Survival</font><font style="color:#000000;">.&nbsp;&nbsp;The covenants, agreements, representations and warranties contained in or made in this Agreement shall survive the Transition Date or any termination of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">10.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Third-Party Beneficiaries</font><font style="color:#000000;">. Except as expressly set forth herein, this Agreement does not create, and shall not be construed as creating, any rights enforceable by any person not a party to this Agreement. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="text-decoration:none;Background-color:#auto;">11.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Waiver</font><font style="color:#000000;">. The failure of either party hereto at any time to enforce performance by the other party of any provision of this Agreement shall in no way affect such party</font><font style="color:#000000;">&#8217;</font><font style="color:#000000;">s rights thereafter to enforce the same, nor shall the waiver by either party of any breach of any provision hereof be deemed to be a waiver by such party of any other breach of the same or any other provision hereof. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">12.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Section Headings</font><font style="color:#000000;">. The headings of the several sections in this Agreement are inserted solely for the convenience of the parties and are not a part of and are not intended to govern, limit or aid in the construction of any term or provision hereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">13.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Notices</font><font style="color:#000000;">. Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed given as indicated: (a) by personal delivery when delivered personally; (b) by overnight courier upon written verification of receipt; (c) by email, telecopy or facsimile transmission upon acknowledgment of receipt of electronic transmission; or (d) by certified or registered mail, return receipt requested, upon verification of receipt. Notice shall be sent to Executive at the address listed on the Company&#8217;s personnel records and to the Company at its principal place of business, or such other address as either party may specify in writing.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">14.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Severability</font><font style="color:#000000;">.&nbsp;&nbsp;In the event any provision of this Agreement is found to be unenforceable by an arbitrator or court of competent jurisdiction, such provision shall be deemed modified to the extent necessary to allow enforceability of the provision as so limited, it being intended that the parties shall receive the benefit contemplated herein to the fullest extent permitted by law.&nbsp;&nbsp;If a deemed modification is not satisfactory in the judgment of such arbitrator or court, the unenforceable provision shall be deemed deleted, and the validity and enforceability of the remaining provisions shall not be affected thereby.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">15.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Governing Law and Venue</font><font style="color:#000000;">.&nbsp;&nbsp;This Agreement will be governed by and construed in accordance with the laws of the United States of America and the State of California applicable to contracts made and to be performed wholly within such State, and without regard to the conflicts of laws principles thereof. Any suit brought hereon shall be brought in the state or federal courts sitting in San Diego County, California, the Parties hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over it and consents to service of process in any manner authorized by California law.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><a name="_Ref154381286"></a><font style="Background-color:#auto;text-decoration:none;">16.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Non-transferability of Interest</font><font style="color:#000000;">. Except as provided in this Section 16<a name="_Ref154381286"></a>, no party may assign or delegate any rights or obligations hereunder without first obtaining the written consent of the other party hereto.&nbsp;&nbsp;The Company may assign this Agreement to any successor to all or substantially all of the business and/or assets of the Company or any of its affiliates, provided, that the Company shall require such successor or affiliate to expressly assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place.&nbsp;&nbsp;As used in this Agreement, the term &#8220;</font><font style="font-weight:bold;font-style:italic;color:#000000;">Company</font><font style="color:#000000;">&#8221; shall mean the Company and any successor to its business and/or assets or affiliate, which assumes and agrees to perform the duties and obligations of the Company under this Agreement by operation of law or otherwise, or to which Executive&#8217;s employment is transferred prior to the Transition Date. This Agreement is binding upon, and shall inure to the benefit of, the parties and their respective heirs, executors and administrators (including the Executive&#8217;s estate, in the event of the Executive&#8217;s death), and their respective permitted successors and assigns.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">17.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Gender</font><font style="color:#000000;">. Where the context so requires, the use of the masculine gender shall include the feminine and/or neuter genders and the singular shall include the plural, and vice versa, and the word &#8220;person&#8221; shall include any corporation, firm, partnership or other form of association.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">18.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Counterparts; Facsimile or .pdf Signatures</font><font style="color:#000000;">. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered will be deemed an original, and all </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="color:#000000;">of which together shall constitute one and the same agreement. This Agreement may be executed and delivered by facsimile or by .pdf file and upon such delivery the facsimile or .pdf signature will be deemed to have the same effect as if the original signature had been delivered to the other party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">19.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Construction</font><font style="color:#000000;">.&nbsp;&nbsp;The language in all parts of this Agreement shall in all cases be construed simply, according to its fair meaning, and not strictly for or against any of the parties hereto. Without limitation, there shall be no presumption against any party on the ground that such party was responsible for drafting this Agreement or any part thereof.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">20.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Withholding and Other Deductions; Right to Seek Independent Advice</font><font style="color:#000000;">. All compensation payable to Executive hereunder shall be subject to such deductions as the Company is from time to time required to make pursuant to law, governmental regulation or order. Executive acknowledges and agrees that neither the Company nor the Company&#8217;s counsel has provided any legal or tax advice to Executive and that Executive is free to, and is hereby advised to, consult with a legal or tax advisor of his choosing.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">21.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Section 409A</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;">This Agreement is not intended to provide for any deferral of compensation subject to Section 409A of the Code, and, accordingly, the severance payments payable under Section 3 shall be paid no later than the later of: (A) the fifteenth (15th) day of the third month following Executive&#8217;s first taxable year in which such amounts are no longer subject to a substantial risk of forfeiture, and (B) the fifteenth (15th) day of the third month following first taxable year of the Company in which such amounts are is no longer subject to substantial risk of forfeiture, as determined in accordance with Code Section 409A and any Treasury Regulations and other guidance issued thereunder. To the extent applicable, this Agreement shall be interpreted in accordance with Code Section 409A and Department of Treasury regulations and other interpretive guidance issued thereunder. Each series of installment payments made under this Agreement is hereby designated as a series of &#8220;separate payments&#8221; within the meaning of Section 409A of the Code. </font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;">If Executive is a &#8220;specified employee&#8221; (as defined in Section 409A of the Code), as determined by the Company in accordance with Section 409A of the Code, on the date of Executive&#8217;s Separation from Service, to the extent that the payments or benefits under this Agreement constitute &#8220;non-qualified deferred compensation&#8221; subject to Section 409A of the Code and the delayed payment or distribution of all or any portion of such amounts to which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A(a)(2)(B)(</font>i) of the Code, then such portion deferred pursuant to this Section 21(b) shall be paid or distributed to Executive in a lump sum on the earlier of (i) the date that is six (6) months following Executive&#8217;s Separation from Service, (ii) the date of Executive&#8217;s death or (iii) the earliest date as is permitted under Section 409A of the Code. Any remaining payments due under the Agreement shall be paid as otherwise provided herein.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;">To the extent applicable, this Agreement shall be interpreted in accordance with the applicable exemptions from Section 409A of the Code. If Executive and the Company determine that any payments or benefits payable under this Agreement intended to comply with Sections 409A(a)(2), (3) and (4) of the Code do not comply with Section 409A of the Code, Executive and the Company agree to amend this Agreement, or take such other actions as Executive and the Company deem reasonably&nbsp;&nbsp;necessary or appropriate, to comply with the requirements of Section 409A of the Code and the Treasury Regulations thereunder (and any applicable transition relief) while preserving the economic agreement of the parties. To the extent that any provision in this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner that no payments payable under this Agreement shall be subject to an &#8220;additional tax&#8221; as defined in Section 409A(a)(1)(B) of the Code..</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;">Any reimbursement of expenses or in-kind benefits payable under this Agreement shall be made in accordance with Treasury Regulation Section 1.409A-3(</font>i)(1)(iv) and shall be paid on or before the last day of Executive&#8217;s taxable year following the taxable year in which Executive incurred the expenses. The amount of expenses reimbursed or in-kind benefits payable during any taxable year of Executive&#8217;s shall not affect the amount eligible for reimbursement or in-kind benefits payable in any other taxable year of Executive&#8217;s, and Executive&#8217;s right to reimbursement for such amounts shall not be subject to liquidation or exchange for any other benefit.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;">In no event whatsoever shall the Company be liable for any taxes, penalties or interest that may be imposed on Executive pursuant to Section 409A or under any other similar provision of state tax law, including but not limited to, damages for failing to comply with Section 409A and/or any other similar provision of state tax law.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;">To the extent that the payments or benefits under this Agreement are &#8220;non-qualified deferred compensation&#8221; subject to Section 409A of the Code, if the period during which you may deliver the Release required hereunder spans two calendar years, the payment of your Termination Benefits shall occur on the later of (</font>i) January 1 of the second calendar year, or (ii) the first regularly-scheduled payroll date following your Release Effective Date.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#auto;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="Background-color:#auto;text-decoration:none;">22.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">RIGHT TO ADVICE OF COUNSEL</font><font style="color:#000000;">.&nbsp;&nbsp;EXECUTIVE ACKNOWLEDGES THAT HE HAS THE RIGHT, AND IS ENCOURAGED, TO CONSULT WITH HIS LAWYER; BY HIS SIGNATURE BELOW, EXECUTIVE ACKNOWLEDGES THAT HE HAS CONSULTED, OR HAS ELECTED NOT TO CONSULT, WITH HIS LAWYER CONCERNING THIS AGREEMENT.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Signature Page Follows]</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:11pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="letter-spacing:-0.1pt;">THE UNDERSIGNED AGREE TO THE TERMS OF THIS AGREEMENT AND VOLUNTARILY ENTERS </font><font style="font-weight:bold;font-size:11pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INTO IT WITH THE INTENT TO BE BOUND THEREBY.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.9%;">
<tr>
<td valign="top"  style="width:6.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated:</p></td>
<td valign="top"  style="width:0.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 25, 2021</p></td>
<td valign="top"  style="width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:50.44%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Frank Hsu M.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:50.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Frank Hsu, M.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:44.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:44.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:44.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated:</p></td>
<td valign="top"  style="width:0.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 25, 2021</p></td>
<td valign="top"  style="width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ONCTERNAL THERAPEUTICS, INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:44.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:44.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:44.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:44.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:44.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ James B. Breitmeyer, M.D., Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:44.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">James B. Breitmeyer, M.D., Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:44.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer and President</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">Exhibit A</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_C6"></a><a name="_DV_C6"></a>GENERAL RELEASE OF CLAIMS</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This General Release of Claims (&#8220;<font style="font-weight:bold;font-style:italic;">Release</font>&#8221;) is entered into as of this 15th day of March, 2021, between Frank Hsu, M.D. (&#8220;<font style="font-weight:bold;font-style:italic;">Executive</font>&#8221;), and Oncternal Therapeutics, Inc. (the &#8220;<font style="font-weight:bold;font-style:italic;">Company</font>&#8221;) (collectively referred to herein as the &#8220;<font style="font-weight:bold;font-style:italic;">Parties</font>&#8221;).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Executive and the Company are parties to that certain Employment Transition Agreement dated as of February 25, 2021 (the &#8220;<font style="font-weight:bold;font-style:italic;">Transition Agreement</font>&#8221;);</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Parties agree that Executive is entitled to certain severance benefits under Section 3 of the Transition Agreement (the &#8220;<font style="font-weight:bold;font-style:italic;">Termination Benefits</font>&#8221;), subject to Executive&#8217;s execution of this Release; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, the Company and Executive now wish to fully and finally to resolve all matters between them; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, defined terms used herein without definition shall have the meanings given to such terms in the Transition Agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of, and subject to, the severance benefits payable to Executive pursuant to the Transition Agreement, the adequacy of which is hereby acknowledged by Executive, and which Executive acknowledges that he would not otherwise be entitled to receive, Executive and the Company hereby agree as follows:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="text-decoration:underline;font-size:11pt;color:#000000;">Release of Known and Unknown Claims By </font><font style="text-decoration:underline;font-size:11pt;color:#000000;">Executive</font><font style="font-size:11pt;color:#000000;">.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>In exchange for the Termination Benefits set forth in Section 3 of the Transition Agreement, and in consideration of the further agreements and promises set forth herein, Executive, on behalf of himself and his executors, heirs, administrators, representatives and assigns, hereby agrees to release and forever discharge the Company, and all predecessors, successors and its parent corporations, affiliates, related, and/or subsidiary entities, and all of their past and present investors, directors, stockholders, officers, general or limited partners, employees, attorneys, agents and representatives, and the employee benefit plans in which Executive is or has been a participant by virtue of his employment with or service to the Company or any affiliate (collectively, the &#8220;<font style="font-weight:bold;font-style:italic;">Company Releasees</font>&#8221;), from any and all claims, debts, demands, accounts, judgments, rights, causes of action, equitable relief, damages, costs, charges, complaints, obligations, promises, agreements, controversies, suits, expenses, compensation, responsibility and liability of every kind and character whatsoever (including attorneys&#8217; fees and costs), whether in law or equity, known or unknown, asserted or unasserted, suspected or unsuspected (collectively, &#8220;<font style="font-weight:bold;font-style:italic;">Claims</font>&#8221;), which Executive has or may have had against such entities based on any events or circumstances arising or occurring on or prior to the date hereof or on or prior to the date hereof, arising directly or indirectly out of, relating to, or in any other way involving in any manner whatsoever Executive&#8217;s employment by or service to the Company or any affiliate or the termination thereof, including any and all claims arising under federal, state, or local laws relating to employment, including without limitation claims of wrongful discharge, breach of express or implied contract, fraud, misrepresentation, defamation, or liability in tort, and claims of any kind that may be brought in any court or administrative agency including, without limitation, claims under Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. Section 2000, <font style="text-decoration:underline;">et</font> <font style="text-decoration:underline;">seq</font>.; the Americans with Disabilities Act, as amended, 42&#160;U.S.C. &#167;&#160;12101 <font style="text-decoration:underline;">et</font> <font style="text-decoration:underline;">seq</font>.; the Rehabilitation Act of 1973, as amended, 29&#160;U.S.C. &#167;&#160;701 <font style="text-decoration:underline;">et</font> <font style="text-decoration:underline;">seq</font>.; the Civil Rights Act of 1866, and the Civil Rights Act of 1991; 42 U.S.C. Section 1981, <font style="text-decoration:underline;">et</font> <font style="text-decoration:underline;">seq</font>.; the Age Discrimination in Employment Act, as amended, 29 U.S.C. Section 621, <font style="text-decoration:underline;">et</font> <font style="text-decoration:underline;">seq</font>. (the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;</font><font style="font-weight:bold;font-style:italic;">ADEA</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">); the Equal Pay Act, as amended, 29 U.S.C. Section 206(d); regulations of the Office of Federal Contract Compliance, 41 C.F.R. Section 60, </font><font style="text-decoration:underline;">et</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="text-decoration:underline;">seq</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.; the Family and Medical Leave Act, as amended, 29&#160;U.S.C.&#160;&#167;&#160;2601 </font><font style="text-decoration:underline;">et</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font><font style="text-decoration:underline;">seq</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.; the Fair Labor Standards Act of 1938, as amended, 29&#160;U.S.C. &#167;&#160;201 </font><font style="text-decoration:underline;">et</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="text-decoration:underline;">seq</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.; the Employee Retirement Income Security Act, as amended, 29 U.S.C. &#167;&#160;1001 </font><font style="text-decoration:underline;">et</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="text-decoration:underline;">seq</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.; and the California Fair Employment and Housing Act, California Government Code Section 12940, et seq.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the generality of the foregoing, Executive does not release any claim which, by law, may not be released, including the following claims:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:23.08%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;">Claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state </font>law; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:23.08%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;">Claims for workers</font>&#8217; compensation insurance benefits under the terms of any worker&#8217;s compensation insurance policy or fund of the Company; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:23.08%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;">Claims pursuant to the terms and conditions of the federal law known as </font>COBRA;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:23.08%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="margin-left:36pt;">Claims for indemnity under the bylaws of the Company, as provided for by California law (including California Labor Code Section 2802) or Delaware law </font><font style="color:#000000;">or under any applicable insurance policy with respect to Executive&#8217;s liability as an employee, director or officer of the Company</font>;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:23.08%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)<font style="margin-left:36pt;">Claims for Executive</font>&#8217;s right to bring to the attention of the Equal Employment Opportunity Commission or the California Department of Fair Employment and Housing or any other federal, state or local government agency claims of discrimination, or from participating in an investigation or proceeding conducted by the Equal Employment Opportunity Commission or any other federal, state or local government agency; provided, however, that Executive does release his right to secure any damages for alleged discriminatory treatment;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:23.08%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi)<font style="margin-left:36pt;">Claims based on any right Executive may have to enforce the Company</font>&#8217;s executory obligations under this Release or the Transition Agreement; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:23.08%;text-indent:0%;color:#000000;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vii)<font style="margin-left:36pt;"></font><font style="color:#000000;">Executive&#8217;s right to communicate or cooperate with any government agency.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;">EXECUTIVE </font><font style="text-transform:uppercase;">ACKNOWLEDGES THAT HE </font>HAS BEEN ADVISED OF AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#8220;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY, AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.&#8221;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BEING AWARE OF SAID CODE SECTION, EXECUTIVE HEREBY EXPRESSLY WAIVES ANY RIGHTS HE MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:36pt;">Executive acknowledges that Executive is entitled to have twenty-one (21) days</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> time in which to consider this </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Release</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> after the delivery of such </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Release</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to him.&nbsp;&nbsp;Executive further acknowledges that the Company </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">has</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> advised him that he is waiving his rights under the ADEA, and that Executive should consult with an attorney of his choice before signing this </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Release</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and Executive has had sufficient time to consider the terms of this </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Release</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Executive represents and acknowledges that if Executive executes this </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Release</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> before twenty-one (21)</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">days have elapsed, Executive does so knowingly, voluntarily, and upon the advice and with the approval of Executive</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s legal counsel (if any), and that Executive voluntarily waives any remaining consideration period.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;">Executive understands that after executing this </font>Release, Executive has the right to revoke it within seven (7) days after his execution of it.&nbsp;&nbsp;Executive understands that this Release will not become effective and enforceable unless the seven (7) day revocation period passes and Executive does not revoke this Release in writing.&nbsp;&nbsp;Executive understands that this Release may not be revoked after the seven (7) day revocation period has passed.&nbsp;&nbsp;Executive also understands that any revocation of this Release must be made in writing and delivered to the Chief Executive Officer of the Company within the seven (7) day period.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;">Executive understands that this </font>Release shall become effective, irrevocable, and binding upon Executive on the eighth (8<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup>) day after his execution of it, so long as Executive has not revoked it within the time period and in the manner specified in clause (d) above.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;">Executive further understands that Executive will not be given any Termination Benefits unless this </font>Release is effective on or before the date that is fifty-five (55) days following the Transition Date. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;letter-spacing:-0.05pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:36pt;">Executive represents and warrants to the Company Releasees that there has been no assignment or other transfer of any interest in any Claim that Executive may have against the Company Releasees.&nbsp;&nbsp;Executive agrees to indemnify and hold harmless the Company Releasees from any liability, claims, demands, damages, costs, </font>expenses and attorneys&#8217; fees incurred as a result of any such assignment or transfer from Executive.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">2.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Additional</font><font style="text-decoration:underline;letter-spacing:-0.1pt;color:#000000;"> Representations and Warranties By Executive</font><font style="letter-spacing:-0.1pt;color:#000000;">.&nbsp;&nbsp;Executive represents that Executive has no pending </font><font style="color:#000000;">complaints or charges against the Company  Releasees, or any of them, with any state or federal court, or any local, state or federal agency, division, or department based on any event(s) occurring prior to the date Executive signs this Release.&nbsp;&nbsp;Executive further represents that Executive will not in the future, file, participate in, encourage, instigate or assist in the prosecution of any claims, complaints, charges or in any lawsuit by any party in any state or federal court against the Company Releasees, or any of them. unless such aid or assistance is ordered by a court or government agency or sought by compulsory legal process, claiming that the Company Releasees, or any of them, have violated any local, state or federal laws, statutes, ordinances or regulations based upon events occurring prior to the execution of this Release.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">3.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">No </font><font style="text-decoration:underline;color:#000000;">Assignment</font><font style="color:#000000;">.&nbsp;&nbsp;Executive represents and warrants to the Company Releasees that there has been no assignment or other transfer of any interest in any Claim that Executive may have against the Company Releasees.&nbsp;&nbsp;Executive agrees to indemnify and hold harmless the Company Releasees from any liability, claims, demands, damages, costs, expenses and attorneys&#8217; fees incurred as a result of any such assignment or transfer from Executive.&nbsp;&nbsp;The Company may assign this Release to any successor to all or substantially all of its business and/or assets or any affiliate. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">4.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Severability</font><font style="color:#000000;">.&nbsp;&nbsp;In the event any provision of this Release is found to be unenforceable by an arbitrator or court of competent jurisdiction, such provision shall be deemed modified to the extent necessary to allow enforceability of the provision as so limited, it being intended that the parties shall receive the benefit </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="color:#000000;">contemplated herein to the fullest extent permitted by law.&nbsp;&nbsp;If a deemed modification is not satisfactory in the judgment of such arbitrator or court, the unenforceable provision shall be deemed deleted, and the validity and enforceability of the remaining provisions shall not be affected thereby.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">5.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Interpretation; Construction</font><font style="color:#000000;">. The headings set forth in this Release are for convenience only and shall not be used in interpreting this Agreement. This Release has been drafted by legal counsel representing the Company, but Executive has participated in the negotiation of its terms. Furthermore, Executive acknowledges that Executive has had an opportunity to review and revise the Release and have it reviewed by legal counsel, if desired, and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of this Release. Either party&#8217;s failure to enforce any provision of this Release shall not in any way be construed as a waiver of any such provision, or prevent that party thereafter from enforcing each and every other provision of this Release.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">6.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Governing Law and Venue</font><font style="color:#000000;">.&nbsp;&nbsp;This Release will be governed by and construed in accordance with the laws of the United States of America and the State of California applicable to contracts made and to be performed wholly within such State, and without regard to the conflicts of laws principles thereof. Any suit brought hereon shall be brought in the state or federal courts sitting in San Diego, California, the Parties hereby waiving any claim or defense that such forum is not convenient or proper. Each party hereby agrees that any such court shall have in personam jurisdiction over it and consents to service of process in any manner authorized by California law.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">7.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;letter-spacing:-0.1pt;color:#000000;">Entire </font><font style="text-decoration:underline;color:#000000;">Agreement</font><font style="text-decoration:underline;letter-spacing:-0.1pt;color:#000000;">; Modification</font><font style="letter-spacing:-0.1pt;color:#000000;">.&nbsp;&nbsp;This Release, together with the Transition Agreement, Proprietary Information Agreement and the other agreements referenced herein and therein, constitutes the entire agreement of the Parties in respect of the subject matter contained herein and therein and supersede all prior or simultaneous representations, discussions, negotiations and agreements, whether written or oral.&nbsp;&nbsp;This Release may be amended or modified only with the written consent of Executive and an authorized representative of the Company.&nbsp;&nbsp;No oral waiver, amendment or modification will be effective under any circumstances whatsoever</font><font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;color:#000000;font-size:11pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:-0.05pt;"><font style="Background-color:#auto;text-decoration:none;">8.</font><font style="font-size:12pt;margin-left:36pt;color:#000000;"></font><font style="text-decoration:underline;color:#000000;">Counterparts</font><font style="text-decoration:underline;color:#000000;">; Facsimile or .pdf Signatures</font><font style="color:#000000;">. This Release may be executed in any number of counterparts, each of which when so executed and delivered will be deemed an original, and all of which together shall constitute one and the same agreement. This Release may be executed and delivered by facsimile or by .pdf file and upon such delivery the facsimile or .pdf signature will be deemed to have the same effect as if the original signature had been delivered to the other party.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Signature Page Follows]</p><a name="_AEIOULastRenderedPageBreakAEIOU1"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PLEASE READ CAREFULLY. THIS </font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RELEASE</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> CONTAINS A RELEASE OF ALL KNOWN AND UNKNOWN CLAIMS.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THE UNDERSIGNED AGREE TO THE TERMS OF THIS RELEASE AND VOLUNTARILY ENTERS INTO IT WITH THE INTENT TO BE BOUND THEREBY.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:99.9%;">
<tr>
<td valign="top"  style="width:6.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated:</p></td>
<td valign="top"  style="width:0.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:50.44%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:50.44%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Frank Hsu, M.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:50.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:44.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:44.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated:</p></td>
<td valign="top"  style="width:0.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td colspan="3" valign="top"  style="width:50.44%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ONCTERNAL THERAPEUTICS, INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:44.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:44.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:44.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:44.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:0.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:44.04%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:44.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">James B. Breitmeyer, M.D., Ph.D.</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:42.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:6.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:&nbsp;&nbsp;</p></td>
<td valign="top"  style="width:0.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top"  style="width:44.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Executive Officer and President</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT B</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PROPRIETARY INFORMATION AND INVENTION ASSIGNMENT AGREEMENT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>onct-ex311_8.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex311_8.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, James B. Breitmeyer, certify that:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">I have reviewed this Quarterly Report on Form 10-Q of Oncternal Therapeutics, Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">d.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:53.85%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ James B. Breitmeyer</font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:53.85%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:53.85%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: May 6, 2021</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>onct-ex312_9.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex312_9.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Richard G. Vincent, certify that:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">I have reviewed this Quarterly Report on Form 10-Q of Oncternal Therapeutics, Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Based on my knowledge, the consolidated financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">c.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">d.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">a.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:11.54%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">b.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:53.85%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Richard G. Vincent</font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:53.85%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:53.85%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: May 6, 2021</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>onct-ex321_7.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex321_7.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Quarterly Report on Form 10-Q of Oncternal Therapeutics, Inc. (the &#8220;Company&#8221;) for the period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, James B. Breitmeyer, as Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:53.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ James B. Breitmeyer</font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:53.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:53.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: May 6, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>onct-ex322_6.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
onct-ex322_6.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Quarterly Report on Form 10-Q of Oncternal Therapeutics, Inc. (the &#8220;Company&#8221;) for the period ended March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Richard G. Vincent, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:53.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Richard G. Vincent</font><font style="text-decoration:underline;margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:53.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer </p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:53.85%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dated: May 6, 2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gbhcmm0hydxa000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbhcmm0hydxa000002.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 6#!Z0# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP<>F: +%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% #&=$^\P7ZYJ/[3 0Y$@.SENO'Z4RX4.54C.<C^?-,2VB
MA1V*@AAEP>_3@YH G2XAD&5<'\_7%2@@\CD5S48GCDNKD(?L\0WQJ  K;5'3
MOSS6[:3FYMXYBFPN,[?2@"S1110 4444 %%%% !1110 4444 %%%% !1110
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M\OV<- O[?QSI6N:5JOQ"F\/6"R/+X>\(7$>IS?;Y(D1DM?L\)61V8@*K$]*
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M .SG<:Q>Z'/X?LY-,NM9-^Q_MB>S*>1)?AOF\YD.3R5/.?4/V\_V[?@1H?\
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M%,B[E..1ZU_=S^Q3\=[?]H#X-Z1XS_MV/4;RX6%)2KCS $@1?G!Y W*1G H
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M#^?]: 'T4A('4]>E,\V/=LW#=Z<YH DHICR(F-[!<],TCS11H9))$1 ,EF(
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M'#:^9"F,HIP/J,^WK['-20L6B1B,$C)'O3]Q!$0B.WH,CC YYY_R:>$(& ,
M?3_&@!M*.H^H_G2[&]/Y?XTH5LCCN/2@"6BBB@ HHHH **** "BBB@ HHHH
M**:64$ G!/ 'K2D@ DG '4^E "T5%'/%*6$;AROW@,\9]:EH **** "BBFLR
MJ,L<"@"M=E57S?+\V6,;HDSRS=0!^('Y^U4HKA[E7-]9FW6/!!9LY#=?R_\
MU5\5?MK_ +??[/'[%?AJ&?XO?$31/"7B?7[*1_!FC:EN^TZ]>J^U+>T((7>Q
M! SGN:^8OV#/^"LOP:_;@U_QUX,\%ZY8ZEK/@AM.AUJWBSYEH^H%5C$F?O$L
MW09Z<>M 'Z_0O"Z[8W#PXY'H.W(_#GN:^7?VI?VC/ ?[*WPF\:_%/Q-/:VO_
M  C^BWFL1V<]PEL-3%G$9&3S6*E>FW=G@5]+6L M&,0&Y)0,>@! /Y<GZGH*
M_,W_ (+ _ X_&K]A?XZ:)I&@#7O%"^ -?M]!M(PWVJ6YFLV$<=N5(PY8<<4
M?+O_  3^_P""TFA?MP^,9/#GASX-)X?LRJM_PD,&LQ7L5U&9"@EVJ"^"!N^9
MSR>U?NW*[-%DIP\8;RR?];D9VYZCG&>E?YB'_!OEKO[2O[._[0-WX$\2_##Q
M<L-LPT][>X4^7:F*Y.5&5("KG PV-N.!G _TQ_!VLZAKWA+P[JU_ITMG?W]G
M%)<6TO\ K;1R "'X'/Y8Q0!N@1Q2V'EQB RR8DC'L,@'MU']:_RS_P#@H_\
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MS@THP_)'MU_'V]:AN;BV@4&XD6,'.W=GL.V*YR:[N96_T,-*@Y)3I@].N>M
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MMQ(P>16'X$'BC]C'XJWEN=0O+W7)K?RFTVWF<S6<3R>?%/NW$8"R* .W'?H
M?Z:FGZA'J^FV.KV+9ANK>*9,<C#*#MSWZ]<5;Q+/M9LK@CJ,Y'7_ "/UK\C_
M /@E/^UBGQV^$?AO1]4UN:^\5VME=O?Z3=N6N[6&(KL,A;&5V\K7ZZ/*4@C.
MW:2Q7 ^GM[\4 2RL&98@^TIACCDG';&/\YJK>":9(=@VLL@9@.I Z]\C//KT
MIT\/GE6CDV2*P9A_$RK@X_&F7=Q=1QP/#;M)(\@23:,%5W8).<\;3GIU^E &
M/XETF'6]'U+1M0B-QINO6KZ7?0#@+;3J4F)/<&-V4CG()!'%?PV?MH3^+O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+:V6K^'O.DTV=SEHVPI3;D>OZ=Z /39;ZQAF:.2[02+_  $@-N Z8XY.#_\
MKKX\^,GQ#^*J^.O"FB>%O#%ZFBC48UNM7@222.>*20*2QS@!%&>._;BOK*SM
MM/E@BDNX$DO]H9PW,GF#MGUXJ9)'O&FM9K0VD=N/]%G<!EW$#YEXRI7UR/\
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M(6-4[ 8&: /UNA:42M&Y)4*"">Y(_P _6KE4+2XAO=EY;2"6WFB4HXZ'BK]
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@'//^?PIU% !1110 4444 %%%% !37=(U9Y&"HHRS'H!3JCFB6:-XW&5<8-
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MT%OC+\,?#GQN^'GB+X4>*+"*^\.^*K5K+4XYHUEBBCX(WQ,"']!^-?S#R_\
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MB3;!"03%Z!B!_.OW)\8:L?"W@W6=>:(N=+T<3NN=I401*'.1TP0 <?7I0!^
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MGV?D8+/M)SW'H*_:Y'6621\>8T'"=,Y  /;CGGZU7T\MYUUE-N74YSUXZ\T
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M?^TY^U=J?B;2)]&U;X)>&])B:ZTG5X8YKJ+Q"A8JENN]MH!4;N!Z5]:_ _\
M9K'@JV-SX]UR3Q;J4C^:;F]MA"^Y>5)!&?;\\<T =3)\1O'7BUI(]"\/:E:0
MJ"PNX%VAESP1D#L<]^>N*YOQ7^SC>_%JQT]_B)J\NIZ><//HVIR-Y219^:%@
MA7@XR17U18:%;:4S2:8WD6Q Q"@.P+UXQ^7M71 +<1*74$,,X_S[4 >)_#SX
M$?"SX9:;'9^#/!NBZ5. !)>6D3&0D8*,7D+'Y<# ]N2<XKU>UL+E'W27KS(.
MB'&![8 ]#C_Z];"1I&,(H4<=/;I^6:4*J]!B@"+:1QC\AQ_*D>,%<LP0=2W0
MC^7X\U8I&4,,,,CTYH KP,F6591)CL#R*LU$D,<9)10">I%2T %%%% !1110
M 4444 %%%% !1110 444A.!TS[4 +15?#@&4L3C)$?;CI^/'IWJDEY+</L2/
M9C^,<]?;_/?% &K15(F6$HB[I2QPQ_NJ3G/^>YJ)KJ6*8QB(NN5'T)X_S_\
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M=64]CW[T 1V=Q'*S);QC[,J@K*HPK-Z#OG^6/QK0K.GMO(M@+0^2L.7V*.'
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MYW.(T9X]OW!T?(/RGZ@\U\ZW/QL\6MXOO/"T?@20165NMU]O,KG>-VW;LS@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS7W9"AC@XX/^'Z4[R)?-#"9@BG.W'#?IS_GF@"Y1110 4444 %%%% !1110
M4444 %%%% !111G].M !3),[&P"3C@#@TYF"J68X4<D]@/6H9KB.&W>Y+#RX
MT+EL\;1U.: *ZW&<1R(0>!SR<]?\.]-NKR#3;62ZN90B1QEV)SP..G^'UJC'
MK%A=".1)8]QY4@\G/MZY]?U%9^LZ<VNVDUCYQB$\9CW+VS_(\_YZT <_:_$O
MPYJ4]W#;31S36.TL ,D%L$9[#/)'KFK5WJ>H>(+-ET^.6%2,AE.T,,X'K^OM
MZ5R_A#X0Z?X7O]3NYYVU ZJ\?RR''E>7V&,]>_\ /BO51!!IT!BLHD144>85
M9<QI[@D'&1Z9H Y/1?#UY+;2P:NQE5@0!+\V5((QC\\^_6MC2-"T;2I[@Z5#
M;I=J )EB4*2!ZD\=?UQ7GWCWXPZ'X0TB[:VO+6^U:WMI7:S$F94E7[JE5'5C
M]WGZ=*\F/BOXB?$CPI%_PCNE7OA6\U2$'^VK2-F;YB0'&XCIP?P_, ]-^(?Q
MS^#_ ,,WGF^(?BG3?#,T(WF6[R2A'1QL#'(R.W7O7C%K^UAH?C>98OA)ITGQ
M/LEPUU>V \M+2-\"-VW9R) 1CZGK7ROJ7_!-7QI\1O&<7BSXM?&C7/&&CS:A
M%>S^%KZ-4MS:J=S63,I8[&P.V<?4U^C?PH^ OPS^#NF2Z;X#\+6>@^;&D<\L
M)+M,(_\ 5;B>R]ACMG/H >:V6C?$[QI="YO;G4?".FRGS)=/DE)1(B 3"0HQ
MCD_K7<VGP3^&KM'=ZSX?TOQ#K*,&.H30>9,7'W3N8]<\]._UKW$K(D?E./.4
MKM8D8SD<\BD@MH$.]+<1L<9..,YZ].<8H KV$5O8VT%E#;I8VELBI;P(@1$1
M<;455& !UZ<]R:FE-O/(JLX.T@;2#SWQT!_6II(_G+,IDR<@8.%&?;O4(B5F
M#"#:0P.1D_RZ?G0!%/="!XH$BRC,5('0#Z?Y_2M10   ,#L/KS54JI<%H,[2
M<'#9[U:&<#/6@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBH_-CRP
MW#*YW#TQUH DI"2 <#)["HOM$.UW$BE8U+.<\*HY)-$<\<T0EA8.C=&'(/.*
M (F$GEER<#&=F3C^>/>F6SY&?*V@\LW'/7&/\Y]>U5GU!$GD6X=(H$!8L[*H
MVXSSDBO'?&GQ0N86N=-\%V<>NWMDA>^CM'61[1?X'D4-@ \<Y_K@ ]&\1^(=
M+T>"6YN=42"6V!?R2?FE"\^6.>IQ_/->2:Y\<?"&FV=AJ6NZU#H-J\P!N)S@
M/''G<QY' ZG]2.M?$/QA_:/\$?#>'3M<^,OC?3?!K7]^+?2-)U>X$(UO4&;Y
M--B"ARSR9 VCUKXF_;/L/C!^V?\ !$0?LX6>L>&9K32=56PU?PM ]RU[<O$W
MDNF=F2&((''UH _9F^\:67Q5*V_@:_7Q!8Q,)OM=LX$8C; WY!/!Y[]?RK\,
MO^"P/PQ_:'O?!VG:1\"]:UL^*YI8H9[#1;MX+B!Y3A0S+GG&:^B/^"3W[-/[
M5/PO^$<NB?&CQKXM3Q1/H@M1?:[:?9[F*</+\^UG;Y\%?K@?6OU0\,? &.SO
M!J7CG6)?&>J12_:!<WZ+NED&3",?,/EY H _);_@EK^S%^T+!\'+%?VC-4UB
M34XMK1VVOW$ES*&*_, 6 .3WXQ7[G:-HFE^$O#L-O 8;.PL(&:ZG0;42%!EV
M8>G!)%%[J>G>%M,N+R_C@TK3K5&>&%RL<1*+E@,=]N<\>E?G_P"+?C[X\^+7
MBF[^'?PZTBXET34KG^S;_6M,1I4M+%V,<MTS< (N#N/."><T 87[2/QA\5_%
MKQ3:_!CX0)J$^F&9+'Q-K&G2F*V>PU$B&7SQSOCC1B6'IGUK[3^ GP*\-_ S
MPK9>'M(MK(7T5LL=WJMO"$>Z,A$LB,Q^8@R,QST[C@U%\'/@+X=^%6G M;+J
MOB:[R]_X@F&;F8$ HC#'!C(X[].E>[3VLQA$2NVY,,' ZXZ#/'3CCVH M1NG
MVB1!RX4$MC^O_P!>K=4+"!HH@TI+3$G+GJ1QC/)Z=*OT %9=^(_W9RH;?@Y'
MTK4K/N)(0Y$\8 'W&/\ $QZC]?\ Z^* /,OCCXB3PA\&OB3XG\WRET/PAJVH
MM*GRE!;VS.6!['%?Q/?\$:)+C]HK_@LS^UA\7Y5:^TQM*\.16]]<9ERVF%=V
MUCGE,9[^W>OZ[?V_O$-OX;_8G_:6U-[N*QFM_A+XJ:V:2548W#63+"J!B"69
MC@ ?7I7\H_\ P:D>!/%&H:Y\5_C9KNFW8@\5ZMJNG6^LS1$0W@M)-BQQRGAR
M!P<'UH _N)HHHH \&^/'Q#D^'6D^']4S(MO<ZL8+MD. (51';?ZK@DX_G7<^
M _&FE^.=!M-:T6=)[2[@RI3@!U #]/\ :R#Z\UC_ !B^'EG\1O"<^D72EI(%
MGGM=HRWG/"4!48//3T].]?._[,N@^._ 5[<>#M9TN_BT'3Q<_9+^YB*QS;Y&
M9 K$G(Z?@10!]I(^V-4D^_NYX]>AJZ  /E&!U_.LA!++=,TD;(F%*GC!/L>?
M4#\JUF8(!DX'3G']<4 .I&&X$>M(KJW0@_B#_*HC/&3(B.#)&NYE[@<\X_"@
M"E+<K9XB";B6 R..6XP,8]C5@211H)IRL6[@!NG]<G)J R6[6KWUQM"P)+*[
MN=JJL0+%F)P!@ G)KX:^+7QJ\8ZMXB@\.?#6PFUV2V</>KIJM,T,3.!O?& !
M_GWH ^Q]:\5^']*-L+V[B47,Z01<9 D<C&,'\>E6;K4KB)89+&S;48)2/GC.
M%"DC.!SQS^0[5Y7X4T6W/A2TUWXCQ1V\\, NI(=1ECA^RR)@^8P9P0R ]#R,
M9P1U_(O]LW_@M=\._P!F3QQJWPD^%NE>'?BKXZT;3A>WGAZRU&0ZAI\<RGR)
M)8(70%6.-H;<#TQCB@#]J=2T&^GO8M4.N?V3#O5C:-)M&>#Y?89.>G/7T-?/
M7Q6_:*_9*^#_ (EU"?XH>.O"GA_QK86<,UY)?>8VHA8XLVS?(I1FP!Y8WCGJ
M1SC^,OQM_P %J?VF?CMX]N--TCQ1??#+4+*9M1G\(VI(E2W24_NF21E(7H/Q
M]Z^*/VO/%WQ#^/&H1^/-=^,VHWOCG7/LEAJ7@X.1<6\$ \N*5H@V0)P=W7!S
M0!_8?XA_X+4?LAZ1JFNIHOBS2M=O]*T^6[FNH8L-<Q1 XBWD\Y"8Q[\U\,:?
M_P '+7PPO_%5YI6G?#ZYFT2VN)84OT9/)<0L8V<#DX+#=UX_.OYO](^&'PYN
MO@[JNA&:VTWXJ:997&H:C=&<_P!IZC8_9W*VDD9Z([@#[QR3CTKX%^#^I^ ?
M#%EXNE^(DEIX=U"VLM;31=/OW=)-2U-))%LK>%0K%I;I@"@]3Z4 ?V.>)?\
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MD[003C. >W^?\]*=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFMK;^(;V4 R320C<QZ\[AD]#V_IGV'3+*VT^QM[.SMUM;:% L4"@!8Q_= '
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M** "BBB@ HHHH **** "BBB@ HHHH **** "D)P,TM-?[I_#^8H ;YGM^O\
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MG 4G/'- 'H/C?XV^+M:\3/H/@?PR^JZ)//%:6_B"WF8J1+\LDH120?*ST_\
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M/$'B&3Q-<6TAECU6:+R&*,BJL/EG'W-H'XU[VHP.N<]_;M_.L]1%*=Q*RJH
M5\9^9<]/?C'I5R!G:,%TV$9&/8$@?Y_2@":BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*^5_VT/B9?? O]DGX]_%[3Q--?\ @3X?:GXDLO(<Q3QRVKQ*/)DZHWS]1C%
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MY]E!':VL-O"08HD6--JA0%50J@!0!P .U &&IN)84NFD:T90%2SQU$>$2/\
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M!K^S"';&!=1AD(R1SDU]$?'/_@II^Q+_ ,$TOA/<^$/V./".B7-[K%NOA_\
MX2?P=!!I)6.&U6,2G8S,5\\&4+D8//7H ?.7PC_X):?LM_L]_"KPE\4_^"C_
M ,<;./QA9WCZ_=_#_P =/;:8TMTD@N-/TIQ()743*?+7N1Z5\A_\%#_^"XFB
M_L^^&= ^&_["WPXT+X4^")[V2V?QSX8O6N8[[</*"90QI^[&9.AZ5^%W[5?[
M67Q,_;Q\0^,=0^)'BS5]:MHS<ZK:Q:O>RW:VBV^XP! 2 /)4@*0.,?G\@_"[
M6K;Q_P"&M7^$NH:?_;D>A0W%]:7TQ\R."6970-&CYPR;@0>ORT >@_M+:_\
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M L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#0O"UW)I&I3>&VUFX$#:A?64!E6&U &7D#;1@#JV,&OBK_@G[H>F_M"VM_\
MM4>,T7Q7I?C?3OM7AD7@+V=O="Y+"6SYY>2&,*"0 %;//0_G3_P4P^ VN?\
M!7?X]:%^S[X3\8?\(%X8^"^J6T^KZV+7^U8M7MM5D_?A[8"00^7&V#E1NQS7
M]!?[)W[-NG?LJ? 3P;\%-*U?_A)+#P;906MO?"U6S$YB0*9%@0[8]YYP.F?I
M0!]!Z5;I]@B>* 6L,0)@L0 %@5.  ,9Y ]*O1.RLLN/,:9MK)_SS]_RXQ44$
M-P-UR2R";_EVQ_J]N1UXZ_UJS!!)!*9N6$N 4_YY]\Y[\D^O'- &F.@HHHH
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M_P">U5T,AR)5)_N[N,M[>]/N59E0K_"V3[C^GUIT<OF%?E]3G.<8!'IZGUH
M_)/_ (*Q?$W7? /@;X7:3H!E%QXV\5GP]>PP9WRVEX(8&0A>=I,KKGIFO=?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444A. 3Z4 +1
M47FCV_[Z_P#K4>:/;_OK_P"M0 22;.QP0<GT_P#K]:C>6&*,RG;\H#$T]VW1
MN1U .,'/)J&.)98G1QPP"_3CTH YW_A*+%[HVLA7APN"#WXKJH61HU:/&PC*
MXZ8[?IBN5'ARQ6],[D9,@8C Y_\ UD_YZ5U:*J(J+]U1@?2@!]%%% !1110
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MN@Z<?GTKX&_X*'?$>S\+_ KQ-X6NI8H;CXD>';OP[;J[A6:6\V(HC4_?8\X
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MSU]<'&#_ $A?$O4H(O\ @HM?V[[=W_%,9!;J/MUO^72OY4?^#@3Q'XT\,_\
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M#2-!N]2@\>EK:6!W6*#P]@@&XMV#[E48.Z5E [CD<5ZK\--1T[5=._X2"_\
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M:UB>S\ 6]Y)+#*&9B9^05'3D_P"<5^^$,L<H8QD$!V4D'(R"03^)% $U%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2$@ D\
M<DTM1RDA&PN_@_+Z\'B@"M'>Q22M&#]UMN>>3U%3?:(C((PP)[X[?Y[U0B*Q
ML6>V$>YC\V<<'OU_+T]*L+"A?S1'@$Y[\Y_S^O>@"Z#G^GN/6EJJ9&8D1Y^3
MA@.>GK^']:F1\CGCTSP>] $<MS#"#O< ^G)QSCFID=74.IRK#(/J*Y_4K&>4
ML8RYR>WIT'\L_A6S9HT=M"C\,J#(/;_/6@"S2,-P(]:6B@"#R!_>/Y4>0/[Q
M_*IZ* &(@0$9R#ZBG  = !GT&*6B@")XE<Y. ?7 S^=2*-H ZXI:* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *:[!58L<* <GT%.ID@4HP?&
MP@[L\#% &>@^6X:)MQ8#:5. ,XP?\^OO7P[_ ,%* 8?V!?VJFFS),_PEUT*G
M.[S"T*QJ,?Q%MV,?RK[I!2,+]G&5Z''( QD=?\^AKR[XS?#?1_C)\+_'?PPU
M_;)IWC31)M#O(F[Q3$%ACG/KZ<\T ?QX_P#!I!IAM/&7[:]X\#0R7A\&EMX?
M<2!;'JQ[>W;WS7]M=?G/^PC_ ,$\?AE^PY=?$"^^']O'!-\01I_]JA  2=/"
M>5G ']WH<U^C% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !2$X!)Z 9_*EI",@CU!'YT 9\>!)*SR>:L@ 6/G@YY//J*_#'_ (+ >&];
M\:>,OV7]"T+5);-(_B5HJZE:Q.0LML]QN:*51]X,K8P<].G-?NP(HEV]-P(Q
MSSD?YYXS7\W'[8?Q.\3>)_\ @H!X*^'4OF3Z1X;^*/A>.UBQE421=YZD^W;O
M]* /WX^#OA=/"7@32-&:-%-J3MVC #;4 P!WR",]\U^#?B%#\=_^"EGC#PI<
MVG[CX5>+X-9L;BX_>1O) @(, _@;C@\_X_T,M.;'3I24\K[($DQ],'_ZW-?A
M%^QG;6OBK_@I5^TUJ5P%DD@:YG!'/S+YB@Y^N.G/'XT ?N_')Y%K9[H3YT\:
M0NQ/.U1CG/IGO6W%'Y2!.N/;%5!Y<THBP/W&WOR/I[\#^M7Z "BBB@ HHHH
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M5BER'U&] !%Q9R,9)(9"#]P!BO?]*^I-1T7PKXMU._UW7+.W311I2OHR.P6
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MD"3:3>^!8[%=413L:?[1DP'J<C([]!^%?TE1QI$"L:! 220!W)))_,U^%?\
MP2FTH^-[GQ7\4IX#*)=9OM*740,QN8;B5A%O/==H_E7[KC..?\\T +1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 5!"\#CH*4*HZ*!^% $33+&/F[#UY/;_ #S4JMN4,.AI&C1_O(#]1^-. "C
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MNN.G3O6UY,18L47<>IQUIQ1#C*CCIQTH =1110 4444 %%%% !1110 4444
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MV;FTQ65C=^*=0U3S53;N%P=^T@8Z!SD\YW5^E4,HE3<O8X]>G>O*OA/X*M?
MO@K2/#6FV:6-M':6]P[0_*IDDACWY]3QS_G'JD")&@5""O8CN>AS0!-1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MIC@9[D'.?7IQ4@1P!GD]SD<T )3D^\/Q_D:-C>G\O\:<JD$$C^7I0!)1110
M4444 %%%% !1110 4444 %%%% !1110 444C,%&6. .IH 6BFAU(R#D<'//?
MI1O7UZ=>M #J*:&4]#FD,B#=E@-OWO;ZT /HJ-)HY,E'#8ZXSQG\*=N48R0,
M],]Z '5%.0(GW/Y0Q_K/[OO2/<01D+)/"A/0/(BD_0,P)_"O ?BU^U+^S_\
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M[_P3U_:6\2_MP)\-OB'^T=XKE\.>)O'DVF6#:EJL\EIJ$.%("QAP-C ]/?\
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M?P/_ -;M4-Q->0;+>"%IM[;9)E)R@8@9P.N.G/X4"^M$N98T=#<Q@M>#IY"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:KI_V26PTQ?LMII$!G,CWYBRR,%#-P/3\* /Y:]2\.0?LD?%CQ;\%OCSI_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV9!/+= !T[GZ?A33<J6VQ_O OWRO.SZUQ_C#Q7HOA6PB37-0DL$N5*)>",L
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MC';^*_$EE_8E_P"-IB%OK02.)1;[)&5D<_>_7TK^OY;<,H"0R1O" (SO)"X
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M#,OVJ[3#3==HR"1^/M7]'<FZ(NT8)(CD;:!@9",5'XD#\:_F[_8\N-?\:_\
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M])_ML_M3_M2_MT:/9?$7Q#\0/%>H:SJMWY$OPZB=XUTRRB<F.X$2,N%E4C/
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M^S-Q^\; (X[?R_"K*J$&U1@4ZB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!BOD$GM_3/^%4+F_-N^WR]PQG.<=:O*,(Q]<_UK+NX?,;
MD9X&!CT//>@"_;W'G@_+M(S].H%6:HV<80$@]CD8]_J?\BKU !1110 4444
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M_!O@WXUP6>U?A#>C5Y-3C7$ED)65?,#+\P)V8XZ_G7[8RM*LC?N!(0<QMD\
M_A]#UX/%?)W[<_@?_A8_[*OQ:\*/;M-/JV@,D$:H6?S4D4IM7!SA"_;N2>E
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M6LL49_X]@[9^6=3DG'Y5]?>$?!GA[PG:B/1-+BT[>H63RU"F3 ZG: ,>WJ*
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MX3^'GQ<L[TZW8>.M#LFL=>^WPCS(ML\+"/S#)R&*@;FP1S7YM>#?!W_!3/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !112;AZC\Z %J*90\94G:#WQ4FX>H_.FL1@\!NO'X&@#/=
MK%@(I=I(&W<5XX_+M@>_2GQI&BEXYL1#.5 P .F/\/\ ]=8NG^(/#^K74UE:
MW-M-=0LZ/%'(&=70X=2%/!!]>]:!=(UDML@2R-F./G)7V_ ^M &A;"(!_+;=
MDC<<8YY_PYJU5:UB\J,+W/+>N><Y]*LT %%%% !1110 4444 %%%% !1110
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M"_A[X:\)^'$\7FTBD\4>(].TZ*"\O]2C55%S=38WR2K@G<Q'7I6__P $\/\
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MI]Q;2.\T\EZDGRK$_2(YR&7'KC'^<4 2O% (HWC56M(D3RXP %@1 %!4=/E
M ^E:5O+'-$'BD\U,D!_7&/Y5FSZ=+-M$=PT$6?GA7HR]U.>Q_'M@5IP01V\:
MQ1*%1<G ]3U- $U%%% !1110 4444 %%%% !1110 44P2(W1AGT^E/H 8Y'&
M3CGBN=UG2YKQ0\,AXY[_ $^M;\R>:N V"#GCV_\ KXJ*))$SEF(^GM_GM0!C
M:+;7EJ/+F9G&WC+9 QQTX_"M&Z5;>1KJWM1+=,NUW488J   3]/Y5HMP/E'.
M>P[?E57$RL9.6W?+Y9' QGGZ?C0!!;W'G8;8(KG(\Y<#<8P>YQZ^E?(?QE^
M/PM^*'CC3/$-[)H\/BC0=6L=9GEFLHWNA]@.]6,N-Q;N">?7FOK68/;RBZBC
M\QI#L:+^ZO'S?I[Y[5Q$_P /H)_$-]XB\QQ)J,!@> ?=0,,,W//'^% '4Z?K
M&A:C9QQ6UU#>+:1JAS&K<Q(J]&7 Z <8IL/B?3))'M?M*6TD:G"[%P .!@?=
M ]L>U<9I7@U-*OKBTM[R14\OS'&?N[NIY(R._P"%;VE>%]-2[EN3*+S*,"&/
M&>_X@GZT :,'B/3Q?2P/JJR?NQM3;@*2!ST'(/YU4U"\:P@?44O7O(\DB')
MZEAZ_3^1-:D6BZ*\\@73X5FV &3G=T(''Z^W6IK;1($1H;A/.@(XC<?*#GT[
M\8[^] &+X:\53>(('D^P- %\P*6/79P",^O'-;:I:W\16]M4;=N!+@-UR,>_
M'KZU8AT^VL$:"PM$@1AUC!P"W4C\>N<]*LV]KY47EN3(1E@QSU/;Z^U '/V?
MA+2;"X-W;V]O&>6RD>#R<GGU/YYKH@(R5$2C<,!B..!@<]S38XI02'+;,-@8
M^N/\FDAAD25N3L(X)'3K0!>HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "J]6*KT %>/?'7XM:1\$_AWJ_CS6E#6.GPRALOY>)'B98OF) '[PKU]
M:]AKQOX\?![2?CI\/-2^'VLLJ6&I-&TQ?=MQ'(KX^7DYVXH _/[_ ()U6_Q
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M]^SM\-_$OQ-^,7C?0?!_A;PQI5SJFKSZY.L=LD4$4A4R1AA(X,@1/D4\FO\
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M3O@UK4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKX4*3D X&1^%?T_^ / OA#P)I5MX9\!Z)IWA;0-*(2#3-)@6UM-G152)!@!
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MXE\8:,7G?1)II'7][T0/Y:YZGKQ7Z!_ S]G+X?? :SO#X6T2"37[Z%6U[7B
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M\2KBTDM;CQ7HJWKQ2R>8\>9&3+/SN.5(SZCUXH ]N:2XAOE6-"("Q!X^7 /
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MC??!;0;OXO>-_AAJJS:=J>H)ITLEC9Z4SR6RW80%=K,A!WF1U89P@-?VI?\
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MJPQ* L<?(  [#O6<I997WY6U!) [$]/\_P"36PR(^-RAL<C-#1HZ[&4%?3%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BFEU!P2 :BAN(9
M]WE.&VG!^M $YYX]:R_(^SLRQ.VZ5@Q4<\Y_QKC_ !A\5? W@.Z@L_%.MPZ7
M/<A&A24??$C!$P<CJQ KI[.Z347LM1LIOM%A=0+-#*OW6B<;E([8(*X/^0 7
M/(FF&V1V5< <\=.<XJ6&W6%@OF9/7![\_P!.U(_GFX3;E8_F!/7CH#CCW-*M
MJPF$K2EL?PXXH N4444 %%%% !114#W,,<J0NX$C_=7UH GHJ)YHXUW,P ]:
M>K*P!!R&&1^6?Y4 .HIAD0-M)YIJ31R$A6R1P?KTQ0!+11G/YXHH ***A:>)
M)5A9@)'&57N1G% $U-;!4@C</3UJ,7$1D\K=\XS\OTJO+?6XMKR99,I9QRO,
M5Y*")&=OR5#F@#+O;SRE=;M4L[+GS+F5T1$P<9)8@>]9VDQW\%O>3N[:E&\@
M:QRZ2*T)Y4IM9OE(QCTK\2OVQ_VQOBA\5=5O/A#^S3X<E\0ZKIQN+#7M4T^_
MD6;3M01V2*)X8GR6<J3SSP>,9S[I^Q-\<?'VE?V-X"^.\MSHWC'[*NGV>F7=
MP\D][<0IB4A9&+!ER#C'\Z /UMMBYA1G4HS#)3^[[<=*GK#TR-[9)KFXNWG2
M]D\^%77;Y,9&0@R>X(/ZUKM-&D9E9@$ !+=N>GMWH EJG/<L@S%'YP7[X'./
M3^?>I5N(9(S*CY0?Q>G]/_U&J,8BLHKBXEGWQ2-NR> HZXR: )X)8KD%M@++
MRR#L?0^_/\_I3XG3>0T:QMG"XZD'O_CZ5\]?M!_M ^$/V>/ .L^-/$4L4<%I
M:Q7:+,X@CD69MJYE)&/FP!D\G\Z^>_V>?V^?AM\7-9M]!NY;33-7UZ2%_#EL
MEVMQ)J%NX&9$&YC@$CICZT ?HI11358-G:<X.#]: *6H%_(95)0'&9/[O/;W
MX_SFN8UG5]&T#0[O5O$FJV]IH5C;-/J-W=R+'!!%&I;,K,>!E?YUJZK>V-M#
M+J5W=M%96(/VE0,@GW^G YZ=:_"/]IC]I+Q!^VKXX\2?LF_ .5M*TB]O+CP;
MXS^(FFW)N)O"EW$&,DTMA$V)'49785)XYS0!?_:B^._CK]KSQ58?!3]E[Q+>
M2^&K%;JP\:>)/!DJR+I%S*Y2S^V2;L([+M,>#[]37Z8_LT_LR^$/@/X$\.Z2
MFBV^H>*)M'M4\6:_< -J&IZKM#W-[>N2<3R,V'^;'%?A!^S!\!/B?_P1O\3^
M.-1\0:_=_'_P'\4M1AU;Q5X]U&-M"3P ^DMM2W,9V+<"\1-Q9L[<U]M?\%#/
M^"SWP!_8\_9"\4_&[1M0T_QEX_U+PI8ZEX+\"2WZ6(UR[U=A;1Q17P==JVY?
M<"IRYVX- '5_\%4_^"I?P6_X)H?"?4]9U_QYX;E^*FJ:)?ZMX"^'U[.9]3UE
M8$:)4LK:W$LA'G'Y05&2H..]?S0_\$O/^":?[4?_  5._:2L/V^_^"B-EX[_
M .%2:=JDOC[X4_#/QTCQ>&?$.B^(RTMK;V%MN#&TAB8,@DB!4!<@<5@?\$V?
M^"<WQK_X+.?M#O\ \%#OVY[^\\,_"CP;XCT^?X:_!W6;-M>TKQ)X8NPM]=0V
M^HW:S)!!'++Y.8V 8*IQ@U_>]X-T/0_"'AK2?"GAW28="\)^&K"UTGP_86X"
M6]MIEI&(K2WA1?ECBBC4+&B\!0%'2@"CX1\ ^&_AWH7AOPEX!T6P\*^$?#NG
MM9:7H.DPK!8VD$<9\J%%ZE=P4#)).,\9Q7\5/_!;S_@G_P#MX_MZ?'KP1XT\
M!>!OB&T?P<OM=M_"NL:/"I6&WOYV*/;EF PR@<]2I(Z$BO[>3:.6D;^T&5)S
MO@^7[J>@]1CI_P#JJ6WNW@CE:99?)M^'FY<OT&X*<[<9!('Z4 ?Y[7_!//\
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MJ%#$\'&#]: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MPZ_:8N]$^%&IZPGA,6]YK5XME=:M<:<IAN%ECF'+*&=W SCH3D$#^X_X3?\
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M2=%\16.H>'_$&DV&KZ'J-NT&JZ?J$$=Q:7EM(N&BGAD!#ICJ,<\]!FOY2_\
M@K!_P3]\9?L[>,-+_;#_ &+-;N_@/X=\%ZSIOC_XF:;\-+E-"LM4\.^'L3:U
M!J=J'"2VMZ-SW$*+\V[ &*_>O7?VR?A)X?T:_P#&?C3Q=IWAC1--B,URTURJ
M0NB$[D9Y !@*I)/N?:OY3?\ @H;_ ,%-/C!_P5-^+FN?L&_L'Z"NO?#R?4K3
MP;\0OB3X.NI]1NK?PGK1,6M:G<6\+I"JV2*05PR<$$9SD ];TC_@N5XY_;M\
M+>!?@Q^RS-KGB/QG+JGV7XC:YX;\VUO/#FCW@%G#J5[=3($D1'=I $;(*U^X
MG[/G_!-?X4?#GPS8?$76O"WA[5_VA=1TU;_5OBY/%YGC'6=5N4%R@NK]7^>:
M$R-$&([?6OE_]A'_ ((L?"#]@?\ 9UBT[P'+-JGQ?D@=;_QH]BEKJ_B!Q$9+
M>SG2.-&VI<$8RQYQZU]??LM_M@:;_P )U>_ +XM7]MI/CWPX9;,VEW,5O6N1
M(PMU:.3HTD04CYAZ\XH ]O\ AQ^T /#7C"Z^$?Q/U&71-6TEH!INL:GN:?6Y
M+DJL5J)AA2%+;1DX&/:OM$WZ*Z&]*V0N"%AF5E<3.W104R/F&#Z8/:OSD_X*
M#V7@_P /?#__ (3/3EMH?B7]BU"X\,R J;K5=4@MV?3;9<9;<UR %VD<D#U-
M?+G_  31_;.^+7Q$'_"!_M/>%U\):_96,C:?<7\D@N+B]2XDBMD"3,1N>!8V
M'/&[/M0!^XMRES"1L+30D@S#^%82/F)!YY'7UKXA_;4_:Z\+_LH?#EO&,5Q'
MJ=_?S7-IIVC0QR32)<6\#3!XD0,59G&S)')S7I7[0G[1&E_!'P_!)!]EUG7=
M?B-MHNF3SA6N[Z=2EG;QA#EFF?@#W!ZUX?X _9]TWXXZ*WCC]H/P^M_-J4?^
MB?#W48E-II$[-N\^)G#L7E0XX'0G/84 ?/W[!MMI?[5^GV?[6?Q%U9-9U'QA
M)>W>D?#K7'+MX8N]-G:"TN;:V=E,4I!W(2@P*^_/C[X.\.ZC\/KOQ!J%S:^&
M=7TFSO;FWU8%8KDO# S1>6X*G=&P#+P2-OI7Y??%/X=:]^PCX]USXZ^"=;NV
M^#\#QW^I?"YX_(T#P5HENI:_O8YU*@I@B1R5P,=.!7.2?MDW/_!2ZUT7PI^S
MU<0IX5TV_!\1:]X>N&OQ):W02":.49 1(TWMC&.O% 'TI^Q3^V]IGC#7K[X2
M^-M?DN_['@N8].\2ZKYC'6+B*Y,4=NLQ7!;8IVY.#@=.H_5"Q,)<ZB]V#9W@
M M[8,#"IQU4#.">O7J/I7P#'^P1X!\(>!-.M/"6H26?C?0XUOVUR*WC^V:G=
M@+*\$B@ @-)NY#;L'! Y%=M\'_C%8>#)8/AW\5=:CM?$=O<I!:K?MY=Q(;A@
MENNQSCEC\O/44 ?9K"*QNC/>7'E6]R?+M;=R/+68XQM[*2O<X'6OG?X^?M!:
M3\--/U+0(;M&\3ZG926&BVMN?,N3J5]$\=FJ%-VR0NP*%@,,!TQ7/_M0_&6?
MX7>!M0DTRVBU?7=;#Z=X8@DD&_\ M*6/? UOL))D)*8 Q7Y"_LJ:I\9+_P".
M,WBG]K/P[=6>E:SK,">$X-921(4NC+C3S;M,7!8Y&S&W\* .E_9J^'O[0GAC
M]ICQ?\4OVGO#_B+Q'\.?$NDVVG^$+/QA,+[2M&U99Q(U[80#_4S^7@E\=!BO
MW3U/QUX%\/>%)-9GU_3-)T2TT\SK<JZ*D$21@@)&I#'R^!MP>@Q[\W\8Y-&A
M^'OB"Z\2P0V6GZ9I\US87,LB;;>9+=F$BY+<HHSTSP<=*_CAL/VPOVAOBU^V
M,_P+O)+S3?V?K3Q;#:6GC>(S/;Z[8FX=)[)U),(3"!#\N* /V\\?#]IO]H3X
MR67B/X+>-_&ND_!OP[?V-])XFT.]-KI7B06US')>Z7-&P#NGE*R2 G!4D5^O
M'@WQ[X>\11+IUM?0R:_86$9NM&8[)4F@C5)9"7PI9I%9CCG)K.^$/A3POX%^
M&V@:#X,2*XT.?)+Q%50S72J)3A<+EB.>.>^>*_)W]O;X^:I^S5XS\+7'P@M(
MM>\7ZCXOL].\0Z/&Y62WTB?:\\LGDD':N]LY)'KF@#]LK&YEN(6FGB^S7A#?
MZ/QNPH.SD<?/D=^_M5F(2SQ+/+']EF!^?LQ0'(&??'3_ !KYL_9N^.%O\6/A
M]H>K:Y#;Z/XMG4B^TE)-[Q[0/++;SN!?/.<GH:^CIFN+K$05H64[CCDD>ASB
M@!TBF5DFARQ+#)'7@A><_C_.K+A%VM*1N8C;NY^;J<>G)JL&-I! .I+8R>..
MO<=2:J7TDL\T,:CA75B1SPQZ?Y- $7B.^L=+TVZU?4=332-+TB%K_4M08[8X
M+2)<RO*W_/,*,G'0<\]*^%9O^"FO[#%S\1E^%L/[1WA&'QG'<6=L-*A^U/+-
M<W<BQ06YN$B*%Y)&"X*J 2<GCGY _P""Y_\ P4=TK]A+]DGQG+:Z9INL^)/B
M%I]WX"TN.\O&MWL+[6K4P0WD2(<RS0&7?&C _,H/! (_##_@A'_P2[T+]K']
MFB\_;%^)WQ(U.\^+7C'Q'XC@L=*EL(6_L%M/._2;J&653.TBRM')%C*_(<E<
M+N /[?)]4BF@MIM-D345N5B93 ZN!#-&LB3C:3PR.'&>Q%:EM')Y2K."W<[N
M?O9./P/I7\UOQ(_;M^*/_!+6#X?>&_BQ _Q8L/&GC:T\!+XA\2W4^G3:='-,
MH@NXO)<DO#;E8PGW65>>*_?/X1?&WP;\8_!?A_QEX=U.UEM]?LX9U2VF65(I
MI(PSQ*Q(8^6>,GF@#V-EBC&U B,?3CZ_K^M4WLW9A(TY&6W!?7V''TISPM%(
M':1G!X&>,<YS_CZXJ691,(]DNW!&<#J!U'8\F@"4< #T%+0. !Z44 5[A9F"
M"$D'>N[!QE003^F?SJ9BHW;0')7#J!VYR??G/^<4_+;6"@Y(P#Z>_P"'7\*K
M1P_9B9)92^X$'<,8SSV^M ')>,-/N[KPYK,7AS?;:Q+IUVML]J=D_P!I>,B+
M:W0.7Y#>]?FE\"OVG]9\#?&/6?@Q\9M<O+&^BLQ>V$FN2-*97GF*1QQOPN<,
MN!S^I%?JU'%\[74?=6'E@<$C_'],FORU_;6_9+O?'?B;PI\5O!L]W8^+#K=M
M;:DEI;B5SI\4T;C>_#!>,\L10!^GDL]B8+:ZGECN;2Y\J2W=OF5A( T3K[D$
M'J:F5)9[D2986VQ=@SB//'0?S_SCAO!6C7]CX*\/:=KTTD]W:V=BDTLRX??%
M"@((.<'(Y';M7?LIF"10L8XTVG<G.[ ^[STX''?.10!I44#@ >E% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=]1M_P!I#X7OJ^K?$M#'XB\2:; GF3ZSK)(:XFNESGS#&SDXR  ?2@#Z=/\
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MTNV,$=]X?C47U[+MQ',Q^3+IM!!R<=N*X[]AS]N:RNK^X^ 'QGU[3=-^(G@
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M-_QQ^,MWXCO?"EQ+?6EIK;274AEN2K2;)'4;6R#D]R">>M?OAX7^/FG?L/\
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M @8)&",@'ZQ?$'_@L[^P_H?VS1_!OQ<TWQ7XOM!)#%H-E:7&Z:\"YBMC)($
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MKU[J/C']J'XZ>$=+O7:>31S&J6\:RG<;?!G'RH#MZ5\3? K_ ()Q?&KX8_\
M!1?[1K_QV\;W/B35_B/HYUC7+QD6[:9M_P"_E_>'++S^8Z4 ?W>>(/VEO@EX
M;\2Q>%=9\>V-EKJSFW;3CN+^<IP5+=!@G'&ZO"?VN_VFO@/HO[//QBD\0>/K
M#2K./P=>F:Z:-F\M2$*R*/XL]#G:0#D9/%?!/B3_ ((R^,/$WQ3?XDZA^U'X
MZN93?/>"TD/R@LX<H<.1R,?I7F'_  4<_P""<DVB?L&?M2:SJ7Q6U^^N]%^%
M&JWEK-*V [6GEAF8AB1D.H&<=Z /)?\ @C9^VC^RGIWB3]H&6R^,6G:E]I.A
MF-#!(N%18S\IR06)P #@$9)-?T5Z=\>_A=JOAZ3Q!I/BBTO+-K<7(=?E_=L?
MO$9Z'V/X5_GO_P#!M'_P3SM_VA+G]IJ2_P#B-J^EMH,7AE89;9RS2-<+&=Y^
M8GCS,<_W17]<<?\ P2F\:Z?H<N@Z7^TMXTTZTE@^S1I$P"I'GA5RP/ '84 >
ML?M\_M:_ N#]D3XW:9/X[L(-6U#P#K5M!:@,91.T! 4\X&2PQ@DGN!7F?_!%
MW2_#"?LP>%O$.EZ]9:C/K?ANQ\Q Z)(@+2'+9.[\,9 Z#%?@=_P5P_X)C?%G
MX.?"S6=2M/VAO&_B6UU?P]J<DEI<./+F\M=IAP),G)'->7?L9?\ !(;_ (*$
M+^S+\.OB3\'_ -N;XU^'K+Q'H\$P\%:.4-GI,)5F2&)6F5MHP=N0.M ']Z$D
MT2P&)9X1*J_(J2*2Q/('7OVXK\WO^"M'Q"C^&_[ GQVUJ34FT_43X-U4V+QO
MMF+QV-Q(VQAR"ORGCN<5^%FB^"O^"N/[)>CIKMKJ?Q7_ &D=0T.$W_\ 9>LV
MOG'4WA/%M($E;(D'US7Y&?\ !8S_ (*>_P#!2;XD_ +2OAU\8OV6=?\ @[HG
MB73?$%K=W$MA<1"_CDLYXY4?&=WD*6. #]* .(_X(S_ME?\ !3KX*Z%K7Q,^
M'7[+WC7X[_#K7[/4+VRU-->6*W.FF_G)G6.53\L393&>2F:_I-^&'_!P-H^E
MQ7&G_M9_#&]^ &M0;1-;:B?MS!#_ *Q]T14?N@#[\=B:^G/^""7P9T'PG_P2
MX_9=U9]*B?4/$_PP2XU>TG@0-,UY>3F2*3>F[)8/D'')'X?<'Q8_X)Y?L<?'
M"SO)?B3\!?!VKZK?V\T)O+JW=;Q'D4C>LBN%&&;./*/'?^*@#\Z?VG_^"WG[
M"EW^R#\6_$GPS^.VG:YXUMO ]U<Z#HEI;7-OJ5[JI:+R[6,D;(]P\S#"0L-G
M3T_B$_X)3?"3Q?\ \%"O^"E8_:1U[1V73(_BOX?UR_BU9O.%U:V-PQD$C2C#
M!HU&[/8>G-?VD?$S_@W0_91\:VQL/#>GQ>#-->1S-9:>6,,\#$E8'']T D<B
MOYE_^"L/CCX1_P#!)N\TC]G+]@CX@6"_'_+Z+XVB\*2BY\2:!KEV%-H\L<"D
M+=K&^]%W'[PS0!_4U_P41_X+G?L<?\$^M(U#PCX2\3:-XJ^*?AFZNK:^^&.B
MQ/%)%]CAPL3N=D89Y!Y8";P<YR#FOY-/VB_^"V7_  4M_P""F.D:_)^RI\(_
MB#\-M*MK>:6:^T'Q*;$6%C%\C31JC /@(>CA6ZAB.:^'/AK^S3\,;3P5XF_;
M"_X*!_&NXUKXLZQI@U3PQX+\?W0CE\:ZVJM<WEAY))=Y L:K(/+08R0!G%?"
MOQ6_X*;^,EAO-%_9HT6V_9]TIS)87">"]J?VK8H3%AF>,_\ 'PH#GY6^][\
M'U'<?##Q!\5-&B@_;L_;F\1>!_%L*.6\.^*+Z^UF5&=<S@.K*/4'U&1WKZE3
M_@BG^PEH/[/U[\>?$?[<GA\65WH/]L>%K2?3;HG79]V?LZ(9=JLX'5@W6OS.
M_9X^!WB_XNW$_P"T+^U=JVL7'A+1Q;:GX>_X2B1(K+QJ8G\Z]LP5\LO'Y:[6
M BR,M]*\._; _::U+XD:G/X2\!:FVA_##1[LP:+X.TF:3^R]-LX8_*6&')&8
MRR;R, Y;UH _N;_X(C?M#_L=? G]GSQ38?#;XOZ-=:G\/-/N+_QK<Z=9&SGF
MM845U:<[MTPV+QVQ]#7ZZ_!G_@N+^P1XUU2;2KK]HFPA\07JF+1]&G@DWWMZ
M&*&W0ER%;<H'.!R2#T4_Y/'[/O[0/C[X >)/[<\+ZW>V_AZ^N;:3Q=X364KI
M_B_3(''G:5J2]6AN%)C<CG;US@"OT$^.?P7\._$#P9H7[6O[(GBBXO\ QDTQ
M\1?$GX5^$YO.3X0Z8T#,EZ\999HX'N$&\ -W.TL : /]>_X?_'WX=>//">E^
M*-#\0V5[;:A";AGC8%Q&&^_C/.4((')Y(QTKUW3M:T_7+>.YTNY2XA<CYP<8
M#8P<=>?\^W^-=^R%_P %I/VQ?V8O'WAO7=:^)?B/Q[X0\.ZW8WEUX!UR<MIM
M_9V;XN-+E7Y&CMYU&R2-U9U*G+<X']XG[%G_  6L\!_MI:)H_B_PGXJ\.^#?
M&ED(+_6?A-HMV/W"7/$5M)#)M?:TB&,  G)Q0!_4/#>*+ZYMI 4$+85_[Y_^
MN>/\\;7F;8U(YSG![=:^9_@O\?\ PU\6$^R2M86/BF*V5]5TA)<7-DX (+H^
M&!8?-@9XQQZ?1V"8E\D[U!)! R/3_/YT 7-YV;]N<=L^WO34FWH6 ^8 _+].
M>M,A)9=CXSCG''I_*HYHA&'=6VC:?IP!G/\ 2@!WVH!077:['"KUY]/\_CBE
M:Z2-"\Q$8QD9_K61<WL-LED)=K-=2F-';J#ZKV].O\JIZQ>PZ#9WNKZG+&=)
ML;9[N[N+AT2*VMXU+22$LPX4 9Q[X% &5XN\9Z+X5T34?%/B:[CTO0=$@DO9
M[R0Y5H(5+RMMR"=J*6QG-?C=XW_:F/[17BZ[TNQU:;0_@C#>M]K\1?:"-/UO
M1X6\N>.2T!RT1=2"A)SUK\[_ /@KU_P5$MO!\EMX-L/%ECX=\-[K^/0[6UG+
MQ^/Y=KB32F6+<S*0/+Q@<$^HKY9_X)G?L8?M;?MP:A9_$WQKXH\>_ CX'21'
M7=!\/V-NT.A^(;0SE!IR&1ED:&Y!$S?+G#DXH _IR^#/QZ_8P^%UA8>#_"/C
MOP]:W-Y*D$1MK)K87-Q,0NW*J_S%B!DD+^>*\J_X*?\ _!.CPY_P4X^$O@KP
M9_PL.R\,6OA76SXAT[4?+:Z6XDDB"JB",$QDK@AFP,<=!7YZ?MQ?LL?"#X/?
M#R^\(^%OB0-*^,NJ:1J%EX,2TGWZR_B.2%TTUK6.,M_I!N=OEAL N!STK\E?
MV,/VW?\ @I3_ ,$N_'/AJ+]O+1?'/B[X,?$J^B\*6?C#XD6T\.G^&@EV)TU2
MVG@:4H[6C*C%R%,.0V02" 9?QA_X-@_VE?#'B;P1XC\)_M!:MXZT'X9>(;'Q
M1X.\-)+.EMI=YIUPMT@T^-EVV\K.!\Z^OI7]F'[$OAGXB>"O@#X4TGXL7-[+
MXRA1!J3ZC,;FZ^2)8@'E;!;."/4&O3O@=\:? 7[0'PY\/_%WX3^*-,\8^"O%
M]GYNFW^E3QSV7G1 +=11'(;,,GRNI4$<9X.:]82ZB9DM(XTGG#9N(P,&%"2-
MQ &.>!WYH _G<_X+2_\ !%/P%^VSX,\=_'OX1:=H?@S]H[PSIL_C'2?$VEZ8
ML/B/Q?X@T*SWZ?92ZI$I=9Y?)6**60\':.3U_@O^!WPJ_:]^.W[4OAS]D+]I
M;QIXMT+6O"?B'2(/$>C>(-0FO[<:?JUY%;-YJD;6C9)#GCE<YQG _P!?R5"Q
M>%(P\ 5A+!@%)%*G,; ]B3@CWYK^5GXE?LK_  KUW_@HW\7O%^DZ-8Z5\0=9
MM=&AM[^T4"]M+I9D%M-$ H DCEVE3D<]Z /U#^"O_!)O]F[]FKX8^%O^%0>
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M8&./QYS]:SIK.9KUIY&,L.P".(C(60#[X!R > ?6MJJ;3L9I80OW8\@XX)-
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M=]L%K$\TYQD%40L,_C]*_"S]M?\ ;_LM)T_Q:='FFTSPO\.$N(O%>J0W+!(
M^XH\J*V  !D!OUK]'?VS/BF/ ?P3^(MEH]XMKXYU+PY<#P?IT#A;[5+H;BR6
MI!P&$:G[WO7^8C_P6>_;C\3^+]8\)?#?X;>.]1\-:G;Z3J]A\=/#.A73V[:K
MJSRQ+;?\)'U$\D4:RQJ$('S'D$<@'WM^WC\=OAO_ ,%5?AGK/A#]GSQ6O@OX
MC>"[4I;^"M.7[0WQOO(F82Q7;1%O++ &0F0?Q?2OYS_A%^PO\7O$7Q7N/AIX
MPTF;P/)IVJ0:?XMUK8TTOA(,68RO$ Q8J%)*\5T7_!.GX9_&:]^,_A?XL>$+
MOQ)X0^%GP]U5=2^)GQ/M)!;:5X+T9HI1+>WIF93,CR+%%B))-VYBQ4J%;]._
M^"DG_!3;X6:UI>B_"S]GFP\/?\)+!I=WIWC3XU>%[<0:SXWU";*Q:MJ=R5'F
MW$0R593_ !'\ #X\_:'^/?@GX :!?? OX,Q13^(=)+:'X@\=:>PLKGQ$UF#&
M+RYBCVOF5\MAQQC\:_(S6+Z\U+4+K5M0OI+K4-5F:?5)'),AE<G<9&;ER1CD
M]??K3-4NM2UK5YKJ]O[C4]6N)WDNM1GD+S7$KL6:21F)R23S_G.7=1,DOELS
M;P,7!/!'49;M^E %RUA1KB...?[/ Y_?3CHH[<=QU/;H:Z3PMXQ\2?#KQ;8>
M)_!/B2ZT?6]$O/M6F:Q92/!<V\W0RQRH0R$J=IP>G'M7*VJFY9K5"<' $@SR
M*2[L9K+B:$Q*/]66((N!GVSU_P ^P!^N]E>_#G_@H!\.UAU?5+?X?_M"?#>T
M>WTJ7R_[0U3XW:K?+F-[JY(::":&8E?F)Y(())KY<_9[_9P^,MK\;8[R\N;_
M .&G_"M-<%SXT\=1!GG\#")9!)?$(-PESF('Y3B5N<5\F:%XBU_PAJ&F>)_#
M>H7GA?7M+D2XTO5;"8PW*31L&62)AD;D(!!96Y]2*_:/Q7^WEI?[2'[-&C_!
M;P=X%TKP1\7(?#MKIWC7Q3H\*6OB/XS:E$F)Y]:N=JB::5B)'(;DF@#Z^_:,
M^,?[-W[9'PX\)_L\^$M&TOQ+\=_ >DR>&[/XH/%%/J_Q=UV<*UK>7 .Z>.6-
MHV5=_P W)-?IK_P;J_\ !43QY\ /CEXA_88_:(N-1N-2G33?"GA'1K[497C\
M.WFGRQ1S1VMK(^(]P.&5$R5_.OX?K:[\??!_QNNJ:5J&L>"_'?A>_2YBNK65
MH;_2KY6RDL=QAT,B*Y96^<=?6OV(^(%GXF^+WP3\!?M-?LXZC>-\<_@O8'Q!
M\9?BIX4G%IXH@O+R!C'?ZU<$KOF>50595/S#D4 ?ZZOB?QYX2\%0?;/$NN"R
MM[^".>%)1@>7(H9>"1UR/Q_*N U7]H;P/H/]C70OHY]%U/<6OMZJL"+U;&0#
M@<_6OQ1_X(2_M5> _P!NS]C3X1Z/X]^(]K\9/BM\//"OV/XG2:Q))<:U!J4,
MH15U=R?FF5% !7C%?N[=_"CX;W&G1Z>_A#2+S3G&VV@:-C%;*."$&<@,.O\
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M"I(X?A_X0M'(\/Z'$8T\^'3+9!N4--N+EBVXE>!MR0#]+OVV+4?\%%](TO\
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M=1MAF!.X.I (*X/-?Z4'_! /]N^Y^,?AC5D\4>(2-,O?L-OHVB7<I-OI+R!
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M\7/[5_Q?_:3_ .#A[]KU?A3\%O"GBCQ+\#='\9Z)"?$/A^-HM T3P_"YCO\
M6%:=%26.W3$DF6<YPV2W- 'F7_!0']IK]LW_ (+>?'/6O#/[*?P]UCQ=X*\
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MH^DZ3IL_F7$]P(-X81)(V'.1MR2-Q&T_RJ:4^N^&_%&FZK9)>:/KOAS5+:_
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M_%]E<&XL?MMTZWDL*(TCSQ&&25X69@JE4*YP>0#Z.^'G_!/W5_V0?"EU\4?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MGP9T:&VMVMK.+Q3XCAABM;C5M0L(?L\%]=P6X6,3^66 P6VAF ;!./JNZD$
M$;7A:Z3"PKWF()R2.H)&2:TVM'MM[6\6XMRX7CS3G@MZG']:22$/+;NUDK2,
M QDQDQ'GOT_^L: .-\=_#WPS\3O"-[X3\;:3%XA\*ZQ:2VNM^';CFSU2*9&4
MK<*?E8#=NPPQG'2O\V7_ (+_ '_!!^7]DG6M3_:3^ D]_P")/AIJNMZIK7BG
MP\FDBUTSP1:W\KR6NGI<0QJLD<0&Q"W4'L<BO],HVMW<7$<HE>WBA^7RU.%F
MY^\1ZXXKD/'?PW\$_%3PMK?@+XD>#]'\7^#]?C:'5-$UVSBOM/O@!\IGAD&&
MV$_*1R#TZD4 ?X3W@SQ;XC\ >*;/QAX(UJ?0/%FBWZ76E36F5EM+FWD4@QOP
MP*LOKSS7^CM_P;R?\%UM)_:.T2[_ &<_VA!I_A[XH:+;:/I?@F[FU0W%_P",
MY8H8X;Z?R9V+HZ.3(ZKCD<9!S7X:_P#!>K_@@7\1OV6_'WQ)_::_9_\ "8U_
MX,ZTUYXSUBV\.0_9=.^'L!<"6PBLPI;RXQ\P6/Y2%R.&!K^5/P9XR\?> ->T
MSX@_#S7M9\(^+?#;>;:^(]$NY-/U6PED!'F0SIAE9MS#..>.^, '^Y]\;?@_
MX+_:*^%GBGX1?$?18]9\&>.M&DTS6;.Y DMY(94\R%Y('W12^6Y60*ZD,0*_
MA\_;3M?VG?\ @WK^*B)^SC%J'Q]^&7[11N?%%MX8OEET'3?AK'X>F^SPZ+8F
MU:-+F.6+[[%<IL"CK7L?_!(O_@Y$\,_$+X#^&/@A\=?$=U9?&SPCX?L_"/AF
M?7+AKO5?B5JT:!5OVO0VT3R;E!:3Y@5(.&!K^CGX4? RT_:J\&:WXT_:"\,Z
M?XHL=6=)O!2^*(HM672;&X7S+N+3RP/D1R.5W@?>H ^"_P#@F5_P34TCQT?"
MG[=WQ_U^X\=^//C)I\'Q.T;POJVG1JOPSO\ Q"@GETO3;]T>69+7 C$H?+#J
M:_HGTO3DT.S^QV,CSVD V6]NS'_1X\YV*W)P,YXQC)-?EWX2\;^+/V0O%4'A
M3Q3:WI^#5Q=-I]IK+-OTKPEI$9VV4=K;C_508RL:)PH'Y_I=X>\2>'_'.@Z5
MK_A;6(;W2-7@,]E>P' N8\<-MZ@\C[W3ZT ?G+^VW^QU8>.="F^(7PPCDTSQ
MMIS2W=[X>T^W#_\ "57%PQ+_ &J9<2!D)#;B3DCL37XBGX\:U^PK_:_Q@O;D
M6B^!96U;XA^$9G^R6KSHQ1[:^GRI'W@2S9Y[U_5)\3?BU\/O@?X$\0_$[XL^
M)+'P;X+\)1>;JGB+4&_=P1G +,H5G?)Z (2>3VS7\(_Q@OOB9_P6W_X*&+X=
M_9E\,:E=_LD>$?'4OAWXK^-M-+6/AKQ;I$<;^9J>KV3#_38C)&%(W=<?B ?H
MQJ?_  4'MO\ @HQI$$^@:-8*AB\ZR\)VEX+^WUI-1&](RQ+?*F\*"!DCIQ7Z
MV_L(_L26/PPMM&^('Q"M7N]3G@74] TZ\M5C7P6TV=MG8R,N[;&#@%2..^.*
M_D;\5_!_XH?\$&/VSM!\6^,O#.H>(O@#\1=6U"^TC6@7GT7PMI.AW+M$L%J
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M_!2;X]^/_B1;6-SX.\(R:G9W?Q"\0:? =03P^NJ2.R3S[OEDW $9DR75 #P
M*_MT_;'_ &=?C%^V#X<_:3D\9Z-=?"7X5^)X)IM>\8/=(;!M&51,U_,J?ZZ.
M4+M(#9(;O7\IW[6?[4?P[_9?^'VC_LS?LEZA9P30:9-IGQ-\:^#8QIDWBJYM
MD$.GW6L2#<]U(JCS(V)!7W/4 XK]M3]L?P=\./A?!^Q_^SMX7T_PEIW@[3X/
M!'Q#\<:3>;;GXJ+IR@R:CK-E$419+B5B7CD5@#GOS7XG2K=2^1,T BP"P=%
MW]LG'0CD]./S-:%WJESJE]<75XCZAJE[+)/=WD[;YYYY&+222R,<L[$\GO\
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M%/@74KN^\2^!M(U^;3?!GCB[MGM3XJTQ0IAU%8<!$WDD!5X P/<_[0J?LU?
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M%]NUB6!(.\$?-^%?S5?%/X[^)?%4DGA?2]8OQX%T?S+70=&BG*:;IL!X?[)
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M$32?VEOVBI-77X36/B.RUKPAIGBR9[_3]?M=,F#W%K%:, R1W'1PP(/4D 4
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M&UJ4P8&F2SLGF;9'8."7X8^U?VJ&%H6WQD[,C,8X&.^!SUZ>E?QO_P#!T_\
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MI'@7XO>');#Q#=#PU;?8=<U8>%6_M"TMY)[8@D7,D0C0%.O.#7W=_P $6_\
M@I7H?[<_PH3P#XR\0W&G_';PGIT6J:UX1U5W;5XM)L6&G?;GF?&]99(0[  _
M?R>* /W9FTTW8CADN#F)UF4D9SW /_ZO\*U1+*OR^6& & >F<<?EWK/BBF:"
M&1G<.K8=L\LBL,G/<8&?\FK<=S,]R8E@S;A1B;LS8^8$>WZ_2@"0,ESE6 ##
M# @YP1_GVJ3RFSM\UN!QT]NGI3EA"2,Z\9!X[=OQJ-5D$SDE@@'WL\>O3/\
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MW#Q:O<SHT4MU-F1,RM$[ X#9YSS2?MM_#F.T^(=Q_P $W?\ @G1?'X@0^/\
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MME(2',MO-&08Y-N0&'S=,4 ?[G7Q*^&OASXS^$-8\(^(]+A%AJL 6PU!2DC
M+B2&:-EW*W;;@X.3U[?EIXK^,6J?\$ZM<BC^).O-)\%X_,OVUW7Y!;6/AS2K
M<.)%B?) C#! WRCD]*_'3_@@Q_P<&^"/CCH?@C]F[]IG4[OPO\0_#OAVQ\,^
M']<U:^?4KCQOJ&GP 27K-(^^.6<<MN&<ANPYG_X.#_B7\6/VD[+2/A)\/?!E
MW??#;6=!GT[5/$\=V?L@@GNTDFGDM0<.-@8[3V.* /.OVB_C;\?/^"]OQATW
MX%?LZ>*=9\%_LP>&]6O+?XB>*_ JS7FG^(=)G?9IMQJ4TIC0K()-Z$!P:_J
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MFK6EG-X2^#>G:I OC_XDX\R#P;HHS)<ZD8%!:4Q(,[>!R#GCG]C-3_:Z\$_
M[XV? W]FC]C&-;&3PEJ\^B^-_BUX6(TBX^)]K9E(K:[U.. B20%R)%649!%
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MZ\D_9#^$]MJMZK&2_M=,EMIFE88\P[I9LOGN&'\J_4BHIR1#(0Q0[3AAV]Z
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MNO%/CW7KWQ+K^JRO-?W6J2--<2R2-O9Y&)(W$\$\8XKFS=17LMK92S?9)(Y
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M S+R*26WD>UN&7#+PG'&>GY$\<]!Z4YS]G@B*Q^=>E 0#]\C S\WICG].E:
M10"H4 'J!WQ4<L0D PQC91A7'51GD?C_ )[4 5))$O;9C^[EBQLN+:1$92Y
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M-/ECG;/WV4<<< >U:UOL\N(1($AB1$@P2?W:@*N,]1@#K[5+L3.[:-V<Y[T
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M0?V$/%>E)X>T[3]0T7XL?$;X>0?V8_Q0.&@L+WQ),P9[QHXD4Q'<"H-?CO\
MLL^!OVH_&?Q1TC_AF*V\:WGC][P-:WWABY:VOO,9P97-Q,=F74MN<AR<U^C'
M[)G_  19_:F_:;\8W5CXU\.^*?"6DZI>6=NOB>+2FF:9)6 >X"R)L8(N/E96
M!P0Q8'%?V\_\$Z?^"*WAG]EW3;;3(M*O9O$NDZ9;V</C>XLQ!J,UQ&,O>;0H
MP[YYYX]* /BS]E_]D^W^(FG_ +,:/^SGHNI?M->'KBW'[1/Q6FTZ(^-M!UXR
M1^5J>NZH5 NKN*)6*R1@ #WS7]??P1^"GA;X1Z?J366E:=!K6L01)JWB2&$+
M>ZR\84^9=R ?.Q.#VZ55^!W[/?@WX-6>HZE;6JS>(_$#K<:[JTJ^7<ZA,@ 5
MYL#+, 3]XM^-?01MEO44 [(@/E R1@XZ=,<?UH ;8S7#EXI(B(8CB&<])D_O
M#'O^GI6C34C\F-(@VX(N 3_G_(IU !1110 4A 8$%=P/\)Z'V_&EIK,54L!R
M!D?7M0!3>:6//^B 1IT/3;U^OI_A7PS_ ,%-?$6J>'?V OVJ?%GAO6KO0]7\
M/?"76]3LM1L)##<V=S:^40\3KRC_ #D!@>WO7W3+%)-"79S'D99?X3[?SZ=>
M]?'_ .W7\,M4^-G[&O[1?P@\.PSOJ_COX;ZKX:M#:)YMPT]ZZ$M&G\4@$> O
M<-]* /Y2?^#0KXZ_&+XT^._VXI_B=\1?%7CFQTL>"SH</B'49+Z+3FF>$R_9
M$<GR0\;*&5>#UZDU_<37\HW_  ;9_P#!,GXK?\$^?$?[4M]\1EUQ;7XCQ^%U
MT<:O9&T5CITB/*\)_P"6C $QDGG:@'0#']7- !1110!!)U;Z?TJA<(TD+HN=
MS*0,<$D]/UK5*@\D?SI-B^G\_P#&@#G9;65[!8OF,T,?//S*W)X/K]*?:PS_
M &,"<-^[5OF?#'I^/<8_&M_8O/R]>OO054KM(^4C&/;TH Y>_P!'T?Q!H]SH
M^M65KJVCW\!@U+3KR(2VMS W!2>)@0ZDX./4#M7\_?[:?[ &A6GQ/@^('_"G
MM#^(GP8-['?Z_P"#KNRCN/#FE:+!N-] ]B02;:8'=(BX)Q[5_1&_V>W 0@()
M#@CUSVY]_P!/QKE]>AL;ZUN]%UJRCO-#U.&2VN8)O]7);2KMD1EZ%3D9!S^M
M '^4/_P6"_9W_:(\8>-=5UWX-_"C7-"_9I\&W^I:AX?\/>&0EGX7\+63\1/8
MZ<&BDCBV>8, N1P ISD?C5^RQ^T[\4OV6?B9X;\8>$O%/B6PT*TUZSN?'OA*
MTNYH+#Q+I=O-B_TC6;-\I=6US$62:-UY^]]X9K_6F_:^_P""?'AWQ;X>-QX+
M@N;OP_>R3G5O"-M"&L;NTQN6VD"X'EMDIRN?FXZU_(%^V%_P;T>%-='Q8^+V
MB>+=<^&VHV5C=:YHOPYT[2XY+*]O(00FEJ[1Y NG.XN,,,G!% 'QW^U9\+OV
M<_\ @I-\%](^-7[*>F>$(/C=H]M?WWQ4\"^%+5--U;3Q/$\FFQ:@TC!;CS'*
M+&(UX8BOYH_&'ASQ!X*O)O"?B33;O0_$6C7,MIJ^G7*%)K9T=DVR,?E8D -\
MI/7@D5^PWP._9!_X**_L=>,[;XL>"_A1XHD^']S=6M[K%HUO-!IGBO3M.?SS
MI]WL*L(R5?+%R K-^[.<U^J7[0'_  2GU;_@H1\$M8_::^%GA"\\$_%FWT,^
M*_$GP[\/6:7<#7:0F"6QF=P)-K2(9-Q)(8Y&.* /Y#;-7MK<R7.G^=!=C;%=
M[2\B= '55RV5SGCFOVH_80_8#TW3M*B_:F_;+2V^'7P,\.V%MXC^'">,%CGT
MGXOZ@KNS^'TL5?SBC0IO;SD3);;MP 6^H/V"/^"$7[2E]/K?QY_:7^'OB?PG
M\/\ X/M!XITKPKJ=@/[)^(D.DG[3>Z3<RR#,=K.H$3%5)P2<GH//_P!N&W_;
M=_;)U)?!'PF^"^J>%O@MX5O[BY\,_#[P\9)M'TFV5?LT:6P<L@3",<)$N6;@
MC'(!\(?\%"/VUKS]H?QS<> ?AM?W/A;]G3P9/%8?#7X=Z 6M?".AVL2*MU_8
MVFQ;6C2ZE_>2*=V]P<BO0O\ @F]\&/VH=(^*&@>.]&\*>*+3]GB\U+2E^-FH
MO<)!X=UCP7YIDG77K2X?SKRV2(N?(CB!"ESOR<']./V"_P#@@CX=\:6WPO\
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M=% %?U:>#-5^'4_PW&K:3?Z1J'@=]&F>^N B"R:Q2W)O$GA?),:QEE=&'(R
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^6_]J;_@M3^R1\7/C3_PIZU_::\*^!OA9:7>JZ-XP\26&H;8;6;2R\20W+D
M!KB56C.,YYP>E 'Q7^U1_P '#6D^+/'4G[-_B+P]>^'8=/']B:WJ1G,BW,B2
M>7--)&&S)YBAU8]PQS7Y3?M9?&[XF_&#XA?#OX3_ /!*WPCJGA_X@>,=/ED\
M5Z[\/6;PW>WURH"W4M[/$V96F=C+*Y)("D@,<*?3=$^"W[.7[6W_  5I^!UY
M\!=#TCXT?!1+:"R^(?B72HIKG2=3ULW.Z2349A&$%P\>XL,G@_6O[Y?A)^PC
M^QW\#O$>D>*OAO\  KP+X0\9V-L8[/6+"Q<ZE$&&)=LK2%,L<DGRUX/3% 'Y
M%?\ !%/_ ((J>&OV)/ >D_'/XU1:5\1OVG?'LR>/O$OB/7-/6Z\3^&?$FK(S
MWNG_ -KW \R6:!I#YDB]6)[U_0Y>7"0$&Z;][+EQ98R'!.68]OE)_*K]W;W%
MP'MX&>U5L8EC &T#TX''0>U(+(--;K<0B<PIM$[C)XXY/OUH NPR+)#$R*$!
MC7Y .$Z_*.!TJ6F)G+ 1;%5BJX'!4=#]:DP?0_E0 E3CH/H/Y5#@^A_*IAT'
MT% "T444 %%%% !1110 4444 %%%% !12;AZC\Z-P]1^= "T49STYHH ****
M "BBC- !12;AZC\Z-P]1^= "T49STHS0 5^5'_!7#]J'QG^RO^RM\1?B-X'\
M,WNN:]HGA35-0L;O3IC;WEG/%'M7R9%^96^8L,<\_G^J]>:?$OX6?#KXO^&]
M0\%_$SPKIGBOP[J]I/8WVD:M$9;6[MKA#')&Z[@=I!SG/# $@@8H _P[?V@_
MC_\ $']IOQSXG^(?Q-\7ZUJ6J:CJEYJ=GI>L7DUXUI)=S.\B(TG*D X-)^RK
M\&6_:+_: ^%/P5N]371(/''B2STC^U9AOCM(6?>SD=P0FS'^W^)_L^_X* _\
M&II3XSZAXM_9RN_$VN>&_B!KNJZG>>']'A@.G^"+>>7S;:QMV)4K"B@1HC?*
M /N\G/\ (3^TK^SQ\=/V /VAM4\/WH\0>"_$?@+Q R^&O$3M%#J$<D7,=U"Z
M%U5QC'3GITH _P!3?_@G#XC^!W[&/P6B^#7B.ST'P!JFBV]AIMIK=I;Q13?$
M3^SX1;R:A,8@"[Q;#@28X=B#P >L\6_##QA^WCXTU#0_B#ILFE?!^._FBTZU
MU)A>Z1XNT5 3:R/:X*F-G7<J,>"<U_F*?%3_ (*R?M3?$73/A0LWCG6--U'X
M;:?=6D]]%,RR>*)KD8^T7V&&]D/S<9Q7^CK_ ,$,?^"I7PH_;*_9Z^%'@.[U
M?0+?XL^#?!.F:1J]C&7BU+4];M8RMQ]H,J1K)/(!O<J[=>#0!\?_ +7G_!/[
M5O@7--HGA?38(_AQ>P3N9;&!8;'1K:+<NV.!5P%V!3@$U^61T>;X7ZG9/JUR
M\FGF7;HNJ'.8(E(V/$.#'D<=>,>U?WT?$CX9^&/BKX9OO#?B?3;>XBO;:2V:
M1U5FB612IV,,CGV[@?2OY6OVY?V/K_X1:W(M[I=Y=^ )=0NE?7KF(_9?#]DK
M;HI$<<*IZ#.. * /LG_@GS^W-=>&;/P[X'^(MQ=R^'=1N(;;0]:OKAIXK:Q/
M'F0HY'EKWP/4U^BG[2W[3ZZ?H%K'\)KJ3Q&MT9?[8U#3;@QMI"IDQ,3P6WGH
M,?CWK^$W]K+]MR']G_08/ OPOU:U\1PSZ>\,OBR"0M=>$)#A0\!3[K1GIGV[
MXK[%_P""'7[=/Q#\8>/?$_@CXTW4OC?PAXI73TLM<\0%V2TBC9=TT+ON \Y>
M6)P#0!^S?A?]GGQ%^V7XVDT+QGX936? 'B#4'M?'4FL(MY9W=BV[<;ZWD#"X
M4/CY3UQ]:[VR_8]\0?\ !+7Q!>^-?@#HRZG\*/%,W]H>.-'\/1?V5I^C0Z7G
M[)#<6B@+,K0X1,<!<@>@_<#X?>#O!GA;1H-9^'MI90V.I6T=XXL&1XK@2 %B
MQ4D]6/7FO0]5T/1O&.A76C^)M-M=3TC48MFH:;>)OMY588*R#()4\_Q ^_8@
M'S]\(?CI\,_VH_AR'T9K36([[1XV\1>%KB%'B42866SF1]P=4=22OJH/;C\O
M_P!L?_@B)\ _VJKIO$7@*U\+_!CQ7%!-'=ZMHNB+#>S7C@M%=236RYWQ$X#-
MT-=?\7/A%XZ_8B\;:E\7_@Q;:I?_  ZU/59=3U_P_;HSZ1H6ESN +?:N6$$;
M,<?+T/3'3](_V=/C]X1^.GP^A\4:+>:<^KQQ ^(=.@D\M["Y*[PDJ2;&&1TP
M#R.Y(R ?PD?M2?\ !"K_ (*@_!B/4/\ A1_Q_P#B#\1/#WGSQG3+/7;FSM#:
M(3Y0,;IM"8X [ X^GY6?!/XX_P#!1G_@GQX]\:>+-;^'7C&[C^%^K_VKX^U2
M+72)2EMN,LLY"@W!*YS]?6O[_?VZ/VXM4T>PF^%OPFNK6YUC5IY].UC5=/PU
MYX?\DE=ZG& Q)P3DGCKS7YR_!;]C^Y_:W\3Z=%XVT"XO_#,E\L'Q0EDMQY'C
M2TDSYQU=B@#AEX.TMQ0!\"?L<_\ !RSH/[2GA7XI?#_5OA:/ OQ;U>UL1X1O
MS<P2:CXQOYCM?==Q,VR:*7YN23@@D8.*_5S]D[]G;X!?M:W.G>)?$$/A_0_B
MY9R+J/C2RN-.BGU*[UEG+NEU=];B7R^=YZC ZU^7O_!7[_@WY\/?#'P_H/[0
M_P"Q'I&J^"O$_P .3J=Y_8G@J+*7KR%Y+*.9!L9C%M0)P?\ #\UO^":/_!3G
MQMHOQ-\/?"[QQJO_  @?QO\ "NM'P_JFB7;26>K>./$%H6#P:@DVQ6G:"/<P
M!(P>O:@#_1%^'GPH\+> =&@T*TT33M-MO#@5%U&WM8HS> 8^?"C/R%??\*]<
MD9KA[%M./^CR &21!M!3'4^O'O7QO^R;^U+X6_:!\,76EW&K::WC?PRT=MXG
MT2&9?/ANIP"D4^3M))) V%AD&OM"PAD_>)M-JD7"QK]Q1Z#Z<]\4 7&LO,.'
MG+XP""">OX_K5M,1 1JHPO#=NG2J4,3(\CFX+!,$DG@8'^<=*F@=]SLR_N^J
MOVQD\_EQ]: ++##$Y)SSSV^E-I@W%V;)*-RGL.!BGT %%%+@^A_*@!*9+GRV
MP,G' J3!]#^5(S",%W^5%Y8D< 4 5HIP%CBG')^4YYY'_P!?_.>*QIFO;2YN
MY;.W,P#%EC!P" .%Y_SZ]ZV8-DS-,R@Q#F)R" <GK_G_ .M3E.&D9<".0G,A
M.%0<C.3P/Q/TH R-!U35]0FO$U+2VT^.';Y#E@PF#=<=QCWKIJK0%B6^=9(_
MX'5E;/3^Z3ZGK_A5F@ HHHH **** "BBB@"K<K$X4/@.<["1R#@]/\GZ55EA
M@E@\BY"DG(1G&[!;TZ]__K"KMQ@)OV!W'W <]3Z#UJLDBS1MNC5IXP28SU!X
M(_//Y4 5(K6;3X)!%_I<;@!8C]U0!V'OT[UYKXI^$_@_QKI6M6>OZ)IIN=<M
M)+=)KBV25K1V!Q(N1PRD C_Z]>CVUQ+=RS1.QMVC4':.,9_+IZ<=ZI>)-9LO
M#.A:CX@U*XA33]$LYK^]N)W 2*"!2[NPSG  QMP2>P- 'YE?%']B33]$\&^(
M-3USXH-'X.T.PFNGTB6'=96=O&A,RI$1CYDR2H.2,]LU_-7\9/VHO$7['VA?
M%;X@^&-2OM$\#6%C=2>$QI=R;:/QPD4CJ+/[.OW%D;G#9ZU^K_[>7_!4#3_!
M.B>)=7\6/I7ACX<^'+2\OM$\Z=A:?$F&*)FNK":/F62-(U*E53^]@9)K\*?V
M(OV3?CI_P6:^/VE?%?XG^'?$7PO_ &1_#NMMXN\'^&K&V>#P=XXT:*9HETIO
M/\MWM+@QLY!CR2_>@#X.\$?\%@?^"A?[6EQ>V'PW^'?CO6? =BXAO= _M^2'
M35M)3MFA\AEV.DB'YP,@C('')_=/]C3_ ()2^/\ ]IJ+0?BS:?M+ZQ\)?$21
MP:MXI^%MD]P_]GQW!'^AR^2C*ZK(""<;?F))Q7WQ^W]^R9^S1^QM\&]$N/V>
M/A_X:^'GCO3M)U"ZTKP_X=@!NOB!JMM%FUTZZC0,SM/.A5250%2JX)4L?PE_
M9'_;@_;P\!_$'5O%>O?"[7_ =O?Q;=5T-[66WM(+=)/DC*N%R"BJ^ #][\@#
M^T+X&_L<> _@EX:">)WTSQEJUC:;M1\47EFIOI6C7_CYE:0!R\8&1D=_2O7M
M6^(7AO3_  IJ;>'=7%I:>'8/M(,"B%;E<$[,#_=]>U?%?[%/Q4\0_'WPQ>^/
M?&'C2:VM;RRDNM;\/37$45OIEO NV9-DKJVQAG. ?IWK,^)AU/\ :*\22_"?
MX1^?X?T/07?^WO$WA]6+WMG>8AB%Q(=JE8B6=<,<'/M0!^)_Q!^#'[2?_!17
M]L>3P_J$^MV7P2\-^-X;O5%N[Y[C1M:T"%BLT$UF<H\$FWE#P:_3'XZ?\$H?
MAEX ^',W_#.W@SPUHOB:VL;M_$4'A[2X--G\3!(B;>VO9(US(&/R -P!]:_4
M#]G_ ."6B_ G2K+POI-HNKZS;0?9M8\32J#?7[2D2-+.PZD%B."?3FOHBXMF
MM)IO*C6879"7+R;<1)G&3NP .1U]: /Y#/V1_CK\3_V._BE=6OBVWU2WT*9W
MT[Q'X6>\<6'A:R25MTZQD^6XZMM7USWK]>?B)_P4J^'WCW2K#PU\%M5_M/6]
M9A_L[49+&3[-+IEQ<CRUE+;B69&S@C_Z]?FW_P %[_"MA!\.3=?LW0)+\3#J
MLI\8+X= >^GMM@\Q+K;@; V>AK^+_P"''[:?QG_9W\?Z/I=[?:@_B>77+5/%
M.G7S.)M A,P*SN&.!\GS#DX_2@#^MS]I.?Q!\/M9MM;MKBXU[Q;XDOI+74?W
MC&YN1_K LTI^^"2!SW/IFM/]FOX3#XD>*+65=*CN_&7BNZCM=<TV6(-+X7>4
ME$NO.(.]E7Y_E&>M97[*FO-^US#X=&G1KXZU2\%O/J=[%^^FT&*=547HS]T[
MC@$_W:_I6_9[_9>^'WP4TS3I;31K6_\ &+6ZOK&L2KF]21P&220X(W1*V!@^
MWK0!\*^)?^"3_P .+S0(O$OA>/0[;XR>&4EOX==M]-2+6+R] +V:_;5&]62;
M:58_=V?A5#P!_P %)?#OP+T:^^ ?Q_U2YT?XR:':2Z#X9_M&0W-[XH\1%F6S
ML1<$J4>6/85=A@;L5^G?Q5^-7A'X2:==ZAJ%_I\&NS0S?V#922_OO$5W"I(L
M]B$ODD!.@()XZ5^'WQG_ ."=^N_MS^+X_P!I'7M&U7P%XPTG51XQT*RT]"AO
M[^S^6WA4,06\Y$5^<DALF@#[X_9W\+_$/XN^(M1^)WQ7T>9M#U.2&72=*U>?
M[7;Z;'$0S30!OE3?RQQGUKZH_:J\)_ K6_V<?B%IGQ<N_#VG?#2'P[<'6=4U
M"VM[NTTRS"E9+@V^<G:N[Y1AN#Z5_.O^WU_P5B^(W_!.;]F<?"[7M"CL?'"Z
M!K=KI^K:C'.NI37/V>06K*41H_,5SA3N&3M!/  _-+]FC]@W_@HO_P %4/V<
M?!WQ;U_]LSXQ>'?A?\;8I1KGA/3M1M?[&MM(NII"8BC7@ECA6-P/G1>#ZYH
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MF0.I% "T4FX>H_.C</4?G0 M%%% !11G'6DW#U'YT +12;AZC\Z7- !1110
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MW^UDOQ2U_P .Z9=:;XLLF\,ZDVMQW4%IHUCJ&8Y=1238/+D@5MZ'*GNIR,T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR1[D7>Z\JG]X^F:HVJ[6:ZE;RY90"\77: .%S_C_ /KN7TCQVTCQ)YDRC,2
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M+3[3QK8Z!K,.FWTNFQ7MTU[/;2"W9)&1W5TE(*L#D$=J_AS_ &;=5_X*\_\
M!+_XA^*/V>?"?AGQ?\6? ^HP7/A#P)HK:]?:;8Z3-]ID\F[L[4.D<;%'C78B
MYX!YSA?]/2\6XA:U%C "P=?M.  %3(R7SP1C_/%?A3_P5:^('AK3]"NM(_9Q
MT31_'/[3%MJ,BP:'H4$(\0Z3>!!Y=T+J2/R8Y/-VC<6*@@?,>@ /E'_@D]_P
M6.U[Q3\2;K]C/]L[PI+\+?CSX0O;73I;74M3?4KK4-2UPA]+MW$LAD0R#@'
M]>:_J+A@,.H3O)<&1)%7RH"#B,G!)'/<<>M?Y ?PNN/VK]8_X+6?"R\^.MIX
MN\)?&:;]H;X9-\0].NK@7&IIIT.JV\MHFHSV.;=X);*,Q8.%6.1LX.<_[ QF
MC>\>!8U>2,(7;NNX*RDYXQ@B@"_1110!'(A<#'8_Y[BH?);_ #C_ !JU10!5
M\EO\X_QIP!7@]O\ ]=6*A?[Q_#^0H ;2CJ/J/YTE*.H^H_G0!/1110 4444
M%1/U_#^IJ6HGZ_A_4T ,HHHH L4444 ,?I^/]#452OT_'^AJ*@ J9/NC\?YF
MH:F3[H_'^9H =1110 4444 %%%% !7,:G%$\]S#<S&XM;Z V=QI[<(\$Z&*5
M&SP1)&2C>JL1W(/3UF7"P+.)/*664LH((Y&,8/X8S0!_-[^WK_P;A? ?]M+X
MP^%_BYI_C.V^&$NCZU!JFJ:18>&[6[CU>WCF2=[&>;Y3LDVL#G(&\UP__!2S
M_@W0_9V^/O['(\"? S3= ^&_Q8^'>CQZS9>*])\-VAU#QG?Z):JR:5=-!&)8
MEU.2(Q.P+8,@R1DD?T\2PW'G"X69_+. 8E/RJ/<8^G^>:?'+;L[;;@<*=\>,
M\8^;<,8QR<C_ !H _P )_P#:._9Q^*'[+GQ-U?X+_%SPNWASQQHC"XFMI&)E
MEL)WD6UN&5L$"98V8*1P.G3C[I_X)S_MTW'[(WC"WT[QII/_  M+X<>)["3P
MQJ'@C4;HPZ9X7BU&7,WB..*1A#)-:!B^W'S;3SD@5_H\?\%G?^"('P3_ ."D
M?P^N?&'A;P[H?A/XZ^'K'4[^R\8Z)9I;>(_&$MK:O-IGANZN5"I)'/=)'%&'
M&,N%P>_^5E^T;^SU\</V5/B)KGP8^.7PVU[X:^/-"U&XM+NSUN#R[N>T69DM
MY!/$SPRQSQ!94*N'9&5GCC)V@ _TY?\ @FA^U-X4\$?"?P_XY^$DG]N_ #Q!
MJ4XBMK1_LFF:1JLS+_;1BA0B$R6_+.0"6*\U^J7Q:_:7T3XP>&7\%? M_P#A
M+=0UT_9-8CMY?).FZ=<ILFNR$;]X(G9U*GA@IK_*N_X)M_\ !2WXC?L:^+;?
MP'XG\3ZKK/P1UJY@TZ?PAJEP\_AOPRFM7'DZMXC@ML$Q26\$K2R;3R(@PP<X
M_O,_X)X?'SP#X+\1)\6OA7K>F?%'X->+--M]'@\<VLHFL[?4+PI=30) [O<1
MM;O(\!<J  A&<4 ?47AG_@GQXU_9GDE^//@?QM<ZEXQ>XFU[7_#,%JUH_P!@
MW&XN+:6Z1071DRK;C@]R:_6/]F?X_P!G\<_"'VZ6V_LOQ#9,T-WI8D\[:D(V
M&0R9ZR.C$\\5I?$'XX?#;3/AG'XV;6]'N[#Q%8&QTZ-628ZM?SQ[5TDP(6D'
MG2DPD,F!GKBOQ'L/@K^U#HWQSU#]H;PR?&/P]^'NJ6<>GKX&TJX$.@EHIA,]
MZ+1>=\\8)+;?NN0* /Z,Q-( ;FZS;(FXE,DC"YP3[-^F:KQ7>GB3^U/M@\B8
M^0BXX,@('7N>OX&O"O@G\9M-^(.CV>GZK<VRZK':".Y@N&6.>2:!5C<,'*DL
MQ!R,<DD^]>[Q06TD@LVT^)+2/][& ,IYA_B&._4X^O)S0!O@Y (Z$ CZ&EH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTSXQ_9/^-7P[^,G@, WW@#7K36H+,3O;QZR\+J6$LJ$-'N3=SQUY(%?[ _\
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M^$EC\>OAO^WS^T'\6/$TVG^--5^%?B77+/Q,\"SW>E:I;/+'#>13R!I7DB
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 8&,=J !^GX_T-4T_P"/C\?\*)2P .\G.0?RJ&WWF<$D[>>/Y'KDT :M%%%
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M#\-[#QAX1U_2KW7[9$7Q!HNGW"L=,N9%#) T;[9 6W="N?IS7Q7#_P %>?\
M@E)^UEJUI\!YOC+H'B^_\<N^C:1H>HZ8LUOJTK(=H57,B%E)+A74;@IY!%?F
M'X^_9?\ BC_P3=_: OOVFO@5J5UXC_9\\8:M#XM\1:#HSOI6E:#I^G2-YEL;
M>,)%,CQE3C)[8- '];+1N1.QE+3O_JTZF(GJ!].![=?I$T+RQQM'(S30+^_B
MX/FD'H_;!_SS7R5^RO\ MC?#;]K7PF=?\ WB/?KI]K>ZA9*?FL#.N/+W\DD,
M.37U-?:O!HVGRW=V1!:VD,DNIWN>;9$4NSMW; &>3WH ^??VG/V=/@Q^U!X
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M;]G_ /:;U*UMSX>U>RTSX-1:PHOX%U'4"'B2PBD8_8RL^ 3& >"1F@#^M_\
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M)L$0EB]#R!@=@>A]^U &2]N)[WS+=!; ! +]!\\NWDH?;IGG'6OP1_X+:?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7-%U-=EWIL_,$J'^%D/RL/J.>./0 _RD?^"4O_! 'XT_MM>+["]^,GASQ?\
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M/W?''4@CC/\ ,]HWB;4/!NHV/B/P_J;1^)[>:*]M=7B.+C2[F%E99+>3[P?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "HY5++@$CG.0<<=_\^M255O)'C@9D7<V0,?7- %615#%8_EB"MN<<#S
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M^UCX@_X*F:MI7ACX$RQO\&7C2\\6^-?#LS7@TNZ(#6EFVX@$3JRC+*20>2:
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M=NE?RV^'=4U+PQK\?B?2M4F\/>+?"U_'?:1- NV:*_M'S'(H?#*Z'IC!&>M
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M0 4444 %%%% !1110 51+1+<N6P"5 )(Z\8QQFKU5I5B=PK8#$C/KVQ_GVH
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M.2.: /W[C4,^P@I=+RS#_6&/C +>G7@^WO6N. ![5D*?.DAFC'[V6W5V ]&
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MW'^K%Q%&-B^BA>.37[$:#XF\/:V^HPZ!JUMJ%Q:79AN5AEC9H9AN!C(SSWZ
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MBMY[P1P/?13R%8A-$WSAF<8+'D G/]A_PW_X)R_!+6_@EK7@CXD:78?%F_\
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MH'/7[WXU_%C_ ,%=K=+;X??"A _VB\2>Z^W.W,BM]L;:'/<EL*,#')K^[/\
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M_!:O]A6Z_;_\7>&=4_8WT:W\)_%#P?XKN-:^(/BS1+51JGB&W8*I%]<0+Y[
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M_HBZ?K7C^#PU;V'B+QI%I4.G:CJUU*OGSRW3)$DK,LDCJ0QZKSUK._X)/_\
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M "LR>.:XN=@4PI'AEG'5CC.,<=S_ /7Z5IU0F$Z-/*C,P$1*Q@\ @9R/?O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 AZ'/3%9JM UTOE[1P0W;GG_Z_YUIU!Y2(^Y8UZ$DX_P ]O_U4
M 5W(%S\O7RC[Y^G6OP=_X+=_!3]ISXY? 6_\(?L\:AK-CXH<PW*/H\<DD\MO
M!.DTMN1&ZG;-$C1OU^5CQ7[Q;HI6\^.1<(=AS\N#]33F,8D$K(AD";1( &.S
MG(W8]#^/2@#_ "5_VA['Q1\*?CKX/G_:%^$NE?"V32/",FCR>.G@+7]UXA@M
M_($LADC8K->7"&5QNSN8C-?UO_\ !L?J/Q[\5_ ;Q+X@^)7C36/%G@U?B'KT
M?AE]0$WV>/0 '_L^*$2L5$48"E-JX'. *_?_ /:._8?_ &;OVH-)32/B+\)/
M 7B&1-2AU+^V-:T&VNYXYH69B@9E#9D/4YY/XU[1\-/A!\./@EX.TOX??#+P
MAH7@KPMI]O#&;;P]81:?9M/&H#2&&(#+/SECSDXSC H ]@L(1 DH6X:X5I"R
M[O\ EFISA![#MVP!BK]5;3B( ($5<!2/X@!C<?K5J@ K-G0WL$ENLA@.[AT.
M6&,YX/\ G^FE7CGQG^)'A?X6_#S7_&'B[5_^$=TRV0VJ:@%9R+VY#+:QA4YW
M2N, ]!GF@#?;7M/L/$%OX*NKSS[^^A^U1%R!*$;H N>F<XYKKX)6@N%M N\$
M<OT("Y'3]/K7X[?L8CXE_&+XA^(/B]XEU+6$\/:=XHO-.T.YN[EY4N=*C):W
MEC0\I&Z@87M[5^R-IY;AG4AR&(\PCD@G.?QX/J* +M%%% !13'D6-2SG"CO3
M9)HHH7GD=4ACC>5Y&.%6-%+NQ)Z!54L3V )Z4 2U\2_M\2?$>U_9]\67GPDC
MGD\<QPQ_8EM2XF-L&)N2"A5L"+>3R. *] ^$?[8?[.WQT\2:UX1^%OQ&TOQ7
MK_A_4+W3-6L+*.X$EI>Z?,T%W"[21JI,4JE202,CBOH#4_(FL[C-K%?;P\$D
M,J!E*2#8ZL&R"-K'\/S !^0O_!,Z'PGXDTC6]5\2+$_Q&M+R"*]MR%6<7!0?
M:RS,-Y87&[=DGJ3[U^N5R'>\B*NRV<*;94_A#J!A3^.!].E?E3^U1\$?%OPC
MU&T^-WP0T^6VEM2Z:OX<\/N+".^EG?S9+FX2,8D=,DY/IQ7T!\ ?VQ_AU\1_
M :ZMXCUR+1-8\.V+6OB'3[H,)$U.SC/VM').9'5U)R!\Q],T ?5OB7QKI7@?
M1;WQ9XPNTT?1-.,BF5W C=41G5V+$8WA,8QSS7\Z_P =/BGXU_X*C?$,_ 'P
MIIO]E_!DZY*-=UG2Y9;Y9W\/3[K::>!B8F:=@&.4;;DXQV[O]I'XB?%'_@H7
MX]/P9^"4^M6_POTYO[.\3^+].N9+*VM-6BN<?99(<$REX8R-PXVOSS7[,_ S
M]F[P'\!?AWH/AWPOH6C:1K=AHFFV6JZWIMI';WE_?V\"I>7ES,OS/+=."TKD
MY8G)[4 6?V;_ (+Z1\"_A=X>^'?AV0W%OI]K!%>7AA6&07"(J,"BA1G'7BOS
M@_X+)_\ !8+X6?\ !+;X,W>M3V6A^/\ XUZQ';1^#_A3KFHFQAUW3Y]R7NI2
M26Y,ZK9EH2% ^;S&4J1P>E_X*E_\%8_@G_P3@^'-YIM_KEMK/QUUGP[+J/@W
MX<VL3S7^MFZ,EC:W9F0;('%\T6S)+,,L0!C=_-S_ ,$D?^"4WQV_X*!?M$ZS
M_P % O\ @H_'JNOZ%IUYJ-U\/?A;\4;A_%&ESZ#XIG;4;5;2WG7RK:VM('14
MC/ *(OWMM 'H?_!!?]K3]EC]NCXT>)/CA\==.\,^!OVI=4^(FL7?P]\,V,JW
M<L>F38=8["]O(4NO*1, ;63)7I7]J/B_QGX9^'WAZ7Q-XCOTLO#]F&6XNI77
M9YA#% WS8RS#:"/UZ'^4G_@LU_P1P\(> ;2#]NW]C2#2_@GXU^".B:=-IO@+
MX:V8\,G7VL)1)<W'F6@$?F3P0%)"<LP;YN3S\R_\$S/^"E>O?\%-?'^E?L[_
M !E\2ZS\/->\#16^A77AS6;N62W\430!89]2N68A)9%DA;+'DD_F ?N-J^D:
M[_P45^(5SX>\4Z<_A+X3VE]>6H73]U];:];:8Q;3]1GCF)A\VX/S@$8!(Y%=
M1+X8\7?\$_=8LFL-3O/$GP=")>:IJ5\OV*WTJ82+$EFJ(RQ[50CG:>F/>OTO
MC\->#_A;X.T[0],M]-\-Z?I6DVT,VMV<,=MG[+ %,I9 &=KAU))8DDD]N*_-
M7]H6U\7?MN_:?@[X-EOA\+;<C2_%/C:*4QV]EJJ2+^Z>(@O*Q";MZG'- 'ZD
M_#GXH^%OB3X>L=?\*WT>IKJ-G;7_ ):.K(BW*"3:I!Y"[L ]#UXKT&X>5X0T
M *R 9=5/((Y/Z# _#BOQVT3X;>._^"?NGZ+K4.HW_B_X;Z9:VFF:KJ\EP3;V
MH9%BMR8&^8A@O'/'X9K]/OAA\4_"_P 8? \7B;PIJMO=_:[-UNA P5[2[EA9
M3$P!)!1N1[@$B@#Y"_;F_;U^&'[&7PFUOXA^(-1L-6UBQ'V:V\.:C=QV\%U)
M(K"1V?.X&([<8&2<U_#]^S]^RC\?O^"[G[:9^,/Q5NM5\'?L[V?CO4999]*M
MCJVGQ:/93+<6%NLMRS0A)C'Y0)VH-V20,FOIC_@Y;_8/_:>.A6WQ\T/Q%XKU
MGX9Z!?W(US1X=2F;3V>ZF>6%9;-01( C  ]!CGIS^IW_  ;K_P#!13]F#QW\
M"O '[.FERZ!X&^*%MI=OH%UX<MK);2XUK5].A87-U=3 C=<R Y9GP23SB@#^
MB;]FW]GWX>?LO_##3_AG\/-'AT71-&CMX+B\AB2)];N+:+R%U*>.,!$FDB4!
M@H([9Q@U]'QL'1&4Y5E!!]01P?QK!N$(NH%:3S;5E.Y<AH^#TP,Y.#_/WK=5
MHP%5< 8&U0,  8P * )**CEFCA&Z1MH_'_/:DCFCE!,;;@* ):*** "BBB@
MHHHH **** "BBB@#^3K_ (.B/V[?B-^S+\#[#X7>!=.AC_X6)X2O+JX\0BYD
MBN],D;5%T[]S&C#S (V+_-WR*_'O]I__ ((V_#GX/?\ !'E?V]I?B7JWBKXJ
M7OP\\#_$!(K_ $73XX;2YU^*-[N".]&;DN)9.20 RC)8GBOZX_\ @JE_P3.\
M*?\ !1+X83^&M5DT^UURRT2ZTS2[VZM1-<1>9,;I/)E(_=XF .,YSR*_F9\:
M_P#!+/\ X*?ZU\']1_9"U)O'WBKX+3I8Z';-?^)&FT.#1M&(BLE2P=2JP-&J
ME(^P 'K0!_,[\3?^"C7QF_:J_8UC^%7C#3K>+P]\-/#FG^#K,1W,MRE_8P3P
MNLCQ3';$^T*"JI@.#C( )_H5_P""%7[,WP8\3:?X4OI_A%X<O]7GTO2Y)]5:
MPMS<I*]O&[N7^S[F9V)+$MG)YS7TA^T;_P &V>NV_P"RWX*\)?![0]//C67P
MOI)\566EP1V<\FL1WL$UVMS+M_?2>6) [X.>1Q7].?\ P3Y_8]\-?LK_  $^
M%W@Z?P'H5CXOL_"VDVGB/4X;*!;ZWO[2QBCE6:;:3(QE4Y88.>XYH _RZKOP
M1H7C#_@M_P"+?AGXH\.V'BOPK%^T3XIT8>&;^UA>RELK=97BLC&T;*(X610O
MR]8QP,XK^O7]I7X!^"/A3_P2#_;"U'P!X$TGX57,6H*T8T:TAB6[,4<>R9PD
M4?,8&%XZ=^AKC_V;/^""WQ@\)_\ !977OVTO'F@^?\-I/CGXL\>6<5VR3VD^
MF:MNDMG: KV:1E4'HI^M?T:?\%*_V/[K]J7]BSXO?L^_#W3;;0=0\8P30V\>
MFHEJ+EW)/FG8.2<XY!Q@8H _S;OBG_P4.^*G@_\ 96^%7[-GA_63I>G?$_PM
MX9TS6]>@GD2X00X5I# I$<ADW@,'R!^5?T2?#7_@VP_9^^,W[&7PD_:,O?CA
MKOP^^('BCP1I/BW4_%&F^'-,EG6^GNT9)_M!03M,WV=]S-U1A\Y/ ^A+W_@W
M+T_Q_P#L4'X:^(=&T?2OBWX9\+Z%IOAK77M(WUE;[3O];+:WH&Z&27C<P'.*
M^*8/^"4'_!7N]L_"_P"SU;_$KXN^&_A#X=2TT&VUBU\8SQZ9%I,%S&Y>.T51
MMBVK]SL&H ^;/^#F^T\6?L^_#+]AGX1>"OB[K/B.SM?!DNEW$\\8B;Q$;&S\
MF.^NHU.U7?;DJ,CYR.O->P_\$/M#^/.D_$G]F+4]2_9LTF\\.ZK):W5UX[D4
M)<- \>?[0.!RS=>>_K7W)_P60_X(8_'S]IKX ?LZQ?#R_P!4^(GQ(^"/A>'1
MY$EN\7^IW(MO+EE>XE!RS2*KL3U.#UK<_P""3'[-G_!33X">-O@CX.^,/P:\
M3:%X \&2Q:7J&KW>M0SVUMI\2[5E\D("4R!\N>,]>] ']?\ %'F"2:50H#OY
MEGC,<6&.0.#UZ_YQ7\A__!UUXS\4>'O@#+I>@Z[/8VFI:9I8ETZ,9ANS]J4H
MC G!#,._8\5_7[;VTT*7$D@,KW$K,R'!V@N<?7(QR/6OP0_X+P_\$V?'W[>G
M[/\ KEK\,H9=0\:Z3I^G_P!AZ)#((IK^>"X$AC21@0I4#K0!_FK_ !-\3?''
M0K/]G:[^(6E'X2Z3=>&X9?"WC>T0&YU'3UEA+:BH)^5EP#@$=:_<7X/_ !;^
M)'CK]OC_ ()S>%],^)>I^);5]-O$.I2 ^;=)'9Q[9B6; +YYP>ON:W-<_P""
M ?\ P48_:<UWX#_##XM_#[7_  IX!^'FBP^'9/$M[JT5S!IUE))%YDD42H&5
M0J<@'.>:_:;]L'_@WR^($FA?LV>(_P!G#79_#?Q"_9]T"#2(-7\+R?V7JNK3
M):BWDN#=H-P=R S$]<=<T ?'G_!:?XV?&+PS^WY^QOX:TOQ-?VMCI^D0V^HP
M"0E;IQ;$EI=LA"D<''?/-?BY9?M*_&JQ^%G_  43CTSQWJ,EV_B:#[+M9P;
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M2K.&?Q(UDB+<7,\AC+AHY< _-]YL5_9/^RWXFT'QQ^SE\&?$OAG7CKOAO7/
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M<GB&-/V@_BD%\0Q-'<X\3WF)%8$?.,\C!QZ]<UE>&/V[?VM_#5KK.DV/Q_\
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M?M)>!OVA?VA_B-K6N^)_!_C?0/%DVI^)+V34[_4_^$=N5FM89;AP&/" )G@
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MUUK'P0^,TGBS5_V3)=>M-1T/Q-=:C->^&]/B\5W*_:UMM-'$2Z?&S'@XPO%
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MP!K-[>16]_J^MQRZ!::)<3^5')-?QF%-I0[MS*[+MZ$'O7Y_?#C_ (*+^%?
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MV1X7T:WCUJ[>.YU"]* 7.J7:IL>\G(7!D9B23V)KX%_X*N_\%/? _P#P38^
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M^&\O[/\ \2=.G\+_ +5'@B\M_"!\(SWQNKGQ!*B^1/J4EZ7++(L_F9!P2<4
M?KW^W)\8O"FN^#;[X*Z5>6FJ^,?$<D<5EX:0F2>7[-N629%0$;K8DL,L,,37
MP'^S-X%^,'_!/VSU/Q-X_P#&GB/Q+X"\9:V?%<T'B)76P\-6U^^Q-*M2A?;;
M0F7Y<KVK]"/@1^RZUSXEM?B;\1!%<^)[]6U33GNX1<7-BM^!-);Q7#C<%7)7
M(.#CK7I?[8/C?X9:-\.]0^'GC""SU+6=4T:2/2-*NX8YDN#(C16SC?@#;-L(
MX^4CVH ]#UO0/@U^V1\)9]#\16&C^-O!FM6D<M]H\CQSVGGSP!X7=/F(9 Q*
M[E'0?2O\[K_@I;_P3-_:$_X(V?M">(?VNOV7M5\97_POT_Q3+XVO+E+8II'A
M:+5M0:8Z4CV^#]FB5S;(S [8D49"JH']#O[+E[^U[^QW\2=6\2>/O#>JS? _
MQ+?R7MM?R:G+]CTNUDEW64$5H2$">0R!<< <"OZ!?&?A#X1_MO\ P3OO#&M_
M8/$'A?QCX>2'4])U"UCO+0RRP-M,UO*&5S!*2PR#R,B@#\@_^"&'_!:CPO\
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MVSPI<F87$=P?,MI2,_NSC&/3M5FR67=*9EQ\Q$6>?DR<?3B@#2HHHH ****
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MDT8^T@J];#.26(P_LG7H-VJT56BYT74A\455@G*FVK3BFXMH****S+"BBB@
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MEN*5GRPQ>!K2H8F$)_!6A"K"48UJ,IT:J7-2J3BU)E%%%04%%%(Q(4D#) )
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 AR00...M5H[8*&$C&4,<_/SBK5% %>*W6%&2(!=QSD <$GGD@
MD^G.?;%>,?$#]G'X)_%?4[;7/B7\-_#'C76[*.."SU77+$7-Y:VT,PGA@AE)
M&U(Y5#A<'YAG/2O;Z* ,NUT;3;&PM=,L;."VL;*"&VM;:)=L4-O;QB.&)%YP
ML:!54>@'I5R2 L@17,8 4 +T^7C'3IC]:L44 5I&^SQ#8F3D#CO[GU/3]:5I
M]BJ\@"HP!W'H&8< _P"--N(6D VN5YZ 9XQ_^JN<\4:Y9^&/#>LZ_JLBQ66D
MZ;>7+;B-NZ"!F7GL688![9SVH R-5^*?@C0?$]EX.UO7[&P\1ZC;?;+'2Y7_
M -(N+4OL$R $_)GCIU_7M)K4W+I<1S%5*AE*]"I4;6''<<_C7X(_L^^*]?\
MVT/VJ-4^+-M<OI/AWX;WL_@4VULQNH;A[>Y=UGD=MPC=@@RM?OU#'Y,,4(.1
M%''&#ZA%"Y_'&: $,;% N]@<8+ ]O7IUIICCC(D)("CGW(Z=NN ?KQ4]13*'
M3!Z9']: ((KHNK97#@G8OJH/!^GO^--DNF,3/:KYSHV&0=1Z^M.?RXCYC_(-
MFW(ZX(QD<^O:J$4'V#S7AD:=I"963H H^9OTS_\ 6XH ^#/^"G?[7-I^QA^Q
M9\6?CZ]M8ZDVA6$&AQV%^28'O/$*RV$:F,?,TJ,X>-<') .,5_+%_P &V?[(
MVI?M$_$WXW_M[_&#P[=2>(A\;-0M_"0UB,LD7AV?S[J!+'S1D6HW)LP,<"H_
M^#BW]K/Q]^T?^T7X#_X)F?!C25U?1_B?J_A_5/$FM07;F:PN?#EVL]] -/1]
MDJ[MREF4D 9]Z_JQ_P"">_[.6B_LQ?LI_#?P%H=NL&H:EH6FZIKI6%8&.K?9
MHHYBR*%+,&W?,PSSZ4 ?>$SI"R#8L:( JOTV@=%&,X&/_P!5&Q7<2Y#97;E@
M#E2"",$=&!P?;M44"8413'S2V&(?J"!V'Y5;Z< 8 [>GM^% 'S?\6?V2OV>_
MC5:3Q_$'X5>$O$5[)'*L5_?V(-S T@.YDD3;C))8C;U/45_.]\5/^#:FPUOX
MCZI\0_AM^T[\0?A=97&J7-]:>'/#FH3VVGV5O<R;OL<*LZJL2*=BKGD=LFOZ
ML:9(H9<&/S!D':?;O^'6@#\4_P!C[_@CG\*?@7:77_"Y-3?X[:G-=K=6M[XY
M=M0EC@B7<R* Y'EEAN8<$D=>X]#_ &G/^"E'[#7["?A;4XKGXE^!? U]X>4:
M;%X4AA:."26W_=K;,L 8)Y1&P MG(]<5^JTTDTETCVT(F2."5&7/W7,383MU
M/'XU_F\_\%YOV4/B?\-? /QJ\3:[9-XQTKQ%\2IM3M?$^IVY6?PY'J>IO+;6
M5JQ4G:@(1&![9'- ']@'_!,'_@JIH7_!1VP\;Z_X1TK1Y?"_A;QG<>%DUC2H
MY1!<JL1FBN':4??DCV/P<8:OUXGG.DFYFU.:&+1((Y;FXO+R:.&WMXXLMDR2
MLB@!<X&<G!Q7\DO_  :0_!75?A_^PM\67UJW%O-XD^*<FN1:LJ;9K>V@TU8@
MD8(!?*0@YYZXZ#CQ_P#X+J_\%O?%VHNW[ W[$^B1^*OB!XRDEAUOXCV6LS6N
ML>&W\/S3PWMC#86TL?F?:I,K*YR0$"YY;(!XQ_P<<?\ !=OX?Z]X'\>_L-_L
MI^+]*\<7&M"TTKQCXR\*1W=Q?>$M=TW4"-4TQ+I8O+#VP\Q9"F,X*AF !KZ_
M_P"#7[XD_LX^)_@AXM7Q=XY\,^+/CCIOB#1XK*]\13 >(;"PCTUX[FTMFN75
M54W15Y%*CYE)R",'\!/V&OV,_B-\//!WBWQG\5?V;-*^+/C[Q7/K6O:G>ZY%
M&ES)=ZE;S//<-+(I=WB>0S[BQ+..2>:_(,:O^TG^SI^TGXBTS]G2ZOM UWQ7
MK%YJ,_AK399;-=*E:]D4643V[Q[D@WF,-Z(* /\ 4U_::_:MU;59]8^"?P0B
MM/B!XK\2/-H[VNFO%/<V\;_N]2C0Y>+$$;9;K@=#SS_-M^V5_P &^'Q6\(^(
M[7]M;]EJ3Q1>?'YK=-7U+P)X=O8()YM6^T1W5P)8VD5/,),B/A<$#GH,?;W_
M  3/_9(_:K^&'ACP/^T#XTO-7\8>.-5T2U\02:3?B:+;<:Y K7""Z9MY\G^\
M6RV.IK]H)?!7Q]\6M'<)K^L>$)KN&1;E+*6X8P-.I1AN5P3A7(!S0!^2G[&_
M_!>+X7>+OA=<?!;XK^)O#_AK]KOP/:6'@RT^&.HI+%KVKZUHL26.NLSNJPO<
M6L\;^<58J6!(SDY_1C]G/X'>./CGXDC^.OQ_M;\PK?BY\-:%K#K)87.BMF2U
MD@16PT)(!7BOYVO^"D7_  ;T:WX&O=4_;A^!'Q(U:\^,'A/7GU^;PG;Z*D/]
MO2ZI-)<:G<W&I1HLRNN^3+ER3O;)^8Y_2/\ X)5_\%N_A7\9_@K>_"#XV16'
MP]^+_P %+IOAK<:3#J9OIM?OM%MY(H;VY$S,]O-/)&B-&, 9X&>: /VP_:W\
M:_ _X>_!S4?^%I3>'[#P_$D=O8V=_$)(PX0K (H8@9>/E"X!Y S7\SW[''[0
M/[=_P&_:'U/Q9XT^%_BFW_8TU?QAJ=_I_P 0-05F\.6'A"^?9I,\$84RI;,&
M;RA@$8SUQ7ZG^#_A)XW_ &Z?B-/XM^+WF^$? /A.[GMM$\(JAU'3O%]E+*3;
MZG<>;OCB=(BK*, 8]!S7Z;?%7X:?#VU^ >L?#K7@FF_#S3O#WV&:YVJ\%E'9
MQ$VP%HV8P@E  &S:&(XSB@"S;7?P2_:D\ _;I8_#OC3P_-&8[YYHXYEM'N(&
MV1LC@R N'! (!S[Y-?Y[O_!2K_@G=^U#_P $POVC]7_;)_99\/\ C-?@_IGC
MC4_$?BB[\/NPT.Q@UZ[WI%/ FY_*&,*%3@"OVO\ A1^U9\3_ -CKXQ^)KG1M
M%7QU^S:-9+Z_XFO+N2RMM#GCG:.VLUMU98F#PE2#MXK^CSQ1X5^&/[='[/-S
MX>N763P3\1_#=CJ%U BI<VJM=0>9;,(6!CE$;'<I*'IE1GJ ?E#_ ,$;_P#@
MLQ\'?VY?A?HWPS\;^/?#_A[XXZ+<6WAJ'PS+(UOK&IRQQ9-Q()BB^:S@JW R
M1SDBOZ!;6\FCE%M<_)/&-D"D@_:4&09,CY>1@YR1QQ7^9=_P42_X)J?%O_@C
M=^TK>?M2? +Q7J7BOPN]T/&4UG)9-HT&E2)>*[:?%<0"/]V(F/SCUZ],?UR?
M\$<_^"S'@3_@HSX'TOPMKVD6'A+XF:+HVE0+;V6H"_GU.=;=%O)7+NSH0^20
M",GMR: /Z!/ML4>%F81R'^$Y_IZU*;B)0"SA5;[N<\^M4)S9V<<9O&#,H #N
M!D\XY]_7'TJ8K"8UG=_W3#*<#@'I_+UH M0R.^XLN%R=A_O+Q@_C_DFIJAA.
M4&!A0!L_W<=:FH *AN((;J":VN(UE@N(GAFB;.V2*12CHV"#AE)!P0>>#4U%
M*48SC*$XJ4))QE&24HRC)6E&47=---IIJS6C&FXM2BVFFFFFTTUJFFM4T]4U
ML?QQ?$CX!_![X'_\'+7[,<_PE\$:=X(;QQ\-/&6L>*XM*FO#;ZOJTEF[S7\T
M%Q/,BS3.H=MF!D5_5+\=_P!GSP7^T-I?A[P[\0KC5+GPEHVL+JVJ>%K6Y:'2
M/%:IY9BT_7XD*O<V,<L2RK$K#Y\Y.*_F_P#VG+6X/_!RG^QP?*;#_!_QC*O3
MF,6$K%QST _PZU_4/X_\>^$?AAX/UWQUXZUS3_#GA;PY8RZAJVK:G<1VMI;0
M1#(#RRD+OD?;'&G)=V"@9-==&M3I>&_AO7Q,XQI8*CQQ4ISK:PH1P/BAQ>L+
MRJ5THX7V-..'@DU2=*G&E%.$$M\Q5>?'6>QPRG*OB\@X'IOV46ZM>>.X5HPQ
M&L5S3JXGV]1U*EW4G*I*;ESRYC^:[_@XO_9U^#$/[*7P-7P'X'\/>&?C'IGQ
MW^&VC?"*_P##.GQV'B&VG^U/$EM;2:>B7LUJ!'$LKR-(BX_>$YS7[0:;^S+I
MWQO^ W[//ACX_P VK:L_@SPOX<O/%_A%[ETTCQ7K=MI5FC0^)(E8274=I=0B
M94WC,I;)YKX@\!Z9X1_:_P#C1#^VS\??$7AC2_@3\)8[_P#X43X/UC5;3R;R
M"V>:2;QSK>GW4NR&Z@GVS:<X0R,DB%2%^8?J5=?M&_""Q^$6I_'2]\7:;I_P
MRTNTN;L^)+Z>*TL+F.V7]V+25VV3?:GVPVH0DRNP"C'3.A-Y3D./P^/<Z>,Q
M7$T>-,=AL1-5%P^_J&%RS*:4H-/ZOFF.^J3S/,J-Y3ACI86C*V.PV(C3PQ+^
MO9QDD\!#]WEG#^9<'87%44E_;M7,,>\QS*EAG'6K@\KI3AE^"JQ:E.-7&UJ*
MAA9X>K5_G@_X.)_V>/A1_P *H_9,F^&7@O0?#/QVMOVB? >C?"_4/"M@FG^(
M$C6:)&M=VG+'=36*)$BR23[XUP0[$DD?NIKGPB^'?B?X+?"K6?VE[6WU6U^&
M'@G0M6\2V^LB>?25UG3]%LS?ZAJ=K 'DNGL[B&255V/EPV5.<5\#?"W1_"'[
M2OQ@D_;Y_:/\2>%]'^%_P]M[R/X!>#-8U6S>WL-&@N)77QOJ]A<R_P"BZQYQ
M!L]D?F%)$/RK@G]4M,^-_P %_&&F>&HY/&'A4VGQ"2>'PMI/B"\TZVE\66\8
M E_LW3;Z4_VG;NIZ1QRJZYR.U/#TL9@<BKY6ERYUB^)J_%M3"XE/$QR'&XO
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MWVLZH($%[JNHW4WF37%U=S;Y'9W(7=A1U)_FC_X.3/@!\1/"'Q0_8S_X*->
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MLS7"89U*4\K>99YF>84:>(S&#=3$YAE-"AEU&$<11C/"8AXZM7Q57VKP//\
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M%_P2LR!_R<8"#M&?N60^]C=V]<5_49H__(&T?_L%:?\ ^DL5?RY?\' ;)?\
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M_LG_ !:\>^ _@]^S'X)\"^/OC']JUFQUR_\ ">GO/K]K<7HFCL6EG@5DWN[
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M+I*4JE.,(RE)SBHQBG*3;:LHI7;;Z)*Y_+1_P1/CAA_X*B?\%8HK>W@MH?\
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M^6MM<VEQ)B02)N'!*_+Q\;?\$J_VF?CY\,O^"C?[2G_!-OXG_'OQ)^T]X$\
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M-+_1+:T\*_%?Q-\._B)X+U+PEIMT+]8;N+1;BSMG$Q8O(;V8HK(?NDDC.0
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MV2@J?NGYW_L^?\$U?@C\ _B/!\6I?$_Q-^+_ ,0=.TV/2]!\2_&+Q2WC&_\
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M<;K/ZQSJM:HJF:T<\J*234\XPT)4Z&8R5K2Q=*G.I"%9WDH5:L=JM12_'O\
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MOV /V*?CEXJO/''Q@_9A^#GQ'\8:@J+>^)/%G@S3-7U>Y5  BR7MQ&TI50
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M*,94ZU&48RHXBK*OB*4DG3KUY2<I5JT'[M6K*3<I5)J4W)MN5V>(?%_]FKX
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M +4O[-VB_%_P^M[X:GF\-^/]$NO[7@U'38@U]?>7&=MI*QP?*=U!X((SWSP
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M<HR21L#P0R\8.<CM7\W7C[_@BSJWPM_;,7]H?]F/XH>+OA1X.O[72$U+X?\
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M%'@;X8_MP_MHZ=X2L].@6#5[J%#96B6V$-WD@;>@P2./?M7]+T6\EW?*YP2
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M3^(_#=R\45U#:S7UB9(Q(?M<$>Z#8>S%N%;'!KZ!F6=T$@B)E&5V]B.H/IZ
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M,GUS74ID*H.<XYSUH =4<O\ JV_#_P!"%25'+_JV_#_T(4 *G3\?Z"JH^_\
MB?ZU:3I^/]!54??_ !/]: )V_A_W13:<W\/^Z*;0 =C[ G\A7YM_M5?"#XC?
M&KQ[X:T/2]1NK'P@EC*-36-GD@>?S."\7*$[1U(SST'%?I)6?J$'F6\AL8U^
MTYX=% <<\X8\_E_C0!Y/\,/AUHWPH\/Z+X8T"R@,R:=;PWEQ%&L!DN(E ED=
M5"Y9CR<@FO6F9(2D)?\ TJ<%U7H0,<X]??\ D,53O/M%M:Q^3!Y]\8XR6X\P
M'GS?F[8_E7B'QD^.?AWX86,*374$OB2>R=K>R\MY9_WB^4NTIG!\QL 'O]:
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MQ+\!_!R*02?">FCO_P \$X_+\* /O*QG+2-'@C#8'\Z\,_:8#7WP-^)]M'&
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MX%DB1XW)D'W\'DG..>/QH"1W#R)=*"(#P7&?<_AG- &2X+Z;%>7DI!'S;3R
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M6W-NK9?YL9ZC=G@?3FGPN;:%1,Q,C.?O<G;VZ?6@#1HH!SS10 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"V$>HSO>2L%ED)CW/)_&WUKW/]J?]KR2VD/PI^ EW=>./B/>LY>RT]GMY+9
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MC_04^F)T_'^@I] !1110 4$X!/I12'H?H?Y4 ,\SV_7_ .M1YGM^O_UJCHH
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M0 E%%% #OE'WB0??@?X]*,Q_WO\ /Y5!<JT@(3//<'':J<4$JMD],^OU]<4
M:?S*?E7=_+'7-&^3_GG5>ZN#!&A7DDX(Z=O6J']I/Z'\Z -??)_SSJ4$D D8
M/<5A_P!I/Z'\ZO17#2(K8(S[T 7Z*J>:??\ [Z_^M1YI]_\ OK_ZU %NBJGF
MGW_[Z_\ K4>:??\ [Z_^M0!;HJIYI]_^^O\ ZU'FGW_[Z_\ K4 6Z*J>:??_
M +Z_^M5A"2H)[\T /HHHH C\SV_7_P"M1YGM^O\ ]:HZ* %>X6/;NXW':O/4
M^G2H_M<;2-"GS3(,LF>0.WYT2*I0DJ&9>44CJ^#C'O56.(LHE91#= _,>C,!
MT#-TZ$\GH/PH MM.X5=J#>QP%)P,YP.>/QK\AO\ @JQ_P4W^&?[ 7P/\2^(]
M=DTJ^\:WJRZ1H6BZC>QVZKJDL'F6[Q,K%]_((Q@U@_\ !5G_ (*L?!G_ ()[
M_#2^N=>\60+X\U_3]3M--T.++W%O<+:R?99HW1AY3O. JG!P0&'M_E+_ +;W
M[;?QB_;1^(>K>-O'_BWQ1J^BWNN7=_IFA:SJT][9VA:618)8H7;8C"!E4$<A
M>!C% &C^WQ^W+\7/V[OC-XE^+?Q%D%CI>HW"6^EZ'#</=65M#8,RPO%+*6.Z
M0')*' R ,DYKS#]D[]EWQW^UW\4K'X?^#;&Z73;'[+J/C'5+*'SW\/>&WF$-
MSJWELIC<PJK.J-P2"<, 0=[]DG]COXV?MC_$+2/!'PR\*7VKZ-I^L:2_C74(
MI%AM?#_AN:^M5UC5BTA E%CIS7%UY<0:1C&%P,U_8OX1_9YLOV)X_ ?@'X3>
M"+*[^%MSK%C8^*_V@](L$L]3UW33%#_:&D:GM7[1/9P.UQNC<[6\L^M 'E_P
M=_9\U_\ 82U'X=_#S]F30Y/B3X)LM7TE_B%\<YX7T[6=0T+5'6;Q/;7<%HL,
M7V?2RS0HF#'L&-NT8K^W/]F_0O@O\2?@99P^!8;77_#^J!K/5Y8_*$;B:$QW
M<,D:!0P.^12&4@C/454_9L^%G[-GCS]FK1K'X;0>%_$_A?Q+H%WII\1QZ9#'
M<3WMW"$U 2Q.#*KPSG!8D;CQZU^0WQ,\ ?'[_@G!\9+;Q5\.QKOB?X+>);F"
MTO\ 3+*_>WT70X$G62\OTL/NAQ"9"V#E@"/:@#T;XQ?L^_$;]@#XOI\>?V=X
M+OQ7\/=?UJ+3]=^&\L1L?#_AW1[V4R:EJD$EOY:M)$TC/@K@D#.:^O?&?_!0
MSX0:[\*(0MOI&L>*O$5G=:,WA&2Z_P!'@OKB%X(T0+EBTLK!"",'/J:Z'XB_
MMX_ 3XA_ \Z?X)URP\9>)/&6E)H=OX?-MF6+5KNW2*9&5L[&BN&9-_/()XZ#
MXU_8<_X)AS>'OB=J_P"TA\7[A%_X22YA&E?#?4U^V:;I+VDHE@O[:(_NHI9R
M,Y'.<9H _.NW_P"":7Q \)_$NQ_;)F\2ZV\!U(W=U\$GL=OAK1+*2=KT:I#<
M@;C($*CD=#GH:_IT_91_:%\'_''X=Z&^BBTTS6-/@DT^]T*TFWQVS:8HB=_F
MP_[S&YAC@DXXKZ2NM T74;";2;S1K%M/NK<6KV[P(T#P! JQ,F,;=@  ]!@G
MC-?EE\1_V:O$_P &?C9K?Q@^%_G:-X0NH[.XG\.Z'(;+3[9+<!KZ3[-'\N91
MN\W'W^>G< _5 _8%O9?(M8CJ@C_>C #+&#P=V,D9]Z?\LD4T$D(GFN8Y(KJW
M8X#0N"I0GT*DJ?8X]17C/P;^,'A;XHZ4QTJ]1_$\$.Z]MG4QS+&H" EVX8%U
M8GOGIG->QV=S#C[/<OY.I?,K C+X.=OS=P<=<T ?"WQS^$NL^#+S_A8'PMCE
M?4XM]Q?^%H(REI'#:YG$QD3:W[XIM;/KG%>C?LY?M+VGQHM_["US2K+1?&EA
M:2O=:1!.7*_8R8F8^8=WSE,G!XSCM7U5<6&^!HV19&G&R=V .^!N#&^>JE20
M1WQ7YB_M?_ #Q9X-LE^+?P.CFM?$EKJD=QJ%AH3G3YIM/7]Y<))(@^>-SG>F
M>3UZT ?I[:W45P[VUQ&L-T5/F6H.1Y3#Y6/7&[G\,59DTZS^R2V?D+]FF5E>
M%>%;=DG\_3%?!G[&O[3NE?$SP?;>'O'L[:+\6+"ZNK75=%O TEXEJI5;29KD
M\,L@)..W'KQ]RR1SQRJZ2O)$2%//')R.WI].* /E36?V3?#,WQ)/Q)\-^*M1
M\&ZE-<6LUY9Z;;Q>7=10-NEMYI/D?9.!AC\W%?6\5D@CA$$[)'&B*0@ #E0
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M, 5UL$9B3:23SGZ4 34444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5!<*&C.5W8YP?0<DU/
M0>>#T/% &,UW+Y9%I%YX#;&!Z#H",Y[#K]:_-K]KK_@G'X,_:;G&KV7BK5O
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M'*RTNUT'Q#>?#31)+:;QWXALK*7R=(L[]TC@E:6540^9O."I8&N6_P""8_\
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M!0!@#_C\/^__ (5T*?='X_S-9&U2Y8#G=UZ'.:U(<^6N<_C0!+1110 4444
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M+_V?[S28AI_C#4_B%HL^B^%[:YMTD.GZ[J]LL=I/%YF=D\$QX=>00"*_._\
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MW;:W:AHKVWN+62V<?)'%*"GF+UY*G_(KG_ WCSPO\0]'M=1\/7*7D1AAF=6
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1110!5GMS*P8.R\8(''X]1_G]$<""(/(=X4 ?-SSV'3U[^PJ21EWA V'(X7
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M&BA$D@5%;!!&3QS7[4?MC_M6>#OV)/A!<>*HM*L[C5+...V\-^$I9_LUG?Q
M%#M>-@T:PJ@"A<#@@^E?BAX"_P""=/B;_@JE%JG[0'[5>H7_ (/T[6KUM6\
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MO7^DK\-O UA\// 6A>"?#VFPZ5I^CVYACLK51''"IZ  8P>F?ISGMX+^SO\
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M+ALRC^X!QWY//^<5A>,O!&@>-M+N])\2Q+=V%RK*(Y4#*@;AB%((.1QR.@H
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MI=V<RLDD4BAD=2"&4J?4'OZU^+'[:W['?BCX>^(Y/VD?V<A,WBC3;VSU/4O
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M3]C+]C[P%^SMX:T_4;B:;7OB7KD8U;6-8U*%$U"PU6_BW7]M&5!; =MI+'.
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M&G]N>+X=7WAOP[I/PA\&WR^'+V6TN;JXM]42ROTEGO[HG>@E* G!X5?E7"@
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M;>XE,GFJ#!(>=ZGY@P(.#D$ =1G-7;:(PET<[OF_=EN/E]!^(''M0!=HHHH
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MB/*L74AB!Q0!^HGP[_X+ _M8?M'VFD_L]?L_^&O%_B3P?X:C&AZS/I%U+9V
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M+X]N(?&^LZ]9>"OB?X(\#22Z7!JU[>>7_H.KO"_E7R,I+N/N'!4A@<'^G?\
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MVU&!)[6*"6-B=\;@@@$#&.A/;-?Y8O[4'P3\:_\ !*K_ (*C:+J]S8:AX#^
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MN_Q3_P""I^B?M1ZGK?Q ^*&NW/B?4KB(SV?@CQ&LU[;V!8%VCMX),*@GR58
M?,"14/['W@?]J;X6?%?0OVJ_@!-XK\->#]<U%=<UKP)X:U8Z3H>K:+N._3+[
M3S\DMFZ[F,) ^\3QFO1_^"I/_!&+Q)_P3P^.WA7XK^%M)UGQ1\&]8U2YN=87
M5+#9IMEIVF,)95WPH?D:W3+!EP 6( );/ZC?LA^%;O\ :H\,> -!_9WM'D\/
M:_:6UMKZZ&&=?#>F*JQ3SP(-FW9(K@[E'0T ?5U]^U+\$/\ @I'I>G_L]1?!
MWP/;?'(Q_P#"-_%,OH44&JV#:L##;S7>IL ET<,65D/&!7PC\4?^"?W[9?\
MP0Q^(?A;]I+X"7OCC6_A%JVM-%\3-&\/:V\6@Z7X9M2E[&]W81[A<6RN#MC7
MH5SSS7[A7/\ P1_E_9Y\-P?%WX,ZCKMY\7HX7U?Q'.ELJ76K7MB/-LXKQX]K
ME<C RS$ ]J]%\6?\%%_@/XZ_9[U?]G;]I-O#]Y\9[K2#I%KX*U2X#7&I:TBM
M%):O!(KLSD!05Y/SF@#]%?\ @G9_P4>^#'[>GP"\)>,O _B[3-0^(-SH3_\
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M1)%:&(1D 84** /BC_@FG^S=^U9^S[\3YO$'[?>I^,K_ .'^O:[$? VG>/\
M5V\2:3;)<7"_8C8VO2UXY4D_+WK^N33K"QAB@NO#:V^H:1,L*164!06UJFQ2
MLT<8X!*GMVQ7$?$SX.Z%\3/#2^&]<@W#3+-UT34" \\%T(_]&EC#YP\+8*<#
MGO7R;X0^(&O?LTZEIOA#QIJMQK5GK=XFE:=>:N721[II5"(A4D;@I5<$@8P,
MD4 ?H1<3KND@U'[-8VBQ_N;F>:*(+(1GY3(R@%3TR?SKEM>\*>$/%6CFUU6U
MT+Q5/:B6;3_MSVUV8[K!*F)A(=K[L &OYB?^#E7]O7XU?LL_ SPB_P ([]]"
MUGQ+K6DZ<+VTN'CG5-3Y#HR.N2H(QSUK\'/@E_P5F_;#_9Z\'_!/QAXS\4ZC
MXV;X@>/+'0;BTUNYG>.*%[J!6,?ERRDL5?!W<=* /[I[/Q=XS^$'BF*?Q':S
M:=X6N[K^SEM)[A?[.LX96*I*D9PJA4VD<\#'/I]A:9JEAXBM[;7?#>HP:UI=
MV%3%K.CP(ZD>9PA(W \$?KSD_P VO_!<S]N[7_@__P $V/!?QSTV"TT3Q1\1
M#HFEV9CG:-K2^U2QMIQ+;9(E\R,RG9D# 'H*_-W_ (-AO^"MGQ>^/&O^-OV=
M_C'J$.LVGA@3Z_8>*;VZD?4IH[]RJV[!W91%"0P4@]@30!_<%/<62W+6\M[8
MVH@42^3)<PQ#>>"-K.#P>OI5#6M"\-^,M(N=.U>WT?6+*XMYX!#.UO=V]MO1
MHS,G+ ,OW\J0P(&#UK^"+_@I7_P44_:#\??MU_$3]G#X??%+5OAKX;\ 6%WX
MK@\0>'KQDO-3%L[*-,N%:6-/L[[<G!./2LK_ ()R?\%:OVHG^(O[1OP8US7;
MGQ]9_"[X3>)_$^G>(-3N9I;V>[M])>Z5I=LCHHC<9!!XR* /[*=%^'WQ,^%_
MC#^S? ^G2WW@:4@/?VM]'%8P!Y,R,$)(!12>_0$'I7V[ID]F8(HQ?P37$<2-
M<3+-&_SX'F+YBL5.UNO/ Q7^=+X)_P"#I3]H37_@;H'P3\.?#[PSK/Q6\2^+
M=0T%-3.H7)U:*WN[F>UM)(XP^"^]XV0DYZ*, D']_)_CM^TY^R[_ ,$K[/XR
M_&BYU&S^+U]HFKZW):ZJ\D<B+?HE[I\88R,^SR90$.[E<4 ?TRWU_8V\*2-J
M%M$9'*Q2-/$/.?\ YYJ<X)/W>#WQ63).M_*L5Q+!IUS$ZR%VE2)IEZ*H8D;M
MPYP >#GI7^=U\2/^"Z/[4.E_L1?";XS1PVYU2/XLZA;:@3=S!+O3].N'E%O,
MWF;C&Z1;2.?E->T?M,_\'"7Q3^//P%_9Z\6_#>'2/ _B_4?B7X3L_$5KX?OY
M2USID200WL,P+I)Y<SB0N#E1NP.   #^^^1MQ<.\-OY2;A<F5$$F!T,A(&WU
M]!GWI]AJ,%S:Y%W92R*"SI;W<,Y &0<B-F],X]>N#7\*O[:/_!?GXY2:;\-?
MV5?A#X=T>7XH>*9?#V@ZMKEE=W#:[9Q^+YDL(KZ.-6'[ZW,XEBYY91NZ"O2?
MV9O&_P#P5#_8:_:CTKPW\0_^$C^-7@?QCIVFZ?._C>Y,:Z4=9$%ZUW;(;MV,
MENET4C^3)5%[YH _MA>YFGLTELX_,S(5*KA?E!P<Y_SS4MO<I)&(Y#':RJ<E
M-RJ#QC@G@D=\5QFG:OJ,VA:+J<%L!?:II-A<:AIR$^58M<P+)<%"#G,3LV"<
MY"@Y.:_%_P#X+E?MY^.O^"??P ^#'Q"^'^F6>N7OC7XHQ>%+Q]0E>(+ XMG;
M:R$$D&<KSQQ0!^YEQ-%8R?:KNZ,<#?*H#;T)..P[^_OQ4*78NIS/"89;(XVF
M21(U#=R$<@]!G/?T]/BW]B?]H+7_ (\_LU^'?BUXVT:SL$NO#<>M7 C<M#N2
MT2X;YFS\H7>2?09K^?O]IW_@KK\<_''[>NJ?L??L[>%=,O\ 3['2M$DN]6TN
MXE>_M3J]U%:RR[(V508%E,B_[2\T ?UN2WMLSW$=M=0W%W# 9191RH^<#C@$
M]^.?2OB[Q%^U)=>$OC#/X$UNTM=+M@;% ;NXBACV7;*H;]XRCG.<_B?;^83Q
M)_P6$_:+_8 _X*!^'/V8OBGX8L?&7AKQ?_9NBCQ%XHN[B#4(;[6#%+MB"2'Y
MHFD**,C*KAN"165_P<\#]HCP;X)\*?M*?!3Q;XB\(Z?XGT/PG/)-H4C1HDQB
MCGGCCFW@^88R&#%6QO!(8<4 ?VHPM87I74=.UB"6WDB1A#9744T6]U5N/*=A
MSGG.#SR,U=#FZBN4U*W1;.ZADMIED4.DT3H4D5U_B6120P.,AC7\5O\ P;<?
MM7?M;:W8:CJ'[5'B+6]?^'>K:4NG^'?$WB*:5VDUUV*16R22.8VD"%.0%R1G
M S@?VBP7B60@MKIA/8W<:3P73L&+BY^9%&TD8&>.>1@C@@T ?CK^VI^R1\0-
M%UFT^,O[-,VH^&-3TZ=;K7+7P9<?V0]]96#B[DAN@O$L<RQ,KICD,1WKZN_8
MY_;6\#_M!:!IOA;7]3@T3XOZ;:O;:QX6NXWAO572PMM/=M,X"2O*\<DC\@DD
M$!LU]Q7,=@3-87JJVGW$!$D#<QNLBX96 /(920?J?6OQS_:Z_8SO?AOXC;]J
M+]G*]U+3?$&G7\-QK?A/2H0FERZ0 TFI2N8RLFQOG:0-GK_%B@#]E_*629IH
M;II'\H,D>[AF RJ^G)Q7G_Q ^'7AKXP>$K[PGX^T/3=1MKM91!::I;)=16DS
M*8UNXP1\LJ@@JPQ@U\Q_L@?M6:/^TM\/;0/+9:3X_P!'U"?3-5T:UEVOY>G@
M*+ATFV,3+@EP,@D\<FO>_C]\;/#'P ^&?B3XG^+KNTM+?1;"=X8KR>.**>X@
M@,HBRS!R6V\A1G@8'3(!^!7QN^(MQ_P1U\8Z[XT\8^*KO0_V:8XWU30T^U--
MHC:W?@RR6,6C1GS4D,P\LMCDC&*_'KQ1XI_:T_X+Z?&ZP?P+IOC"+]DS07M[
MV34H=1DL/#5[J45PB312:5*%+.UJLF6SRK$=ZXGQ[XJ^.O\ P<+?M;7G@KR+
M_P -?LK:%XELK6&Z\-)<W>FWK>&+M5U%)/M/[IC.H83MAL\DDY-?VM?L?_L>
M?"W]C'X:67PN^%FB0Z;IT44$]Q>QQK!-<7"VZ(ZNL:JOS,&SUY8@=> "I^QO
M^R#\+/V./A%X:^&'PN\%>&M&.FZ;$FH:GHFG0V<[WTT*?;Y)90I=Y&FW/(V[
MYFY(]/KRRM+NW@^SBXDNOWN\SLWS+D@F/)R=J^GM4GVFXBA^6T19&?#@9QY;
M<%^.^.34J3 JL2L8XI&4><#SYC\!0>V,\>] 'BGQW^#_ (,^,?A&]\+>)?"V
MB:[=R[9[2[U2TBE?3[M4VQ7L,Q ,<T/!1]P P#7\S7Q0_P""I_@'_@D9^U%9
M_L9^._B#+KTVHW?AK6[>QN6EU2"QL_'MU'%80(T)9(0H<;8VP8RG(R*^P/\
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MV%/V>?@UJGP>\%:/XX3Q/XP\)>#KK[>+@+;V%Q86$7GKY$>0RHW?"\8KY?\
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M$@PJ ^R@# ],5K6&[R2&A$)W'Y1_%_M?4]?QH NT444 %%%% !1110 4444
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M#!./S&?K_*JUK(US'*LBX <J!V !XQQ_2I;:(1;E)^8L3CV_PZ_C0!;HHHH
MK2M\^TJ"@4LQ)&!CG.._&:_C_P#^#DC]O*SA\*:C^Q#X!N;BX^(WQ%GT"UM(
MK*5HI%26?9<_,C=$5^1MY'T-?U-?'?XK:7\'_ ^L>+]?O+32]'L[*Y#ZC>R+
M%%'/]FDDB3>Y499DX&<\$5_!3^PWX*O?^"J?_!7]/CGXZM+GQ3\,_ /C#QII
M2W01Y='VZ)+_ *!N=@4)!3Y"#@GIS0!S7_!.W]GOXT?\$FOC[X'\>>(="O/$
M'AOXH^&X/&%]?^:P-K?:O&(1;LN%+,K70;=D_7K7]"7P!_X)<>/_ !=^VKX=
M_;W\0?$35?#=T-#\07>E^"DDE>*^L_%J27$#-(!M4(DHX)[<U^YNN_L_?!;6
M+70E\:^ /#VM6GA>PATC3'U&S$RP6]LRF%55<':A1"HR.?7I7M5E9V4%E9V^
MG0Q:?:V=M#;:?! NR.&SAC"01(O9%C 51V&!SB@#\&M<_8(\9>(_V[O#?Q>\
M4Z/#J7@JQT$Z-?:)>!)['4A(OE275Q"X*.TB%MV>>Q%?E1_P53_X)M?&']CC
MXG:)^V/^P_%<>'8]+N[F+Q+\._ \A\-V6IKJ4[75Q?W?V,+'-)!YC<MR<8&:
M_M'CC6=OM-S;(L\7[M)BH#;/O @XS_@?PK \6^$/"_C;0[O0?%VDV6N:1>HZ
M36]_$)H\NNS=@C@@=,4 ?E/_ ,$M_P#@I=\,/VU/A+X9T&]UAM-^+_AFUB\,
M>)]&NR6N_P"W])A":BK7#$M(^].6R-V2>M?KLXC1UGE(+Q (N#NW <%LGGID
MXK^*;_@II_P3E_:&_8-^,=W^V+^P9;^,(/#&EZC;>)O$/@KPP67P_/->W*RZ
MQ-=VT9+$QVZ2,Y"?=SC@BOW*_P""6'_!4;X>_MJ_#O\ L'5_$&B1_%GPQ)9Z
M/KOAYG-K?B_6!4O/-CNO*9W2X612R@C(/- '['"8"82)_J-OSR#C8S 8X]L'
MG\/2O@K]NW]@#X+_ +>/PTU/X??$S1= E\2W%E<0:'XMU/1[?4=1TJV96D@B
MMII$,D445QMGVKT92P&>*^YTE_?'[6JVV&PMNOW)1T#_ "\'UR"1GOP*NW/E
MR&+RT'VG:!&Z_>V],#KQQW[&@#^ /]C#]I+]I'_@B7^U1=?!_P#:TN/$EU^S
M%J&J:[I^G_$+4M5N+ZRTFQLKIX- M;?3790D,ULBB-% $:X XK^DKXB?\%#_
M  I^U_HVA^ OV.-:N/&5WXST^T+:]8.^FSV$EPZ_:H P8MF*!GW>N#V(KZ*_
MX*-_\$Y_@I^W[\&-=^%WC+0[*P\57<D.HZ9XCLX536(9K0$B.&<;<"1CR"P.
M?4GC^0K]DOX@>.O^"#/[9>G_  !_: \-W$?P9\1>(Y-<TCXL>-+>XN)=*T75
M9EL[*"TO(DDCAM]TH1 9%((!SQ0!_:]^RS^R]HWP#T9M8UZ>WU7QIK"PW=_J
M4T"O?65Q)&&NH!<L-[ RE]QZ,3D=Z^O81:>;)=11JY9F<S[0'W'WZ\^O7]:X
M#X5_%7P'\9_!=AXY\"ZYIWB?1-4M[>\@NK*>.>(1W<2SP?<=BF^-U(#8.*A^
M*?Q5\*?!GX>Z]X_\=7MEH&@Z1$HDN;EL+YTVY+5"@RY,DNT  $GKC&: *7Q,
M^*_@/X5:9+XD^).MKHNEP*Q2,H91.JIN5B@[L< >Y .*_"#]H.3XK_MP^#/B
M/K\EUJG@OX2:'#JPANHKJ1K34K&W5_[,G>S4D?Z0A! (^7.*]BC\/_$3]O3X
MIVVKW\NK6WP>TM?[/#66^+2[X-+YL4\JOM+,\07D C:V<^OZQVOP-\ :5\-+
M[X0:396MCI>JZ/'IMSY"J&F\J+R_.;N7/?GJ3S0!_E"_LP^!OB?XT_:7^-7P
M9^#W[.NC_&_7I/B3KNEV^LZDD$4\4DHG@"K+,I( 5C+Z945_5G_P3B_99^)W
M_!&S]B[]I?\ :+_:$T<>!]2USQ"@LO"4$PDB"ZNQD*!D"J%@W,B<X(4XK]P_
MV*O^"0_P3_8Z^*'CGXK^'HEU/Q1XO\:7GBY;F[CBDEMI+H.3%&WS;8U+< XZ
MUA_\%IOA]X=_:E_8_P#%_P"S5I?B^:S\:^+M:TJ[LM.T:0-J3V]@\GG8$9("
MQAQG<<G+9H _R7?C9\6=1\7?M>?$3XS>%[N_T^?7?B]>>*;'4-/>:.>W6?68
M[GY9HCN'W0"-V& PW%?VS_\ !2O]H/P%^UO_ ,$7O#GBC1/$%Q?ZW\+],\->
M%]:CDA=YY=2:PL$?S'9F9B\RMN;N22>]?H-_P3Z_X-JOV;_AU^S?K7AWXR:
MGB_QIXWN/[:@\4>([>*35]%\]/D@LW0814(1NQ+99LL23^BW@K_@B7^S]X'^
M!'C3]GV6YF\0^%?&^NVFNRV=^-R6TEF4V1Q*W 3Y%'X=J /\UKX\>(_B;#I7
M[/'PL^//PBA^#VA>)M#\$S^'O%MN4NI-5T5)8FL=3=8^4:_4@LIY&<_3[I_X
M+B?"S5(?B?\ \$]]"^ T][J7B;4?V5K*>VN]'!L;IY4-DSNTRD$,T FZYZ^O
M(_O6_:Z_X(H?LP_M8?#[P!X4UW0=/TK5OAQH?AS0?#^MV<*)?65MX=*^0D<F
M%V[P@#<]*]"T7_@DI^SPWCGX.>._&WAZP\::G\'/!D?@G05UF))Q_9D<2Q[>
M<\':#QQG]0#^4G_@U3^-'[*/@N?XJ?!;XSVFAVO[7&M7FL_\(G_;.B17>O3V
M=DDR:O\ 9M7<&6"5YO*:3! <!_FYY_,/]KO1]:@_X+$ZK)KMG,EM=:AKTVE1
MLIEAEL3:3['7LJ\CY?\ ZPK^T:Y_X(4? #P_^W!X-_:_^#L4G@/5/#7]OK?:
M+X<Q;Z?=OKC,9Q<QADW%2>.#BOJ#Q[_P2,_9P\??%S0OC)X@T2QNO&^FV+6W
MVB:)#-<&2,Q.SL?O%P3N.>^* /\ +=3X/_M6VOAO]I;]H3X766OGX#^!_B)?
M:7X\-CJ$UI9)J5W?S&T\RQ4A9SAEPV>.*]<^ 5Y\7=0_X)N_M(>)-#L=2M_A
ME)XJLKKQO?VEPZPQEM2)N3-;)_Q\[@)-Y;J#S7^GSX(_X)=_LU^%?A/\4/@T
MO@?1?^$+^*6M)KOB;1&MH_L>I:A&Q,=S<+MYD5CD'C\Z\B_9X_X(_P#[,GP>
M^$?QA^ -YX$T>^\!?%75=2O9] O;9'LECN1*UN(U /RP-)OCSW [T ?RM? /
M]KK]E#X)_P#!*'QWXE^&'P5\#_%V_L+S1!XWM;_1K*UF_MI=.MSY=QYH#3R,
MVXF0Y^:OWO\ ^#</]L;PQ^U_^SUXYUKPS\*M&^$T>A7=O:2Z7H<$,-M)LE,6
MY/( 5D7 *' R".!7RGXU_P"#4CX9>(T\<>'_  K^T-\0OAQX \9:N=4N_ 'A
MZ[6/0YF5V,3& /\ \LH\1+D#"@?A^V/_  3._P"";GPZ_P""9OPMU+X9_#Z^
MN-6748[9)[J[PT]]+;E2;B4J2"\Q +9.?:@#](_$<DTNA:M;6@,\AT;5TP3C
M,C:9=(@S[R$#IWK_ #J_^"&_Q ^'_@__ (*\?M!^'_&%];:5XCU+XK^/GTYY
MD7>5CUN?S0LI.5 (Z#@C\:_T5+FX$VF7ZZDHTM)X+FW$R##!;B!X XXZJ9,C
MKR.U?R4>._\ @U<\'>)_CUXJ_:"^'?[3_P 3OA1XQ\5>(=8\3)JWA2^6WN8I
M-8NY+N6.,K(&$;-(1TQC&?8 7_@ZDU/7]6_9<\47'A_5)+GPDGA;39]3AL[H
MM;7.R_CGVRP*2K[UPI!QP3GO7X%? ;P;\*/VF/\ @D7\8O$_B2WTKX42_#*X
M\,Z(EQ9V4;7.N&:PME^UR>6-VX'#'/.37]'.C_\ !$;XT^,&N/@C\>OC;\3O
MB[\+[\OI]]K_ (OO%O-UA&N(F)\QB0"=P [@ 9J>Q_X-DO _AO1]7^'/AGX^
M?$"Q^%?BJY2\U_PG!="/2IY;9@;830;P6,:*J+A>1Q] #Y _X-'_  M?_P##
M)_[4'A[Q':MK'@J:_P#$EM8G4HM]GJNFXE$,_P!EF#)LDB,FP8RG5<8&/P>_
MX)Y>&M&D_P"#A3Q7I-I80V]O;?&#7(]-LT@"VZ1F[@W!!]V- %3&, G.!Q7^
MEA^S;^R9\%/V5_@_IGP?^$?A+1?"EA:>%X- U:_TNV%O<ZW<16)MKC4]0ER!
M+<W#L\TC8&&;'.-Q_"'5/^":G[-?[)G[6FJ_M&>!-0M->^/'BS5IO$FE:7OC
MGNC*\\I81^4S[<23-PVTDJO& * /V"_;6_:8O/@OH47@OP!I[Z[\3?$J10>'
M?#UM)]G::%QBXD\]2!&84(;'7IQQBOG']DC]B866K/\ '[XTO%XF\5^)=2_X
M2)-/UV$:C/X8\WE=-M+B=25CC8@C8=N1UKZ&^!?[.]YK/B!/BS\;!=Z]XFN2
MVJ:3#KV)1H_V_$DEK:#^%(P=J@] #S7W4UI80VZB*..'3[= BVJ "$KG .WC
MH2,=>P]Z "6TL-4TM["YTVWGTV2,)%9/&K0/#@A08\;0JCH,8ZXK^1G_ (*Z
M?\$QO%GP#\1>(O\ @H1^QU>CPYXK^&T@\8ZOX#\)8\/#Q/JKRAKTWEQ;!5EF
M>-'WR.V7W<GFOZWM3UC2O"^D7&L:M?P66EPHKM<3R+'' O554N1UP1CVZ5^
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M %%%% !1110 4444 %%%% !1110 4'D$>M%% $?E^_Z?_7H\OW_3_P"O4E%
M#57;GG.?:G444 %59KI(I(XR?FD.%X/K@_E^/6K5<_<_.\MS%F::TR4B/0DG
M!_+^6: -,7$X\X-#AE_U0S]_O^&.:8EU!<QE)0F  MPDA 56(R%R>#GGZXJN
MIE6U;4)'59!&9F21U2&/ .X,[L$10.=S, O4D5_(+_P<.?\ !=A/V3O#.@_
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M90"Q D< #''+<#(]J_U9?^")G[4%G\._V6O@7^QY\8O#\?PW^)_@K08O"5Q
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M\$V-=U"^^)'[6/[1?PVN-6U&[T31=;^#_BWQ+ 9)3=W#+-/<:9(XW!V5,NQ
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MY2?P\_X(M_MR?#SP-X5_:WT3X62WU]X0\?W^MG1$O!$\]MI6HSWUN-^W@/%
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M!'PVU7XJ>/\ Q+I/ACPA8:7_ &A8ZQ=74*PW]R\"SV]HP#[V%P&7"A22#TH
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MT2(\BC!(&,T ?LF!%,@N(@KW,>$:; W1G^-0W7TS[?6O@/\ X*(?\$[O@_\
M\%"?@UX@^'?CJ"RT;Q+>Z8+;1O&_]EVVH:EH[V[-/;K )U+!%N=LF(R&4Y*A
MFK[ZEM98\3V_5!M,"D;95(YD//S'H<_TJ.U$:6\Q%PTSM(9#NY,+YSY8]!G
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MXBW5!UPN>V,<]/UJ1!+LD>2 23*_[K)R=O;![>_M6D(HQMPB_(,+QT'H*DH
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MP<%1D8./K]: -&BL-+UFED0,3/&<+%_>.1GVX']:D-S?"X@0PD(Y'F'LN?Y
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MZOXOGDOFOI-06^9+98Y_,=B09?E&[JW'6J_[2OPL\7_\$^OVT]._:"\#AI?
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MP;]?M&V?BG2;NX\7?L\_%C5+6*UMY)'T?3_#UCI4@:^EM[6/RH6)A3>5"=&
MZ'%?L;_P41_9;T_]G"T\1?MB_!744^'-E\*E'CS7/#GA*>/3;75;'38U$VGW
M-A$P:XAF8$M!''\W9<<5^/WPB_;@^"__  78\*?%'P5^TCJNE^"]'^#FE/-X
M9N==L);07TFJ0!;DVYN%A9W4$ ["QX% ']<'[,/[7WP\_:S^%7A7XG_#&=-6
MTCQ'I=MJ%ZF]2EI;21+YKJ03OQ)O7GCBOK*Q:%H4DLL-;2?=48"KSSC''?\
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M*VQWV@S(8KG[.HV1W+R/M1C,<=.IH ^G?&6@V_BK1K[P]?'RK35;=[2:XQN
M21"C H>&R#G'KUK\,/BO'\3O^";_ ,8)_'G@71G\=_"#6I=/EU31[B9M-L=$
M@OV7^V]1BBB98GEM8M\O&2Q'6OWIN9+.)RES=8>0;(D)W#<V<,IX&3V/YYKC
MO$_@;PIX[TC5/"/C32--\1V.H6%U:&/5;9+J,1WL,D1"A@<8$F00=P(&#0!S
M'P0^.'@/X]^!;+QW\,+]-5\/321Q2W"A5$=X8U>>$ 'GR9&>,MSG8#TP*]CN
MH5F.Z*3RKJ-0Y9?O$*N=A(Z9Z5^&&O\ AGQ]_P $VO&-KXH\&6.I7WP8\0WO
M]DW6B0.TGA_1Y+B<S3:BE@N]DECBD;YP!P..E?I6G[5OP4U?X2W7QM_X6+H^
MG_#W2]"GUC4?$#3+ 8I].@$FH6K6;NMPQ@?*,@7YB,#.,D \8_;^^&/PEU[X
M0ZG\1_B-=VWA;6?!]GJ6LZ9KJVL5S>7\^DV,UY;:>9&!DC1Y+=0"",!N.,5_
M%7\*_B?^UQ_P7#\6P?LWR0:E\//@7X<\5WMZ/'-EJ-SJAU6Q\*W[V$=C+IYD
M>,17<-NA;Y,)N(P*^LOVK?VC/V@_^"V?[2J_ ']CSQ!XSU?]G3PC]EO->\=>
M$I[C0]+NYVO$M]5TZZ6X5?.C6V$_FJ'(9,^M?U?_ +"7[!_PB_8B^%'A[X?^
M"/#FAQ:]8Z9 =3\06UHB:G<W\T2/J/GW')=I;G>TC9PS$L.#0!5_8!_80^''
M[!OP,T3X7>!(;34M8CO+G5M4\0QV$6GW5Y/J"J)8Y5B1&94^=6+#+;CD8 S]
MT7<,M\Z1#-I-&RRM+']Z3!YC..=I(/Y5?2X@:79(XBN5'* 'A!]TYQ@@C_/%
M)+)%NWR.L47_ #\;@.?1FS@+[L<?3N 1R1O$R3L3YLI6 (>[,=H.3W.1_GI_
M.Y_P7._X+,^&_P#@GS\.]-^%7PQTJW\??M%_$'4O^$=L?!DUX=/?2K+4X?LD
M&M17,<BNTL=S<Q>6@VC*#))(QTW_  6/_P""TOPQ_8-\,ZU\(_A3XGT_Q]^U
M;X@LH=#TKX6:?%/>ZO82>*;1K;2-42>%&AM[A99EDB!+F-U5G(.5'Y??\$@_
M^"1?Q2_:/^)E_P#MY?\ !1;1=8\9>.M1A%CX=\"_%2Y&NV^D0/<'4K/4[&!R
M%ADB4PB-MF5VH.<4 6?^"+O_  1B^*_Q&\::7_P4"_;\\3:CXF^)/BFYU#Q)
MH_PU\2VAU:WTNSU";[9X>N8-2OA*ZFVMI4\G9)E, **_L>,%U8Z38P6FGK*E
MFD=K#9LWR1P0@1Q.O^ZH4 9X QTQ6CI5A86,=G8Z:L5IIVFV-OIUGIMO&L5M
M;6UI'Y,,4,:@!8XD550#H !GBM^@#E;BPDD*7MQ'YS,HB^RMRL19?OJ3GYD/
M3Z5>M[:*&V\B=R)&9CN(Y4-C _ ].WL:VR >" >_(J.2-&!)4$\<D<\$4 4;
M>".W1HA<$_*<\8_'\L?_ %JR5E_TI[>&X8E<O@9 R,\?Y'?ZUT<B(%)"C/(S
MCM@UDV447GNY1=YW9;'S8P3UH S];TZ'6_#^K:5>*$&M65SI,S=3Y-["]LW^
M\ LIRO0^E?YSO[3>B^-_^"-W_!8S2OBEX!T9=;^'GCKQ)'X:F*L=*A6X\;W4
MLLKXB\M7*/+T.=_.0:_T@)8HI8]@<?NVW^F""""/<$=J_G-_X.+?V&O^&GOV
M--4\7?#[PXDWQ+\!^*M&\;Q^(M*C6'7K:U\.%9W=+H#?M0(3@<D4 ?OE\'/%
M$WC;X9^"_%=Q&(9M<T*QOY(@V_:UQ;K(1OR=V-QYKTZOY5/^#:C]O%OCK^R]
M>? ;XG?$C4-8^,_@3XAZ_IO]G^()Y'UR+P_9[4MHQ+*5)MT$*I"H7 #$#K7]
M2L<KS2.I<H(<J<'KL..>QSC/'7/% &M16;'<;E,V\X+>7@]!CC/U_P ]:T$!
M"\DGOD\GF@!U(2<' R<' ]32T4 9D,3R%IG)1MQ7'7@GDCC\_P#.:FJZMIV@
MV%S>7TV(K:":Y;(QE8HV<CVX7K5V2>9+H0K%F-ARW8$CCO6#XDT&W\0:7?Z3
M,Q,MS8W4: _>S/ Z 9[<D?\ ZZ .2^&WQ*T7XGZ/=ZSI)!%M=361 .3\C%#D
M_4=*[=+2$Z9>:9<P)>1W<=PDUI( 8YH)T(>)@<@JZL5;.>#WZU^!_P ,M?\
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M<^7DE?W<+/&VT=SC'X^F,_YS&O>/_#?_  63_P""\7ASP#XBU,6WA'P;J_\
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M5]@SN)QD]:_6:VN&:\DM-2@57,FVU8_-YB=0<YZ^X_\ U_YBO[6O[&/[6?\
MP0P_:+C^-7P63Q*/@_XEUG5+S6AX9U273M-%K'<,]FL]G" KIY2Y0'[H7'M7
M]JW_  2)_P""K_P2_;]^"OA*#3?%L-U\4M#TRWTOQ%I%\C1W\6N0H?.B::0E
MI9/E)+X^8?7% '[00"0RRQ3KLB#8B7. RY_P_D?>M90% 4#  P*S4D%U+G.'
MM6*2 =-^<8'KW%7S(BJ6)P!][VH DJO=%A Y2,2MCA#T/UH:Z@5HT+_-*,H
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M8,'.Y.2W^T>^>U7(KJ"?>(W!*$ANQ%<7X@U^Q\$17.N:]?Q6V@I'-<WU[=2
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MJ?\ !;;]BCQ/=_$_QK!I?A.WN]2U^"Z3P58^6B+=S%9 J6[;<0Y88STXS[T
M?@U^U%^R1\(?C?\ ""+]LW]E7Q#-KNNWL(\8?'CX,6%K;_\ "/?!JVO(BS66
MEW$2)<RVT<J%54[ER20N237XMS73N'N6M(TAN6*08SB,H2&VC'J.>G/&>*^L
MO@K\7/BA^Q'\9I(-:LM1-M8Z@;+XC?"Y[QO[$\66L#$'2M=LPYM;ZW'RX23.
M, !N6!_8']K+_@F#XR_:'_9TTK_@H7^RWX(T_4/#OC?PK=^-OBK\/])2'2;/
MX5V^FJJW$>GV+86X+JYD*P-ECS[4 ?S<T5-]FN%E2"2&2.=QQ'*K1OGD?,K
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MM>%O$=HEYI.H6W"31OG=\F<JRL&##G!'!(Q0!W]-;)4XZXXJ*:YA@ ,KX#'
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MMX_"O3?ACJ/_  N7Q3%X4\6>#=-U>_UK3[\&2YCL]'A:7SL_>D9T0E5P-QP
MPH ^GOVE]=^&FA_#/Q'?_&>UL$\%6=A<RB^O'BQ#=I;R-YBK*2N]47<,(2<,
M,<Y'^>SXZN?VC?\ @H%^VC??L]?L5^.]?G_95/BV*/5[S0%N'LSI$5VZ>(X'
MMXVBMC%&H99,QD$#)#5]P?M6_M+_ +4/_!<+X[:9^SG^R7:^*?\ A0/A/5O^
M$E\0?$#3-3FT>TU&WM[S['=:;<VAR9X3#'*2AX921T-?UD?L ?L#?"K]A+X+
M^%O _@WPMX;3QA::;YNO>)K#2X;35+V^U"*.34EN;H 22DS;Q(2?WA!;!!H
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M HHHH **** "BBB@ HHHH **** "BBB@#E?%6@Z5XFLFTC5X$FM)<%E<9'/
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M39V/B#5/'NC:5XFA\0[X9YIH=7LXKWS8YHBZL)EG#O\ -P_RMA@17Y%^//\
M@AM\//VIOV6-=TKX[:W;V7Q4\86\NKIXSO=)@U36/#]R8FG@LH+JX5I_+2Y
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M42,(=B%E8'_7(!N+L<=P#^5 !$!*9(H6_>2DL[=/*;J0/<#MS^>:_.;]L/\
M:NU#PQGX*_!Q;?7/B?XI9=-L+6T+RWR3QNIO3&8MT:21QCDNRGD^IJ;]JO\
M;*MOAO<0?#'X;V/_  DGQ1\113W&CZ2LQMO.\IC$P,P(*G.2.AXKHOV4?V3D
M\"P+\5?'UP/$?Q%\7!?$[_VC LUYX/U#5%$MUIMC>2 R[(2WE[U89*D8(P:
M'?LH_LU)X?T*3QM\4].DU+XF:Y=1ZG!?ZLFZ]T%]N6M;-B6*H';H3Z\=Q]W1
M37*1LM[$$CA^03G[SCH#Z\GCIT]ZNW,D=O;H]P^V.)?GEZLI/I^F3D=:XSQS
MXP\/^!?"]WXU\3ZB;;0=-B22>1EW*^__ %65/<X/?L3VY (OB3K_ ((\.>"-
M<UGXAW5C;^#[;3;AM5_M!T%M);/$Z,LBL<G<"5X!Y(X/0_Y]G[<7P"^-]O\
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MUTP,D,%QD\_,2H]1[9K]-[E2=P S\P/]*SI4BBL;TO=O;Y3YYDR&A^7JN#U
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M*^&-O;7ESI,?CBXTJZLO&W@6(LD:PVQ^S7-O<07"I)LE!97&" N<80<?EO\
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M^+;WQ?\ V5JMKH5GI>H6[#S7>XT>TBMY)2Y8G+B,;ASSZ&OIQ_\ @H1^R6$
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M%_X*1^#OB/X@^&%CX%NQ?:1?7$:,/$6HQN4M6?)V"Z&,B/GV- "_LX?L5_\
M!8/X(?M3:A^VQK'P"\6ZIX^&J^);G3K'4]8TZ=K:'Q5>R7D\$(:1MD5L)#%$
M !A!R QK]]_#W[37_!:;6;6VN)_@7XEL;EXU"VZ:SIRB,$;1@"3  '3^E?SB
MZQ_P5Z_X*$WGAW4];N/"UU;V.@:@-$O0OB342GVQ6\G+9NR V\'\^<5CP?\
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M_"+]D[XV:KXOU.]\5ZSIC:MI+/%J&C):.4!@E?)&]<@DD\9&<5_J=3_\$^_
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M=HFK>(1NU+5+AM[),+B3:K/@ ;@3CMBOVY#);+_HMNA#_?"\$#L./K7\VO\
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M\:?AA^WK\"K>;4K6TD34M+!UC2T9;J"W**+>=@),[QYJR [E_P * .I_9_\
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M!5>2W^>F*^(OB]^VAX-\$?$#P[\)O#UUI^K>)_$"3>1 SM),OV0XE"^4"HY
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MF;-QDU,J%DSO;RFD,6>!@[,C!P17YT_\$G?V[_VZAXJ_:,UG2/V:] FU:_\
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M6;XHZ78W5OKGPU\.:UK7VNP@$CZC-;0O-&ES\I8 '@8S7\AG_!,_]NC]H_\
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M\?2KNKZ7^U.^K:;J=OINI+##<HTUD-_DLH8':_S_ '3WH _4.(SJTCG!4A@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ /((]:SI$,+YR=I/7Z\<X^N:T3GM5"<S-"=RX/F8'^[G
M/7\C_P#KH F+C<(LDEP3CI[$9KX:_;H_;"T']CGX42^.9H%U/56U[1=(ATT'
M:7&K7 BWY)&-F03U_2OM%WG2^6<J3:) =[]1O Z=?0&OP,_:M^%_B_\ ; _;
M:\-_!C5;34)_@NJ1ZSJ-_&KBRBU#1<S0HY8 9#+SSSTH _8'X$_%34_BYX"T
MGQ[>Z,ME%J<4#Q(SALQS1K(I&<]-WKZU[N@G^UI/("D(C/ S@\#' ^OK]*XG
MP!\/;+X?^#-%\$:3&8]/TNT@@61>"#"JHN2/9>:]";SA(D.S= (P"^.2P& #
MUH LQN'!8$D;CC.:?55YXK6+?,1$N['0]3@?K4AN(5*@N,N R^X/0_J* )6&
M01Z@C\Q7Q7^VY^TUX&_8^^ ?B7XG^/=7DTW2/+U"RCNP"66ZN-/N%@51D$8=
MDP1T.*^T7ECC0R.P5 ,EB> .N2>@ ')]!S7\,?\ P=I_M^IHVE^$OV)O#]_9
MSMXRTVS\47$^G,;C4XGGNK>SV VV\A27*[200>HH _!K_@C#::=^WW_P7,L5
M^+UVWQ \':O??&'Q9IUMXH7^U[3[%I\SWNCQI;W6]5!B8>5_<W8!XK_4(\._
MLY_!/0]&L-%TSX>>%4M])@6T1DT>T0 0\;0@3@8&!V&*_AC_ .""/_!/J#]D
M7]O#X$>-]:@U!/'7BSX1:EK%GI^I +--IOB/21+<74:]0%B9F4$ @^]?W\P;
M9)8KWS&@8IMFM5X0R<AB1ZY)_P#K4 ?$G[6GP!^$FH_!?Q ^F^!_#-G=PR1E
M)X-+MDDRJ-N^8*".B].N?PKXX_X)#?"#P!=_![XCSZSX1T*_N+7XEZ_:Q/<Z
M?!*RPQNZ@*S*2H'85^DG[45BL7P;\2,L\B;G#X!X.Y7_ )$5\0_\$A5DM?A#
M\3O.D+PGXH^(&\QN?^6SG'X_UH _02;X#?!LRG[;X#\,+*S$QYTFU8X)XYV\
M9]/?'K7X0?\ !5#X(?"_2/B)X7GL]!T330]_X>_T>#3H$4J]RFX':HZ]/?BO
MZ2C%!/(LLB!G  7(['H?\^M?SO\ _!7^UCE^(/A5I-0EM9/[0\,;(U;"L#=1
M@?GQ^OX@'[&?!;X-_"RP^$_@53X)\.W'G^'M/F:5]+MRSE[>/))V_3KU[UT?
MBKX%?":XT'7%;P9X>C9])O9 5TNW^7%NS9&%[D ?C^%=%\$R!\(OASYGSH/"
MNEC>W)Q]FCP?J>>/:NX\22*?#>O3",$II5^!QU7[.Y_+O^% '\PO[$OPJ\ 2
M_MQ^(;-_#VD36T7BO45$+6$1C&QV(&TC &0OO7])E]\+_A]*^7\$:#(JL1N.
MGP8 Z<97US_GK_/5^PKK%I??MR^*1:K&[Q^,=4B<J.5?<^1TZ\\U_3&Q#$QD
M=03[9H _'3_@KCX"^&_A']C'QEXCMO"NB6<\.JZ!$)8=/A1OW]^JD @ CDXK
MTC_@G?\ "KX<ZM\!--U.Y\)Z'=2W,>F.))=/@9MK643]2N><8_Q[\3_P6WLO
MM7[!WCB$W#P Z_X8SM.#@:HA_#C@^G->[_\ !..PAM/V>?"ZV=TUQ"=,T?S<
MG[LG]GP$CZXS0!]<R?#CP*JRV$/@W0X[.2WD21UL8 %.S ^7'8GK[^]?SJ_%
MOX,_#K0_^"UOP,T!_#FBSV>K_"^+49;5M/A,)=YQP4VD%O<CKFOZ9[LI]FN6
M+>2 CYD'!'XY[]/SK^=/XW-$O_!<?]G?-P9IO^%26Y1&/5// X_E_G% '[P)
M\&OA*7N7'P_\,(\<K NNE6P.=Q! ^3N3^M?$O_!0KX-> KG]F+QY=:?X4T2P
MNK?2KORGAL(4;]W%*0591P01CU]*_225)'9XMGE1,Y8RKP3@YZ^K$9]*^-/V
M_;$WG[,GCNS2X> MI5T R'#8\B7)_'/?L* /QY_X(!?#GPAJOP6^/=SX@\-:
M1JDUI\1X;2+[99PS%8UCF?"EU^4%HUX^M?T!#X-?":X03W7@'PSL*;0KZ7:L
MI!!']PCW%?BC_P $&- .D_!'X\P6LTEU)/\ $B%B&.2&$<[''?.W<37[[K%(
M\4( +*J*LD?8., \>W^/X@'\A?\ P6"^&GPV\-?\%"?V?-'TSP_H^G6NJ?#=
MKJ6UM;"&*)FCU9(P[HJ@$L!G.,@&OZ@_AG\*/AC:>!OA]%'X&\.DR>#M"8S?
MV;;A_FTRW=F8A<DEG))//(^@_G:_X+ ^!M-U[_@HU^SC>7.I2V]S'\,98XH%
M. R1ZN%SCU)7/IS]<_TY^ 8_L_@3P3"(][0^%-#A5V^]MCTVV0'/JP4,?K[T
M ?-7[4OP\^'<'P;\:JF@:3:./#NO.OEV$0Z:3=MQM48.>GU)K^5[_@UNL],B
M\=?M>3B"+-M\6-;A@(C4$1C6)@ O'R\#&/I7]:/[5XC@^!_CB41">=O#VO,H
M;J!_9-Y\OT'3\*_DV_X-:YWG\??M=*;11"WQ8ULR-MZ$:Q-Q^G^>M ']L#[6
M590=HVC& <CN ,'C -02R):6[2R8D!(QQGC' .?R(]ZDD!=MB8$2X5V';C/'
MKV'Z5#- X' ^T)_<;D<^WL>?I0!%/*PC2\+% %&U%_B5^,=\=.GX_3\N?^"G
M7_!-SX9?\%$_@YJ7PWUU]+\*^,[S3)X-'\7#38KG5+6%$\Z*.&YV-+&K31J
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M9B)+FPNG>(CBV?R6_=J.P'T^E '^;5^RQI'AC_B(&\3R7K1?VPGQ$U,V5D8
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M/H#]C#XRV'QN^$-MXMB>VFO-#OV\-7/E</#)IR1Q2HZ-\X8-GDCGGT)H ^T
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MH GHJ..5) 2AR <$TJR(X)4@@$@GMD<4 /HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** $/0_2H?+#JR[RV<@G'KVJ<]#GIW^E91NK>:3;#+R#SM! W9Y'3&3T_/T
MH 4L8-T,B[XG!SNXX.,\=^^:YG3_  ;X5MO$(\16-G;Q:J(Y$,L<:*W[T$/\
MP4'D'!YY]\UV3[-HRH<\ [N>WKC_ #DTV&%%(=8U7))RH ZYH M4444 4+LJ
M2$EC5HN"2PS@Y[#\A5>41!UE?"JJ%5';@''I^%7+R,R1XP?O+R#@\G^7>J\T
M<;LD3D#"AF!XX QD_4=?>@#P?X__ !7\/_ _X*_$7XD^*[\V^F:1X9UU[<D\
M&[-A/]D123\I\[: W;H,9K_-\_8/^&'C'_@K/_P5:\0>/?B[8?VC\/\ P==Z
MAH>FW%^3JL:V]KJ\US:JJW'G*BE84.T;0N!BOWO_ .#IK]N>Q\#? GQ!^RUX
M(\9SZ7\0O&#^&K:RT?2WDM[Z=M1N?*>))4./WC2!&)X/K7O'_!L3^Q1XD_9J
M_8^\6^.OB]X&73?B)XS\:V^O:+JVKHESJ]QHES:"99([D+N6&5I]VWUZT >J
M:O)8>&_^"W'[//P]\,0)%8^&OA)JVB0A,1J+/1]-:# 10 J!$^Z % XQBOZ/
MX2A@2.10LN,O[G<?SSFOYM?%FESZ;_P7C^$/BC:SPR_#[Q7;R(K@C%[9RJ^$
MY^8;CCTP*_HZL[U]1L/MGE[)/-*[1D' )/L>P_,T >#?M<.8?@GXA=<_+Y>,
M>Z28Z_G7PU_P1]G-_P#!+XG[@,K\4O$"YSD<2OU^I%?;W[7<GE_ ?Q,\N!@0
M\D9Q\DH_#GW[5\$_\$6[V.[^"?Q4",&V?%OQ$/7I,_N?4\?_ %J /V5XB120
M!@!>OY\_45_/-_P5XT_[9\0?";XQLOO#';.<7,??MR/2OZ#V,DJLNW=AL$9S
MT[\FOP+_ ."M-_;6OCOPK',R*6OO#1^8<G-Q'T.10!^U7P04?\*B^'T;<?\
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M\FKW[_@H\,_L;?&48_YENY'YI)7A/_!)I-O[/OAT$#_D5M)QWXRPH _5I?\
M5#_=/]:_#;_@X-G@/_!-+XZF-1N71Y-_K_J9NI_0U^X['$1[#!'\_P#]5?AO
M_P '!\\-G_P3-^.V(DD:;1I,DK_TQF[_ (_R]Z /D7_@V:\:Z+>_L5^#-/\
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M@8?#'QY=!+6ZL=-M?#4<ETTB"X.U)?*C9MJ9Z-M ST^G]0O[>?[)WA;]K?\
M9W^*7P]U70-/UG6O$'@+7=%T%KF!&N(=0NK=_LYMY7_U<AD 5&)&#@U_F0_"
MCX2>.?\ @F_^V+X@\*_%;PU<:/X>\#RVLFA'6'\^UOIK2X#S1Q*"%8@+SC/!
MQ0!_J27_ .TM\-X-!L]374OEEMDN'AQ\JI(@< ]<Y#9_3G&*\^N/VUOAA8Q
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M]B-.EY/Y_I7Z A]URR$#"-QWZ_H.]?!__!2&(2?LS^/V(^YX7\1$'C_H&34
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MHH ^+?VNOVAK#X/^$[C2[3G7M<0Z3IRB3RF2\O1M@*D$'.3Q@Y]*XO\ 8_\
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M-+% \D<;LQ'$A0@X.>:] GW,X0#</E(&>,YYXQ[5_,)_P<Y?MG67P(_8UN/
MWA/Q9?:1\3-=\1V@M=-TRYDM+J?3FB5)<S1D'9EVRN.<G'>@#^8'QEK&M?\
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M.H KT3_@G=H^M^&O@/I^DZ_9O9S0)IJA9"6/R64:>G &/S'M0!]ZJZR1RC^
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MP\,ZS<W?AKXH6ZV=[X4^(^EV<5[XAT*;2G$RV]AYJ,R)=8V2;'4!>U? ;?\
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MV?Q(J:O>6L=EG:UC+,I>T(:0$;3^-?V5B*[=O.*DH[9^S%AM'3 QZ CI^ -
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M&?'@KQ%GY5CLGZ=P #@_CQ7XY?\ !/&U0?M=?M%7RS,YNIF.PCY1A7'R],X
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MTN&ZC>#[P0R74L@P .,AL]!C-?8%RC1" (3M$@.>F!N/:@#\N?\ @K1):?\
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M^+?@7H2Z]##I>KV][=026,18JBH<(WSC.7[_ (5]UWTUPZVKV<*SJ\JB3/\
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MKG.*=#,\B#>@23.&3L.W'?\ 'I5!HY"%FMAM4X*QJ=H)'/3W/6JD<\\\T\;
MQ3-%AQGB,'C<,?@>QZT ?@-^WCX7\7_"3]K'PW\</#<4KV_B'QAX5LM9RCK!
M'ID9$5Q*'3KA.3N.,YR*_<3PUXZM?%ND:7K?A25=4CGBMX;R/>NR "%!(XY'
M.X-VZBI/&7PP\,^/= FTCQ'86&IQA)/*O;ZV2YE@D(.V6,N"5>+JK Y%?,NE
M?L]^)/AQ-=:CX%\2:AJ5I*C!=,CN'M[="A)&V,_+\V,?C0!]O/)$3&9$ W%<
M,#D[\9*_ADC-1WOVEVA$40=5<,6)Q@'&.!WX[5\5R_$7]I#1=-U"*P^&/]K_
M &*VE>VEEOD#3.A;9C=CDD9S7!>!?C3^V#JJ7U_KGP7^Q6 \Q8I&U*-\",9+
M*O4$<^^?>@#]$IGA>=(40/<(59AGE5'(;.>Q^F*^6_VC?V1_ G[0T$$NLZA=
M^&M7$D/GZOID$$UW<Q0\1P2&4C* ': "0 <5XQ?_ !:_:U.EW]UH'P<%\]Q#
M+!'<'48XY$))PRD_,"&X&/3BOFCPM\3_ /@H);^)[R'5/@I=R:3;R&XM+F;7
M4=;B0'=Y.T]!N^4?AT!H _3;X+_ +PQ\#O#JZ!X8#W$[ +/K<L<<-[<1\#RY
M%B.,*06&&ZG(QTKV7R(K15+2L74[GN#]]OXMK>W;Z'M7YC6/QC_;PDUA+Z3X
M"E;2YV6\D#:Q%Y<$889E52< X!.?ZUU&O_%[]L5;Y=.M/@B)K6'R9'N1J<8+
M' ,B$]PIX'8^E 'Z+1;)M]Q$HVE.9\@.VT'(..> ?TIDD\TEFIM!YI=]KL2,
MA2<$@Y'/]/QK\</'/QB_X*,6_B2.?PC^SO+?Z&RQ+(RZ[%#&&W#S,QG_ &>3
MZUM>-_C)_P % 5\*6$NF_L_O!J1N8?-M8-:CC;!4;P2ON2#ZX!H _7FR\NWB
M,6=\J9DDR1D ]<\]ATIR:C%.H-L1(<X;/89P3^'/Y5^-'@#XL?M]ZAJN[QU\
M#KCP]I;LD<%V-;CD:X8D#RV5>0">">>M>E^(/BY^W59:A_9GA_X +=V:*)/M
M2ZM#&67 ^8_7/3K0!^J271>=X@GRHF[.?FSC./3'O_DJ;DK&LA4#<^S&>GH:
M_(.Z^.?_  44MKQ[*S_9L%Q;D#S+L:Y"&1'&'/\ P <X^OO5?2?BK_P4$NM7
MEMKKX"RQ:4L0DCN6UR(YE)^9-N<C:.G4?3!H _8*:[\IE7;PQ49)'\7T/:D>
M[\MW:156V2,R&4L,X R>,XP*_);Q#\6OV^;6"&'1/@(VHR^:@<G68E94(^9@
M3_=P>F.^*]_^&LG[2'Q!\)R6_P 3?"%QX'U603Q&*+4EF;RY(RJMN0].?I^/
M0 ^<O^"FGQ2N[_X<Z!X0\(V<&K2>(?&=GH]VY+,]K;W $<ERBIG+QDG /I@U
M]2?L#?"5_@?^S1X8\#W5Y<W2?VGJ^MF[ND\N8-J\L<[1%/[D9BVJ>I!KLO 7
M[/.CVFG6UKXPM;37+NSNVOXWU.!;ITF$A=71I <,I(PW!X]*^C4T^W7;:VP2
M&RMX%5+>)0L:;%[(. ..@_IF@"]#.Q4^0HDAP=LIX)8@<8_7K7Y#?\%F[H6?
M[,-K<7#F/_B>68V 9 PXQVST(_2OUPL@\D;(H\N&/D$=,KVQW/;_ !SQ\C?M
MI?L\3?M,_"Z+P? JR;+Z*X*2J&7]TW+8.1GH?P^@H \(_P""2UR;K]DG3)[;
M$I?Q)?J0>F%$(./0XP>:_4579FPRC 7.!V. <?TKY2_9$^!\G[.WPBM_ 4X5
M'74I[H(G"@2X!( XYQ@XZU]69\I"!\S@%^?IZT ?EU_P56U&&Q^"6A-<JHWZ
M\@(YX4F,<=^@KV_]A26WO?@1I26SY426TF?^V2,?\XJQ^V=\%KKX\?#S2M!L
MXEDEM]624HX!&%8<\@^@/3_"O4OV>?A?+\(OA_:>&YE"2KY(*+C Q&JD\=,<
MCZT >Z7$DQ:)8HPZ[ERQ)ZY'IQ7\W?\ P<,OIL/@+]G*6:X9;D_'#05\GL%%
M_8_-G!/\N!7]'<;[+YK3>V0!(>3@#K_A7Y5_\%-_V-]1_:FT/X9QZ9&MTWA?
MQ[I^MR(X!");3V\AD&X'GY"<_E0!^D_PW+R?#_X<R1*&B;P'X2(?/8Z'9'M[
M8-=W-).@C\F(29=0VXXQG@XQZ#GFN6\&:>/#/@WPIX>D<O/I/AO1=,;_ 'K2
MPAMS^17'X#TKJXQY*9D<C<W'/'/3\1GU[<4 ?@+_ ,%)M+@U+XV>!OW[I<1^
M--#?RU&1\I3(S]:_=+P2S0>"?"R2_(W]B::GK@?9HP#^*8/XU\%_M(_LBZC\
M4_B!HOBZWN&DBLM:L]0.X_=$39R,@].G]:_0+P]8G2-&TC1I&^T/96%M 7?G
MF- N,GTVG'MQTH V84"L55]P'.3U)]OI7\[?_!3RZC;]HOP; Y*;?$O@H!EY
M)87$0Q^/Z5_0_=Y!&T8R5!(X./\ )S7YV_M*_L=S_&;XFZ3XR0))'8:GH^H$
MR*"1_9TJR=QGCM]![B@#[[\*2$>%_#A< !M%T]>/^O6$#KZ@?K4D%Q+'K;V?
MEKY A>3SB?FS@<8].@],^]6]/L1;Z3IEB#_QY6MK;G Q_J(4C(]ONCCO2M$@
MOG=\ /$8RV.N1CKGVS_^N@#^=C]OO['=_M\^'@MPPFCT#P>K*HSPE_; X//I
M7]#MC*\>AZ.(E60G3=.ZDCY3:Q?-^/7FOSM^-?[(-W\0OVBK3XH1V\4]O%IV
ME6XE=06!LKB.4C)&?EV]/Z]/T9MH&LH;.'[PAL[6W(SP#%$D?&<?W>..* +\
M/F<>8NW !X[]3Q^5?@1_P5.^!6KZ%XT\%_M(>'-5U"'4UUVPT&ZLHHV-L;,W
M$3LS2("V6"L,=/6OWLDN6%Z(P#@H,C/8C_&N<\6^%O#_ (UM?[!\2Z-8:OIR
M8NHXM0MTN8([A0=LJQN,"1/X3U'- '%? [QK'X_^&/@_68ECCNAH&DP3HC@_
MO8+*"*0G<0V792Q&/XJ]!\7>'+#Q9X=UG1=3M([B.[TN_MD5P&,<MQ:30K(G
M^VK."IZ9 SG-?*GBOX*>)=(M!??#;5;R%;:[C,6BV$[65J(U8;D"*-FT# P.
MHXZ5GZAK/[0,=O'I^G>%;FXO84!+&_VM( ,#+$\[L9_&@#\]_P!@#5O%G[/7
M[47B#]EG6+<:CX;O[;Q9XFM?%&HMY.HQ3O>3W-K8K&6"&#E(]W7: :_=F:=&
M9+: [G?$WK\A()/<<5_!1_P4J_X*'?'C]E__ (*!^!['Q7X,OO"0OO$.F:+=
M:Q:WI4FWO)BK1M+&1N25>64]>_:O[:_@#\4="^*WPA\!>+M'O%O[G5O#NEO<
M3(/G6X>V!EC:4Y)((YY)YH ][CG61]B8(5?F/OQ5BJ=M#Y!*8!)&XMW![CU(
MR:N4 %%%% !0>>/6BD/0_0T 4)H@"-S,@[S+]_!_Y9_3G!^IJC]E99Q+9@B+
M&&0'AFR<D^^#5O:[6QZL3*W4]B01U/Z5,RAX_+WF)A\Q*\8&!GIQ^/2@"M))
M]EF6>8^7$5"X[;SC@>_:K@N0L1FE 1<_+SU';O7G2^-?"2^*?^$+CUE+WQ04
M:X&DR<GREY+Y/ V@9'.?:NG"0"7^T[BZ<6\2F%H#N,8=<\[?;'''4?2@#SKX
MB_'SP!\++.[N_&.K6NF_9XV9%EGB3S'(_=I\[J1O.!G]*_B)_P""S/\ P4\_
MX7I^V+HO[)?_  EG_"K_ (4:9X/T+QR_Q"\.W$D^KSW^G7L6I/8R1 F,PS>5
MY+-C(C;CCBOW;_X*8?\ !*_QQ^WAXEL?%'@/XV^*_!NFV^M:;=7FF:1J-S8V
MK0VCXFC>-!AT(/([C\SYMIG_  ;M_!#5?'7ACXF^,/%]KXKU_2/#5AH-\FM:
M6+Y[I+14$JS32*2P?:P8-@$'/0T ?8O_  28_;^\(?MC?!Z&#PM?VNK#P7:6
M'AA;Z-YC-?+HEM'IINYQ(J8EN/)$L@'&XGM7ZVS33P2"2/YK@_\ +L<[/+)Y
M;(YX'(KYO_9R_94^"W[,7A:70/A/X/\ "WABW=E^TMX=T>#2Q<3JH#O*L(7<
MTC LS$<DYZ]?I(W%XMJ;@V:&Z5MD:Y&7BSP<]L@=^O0D=  3+J4DSD6T4<B1
MINF9I5380.0-S+P.<D\#@DBOR8_;:_X+%_LV_LCP:EX7'B#2=>^+L5W;V6G>
M"[RXDB2XFFD,;!I;4M(=I  "[1[GBOA3_@X7\4?M$_"'X!:1\8/A!X@\6>&H
M[?Q!:Z9J<'A75KC3W^R.8GN)I5M\%U$?F$YR&P:^?_\ @DQ^R?\ LJ_MQZ?X
M+_;5\5>(=.^+>OZ#I\>D>(-$\9:(=2=?$<$0BNS*UX"9)K:ZR!*>2W/ XH _
MH"_8"_:H\9_M=_!R^^)_C/P1IW@6X7Q'=:7IFGZ;<W5U!>:9%$DD%\9+IFD#
MRAQE1A1VK[GKA? WAS0O"&D0:'X8\-:7X:T2 C[/9:3;1VEKC:%$@ACP =J@
M'CMCTKNJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **K7$;2(R[R@&"&'7CMZ\U46Y6"/9*^6W?F,
MXS^)Y_\ UT :E<UJ&D:+=:@M[/IMO=:DBHJRR("ZJN".<=N,5IRS).5MFD\J
M<X< <DKU_P !5Y8T&&P"^T#=W/'6@#)EN51TAC53=!!MC ^ZG&0!Z?R J_ [
M288IM(&&X/WL8_S[U/Y47F"7RU\P# ?'S8/;-)*PC3('5A^IR30!+15,L%=<
ML0I7T[]?\_2HI%# S>:R*N.!W/I^./U- %?6M2BTG3=5U.0QJNEZ7?:E(9&"
M)LLK:2X.]R0 F$^8D@ 9.1BO\R+_ (*'?$KQ!_P6Q_X*G>$?@=\+-;OM4\+^
M$;/6[;6-+\,F22T-YH&L""Z>8D>5YL8@\M^3\LIQFO[ O^"_G[<&H?LB?L8^
M-]0\*2R#QWJ>F3:=96MO=M:320ZQ')IZD3(RL-QD!QG\.U?C%_P:K_L'O%IW
MCW]M+XA6<6C>-=1URXBL+?[,LEQ-:^(99=0FG^V$>8#+YP+@-\S;<^P!_0U\
M$/\ @EU\-?AM\(OAMX-T2]U'PW-I'A;08-:M+0)'Y^IVUNANC,H(S([C;)ZD
M'-?=OA+]GKX6>&_LUK=>'[#4M3MX4$5S=PAYG1 ,$D#KD9QGJ>_;W';ON!?+
M(0!\HB[$'^+/KCC\:U/*B,@F,:^;MP'Q\P![9H YZW_T:T\B2QCL;*!DBA2-
M0%$:$+& .. /;I]36["P>(-&<C&W'; 'IZ^E3/&DJE)%#J<$J>G'(I554&%4
M*/0"@#$O-/L;ZVGT[488[B*XSF*4 CG/;'H1^&:YOP9X$T3P#8:A:Z'9QVL-
M]?37\B1J%!EF.6.!ZYS7?&-"P<J"PZ&G$ C!&10!0G>Y,0\J/<YVGISM/IVK
M@_%7PW\%^+;RVO?$&D6EU?1&-UDF0%E>-@R\D'ICU]_KZ93&CC<AF16(Z$B@
M#'MX!IJ6MG96RI8P0B-%4?*H7@=/;C_(!F,,MP7AN$#6TD;JX;H58>_>M3 Q
MC''3%+CC';I0!YKHO@'P=X9U"XUC3M-MHK^:X>=YU0!][\DY _/MVKO/W^#*
MHRQ' Y(PW(/UYJR88B,&-2#UXJ4<<#H.* .$\3^$=+\<Z#=:+XHLHKFREG21
MX95!#>2X=>""."/K[U8L-(TK1M&&F^&[*&UA@"1F&!-O,8"@GIS@=< <5V1
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MH,\G\<TV736DF2Y2,#]VR3VV!Y<F_P"]N'?\/?%=!Y$6\2^6OF#H^/F_.I
M,D#KR: /E?Q9^R/^S?XY_M.YU_X+^#[[4]3EDDO+F6Q7[1<SR?ZR>1R""S9.
M?EYZ9KQ$?\$M/V*)5F^T_ WP<9+IO,?-E'PQ))_Y9^O^>F?T5"J#N Y]?KUI
M< G)&3TH _/O3?\ @F/^Q9H\3P6OP0\'H).0!9)Q_P".?B/_ -57(O\ @F_^
MQI8+(5^!O@V261M^TV2?,#_P#J>GTK[XVC(.!D=.*0HK'+*"1P": /SPN?\
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M _Q$\9ZQX1\#Z!J>L: +/[3/>6&HVPU"[1II+1F:+"K#@+L[_2@#^TWX7?\
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M].:\K\&_%32/%"JM[*;&^M]A>W!X)<#(+9YP>*],6>UU%9OLTIE9<D#' //
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M070,1T)[?2@# VO:/<7,TSRFX&V*!_N!@. HZXP1V_#M5FUD=8%>2U6/.2Q
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M#TM+2TEL-1!O7NKB[OH?/M8FBC+0+\K !MH.#\QSS7XY?\%V_%.@_M(_M+_
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MXBQ7#?"JP^/VEZQK.FW"-/9-HT6O>??"6U<&-EECYD4CYLU^JW_!4+_@KO\
M!SP7X1^%UA^SI\+]#U_X=Z+J%M=6EJBQ:?96FI06\7FW$5I$-D<C2*VYU7=W
MSC- '^A=X0\2Z7XV\)Z)XDL)HC::KI5A?R^3@1EKNUAFEA'0[5>5EQ[5D^*?
M$]KX3\/^*/$&I>1IOA+PKH>H:]>WK%8XC;:=;/=7AD)P-BQHY<C_  K\V/\
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M46:1,PP'\QTC!/1B2Q4$CDG!.:/)#Q$H?G+!M^/FVD^N<\@>M?$O_!0#P_\
M&[6_@-J6F? *VN;GQQ.9HHOLMY)8S)'-%M,JS1%6S'EF !'3UH Z_P#:9_:M
M^#?[+7A;4/&?C_QAI6EM!;2+;:9)=1SB:\92\:-;6[2SABV!S&"!W[U\H_\
M!./_ (**Z[^WAX4\0>,]+\,:?#X>TSQGK/ANQOK2WO($N+33)"D<Y%S'&274
M9R%VGL?7\NOV-_\ @CI\6?%7BEOC!^UI\:/$?B\QO- ?AIXF-QK6DM)=2F4S
M'[;YL9:VW[$/7:M?TC_"+X.?##X&:'8^"?AAX/T/PEI,<0N)HM$T^VT^&>Z=
M<3W+Q6\:*992,LQ&2: #XV?!CP'^T!X*O?A]\2?#MCX@\-7L;M);WL2R10W;
MQ/&LJ*P8!TW9!]1]*^8OV$?V OA?^PEX,\0> _A[<3S:'K?B35-?6QN OE6S
MZG.;@0PJIP(X?X!V'I7WDLLK3F.&/?;8.]R>CYV]_P ^]<AX[\7:;\.O"7B/
MQ1JSEH-"TF^U:1CR0+6%I@@/IQC- ';16K"<7!D:.-%V)"#B/;D8)!QS5Y98
MG.$DC<^BNK'CKP">E?R@>,O^"V7QT_:7D\7_  __ &1?A!:>,O$VAZYJ'A:5
M?[9;3Y$FS+9FX!1P=T>?-!ZY7CTK\N_V;O\ @HG^V5^P!_P40\)?!K]KB#6=
M6M_B%I>L7QTO4/$=WJ-M83ZQ*\L5ND4TS+_H8<QQL!\H48/% '^@/17"^$?$
M]OXO\&^&/&09K6#Q!HUAJJPK\P5;R%9@OOM#8/3@5VD,D<J;HFW*><_4"@":
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@#)U6*6>(1P2R)*)$;"''R#KUXY[\_K5/5;^STC3+W4+PP)%IVFWE
M[)).P52;*W>=PQ8C/"$G'7' )K9>-O.$HR0%*;<<8(ZY]1_]:OA[]O&X^*EO
M\'I[+X0Z6-:\4:A=1V,]H9'B":;?2+;7DX*,I)C@EE8#OMQ[$ \]_9G_ &IO
M$W[1_CS6-9T'3EN/#/A^ZU+19IK=&CMQ+:W4MLC,& W-^[#9!]\G-?I3&6,:
M%UVL54LOH2.1^'2OB[]BC]G;2OV??AH;"QNI;[5/$)MM8U<SPB%K?4;V%;B\
MMUVJ"RQW$DBY/4*#GFOM04 %12NB)ER /?./TJ6F2!2I+@%5&X@_[/- %&66
M+>(<J92H=5(YV?RZ?_7Q6;JFIVEIH>J:G/+%!;:9:7-W/*Y"1H+6)Y6WL2!@
M!3^@JY9S0W\CW40#&)C!P>FTX(_3]:_+;_@L?^U;;_L:?L,?$;XJSK%'&^H6
M'AM)7F\@++K6^*/#*0Q9SD8 _AY&#0!_$Q_P7/\ CA\4?^"DW_!37P;^SM^S
MOJFI^.?"6C1>#=%UWPCH-PPTV6ZTW6[1M5>YA)*O,D(E:1NA ],"O]![]E/X
M$>%_@3\#?A_X0\/^';#PO)#X2\-IKFF6$*P1R:K;:1:17#3JN \Z31N&;^]F
MOXF?^#8?]B2+]IKXT>._^"G.O^*]4EN]/^+'B;P[;>#&MB^E2QQ SP737;#=
MYFUHV*=C@'!K^_<6DUQ,)Y&:%8BRI N"C#LWX\8 Z=<4 /:6:* .(%W*RJJ<
M<C. P]OKTZ5IH254D8) )'I[5ELER9!<;>4^00Y^1@#]XGL1C\SBM1<[5W
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MRO;)K^./_@W8_9M'[7GQV_:D_:$^+MDND0>)/$.AWOA.YA@%V;Y40,Y,LRL
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M)Z<^IJS=RO%%N1 Y+ %3GH3U_P ^HJC-=R0W,<$$"L70.W.,9QG]"?RH N%
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MVW@$ 9(- '[C)-.6"O%MRW'(Z?Y]JE9V1LL%6/J7+?=X]>GY^_-1D2M+&2,
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M +KD\]/U_+@\^@K,U/7[/3KJTL'E07MZC/;0L<&0*2#C\0:NR26[*A\]E4*
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M .M69?:]!I%B][JS):(HR,GKTS^7/Y5I[75(HU4#<HW'ODC!Y^G3CK7YR?\
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M.0>*_3@JK?*P5@" 00#WQZ=ZP=1U)H([J&T@CNQ"K!X& *\C.TCH1CCG^8H
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M].\7^#+PZEHNJ+(]I<E=GF)&Y1SMSV;%=R9)%4.RC;GYL'H,XX_R?PK\]O\
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M%NF;O(<QYQ<@#'(Z]_QH _6O0/%FC^)[ :GHMQ]KLG"F*<+M#D@-@CG''?\
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M_B M8P6^I.37E7[0)B;X(_&#R6*7EE\./%US R</')'H=Y)&ZG^\)%&.G.*
M+WPD^-G@WXQ:,=5\)WXO AFWKMVX$,C1$YR?XU.:]5^TRF-6"98,=Z^B^O\
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MD$*>+?%]OX6C4@$)+,RY<<X. R\ ]^_?ZB ,H\V'*1#^%.,A<9R/7UK\1O\
M@M_9B_\ A#^SH(9'M@WQ\T7S#%E2Z9@5U)!&0<9(- '[.^$_&6E>--!TK7]
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M%PF,9^8,@QQU[CM^&_\ P3DT[XE?M(?%KQ%^T%XRUK6[GPO;-XAT"VCEF/\
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M?:KF1U9H'/&UOO'_ (#D_I7DW[/""']G[X0(@V>7X&\/HFT8V+]CC&U<=
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MQO<$Y]#\P^E>W_\ !./4'N?V5OA%#(N#9>!=(@//.40YX_"O%O\ @LW;2O\
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MK7ZM?L\1-!\#/A9$Q):/P5HZDGDD_9ER2>Y_KUH ]4B20W@D#'RQORO8Y5L
M_0D?C7\Y7_!-?49;#]MC]JRS$C&.?XBZX&!.,@7_ *=#P>_]:_HY-RL*NQ4
M()'Z<G9&S]AWV_C7\Z'_  3KOX;K]L[]I)1:1JTOC_6B91'\Q_TT<DX[Y'?%
M ']'()DY P,#'TX/Y\]*_-?_ (*:7R:9\!];NY,YBMY2O8?=<\'Z=J_2,LR(
MX!Q@8'MPO(]*_*S_ (*OWOD_ 2^C+X$EO-O7D@_NVZ_YZ'K0!]F?LC7:7G[,
MGP4NV^;S_ NER+WSDR\?AP/:OH>)!')P>)"3CTP#^?>OFO\ 8Q99/V5_@00J
ME6^'VD]N 1YN0,^^?RKZ6;/VF,=@'X[9V^GYT ?@_P"'=-5?V\[6^24X;QQK
M+X_WBG'\O\\5^[[ OY0S@D<G&:_G,^'>J:A-_P %'+JVDO)Y+6+XBZ\B0,Y,
M:*K)A0G90,\#I^%?T;HRDG@8!PO'3TQQQG- 'PG_ ,%&/LMO^Q[\76N9F$(L
MH2S$9.=WW?RR?J/>O+O^"9$5G?\ [/W@R>TO9'6/2_ECP=K8D?(_#OU_.O5_
M^"C A?\ 8^^+BS(CQ_88MP=<C.\'/UZ\UYQ_P3%-K%^SOX,^SQQ1@:4Q(1"/
M^6IZX]<4 ?I#=- D*6\S;6D!"<>_/'T_^M7\_P!_P41_M#6_^"CW[!?A>&]E
M7PY?>,/(UJ($^7)"MM&P#QYVL W9E/...E?T#OLD>W+QJY;(!(Z9ZXS7\Y_[
M>=Y=?\/7OV";>"206J_$"5)85.(W46D?RLOIG]1VH _H>L+6RTS3?[+@&RUL
M@T,848"IN;"XZ#;G&*@U2RM=9TR?2IXEN-.N;:1+D.H8; O *G((SV(/3M6M
M<HC03C8HRQ!P/O<GD^Y/6F($BM0 H -M)D8ZX4]<?E^)H _$G]A>WM/!W[6/
M[3VEPL%M;OX@*+. *$2-&67Y5 ' /?'KVK]R*_!7]E&_#_ML_M#J7RJ?$6$!
M#T'$@(Q^>/Z5^]((/2@!:*** "BBB@!CX W,<*N2:_E+_P""^_Q&O/$W[1'[
M)G[*]FQ6W^.>K6GAFYD5R3LOKU) 3!G;)@8&"/3VK^K&?=Y;E%WL%)5.SGT-
M?Q;_ +7'QUB^,'_!:C]F3P)+HUAKD_PR^,6CZ7YEQ&LLVCL&+?N6;.PX7MZ>
MU ']7W[+GPK_ .%&_ OP'\+7/[KP9ID.EA]H3<MO$L8^08"@X!P,?EBO>)7M
MHV,<TQ*WO$2D97H,#VZ>U67B<M=?+N#[=BGI]T=!ZY'UJI*%54,T:?:8XV^S
MHPSNE*': >WS'\* /QH_X+3_ /!0[P#^P)^S5J[:CJ)A^)/C?0-;F^'5F)1;
MO<WNGP,I5)E(>/\ >\;E9<5_D0?&?XG:M\:O'_BGXK>(KE_^$F\<:Q>ZSK4/
MF-+MN;J=V/[Z3]Y*" #E^3GFO]#W_@X"_P""9W[6'[>'B7PUKFF>%O$&IZ7\
M/K75HO"5E;ZK&MM=B[,CNJ0]$W%AE3GK^-?P._M)?L5?'S]E75#IWQ:\ W_A
MCS;R6R3S9TNY-\3'*E8AN!X&>,T >J?\$VO@'I_[3_[6/P4^%NJ-]ATW6?&^
MC:/>S1P"X^T17-SEC)&5*MC9C:00<XK_ &0OV>/V;O"W[/7PY\-?#3P?;6]C
M8^'+&VL+F\M8$MSJD5O$$0RQQJB]\@8/';U_R%/^"4G[?'AO]@_XY^'O%VO>
M#M U^UD\4:7J<^OZWIWVF[\.):$ SVNX>9&R*-Y( .>>^*_L4_;/_P"#C.T_
M::\._"O]FG]@#Q0GC+XN?'2>XT+Q'>Z$LOAS5/!4RQ%K>2RU:[Q%$TL@7YU;
M@CK0!Z/_ ,%F?^"G;?'SX\M_P28_9QM(]6\4?%37[7X+?%'78KEXKKPA/J,D
M<LUS;6\)"W+)&C (^X-CI7[^?\$VOV(O#G[!_P"S=X8^&&E^3<>,XM.M++Q/
MK:6D=K=:]/IT20V\UVT:HTCX!92Y)&X@'DU\,?\ !(__ ()&>#?V5]/L_P!H
M3X_Z+I7Q#_:C^*,J>+?$WBKQ>;?Q/XI\-^)I7,L=Q::W^\3[2L3F,3QY*)P"
M&P1^^S.(II_M)#A=H68_.Z8P2PQT/UXZ\^H!7LM)D@,FH73-<7DOSQ0O\RVK
MGC]VQR>W;&#7A'[0G[-_A?X]^$[S3]09='\2FRN+?3?$,-ND]_I4\JG;<6SL
MK.DD9)92A'7CFOH.UC%H[W)NI+B"X^9#(2?+!/!'ICI4LI998Y8'9XISF1\\
M)SR0/IDT ?BU\$_VCO&?[,?C>S^!OQP64^'+6<Z'X6\97-S))?:^ULX7S[F&
M1B(V9#DCC&/>OV-TG5M'\0:;I.NZ1=L^GZS&LUG,N/WZG(YQP/IQ[5\W_M1?
MLP>'?V@/"<T+:790>)-*$EQH6JQ1*FH+<L"&DAN.L;DXY/<=S7YO?!'X[?$O
M]E'QW'\%?CK#J6F>"SJL.E^&_$NL2-?#[#.Q'VF*11B$)A1\S8'?% '[G6TR
MM-<VX8L\6 3Z<\?YS7@W[17Q%M?@%\#?C%\8[M1>1>"O"E[XB>VE8HCBV*@(
MS]@Q;&1T ->J>%_$%AK>G'5]%GM]2T6:,/9:M"ZO]LCP#O;OW!!;!-?"7_!6
MB6XC_P"":'[:%W8^;/>S?!+Q"UK%"&,JS&2U2-8E7YMW+$ #/!Q0!\T?\$G?
M^"K>A?\ !2_5?C+X9TKP_9>'Y?@S_8ZW4UE=?:&O/[6$>#+\QV;"^!SS@U^T
M-M;#S>)G;!P>_P#6OX+?^#*ZWU:/6OVX;O4["[M[Z:'P66%W%)$\[A82%+2@
M;OF&[C(^:O[U+0B592S^7=X)E@^ZL39X )P,=\_K0!M#Y0%Z]A_G^=?$7[8?
M[56B_L_^$532HH]4^(.O/-:^%="=_*34]0A#,;>25#N4%L#=D=?>D_:O_:FT
MWX&:"NBV5[%=?$#Q#97$7@_0[=3<3ZIJA!2VMV>(L(&=^ 9, 'GI7Q7^R_\
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MSY\08925^T^!_%,)]A)ITH_'@YKYU_X(_6%OIW[&7A:#S"RC5+\Y(Q@FYD*
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M2#^!"U^+G_!/[5DN?VB?&5N7)54F')S_ ,M6 R/?'./7ZY_:3XD;%^'WC1L
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M->'_ /!(4^=\#_&<S')?Q;!T][25OZ 5Z9_P57NFM/V-O'\HR"LFG_=/_37
MZ5XM_P $9;MKK]GOQC*2Q(\76W4\Y^PR$X/I0!^PK .VUN@_H,U^ _[;.II;
M_P#!4#X!VO&3\,U8D]LZO)_0C_\ 57[Z$^5&SR'&1P>N"0<#VYK^<G]O.._/
M_!5[X ^6I\EOA= 5;?MSC5 K<?[VX?A0!_1=IQ!TJQ/8V5L?SB0FO/\ XHW=
MG#X!\5R87*:#K).1_$-/N,G],GH.:[O1PW]C:8I&6^PVH.3_ -,DSSSFO)/V
MA->T;PI\)?&>KZQ(EM:1^'M81Y-@;]Y)I\ZH,=\L<?CF@#\:O^")^J6>I_\
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M +)WP/EN582S?"WPM(NYCDAK($<GO[U]?P+F*:*3Y6<2 9Y^4HRDY[<'OZ4
M?@]X3\1Z;>?\%*? MNOEAXF\5("K#.%=LY'K^O%?O+'.C"9QC < <X'_ .L_
MSK^9KX76NIO_ ,%4_!ZL)3!]L\9!6W'9M\Y\'TZ<C_ZQK^E"\BDLK.1R21N4
M_*>>H&>.M 'YB_\ !9[48K']A'Q]/+C:VL:#C)P#^\N>_P"(KW'_ ()Y7D5_
M^RE\(YH /^1%T?&WD#]V<COGO_\ 6KY!_P""[8U6X_X)[>-GTN-W<:UHI<!B
MI )8IG\=_']*]W_X)3MJ*_LD?"*+4U=)V\$:.0K,7! C;/\ DT ?IA&!M0G[
MP7'^/%?R[_'+;<_\%S?V5 O#+_PEPXY/%H?3////'I7]02[O/'H 0>?;T[\U
M_+]\4+&\3_@NO^RT;F,!#_PFDL8+!LH+(D''T&1[?C0!_3GI2O'$5.?OMVQ_
M%[BOG_\ :\D:+X$>+W4!B%MQ@_62OI,O$CK'@!VY50,9/^?\\5\A_MT^(X/"
M?[-?C?6KO_4VQLPV1N_UAE &/?% 'P?_ ,$<9_-\)?'5VC4,OQ$U7IGM(^1^
M.,5^TPVJL06($NN?RZ?7\:_G)_X)#_&V?3_ OQQNY;!UAN_B!J4]LZ*?WD;O
M)M; _E[5^V&D?&*]U3[,UOIS-&(P78@C!(!''?/UX^M 'YK?\%4=#.JZKX<F
M*$&!])QC^("X0\_TK]3/@$WV3X.?#2U<?>\.6:YZ$;(E/?C^(_C7X;?\%;/B
MUXIT"ZT+QJ-'F7X>^'Y]&B\2ZPK$+9-+>(D8,/\ &68[3CM7[4_LK>*]'\>?
M 'X8Z_H\_P!HM9_#=@PD*[2K-"KG )X^1D/X^E 'NFIV;+INJ>7*^][*ZQG'
M7RG88/Z5_.%^Q-'>W/[;GQ6GDW.+3XHWD:D\\ R]^G/7KVQ7]'.H6<GV+4F,
M[!397?1CQ^Z8_P A7\_W["=N(/VN_C0)P@D;XIWAB;(9G'[SGUR* /Z&$G!:
M4-P$?:/P)'K[5^7W_!6F*W_X9!^)XP \UMI/ISG48N1^>:_3.=XP)UW8<R'C
M;Z,>_M7YB_\ !6>WGF_9*^()B!*BQTC=@XZ:A'C^O6@#V[]@"$6_[-'@5EQD
MZ%H__IOMZ^T6<S1RQL, P2KQU/RGU[U\9_L%I+#^S9X&28%,Z#I#+SGC[# /
M\?RK[-NI%M[&XN ,[+=V'&#G;@?KUH _GZ^+^E?8?^"G_P  VC8_O[<2,".
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M?P*NE!QFVN.3[1/T_*OUIB94\R1OE0G.>GI7X\_\%@[ME^!LN 0KVL[(P/!
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MZ>J^M '[#?\ !MM^QEI7P[^&_C7]H#5;2^@\0^*_$_VQ9;N,IYD.J!KQV3<
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M=N9-W7C!]/I]>E?@'\,;'R_^"J_A^8=!X;\:'I_TPG/XU^_18!7)X&\C\B*
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M\5^)/_!#/4--U7X,^*-1L)"RW6O7,H&, [M^?TR:_=8.9UE ^7:VT=^Q]/\
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M96&,^Y]<>]?SY?LB_M#_  ?N?V[_ (A6EIX@N/-_X63=*R&# #_O>!Q_GUH
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M*T*W56:[;)VQH!W..!C\: /U098SL6%5 9UW8&.,\^H_^O7\[O\ P3]:9_\
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M(;Q'P1XMRH69=%NRQQR3Y9(.?8_Y[#\8OV [B5OVOOC,CSNQ&F6FQ"?ESM&
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MF517[5EW6-G6%3(J.RC/\0#8'].E '\^_P ,8(O^'R?[0C>>1(/ GAG@,/\
MGI!_^JOZ 5,,9S),S,X5=AZ'*C&?QX__ %U_,I\+?$?B#_A]Q^T-;FR'D'P/
MX44-YA(YF@R<=.F.W7FOZ;"/,8'R@7$4; 'KG8#R?ZT ?'/[=]Q=6O[.OQ*-
MC$K _#_Q7P>V=,FSC/?_ !KYD_X(PSS-^PWX/EN4'F'5=2^0\C)O'  Q[YY]
MN_?T;_@I5K_C33_V=OB2FAZ*ERJ_#_Q6Q83%"Q_LV;/0Y'&./_K5\]_\$)M:
M\3:M^P?X5?6=*2VGBU/4&C4RE]S-=7!()/\ =*K@YXSW% '[0,\DMI<>;$BG
MR),#''W>G;_]=?BC^S.ZS?\ !4;X\Q @"+X=:8V!C_GJF/7T_P YK]4O&GB#
MQC:0:A]CTE65+:0AQ*02-G+<$?A[=J_"7]AGQIXCUC_@K1^T1I^HV B,7PRT
MISF4MG,R@XR3C&.W^- ']'6Z!V>.-OWD9+GTR#GT_,?6L#Q7FX\'>(T(#-)H
MVIH%QUS;2 ?J:V7C2-FDEQ"9&8949/)]O7\:SO$+)'X:U\1?O&32;]@AXR?L
MTI Z]"<#_/ !_/E_P36U^0?M^?&;PM*55K+P%?7(B+#>"=9(SMSGH>>.AS[G
M^AVU,\LC7!0#<"H'1<#..O<G!]^E?QI?L%_$7XSV?_!:#XYV.E>%$N-#?X;:
MO%O-XZH%&HSG=LS@D 9]B 17];>I>)?B!%H\+V_AR'SWME9E\XC#E?7/4=>O
M4]10!^6?_!:.=H/A]^S26BC&[XYZ>IR5 0_Z#C'..1SQWK];_AY+%)X#\&LT
MI0'PYHORJ>"390\#G_/\OYN_^"XGC+XU)X"_99!\+QK _P =+(&07C?-^_M@
M,\]E('X>]?OO\ [[Q5>_"7P/-JFE1PW1\*Z0^PR[CYHL8"!N))Y/ /I0!ZW\
M1?E\ ^+-HW*?#^J!L]-OV.;)/Z9_*OY^?^"6\VGG]K_XC1V(A,A\/^(O-92"
M0!J,^>AS][ Z?I7[;_$_6O&@^&WQ CBT2,RCPOK1A_?'.?L%QMZ<@[@/?WK^
M5W_@B_XB^- _;T^+46I>&(VLAX7\7-&)+UBI8:I=&/@M@=L>_P!* /[#Q'*8
M]CKY&UMR[, NW7:?9O?KS7X2?\%[OB%9?#KX#?LZZAJDRV:ZE^T-X=TGY59V
M#7*@\+&K$9"AB2, G!()K]9]'\3?%>75+G[7X5@$*Q#R0;HD-(%P."<+D\5^
M*?Q^N4_:7_:@U/X-_M26$'@_X;?#^S'CGPGJ$BKJD5WXJM)0L%NMM,)(XI/*
M0,LJJ&&< \F@#]H/V7[VWOO@'\.[[2'74H;K2+&3S'.6 >&,N=IR04Z\C@&O
M>W5_M,X>5_*\H;DSP,D9!^G.><U^1'[.7Q=^(EA\5M4^'/PT\.IK_P .-$T=
M8M%U.6Y:WCG,42@[;8$)'C ^ZHYQ7WW;^,/BZWA^ZDE\%VHO3O4@W1)VC<!S
MG/- 'XR_LZW5@G_!<7XUVT-RKR?\*ZU8!-W<VL_ZY_2OZ)8(-@#&9B&)R&88
M([#_ #V[5_''^S+J_P"T%<?\%Y/C1<1^"X/)'@752=U\P4*(I^OS= I]??IQ
M7])=UX@_:(>&+RO!4($;AGQ?D<#K_%VYH \I_P""J65_9KN$$:"'^VHCSC&X
M1-MQ[G)KD_\ @C"7?]B#PPK(!$OCCQILQTYNX=W/L=OYUX-_P5E\:_&"#]CR
M"<>$(/MS>*+:.4?:SD*+?DD[O4MCUQ[5G_\ !%OQC\6)/^">W@^<>#[<W9\?
M^,DQ]JYV->*6)^;D I'U/0]>: /W'\4GR_#FMG:JXTZX/7&?W;^IZ_XU_.7^
MR/J"W?\ P4[^(T$FI36G_$JOUV1MD 88<8_#O7ZY?%/Q=\>6\':S_9'@FWFF
M^QSF5?MI7;%Y3 G(([C^OK7X'?\ !.*_\>:O_P %0_'Z^+]$BT^4Z7J)F F,
MNW ?G))S_GUH _JH\,V45O;LT%[+<G)/[P@YSGZ]:;XPEF;PEXD!3]XNDWIP
M >GEL/;^')K;@MAIUM_H\:L<D[<;1TZ<8'TZ<>N*YOQ5<7#>#_%,\D(1ET:^
M*@'()$#_ /UO04 ?SX_L77*'_@J#\2XY=HF/A*TP20#RJX&"?Y9.:_I!9FCR
M6(5"3@\9Y/7D^E?R/_LR^(_B$O\ P5I^(RZ%HB7-NOA730/](**6W)G.&P>,
M#\1]*_HU\1>)_CE+]@2S\%P-']NB\YA>%2(<KN. 1D8]N,T ?B]_P6+OH+?X
MJ?#/%T=__"P? &8V; !.I1#')Z#G%?T6^&?](\,>'&+(/^)'I)X8'KI]N>H)
M%?R)_P#!>G6/C:?B9\-#X5\'6]Q.?&_P\.%O#&?-.H1Y&58<Y[C/Y&OVV^#^
MN?M;1:7X;&K> XDM?[#TGYCJDC#'V*V'W2^,[30!^C/CZ>!/!'C5#*9'3PQJ
M[%3R !93 $=N&(_G7X)_\$V[Z_N?VL?'8?:8!;S 88=?-8'*YSP*_8/QMK_Q
M+7X5^.6?PA;-JO\ PANKA(_M)YE-FRD;L\XR3^&>@K^8C_@FWKW[4UO^VKX\
ME'P^@.D-"P#_ -HOM"_:27.W=C[N>WYCJ ?V(+=6BW;VP54FPV3T)QG/)P.1
MD]?Y5^7G_!6#5M-TGX$V,EWJ(M%_M> .B.IE,1D4LWE+F3:1N&[;M..O!KZW
M\6^(OC*^D33Z3X'M&U,(!M%T58G;\WS YQN..#SCCK7X;?%"7QOXY_:X\7Z%
M^U))<>#/AA9^"$O;"$32:E9->1VWF(RVDA>(,[]6"YR2: /U7_X)^ZU:7/P%
MLI?"K0ZE ;V#S7+J'R85$F4+*WRC<>G7-?=.I2K':W;0 O/)92^;;G[B@I\W
M0?PG/X"OYS_V'?''Q)N_BW?>%?@Y:2ZY\+[>&XE;4#<O:1B2*Y>-?]%5E3_5
MC.=OM7]!_BN]UBR\&:H^DZ='>Z\/#L[>0S[/]*^R$%?,ZG#GK[ T ?AS\%=7
ML;/_ (*U^);96A5I/A;$2 RY!:Z&1U^H_K7] LHCB;SP%W="20,Y[CISGW^@
MK^*_X->(OVH9/^"POBMAX#A,*_#4>6QU&3E1>G'\1 X /_ZJ_IG;Q-^TI)'&
MK> X 04S_P 3!B3CDG.['L?I0!J?MX7-O!\$M3FN5C*M:ZH@$A&W/V)\8SWY
MKP/_ ()&SS2?LX77[I1$?$5ZR;>A8S3<9''W23^'2O(/^"@VN?'"^_9[DL]8
M\+QZ6FZ]W7$-ZS.<P2;E.#G[O.?3CI7I7_!'*+4;3]E4+?IBX_MZ5B"V[EFE
M!Y/U/7TH _5EYDAO3N0 E!S@CMGUK\E/^"SKA_V7M 9<8/C_ $K&!Q]TBOUV
M?RP_F2J.$!/&>W^?\BOR(_X+.LC?LNZ T?W#X_TO'&.@8']<T >S?\$P/^3:
M/#GT/\EK]%_^6W_ :_.C_@F!_P FT>'/H?Y+7Z+_ /+;_@- $U%%% #)!E<?
MYZ&H8D4*N2?O9'UR,=O4U.QP#GT/\JJJ21&%Y'F GVP>?KWH _@*_P"#KR[-
MO^T)\&0HQG5?#O;_ *BNGYZ5_9C^QPEOKW[*?PGTBZ07,6I?";PI974#C*O;
M7.A10RJP[@QNPQZ'FOXR/^#K:W+_ +0_P9+#IJGAWJ/^HK8>]?VC?L3116_[
M-7P=DB^:9/A9X/81G@'&BVYQGTR!W_QH _@D_P""_P#\#/%__!/S_@I1X&_:
M7^ >GWW@KP/JWA[P2NO:MI<;6^G/J$OB"Q?4_.DC 4N8&D,F?X<YK^^G]DO]
MH+PG^TO\&O OC/P=K-IK&GR^#O"DFIZA9R"5?[7ET:TDO(6<$@,)S)N&0<YX
M[U^<7_!;C]A:\_;^_8\U[PQIEG!IWBWP^FM:O!?)"LMR+32+">^B42%2X&ZW
MR.1C.?2OPL_X-2_V]XKV[\3_ /!.GQ5)/)XY\._\)7K46J3S-),UIX)O)[.:
M! Y+#<EOC ' <=,T ?W1*-JJ.N !GUP,4M,C78B)G=M4#<>^!U_&GT %%%%
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M1N[>!7C@BN[J!7E"+(%;Y6/&1VKVJT$-G*;%KAYKJ<^<N_DHA(X!&0!GCK7
M_#7X8>&_A%X!\.?#_P +VMO8:/X>T>RTNWFM;>.V$RVD0C20Q0A55I.IQP.E
M>@:?;-;PR33('GWX21N7V=OF/..^.E &Z.@HI%)(!/< _I2T %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5CR/*+G?.S16Z@Y.?E&#D<?2M@G
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M["X0Q:C%*$#G!VDC:P[@^U?LUH>X:3HF.@TNV]S_ *A/_K5^;'_!7/5&TO\
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MH!Y"?:D"]SG@MP*^I_\ @GZ=,MOV<?@]!'=.UW-\,?"#R*1U?^S8MX^N3ZT
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M?I0!^F\!N/M$WF1[8SRC>O3^F/UJ[52(3">4,#Y?&T]CQ^G]:MT %5Y_X/\
M@7]*L5!,,E!ZD_\ LM #V7<$SG@K_*OB7]OL&3]E[XY0#_EI\-O$J>_S6) K
M[6E.#&O?(_S^E?'O[==N&_9@^-TC'Y4^''B-N!Z634 >)_\ !)&W:W_88^$=
MMMPL6G/M)[YD;.>OH/SK],%?"L.NT9[_ *_6OSB_X)0R"7]B+X3,O3^SI#^
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MN>N[GWY!%?A)_P %]I4A^!?[/<C_ ,/[0GALC_OVGK0!^DO['/@71/#?P*\
M7=IIUL-9FTFUDO-;\I#J%TTD,;/YT^"S[B<'G'UKZVE54A=N IPI0 ;3T.<>
MO^)KYZ_9,O([[X"_#^15P/[&M1P?2"/KS_G\*^C+A0T+J>F!^A% '\[W[.K6
MR_\ !;WXV1111K(?AUJ[%E0!C_HLW?']?7UK^@V"WE2\=#<2,G4J3U[GM^'Y
M5_.U^SHKI_P70^-B[N/^%=:N2/\ MTN/\*_HP5#'=R2'. GIC/7\._Z4 ?F9
M_P %:+07'[+=W&J#;%K<,H4 8!6&3'4'NQ)KBO\ @B-*TG[ WA)Y$4;/'?CU
M0F!C:FH6H''3/6O4O^"H*)=?LO:FS9XU)2,8Z^7(/Z5YG_P11CS^P7X6C4]/
M'GC_ !G_ +"%M0!^HWBF6%O"NMO*1$DMA<1%E7H&C(SCU +'VK^;[]B[0HK?
M_@J_\2OL=])-!'HFHW&-P ($;NZXZ]NW/\Z_I)U>R%[X>U&S;GSK:6->!]]E
MV@C/?GC]*_E-\'?&*R_9E_X*]^-=-\0)&8-4M(K!FF9HRJZFK+E>.2!T ^M
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MG_'FGTBC &![_B>M+0 55F4-!-&PY:*4CO\ P$?I5JH)ONO_ -<I/_06H _
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MG_M.-++(P_X7!KF=^>F^7'7WY%?T=72>9*D+Y>)AEE;E201SZ9&>* /Y5?\
M@K%I/[2>N>#[/X4:A'KG_"+>-7T%]6BEU@M:,D=]%+B:!CM<%@#@CJ 3TK]^
MOV&O ,'PS_9E^%V@*JK=2>&["6=5'_+6.VCC*DCJ0J@Y[YK\X_\ @KL9(KKP
MS)"[1LAT<*R\8_TN/^G'TK]:/V<U+_ KX8NQRX\+V!W=_FB.3G'7@4 >KR,D
ML&HLQR\=G=@ \[1Y;=#[8'05_/I^Q_XF@'[9OQ3M,D&/XEWBXQW/F<?G7]#5
MW%&EA>%% 9K.XR1U/[ELY]<GK7\X7[*M@8?VZOB RQE4E^)%R[C!PYS(<_F:
M /Z0TCS*TGHQY]1D_B.GZFOR2_X+5W!M/V$?C+>1LP>"RT7&W.?^0I#T-?KJ
MIR6X'![?CUK\G_\ @LIIPN/V%/C/O'F1FRT?*G_L)QX'2@#O/^"7>KRZE^RQ
MX",K,Q3P]H6-Q]=.M@?6OT7F10YSR3#-QCI\A/T^M?G3_P $O[5;?]ESP8%3
M;_Q)-#"@#H/[/MS@<?CQ7Z/R@>3(V.1"^#_P T ?S@?'1W3_ (*J?L^Q6[,J
MS6X+JIV@M]J?E@?O=>O7FOZ/7E59HTQEF#8^N.Y_"OYR/CM:F?\ X*N?LXS*
M2@6S&Y5Z,?M+GG^7U';%?T>,JEE)4$\X/<8H ^0/VZ8#=?LM?%:$C=NT6?(/
M/ 4_RYK\RO\ @AA.C>%_CO;!LF'Q'HX([ "UE4\>Q[?6OU%_;:N(K3]FGXG/
M(H93HER=K?=/RL.?KQC\Z_*C_@A)<+<Z+^T4X50/^$MT?:!V4V\_'TS[4 ?T
M ,L8EBSUQ\OR]>#^73]?2OYU_P#@K7.8OVXOV,C"<SCPOXA(4<$_\3FYP"??
MK]!7]%P4$DX&X$@$]O2OYQ_^"M<+_P##<7['<XS\GA?7,9S\O_$UF!P,?4]>
MM '[\>"YKR7P9X31HRIET2Q+G=R"(5ZGGU'XU\H?\%'- C\7?L@_%GPO@//J
M.@31+&1U8*3UZ9SCGFOKOP$0?!7@\D DZ)8>YYMX_P!*\$_;7@63]G;X@D*-
MPTBXPP'(RAZ?E0!_/+_P2%^ _P 8-3\)?%"RT_Q7XDTFST:33;:WALM8DAB.
MU0$"QKTPBL%&/NY["OU\T3]F'XWIJZ-J/Q%\:+:7$S$A]=F9/+(X^7TR>G:O
MG+_@BGYPTCXTQRNSK_:FF8#9.!AAC]37[HR)BXA(Z9Z4 ?R??\%9/V9?C+J.
MM_#GP0OQ,\:?V3XDTO5?.@&NSBUD$<C+^\CSM8C'&>G/I7]'_P"R1X6D\"?L
MR_ [PE<3-<3>'OASX?TN6XD;?)-);VJ*SNX'S,[<L?6OS*_X*WWC6?B?X/31
MG9-'I.ME) <,G[^7IR#[\5^L'[/LS7'P1^%DTAWM+X*T5V8\EF-K'D_4]3[T
M >OJ1(0W'RY'3/4>I_SU]:_GB_X)U74D/[9/[3L&6"GX@:TH4GY6VWOIC_\
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MX+KQ_P#"SP1XMFE3]Y/X@T&PU*6$>TEQ \@SC^!U^M>SLH8$,,@]0:0*H7:
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M@@\&OZ<47#$')4XX/*XSC\Z_FB_X+-VT9_:#_8ZVH-L?[0?A-@H''^LB^O-
M'[W^'O@GX%L;.RF;0-'8W&GVP):RC.&,*G/0\D-G.:\S_:3^$O@J']GWXMK#
MH.D)-_PB&H.LB6<8965#C#8R"=X/MMKZSTS#:;IH(&/L-J1[?N$QC\J\<_:5
MQ#\ OBP^-^/!NID[N^%7'\Z /R*_X(R^!_#_ (<\):G?6.FV-OJUSJ6MK=W,
M,"I<2HLWR+)-U8!2, ].:_>"!QY*E^,D]?F_D#7XA_\ !(+46NO#6K0F)$$>
MHZT 5SSB;OD#]*_;V <D8XQTQQUH _GX_P""Z5[:VEQ^QZ\F-Q^/'A+^ L<?
M;R5[=,?E7[J_#JXBNO!ND2Q<HUM%VQ_RSC[5^&/_  7+%LUW^R")HDDQ\=_"
M?# ''^G'L?;I7[F_#ORQX.T<1*$3[/%A5Z#]TGI]/TH N^,EW>#?$2^NEW8Z
M<?<]*_%']AEF7]N[X[P'(V:-IQV@\#=&.PXY_P ]Z_;3Q@ GA7Q".RZ7<GGG
M_EF37XB_L-2B3]O[X_@=!H6F]!Q_JP>>?7I0!^ZL3'[7*O. I^G7T_STK\C?
M^"NL8?X9^"21P/$$'.,X_?5^N['.&P 2^"1W ]:_)S_@K) )?AAX4SSC5X\>
MS"48;IUYY- 'U#^PPV?@%H/?$C8/K\B?X5]@1N'G;_9R1UXXQZ5\9?L,1R+^
MSWX;^9LF[8,?4"-1C\<C-?:2A0_ &2.?7.,G\: /Y=/#OB5K/_@N1\?=/5Y
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M*Z#<J--MGV3:="XPT$8)^[R2>3DD\<8%>;_%'X3?#_1_@E\2K#2?!'AN)O\
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M_3G</8#GZ\5\N_L=F.T_9M^"\4A"M_PK;PV,=R1:#TXKZA+QM$?G&TJV2,\
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MKD)(<(Q^7CM@>G?ZT ?,/[9MDNH?LX_$R%S_ ,P2YY/(P$<].G';_(K\IO\
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MO&W@;XX_":S(NKCQ*^H^,O[//V&9K-@A_P!(DBPUP"P/#G\!7Z<?LU_$2_\
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MWSCK7XU?\$8M?TSPQ\ -*^"6LW#67Q%\$:1%+XCT"X5XY]/C:XE52V_"M\S
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M-0?Y5_,;X966;_@N#\?EA3>8_!7A,GL/]? >N<'KV[5_3LK;(%+\8B4M[?*
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M'TKA_C=-'_PICXIREAL'@#Q86;TQHE[GK^GX4 ?AA_P1"<>7XF4<YM-;]?\
MH.W'M[5_0U&Y,Q0]%4$>Q/6OYW/^"'<GGP^)9H_FA-KK8#8(Y&N7/&#[GCCI
M7]$J!=[$?ZS 'X?Y]Z /P(_X+YHY^%W[,81O^:[68/\ WS8U^PG[-[&#X+>
M5?.3X?TH ^N;2$_R-?CW_P %[;A+?X9?LOFY.T/\>;-%XSES]AQQS_#@YK]B
M?@*A/P=^'^P<#P_I#<=@;* _Y_6@#TKQRN[PAXCQ_P! >^Y_[=Y?\17\]'_!
M-E-O_!0'XK<_\RCKO;TOY1_6OZ%_&4T0\(^)26&(M$U!GSV M9.?TK^>/_@F
MK?VEY_P4 ^*S6S[P?"?B  [2/NZA-GM[&@#^C^4_O%'IC]37X4?\%[_^2"_
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M='PNEZ6N>?[/M<<?],(J\_\ C=Q\(?B6>Q\&Z[^EA-7>Z2P_L[2N?^8=;?\
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MZHWEE<;#G(QQV_'O0!6LH8[;,2S/*V23G\_S_P *T:HVZ2+(=T8 Y^?N>O\
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MW.WW].13AT'T%1SQF6)D!(W8Y!P>"#UJ0#  ZX &?I0 M%%% !1110 4444
M(>ASTQ65<SP1P$Q*/]9@@<#.[\N>H_"M8^_2J,ZV_EG*KMW9/!QNS@?Y^E %
MA?WL:-DKP/Y#]*_SUO\ @XMBU&\_X*I_!BQ+.;1KWP=+LW-MPLD97Y<X],8[
M=:_T(V+YC\O.WCA>,CCK^'>OX#O^#@-(9?\ @J[\&%D(9OM'A+"GG[K1X'MC
M% ']Q7[.T9MO@%\)HCU7P1H/MULT/]1^=>X'E #T( S7C?P+VK\$/A:.F/!>
M@X'M]BC_ )<5ZU<NRQ(0< A<X.,\#CZ4 6T4*,#IG/YTZF1DE%)[@?R[^]/H
M *JW$ZVT>]SD,V"<>O!JU63*RO<BT8[T9?,^;G! /'H#GU]OI0!^*'[7OP,\
M>>$OVL_"'[3W@^:>YAT2W&F36Y+QQ^7J8*2CS%(X4'[N<$<'BOUL^&?BUM?\
M#:1J>K+]FN_(B2?:2Q+[1G+'W_E72ZKIFF:G;MI.N6-M>VSR"55NX5G53&<H
MV#Z?P^E.N?#-C_9 L-.CCM(=P8+;J(U'<  >_'^/- 'R_P#M4?'*[^'WA2[T
MGPYID.HZEJR_8U#N8R([A"CL"O4Y_P GBOF7_@G7^RM;?#[3_$?Q.\10)'XC
M\2^+=4\0PJ8$W1Q7[%E"RE=^.N#FOT+?X9^')M0AUCQ-86FJK;IY4<6H0I=)
MO/W7"MD%E/()!''/%=TL5OIR0Q6-K!9Z<$01QV\:QQ*@X "( !Z<?E0!IE1Y
MGD[O,C<[SGMSG;CT_P *_+'_ (*_0/K_ .R=K'A:UC#O-XO\'SGC/^HU-6X&
M".,G]>E?JQ ( !M8,QY!(.<'MS7C?QL^$FE?%?PM-H%_:VUX)+VSN_(G164F
MVD\P'!XRO4?GU- %+]FM3)\"_AY:R*%:U\-Z7;,/0QVD/Z\D5[-=E$L+OST#
MJD$O&,@@(0#CZXQUK+\,Z';^%?#FG:-9QI'%86T4"I&,*OEQA< #I@+T]*Z#
M"7$3QNJD.A4J1P0P.<\?C0!_.3XCN;A?^"R?PRU:"T5;"#PA;02. 0-^Y >1
MQDAO6OZ,?*59&$9"K,Q9BH&=Q.2??.3SWKYIN?V</"<_QJTWXLMH^G'5M/M!
M;I?&W3[0@4Y"JX^8#@=/Y<5]-,Q<$1J.&XP,' R,Y[4 ?!__  45.W]F'QM8
M6\0FFFCB(!'4ESG.,GCU]^*^:_\ @CM%)9?!SXA6%[;+!))XR@G  (ROD.F,
M$>KAO\BOU5\9^#-#\>:%=^&]?L[6\MKQ 'ANHA,C!>>0>N,X[]!["N>^&/PM
M\*_"K3K[2/#FGV-@M_="[=+.!85=U7:"0O?ZT >H"W5-S,=X&XJ&Z  9'7T_
M2OYL_P#@HG-?)_P4_P#@/JMK:+-;6'PSM[>20@_>EU438)'IOQZ\=J_I&B>5
M9O*E!*OD\G/7/]>.]?-WQ&_9N\)?$/XM^'OB/J^C:=<WNBZ2NG1W<]NCS)&D
MWFA0QY '& /;'2@#VOPU=K<^$](N88@DATRQ8X ^\T*[NG;I1J]XR^$_$US,
M!OBT/674'N(]/N&V?B5QCVKH[6WMK.*#3[>.-(8HEB5%7Y0L8   Z<=NG _)
MEY!;30W.G21HT=W:W$#(5^5Q/$\;JP]&#8([YYQ0!^$W_!%NY<0_M4OJ=HD9
M?XMWSP[@3NB-_<@#D<=0>/0#FOWG2./R\(H5' ;CMW QW_\ KU\X_ /X#^&O
M@K%XRM]+TJQTYO%>O/K$_P!GA5//=GD<N^W&26?)SW[D=/HYY-@"I@C ]1CG
M_"@#\"?^"RNI:HMSX4LM/M5G1M(A9N3E2VH0''R\<#/_ .JOV:^"-Y"WP9^%
MDHC19U^'OA0;<8*E=(MHW ./[\;G'O[UA_&?X!>$/C$MI-XATNPOI[2-8HC=
MP+(=@=9  6' #+T_*O7]#TJQT'2]'T.WABAATW3;:Q@BC7")%:0K'&J@=  N
M0* )-09TT;5KA_O?V;?LJ>R6LK8]?X:_F>_X)&66MZ;^TU\=DOM/2"VO?'OB
M2>*4;LE&U6=@>F/F!SU_GFOZ<9_),3B<#R7CDA=2,J5=65E(QW#$'L0:\1^&
M_P %/A_\.M6UC6O#N@:18:CK%Y-=S7-G9I#/))/(9'=W4 L6).3S0![.EL;8
MS3,[.#(6V'IST_#_  K\O/\ @K]'?WO['7B;2]&@62ZO-3T]MJY&T1RHQQMY
MR2Y!^E?J5&C@.TA++N) )R-N.A'6O.OB3X!\/_%;PK>>&-9L+2_LY)HV>*[A
M$D8,; @[6R.O4>U 'E_[)D4MK^S=\&8KN$+<V_PW\-12KW$BVH##GIBOIB!T
MDC9P@&T%3CN O(_$5S_A[2=.\-Z'I7AVP@B@M]+T^WT^"&) L:16RA%5 #P
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MI2<H-W&.C9[_ (5RWC#PGH/C?0]1\-:]'!J.F7YC6[LKR/SK:01N'"R1ME6
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MGTK]L'9(57* LBC:>G3L/P_2N3\'>%?"'A=+N'PKI&F:6LS+]L&G6JVPE=
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M<> /!EAK+^)TTG3EU$RM<FZ6U43F63[S[QR6)'->@PM$T0E4@K)EEX^7Z 4
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MB.&*J1D$<?7-9.HZ5I]]8W5GKMC:ZEI<D;1W$=[$MQ$\+$;E>-@=R^H[Y]*
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M+[IHT>)>4\S# /G(*Y/!Z >G- 'C?P%^'-U\-?A7X9\'W$SROI5M&"77&<(
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MY7PTT[N_VU9""FW 'L!^&?2OIA]KJT$G1X]I/^\,'(/YU6E20S;$4+$ '.W
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MH>';CPSK-]J##2R1?Z?;J/M#*$GE2.!NFU7^E?WX_P#!3_\ 8&\$_P#!0/\
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M^= #RNR-2O)&W^7I7^>I_P '"M[>Z=_P5I^#5W;C[01?>%(Q!(2$VM-&-WU
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M+#<8Q@$]_K3O)C[(%/\ > P0?K4M% $'D<@^8_&?UH%O$.2@9B<EB.2:GHH
MC2-8\[>YS]/:J7]G1F?SVD=CG[IQM^GM6C10!4ALXX&=HR5W\L!@9/\ ];M3
MX[9(RYY8R')ST';I5BB@"DMC"HE&,^:?FX''3@?E3H;18?NNQ'IP /85;HH
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M=4%M;?:$$ID;S/*3S07[_/GGWKM+.'R80GFM+@#YFSGCW/\ GC.>: +=%%%
M!1110 4444 %%%% !1110 4444 ,D*JA+8V]\]*<#D CH0"/I00",$9%+0 4
M444 %%%% !1110 55O/]2?\ >6K50R $X(R,#^= $B?<7_=7^0K_ #QO^#E*
M2WM/^"G'P7N+@+L_M+P-D-C!+318XZ]:_P!#-20X'; _G7^=I_P<LV<]Y_P5
M3^!L0+& W/@5RG4$J\39QZYH _O;_9MD2?\ 9\^$$MOA4/@/P_M"].+% 0/J
M1^M>S0K,+D&3( 0Y].G;UZUXQ^S*HM/V?/@_$1C'@30OP_T./COZU[><_:E(
M/R^6>/7B@!]NP9#C'WVZ#%3U'%C:<#'S&I* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<@8Y5>00N,XYH T:*11M4+DG QD]3[TM !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 !J@UM(90=[; 0>O^?RJ_56=)%0F,DMNSSGH>U $)F47J
MP%.2@(/7OQ_C7^?O_P ''7A3X]>+_P#@I5\)H?A-H.J:R]C=>#[N6WL;IH0;
M&R>-KF4A<Y")\S#OTXS7^@0A11YS_?&<$]< 9QZ]OIUK\-?BMI/@KQ=_P5,\
M%MK'A32?$UY;^%KRW%KJ$0DCVQ6VP7&&4YEBP'7CKSZ4 >P_"'_@HK\!?A#\
M+_A+X(^//BB3P9XKC\&Z#:2PWFG33)YSPP6L8>X P&,[*C'!Z@D<5^ENFZIH
MZ6%CXBBU,:GX8UFTM;^RNPWGH\6I1B>Q<1C[N^-T(XXR*_&__@K-_P $V=$_
M;"^![:E\*Y=2\%^.?#%D]W;2>%42*4#0E_M."W+'8=LLMJL+ '&U^/;YH_X-
M^O\ @HEXJ_:[^&_B3X1?%N+2U\3_  MU;4/ 5O#%(S7=S'X$N3HGVFX60D^?
M)]E+3,!C<3@T ?TN64BHH16:5+A3+"6_YYD':.>G&.#7C/QZ^)]C\&_A]<>*
M=0F-K$M_'#N52<E^0"!^!Y_*O:O-@CB$D8_U0\M!C@ ?+^G:OA'_ (*)0QZK
M^SG?J\C0M_;=GM9.#P'SU([;: /:OV;/C;H_QV\%S>(-.N3=I%=RVQ9D8#,1
MYX)[?A].M?1\IAAB)D V*I/(R %7M[<=/<U^8O\ P2\TU='^ U](DC3/_;EV
M2TO4@N<<C/I7Z;OB:WD9P,&)^/JAZY^M 'R38?M)>'=4_:$TSX.0W@:\O+'4
M;A+7RR%8V2-DGMP>^.PKZU5P9E"#"8/ X'7'0?C7X4>")'/_  52\,6XD?R!
MX:\8/L_AWI!,5[^N.>IQWK]V9%V,'7&%&/8'J<^GXF@#SGXH?$+3?AUX6O/$
MMXP1+:00[]F[!8'(_P #]*\T_9O^..D_&C0M6U73[C[2MIK5W8$E"-K0$_*,
M^G3\*S/VR1!_PH_7?,PK-=6K*0!G.)-W7U!'Z5\P_P#!+"*%OA'XSNRV]U\=
MZPBL<<*'8?IR!0!^GKPNDXN,D*%*E<_KCOV_+%?%OQH_:O\ #_PG^*FC>";Z
MZ$=QJ(A40F(D$RG;SCC///XFOMU\8!/3(SZ8K^>7_@HOJT-G^V=\-K#<$$]K
MI4C@#)8GRRQ(]R3CMS^0!^_?A_5X/$.C:?JML0([VWCF#@;<[U!''OG-3ZE=
M0Z5IFI7=PVY+2SN+Q]P+\0HSYYS^7YUSOPY\IO 7A,P *&T:R;Y>,GREW9Q^
M&!VXK5\8)CPQXED?E1X>U5><]19RMD_0@?KZ4 ?%7[+_ .U[X=^-^I^.-'LK
MLW<GAOQG?^'75XV.R2T8@H">@7&!_3BONZX@-PJO#(R\ A02O&!V_ ?TK^=K
M_@CK-#<>-OV@_MGSR)\=?$RQ!Q@; \N OX5_12JMYY*9V#</8'- 'R!^VQ^T
M+I7[-7P8U#XD:E.;5+#4-'LFN@A9T:^O$MPNX$'DL!WX]17N/PA\?:7\1O O
MAGQ7;[9/[8TFRO5E,6UF%Q;Q2[LXSSOR?>OR]_X+HQK)^PIXKB1BMP?%G@X@
MJ,OM_MN'=MXS@@U^@?[(\>GG]G?X3);!1(/!>@B5@ &\T:;:[L_H/KQ0!]%D
M-;07$K,6"QR2 'D812WY@"OA/_AJ32Y/VE-%^$4MVXFO=/\ /%N48JW[S;DC
MD9S^GM7V_=S/'%>1R_ZO['<G<>O$9_IT]Z_!2RN8)O\ @I_X)#/F >'\.O&W
M=YQY/^<Y- '[ZS$20R1VRX8,,[?EY!/Y].?<FGP,$58F;,S#..I]3S]#UJ9Y
M8HVQ\H)/.1WZYZ^YS5&\'EF>[4_ZBRN),#[I986(_+'YT >&_$7XV>%?"/B?
M3/!$NH)_;>K0FY@MEC+LR1DJQ+#IS7M*:@O]@Q:J1E?[/^T],\>67''7_P#5
M7XM_#>^OOCK^UXE_JMW*ECX7_M/31% V8FQ=RJI<$_>P#T_D1G]KWAM+*PCL
M9!_HBVZVG(Y\LKY?/U'Z]?6@#Y#\%_M4^"M3^),_PQUB^2'7KF:22QLI8"3-
M KE-ZMR  PX'/K7UE;2RQP3S,"%67$0S_ Q^7 [#' &, 5^#W[2.C)\-_P#@
MIO\  Y-#GFBTG7/ %UJ%_">(GNA?M'O^7@_*,\YQP/K^\5O.MY;6T:J%6>WB
MD!7OE0<Y_P ^M &G&%RDG W+N/'0GWYK\]OB'^T^/"W[9'PU^"$ES/')XHT7
M5+Y+12_E3"U9LLR@A25QU-?H2BF)0&/"D<GICZU^!_[2&L6=O_P65_9:M\H8
M7\ >)O/4CY6E&_)..^>GN3W- '[U)<J\!G2,!\ GY0#DXSC\_7UK@?B=XK?P
M1X*U#Q A8M;C<,$Y ,;']-M>B0M!*A\O;Y9"X(XR" >_Y5X7^TD=OPLUI H;
M<C !O^N4OI]: /F+]AG]J&Z_:(TWXC7S[[M?"WBK4-)+S9)C^RS>7M7=V&#T
MXQVK]";<M.%F<;64[0/7/(_Q_K7X;_\ !%&"YB\*_M"":$+O^)VOL@(/(-V<
M+CW_ /U5^Z*@!H@/ERN=HZ9'?I^7K0!\1_%_]H_3OA]\>O _PWN=0DMYO$5O
M=RK;+N*R>2"><<=1UYZU]E:9?1:EI-GJ41!6X@20-C!.[G.<9_\ UU^)O[:.
MD2WO[??P#>.:1(AI&I-(J$8),1SG\>@ZU^T'@^V\OPIH\ 8L%LH@2W4G;_/_
M /70!>U/4K&QLY;^=%+P12,'*;G4*"QPW4<=/RKXE_8__:?T[X^:_P#%32[2
MZ>\_X0[QKJN@,)%;]RUE(1L4MD87' _' QQ]H^(WL(-%U'[7M"&TFY;M\A'\
MO6OQ9_X([6%LFO\ [6M\'+L?C;XG:#.#MC:[(^7VV[OTH _<I25R6) !('?.
M.^!TZ=*^"/VSOVF3\ / VHZJ ;/&H:= LT(*R'[1.$SE>?FYR><U]UB4W$<@
M^Z%? (ZX/U^IK\'O^"S^N7=O\.3I:01J9]6\/[6'WV"W:DL>N<C^7:@#]EO@
MQXVE\>?"WPGXPE4YUC2;>[$C\LZR(&#]SG)/7T%>AW,DL>GWEQ&#))'!(Z(3
MQ\JEB>?0 FO"_P!E:(-^S7\'E5=I?P1I3.%[N4<,3Z]!^0KW6^1X=-OC%F27
M[%/MC/0_NSGCZ'O0!^-O[.?[:.O?$']JGQ/\);B6ZFM['QMJ&C"*65FA5+;<
M0@0M@+QG'%?LS)(RSK;B)0CY)/&#V'XX/Z?A7\O'[$]K=Q_\%#/'USY*F3_A
M:VM$C(XQN_I_.OZB9@XF63:,+G!]>G^?SH ^6/VTOC!=? W]G_QO\1+,/&^@
M#30)HB5DC-U<B,[""&Z8!(Z#ZU-^R9\7[WXQ_"ZS\77L;%I([0K)*=SLLT*.
M2">?XB?7G%>'?\%52(_V%OC++)&K?NM%?#>G]KVH4\]P"1SV)^E='_P3O\D_
MLX>%EM847S-.TUI-HZO]DA'.,_6@#[Q:,+$^T[6E^88X(SS_ #/-<-X_\<:'
M\,O"6J^+O%EXMGH>EQ&:[N9%\Q8U R"5XZG@8/KWKM'1Y)82K-M50&4>N.<_
M7^AK\Y_^"HVM7UG^QK\5(;&X:TU![>WBMY(R5E"O>0H2OOM8_C@_0 ^GO@3\
M</#_ ,;K'6[WP_=_:["REA\B81M&K12X9"H_VE(^E87[6WQD?X ?!CQ7\4(U
MD^S>%K:VFG\I2QQ+.L3'8N"W!.<'\:\^_8*^%]C\.OV>? NK0W4]W?\ B?PI
MH%_?-.58B9[&%VP5.>6)SGDUWG[9'AO0_%/[-OQ(TGQ$ VEWND[[D. 0/+)=
M.HQC<!U_"@"+]E;]HKP_^TO\.!XJT&X$]U:1V4=[B,Q/%/<P+-M)8^[ _P!:
M^GHH3$0NXM(P^;GD$=<GUR .M?C%_P $;-0AF\-_'32+%LZ;H/C+3;"R ! $
M*VLH''3[J#IT%?LW81RB>Z:7/^M;R\_W3W'MB@#PK]HKQ7J'P_\ ACXA\4P3
MSP'3K667S8I"CIA,\$<]FQ_]>ODG_@G=\>]3^.=GX_N;R]N[Q-)NHT#7,K2;
M?,? "[B<9&0:^A?VW)6'[.?CW( )T^X (Z8$9Y[=S^E?G-_P1:VIX4^,,H.6
M&I6A]ACS#C\P,_A0!^VY#?:#;O\ =ES@$Y[<<?EU^O2ORQ_;B_:&\4_!_P"+
M_P )_"VG7%Y:6WB.TU&39;3M&DH@+ %U4C)&!UZ<&OU@5$D$-P1A@ >/T]^3
MUR:_"G_@J+/&/VC_ -G9;F--G]EZR%+8!(+OD\D=SQU(Q0!^TWP^U"XUSP!X
M7U6X=C<ZEHEE=S.S$LSS(&RS9Y;GK69\3;N[TSP7J=YI\TPNH(Y/+:-S&X_=
MLQ ;/!&![G-.^%4V/ASX 50HCD\.Z?ZXP(5"CTZ8]NO:L[XRWL.G> -;FX8K
M'+A6Y&?)DS_(#/'!H ^ O^"<?QAUGXLZS\;[/6+R[O?^$=\2W5CB[F:81LMR
M(\*&)_#Z<5^I<<D,@>%U7$1VC*Y'' XQZ\_7\*_"W_@CA=37/B7]J:=^ _C>
M_D3&<#-\2!]!VK]T7C$=LSKR[X;!]>,X[T ?E'_P4:^.7B+X5ZKX$L=$U&^L
M+75!<BX6SN&@1Q&3MWJ,;N!W_/FOO[X#:W=:Q\&/ 7B2_EEFEU'PY:WKO*YD
M=C+D!BQZDXZ^WO7XR?\ !:'4I;&^^%C6X D9;W=U]'Z=SC%?KQ^RCYE[^S+\
M&_.&&G\#:86QGUEP?QZ_2@#WV"]@NWBCV*Q=6;E>@VD_3M7XF?LW?M4^+_'O
M[8_Q4^&D^HZI/I?AOXDZYH5O:RW4C6T=O9L B1Q$[51<_*OY8XK]N[>&"$HJ
M#]XHVYX_NG/Z ^]?S'?L-:Y9W'_!1/\ :!A58C(GQH\4H<?>R'Y_+\>10!_3
MFP#0!7 #N.G/)W>O\\U\3?\ !0CXI:Q\&/V5?B#X\T6ZNK+4M'6P^S3V<QAG
M0RNRG8Z_,O YQS7V@"[W$9(PA+  9]3STK\N?^"PFK/:?L6?$Z *C(YTT,#G
MG$K@9X/H?TH ^I?V+/&VJ?$[]G#X:>-M:N+BZOO$&@)>2S74K32NS$ -(['+
M-AN2?4U]4+/%YBVS8R<@#!YQR?IS^=?"'_!->\DN?V//@BVP(J^%8@  <8W#
MV'IQ_2OO 6JF=9R2&3.!QCGK_GW]J /P;U/]KKQ<O[?OA?X(1:MJ@L-3\?W.
MBQ60NY/LSQQQY">7G:$R?NFOW>C1K>UD:7+.68G/)ZX7G]?QK^34ZBT__!9?
MX<J0/+@^,-^C=<#$*]>V,>M?UFH[327$3#"+(4&!Z'&<^M #) [P*T9.?+#<
M<8P,_K]*^:]>_:2\(Z-\2-#^' ODEU74IEMY8/*+,LK$KM9QP#D=^WY5].S$
M0P2A1PEO*P]?E4G'X_TK\"_@MJ4GQ1_;@^(,^H7#,G@3QQ!96L*$% F96*N#
MT)QV_6@#]ZA&UQ*DBNRI&2"@) Y.,;>G ''TKXA\>_M>>'?AC^T!X)^"FOW'
MD:E\0M7BL-'5X6D\WS.@608"9R/\\5]P7"S+<1-&#L<GS,?08_QK\$?^"C<&
MG:7^WY^QAJD4GD7O]OVTC(N )&28(N_IG<H&: /WNGM(Y60@ X+#)'?ICGW/
M7I5J*!8PN ,@8X%9^E7;WEG'<$#+O(>!GJQ]/K5QGDWCC^^.A[ T ?CC_P %
M /CMXD^'7[7G[(O@K1-4U"SL/%POFU6VM+IX(+C;J$RI]HC4@2_)@#/TXK]@
M-/2&>UCF3;YTD4;NX'S$NJDECGJ>^>:_FM_X*HZ]J3_\%'/V$=,MQF*3[2)-
MO49OVZ=@?Q_PK^D?0+5[&S@\V1F\RWAX8YVXB4\9/6@#D?BYJ4VE?#?Q7J-E
M,\-W9:5<S))$Q219$C8@AQ@[AMX.?<>M?EE_P2^^-'C'XN_$#]HC3O%>K:GJ
M=EX6O=/@L(M1O'NHH3-+@B)')"#:#G'_ .K]+/C]!+'\(?'T\4C%SHEXRKGK
M^Y<#_(Y[U^+'_!%5KV;XB?M:"X4JS:EI2IQSN9V _$4 ?T$HT:&2,Q(L )'
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MNM.O(+AX6T)IDAD5UCWK$5R%)(STY_\ K5_5O$2T )Y)P?Y4 2%LG ]1S_\
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MR!HY&380H'RD'C([U]<2LWE2G[K!>#SQGWZU\@_MJV']H?LP?&/S99$Q\/\
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M-<=?=>,_E[5^"7_!/R\=OV\/C+"BK@(@Z'@%"#^E ']#L["/RE '+].G!/\
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M^"3][_:'P.\;R;0A3X@:PF!R/]:W].OKFOH[]N^9H/V=?$K@[<W]ES[8F_\
MKU\H_P#!'FX-Q\!?'63DGXBZUS])&P/IU_ST /UZVAT13QA4;/T[?Y_^O7\W
MO_!3>[.G_MI_#"\$*R,MKHR -C!W^6,_UK^D(_*8^2!M ^O3@U_.=_P4[LA<
M?M>_#5ROW;?1#G'<>6<]/SZT ?O=\,W(^'7@ZY"C<=$L6*=OFB4D#L.A_P \
MUT7BE\^$O$CL/^8#JK%>HS]AN"1Z<GVK!^%L>?AOX/0@G&B6/7T\D>M=!XO4
M+X2\2JHQ_P 2'51_Y(ST ?SQ?\$AM3^V?$OX\V?V=(E'QP\2#>N 20\O/'<_
M2OZ,SNBD:%1D.=^<XQR21U_SC\:_F_\ ^"/43+\4_CRQ7K\<O$G./]N7VZ?T
MK^D6<;6$O?[O3L<<^OK0!^17_!:N2UA_8B\4WMSAVC\3^$D\ME# EM9C523C
MJ#C_ #U^X_V1S:+\ /AD]NV3-X3T211MQMW:;:Y'IC'3Z_E\&_\ !<58T_80
M\7,\@C8^*O!W ('76HL$=^XK[M_8^M8Q^SS\+)%D+?\ %(:%CG(_Y!MJ?4]L
M4 ?1=W&S6.H"3[K6ET=YY(S&QX^GU[5_/=I&H1+_ ,%4/!&BHH99?#QE:8CD
M'SSQCKBOZ$]3G5;2]A'WFL;H@=/^63#CMT)/U%?SBZ"&'_!6CP.X8DCPZ01G
MH///:@#^D26/S)0I4;<9+>__ .H?UJMJ2;=/U$9_YAUV.G_3"2KC/O5]OWHW
MP<=L''_ZZJZE_P @Z_\ ^P==?^B)* /PK_8QC>[_ &E_&@$KPA-<U480XSB]
MF&3[U^[,ML&BVM\^-OWN>GXCO7X6?L2?\G,>./\ L.ZK_P"ETU?N\W*GZ?RY
MH _ O]N+7(X/^"F7[.>@LB@7/PSO)?._B4+JCC:/P^O6OWATM(UTW357&186
MN& P<"%#G\3GO[U_.+^WY?7,?_!6W]F>%6/E-\*+ABO( )U'+'/KS7]&%B7&
MG:2RY_Y!]KGZ^0F,]^] &TV&(C]1G\.1_GFOYY/VHK6X@_X+'_LOB&)9$D\#
M>)FWMC<N=^.?QZU_0XHSM8_>QC_/Y^M?@'^T].R?\%B?V7!Y:G'@/Q*,XY(P
MQ'8]_P Z /WSMXQ]C@7 C_<19P.AV+Z>]>$_M(9;X3ZYU& P#=\"*4CWYQ^E
M>SV=S-++"CC"[%P,=@H]N?6O&OVDBJ?"C722  &R3P ?*F'Y4 ?EE_P14OC=
M>%?CZ6&/L_Q-UN,CN=EX3D^YK]PFD9)8P%#*P'S=UY[?R/X<5^$7_!#^3S_"
MG[1.UMV?BGKZ#![_ &L@=SZU^[[K@1Y^\N ?H3_C0!^%W[;E]-I/[>?P'\IF
MD^TZ7J+\DCR]Z%L#V'3^5?M9X)8GPIX?;)S/IT,C>Q9!T[\5^(_[>?\ R?E^
MS[_V![[_ -%&OVV\$_\ (I>&/^P7;_\ H H SOB#:*OA#6=SG+PR$.<DKN1N
MGIWK\?O^"/5G%;ZA^U 8Y2^[XP^(F(/?-TW7Z U^P'Q1E:+P7J[+U\A_TC<U
M^,/_  1MOI9]<_:=C9LI_P +A\3_ (XN7(- '[JR*&(AP(P_S97KD=.GK7X"
M?\%LK.^/@JTOX8P?LVI:!M3=_K%:Z7#'WQ^5?O[-PZ,,Y X_.OP:_P""S\&H
M2_#X$(WE_P!JZ!LP1@C[4N.OM0!^KO[(OGM^S=\'FG7:Y\&Z:< ]%\OCI[@\
M?G7O.H@M:ZAM8K_H5U@C@@B,_P"/Z5X3^RD+B+]G#X.@H=W_  A6F$C/0;#C
MO]:]YNMIL-0/5A9W0_\ (+D_J!0!_)_^Q%>WJ?\ !3'QWIYNIGBF^+>N<EV(
M7.[MT_2OZSY(?,()8@<Y'XY'7_/%?R7?L3Q@?\%/_&W7GXMZUW'JU?UKT ?E
MY_P6.OY-,_X)Z_'*[@&9(+;00JYQDG6[13S]"3U]LUTW_!+Z9;C]EOPC=K.T
MLLNGZ69 V?D8V,1VY.?\]*P/^"PUB+[_ ()_?&^W)^5H-"D;/3 U>U&#G QN
MQ^/YU+_P2J1X/V9M#@D8[(H-,5<G(V_84P1]>* /TM3"A]I)9FY'3'^>:_+C
M_@K0FH#]E/QS):Q _P"A6F=K8W$WT S]1G_.:_46,;-[,2<D%<\C!)Z\=?UK
M\Q?^"K.H&']F+QE;2E LME:$ D#/^G6_09YYS_+M0!]!_L/VU[!^SA\.'O)Y
M+EI?"/A]D25BXB']GQ91-Q.!ST]O?%=9^UO;)??L]?$.SD<Q&?19 "HR01E@
M/H<$?2L?]CB0G]G[X81QX*'PAH.<$=1I\.._^>]==^T]'&WP1\<O)C:FD2Y!
MQ@X5@!Z9R?Z4 ?E[_P $8!MT#]HRT$:H8/'VG1B0 !I,6=T,MT/.*_;B,S']
MVZ!5Z;PP)('0G\B?\FOQE_X(_6X@TS]HMXE4"7Q]IY&".3]ENNF#TZ_CBOV4
M0S"8*_&22/?_ #F@#Y/_ &VHY)?V<?'Z!>FGW&.>WE-C^O>OS8_X(BW,EWX9
M^,Z3+@1:Q:1>H(W/DX_Q]*_3?]L=$7]GSQVCN2'L;G.[_KDP_3_"OS&_X(F%
M/["^.2PD%5UN  *0<,&?'3]* /W;ED=)(+=$W1N!ENF #QZ?U_"OYYO^"O\
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MVUY%FRC^)%ND3;@PV'SL]"2/3!^M ']$ERTJOL;B(]9 >5&.PZ@_YS7\]O\
MP5!NH#^WY^P_:(Y$LFNVN<@\@W.Y><?W<9]S7]"]PZB5=^-@8;N_.%/^?>OY
MZ?\ @J'H]SJ/_!0#]A:YLU&R#7[=IG5@IP+KY<@\GY,?AB@#^@'PXCPZ1$NT
M;@7&=V<D-C)^M;LC.(6<*"X0G'OCU]ZQ]!22/2HU?.X,PY(/1L=JUW#LBKC
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MU[?_ *S0!!Y/[XR9.(\E5_A]A_G%?RM:=J$T/_!7'XH)CY9?B#X:!&<C $G
M';M^=?U6Q99,MU;K_G\:_E1M(3_P]O\ B4<#GXA>&SD^^_IQTH _JEEA19Q+
M@;I" >.RJ*F;_7( ,%@P8_\  &(^OX43D!H<_P!__"E49E8GJO3\>/Y$T ?S
M Z!+;#_@J!\4X,*7_M?10'VC/_'VG4U_3Y"N,*><11CGOA /\:_E!T75)A_P
M5>^*4&[Y#KFB# ST^V1C^7N*_K"0_NXCZJ@S[%10!3O%\N,L">58$=!T_P Y
MK^:3_@E_([?\%7OV_$+MM;1X!MSP/^)E"<@5_2[J'^I_!OY"OYG_ /@E]_RE
MA_;Y_P"P1!_Z<8: /Z:%B5(E&-Q1<Y/7..N:^;?VMP8OV</BU*A)9_"FHM@G
MIB!^ ?IU^E?2QY0CU3^E?-G[6YW?LW?%<$<#PIJ*_P#D$Y_F1]* /QZ_X(FR
M/(WBQV7&Z#4^<YQ_Q,)>G^>]?T));*"Q;YP> K#( ^G^>M?S\_\ !%.)4C\4
ME0/^/?4OK_R$7Z?7//TK^@EF(D49X)]_04 ?-'[86(_V8OC6HA0QQ^"M1(0@
M;6&8\\=.P_/G-?D5_P $488VT_Q5<Q6L4)-W<AS&JC^/KP/:OUZ_;&9(OV8/
MC8[=/^$'U(G/(SNBK\E/^")=Q#/H?BWR]A(N+O[H''SGOZC^5 '[X+-()IV=
M?W;#$63U/;([<#C\:^9/VQKB"']F?XTKJ!^SQ-\/M9564;NJKD_7ZU].R*DF
M(8V+20-N90><=.?;//.?2OE/]M)XI/V7OC_+J/EP0Z=\-=<F21V51\D0;<<G
MIQCCU [T ?./_!*%;(?LWZ#):3&6-D7#$'J%P?ITK]/!%F6=E.=X.?8^M?E/
M_P $?KM=0_97\-WT01K.9!Y,RX(8A3N QV_S[U^K=SE$S'PSD_EU[4 <?\08
M'?P-XCB4!F.E7NW/ ),3$=?RK\0O^":EJDW[7?Q\1XE@GLM )8H.9/.U#RL,
M0.=NX-SZ8]J_;SQSYR>!_$,BDEAI5XQ&>!^Z;&*_$/\ X)HW,TO[7O[13)$"
M_P#PCJDGN6&H@J.@^\X4?B,T ?O!!%%!=37#'$\XQL"^@XY].WZ_3^8;]IFS
MAM_^"@_A'5;QFD:^\501Q0.-R0L+NW^9<YP<]<5_4%:L[Q!KB-5N%#%EXSP
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M_"#PTEM.TG^@6A.[J#]EBX.?4Y^E:W[1<2#X#?%7[7.\*-X+UH;@<L"+9R@
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MZ9_\MO\ @- 'XP_\%R/.C_92\("$%V_X7#X0ZG''FRG/X?I7WG^QT9U_9_\
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M%U$23B>-?+D^ROQG/^]SQTK\*/\ @GK\+/!>N?'/XK?$.\L-*USQ'HOQ&O\
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M3E1\=?&"\-Z/QQT[=*_J=_M?3S<0$ZKIA5PP4)?6YWG:V,#>,]_7IQ7\E7[
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M2W78\:31R!2X&<?(>I_"OUT*0P?.2IC;)2/'R+]!VYZ\]:L1,&B=Q\JD'&.
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MWQFOQ%_;^^ OQ:\>?%WP#XK\*^%6U3PS9^(-.F.H"X2,*\5W;NP\IAD?*C4
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MK73HQ<W,^AZK:Q(Q^_/)I]RENA'?S)S&A[D,37\!/_!,O_@E_P#\%(OV!O\
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MOP1]/7M49M.H#L Q)SP,'J/K_P#KKP70=/\ B9#<HU]I[(H'S$W6[D_CV/\
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MR[G;EO;BO1HO^"87BO7]*N=(\3_M-?%9=-G)6[+7L1VY7:>&N=O0GK7U_P#
MS]B>[^"/@*T\'V?Q3\4Z[):Z?%9&]O+VY,CM'P9 [,6.>O('3)]*ZSQ!^R9?
MZ_H]_I;_ !2\663W^2\]M?7"O$64@["&!XSQ_DT ?D7^S3_P1Y^'GP4USXE1
M_#;]JKXL7&L^*M7N[J]BDO+5=D[R[I57RK@$A3T)]!7O&G?L$>)=&\3?8;']
MI[XIWUY<3@RV\]_'A9,'C_CYS@<XSQG\Z]1^$/\ P3!U7X4^/;OQ7'\<?&NL
MPWMY=74D5WJ=XX7[00=NQS@D8  SC->T3?L'S#Q+<>*+?XM>+OM4LS3+ ;VX
M5%+ \!@YQU_3B@#\GOVK_P#@C-X&_:6O]'F^('[67Q;T37/#LDRV-M87]B1(
MTA;S0_FW6X;23C'X]Z]NL?\ @G1X?^#/P]\$>$M/_:_^+<L6DZ+;V=NLVI6F
MYE! &52[X/3C'X=J[?XJ_P#!'C7/B9XGB\6?\-)_$31+F">XG2RL]9U%(9#.
MY;:^PX^3/RYSG _'.T__ ((U:O<7VFW>N?M'_$.Y336C"PRZO?SB5(V4@;7;
M'\(&#@<T >O^!O\ @GO>ZSI4.J?\-2?%B5(S$T3+>1L.5SSBX[Y[#O7P3X._
MX(4?LX?##XZ>(?BAI/[8?QB'C3Q;XEU#7]4MGN;)$34[WF=5(G#X!QRW/K[?
MMQ\+_P!E:3X:^'_[!A^(/B'58P(56:[N9BVV)0HSEB1G'.#^-?#_ (A_X)/W
M^M_%2\\?'X[>-HK;4M:NM6DL8]3O1%:"<Y%O%'D+M7&%[<]: ,B'_@EK'K6H
M_:K7]K'XN/9)(=K+?0<J3GC%SZ?YZ ^&_M.?\$>O@?\ $WX9Z]X ^*G[77Q=
MA\+:R8AJS"ZLW8-"V4^5[AE/S$]>G;I7Z-:)^PE=:)9K9P?&/QHZ@YW-?7()
M_)Z\D^+?_!+JW^*_AW4/#]]\;O'%A'J!#27,-[=&5""3\AW]\\].F.YH ^3_
M -EW_@E#\%/A;X'TKP3\(OVN?B[?:)I$*VEDKW-LN4(^4;89@.HZ@=_PKV#6
M?^"2MQX@GF.K?M3?&&WTUW)9HYTVL"<<[IPO!Y'T_+V_]FK_ ()M0_L[1VMO
M:?%GQ/XEAMKA9@VHW5RSN!_"P?(_#)^M?<WB?X57'B/19=&'B?4[%) !]HMY
MI%E&!VP1_.@#\V/^"?\ _P $^/@S^Q'XU^(5U\-OBWXO^(NK>.?$%WJ7B>7Q
M,]MYEM?39\U8C"[9'S$?-SVXK]:)Q;FWNG2]D/E\,=ZY0D=OF]^?_KU\3_!#
M]B0_!WQ)XNUS_A8FO>(/^$IU6?4=E]=3R&S\[)\N,/T"YQP<9Z<8-?1Q^%5V
MMMJ,8UZ_9KALQ?OI.0,#\\"@#NM+TY7AGE_M"=D*LQ;>"0.<GKQT//TS7B^B
M^/\ PI-XYOO#L7B6:;4(;Y;>2T,\9".<_+@/GL<C'Y=:[JV^&%Q;Z8]J->U#
MS9(/+8B:3JRD'OU&<_7-?&ND?\$^XM#^+ES\4;;XBZ[/+J>JIJ=YI\EQ,(H'
M0EMB#HR'.!TY[ =0#]!;RYM=+E@::4F-R?F8CH.3_DUY/XJ\<^#(=7MVN-?D
MA>"0![=9$"G&/E*YSZ=?Z5Z'JGA%K^TMM/-S(8U7;).6.\8&,YZY/UYS[8KY
M/\4_L56'B7Q#+K[^-=6MW:X$ZVB/)Y)P0=C8Z#/&,$>M 'V'HMYI^JZ<MYI]
MXTMNZJP;(8 'D?3C_'Z;%I-%,)(XV)\O*ELC(Z9Z>Y_I7">"_AZGA#P__8D>
MHSW.8T0RNS9&Q0.,^N,UTNE>'VTY;A3=22>?G#$DE<YZ>F,T ?F/_P %"?V6
M_P!GC]H[7? 3_&;XCZ_X)U'P_87=KH;:*(6,T4[EI9',GW65B2/4]JPO 7_!
M,?X;Q>%+&T\+_'7XB7FC/8P)!.?(#?9PO[MA^\ Y'T'85]1_'S]C71?CSJ>F
MZCJ_BC4-+?2XI88!;[FRLAW$YXQUQQZ5[Q\-?AD?AGX;TSPK8:C<ZE:VUG%9
M/=SL?,5(5PK\D\L3^@H _.KQC_P3%\$S^!O$FD^(?CI\1;;0;JRFCNKH&(/%
M;,I#$;GVYQP,9'T%?+G[*G_!+C]E/X2Z]XMNOAK\<?'=SJFMM!_;,TL=NK3/
M&P*.Y3&XDCN3R/2OW;\<^#1XY\(:SX/N;J6RM]4M)+-KR(GS420<LO.21R >
MW\OGCX7?LB>'_AD]X]IKMU>O=K&K22(0_P"[Z%CZG\>?6@#S&7]@C1+V&.2'
MXO>.?LSIE6!C.4/ Q^\Z8]?Y5\?_ +1/_!(S]G/XCZCX7U7XG?&3QXM[HD=R
MND!HK=P%E),Q!8MCDXQD?2OVTLM':QMK>U2>22.%-F68C@8[9]CWZ_G7F_Q4
M^$MK\28M+AFNFM/L$<T?F)][$O?(Y)!)^G7M0!\!^&_^":/@:+PQX:TCPU\9
M/'G]@V%A%;VY01 M;1J!'P'"@DY'.!_.LWQ3_P $S/AG:!)=6^,WC]+4H[3B
M58&&P+AB=KN,$9ZXX'3FOT]\*>$!X6\/6FA07<EP+6TCM5F9B&Q'SNSQ@FC6
M/!L.L:?/:7,[.TT;)ND^?;N4C SGH/U]J /P<^!G_!(?]DSP[XZ^(&M?#?XS
M>.9-<\2W'F^(R(+9"CE]_! 7/S?WC7U;!_P2Y^&&G%YT^,GCV:4'>JR_9L C
MH,+(Q_3FOL_P'^S7H_@/5=:U73M4F:;76+7(5-GE'.[Y"!\W3'/<_GZ.OPV:
MWG:[BU:ZG<,'$$CML.W^'DD8/X4 ?C9^U#_P3)_92\1>"8;7XU?&+QI::$8+
MI<^3;L/+9&$S8D5API8CZ5UGPA_X)X?LRZ9\(_"-CX&^,7C*?P+X>T5(]%D\
MJ "33E=B"RKA5&XG@ 9Q]*_17]H;]F+1/VAO!L/A;6M2ET@)!/#YT,>]L3H4
M;)'.0#G..N:;\)?V8M(^%/PUL_AU9ZH^I6>G:5_9<$\R$&2/>7W,".,;L?7U
MQ0!\2VG[!'P4\4VTBZ1\9?&MO::>,7?D"%00_3=D@$@<XQ]:_,?7O^"<W_!,
M'P'\:?[7UCXY>+XOB/?ZW<,LAM;,RKJ3$>:5<1ELYZ_-7]$$'[.5E;V6H6UK
MK=S9G45 E$&Z,*0,=5 SCM7Q+K__  2;^'FN>.;;Q]=^)Y[O5+;4)-1$=U:^
M9NEE() D96/7JQP<9H ^8O#W[#?[)FIW=Y=6'[07CW8SJ579  1C(YP.WZ$?
M2J/Q@_8H_8IUCP!K7A+QE\:O%UWIVJ6Y@F$L5O(S!5(/RE6'?WZ=Z_2S2OV%
M?"6GVYC76'B=EP?)@ &=N.VWIZX_"N7UK_@G=X-UUF%]XBGDC))"O#OX(YR"
MH'Z_RY /SH_9K_97_8%\&>$X/AK\-OBEKYE%O)ISR?9K>.:-I&9V8!8U^;/?
M.#V/2O<] _96_9<D\3Q^"[#XJ>)KC6;N80*&BA,@EW!!@A>N?>OJ7P-_P3F^
M'7@36!K.F:D#<K/]HP+-(]SC.-S 9[]>?QKU+1OV/_"V@>-(?'=K?>?JEM<"
MZ2$VX :16# !^O7V% 'P1\0?^"-W[)6K^-?#/B+QEXGURY\0VNI"[TJ:[MK)
MI!=D##JQ#8)&.C UZO)_P2T^"OGV,$'Q#\4Q6Z';#:QQ6OE ?W5VG: <8ZCW
MP*^X_BS\%9_BEJ/AO47UB[T:72;E+B46KNAR@VXRH.<X'''6NFL?A;)I]MIE
MJFLWD_V+(:XDD8R/D_>8D$\9_GQ0!^?7B/\ X)1_ F^\.ZYIWB;Q=XAGT*\M
M]MY'/#9E!$.NX$E><\##?UKR'X'_ /!);]C/P/J^K/\ #?7KY-2N;G?=^7;Z
M>K-/U&=BJQ)P?6OU8\<?""3QGH-[H;^)M3L8[V/RVFAFD#@=^GU_SV^;?A?^
MP]!\,O&*^+XOB1X@OU34(]0>QEN)_)D"9)BD5OE*MN/6@#A)/^"=?P-^URQ'
MQ1K"Z@S$,/(MMP<'''RYZ_YZU\??\%&O^"7W[/>I_L<_''Q)KT^H7NH^$_AS
MJNJ:;=RVMHQ2XM=AB8DJS@G?C(Q@@'.,U^RMS\*H;KQ$WB3^W;Q TQG$".WE
M\G=M(''^<UY!^W-X>O\ Q5^QU^T'X.TN$WFI:W\--8TO2HSR;JXF5/*!/."3
M&>>O4T ?Q]?\&=VG+X<^,G_!0'PY9W,LVCZ9)X+73UDP  2C,VT8 .&"8'91
M7]X<+%@>G?IT[5_%5_P:R_L[_%;X(_M _M^'Q[X?ET:VU>;P>NER22;EN/)\
ML2;<@ 8.!QGMSV']J%K'(@&\%?O<9_I0!;+8ZUX-\1?@;\-?B[X@\.:UXQT2
MUO;WP7?2:AITDD,3D3RX#EBZL0/E!R.?PKW=P3C ]?Z5QZZ'>2W.HO)+)$DW
M^JVN3N/X'B@!MOHVB-:/I4&D6<6G6L/DVR(B[4B"8X&W Z=*X[4M0^&>A:AH
MVEZC9V"ZC/,8].#I'O:88!VG'!)P..YZUW;:+<+;6UO'+("1LF<,0P!/))[D
M9X_GVKQ7QA^SO9>*_$>A>(9->O(9=#NFN8X@6P[,V[&1TP?Z>E 'R;^V!^U=
M^PQ^S%JFC^*?V@SI5EKEK?Q3:1-<VGG/'?D#RVB=89"K@$8(!KF1_P %-_V&
M?&_@31O'!\2P:AHEQ%-+IUM-;2-;!8_F=55K?(!!P1CV[U[G^T3^P!\)OVEQ
MIR?$;2=%UA=+GBG@.K:3;ZEYDD:J S>>C8^[]1G@5RUC_P $W?@EI_@Z/P;:
M>#O"<&GZ;#)%8+%H-G'&_F*<XC$8">_3.?QH YC2/VX?V.KO2=,U_1[31(XM
M1421-':@;@P//_'N#CCOT_&OD>Q_;S_X)JW?[1ITF7PGX1D^)^H>(-.MEU5M
M,S>KJ4A(M9A/]BXD0DX;S.,]17W?IG_!.[X46VC6&G_V?I-M]E3"Q0Z5;K''
MVVH @P/H*R](_P""9WP$T7Q1%XKB\&^$+G6A=0W1U:7P]9?V@DT))65;@Q>9
MYBY&U@V1V/6@#ZB_X6=\(KATN7^RW#3.H@#PAP&95(*X7Y<Y[\8]:Q8_VG?@
M[]LU?P]8ZG%]NT)634+%4*QQC:28V^4@@KVP>I&*[+PS\&M!\.?VL#8V=^MW
M"B6QGMXV\AD'WH@0=AR!R.V*X./]EOP>^K:YKCV]C!>:\2USY5G&&R1CYGQE
MN.YH \;\,^/_ -C_ %[X@:AJ4/AO0'\=7,L'G7IL%>Y:8,OE%91$A5@^#DEQ
M[5]'^,/C;\.O ;:)9Z_=I#_;<\=G86[*VPLZC8J_*0 $(ZXZ^U8/A3]EWP%X
M4U*36+;3M-GOV9)/--A")-T>"I\PC=G/(]*[WQ]\(/#?Q!MM,CU33K!9=.E2
M6"9[6.62)U7 :-B"4/ Z'- ''>(/&_PAM=$U+Q3>VMG<+;VDMVXD@W@K$A;^
M%">W..Q^E?!O[/?[7_[(VO?&;Q7H_@W2=$T[QG=J(=3N+2T:.XD D"X=OLZD
M_-[GKFOTFTCX5:'H^E/HDFGV6K6=S&T,WVNVCD'EN-K!E=2""#]".#TKQ+P/
M^Q9\(_A_X]UOXAZ)X7\.IJ^K?,5AT:U@=6WA^)53/7_(Z4 >JWGQV^'UEJT>
MB75^HFF>**-"#P9@ G\(QG(_^MVF\?>+O 6G>%+ZY\3&*\\.:C;S1W4-PNZ)
MH51M^5(8'*E@1@^]+JOP7\.ZYJL>N7-E96]V9(Y3&MLG[LQ<+@[>O';U%;7B
MOX9Z7XET"/P[<0026;B2.4R1*RJDB%<A".>IH \[^" ^"\NCPZA\)-#TRS2Y
MBD<M:VZQ;EW-YF65$R"V><<?6O2M?\8:#X0S<ZF%CFG#&=2"554YR"!WP>OY
M4G@7X<:5\.]#M-!T&UMXX88C 9X85@<*[EBV% P1D]*Z#6_".GZ]8M8WT$$P
M\MD$\L:O(=^1R2">!B@#Y3^*WQB^$/ASP7XF\37UM9ZM%=V4C7%G=0,]NZD$
ML"%B8G/3ICBO*/V1OVC?@EX\AN;?PKX9T3P_=P3,DITVUDC:5BV 7+0)S_7W
MK[5'PE\*1Z))HUUX=T;6+>YB:&:.]L8I4"L<Y*NI!ZD=/YU7\'_!+P#X)E:X
MT#PEX>TN6=]THL-+MK;!SDG,:C.<=?>@#M)?$FA+"\SW+1QN,$J"?RP.HZ_0
M5\;_ !V_:B^&'@0M%?V]GJ,VDN)"UW#*S!@ <G;$W0CKW]Z^W_[/MS(8FTVU
M: =-T:$'\"".!V[UY]KGPH\%^(I=:_M?P9X=OUO(2L3W>F6TQ=]I&3N3KG!'
M\C0!\X?!W]M#X9^/],D>VFAM%@57,,$4RHN[_>B'K7N"_M$?#QO^8CCWVOU^
M@2M3PE\$OA_X;L5BL_!WANRE?_6K;:5;1@@# !VH,]N/:NP_X5YX,'3PYHW_
M ( 0T ><O^T3\/,X_M$X'4['Z<'^YGBK_@KXQZ)XVUJ_TVS$36]I%YT,RB3>
MXR!\P8 #/M[5VY^'G@S_ *%O1B?^O"&H]$\!Z%X=U"]U+3=/LX9;N+RS'#;Q
MQJO(/&%''7]/K0!;U+Q=H-AYRWDY3[.A=\*3@$9[*?4_C7G$?QV\#R7DFEQ7
MN9\ 1(4?YF) VYV=,\'ZUZA_9R74\@O=(LY(W^4R21HQ93P01WXSUXY[5G_\
M*_\ "BW,EVFA:6)V'RN+*$,ISG(;'!SSGKQ0!-;^(M+BTV'4IRL:RH78@$\<
M%3G'<8XQ_P#7Q-4^(_A+3[4WUS=&,;696"'DKNX.!SZUVZ:7:"S6U>UMW15*
MA#&NT#/ _ 8_'UK+O/#&D7=I]GETC3Y5P?E>WB8?-QP"#VXH ^-_CK^U3X4\
M-Z!H4%AI]CXA7Q%J*:9<PWT4K)!')@-+&%C/S#_:[>]>Q?"[4/!>O^ -'O(K
M"VL0WFS"W@BPJ/NS@ H#C ST]>O;T&]^%'@C4K.V@O?#&AS-:R>?#YNG0/Y<
M@.0R94[6]QC!KJ=.\/:9I-C!966EV4,,;?ZJ*".-%!P#A5&![_RH X9/$_AM
MY1I<D,*1*P 8(=PR0N?N_4_CFOACX\>-O@Q<_$C3] \3^#-"U.7PSJUA>VNJ
M7-HTER]P/WBEV\EERAX!!&!7Z3G1--DEE+:;:)N48D$*%B<]CC^M<IJOPT\(
M:M<PSWOA;0KRX25))+VXT^"2>7&<;Y&7<Q7/'/% 'SGHW[2O@47#:?9Z7I]G
M:1*OE^3#(O/3@>5C 7 KT#6OCYX)TWP^VI,T4GE0F40O&Y0[<G:1L_B/48]*
M]'MOAKX334KB4^%=#CM]H\IEL(/F/ Z #'%;%SX%\*WEM)8S^&]'>W*%0&LH
M&4YYQC;@#M_^KD _)CQ[^U[X2D\<:#+IWPY\-7]Y/J=M%_:,MK.9T(E $BLL
M P4X(R?O#U%?JUX,UBZ\4:3!K]P@A6[M8G%O'GREW1*=J[N>XS^'UJDGPC^'
M<$,./ WA>:>!R\<S:1:>8K@[E=6\O=N&>N>*[=+$16MM!;01VD<+*1#!B.,*
M,?+M4   #ICICTH PX==N(]3O=/DMHU@M8]Z.,Y)QDYXQZ<U\E>'_BKX6U_X
MX>)O"]]X2T=KS1[".[34C$[7;.9 !DLA'Y'/%?;BVD.]YFAC,KC#':#GCN>_
M?K7#:7\-/#6F>)M4\4QZ9I_]I:I;K;S3"TB\[8"#\TN,D>WOVH ZR"6)K:&Z
MC0%98U\M!]U<#@ <$8[9J>)V)>1LAU7E/X>.?K_GK3HK=H/,5$!CC4F%>,;C
MG  Z#\*A*78"S+$/-<XDCSP%!Z]_R_6@#QN-/#^F>.]0UXZ=;_VM?_N)+@K\
MS9..H7K]?J:]E\S[1;6\Q_=G<"JCH<8(X/\ G-4#X?M;BZ%Y-!$'#!\&-201
M@]2./KZBM!X9WE>/8%A1/W1&.6Z_\!]"??V- &=J]O8FQO)+Z,2K=PM T3CY
M2",'MGH?\YKBO ][! D_ABPL8+.QMQ,T7E!E.9LECC 7))SD>F*]*-L;JVC2
MY0!D;=M(W D>QZY':I(+*V@?S8K:".5N&=$ 8C'7=_2@!FG0?9K<0EBS*223
MUYY^M7ZA56$SL1\I7@^O/Z5-0 5"_P!X_A_(5-4;*220/Y>E $=%.V-Z?R_Q
MI"CX.!SVY% %=[J&*0QJHR,=N_M_.F7L\JVI>&$2EP59&SC;@^F?6IXE=]S2
MPHK'(!P"3QP>14BK(HVE5(]"1Z8]* .!T#6V.KS:2^G6]I'$K.LB [V8D\<C
M!_SGM7<W$)=5V,5]EZ'H3UJF+,QWAN4M8M[D OA<X/<D8-7)K3SF#;V0@=%)
M &>O3_/] #GM<DOXK-]EA#>B']XHF) RH_Q_/]:E\+7]QJ6C1W-S:0V=TS3H
M;6'/EKL.%QGGYN];CP/Y*Q E\O\ ,2?X3USZ]/U_.C<P7%JD7]GQ!CO!=>%
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MP7;:!8W,'V03MJC^;]I.Z0*4) V[1G."?SKZ)AL)(0UJH_='<PF!PV6SE?7
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M5H#D?\\R-A^F"* /CK]G']HSQM\4H;V/Q3X+TCPY;0ZO<6B+8>> X5\>:5D
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *CF4O$Z#JRD5)4<S,D3LHRP4X'O_ /6ZT 51
ML2%8'8JQ&!]>G7U%4KK3+2_L[BPU6UAOM.GB,4T-ROF1RPMU1U/WE(/3TS5J
M-1,@DD&U^&P>Q;KSG^M1O)=ID11"523C=W&/3CT_"@#B/ WPJ^&_P_U37=7\
M$>%=(\/:AXB,+:S/IELL#WQA_P!69R "VTCC).*],K/L7NG\S[1;I#C&PH<[
MO7/Z=ZT* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%*CH?;OZT1QB,$ DY))SZFI** #&>HS^%)@>@_*EHH ;M7.<#.,=!_A3J**
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%(P### $>_3BEK/NY9$8*B9! W$]^G3\.* &SH4O(YF=EB";2F?D)/7*CJ2,
M]>O\_P X/VH_V3]6\4?$KP[\:_ -QJ%AKFARP6QLM(N!:Q7$%P0+F65%^\Q.
M23BOTE*FYAVL-I'I]/QR:HQ"\.Z"6!9(<G[Q.<#@>H_^OZ=: *'@Z&\L_"GA
M^VO]YO8=+M8[KS#N?SE0!]S<9;=G)KI-Y]O\_C4:C  QC ''I[?A2T 2*Y)
MXJ2H4^\/Q_D:FH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[.^^*LFGOK;Z;IT5C+,;#:8OM#HH,I7:-I.<5]XU7@D61G97+#(X/;_/%6*
M"IQT'T'\J@J<=!]!_*@!:*** "BBB@ HICD@<>O^-1[CZG\Z )Z*@W'U/YU*
MI^4?C_.@!U%%% !1110 4444 %%0NI)Q\WU_^O4BC"@?Y_\ UT .HHHH ***
M* "BF.2,8R.O]*CW'U/YT 3T5!N/J?SJ8=!]!0 M%%% !1110 4444 %%%%
M!1110 4444 %%%% !1G'7BBLG5;BV@2,W-P\"EB%*$Y)QD@@=!C')H U20!D
MD #DDG@?CTJG)J>G0G;+J%E$W]V2Z@0_DT@-?/W[3'Q0U?X3?LX?&7XH^&K:
M+4]6\#>!-8\0Z1;7"/)%=W=G"7CCE2,,[*QP"%!)]*_SQO O_!:_]L7]LGXD
M?&6V\0ZA!\-)/AUI6J:IX?T_P_/<Z7'J-WIWG?9[6]2\-N2)Y(1N5<DQ.I&0
MPH _TPHIX9UW0RQ3+_>B=9%_-"14N<].:_FX_P""#'[>/[2_[5'@V\T;X_\
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M /Z<[6^LKZ/S;*[M;R+)7S;6>*XCW#J-\+NN1W&<CO5K/;OZ5_$I_P &N?\
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M[OM2@C*%>23TP!V^OM5RDP,YQST_ T 9[W.Z=8H<D[<GC Z_S&/\\4]I;KS
MJP@KW.>GY_X5;$<8.X( WKCFG8[X&?7% $&3C)X/4^Q[U"MS:L_E)=6SR_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_# =ACG'T/MZ5#/H.G7MI/8:E;1:A97$3PRVUTHEA>*52LJ,C=5<$A@>H)H
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M.6,AYVL0?FSN'3T)Q_G%7-DLN%DR@4@Y7C..W7H?_KT 6QP /2BBB@ HHHH
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MU XZ>W3UHR:C9-<PPPR%9'D"DJAY)SQG^M 'X4_\$??^"5FI?\$^OC3^U?\
M$6^U_4=93XZS^'I88KV'RTM?[):,D1'/S;MOX#BOWUJO"C(\A:8R9Q\I;.S'
M7CMS5B@ HHHH **** *S7"I@8_BQR1ZFI0ZLNX@X'^/Z]*KR6Y=@1G[P[CWY
M[585 %VG//7\S0 D<F\L,=/\\^]2U!%&4+9'!Z<@]_:IZ "BBB@ I#T/T/\
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M8FD6TEG%#:^4##;6\=O'/P79845%!/I@8%;= !5"[:8.HA@20DJ&9C@@'O\
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MCC/K44@WIN4GDX/;MCVZ4^$%4P<]3UYH EHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH JW@7[/(7D:-54NS*.<*"?\_XU\Z'X
MX>!;[XE6/PC:^=/%6HVCZA:MA=_V>)RI&2 <9!Z=37TE(JLC*X!5E(.X9&",
M<C\:_%/]OGX:^,/A=\1?#7[2W@BUO&FT2Q&BS"PD*G]]/&[;HD&YN&;F@#]G
MQ#Y2QP*S.P4#>W4XXY]SUJS A12#US]:\-^"OQ-MOB!\/O"^JW\\L6J7FA:=
M/>*T3K(MS) #,&)Y+!NI..>3WKVJP,1B<Q3-,OF'+-G(/H* +]%%% !1110
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M5^#]$\016^C3VEO;7MJMQ:Q7-A$5BD&]&!='7=@%>1U'6OTI_;S_ &0[+7_
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M %BBHDZ_A_45+0 4444 %%%(>A^A_E0 M%5Z* +%%5Z* +%%5ZF3[H_'^9H
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M_7O_ $JCH<7E:)HL?+8TRQ'/!/\ HT1.?KFGK'<+?2D(/)*< L>OJ!Z\]NU
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M\5_1W_P3G_:KM/B+X$T'X+_$!Y-&^+WA*TCBO-+#-)"^E6\2K9S"XD.6>0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD*LH*XP>>!W/-598VE15:)6PP/?L>O(]*LQ[MHW*%/H/3_&@!]%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF.?Z4 1X_P!'QCG9C&._^.:?#Q&H[@<_SJ3&!CMS^M &!@"@!:*** "BBB@
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M\@'P,_X.*/VDM&\=^%?#G[9OPG^&_P +-)\;ZC8Z-X>N](?4#<76I7TD*QQ
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M_%B;PYHGP!^'&K:/JFN?\(UHKZW;:@OG7$KM]C99HBI>9U*-LWD-W!K]8/V
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MM_??+GMBNAH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JK3,6)7&P \D@'<.V,
M9ZC\:FE?9%(^,[(W;'KM4G'Z5_,I^VO_ ,%O?$?[.'[0VB_!FWTJW$&I:I]C
M9SH=].Y59VBSYL<)49 R3G!H _ICCEF9<LH!R>!_='X$YQS4@G#-A.5 .>QS
M].OM7P#X:_;,L;GP=X5\5ZRIMH=<T>POI,:?<X!NHP<[=F1R> 1G.<\BOJ?X
M:_$WPS\0[9K[2;R220[?D,$L*X<;CQ(O/7C_ !.* /4X+EYG?*X568$YSTS[
M9I#?VZN49B"/;-/5$MTD(P-Q)R>^>N?Y]:S&DM+.WEOKS"JI8[B,\*">G7M_
MGL :T%PDXW(#COG@_E3EDW/M X&?T/7I7BUG\;/A])>R6L^O6EK<))+$(6=8
MB=C%3PS*<YZGO7HVC^)=!UO$NE:G;W8+$?),IYZD8W4 ;4VHVT#^6[,#G'"Y
MYSBG2RW'!@C5T*@@GJ<_K^E1,N7S+;QE3T<@9SU![]OUIS2-%\D)WG^$'.!W
M(].!T% %D2X&)!M; X'-)YP5=S\+G&[^1QCUXJO)=VMM'OO;BV@YZS2QH?8?
M.P_#%5S>65P@9;NU,!.089XF)Y&!A&.<GM0!J!PPRO/./3MF@OM!9A@#\?Y5
M&A"1@QD.#R._\/3CZ"F1R>:&5\=.F.G/TH !>0ERF3NR1C'ZU."Y.0/EQZ\Y
MS5;:!DQ1JV&/SD>_(SQ1&UQMPP7.>V#0!99PHR>HQQ]<=^E(\BH,L<*>_P#2
MJJR"9BI)!&<\$9*]OIQ4B 7"$..%.!^7!H >+B(]"3^!IQF3MD^V*KL;: A3
MC>.F03G)].G?'U]ZG(C9<C: ?X@!_A_DT .$JGIG.,]*K-=>4W[WA?4<]<8_
MG4D<,88LKLQP<C/')HE !YC1EP.2.?3U]?:@ CNX93A"3C'..YI?.S+L'3N?
M\C/O4+%E;_1XD*X^;@ _EW_SZT)M=@6^20YR!Q@_AVH <+I1+L;@8R/Q/%7*
MI2VRGE3F3CN <9_SVJX. !Z #]* %HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *BG.(9#G&%)S]*EI" 001D'J#0!F1W$3(FT;Y5 (##U'KW)Y_6I8Q(Y+7*
M+@?,!G('8<?Y%/\ LT:EW.$7@@CTKF?&'BS1O GA?7?%NM7?D:7H=A+J%[,X
M9TA@B4LS, ,D#K]?QH W+""SBN;R2V15DD(\PA N>>Y&,X/Y9K3 VD'.<G'I
MU_.OS@_9'_X*'?!_]KSXI_%SX<_#+Q+8:UJ/PDFTZ+Q!;VD,D4MJ;_'E><6/
MS9R",>IS7Z-3.4>/G@GISCOV% %@G )]* <@'UJ"60#;SPQQWZ=*F'0?0?RH
M 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4N_BM+XQ\5_#_5YC(RIX2NC8(2S%O*(C.X(&( R,<=: ,?\ 9=\%?LX^#_\
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M: /T-S16+$2DS&"1I4+_ #ACC:_<#)/'_P"JKUTJ&(M)(T07[Q0Y]L #UYH
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M\L\'[PR<9]??)[5)\\@PC$E3M(W'/?\ /I0!H45GV]PTC%"<.A*XR.<?H?\
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M7[+_ ,0/B%<?"7P[XLEN?$$:3Y\UX -\,SP.$8N!E7!V_-VX!!KT+XZ_M>?
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ML?@G7_'5Y8ZI]N>VCALH8G\R[BF:%HF\MV^4R*5)/\LU^//[)_\ P3N^-_\
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M_GU_, TZ,L/F!.#R,\^N,_SJ6YA>> I@*Q.?E/T_7C%2>40BJ/[JCZ8 ]30
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M^.].:8PZ5?ZQ=7(U&$A7(G*2EXSTV%>>H'^C?%;2)<M+(QEPF%=^6'4[1GH
M23QT.3W-"K>23/O/EQ;"%*GG<20#QCV- '\UW[>W[(7[8G[:W[ GA+3[#PV/
M@[\<-/U2+4[SX<?#QGM/#L@L&,L5G(@>(FWO3^[N%[H3P>E?S?:U_P $<?\
M@IQ^TCK'@GX=?&+]F;P=\//"?A;Q'I^M3?$#PG:;?$UY':W$*21W,S]4:&(S
M.-QR[9K_ $B)+6^=OLXN)DBSO%PLC"7GG;G.< ]O;WJT+6=;<0BZF9]^3,S'
MS,>F[.['L#VH ^8OV-/V=](_9@^!/@;X4Z+JVJ:S;:'H6FPW5WJY7[4+Y+2)
M+J(A"0%CE5@OM7U;6=9V/V-CMD9T.2=QS\QSS_G/X5HT %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 U_NG\/YBH:F?
M[I_#^8J&@ J5.GX_T%15*G3\?Z"@!]%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS,PL;D@D$1R8()R/D['J/P(K\BOVEX!+JMZKS7FUOM&52_O8U/S/VCN$%%%
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gbhcmm0hydxa000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gbhcmm0hydxa000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ++! L# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#E6&U)'@0$#)ZACUQP?>L:;Q"W_"T-+345\BUM;:Y<33.IXVCD%>,$8/KUH
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MBRQL1M3<RMAL;EX!Y!'&>,$>_$IU76FEDWV:1R%1]F 9BI8D95\#K[]!Z\T
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M6%X0WG4O$Y>3=_Q-7 4-D*-BXH ZJBBB@ HHHH **** "BBB@ HHHH ****
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MM7.=H_*EHH 3:/0?E3/(B\TR>6N\KMSCM4E% #/*C_YYK^5'E1_\\U_*GT4
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M&DM]"\1:/<P"*TA8*MQY4('F1>='O#<<@#M0!U1\92&9HHK.T9RIV*=2B!+
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MECV;0?O#J?XEX[5=&N7<\I:/7;15!)#"6)E*<C=C&>,CBNP^P66U5^R084$
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M\/2NOKD;DRVQGE"O#_IBIYL9C<C]YDY P<'<..3G]0#KJ*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#S;X?7,CSZ=$S%OW%Z>1GI<D#G/]*])KSS
MP,BB\LB\P,H2^&P1[<C[3UX.!],5Z'0 4444 %%%% ',?$55;X>:X'?8OV8Y
M8#..17F,=A:67Q'US4=6\*W.N6<UM$+6:.W6=2P49]LGCFO<+JVAO;2:UN8U
MD@F0I(C=&4C!%<NOPR\'(,)HJ*/03R#_ -FH \XU[3;/6?$'AMO#WA"ZTL6F
MI137$C:>D*M&""26'3&.G?->H>!G23PZ[Q.71KVY*L<<CSG] *@_X5KX1_Z
MZ_\ ?^7_ .*K?TO2K'1=/CL-.MUM[6/.R-22!DY/7GK0!<HHHH **** "BBB
M@#'\6%U\'ZT8P"PL9NIX^X:YWX>R)-?:S('8LZ6;$$],P+V[?F:Z3Q3G_A$=
M:P<'[#/_ .@&N4^&^_\ M+7/,;<_E6.YLYR?LX[]Z /0:*** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT =SX;P?#&E%<X-I$>4"_P ([  "M2LKPS_R*VD_NQ'_ *)%\H4@#Y1V-:M
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M10!E>)V"^$]98J& L9B5/0_(>*Y+X:*HN]6*NIW6]@2 #\O^CCCFNM\3KO\
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M/$,5M%9HTK_9+D+N&.>1]XG(Z<YH L^'H9;35KY9QY2R .#(OS3.6)9MQP2
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MTE<SX"Q_PB<.&W?OY_\ T:WO734 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!QWCQ8&N/#9F=!
MC5HBJL2,GVQWJE\7AGPA:_,RXU*VZ-C/S]#ZU<\?%UE\..CS*PU:$8C. 03@
M[O:JGQ=9U\'VX56(;4K8-M'0;^_M0!WM%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!YQX68C6=(+J^^634B?E.%/G>A'RCCVKT>O-/",JG6],3SB
MRB;4EC+*/G'F@\'\Z]+H **** "BBB@ HHHH **** "BBB@ HHHH **** ,W
MQ#SX:U7"%_\ 0Y?D R6^0\8KEOAX3Y^H9&,6MCCC_IC]?\*ZO7N?#NIC:&_T
M27Y2,@_(>,=ZY;P!$Z7-XYP$:RLL* >?W1YY_IQ0!W-<-XJA\0?\)%#:Z,+G
M[-JT:PW-P"=MF%))=?1BI(^N*[FO.O%/C>_T3Q/=:7:L)GD2V$$2V[2-&7+[
MVPO+<*,#UH YJ?0;JWAT3S+35XWMYYC:K;V2S*6\X[7<'[AVE?F.#@&M=_",
M\NI:>TFBQ%X]8NI%D,0PD;(2K]3QOP1G\JN7_C/7%U*RU*RB4^%_*4SW$EO\
MY??M8'D;2/8'FM/Q[?\ B: Z?:^&Q&'E<R3OE=X1<' #=CD@GMQ0!R5]X?O+
M[1;J$:1>6>MJ ]YJUS(=IP?F$9#<ANH48'/8UI> ?">J^&=:A_M19;L?9S#;
M7,$2)$D8P1O PVX].0>G6M"XU_Q%JOB6QBTH26^CR007$DQM5<[6+$Y8MQ]W
M'0]:[Y65U#*P92,@@\&@#RC7_"]_K8U&V&@S/K4DTGEZQ,ZF-(@<J$.X$ CY
M=N/[Q.>Z6?PRNX$TBUEO'C41,TGE6<3QPR<,%.>HSG!P>GO7K-% 'F\NC7MI
MJ$)N="GU&R:"2"&WB*".%RQPQ4_<R,<CIZ<55TGP[>VOCR6[GTJ\CADN(V4"
M**2%5$6T#>3N 4^@]*]2HH *\T^*5L9[RQ.P%1IVH ,V  QB&.3P#UKTNO./
MB7$K:II4K, JV=\" !N ,7WADX&,=?>@#J_!AC/@G1#$S-']BBVECDGY16Y6
M1X5!7PEI 8 $6<6< C^$=C6O0 4444 5-1U*WTNW6>Y,@C:18\HA;!8X&<=!
M[USE_P"*-4-W$-*TB:ZM'^4NL9W[]V#PV%  #=3VK6\2;?[+4/&KH9XPVX,=
MOS<$ =2#CBK>DF9M+MS.8R^P8*,2".QY_P : *EI//K6D*ES:&UF8+Y\,\9(
M SR!V/2MCI61?3&'6K13<!4F*KY9FVDGYN@[^I]A6O0 4444 %<+K&AZN?$]
M_=P:58:FE_#'%#)=-M6V" [@PQGG<>1^-=U7 >*+^ZL?&MB+36'!E5(VT])U
MS\S!2WEGD\?Q=!@_B 4AX0URZCU;3;W3-+*ZA.96U'(?:A7&T(1G<,8!]*S#
M\,]8_M#1HWOUMM-M!&(8X;@B6&0J?,VL03SC@9[=,5=DOM6\-VWB6Q@U#5-4
M:.>!$N)09G@$J$$JHQG!'0'N*T_$U]>Q?#/3OLNIM;378@@>ZO3L<JP^;)_A
M8^OK0!CP^"]>M?&&MW/V:YFT^[C6.,C4%Q.!'L)E0\DG)Z$8JLGPPUO2]/:%
M+Z;5U:Q,$4,UT8Q:.0<[.Q'89Y%-FO/$VN2Z38:+?W,B6?VJ*>1+DP_: @4*
MVX@D\MC/3(->KZ;<PW5A&\%TER%'EM(KALLO!R1WS0!YU'\/]3N]/C</-IVI
M6=NPM)9+KS_WK8.2>NT8(VG(YZ&M70="\1Z(6MTM]-ECD8>9<N[;]FT J,>_
M3I_CW=% 'F_PX\*ZUX9F"7]CY?F0?OYOMQE4ON)PJ9X !%>D444 %-<GY0$+
M!C@\]!ZTZB@#"NXWTG2VLM&3,CEDA3S4'E,03QN_ES^54+6;Q9;S1/<6HE@1
M2)5,T>YL#KGC&>?T]>+NF*1XHU3"D)NSDXZE4_$=!]<UJ:H"VD7J@X)@< _\
M!- ":7?C4[".Z$+0[L@HS D$>ZDBKE8GA5R^B0$+(L:QJJ^9"4+8'WN>3GW]
M*VZ "N:\7F-1HS/,L;_VE$$#9PW7(].GK72USOBV9X8])VO(H;4H5.QRH.3T
M)]/;(S^E $/P_&/"47S,W^DW'+'./WS\5U%<O\/QM\)QC<S$7-QG<<D?OGX_
M#TKJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR$EB0.N[U(S^%/33M?R5?5KM2[EN%A90-I^7.P%>>X!_PT](L[F%7FOU!O&
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M:,XH Y;_ (39=[1K:B218RQ"/P3GC!QCW."<"G?\)BV\%(+6:$9#2K=J!G)
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M7MTFD1D$D@0!8%8<\GG.. "3G'2B3Q7XIBG2-H6(#?.8[97!&/X<'D^W4 4
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MJJ  *=M7^Z/RI:* $VK_ '1^5-$4:EBJ*"QRQ ZT^B@!-J^@_*C:OH/RI:*
M&+%&@PB*H))P!CD\FFO;P2+(KPQLL@PX*@AOKZU+10 PQ1F/RS&I3&-I'&*&
MCC<8=%8 @X(SS3Z* (OLT&W;Y,>-NS&T?=]/I2M!"V=T2'*[#E1R/3Z5)10
MWRT#;MB[L8SCG'I3%MH$8,L,:L.A"CC_ #DU+10!&8(F+$Q(=Q!.5'..E"P1
M)MVQ(-@PN%' ]JDHH :R(XPRAAG."*-BEP^T;@,!L<@4ZB@!I1&*EE!*G(R.
MAH5$3.U5&3DX'4^M.HH ,#THHHH *Y'XD@?\(;-D H;B#S%_OKYBY7WSZ<_2
MNNKEOB(UPO@J\-L<2!XL'8&Q^\7L>M $_A,EH=65HRNS5+D#=W&\GCT'/M70
M[5_NC\JP?"UQ<7":M]HF>0QZG.B;\_*@;@#/;'I6_0 FU?0?E1@>@I:* $P/
M048'H*6B@!,#TI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "N5\;*'/AY&0,C:S!N!;'9
MST[\@<?CVKJJY/QR[1_\(ZRL1_Q.8 >RGA_O'L/ZXH M^-9%A\.F5O+PEU;G
M]X"5_P!:O7'/OVZ=:Z <@5SGCHJ/#+;G$?\ I5OB0YPA\U>>.?RQ]171K]T?
M2@!:*** "BBB@ KGO$6MZCI.I:5%:6<%Q;W4ICFW2[9>V-B]^N3Z 5T-9E_H
M-EJ6J6.H7/G--9;O)"RLJ@MC)('4\=Z .1B^(EY:1Z@FKZ3Y4\,S1VIBW;+C
M[V""1T&W!/J1ZUL^%_$NHZKH5W<ZMIT=K?VF?,MH90V1M##K]TG/0TEY\/M
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M0)5))/0#FK=<';?#N:*^M9Y-0T[R[>X2XV6^E+"Q*DD#<'XZX[UWE !1110
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MZRO&OA?-)_PDUGYAC8RZ=<8(DWX*W'(!P>F?[WX5[+0 4444 %%%% !1110
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M[''(/\P/RJ)M TAY8Y&TVU+QD%3Y0XQT_*@"@?$)@>/SDG8-(5(2TDY4 \Y
M/)XX_"H9/$I42;7D8(@<L;*0<'GIWX!_,5M?V3I^<BR@!SG(0 ]0?Y@5&VAZ
M6\:(UC"RHA105S@'J/U/YT 9YUN;SW12Y$;*&/V5^01U_,?K61JGC2;3=1TJ
MW;!-].D#1M;.I0MD!@QX8 CD<'%=*OA_25W8L(/F7:<KU%!\/Z04C0Z? 5BD
M\U 5^Z^,;AZ'% %$ZQ.@+"?[2I7</)M&)&<$#[V.C ]>QJ-=?DW-NN%*EE ,
M=JQ"_("<DD9R6&,?KVUCH^G';_HD?R@ 8&,8&!^E-;0]+:19&L("R*%4E.@
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MQN#C;M89]P3S0 :-XD&K:C-9FWC1HX]X>*ZCF!&<?PG(R,$9'(/M7+:T9/\
MA8>I&%S$RV%G\YC+C/V@^W'IC\:Z/0/!UCX8U6[FTA4M[&Z1=UJ%^XZ]U/7!
M!Y!]*Y3Q(/.^(&J)(SX73K,*&B9UQ]ISG"C/7Z_44 >GT444 %%%% !1110
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MFIZKS2RI=VR(N8W+;SCI@9'ZT 6**** "BBB@ HHHH \E^(;2GQ;?1Q;5/\
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MZ_K5V@ HHHH *P/&W_(E:O[6S'[N[]*WZY[QLI/@O6_,=!&+5BO4'('KG\J
M+&A.)+K5W7.&NU(R,?\ +&.MFL3P_,\LFH;Y2Q\V,[&QNCS$G!P<>_:MN@ H
MHHH *0_=/TI:0_=/..* /'_ "A/%^GJH8 1ZH & !'^D)U KV&O'OA__ ,C?
MI^'#_N]4^8$G/^D)SD\U[#0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7(^(\'6--$WE,GVX;04S@>2V=V#S^(KKJY'Q,!_;.E.KE<7F) 9"0
MP\ER/EZ#KZ4 =5!M%O$$"A=@P%&!C'8=JDJ. YMXB.FP?RJ2@ HHHH ****
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M+M^T09W;LMC&,=._?\JFJA>Q[K_3WW2C9(W"$8/RG[W/3\Z +]%%% !1110
M4444 ><>,I9H/%T[PVTDI_L*X;B;RQPZGJ.>G]!7H#W,,$0::5$^0M\Q[ 9)
M_"O/_&TJ1>([LR3N@_L*Y(\I-[J05.0"<9XST'3K6%?W5WI]NNK:FFO[VVPP
MW3WD:(BNHQT  Z\D8.?I0!Z\MW;O:K<B9/(8!A(6P"#TYJ:O%Y-5MO%>H#1;
MA-8NEE0%8O[3B56& QR!RW3T[5J:9:ZZZ7$7_$Z-Q9S>5L740J."H9.J<<8'
M?I@F@#U2BO-VT[7Y?WR6VM&0NSR(=7"XZJ,#9C/ XZ=_>HAHFOF-0EKK95,N
M?^)Y@E@=H RF2,#)SQT/.: /3:*\Q;2/$6"@T[6SEBV_^W1G W8'W>Y//MCZ
M4YM!\0K$H2SU@>6H4@:^3N^7.02O/S$@YQP* /3**\L3P]XB6=5.EZJ0(U#$
M^))-NX,I...<C//UZ=:@70?%2H-FC:BP.%/F^)I,@MC)X7H/\: /6J*\H;PY
MXJ=@R:7?*!D$-XFE&3C']P\=Q3!X>\5+"<:7J1,:,2&\229D;)& =OIR.E &
MU\01)OO2K/\ \@F3:"YV;O,7G;D<^GKTKO(-YMXC(<R;!N.,9..>.U>6/H/B
M4V][;R>&I+N.XA9'^T:^[\'@JNY#CD9!^E-;P_XF21$CT?4/+1?)&WQ'* =O
M1L;>^/UZ4 =9X.0QZWXN0X(_M7((/K#&>G;^O6NA32K!$"BTB($GFC<N</G.
M>>_ _*O(Y[2[TRWNHYDOM*U-1'>@G5I)5F#2*C!S@ D8 'Y5[0.E ',^,=%B
MUY=(L[BWM9K?[<'E6XQ@J$?( [D^WI69J?@.U:)(--G;3=/@<W+QQB-UFF/&
MYO,!^Z.G..G'%:'C:SNIX=+NK*.X>XL[HRJ(>O\ JI.OMG _'H:X'1+._MO
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MPT,HE4"'$BR%@P\E.0">/R&:Z.N7\%1S)9W+2RB19/(96!Z_N(P3TSU%=10
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MTL8L)E,@Z 9Q\I&,\C!SZ5H6?B+Q%JHMKNWN=(LM/CMK>6X:[+;G:1-Q /
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MYAE2.X['\JY?QFI,.J#S(CG3U(20[=N)1SNQT_J.E=A#M\E-I!&.U #Z***
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MY@VLZSX<O[R\D\EUDQ)>"\MY(B,*$0^8H9.=O...174:=XSAO-/-U)IUV@7
M/D;;@,<9.TQDY ]: .GHK*TCQ'I&NQ,^G7T4Q7;O3.'0D9 *GD&M6@ HHHH
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M+;OLD!P<*   .V#QBKNF1_:+&TN[NS\F\*;W5\%T8CD$@#)[?A6A10 4444
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M/@/3O+M88//4S9C4#S QRK' '.,5U]06D*VL"6L<>R&%52/D<@"IZ "BBB@
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M^==26_W?]?;R1YW' QN% '0T5'#<0W"EH98Y #@E&!P?3BI* "BBB@ HHHH
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M "BBB@ J.:XBMU4RN%#,$!([FI*Y/7;FYUG6;3P[9L8XF!EU,AL.D'(501D
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M_P )3X>_Z#VE_P#@9'_C0!K45DCQ1X>/37=,.>G^EQ_XT?\ "4^'O^@]I?\
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M=\E,?D/4G^= %NBBB@ HHHH **** "BBB@ IHC179PH#-C<?7'2G44 %%%%
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MA5'3<6QWZGFI::F/+7:VX8&&SG-.H **** (XH4B4*.<=SUZYJ2BB@ HHHH
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M+<QS2RC!'R[.#@J>NX<BO3_ \$]OHMS%<G,PO[C<=V>KD]:I?#KR_P"S=7*
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M] #T&V01VT2 Y 4 '&,_A4M<CI_BW49M*M9YO#]T97A1GVSP\L0#Q\WO4_\
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MB4SQM*TZL!N/WMI7D]"<UZ,L4:H$6-0@& H' %.1%C1410JJ,!0, "@#C?\
MA'=>M%5M.;1X)T 2*01281!QMP3R-O';I[U"O@W5#+/O;12C,6#&S9BQ*C).
M6X^95/'88KN:* .!F\$ZR?.6&XT)8W*!4?3V;Y5'R@_/U&!BHI/ FKM9K#YN
M@,%Q\ATX[3CM]_Z?K7H=% 'F6J^$M1TW1+B]D/AXI;QF9T_LS@X4Y_BZXP,_
M6H7\,WVMZS-=:78>'8[-8H0))[3S&DW1Y;&#QC( R._M7=>+0&\(:N" 1]DD
MZOM_A/?(Q6?X2Q(LCC=&YBMG<";>&_= 8ZG\\#.!Z4 <T?AWJ@C,7V?PRR,V
M6_XEQ'7.>_H3^?M4O_"OM1>:(O!X; 3/S?V=G [#&?6O2:* //1X(U::19;U
M?#\KE%4E;#D $<9)Z8Z?2E;P+>)!N$>@APA/_(-! (VX'7GI^@KT&B@#RO0-
M8TVZ\8>'8[.WDM!]EG>2,6IC5I7/)(' )*MU].E>G17,<T\\*,I:$@/A@<$C
M.".WXUC^*?"UOXFTUK<W$UG<C!CNK<[9$P<XSZ5C>&O%\T6JR>&?$WD6NLPA
M?)96)6ZCVY# G^+@Y'M0!V]%%% !1110!YSXR,LNOW$(19!LL-D?D*2X-T-W
MS$8(Z<'UKT4# P*\Y\>%!J4P=8PI^P;F93_S]IC)')_I^->CT %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5YSXN\/;O%L5]#J=W#_ &D([2XM
MX)S'GA@K'!&5ZC'^->C5ROB[ OM"8,P<7\8P N"#GKD9_*@#1L?#VDKI]JHL
M( 8X$C5Q&%8   =.E6/[!TG&!IUL%ZD", 'Z^O\ 2K=KM^R1;-VW8,;L9_3B
MIJ ,V7P_I,[EY+"%F)!)V^ASCZ9YQWR?6@>']'4Y&F6F1C_EBM:5% %$Z-IA
M7:=/M2-Y?'E+]XG)--70M)0R%=-M5,N[>1$ 6SU_.M"B@"A_8NEB,QC3[8(<
MY C SGK2-H6DL@1M-M2HS@>4.,]:T** *#Z)I<A8OI]LVY@QS$.3ZFF_V#I&
MU5.FVI"_=!B'%:-% &<= T@HJG3;4JHP!Y0XI[:/IK.[-8P%GX<[!EN,<^O%
M7J* *']B:6<_Z!;\D,?D'4<"I'TNQDV[[6-MK!QD=",X/ZG\ZMT4 >8?$>W\
MBYE%G,+8OI%SYJ-&725 02./NMD\$^OO7H.C?\@.PZ_\>\?4\_=%<!\4)UCN
MGCE$K1MHUV=BGY21L/(P<] >W3K7>: XD\.Z:ZYVM:QD9_W1[G^= &C1110!
MBWGBW0K#4WTZYU*)+M%#/%R2@)P"V.@Y[U->>(M+L)&CN+@AU*+M6-F)+<C&
M!ST[5R>K1>)D\4:I!IWA^VN;;4$CC^WW$J[(UQA@4QEL>F<=*J:G\/;TV]C8
M:?>WL$4=S&QNHKDAX@(R&9 ?N@L3D9(],4 =]IFK66KVYGLIO,16VME2I!]P
M>:J3>*-&M[FX@EO45[=MDI*G:K8W;=V,;L<XZUF>$=)U/1/M=A>V\+!B9#J*
M3,SW#'@;@W(('OCTKFQX0\1WFA7?AJ]BLULPTLS7\;MYUU(23&?]EL]2<\ >
MM '8IXRT62:&)9K@R3(9(U^RRY=1C)'R].1^=6)_$VD6_EA[L,\K,J)&C.S;
M?O8 !.!ZUR]IX&FBUK2)I[K498X+!XYI9+^0OYIV\<,!@\YQ_=%1)HOB?1[X
M7^G1VMW<7%K]F82#RTMV#L?,"C[V01QD'CK0!U5CXITO4KQ[6T>>1T8(6%N^
MP,1G&[&!QC\ZV:\TT?0_$.F^,KBYOK!I[>?4//-U'J#K&NY-ORPC/'U/I7I=
M &5XG\O_ (175O-+"/['+N*GG&TUS_@#_7ZM\P/%IP#G'^CI^5;WBG=_PB>K
M[#AOL<N#Q_=/J#_*N?\  7E?;]6VG=+Y5GN(4\#R%XSD_7MUZ4 =O1110!'/
M-';6\D\K;8XU+NWH ,DUS5E\0-%OM[(M['$$:2.::U9$F5>3L)^]P"?H*W=6
MMY+O1KZVAQYDUN\:9.!DJ0*X+0O"_BRX\/I9:[-90+:V+6]I#$[2 R%2GF2,
M>2<$X ..3QTH W)/B+H:(\T:WT]JFPO<PVK-&H89!)],=ZW]2UC3]'T_[=?W
M*06V0 [=R>@'N:\RO/A1<!;*ZL=1\C5H60M!)<R-;7** &!7@K]!Q73^(M U
MK5=.TB]MFL1JVGSI.UM+N-M(0"N,9.,!L@]>* +L/CK3+AY(H+;4))XB0\*V
MYW@;=P;&>5(Z$5-%XOM9"F[3M5B#R",&2T(&2<?D.23TQ6)%X$2^G@U3Q-<B
MXU*1MTBQL416( 6-2I!*+SP<Y)I]I\/(K+3K&&VE$5PLR27DIDDE$FW)PH=C
MC)_2@"]#\0=&N89I[>'4)K>,,RS1VC%)0I )0_Q#GK6[I>J1ZK \L=O=0;&V
ME+B(QMTSWZCFN$N/#?BZ?PW<Z=+<:?9VMM;M:VEE8C:MQT",[MDI]!S[UTW@
MW3=3TO3)K?4K2QMF,N^-+261UP0,Y+DGKZ<<4 ='7G_Q""">4$?,^CW(.!DL
M T?'H>O<&O0*\Y^)!5;Y"Q7_ )!%V &!.?FBX]* /0+3BR@ Z>6O;':IJAM/
M^/*#@#]VO &.U34 %%%% '$>.1;_ -N^&GFD\IEGF*R?,,#RCD;EY'KU[5U&
MBL[Z'8O)-YSM A:3.=QP,G-<OX]=TU/PYY>WS&NI%0L<8/E-R#Z_7CGFNE\/
MM&_AW3FBSY9MDVY(/\([CK0!I5P6KK&WCVQW\,-1B*':3S]G;C/:N]KSO597
M'CZT$A15&JQ ;L@D?9F/'.#WZT >B456CU&QF<)%>V[N>BK*I)_6K- !1110
M 5S7C3Q:G@_2%OFM3.78JN7"*"%+<MVSC ]ZZ6LGQ/&DOA750\(FQ:2L$*@Y
M(0D8!!&?PH \IO?B^^J:=<VC#2XHYX6B?;=,LBY !8'&.,M_WS],K+\80---
MF8=,6,VP'_'R6*@J!@Y!R>O'MS79/H6D2_#[[=/I<4\_]EF0X #,QBYP>@)]
M?>KQ\/Z)+X8^URZ99,[V2LY9 %;"9^;'U]Z //4^*J0Z*FF>3ILD M?+?]\6
M;:$.X[0/FZ>W6JFD_%MM-\,V.G+!I;1162Q*XF*Y.TX&P#CC:#[G\O0])T+2
M9O ]M>-80&=]/4M(8E!8A#@D#C_/>F>$- T:X^&^D--8P3"32XE=Q'M+#9U]
M0>>O6@#A]*^+<=AHEGIKKIDL"6XCWB9@Q& !E<<=>>>U2:/\68]+TBTL5CTS
M[/!^X\P3$!@.. .>>><5W>AZ#H;>"M.N'TRW/EV& 1$I;:5Y^IX[YJ/PY:Z%
M9?#JRU"YM+,V\5GYCR- I. "><]^U '*>'/&>MZK:6YT?1+N:WL]VY48A)/,
M)P"6Y.%PW'KCZY4'Q!OO"]\FF/;0VOV(E'LWD8F5Y7#9/3)4;L?7KGKWW@Z"
MU\+?#5;P0E$9)+UD P?G)91CMQM&,U8\&:-9OX6MY[ZQ@DGG9YG:95=\,Q8;
MB1G."/I0!YYI'Q531;>:W6&U6)KB25I"K%0SR<_=/ Y]\9&?>3P_\1_[)2ZA
M2.+-Y=R3(98VVAW(P,@^O'3N/J>[\$Z/I9TZ^8:=9%?M\VQE0.I&[C&[D?XU
M'X)L-/N1K^^RBDQJ\_,T*DGI]1^6* .)TGXG?8;RZDC:(KJ%Q]H(FMW4*3A"
M$;=\P! )/IFNH\"^)[C4/$NK6UTJRM<R^:DMM;$1(JJ%P9,?-G!P2<UK>&M,
MT]K_ ,0PM96CQIJ)*J45MN47/&.*T- 6"+5=;AMXHX5CN$!CCV8'R#G"@$9&
M#SF@#?HHHH *Y+QBUO'J7A^6XG\@)<2X?9G!,+C@@9!^A%=;7'>.(BU_X;D1
M_P!XE^VU!&&+$Q/SD_=Q0!T.A;3H%@5<R+]G3#G/S<=><G\ZT*SM _Y%[3_G
M+_Z.GS%MQ/'KWK1H **** "BBB@#EOB&Q3P=<2>9Y86: L<=O-6J^D>(HH=9
MN=%@MI[BX#SW,C*NT ;R %)^\<C''2K'Q$C63P;<9;:5FA96XRI\U>>:YWPZ
MK3?%;4IMK1)'&RJJ.624[FRV#T/'.#CVXX .EB\;V*WT-EJ-G?:=<2Y&;F B
M('T\P?+G'/6NE5U=0R,&4C((.0:9<01W5O)!,NZ.12K#.,@URLVCS^%+N;5=
M&$DVGLI-UIQ?A0#G?$2"01S\N0/3% '745#:74%]:175M(LD,JAD93D$&IJ
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M^Q_D:P? DBFXU1-H5ECM.,\D>0O/4_TZ5M^+/)_X1'5S<+NA6TD9AG&0%)K
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M9TQ\R$CN0.,YY%:^FW\.J:;!?09\N9-P#=1Z@^X/% %JL[Q!_P BWJGRAO\
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M^,H5FOO#H92W^G, ,\$^4_!&#P?7M765RWC Q"[\.^82"=27;R /]6_U/Y4
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MWD .,J><^U 'F?AQ8?M/P_:,; ;6Z**,D,I4'//(SP<=L^U>H5YII'VC^U_
M?VF<W$@MKL&7<&W?*,<C/;W/U->ET %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!@^-@6\#ZVJH78V4N%49)^4\8K&?QWX;
M.@-;_P!HJDWV,@QO"_'RD<C;TR#^5=O7%>*K6Q_X231[B]M+:=S<QQ0-+ KE
M-V[('&>H!SG% &_X8B$/A728E*%4M(@#']W[HZ>U:U06<7DV4,6P)L0+M  Q
M@=.*GH **** "BBB@ HHHH **** "BBB@ HHHH \T^(OEMK\:L(]_P#8=^4\
MPDC.T=NF?>N]T5B^A:>Q.2;>,Y]?E%<-\0D#ZP1*Q$7]AWIV@X+'"],=<=>>
M,#I72:;XGT>#1+5GO=R);J3((FVG"]0=N/RH Z.BL0>+-&8@+=.V6*C$+GD=
M1TZ\4?\ "6:1Y2R>=-M8@+_HTG.>./EH VZ*QCXHTL2",M<[R,A?LDN2/^^:
MB_X2_2O(EEQ>XB)#K]CER,?\!_'Z4 ;U%8+>+M-&2L6H.N,ADLI2#QGCY?>F
M/XRTY$#?9=4;) PMA*3V]O?]#0!T-%<]_P )EIWFJGV75/F&=WV"7 Z=>/?]
M#1_PF6G>:J?9=4Y&=WV"7 Z>WO\ H: .AHKF?^$XT[=C[!K'7&?[/E]0/3W_
M $-'_"<:=NQ]AUCKC/\ 9\OJ!Z>_Z&@"7QUY?_"":YYK;5^QR=\9.TX'XFL7
MP@@7QMKI$07_ $*R!9> #L/RXP,$>_/2G>(O%=EJ?AW4].@LM5$]S:R1Q[K"
M09)&/3WS^%9OAK4'L/%FLW<]AJLB3VUHD3?9I#G:N"!D= 3GMUH ]+HK#;Q3
M:J"?L.IG#;>+-_3/Y?XT#Q1:$@"RU/!(&?L;XY&?3Z?G0!N45A+XIMF<*NGZ
MH23C_CS88Z__ !)_2C_A*K;#-_9^J;5')^QMZD?T- &[16 GBVV=HU&FZMEV
M9>;-@!CJ3[<&I!XFA/E_\2W5!O) S:'CKU],X- &W16(GB:%RH_LW5 6!/-H
M>.W/UJ!_%L8B9TT;6790<*+,@D\<=?<4 =%16 WBR!(O,;2]7&6"A19,2<^W
MXBHF\7 '"Z'K#ML:0@6V,*.F23C)]/>@#I*\Q^)[B/5[=RSKC1=0Y0X/_+/I
M78#Q,&#%-'U5@$#C_1\9'&>_49Z5Y]\0]1>]D^WRZ5J,-I!I=U!*[Q;=K2",
MKST[$?44 >JZ;_R"[3_K@G_H(JU573?^079_]<$_]!%6J "BBB@#C?B'+-:V
M>CWT<,DL5KJ,;SA%SA"&4D^F,C^52Z1XKTBPT6R@OKE[:2.)$?SH74(<=R1@
M5UO6FR1QRQM'(BNC##*PR"/0B@!EM<P7D"SVTT<T+C*O&P8'\14M8%SX7MX+
M":/0V;2KAF,JM;G:C2>KKT8<4_2=;GEN$TW5[=+35/*$A1&+1R>NQN^/3K0!
MN4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4457O;V"PMF
MGG<!0.!W8^@'<T 6*C:>))%C9P&;.!_GZUS40U_7HK.XBN9-)LF#-+%)&#<.
M"3@9Z+@8QQFL;Q]X=TNR\(7=VL+27N^)%N9I&>7+.J_>))SVH ]!!!&0<@]"
M*6J&B!4T.R1(VC5(50(V,C QV^E7Z "BBB@ HHHH **** "BBB@".X4-;2JP
M!!0@@]^*\A\%_$+PW_PAJZ3K"O%<V*LFVZB)$K$MRIY]<9..M>P22)%&TDC!
M40%F)[ 5R#_$SPH(RZ7C3>@BA9BW..,#GM^= &1#K^FW^C>'K/\ M17OUGC9
MHXY2#G:WRGU&#TYKI_ D<D7@714E+%Q:IG< #T]JY_4_%>C^(KO3=/T[[3+/
M]J64A;5AA5!^;=C"C)Z_44GA3QMHNF^%]+T^YDNUNH8(XY8S:R$QL> &X[GI
M0!Z%17-#QQII<+]BU89.,G3Y<=0/3WIQ\:Z7Y8=(=1D&<$)8RD@Y((/';'-
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M@R*2!'=_=.#_ *A^^10!Z(#D9'>BHX/^/>/_ '1_*I* "BBB@ HHHH ****
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M:&57:*>!NL4JG#+[X/>M:N;T6>V7Q;KEI;NNW$-P54C&YU.2.>^!S@?C724
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M,$<\CJR/M@0,QPP/0]1QS[5)X;DMKSPU8RZ9?^;&_P"\:<J"TAR2^X=B3G-
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M8P?\X% '(2_$C2HFVF\L,A5+8>4A<@]<1\=!U]?I3)_B3IB@%+ZP"A@&;,S
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MGG<6QW';H/QJ_I/BS4)_'#:'.9)[%K?"70@5,S8#'G<?E"L.W7/7%;7CX ^
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M'"D<[1V/(H OT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR<XQD<$C/'7'>NJKD=4V_P#"S_#_ .\16^PW7!8 L,IP!U/KZ<5UU !1110
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M\_+U'/;%=!X3N;^:RO+?49VN9K.\DMQ<,H4RJ,8. ,#KC\* -^BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%% !1110 4444 %%%% %2UTRSLKN[NK:!8YKQQ).PS\[   _D*MT44 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>onct-20210331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-05T22:37:37.7157565+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 6f376e511213405db71fc059864ab73e -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:onct="http://www.oncternal.com/20210331" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.oncternal.com/20210331" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.oncternal.com/20210331/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="onct-20210331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="onct-20210331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="onct-20210331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="onct-20210331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" id="Role_StatementCondensedConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="Role_StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" id="Role_StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="Role_StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>100040 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" id="Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100050 - Statement - Condensed Consolidated Statements of Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>100060 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetails" id="Role_DisclosureBalanceSheetDetails">
        <link:definition>100070 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactions" id="Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactions">
        <link:definition>100080 - Disclosure - Commitments, Contingencies and Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreements" id="Role_DisclosureLicenseCollaborationAndResearchSubawardAgreements">
        <link:definition>100090 - Disclosure - License, Collaboration and Research Subaward Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100100 - Disclosure - Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct" id="Role_DisclosureCOVID19PandemicAndCARESAct">
        <link:definition>100110 - Disclosure - COVID-19 Pandemic and CARES Act</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100120 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100130 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsTables" id="Role_DisclosureBalanceSheetDetailsTables">
        <link:definition>100140 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsTables" id="Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsTables">
        <link:definition>100150 - Disclosure - Commitments, Contingencies and Related Party Transactions (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityTables" id="Role_DisclosureStockholdersEquityTables">
        <link:definition>100160 - Disclosure - Stockholders&apos; Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100170 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail" id="Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail">
        <link:definition>100180 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" id="Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails">
        <link:definition>100190 - Disclosure - Balance Sheet Details - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100200 - Disclosure - Commitments, Contingencies and Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails" id="Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails">
        <link:definition>100210 - Disclosure - Commitments, Contingencies and Related Party Transactions - Summary of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2" id="Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2">
        <link:definition>100220 - Disclosure - Commitments, Contingencies and Related Party Transactions - Summary of Maturities of Lease Liabilities (Details)2</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails" id="Role_DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails">
        <link:definition>100230 - Disclosure - License, Collaboration and Research Subaward Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails" id="Role_DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails">
        <link:definition>100240 - Disclosure - Stockholders&apos; Equity - Securities Purchase Agreements and Underwritten Offering (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails" id="Role_DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails">
        <link:definition>100250 - Disclosure - Stockholders&apos; Equity - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails" id="Role_DisclosureStockholdersEquityEquityIncentivePlansDetails">
        <link:definition>100260 - Disclosure - Stockholders&apos; Equity - Equity Incentive Plans (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails" id="Role_DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails">
        <link:definition>100270 - Disclosure - Stockholders&apos; Equity - Summary of Stock Option Outstanding, Vested and Expected to Vest and Exercisable (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" id="Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails">
        <link:definition>100280 - Disclosure - Stockholders&apos; Equity - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails" id="Role_DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails">
        <link:definition>100290 - Disclosure - Stockholders&apos; Equity - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails" id="Role_DisclosureStockholdersEquityShareBasedCompensationExpenseDetails">
        <link:definition>100300 - Disclosure - Stockholders&apos; Equity - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" id="Role_DisclosureStockholdersEquityStockBasedCompensationExpenseDetails">
        <link:definition>100310 - Disclosure - Stockholders&apos; Equity - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" id="Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails">
        <link:definition>100320 - Disclosure - Stockholders&apos; Equity - Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="onct_NoncashLeaseExpense" name="NoncashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_IncreaseDecreaseInOperatingLeaseLiability" name="IncreaseDecreaseInOperatingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_CashlessExerciseOfWarrants" name="CashlessExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" name="AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" name="AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_ExerciseOfCashlessWarrantShares" name="ExerciseOfCashlessWarrantShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" name="AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" name="IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_COVID19PandemicAndCARESActDisclosureTextBlock" name="COVID19PandemicAndCARESActDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_COVID19PandemicAndCARESActAbstract" name="COVID19PandemicAndCARESActAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_LiquidityAndGoingConcernPolicyTextBlock" name="LiquidityAndGoingConcernPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_UnauditedInterimFinancialInformationPolicyTextBlock" name="UnauditedInterimFinancialInformationPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_ConcentrationRiskCreditRiskPolicyTextBlock" name="ConcentrationRiskCreditRiskPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_PatentCostsPolicyTextBlock" name="PatentCostsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_ScheduleOfWarrantActivityTableTextBlock" name="ScheduleOfWarrantActivityTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_AccruedClinicalTrials" name="AccruedClinicalTrials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_StockExchangeRatio" name="StockExchangeRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_OwnershipPercentageOfStockholdersUponClosingOfMerger" name="OwnershipPercentageOfStockholdersUponClosingOfMerger" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_PreferredStockWarrantLiability" name="PreferredStockWarrantLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_CommonStockWarrantsMember" name="CommonStockWarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_CommonStockSubjectToRepurchaseMember" name="CommonStockSubjectToRepurchaseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_AccruedResearchAndDevelopmentExpenses" name="AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_OfficeSpaceMember" name="OfficeSpaceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" name="ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_AnnualBaseRent" name="AnnualBaseRent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" name="LicenseMaintenanceFeeToBePaidAndPaymentMade" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_CollaborativeArrangementPotentialMilestonePayments" name="CollaborativeArrangementPotentialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_ExclusiveLicenseAgreementMember" name="ExclusiveLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_GeorgetownUniversityMember" name="GeorgetownUniversityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_MDAndersonCancerCenterMember" name="MDAndersonCancerCenterMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_ReagentsMember" name="ReagentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_ResearchAgreementMember" name="ResearchAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_RegentsLicenseAgreementMember" name="RegentsLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_LicenseAgreementMember" name="LicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_UniversityOfTennesseeResearchFoundationMember" name="UniversityOfTennesseeResearchFoundationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" name="CaliforniaInstituteForRegenerativeMedicineAwardMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_UniversityOfCaliforniaSanDiegoMember" name="UniversityOfCaliforniaSanDiegoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_NumberOfDaysInWrittenNoticeOfTermination" name="NumberOfDaysInWrittenNoticeOfTermination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" name="NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" name="NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" name="MinimumPeriodOfWrittenNoticeToTerminateAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" name="CollaborativeArrangementPotentialRegulatoryMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_UpfrontLicenseFeesPaid" name="UpfrontLicenseFeesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" name="SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_AdvanceLicensedAssets" name="AdvanceLicensedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_AnnualLicenseMaintenanceFees" name="AnnualLicenseMaintenanceFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_ResearchAgreementTerm" name="ResearchAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_ResearchAgreementResearchFundingAmount" name="ResearchAgreementResearchFundingAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_ResearchAgreementResearchFundingAmountPayable" name="ResearchAgreementResearchFundingAmountPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_ResearchAndDevelopmentGrants" name="ResearchAndDevelopmentGrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" name="DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_SubawardPaymentsReceived" name="SubawardPaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_RelatedQualifyingSubawardCosts" name="RelatedQualifyingSubawardCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_AmountAgreedToBeProvidedInContingencyFunds" name="AmountAgreedToBeProvidedInContingencyFunds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" name="CombinedPurchasePriceOfShareAndWarrantPerUnit" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="onct_PurchaseAgreementMember" name="PurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_PlacementAgentMember" name="PlacementAgentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_JulyPurchaseAgreementMember" name="JulyPurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_AugustUnderwritingAgreementMember" name="AugustUnderwritingAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_NovemberUnderwritingAgreementMember" name="NovemberUnderwritingAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_DecemberUnderwritingAgreementMember" name="DecemberUnderwritingAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_CommonStockWarrantsExpirationDate" name="CommonStockWarrantsExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_WarrantsGranted" name="WarrantsGranted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_WarrantsCancelled" name="WarrantsCancelled" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_ExerciseOfWarrants" name="ExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_WarrantExercisedPricePerShare" name="WarrantExercisedPricePerShare" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" name="ClassOfWarrantWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_WarrantWeightedAverageRemainingContractualTermExercised" name="WarrantWeightedAverageRemainingContractualTermExercised" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" name="SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="onct_TwoThousandNineteenIncentiveAwardPlanMember" name="TwoThousandNineteenIncentiveAwardPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" name="TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_TwoThousandThirteenPlanMember" name="TwoThousandThirteenPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_TwoThousandFifteenPlanMember" name="TwoThousandFifteenPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_GTxStockOptionPlansMember" name="GTxStockOptionPlansMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_PrivateOncternalMember" name="PrivateOncternalMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_TwoThousandNineteenPlanMember" name="TwoThousandNineteenPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_InducementPlanMember" name="InducementPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" name="TwoThousandNineteenAndTwoThousandFifteenPlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_EquityIncentivePlanMember" name="EquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="onct_CommonStockWarrantsReservedForFutureIssuance" name="CommonStockWarrantsReservedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" name="CommonStockOptionsIssuedAndOutstandingForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>onct-20210331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-05T22:37:37.7157565+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 6f376e511213405db71fc059864ab73e -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="onct-20210331.xsd#TemplateLink" roleURI="http://www.oncternal.com/20210331/role/TemplateLink" />
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:href="onct-20210331.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenue" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:href="onct-20210331.xsd#Role_StatementCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_InvestmentIncomeInterest" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:href="onct-20210331.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="onct-20210331.xsd#onct_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="onct_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="onct-20210331.xsd#onct_NoncashLeaseExpense" xlink:type="locator" xlink:label="onct_NoncashLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="onct_NoncashLeaseExpense" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10090.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="onct_IncreaseDecreaseInOperatingLeaseLiability" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10130.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" xlink:href="onct-20210331.xsd#Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AccruedClinicalTrials" xlink:type="locator" xlink:label="onct_AccruedClinicalTrials" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AccruedResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="onct_AccruedResearchAndDevelopmentExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="onct_AccruedResearchAndDevelopmentExpenses" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="onct_AccruedClinicalTrials" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10050.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="onct-20210331.xsd#Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10040.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2" xlink:href="onct-20210331.xsd#Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>onct-20210331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-05T22:37:37.7167559+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 6f376e511213405db71fc059864ab73e -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="onct-20210331.xsd#TemplateLink" roleURI="http://www.oncternal.com/20210331/role/TemplateLink" />
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="onct-20210331.xsd#Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="onct-20210331.xsd#onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" xlink:type="locator" xlink:label="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ExerciseOfCashlessWarrantShares" xlink:type="locator" xlink:label="onct_ExerciseOfCashlessWarrantShares" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_ExerciseOfCashlessWarrantShares" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="onct-20210331.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ScheduleOfWarrantActivityTableTextBlock" xlink:type="locator" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_ScheduleOfWarrantActivityTableTextBlock" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock" order="10370.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail" xlink:href="onct-20210331.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CommonStockSubjectToRepurchaseMember" xlink:type="locator" xlink:label="onct_CommonStockSubjectToRepurchaseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CommonStockWarrantsMember" xlink:type="locator" xlink:label="onct_CommonStockWarrantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="onct_CommonStockWarrantsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="onct_CommonStockSubjectToRepurchaseMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="onct-20210331.xsd#Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AnnualBaseRent" xlink:type="locator" xlink:label="onct_AnnualBaseRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetRentableArea" xlink:type="locator" xlink:label="us-gaap_NetRentableArea" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" xlink:type="locator" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="onct-20210331.xsd#onct_OfficeSpaceMember" xlink:type="locator" xlink:label="onct_OfficeSpaceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="onct_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="onct_CommitmentsAndContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="onct_CommitmentsAndContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="onct_OfficeSpaceMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_NetRentableArea" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="onct_AnnualBaseRent" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties" order="10950.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails" xlink:href="onct-20210331.xsd#Role_DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="onct-20210331.xsd#onct_AmountAgreedToBeProvidedInContingencyFunds" xlink:type="locator" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds" />
    <link:loc xlink:href="onct-20210331.xsd#onct_RelatedQualifyingSubawardCosts" xlink:type="locator" xlink:label="onct_RelatedQualifyingSubawardCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="onct-20210331.xsd#onct_SubawardPaymentsReceived" xlink:type="locator" xlink:label="onct_SubawardPaymentsReceived" />
    <link:loc xlink:href="onct-20210331.xsd#onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" xlink:type="locator" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ResearchAndDevelopmentGrants" xlink:type="locator" xlink:label="onct_ResearchAndDevelopmentGrants" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ResearchAgreementResearchFundingAmountPayable" xlink:type="locator" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ResearchAgreementResearchFundingAmount" xlink:type="locator" xlink:label="onct_ResearchAgreementResearchFundingAmount" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ResearchAgreementTerm" xlink:type="locator" xlink:label="onct_ResearchAgreementTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AdvanceLicensedAssets" xlink:type="locator" xlink:label="onct_AdvanceLicensedAssets" />
    <link:loc xlink:href="onct-20210331.xsd#onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" xlink:type="locator" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AnnualLicenseMaintenanceFees" xlink:type="locator" xlink:label="onct_AnnualLicenseMaintenanceFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="onct-20210331.xsd#onct_UpfrontLicenseFeesPaid" xlink:type="locator" xlink:label="onct_UpfrontLicenseFeesPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" xlink:type="locator" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" />
    <link:loc xlink:href="onct-20210331.xsd#onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" xlink:type="locator" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" />
    <link:loc xlink:href="onct-20210331.xsd#onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" xlink:type="locator" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" />
    <link:loc xlink:href="onct-20210331.xsd#onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" xlink:type="locator" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" />
    <link:loc xlink:href="onct-20210331.xsd#onct_NumberOfDaysInWrittenNoticeOfTermination" xlink:type="locator" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CollaborativeArrangementPotentialMilestonePayments" xlink:type="locator" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments" />
    <link:loc xlink:href="onct-20210331.xsd#onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" xlink:type="locator" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" />
    <link:loc xlink:href="onct-20210331.xsd#onct_UniversityOfCaliforniaSanDiegoMember" xlink:type="locator" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" xlink:type="locator" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="onct-20210331.xsd#onct_UniversityOfTennesseeResearchFoundationMember" xlink:type="locator" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_LicenseAgreementMember" xlink:type="locator" xlink:label="onct_LicenseAgreementMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_RegentsLicenseAgreementMember" xlink:type="locator" xlink:label="onct_RegentsLicenseAgreementMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ResearchAgreementMember" xlink:type="locator" xlink:label="onct_ResearchAgreementMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ReagentsMember" xlink:type="locator" xlink:label="onct_ReagentsMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_MDAndersonCancerCenterMember" xlink:type="locator" xlink:label="onct_MDAndersonCancerCenterMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_GeorgetownUniversityMember" xlink:type="locator" xlink:label="onct_GeorgetownUniversityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ExclusiveLicenseAgreementMember" xlink:type="locator" xlink:label="onct_ExclusiveLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ExclusiveLicenseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_GeorgetownUniversityMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_MDAndersonCancerCenterMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_ReagentsMember" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ResearchAgreementMember" order="11050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_RegentsLicenseAgreementMember" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_LicenseAgreementMember" order="11410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_UniversityOfTennesseeResearchFoundationMember" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="11480.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_UniversityOfCaliforniaSanDiegoMember" order="11670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" order="12000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_CollaborativeArrangementPotentialMilestonePayments" order="12060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysInWrittenNoticeOfTermination" order="12150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" order="12170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" order="12190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" order="12210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" order="12260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="12420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_UpfrontLicenseFeesPaid" order="12530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AnnualLicenseMaintenanceFees" order="12650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" order="12830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AdvanceLicensedAssets" order="12890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="12950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementTerm" order="13100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementResearchFundingAmount" order="13140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementResearchFundingAmountPayable" order="13180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAndDevelopmentGrants" order="13410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" order="13510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_SubawardPaymentsReceived" order="13610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="13710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_RelatedQualifyingSubawardCosts" order="13810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AmountAgreedToBeProvidedInContingencyFunds" order="14000.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails" xlink:href="onct-20210331.xsd#Role_DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails">
    <link:loc xlink:href="onct-20210331.xsd#onct_CommonStockWarrantsExpirationDate" xlink:type="locator" xlink:label="onct_CommonStockWarrantsExpirationDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" xlink:type="locator" xlink:label="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="onct-20210331.xsd#onct_DecemberUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_DecemberUnderwritingAgreementMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_NovemberUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_NovemberUnderwritingAgreementMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AugustUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_AugustUnderwritingAgreementMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_JulyPurchaseAgreementMember" xlink:type="locator" xlink:label="onct_JulyPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="onct-20210331.xsd#onct_PlacementAgentMember" xlink:type="locator" xlink:label="onct_PlacementAgentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CommonStockWarrantsMember" xlink:type="locator" xlink:label="onct_CommonStockWarrantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="onct-20210331.xsd#onct_PurchaseAgreementMember" xlink:type="locator" xlink:label="onct_PurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalizationEquityTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalizationEquityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ScheduleOfCapitalizationEquityTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_PurchaseAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_2" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="onct_CommonStockWarrantsMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="srt_TitleOfIndividualAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_2" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="onct_PlacementAgentMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="srt_RangeAxis" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_JulyPurchaseAgreementMember" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_AugustUnderwritingAgreementMember" order="11330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_NovemberUnderwritingAgreementMember" order="11770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_DecemberUnderwritingAgreementMember" order="12210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="12660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" order="12680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="12740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="onct_CommonStockWarrantsExpirationDate" order="12890.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails" xlink:href="onct-20210331.xsd#Role_DisclosureStockholdersEquityEquityIncentivePlansDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="onct-20210331.xsd#onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" xlink:type="locator" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="onct-20210331.xsd#onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_InducementPlanMember" xlink:type="locator" xlink:label="onct_InducementPlanMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_TwoThousandNineteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenPlanMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_PrivateOncternalMember" xlink:type="locator" xlink:label="onct_PrivateOncternalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="onct-20210331.xsd#onct_GTxStockOptionPlansMember" xlink:type="locator" xlink:label="onct_GTxStockOptionPlansMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_TwoThousandFifteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandFifteenPlanMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_TwoThousandThirteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandThirteenPlanMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_TwoThousandNineteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandThirteenPlanMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandFifteenPlanMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_GTxStockOptionPlansMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_2" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="onct_PrivateOncternalMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenPlanMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_InducementPlanMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" order="10680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10790.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11080.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails" xlink:href="onct-20210331.xsd#Role_DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="onct-20210331.xsd#onct_EquityIncentivePlanMember" xlink:type="locator" xlink:label="onct_EquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_EquityIncentivePlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10730.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="10810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="11350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11430.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails" xlink:href="onct-20210331.xsd#Role_DisclosureStockholdersEquityShareBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" xlink:href="onct-20210331.xsd#Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" xlink:type="locator" xlink:label="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CommonStockWarrantsReservedForFutureIssuance" xlink:type="locator" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance" />
    <link:loc xlink:href="onct-20210331.xsd#onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_CommonStockWarrantsReservedForFutureIssuance" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10160.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>onct-20210331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-05T22:37:37.7167559+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 6f376e511213405db71fc059864ab73e -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCountry_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Country</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid and other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred grant revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease, net of current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 3)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value, authorized shares &#8211; 5,000; issued and outstanding shares &#8211; none</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; authorized shares &#8211; 60,000; issued and outstanding shares &#8211; 49,366 and 48,802 at March 31, 2021 and December 31, 2020, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, liquidation preference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Liquidation Preference</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Excluding Acquired In Process Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_NoncashLeaseExpense" xlink:type="locator" xlink:label="onct_NoncashLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="onct_NoncashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash lease expense.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NoncashLeaseExpense" xlink:to="onct_NoncashLeaseExpense_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="onct_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="onct_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="onct_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CashlessExerciseOfWarrants" xlink:type="locator" xlink:label="onct_CashlessExerciseOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="onct_CashlessExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cashless exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CashlessExerciseOfWarrants" xlink:to="onct_CashlessExerciseOfWarrants_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NoncashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NoncashLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Lease Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid and other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in lease liability</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred grant revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net cash provided by investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of common stock warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Warrant Exercises</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net decrease in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CashlessExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cashless exercise of warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CashlessExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cashless Exercise Of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1" xlink:type="locator" xlink:label="us-gaap_StockIssued1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of 2019 bonus awards with stock options in lieu of cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssued1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="locator" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred financing costs included in accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" />
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital exercise of warrants to purchase common stock for cash shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" />
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital exercise of warrants to purchase common stock for cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ExerciseOfCashlessWarrantShares" xlink:type="locator" xlink:label="onct_ExerciseOfCashlessWarrantShares" />
    <link:label xml:lang="en-US" xlink:label="onct_ExerciseOfCashlessWarrantShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cashless exercise of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ExerciseOfCashlessWarrantShares" xlink:to="onct_ExerciseOfCashlessWarrantShares_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" />
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments to additional paid in capital vesting related to unvested share liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" xlink:type="locator" xlink:label="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" />
    <link:label xml:lang="en-US" xlink:label="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of bonus awards with stock option in lieu of cash.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" xlink:to="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options for cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options for cash (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants for cash</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Exercise Of Warrants To Purchase Common Stock For Cash</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of warrants for cash (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Exercise Of Warrants To Purchase Common Stock For Cash Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ExerciseOfCashlessWarrantShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cashless exercise of warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ExerciseOfCashlessWarrantShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Cashless Warrant Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting related to unvested share liability</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Vesting Related To Unvested Share Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of 2019 bonus award with stock options in lieu of cash</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Bonus Awards With Stock Option In Lieu Of Cash</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Description And Basis Of Presentation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Details</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments, Contingencies and Related Party Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License, Collaboration and Research Subaward Agreements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_COVID19PandemicAndCARESActDisclosureTextBlock" xlink:type="locator" xlink:label="onct_COVID19PandemicAndCARESActDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="onct_COVID19PandemicAndCARESActDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">COVID-19 Pandemic and CARES Act.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_COVID19PandemicAndCARESActDisclosureTextBlock" xlink:to="onct_COVID19PandemicAndCARESActDisclosureTextBlock_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_COVID19PandemicAndCARESActAbstract" xlink:type="locator" xlink:label="onct_COVID19PandemicAndCARESActAbstract" />
    <link:label xml:lang="en-US" xlink:label="onct_COVID19PandemicAndCARESActAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">COVID-19 Pandemic and CARES Act.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_COVID19PandemicAndCARESActAbstract" xlink:to="onct_COVID19PandemicAndCARESActAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_COVID19PandemicAndCARESActAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C O V I D19 Pandemic And C A R E S Act [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_COVID19PandemicAndCARESActDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COVID-19 Pandemic and CARES Act</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_COVID19PandemicAndCARESActDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C O V I D19 Pandemic And C A R E S Act Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merger</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_LiquidityAndGoingConcernPolicyTextBlock" xlink:type="locator" xlink:label="onct_LiquidityAndGoingConcernPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="onct_LiquidityAndGoingConcernPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Liquidity and going concern.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="onct_LiquidityAndGoingConcernPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_LiquidityAndGoingConcernPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity and Going Concern</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_LiquidityAndGoingConcernPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity And Going Concern Policy [Text Block]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:type="locator" xlink:label="onct_UnauditedInterimFinancialInformationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="onct_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unaudited interim financial information policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:to="onct_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_UnauditedInterimFinancialInformationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unaudited Interim Financial Information Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_ConcentrationRiskCreditRiskPolicyTextBlock" xlink:type="locator" xlink:label="onct_ConcentrationRiskCreditRiskPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="onct_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration risk credit risk policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ConcentrationRiskCreditRiskPolicyTextBlock" xlink:to="onct_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ConcentrationRiskCreditRiskPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Credit Risk Policy [Text Block]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_PatentCostsPolicyTextBlock" xlink:type="locator" xlink:label="onct_PatentCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="onct_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Patent costs policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PatentCostsPolicyTextBlock" xlink:to="onct_PatentCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Patent Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PatentCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Patent Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses and Accruals</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Maturities of Lease Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_ScheduleOfWarrantActivityTableTextBlock" xlink:type="locator" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of warrant activity table text block.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ScheduleOfWarrantActivityTableTextBlock" xlink:to="onct_ScheduleOfWarrantActivityTableTextBlock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Warrant Activity And Changes In Warrants Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Warrant Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Outstanding, Vested and Expected to Vest and Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions Used to Determine Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Reserved for Future Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Text Block]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_AccruedClinicalTrials" xlink:type="locator" xlink:label="onct_AccruedClinicalTrials" />
    <link:label xml:lang="en-US" xlink:label="onct_AccruedClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical trials.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AccruedClinicalTrials" xlink:to="onct_AccruedClinicalTrials_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_AccruedClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Clinical Trials</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AccruedClinicalTrials_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical Trials</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_StockExchangeRatio" xlink:type="locator" xlink:label="onct_StockExchangeRatio" />
    <link:label xml:lang="en-US" xlink:label="onct_StockExchangeRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock exchange ratio.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_StockExchangeRatio" xlink:to="onct_StockExchangeRatio_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_OwnershipPercentageOfStockholdersUponClosingOfMerger" xlink:type="locator" xlink:label="onct_OwnershipPercentageOfStockholdersUponClosingOfMerger" />
    <link:label xml:lang="en-US" xlink:label="onct_OwnershipPercentageOfStockholdersUponClosingOfMerger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">ownership percentage of stockholders upon closing of merger.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_OwnershipPercentageOfStockholdersUponClosingOfMerger" xlink:to="onct_OwnershipPercentageOfStockholdersUponClosingOfMerger_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_PreferredStockWarrantLiability" xlink:type="locator" xlink:label="onct_PreferredStockWarrantLiability" />
    <link:label xml:lang="en-US" xlink:label="onct_PreferredStockWarrantLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock warrant liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PreferredStockWarrantLiability" xlink:to="onct_PreferredStockWarrantLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_StockExchangeRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock and preferred stock exchange ratio</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_StockExchangeRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Exchange Ratio</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_OwnershipPercentageOfStockholdersUponClosingOfMerger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership percentage of stockholders upon closing of merger</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_OwnershipPercentageOfStockholdersUponClosingOfMerger_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ownership Percentage Of Stockholders Upon Closing Of Merger</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PreferredStockWarrantLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PreferredStockWarrantLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Warrant Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable" xlink:type="locator" xlink:label="us-gaap_GrantsReceivable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GrantsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grants receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GrantsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Grants Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares subject to repurchase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_CommonStockWarrantsMember" xlink:type="locator" xlink:label="onct_CommonStockWarrantsMember" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommonStockWarrantsMember" xlink:to="onct_CommonStockWarrantsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants [Member]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_CommonStockSubjectToRepurchaseMember" xlink:type="locator" xlink:label="onct_CommonStockSubjectToRepurchaseMember" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockSubjectToRepurchaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock subject to repurchase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommonStockSubjectToRepurchaseMember" xlink:to="onct_CommonStockSubjectToRepurchaseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockSubjectToRepurchaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Subject to Repurchase</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockSubjectToRepurchaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Subject To Repurchase [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potentially dilutive securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_AccruedResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="onct_AccruedResearchAndDevelopmentExpenses" />
    <link:label xml:lang="en-US" xlink:label="onct_AccruedResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AccruedResearchAndDevelopmentExpenses" xlink:to="onct_AccruedResearchAndDevelopmentExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_AccruedResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AccruedResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued liabilities</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="onct_CommitmentsAndContingenciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="onct_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="onct_CommitmentsAndContingenciesLineItems_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="onct_CommitmentsAndContingenciesTable" />
    <link:label xml:lang="en-US" xlink:label="onct_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="onct_CommitmentsAndContingenciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">San Diego, California</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_OfficeSpaceMember" xlink:type="locator" xlink:label="onct_OfficeSpaceMember" />
    <link:label xml:lang="en-US" xlink:label="onct_OfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_OfficeSpaceMember" xlink:to="onct_OfficeSpaceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_OfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Space</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_OfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Space [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" xlink:type="locator" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" />
    <link:label xml:lang="en-US" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shanghai Pharmaceutical United States of America Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" xlink:to="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shanghai Pharmaceutical (USA) Inc.</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shanghai Pharmaceutical United States Of America Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease And Rental Expense</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_AnnualBaseRent" xlink:type="locator" xlink:label="onct_AnnualBaseRent" />
    <link:label xml:lang="en-US" xlink:label="onct_AnnualBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual base rent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AnnualBaseRent" xlink:to="onct_AnnualBaseRent_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetRentableArea" xlink:type="locator" xlink:label="us-gaap_NetRentableArea" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetRentableArea_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rentable area</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetRentableArea" xlink:to="us-gaap_NetRentableArea_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetRentableArea_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Rentable Area</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AnnualBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual base rent</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AnnualBaseRent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Base Rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Discount Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Weighted Average Remaining Lease Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liabilities Payments Due [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Remainder Of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less current portion of lease liability</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedParties" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedParties" xlink:to="us-gaap_AccountsReceivableRelatedParties_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Related Parties</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" xlink:type="locator" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" />
    <link:label xml:lang="en-US" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License maintenance fee to be paid and payment made.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" xlink:to="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CollaborativeArrangementPotentialMilestonePayments" xlink:type="locator" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement, potential milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CollaborativeArrangementPotentialMilestonePayments" xlink:to="onct_CollaborativeArrangementPotentialMilestonePayments_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_ExclusiveLicenseAgreementMember" xlink:type="locator" xlink:label="onct_ExclusiveLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_ExclusiveLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exclusive license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ExclusiveLicenseAgreementMember" xlink:to="onct_ExclusiveLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ExclusiveLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exclusive License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ExclusiveLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exclusive License Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_GeorgetownUniversityMember" xlink:type="locator" xlink:label="onct_GeorgetownUniversityMember" />
    <link:label xml:lang="en-US" xlink:label="onct_GeorgetownUniversityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Georgetown University.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_GeorgetownUniversityMember" xlink:to="onct_GeorgetownUniversityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_GeorgetownUniversityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Georgetown University</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_GeorgetownUniversityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Georgetown University [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_MDAndersonCancerCenterMember" xlink:type="locator" xlink:label="onct_MDAndersonCancerCenterMember" />
    <link:label xml:lang="en-US" xlink:label="onct_MDAndersonCancerCenterMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">MD Anderson Cancer Center.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_MDAndersonCancerCenterMember" xlink:to="onct_MDAndersonCancerCenterMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_MDAndersonCancerCenterMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MD Anderson Cancer Center</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_MDAndersonCancerCenterMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">M D Anderson Cancer Center [Member]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_ReagentsMember" xlink:type="locator" xlink:label="onct_ReagentsMember" />
    <link:label xml:lang="en-US" xlink:label="onct_ReagentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reagents.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ReagentsMember" xlink:to="onct_ReagentsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ReagentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regents of the University of California</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ReagentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reagents [Member]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_ResearchAgreementMember" xlink:type="locator" xlink:label="onct_ResearchAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementMember" xlink:to="onct_ResearchAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement [Member]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_RegentsLicenseAgreementMember" xlink:type="locator" xlink:label="onct_RegentsLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_RegentsLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Regents license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_RegentsLicenseAgreementMember" xlink:to="onct_RegentsLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_RegentsLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regents License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_RegentsLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Regents License Agreement [Member]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_LicenseAgreementMember" xlink:type="locator" xlink:label="onct_LicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_LicenseAgreementMember" xlink:to="onct_LicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_LicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Member]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_UniversityOfTennesseeResearchFoundationMember" xlink:type="locator" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember" />
    <link:label xml:lang="en-US" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">University of Tennessee Research Foundation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_UniversityOfTennesseeResearchFoundationMember" xlink:to="onct_UniversityOfTennesseeResearchFoundationMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">University of Tennessee Research Foundation</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">University Of Tennessee Research Foundation [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" xlink:type="locator" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" />
    <link:label xml:lang="en-US" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">California Institute for Regenerative Medicine Award.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" xlink:to="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">The California Institute for Regenerative Medicine ("CIRM") Award</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">California Institute For Regenerative Medicine Award [Member]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_UniversityOfCaliforniaSanDiegoMember" xlink:type="locator" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember" />
    <link:label xml:lang="en-US" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">University of California San Diego.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_UniversityOfCaliforniaSanDiegoMember" xlink:to="onct_UniversityOfCaliforniaSanDiegoMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">University of California San Diego School of Medicine</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">University Of California San Diego [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license maintenance fee to be paid and payment made</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Maintenance Fee To Be Paid And Payment Made</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Potential Milestone Payments</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_NumberOfDaysInWrittenNoticeOfTermination" xlink:type="locator" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination" />
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of days in written notice of termination.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NumberOfDaysInWrittenNoticeOfTermination" xlink:to="onct_NumberOfDaysInWrittenNoticeOfTermination_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" xlink:type="locator" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" />
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of days after receipt of notice in fails to pay amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" xlink:type="locator" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" />
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of days after receipt of notice for default in payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" xlink:type="locator" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" />
    <link:label xml:lang="en-US" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum period of written notice to terminate agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" xlink:to="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice of termination, period</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Days In Written Notice Of Termination</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Days after receipt of notice, to pay failure amount</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Days After Receipt Of Notice To Pay Failure Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Days after receipt of notice for default in payment</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Days After Receipt Of Notice For Default In Payment</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum period in days of written notice to terminate license agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Period Of Written Notice To Terminate Agreement</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" xlink:type="locator" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" />
    <link:label xml:lang="en-US" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborative arrangement, potential regulatory milestone payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" xlink:to="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential regulatory milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Potential Regulatory Milestone Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment Aggregate Cost</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_UpfrontLicenseFeesPaid" xlink:type="locator" xlink:label="onct_UpfrontLicenseFeesPaid" />
    <link:label xml:lang="en-US" xlink:label="onct_UpfrontLicenseFeesPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront license fees paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_UpfrontLicenseFeesPaid" xlink:to="onct_UpfrontLicenseFeesPaid_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" xlink:type="locator" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" />
    <link:label xml:lang="en-US" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Worldwide sales milestones based on achievement of tiered revenue levels.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" xlink:to="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AdvanceLicensedAssets" xlink:type="locator" xlink:label="onct_AdvanceLicensedAssets" />
    <link:label xml:lang="en-US" xlink:label="onct_AdvanceLicensedAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Advance licensed assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AdvanceLicensedAssets" xlink:to="onct_AdvanceLicensedAssets_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AnnualLicenseMaintenanceFees" xlink:type="locator" xlink:label="onct_AnnualLicenseMaintenanceFees" />
    <link:label xml:lang="en-US" xlink:label="onct_AnnualLicenseMaintenanceFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual license maintenance fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AnnualLicenseMaintenanceFees" xlink:to="onct_AnnualLicenseMaintenanceFees_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_UpfrontLicenseFeesPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront license fees paid</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_UpfrontLicenseFeesPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront License Fees Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares, issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AnnualLicenseMaintenanceFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license maintenance fees</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AnnualLicenseMaintenanceFees_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual License Maintenance Fees</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Worldwide sales milestones based on achievement of tiered revenue levels</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestones Based On Achievement Of Tiered Revenue Levels</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdvanceLicensedAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advance licensed assets</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AdvanceLicensedAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Advance Licensed Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Patent costs as general and administrative expense</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_ResearchAgreementTerm" xlink:type="locator" xlink:label="onct_ResearchAgreementTerm" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementTerm" xlink:to="onct_ResearchAgreementTerm_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ResearchAgreementResearchFundingAmount" xlink:type="locator" xlink:label="onct_ResearchAgreementResearchFundingAmount" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementResearchFundingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement research funding amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementResearchFundingAmount" xlink:to="onct_ResearchAgreementResearchFundingAmount_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ResearchAgreementResearchFundingAmountPayable" xlink:type="locator" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research agreement research funding amount payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAgreementResearchFundingAmountPayable" xlink:to="onct_ResearchAgreementResearchFundingAmountPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research agreement term</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Term</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementResearchFundingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate research agreement budget</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementResearchFundingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Research Funding Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research amount payable quarterly</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Agreement Research Funding Amount Payable</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_ResearchAndDevelopmentGrants" xlink:type="locator" xlink:label="onct_ResearchAndDevelopmentGrants" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAndDevelopmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development grants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ResearchAndDevelopmentGrants" xlink:to="onct_ResearchAndDevelopmentGrants_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" xlink:type="locator" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" />
    <link:label xml:lang="en-US" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Development milestones to be received under research subaward agreements throughout award project period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" xlink:to="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_SubawardPaymentsReceived" xlink:type="locator" xlink:label="onct_SubawardPaymentsReceived" />
    <link:label xml:lang="en-US" xlink:label="onct_SubawardPaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Subaward payments received.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_SubawardPaymentsReceived" xlink:to="onct_SubawardPaymentsReceived_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_RelatedQualifyingSubawardCosts" xlink:type="locator" xlink:label="onct_RelatedQualifyingSubawardCosts" />
    <link:label xml:lang="en-US" xlink:label="onct_RelatedQualifyingSubawardCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related qualifying subaward costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_RelatedQualifyingSubawardCosts" xlink:to="onct_RelatedQualifyingSubawardCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAndDevelopmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grants awarded to researchers</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ResearchAndDevelopmentGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Grants</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development milestones to be received under research subaward agreements throughout award project period</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Development Milestones To Be Received Under Research Subaward Agreements Throughout Award Project Period</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_SubawardPaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subaward payments received</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_SubawardPaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subaward Payments Received</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_RelatedQualifyingSubawardCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related qualifying subaward costs</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_RelatedQualifyingSubawardCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Qualifying Subaward Costs</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_AmountAgreedToBeProvidedInContingencyFunds" xlink:type="locator" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds" />
    <link:label xml:lang="en-US" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount agreed to be provided in contingency funds.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AmountAgreedToBeProvidedInContingencyFunds" xlink:to="onct_AmountAgreedToBeProvidedInContingencyFunds_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount agreed to be provided in contingency funds</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amount Agreed To Be Provided In Contingency Funds</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" xlink:type="locator" xlink:label="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" />
    <link:label xml:lang="en-US" xlink:label="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Combined purchase price of share and warrant per unit.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" xlink:to="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalizationEquityTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCapitalizationEquityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Capitalization Equity [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_ScheduleOfCapitalizationEquityTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCapitalizationEquityTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Capitalization Equity [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_PurchaseAgreementMember" xlink:type="locator" xlink:label="onct_PurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_PurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase agreement member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PurchaseAgreementMember" xlink:to="onct_PurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_PurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Warrant or Right</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Title Of Individual With Relationship To Entity [Domain]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_PlacementAgentMember" xlink:type="locator" xlink:label="onct_PlacementAgentMember" />
    <link:label xml:lang="en-US" xlink:label="onct_PlacementAgentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Placement agent member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PlacementAgentMember" xlink:to="onct_PlacementAgentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_PlacementAgentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Placement Agent</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PlacementAgentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Placement Agent [Member]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_JulyPurchaseAgreementMember" xlink:type="locator" xlink:label="onct_JulyPurchaseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_JulyPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">July purchase agreement member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_JulyPurchaseAgreementMember" xlink:to="onct_JulyPurchaseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_JulyPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">July Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_JulyPurchaseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">July Purchase Agreement [Member]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_AugustUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_AugustUnderwritingAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_AugustUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">August underwriting agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_AugustUnderwritingAgreementMember" xlink:to="onct_AugustUnderwritingAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_AugustUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">August Underwriting Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_AugustUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">August Underwriting Agreement [Member]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_NovemberUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_NovemberUnderwritingAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_NovemberUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">November underwriting agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_NovemberUnderwritingAgreementMember" xlink:to="onct_NovemberUnderwritingAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_NovemberUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">November Underwriting Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_NovemberUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">November Underwriting Agreement [Member]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_DecemberUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_DecemberUnderwritingAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="onct_DecemberUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">December underwriting agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_DecemberUnderwritingAgreementMember" xlink:to="onct_DecemberUnderwritingAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_DecemberUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">December Underwriting Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_DecemberUnderwritingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">December Underwriting Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalizationEquityLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCapitalizationEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Capitalization Equity [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ScheduleOfCapitalizationEquityLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCapitalizationEquityLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Capitalization Equity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock and common stock warrants, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Combined purchase price of share and warrant per unit</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Combined Purchase Price Of Share And Warrant Per Unit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants exercisable and expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_CommonStockWarrantsExpirationDate" xlink:type="locator" xlink:label="onct_CommonStockWarrantsExpirationDate" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants expiration date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommonStockWarrantsExpirationDate" xlink:to="onct_CommonStockWarrantsExpirationDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants expiration date</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants Expiration Date</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_WarrantsGranted" xlink:type="locator" xlink:label="onct_WarrantsGranted" />
    <link:label xml:lang="en-US" xlink:label="onct_WarrantsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_WarrantsGranted" xlink:to="onct_WarrantsGranted_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_WarrantsCancelled" xlink:type="locator" xlink:label="onct_WarrantsCancelled" />
    <link:label xml:lang="en-US" xlink:label="onct_WarrantsCancelled_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants cancelled.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_WarrantsCancelled" xlink:to="onct_WarrantsCancelled_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ExerciseOfWarrants" xlink:type="locator" xlink:label="onct_ExerciseOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="onct_ExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ExerciseOfWarrants" xlink:to="onct_ExerciseOfWarrants_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options outstanding, Number of Warrant</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_WarrantsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_WarrantsGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Granted</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_WarrantsCancelled_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_WarrantsCancelled_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Warrants Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ExerciseOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options outstanding, Number of Warrant</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_WarrantExercisedPricePerShare" xlink:type="locator" xlink:label="onct_WarrantExercisedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="onct_WarrantExercisedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant exercised price per share.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_WarrantExercisedPricePerShare" xlink:to="onct_WarrantExercisedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_WarrantExercisedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_WarrantExercisedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Exercised Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" />
    <link:label xml:lang="en-US" xlink:label="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Class of warrant weighted-average remaining contractual term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" xlink:to="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_WarrantWeightedAverageRemainingContractualTermExercised" xlink:type="locator" xlink:label="onct_WarrantWeightedAverageRemainingContractualTermExercised" />
    <link:label xml:lang="en-US" xlink:label="onct_WarrantWeightedAverageRemainingContractualTermExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant weighted average remaining contractual term exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_WarrantWeightedAverageRemainingContractualTermExercised" xlink:to="onct_WarrantWeightedAverageRemainingContractualTermExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_WarrantWeightedAverageRemainingContractualTermExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contractual Term, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_WarrantWeightedAverageRemainingContractualTermExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Weighted Average Remaining Contractual Term Exercised</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" xlink:type="locator" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" />
    <link:label xml:lang="en-US" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">The annual percentage increase in shares reserved for issuance under sharebased compensation arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" xlink:to="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_TwoThousandNineteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen incentive award plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_TwoThousandNineteenIncentiveAwardPlanMember" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 incentive award plan</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Incentive Award Plan [Member]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen incentive award plan and inducement plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 incentive award plan and inducement plan</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Incentive Award Plan And Inducement Plan [Member]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_TwoThousandThirteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandThirteenPlanMember" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandThirteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand thirteen plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_TwoThousandThirteenPlanMember" xlink:to="onct_TwoThousandThirteenPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandThirteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2013 plan</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandThirteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Thirteen Plan [Member]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_TwoThousandFifteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandFifteenPlanMember" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandFifteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fifteen plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_TwoThousandFifteenPlanMember" xlink:to="onct_TwoThousandFifteenPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandFifteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 plan</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandFifteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Plan [Member]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_GTxStockOptionPlansMember" xlink:type="locator" xlink:label="onct_GTxStockOptionPlansMember" />
    <link:label xml:lang="en-US" xlink:label="onct_GTxStockOptionPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Gtx stock option plans.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_GTxStockOptionPlansMember" xlink:to="onct_GTxStockOptionPlansMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_GTxStockOptionPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GTx Stock Option Plans</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_GTxStockOptionPlansMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">G Tx Stock Option Plans [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consolidated Entities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_PrivateOncternalMember" xlink:type="locator" xlink:label="onct_PrivateOncternalMember" />
    <link:label xml:lang="en-US" xlink:label="onct_PrivateOncternalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Private Oncternal.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_PrivateOncternalMember" xlink:to="onct_PrivateOncternalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_PrivateOncternalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Private Oncternal</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_PrivateOncternalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Private Oncternal [Member]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_TwoThousandNineteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenPlanMember" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_TwoThousandNineteenPlanMember" xlink:to="onct_TwoThousandNineteenPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 plan</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Plan [Member]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_InducementPlanMember" xlink:type="locator" xlink:label="onct_InducementPlanMember" />
    <link:label xml:lang="en-US" xlink:label="onct_InducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Inducement plan member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_InducementPlanMember" xlink:to="onct_InducementPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_InducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inducement Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_InducementPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Inducement Plan [Member]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen and two thousand fifteen plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" xlink:to="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 and 2015 plan</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen And Two Thousand Fifteen Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock reserved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum number of shares of common stock a participant may receive</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of annual increase in shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement Percentage Of Annual Increase In Shares Reserved For Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock shares provided for issuance of stock awards to its employees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_EquityIncentivePlanMember" xlink:type="locator" xlink:label="onct_EquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="onct_EquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_EquityIncentivePlanMember" xlink:to="onct_EquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_EquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity incentive plan</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_EquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested and expected to vest, Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable, Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding, Aggregate Intrinsic Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable number.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable weighted average exercise price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of options outstanding and fully vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Number</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average exercise price of options outstanding and fully vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options expiration term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of options, beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, cancelled</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of options, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, cancelled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value per share of option grants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of stock options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compensation cost related to non-vested awards not yet recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Remaining weighted-average period</link:label>
    <link:loc xlink:href="onct-20210331.xsd#onct_CommonStockWarrantsReservedForFutureIssuance" xlink:type="locator" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants reserved for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommonStockWarrantsReservedForFutureIssuance" xlink:to="onct_CommonStockWarrantsReservedForFutureIssuance_lbl" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" xlink:type="locator" xlink:label="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock options issued and outstanding for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" xlink:to="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Aggregate Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock options issued and outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Options Issued And Outstanding For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Common stock available for future issuance</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>onct-20210331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-05-05T22:37:37.7167559+00:00 -->
<!-- Version            : 5.0.1.615 -->
<!-- Package ID         : 6f376e511213405db71fc059864ab73e -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.oncternal.com/20210331/role/TemplateLink" xlink:href="onct-20210331.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="onct-20210331.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCountry" xlink:type="locator" xlink:label="dei_EntityAddressCountry" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCountry" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets" xlink:href="onct-20210331.xsd#Role_StatementCondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenue" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:href="onct-20210331.xsd#Role_StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:href="onct-20210331.xsd#Role_StatementCondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:href="onct-20210331.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="locator" xlink:label="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1" xlink:type="locator" xlink:label="us-gaap_StockIssued1" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CashlessExerciseOfWarrants" xlink:type="locator" xlink:label="onct_CashlessExerciseOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:loc xlink:href="onct-20210331.xsd#onct_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator" xlink:label="onct_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="onct-20210331.xsd#onct_NoncashLeaseExpense" xlink:type="locator" xlink:label="onct_NoncashLeaseExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="onct_NoncashLeaseExpense" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="onct_IncreaseDecreaseInOperatingLeaseLiability" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="11020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_li0l2" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="onct_CashlessExerciseOfWarrants" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockIssued1" order="11300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="onct-20210331.xsd#Role_StatementCondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="onct-20210331.xsd#onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" xlink:type="locator" xlink:label="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ExerciseOfCashlessWarrantShares" xlink:type="locator" xlink:label="onct_ExerciseOfCashlessWarrantShares" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" xlink:type="locator" xlink:label="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_ExerciseOfCashlessWarrantShares" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="11250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_li0l2" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:href="onct-20210331.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetails" xlink:href="onct-20210331.xsd#Role_DisclosureBalanceSheetDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactions" xlink:href="onct-20210331.xsd#Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactions" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactions">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreements" xlink:href="onct-20210331.xsd#Role_DisclosureLicenseCollaborationAndResearchSubawardAgreements" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreements">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquity" xlink:href="onct-20210331.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct" xlink:href="onct-20210331.xsd#Role_DisclosureCOVID19PandemicAndCARESAct" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct">
    <link:loc xlink:href="onct-20210331.xsd#onct_COVID19PandemicAndCARESActDisclosureTextBlock" xlink:type="locator" xlink:label="onct_COVID19PandemicAndCARESActDisclosureTextBlock" />
    <link:loc xlink:href="onct-20210331.xsd#onct_COVID19PandemicAndCARESActAbstract" xlink:type="locator" xlink:label="onct_COVID19PandemicAndCARESActAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_COVID19PandemicAndCARESActAbstract" xlink:to="onct_COVID19PandemicAndCARESActDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="onct-20210331.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="onct-20210331.xsd#onct_PatentCostsPolicyTextBlock" xlink:type="locator" xlink:label="onct_PatentCostsPolicyTextBlock" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ConcentrationRiskCreditRiskPolicyTextBlock" xlink:type="locator" xlink:label="onct_ConcentrationRiskCreditRiskPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="onct-20210331.xsd#onct_UnauditedInterimFinancialInformationPolicyTextBlock" xlink:type="locator" xlink:label="onct_UnauditedInterimFinancialInformationPolicyTextBlock" />
    <link:loc xlink:href="onct-20210331.xsd#onct_LiquidityAndGoingConcernPolicyTextBlock" xlink:type="locator" xlink:label="onct_LiquidityAndGoingConcernPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_LiquidityAndGoingConcernPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_UnauditedInterimFinancialInformationPolicyTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_ConcentrationRiskCreditRiskPolicyTextBlock" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_PatentCostsPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:href="onct-20210331.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsTables" xlink:href="onct-20210331.xsd#Role_DisclosureBalanceSheetDetailsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsTables" xlink:href="onct-20210331.xsd#Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="onct-20210331.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ScheduleOfWarrantActivityTableTextBlock" xlink:type="locator" xlink:label="onct_ScheduleOfWarrantActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="onct_ScheduleOfWarrantActivityTableTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTextBlock" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="onct-20210331.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantsReceivable" xlink:type="locator" xlink:label="us-gaap_GrantsReceivable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <link:loc xlink:href="onct-20210331.xsd#onct_PreferredStockWarrantLiability" xlink:type="locator" xlink:label="onct_PreferredStockWarrantLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="onct-20210331.xsd#onct_OwnershipPercentageOfStockholdersUponClosingOfMerger" xlink:type="locator" xlink:label="onct_OwnershipPercentageOfStockholdersUponClosingOfMerger" />
    <link:loc xlink:href="onct-20210331.xsd#onct_StockExchangeRatio" xlink:type="locator" xlink:label="onct_StockExchangeRatio" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AccruedClinicalTrials" xlink:type="locator" xlink:label="onct_AccruedClinicalTrials" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_AccruedClinicalTrials" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_StockExchangeRatio" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_OwnershipPercentageOfStockholdersUponClosingOfMerger" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="onct_PreferredStockWarrantLiability" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredRevenue" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GrantsReceivable" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail" xlink:href="onct-20210331.xsd#Role_DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CommonStockSubjectToRepurchaseMember" xlink:type="locator" xlink:label="onct_CommonStockSubjectToRepurchaseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CommonStockWarrantsMember" xlink:type="locator" xlink:label="onct_CommonStockWarrantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="onct_CommonStockWarrantsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="onct_CommonStockSubjectToRepurchaseMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" xlink:href="onct-20210331.xsd#Role_DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AccruedClinicalTrials" xlink:type="locator" xlink:label="onct_AccruedClinicalTrials" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AccruedResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="onct_AccruedResearchAndDevelopmentExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="onct_AccruedResearchAndDevelopmentExpenses" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="onct_AccruedClinicalTrials" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="onct-20210331.xsd#Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedParties" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableRelatedParties" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDiscountRate" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AnnualBaseRent" xlink:type="locator" xlink:label="onct_AnnualBaseRent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetRentableArea" xlink:type="locator" xlink:label="us-gaap_NetRentableArea" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="onct_CommitmentsAndContingenciesLineItems" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" xlink:type="locator" xlink:label="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="onct-20210331.xsd#onct_OfficeSpaceMember" xlink:type="locator" xlink:label="onct_OfficeSpaceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="onct_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="onct_CommitmentsAndContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="onct_OfficeSpaceMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesTable" xlink:to="onct_CommitmentsAndContingenciesLineItems" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_NetRentableArea" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="onct_AnnualBaseRent" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDiscountRate" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="onct_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_AccountsReceivableRelatedParties" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails" xlink:href="onct-20210331.xsd#Role_DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails" xlink:href="onct-20210331.xsd#Role_DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails">
    <link:loc xlink:href="onct-20210331.xsd#onct_AmountAgreedToBeProvidedInContingencyFunds" xlink:type="locator" xlink:label="onct_AmountAgreedToBeProvidedInContingencyFunds" />
    <link:loc xlink:href="onct-20210331.xsd#onct_RelatedQualifyingSubawardCosts" xlink:type="locator" xlink:label="onct_RelatedQualifyingSubawardCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <link:loc xlink:href="onct-20210331.xsd#onct_SubawardPaymentsReceived" xlink:type="locator" xlink:label="onct_SubawardPaymentsReceived" />
    <link:loc xlink:href="onct-20210331.xsd#onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" xlink:type="locator" xlink:label="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ResearchAndDevelopmentGrants" xlink:type="locator" xlink:label="onct_ResearchAndDevelopmentGrants" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ResearchAgreementResearchFundingAmountPayable" xlink:type="locator" xlink:label="onct_ResearchAgreementResearchFundingAmountPayable" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ResearchAgreementResearchFundingAmount" xlink:type="locator" xlink:label="onct_ResearchAgreementResearchFundingAmount" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ResearchAgreementTerm" xlink:type="locator" xlink:label="onct_ResearchAgreementTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AdvanceLicensedAssets" xlink:type="locator" xlink:label="onct_AdvanceLicensedAssets" />
    <link:loc xlink:href="onct-20210331.xsd#onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" xlink:type="locator" xlink:label="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AnnualLicenseMaintenanceFees" xlink:type="locator" xlink:label="onct_AnnualLicenseMaintenanceFees" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="onct-20210331.xsd#onct_UpfrontLicenseFeesPaid" xlink:type="locator" xlink:label="onct_UpfrontLicenseFeesPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentAggregateCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" xlink:type="locator" xlink:label="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" />
    <link:loc xlink:href="onct-20210331.xsd#onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" xlink:type="locator" xlink:label="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" />
    <link:loc xlink:href="onct-20210331.xsd#onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" xlink:type="locator" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" />
    <link:loc xlink:href="onct-20210331.xsd#onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" xlink:type="locator" xlink:label="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" />
    <link:loc xlink:href="onct-20210331.xsd#onct_NumberOfDaysInWrittenNoticeOfTermination" xlink:type="locator" xlink:label="onct_NumberOfDaysInWrittenNoticeOfTermination" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CollaborativeArrangementPotentialMilestonePayments" xlink:type="locator" xlink:label="onct_CollaborativeArrangementPotentialMilestonePayments" />
    <link:loc xlink:href="onct-20210331.xsd#onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" xlink:type="locator" xlink:label="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="onct-20210331.xsd#onct_UniversityOfCaliforniaSanDiegoMember" xlink:type="locator" xlink:label="onct_UniversityOfCaliforniaSanDiegoMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" xlink:type="locator" xlink:label="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:href="onct-20210331.xsd#onct_UniversityOfTennesseeResearchFoundationMember" xlink:type="locator" xlink:label="onct_UniversityOfTennesseeResearchFoundationMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_LicenseAgreementMember" xlink:type="locator" xlink:label="onct_LicenseAgreementMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_RegentsLicenseAgreementMember" xlink:type="locator" xlink:label="onct_RegentsLicenseAgreementMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ResearchAgreementMember" xlink:type="locator" xlink:label="onct_ResearchAgreementMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ReagentsMember" xlink:type="locator" xlink:label="onct_ReagentsMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_MDAndersonCancerCenterMember" xlink:type="locator" xlink:label="onct_MDAndersonCancerCenterMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_GeorgetownUniversityMember" xlink:type="locator" xlink:label="onct_GeorgetownUniversityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:type="locator" xlink:label="srt_CounterpartyNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ExclusiveLicenseAgreementMember" xlink:type="locator" xlink:label="onct_ExclusiveLicenseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ExclusiveLicenseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_GeorgetownUniversityMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_CollaborativeArrangementMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_MDAndersonCancerCenterMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_ReagentsMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_ResearchAgreementMember" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_RegentsLicenseAgreementMember" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="onct_LicenseAgreementMember" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_UniversityOfTennesseeResearchFoundationMember" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="onct_CaliforniaInstituteForRegenerativeMedicineAwardMember" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="onct_UniversityOfCaliforniaSanDiegoMember" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_LicenseMaintenanceFeeToBePaidAndPaymentMade" order="11990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_CollaborativeArrangementPotentialMilestonePayments" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysInWrittenNoticeOfTermination" order="12140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount" order="12160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_EquityMethodInvestmentAggregateCost" order="12410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_UpfrontLicenseFeesPaid" order="12520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AnnualLicenseMaintenanceFees" order="12640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels" order="12820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AdvanceLicensedAssets" order="12880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="12940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementTerm" order="13090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementResearchFundingAmount" order="13130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAgreementResearchFundingAmountPayable" order="13170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_ResearchAndDevelopmentGrants" order="13400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod" order="13500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_SubawardPaymentsReceived" order="13600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Revenues" order="13700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_RelatedQualifyingSubawardCosts" order="13800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="onct_AmountAgreedToBeProvidedInContingencyFunds" order="13990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails" xlink:href="onct-20210331.xsd#Role_DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails">
    <link:loc xlink:href="onct-20210331.xsd#onct_CommonStockWarrantsExpirationDate" xlink:type="locator" xlink:label="onct_CommonStockWarrantsExpirationDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" xlink:type="locator" xlink:label="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalizationEquityLineItems" />
    <link:loc xlink:href="onct-20210331.xsd#onct_DecemberUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_DecemberUnderwritingAgreementMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_NovemberUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_NovemberUnderwritingAgreementMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_AugustUnderwritingAgreementMember" xlink:type="locator" xlink:label="onct_AugustUnderwritingAgreementMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_JulyPurchaseAgreementMember" xlink:type="locator" xlink:label="onct_JulyPurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="onct-20210331.xsd#onct_PlacementAgentMember" xlink:type="locator" xlink:label="onct_PlacementAgentMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CommonStockWarrantsMember" xlink:type="locator" xlink:label="onct_CommonStockWarrantsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="onct-20210331.xsd#onct_PurchaseAgreementMember" xlink:type="locator" xlink:label="onct_PurchaseAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCapitalizationEquityTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCapitalizationEquityTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfCapitalizationEquityTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_PurchaseAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="onct_CommonStockWarrantsMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="srt_TitleOfIndividualAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="onct_PlacementAgentMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="srt_RangeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_JulyPurchaseAgreementMember" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_AugustUnderwritingAgreementMember" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_NovemberUnderwritingAgreementMember" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="onct_DecemberUnderwritingAgreementMember" order="12200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityTable" xlink:to="us-gaap_ScheduleOfCapitalizationEquityLineItems" order="12600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="12650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="onct_CombinedPurchasePriceOfShareAndWarrantPerUnit" order="12670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="12710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="12730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCapitalizationEquityLineItems" xlink:to="onct_CommonStockWarrantsExpirationDate" order="12880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails" xlink:href="onct-20210331.xsd#Role_DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails">
    <link:loc xlink:href="onct-20210331.xsd#onct_WarrantWeightedAverageRemainingContractualTermExercised" xlink:type="locator" xlink:label="onct_WarrantWeightedAverageRemainingContractualTermExercised" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_li0l2" />
    <link:loc xlink:href="onct-20210331.xsd#onct_WarrantExercisedPricePerShare" xlink:type="locator" xlink:label="onct_WarrantExercisedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_li0l2" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ExerciseOfWarrants" xlink:type="locator" xlink:label="onct_ExerciseOfWarrants" />
    <link:loc xlink:href="onct-20210331.xsd#onct_WarrantsCancelled" xlink:type="locator" xlink:label="onct_WarrantsCancelled" />
    <link:loc xlink:href="onct-20210331.xsd#onct_WarrantsGranted" xlink:type="locator" xlink:label="onct_WarrantsGranted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_WarrantsGranted" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_WarrantsCancelled" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_ExerciseOfWarrants" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_li0l2" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_WarrantExercisedPricePerShare" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_li0l2" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_ClassOfWarrantWeightedAverageRemainingContractualTerm" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="onct_WarrantWeightedAverageRemainingContractualTermExercised" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails" xlink:href="onct-20210331.xsd#Role_DisclosureStockholdersEquityEquityIncentivePlansDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="onct-20210331.xsd#onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" xlink:type="locator" xlink:label="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="onct-20210331.xsd#onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" xlink:type="locator" xlink:label="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="onct-20210331.xsd#onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_InducementPlanMember" xlink:type="locator" xlink:label="onct_InducementPlanMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_TwoThousandNineteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenPlanMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_PrivateOncternalMember" xlink:type="locator" xlink:label="onct_PrivateOncternalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" />
    <link:loc xlink:href="onct-20210331.xsd#onct_GTxStockOptionPlansMember" xlink:type="locator" xlink:label="onct_GTxStockOptionPlansMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_TwoThousandFifteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandFifteenPlanMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_TwoThousandThirteenPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandThirteenPlanMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" />
    <link:loc xlink:href="onct-20210331.xsd#onct_TwoThousandNineteenIncentiveAwardPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandThirteenPlanMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandFifteenPlanMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_GTxStockOptionPlansMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="onct_PrivateOncternalMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenPlanMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_InducementPlanMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails" xlink:href="onct-20210331.xsd#Role_DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="onct-20210331.xsd#onct_EquityIncentivePlanMember" xlink:type="locator" xlink:label="onct_EquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_EquityIncentivePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:href="onct-20210331.xsd#Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails" xlink:href="onct-20210331.xsd#Role_DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails" xlink:href="onct-20210331.xsd#Role_DisclosureStockholdersEquityShareBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" xlink:href="onct-20210331.xsd#Role_DisclosureStockholdersEquityStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" xlink:href="onct-20210331.xsd#Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" xlink:type="locator" xlink:label="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" />
    <link:loc xlink:href="onct-20210331.xsd#onct_CommonStockWarrantsReservedForFutureIssuance" xlink:type="locator" xlink:label="onct_CommonStockWarrantsReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="onct-20210331.xsd#onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" xlink:type="locator" xlink:label="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_CommonStockWarrantsReservedForFutureIssuance" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>onct-10q_20210331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:onct="http://www.oncternal.com/20210331"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="onct-20210331.xsd" xlink:type="simple"/>
    <context id="C_0001260990_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_20210429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2021-04-29</instant>
        </period>
    </context>
    <context id="C_0001260990_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001260990_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockSubjectToRepurchaseMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockSubjectToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockSubjectToRepurchaseMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">onct:CommonStockSubjectToRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-22</instant>
        </period>
    </context>
    <context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190423_20190522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-05-22</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210317_20210317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-17</startDate>
            <endDate>2021-03-17</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">onct:OfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_onctShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onct:ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_onctShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">onct:ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20150101_20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:GeorgetownUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ExclusiveLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:MDAndersonCancerCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:MDAndersonCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:MDAndersonCancerCenterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-05-01</startDate>
            <endDate>2016-05-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20170101_20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMinimumMember_20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMaximumMember_20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:ResearchAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctRegentsLicenseAgreementMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:ReagentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:RegentsLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfTennesseeResearchFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfTennesseeResearchFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">onct:LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20170801_20170831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">onct:UniversityOfCaliforniaSanDiegoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">onct:CaliforniaInstituteForRegenerativeMedicineAwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">onct:PlacementAgentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:JulyPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:AugustUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:NovemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">onct:CommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">onct:DecemberUnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_20200101_20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-07</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607_20190607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-07</startDate>
            <endDate>2019-06-07</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandThirteenPlanMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandThirteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctGTxStockOptionPlansMember_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:GTxStockOptionPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_0001260990_srtConsolidatedEntitiesAxis_onctPrivateOncternalMember_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">onct:PrivateOncternalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-31</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150701_20150731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-07-01</startDate>
            <endDate>2015-07-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenPlanMember_20150701_20150731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-07-01</startDate>
            <endDate>2015-07-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctInducementPlanMember_20210211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-11</instant>
        </period>
    </context>
    <context id="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">onct:TwoThousandNineteenAndTwoThousandFifteenPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001260990</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <unit id="U_xbrlishares">
        <measure>shares</measure>
    </unit>
    <unit id="U_iso4217USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_iso4217USD_xbrlishares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_onctsegment">
        <measure>onct:segment</measure>
    </unit>
    <unit id="U_utrsqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_xbrlipure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="C_0001260990_20210101_20210331" id="F_000001">0001260990</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="C_0001260990_20210101_20210331" id="F_000004">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="C_0001260990_20210101_20210331" id="F_000006">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="C_0001260990_20210101_20210331" id="F_000008">--12-31</dei:CurrentFiscalYearEndDate>
    <onct:CollaborativeArrangementPotentialMilestonePayments
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210331"
      decimals="-6"
      id="F_000257"
      unitRef="U_iso4217USD">0</onct:CollaborativeArrangementPotentialMilestonePayments>
    <onct:ResearchAgreementTerm
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20210101_20210331"
      id="F_000276">P5Y</onct:ResearchAgreementTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150701_20150731"
      id="F_000363">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenPlanMember_20150701_20150731"
      id="F_000365">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001260990_20210331"
      id="F_000053"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_0001260990_20201231"
      id="F_000054"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001260990_20210331"
      id="F_000055"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_0001260990_20201231"
      id="F_000056"
      unitRef="U_iso4217USD"
      xsi:nil="true"/>
    <onct:ClassOfWarrantWeightedAverageRemainingContractualTerm contextRef="C_0001260990_20200101_20201231" id="F_000337">P4Y4M24D</onct:ClassOfWarrantWeightedAverageRemainingContractualTerm>
    <onct:WarrantWeightedAverageRemainingContractualTermExercised contextRef="C_0001260990_20210101_20210331" id="F_000338">P4Y7M2D</onct:WarrantWeightedAverageRemainingContractualTermExercised>
    <onct:ClassOfWarrantWeightedAverageRemainingContractualTerm contextRef="C_0001260990_20210101_20210331" id="F_000339">P4Y0M26D</onct:ClassOfWarrantWeightedAverageRemainingContractualTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20210331"
      id="F_000350">P8Y10M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20210331"
      id="F_000351">P8Y10M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210101_20210331"
      id="F_000352">P7Y3M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_0001260990_20210101_20210331" id="F_000383">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_0001260990_20200101_20200331" id="F_000384">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <dei:DocumentType contextRef="C_0001260990_20210101_20210331" id="F_000002">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="C_0001260990_20210101_20210331" id="F_000028">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="C_0001260990_20210101_20210331" id="F_000003">2021-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="C_0001260990_20210101_20210331" id="F_000005">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="C_0001260990_20210101_20210331" id="F_000029">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="C_0001260990_20210101_20210331" id="F_000015">000-50549</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="C_0001260990_20210101_20210331" id="F_000000">Oncternal Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="C_0001260990_20210101_20210331" id="F_000027">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="C_0001260990_20210101_20210331" id="F_000016">62-1715807</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="C_0001260990_20210101_20210331" id="F_000017">12230 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="C_0001260990_20210101_20210331" id="F_000018">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="C_0001260990_20210101_20210331" id="F_000019">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="C_0001260990_20210101_20210331" id="F_000020">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="C_0001260990_20210101_20210331" id="F_000021">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="C_0001260990_20210101_20210331" id="F_000022">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="C_0001260990_20210101_20210331" id="F_000023">434-1113</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="C_0001260990_20210101_20210331" id="F_000025">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="C_0001260990_20210101_20210331" id="F_000007">ONCT</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="C_0001260990_20210101_20210331" id="F_000026">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="C_0001260990_20210101_20210331" id="F_000012">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="C_0001260990_20210101_20210331" id="F_000024">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="C_0001260990_20210101_20210331" id="F_000009">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="C_0001260990_20210101_20210331" id="F_000010">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="C_0001260990_20210101_20210331" id="F_000011">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="C_0001260990_20210101_20210331" id="F_000013">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_0001260990_20210429"
      decimals="INF"
      id="F_000014"
      unitRef="U_xbrlishares">49368545</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000030"
      unitRef="U_iso4217USD">111211000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000031"
      unitRef="U_iso4217USD">116737000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000032"
      unitRef="U_iso4217USD">1873000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000033"
      unitRef="U_iso4217USD">1266000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000034"
      unitRef="U_iso4217USD">113084000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000035"
      unitRef="U_iso4217USD">118003000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000036"
      unitRef="U_iso4217USD">204000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000037"
      unitRef="U_iso4217USD">40000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000038"
      unitRef="U_iso4217USD">769000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000039"
      unitRef="U_iso4217USD">766000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000040"
      unitRef="U_iso4217USD">114057000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000041"
      unitRef="U_iso4217USD">118809000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000042"
      unitRef="U_iso4217USD">1892000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000043"
      unitRef="U_iso4217USD">1143000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000044"
      unitRef="U_iso4217USD">2773000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000045"
      unitRef="U_iso4217USD">3042000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DeferredRevenue
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000046"
      unitRef="U_iso4217USD">885000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000047"
      unitRef="U_iso4217USD">1633000</us-gaap:DeferredRevenue>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000048"
      unitRef="U_iso4217USD">173000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000049"
      unitRef="U_iso4217USD">40000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000050"
      unitRef="U_iso4217USD">5723000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000051"
      unitRef="U_iso4217USD">5858000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000052"
      unitRef="U_iso4217USD">31000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001260990_20210331"
      decimals="INF"
      id="F_000067"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000068"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001260990_20210331"
      decimals="INF"
      id="F_000069"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000070"
      unitRef="U_xbrlishares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001260990_20210331"
      decimals="INF"
      id="F_000071"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000072"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001260990_20210331"
      decimals="INF"
      id="F_000073"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000074"
      unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001260990_20210331"
      decimals="INF"
      id="F_000075"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000076"
      unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001260990_20210331"
      decimals="INF"
      id="F_000077"
      unitRef="U_xbrlishares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000078"
      unitRef="U_xbrlishares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001260990_20210331"
      decimals="INF"
      id="F_000079"
      unitRef="U_xbrlishares">49366000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001260990_20210331"
      decimals="INF"
      id="F_000081"
      unitRef="U_xbrlishares">49366000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000080"
      unitRef="U_xbrlishares">48802000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000082"
      unitRef="U_xbrlishares">48802000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000057"
      unitRef="U_iso4217USD">49000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000058"
      unitRef="U_iso4217USD">49000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000059"
      unitRef="U_iso4217USD">196999000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000060"
      unitRef="U_iso4217USD">195699000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000061"
      unitRef="U_iso4217USD">-88745000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000062"
      unitRef="U_iso4217USD">-82797000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000063"
      unitRef="U_iso4217USD">108303000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000064"
      unitRef="U_iso4217USD">112951000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000065"
      unitRef="U_iso4217USD">114057000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000066"
      unitRef="U_iso4217USD">118809000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000083"
      unitRef="U_iso4217USD">748000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000084"
      unitRef="U_iso4217USD">578000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000085"
      unitRef="U_iso4217USD">3913000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000086"
      unitRef="U_iso4217USD">2696000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000087"
      unitRef="U_iso4217USD">2794000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000088"
      unitRef="U_iso4217USD">2633000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000089"
      unitRef="U_iso4217USD">6707000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000090"
      unitRef="U_iso4217USD">5329000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000091"
      unitRef="U_iso4217USD">-5959000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000092"
      unitRef="U_iso4217USD">-4751000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000093"
      unitRef="U_iso4217USD">11000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000094"
      unitRef="U_iso4217USD">13000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000095"
      unitRef="U_iso4217USD">-5948000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000096"
      unitRef="U_iso4217USD">-4738000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001260990_20210101_20210331"
      decimals="2"
      id="F_000097"
      unitRef="U_iso4217USD_xbrlishares">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_0001260990_20200101_20200331"
      decimals="2"
      id="F_000098"
      unitRef="U_iso4217USD_xbrlishares">-0.31</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001260990_20210101_20210331"
      decimals="0"
      id="F_000099"
      unitRef="U_xbrlishares">49094</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_0001260990_20200101_20200331"
      decimals="0"
      id="F_000100"
      unitRef="U_xbrlishares">15355</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ProfitLoss
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000101"
      unitRef="U_iso4217USD">-5948000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000102"
      unitRef="U_iso4217USD">-4738000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000103"
      unitRef="U_iso4217USD">838000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000104"
      unitRef="U_iso4217USD">399000</us-gaap:ShareBasedCompensation>
    <onct:NoncashLeaseExpense
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000105"
      unitRef="U_iso4217USD">40000</onct:NoncashLeaseExpense>
    <onct:NoncashLeaseExpense
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000106"
      unitRef="U_iso4217USD">36000</onct:NoncashLeaseExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000107"
      unitRef="U_iso4217USD">609000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000108"
      unitRef="U_iso4217USD">-90000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000109"
      unitRef="U_iso4217USD">749000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000110"
      unitRef="U_iso4217USD">336000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000111"
      unitRef="U_iso4217USD">-267000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000112"
      unitRef="U_iso4217USD">455000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <onct:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000113"
      unitRef="U_iso4217USD">-40000</onct:IncreaseDecreaseInOperatingLeaseLiability>
    <onct:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000114"
      unitRef="U_iso4217USD">-36000</onct:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000115"
      unitRef="U_iso4217USD">-748000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000116"
      unitRef="U_iso4217USD">-578000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000117"
      unitRef="U_iso4217USD">-5985000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000118"
      unitRef="U_iso4217USD">-4036000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000119"
      unitRef="U_iso4217USD">358000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000120"
      unitRef="U_iso4217USD">4000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000121"
      unitRef="U_iso4217USD">101000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000122"
      unitRef="U_iso4217USD">459000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000123"
      unitRef="U_iso4217USD">4000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000124"
      unitRef="U_iso4217USD">-5526000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000125"
      unitRef="U_iso4217USD">-4032000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000126"
      unitRef="U_iso4217USD">116737000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000127"
      unitRef="U_iso4217USD">20051000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000128"
      unitRef="U_iso4217USD">111211000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="C_0001260990_20200331"
      decimals="-3"
      id="F_000129"
      unitRef="U_iso4217USD">16019000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <onct:CashlessExerciseOfWarrants
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000130"
      unitRef="U_iso4217USD">1836000</onct:CashlessExerciseOfWarrants>
    <us-gaap:StockIssued1
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000131"
      unitRef="U_iso4217USD">415000</us-gaap:StockIssued1>
    <us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000132"
      unitRef="U_iso4217USD">179000</us-gaap:DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="INF"
      id="F_000133"
      unitRef="U_xbrlishares">48802000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231"
      decimals="-3"
      id="F_000134"
      unitRef="U_iso4217USD">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231"
      decimals="-3"
      id="F_000135"
      unitRef="U_iso4217USD">195699000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231"
      decimals="-3"
      id="F_000136"
      unitRef="U_iso4217USD">-82797000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000137"
      unitRef="U_iso4217USD">112951000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="INF"
      id="F_000138"
      unitRef="U_xbrlishares">88000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000139"
      unitRef="U_iso4217USD">358000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000140"
      unitRef="U_iso4217USD">358000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="INF"
      id="F_000141"
      unitRef="U_xbrlishares">17000</onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares>
    <onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000142"
      unitRef="U_iso4217USD">101000</onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash>
    <onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000143"
      unitRef="U_iso4217USD">101000</onct:AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash>
    <onct:ExerciseOfCashlessWarrantShares
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210101_20210331"
      decimals="INF"
      id="F_000144"
      unitRef="U_xbrlishares">459000</onct:ExerciseOfCashlessWarrantShares>
    <onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000145"
      unitRef="U_iso4217USD">3000</onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability>
    <onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000146"
      unitRef="U_iso4217USD">3000</onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210101_20210331"
      decimals="-3"
      id="F_000147"
      unitRef="U_iso4217USD">838000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000148"
      unitRef="U_iso4217USD">838000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210101_20210331"
      decimals="-3"
      id="F_000149"
      unitRef="U_iso4217USD">-5948000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000150"
      unitRef="U_iso4217USD">-5948000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331"
      decimals="INF"
      id="F_000151"
      unitRef="U_xbrlishares">49366000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20210331"
      decimals="-3"
      id="F_000152"
      unitRef="U_iso4217USD">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20210331"
      decimals="-3"
      id="F_000153"
      unitRef="U_iso4217USD">196999000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20210331"
      decimals="-3"
      id="F_000154"
      unitRef="U_iso4217USD">-88745000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000155"
      unitRef="U_iso4217USD">108303000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="INF"
      id="F_000156"
      unitRef="U_xbrlishares">15387000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231"
      decimals="-3"
      id="F_000157"
      unitRef="U_iso4217USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231"
      decimals="-3"
      id="F_000158"
      unitRef="U_iso4217USD">79869000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231"
      decimals="-3"
      id="F_000159"
      unitRef="U_iso4217USD">-65572000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_20191231"
      decimals="-3"
      id="F_000160"
      unitRef="U_iso4217USD">14312000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20200331"
      decimals="INF"
      id="F_000161"
      unitRef="U_xbrlishares">5000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331"
      decimals="-3"
      id="F_000162"
      unitRef="U_iso4217USD">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000163"
      unitRef="U_iso4217USD">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331"
      decimals="-3"
      id="F_000164"
      unitRef="U_iso4217USD">3000</onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability>
    <onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000165"
      unitRef="U_iso4217USD">3000</onct:AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331"
      decimals="-3"
      id="F_000166"
      unitRef="U_iso4217USD">399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000167"
      unitRef="U_iso4217USD">399000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <onct:IssuanceOfBonusAwardsWithStockOptionInLieuOfCash
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20200331"
      decimals="-3"
      id="F_000168"
      unitRef="U_iso4217USD">415000</onct:IssuanceOfBonusAwardsWithStockOptionInLieuOfCash>
    <onct:IssuanceOfBonusAwardsWithStockOptionInLieuOfCash
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000169"
      unitRef="U_iso4217USD">415000</onct:IssuanceOfBonusAwardsWithStockOptionInLieuOfCash>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20200331"
      decimals="-3"
      id="F_000170"
      unitRef="U_iso4217USD">-4738000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000171"
      unitRef="U_iso4217USD">-4738000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331"
      decimals="INF"
      id="F_000172"
      unitRef="U_xbrlishares">15392000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200331"
      decimals="-3"
      id="F_000173"
      unitRef="U_iso4217USD">15000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200331"
      decimals="-3"
      id="F_000174"
      unitRef="U_iso4217USD">80690000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200331"
      decimals="-3"
      id="F_000175"
      unitRef="U_iso4217USD">-70310000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0001260990_20200331"
      decimals="-3"
      id="F_000176"
      unitRef="U_iso4217USD">10395000</us-gaap:StockholdersEquity>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000177">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.17%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Description of Business, Basis of Presentation and Summary of Significant Accounting Policies&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Description of Business&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Oncternal Therapeutics, Inc. (&#x201c;Oncternal&#x201d; or the &#x201c;Company&#x201d;), formerly known as GTx, Inc., was incorporated in Tennessee in September 1997 and reincorporated in Delaware in 2003 and is based in San Diego, California.  Oncternal is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The Company&#x2019;s clinical pipeline includes cirmtuzumab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and TK216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Merger&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 7, 2019, the Company, then operating as GTx, Inc. (&#x201c;GTx&#x201d;), completed the merger contemplated by its Agreement and Plan of Merger and Reorganization, as amended (the &#x201c;Merger Agreement&#x201d;), with privately-held Oncternal Therapeutics, Inc. (&#x201c;Private Oncternal&#x201d;) and Grizzly Merger Sub, Inc., a wholly-owned subsidiary of the Company (&#x201c;Merger Sub&#x201d;), dated March 6, 2019. Under the Merger Agreement, Merger Sub merged with and into Private Oncternal, with Private Oncternal surviving as a wholly-owned subsidiary of the Company (the &#x201c;Merger&#x201d;). GTx changed its name to Oncternal Therapeutics, Inc., and Private Oncternal, which remains as a wholly-owned subsidiary of the Company, changed its name to Oncternal Oncology, Inc. On June 10, 2019, the Company&#x2019;s common stock began trading on The Nasdaq Capital Market under the ticker symbol &#x201c;ONCT.&#x201d;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Except as otherwise indicated, references herein to &#x201c;Oncternal,&#x201d;and &#x201c;the Company,&#x201d; refer to Oncternal Therapeutics, Inc. on a post-Merger basis, and the term &#x201c;Private Oncternal&#x201d; refers to the business of privately-held Oncternal Therapeutics, Inc., prior to completion of the Merger.&#160;&#160;References to GTx refer to GTx, Inc. prior to completion of the Merger.&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oncternal Oncology, Inc. and Oncternal, Inc. All intercompany accounts and transactions have been eliminated in the preparation of the condensed consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Liquidity and Going Concern&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company follows Accounting Standards Codification (ASC) &lt;span style="font-style:italic;"&gt;Topic 205-40, Presentation of Financial Statements&#x2014;Going Concern&lt;/span&gt;, which requires that management evaluate whether there are relevant conditions and events that in the aggregate raise substantial doubt about the entity&#x2019;s ability to continue as a going concern and to meet its obligations as they become due within one year after the date that the financial statements are issued.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.&#160;&#160;As of March 31, 2021, the Company had $111.2 million in cash and cash equivalents. The Company believes it has sufficient cash to fund its projected operating requirements for at least twelve months from the filing date of this Quarterly Report. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company&#x2019;s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#x2019;s cost structure.&#160;&#160;The Company has experienced net losses and negative cash flows from operating activities since its inception and has an accumulated deficit of $88.7 million as of March 31, 2021. The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.&#160;&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The unaudited condensed consolidated financial statements at March&#160;31, 2021, and for the three months ended March&#160;31, 2021 and 2020, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). These unaudited condensed consolidated financial statements have been prepared on the same basis as the audited, consolidated financial statements and include all adjustments, consisting of only normal recurring accruals, which in the opinion of management are necessary to present fairly the Company&#x2019;s financial position as of the interim date and results of operations for the interim periods presented. Interim results are not necessarily indicative of results for a full year or future periods. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements for the year ended December 31, 2020, filed with the SEC on its Annual Report on Form 10-K/A for the year ended December 31, 2020, filed with the SEC on March 12, 2021. The results presented in these unaudited condensed consolidated financial statements are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company&#x2019;s condensed consolidated financial statements and accompanying notes requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities. Significant estimates consist of those used to determine the fair value of the Company&#x2019;s stock-based awards and those used to determine grant revenue and accruals for research and development costs. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market accounts.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Patent Costs&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses and Accruals&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses consist of costs incurred for the Company&#x2019;s own and for sponsored and collaborative research and development activities. Research and development costs are expensed as incurred and include manufacturing process development costs, manufacturing costs, costs associated with preclinical studies and clinical trials, regulatory and medical affairs activities, quality assurance activities, salaries and benefits, including stock-based compensation, fees paid to third-party consultants, license fees and overhead.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:4.17%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying consolidated balance sheets as prepaid expenses and other assets or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities and all clinical trial expenses are included in research and development expenses. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. As of March 31, 2021, the Company&#x2019;s clinical trial accrual balance of $1.1&#160;million is included in accrued liabilities and other liabilities.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1: Observable inputs such as quoted prices in active markets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of the Company&#x2019;s current financial assets and liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company has no current financial assets or liabilities measured at fair value on a recurring basis and no transfers between levels have occurred during the periods presented.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company currently generates revenue from the California Institute for Regenerative Medicine (&#x201c;CIRM&#x201d;) pursuant to a research subaward agreement (see Note 4), which provides the Company with payments in return for certain research and development activities over a contractually defined period. Revenue from such subaward is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the subaward agreement have been met.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The subaward agreement is on a best-effort basis and does not require scientific achievement as a performance obligation. All fees received under the agreement are non-refundable. The costs associated with the agreement are expensed as incurred and reflected as a component of research and development expense in the accompanying condensed consolidated statements of operations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Funds received from the subaward agreement are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the subaward are part of the Company&#x2019;s development programs. In those instances where the Company first receives consideration in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company records a grant receivable. At March 31, 2021, and December 31, 2020, the Company had deferred grant revenue of $0.9 million and $1.6 million, respectively.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense represents the fair value of equity awards, on the grant date, recognized in the period using the Black-Scholes option pricing model. The Company recognizes expense for awards with graded vesting schedules over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is deemed probable. The Company recognizes forfeitures for all awards as such forfeitures occur.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/p&gt;

&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segment Reporting&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment in the United States.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities and adjusted for the weighted-average number of common shares outstanding that are subject to repurchase. The Company has excluded weighted-average shares subject to repurchase of 13,000 shares and 32,000 shares from the weighted-average number of common shares outstanding for the three months ended March 31, 2021 and 2020, respectively. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares; in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,278&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;841&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,069&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,168&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock subject to repurchase&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,357&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,039&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;span style="font-style:italic;"&gt;Debt&#x2014;Debt with Conversion and Other Options&lt;/span&gt; (Subtopic 470-20) and &lt;span style="font-style:italic;"&gt;Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity&lt;/span&gt; (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company adopted this standard effective January 1, 2021, and the adoption had no impact on the consolidated financial statements.&lt;/p&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BusinessCombinationsPolicy contextRef="C_0001260990_20210101_20210331" id="F_000183">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Merger&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 7, 2019, the Company, then operating as GTx, Inc. (&#x201c;GTx&#x201d;), completed the merger contemplated by its Agreement and Plan of Merger and Reorganization, as amended (the &#x201c;Merger Agreement&#x201d;), with privately-held Oncternal Therapeutics, Inc. (&#x201c;Private Oncternal&#x201d;) and Grizzly Merger Sub, Inc., a wholly-owned subsidiary of the Company (&#x201c;Merger Sub&#x201d;), dated March 6, 2019. Under the Merger Agreement, Merger Sub merged with and into Private Oncternal, with Private Oncternal surviving as a wholly-owned subsidiary of the Company (the &#x201c;Merger&#x201d;). GTx changed its name to Oncternal Therapeutics, Inc., and Private Oncternal, which remains as a wholly-owned subsidiary of the Company, changed its name to Oncternal Oncology, Inc. On June 10, 2019, the Company&#x2019;s common stock began trading on The Nasdaq Capital Market under the ticker symbol &#x201c;ONCT.&#x201d;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Except as otherwise indicated, references herein to &#x201c;Oncternal,&#x201d;and &#x201c;the Company,&#x201d; refer to Oncternal Therapeutics, Inc. on a post-Merger basis, and the term &#x201c;Private Oncternal&#x201d; refers to the business of privately-held Oncternal Therapeutics, Inc., prior to completion of the Merger.&#160;&#160;References to GTx refer to GTx, Inc. prior to completion of the Merger.&#160;&#160;&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000184">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oncternal Oncology, Inc. and Oncternal, Inc. All intercompany accounts and transactions have been eliminated in the preparation of the condensed consolidated financial statements.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <onct:LiquidityAndGoingConcernPolicyTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000185">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Liquidity and Going Concern&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company follows Accounting Standards Codification (ASC) &lt;span style="font-style:italic;"&gt;Topic 205-40, Presentation of Financial Statements&#x2014;Going Concern&lt;/span&gt;, which requires that management evaluate whether there are relevant conditions and events that in the aggregate raise substantial doubt about the entity&#x2019;s ability to continue as a going concern and to meet its obligations as they become due within one year after the date that the financial statements are issued.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.&#160;&#160;As of March 31, 2021, the Company had $111.2 million in cash and cash equivalents. The Company believes it has sufficient cash to fund its projected operating requirements for at least twelve months from the filing date of this Quarterly Report. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company&#x2019;s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#x2019;s cost structure.&#160;&#160;The Company has experienced net losses and negative cash flows from operating activities since its inception and has an accumulated deficit of $88.7 million as of March 31, 2021. The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#x2019;s business, results of operations and future prospects. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.&#160;&lt;/p&gt;
</onct:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_0001260990_20210331"
      decimals="-5"
      id="F_000209"
      unitRef="U_iso4217USD">111200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_0001260990_20210331"
      decimals="-5"
      id="F_000208"
      unitRef="U_iso4217USD">-88700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <onct:UnauditedInterimFinancialInformationPolicyTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000186">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Presentation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The unaudited condensed consolidated financial statements at March&#160;31, 2021, and for the three months ended March&#160;31, 2021 and 2020, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and with generally accepted accounting principles in the United States of America (&#x201c;GAAP&#x201d;). These unaudited condensed consolidated financial statements have been prepared on the same basis as the audited, consolidated financial statements and include all adjustments, consisting of only normal recurring accruals, which in the opinion of management are necessary to present fairly the Company&#x2019;s financial position as of the interim date and results of operations for the interim periods presented. Interim results are not necessarily indicative of results for a full year or future periods. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements for the year ended December 31, 2020, filed with the SEC on its Annual Report on Form 10-K/A for the year ended December 31, 2020, filed with the SEC on March 12, 2021. The results presented in these unaudited condensed consolidated financial statements are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.&lt;/p&gt;</onct:UnauditedInterimFinancialInformationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="C_0001260990_20210101_20210331" id="F_000187">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&#x2019;s condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company&#x2019;s condensed consolidated financial statements and accompanying notes requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities. Significant estimates consist of those used to determine the fair value of the Company&#x2019;s stock-based awards and those used to determine grant revenue and accruals for research and development costs. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000188">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market accounts.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <onct:ConcentrationRiskCreditRiskPolicyTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000189">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.&lt;/p&gt;</onct:ConcentrationRiskCreditRiskPolicyTextBlock>
    <onct:PatentCostsPolicyTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000190">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Patent Costs&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.&lt;/p&gt;</onct:PatentCostsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_0001260990_20210101_20210331" id="F_000191">
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses and Accruals&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development expenses consist of costs incurred for the Company&#x2019;s own and for sponsored and collaborative research and development activities. Research and development costs are expensed as incurred and include manufacturing process development costs, manufacturing costs, costs associated with preclinical studies and clinical trials, regulatory and medical affairs activities, quality assurance activities, salaries and benefits, including stock-based compensation, fees paid to third-party consultants, license fees and overhead.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:4.17%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying consolidated balance sheets as prepaid expenses and other assets or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities and all clinical trial expenses are included in research and development expenses. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#x2019;s estimates. As of March 31, 2021, the Company&#x2019;s clinical trial accrual balance of $1.1&#160;million is included in accrued liabilities and other liabilities.&lt;/p&gt;
</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <onct:AccruedClinicalTrials
      contextRef="C_0001260990_20210331"
      decimals="-5"
      id="F_000210"
      unitRef="U_iso4217USD">1100000</onct:AccruedClinicalTrials>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="C_0001260990_20210101_20210331" id="F_000192">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1: Observable inputs such as quoted prices in active markets.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts of the Company&#x2019;s current financial assets and liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company has no current financial assets or liabilities measured at fair value on a recurring basis and no transfers between levels have occurred during the periods presented.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000193">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company currently generates revenue from the California Institute for Regenerative Medicine (&#x201c;CIRM&#x201d;) pursuant to a research subaward agreement (see Note 4), which provides the Company with payments in return for certain research and development activities over a contractually defined period. Revenue from such subaward is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the subaward agreement have been met.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The subaward agreement is on a best-effort basis and does not require scientific achievement as a performance obligation. All fees received under the agreement are non-refundable. The costs associated with the agreement are expensed as incurred and reflected as a component of research and development expense in the accompanying condensed consolidated statements of operations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Funds received from the subaward agreement are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the subaward are part of the Company&#x2019;s development programs. In those instances where the Company first receives consideration in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company records a grant receivable. At March 31, 2021, and December 31, 2020, the Company had deferred grant revenue of $0.9 million and $1.6 million, respectively.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:DeferredRevenue
      contextRef="C_0001260990_20210331"
      decimals="-5"
      id="F_000211"
      unitRef="U_iso4217USD">900000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="C_0001260990_20201231"
      decimals="-5"
      id="F_000212"
      unitRef="U_iso4217USD">1600000</us-gaap:DeferredRevenue>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="C_0001260990_20210101_20210331" id="F_000194">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense represents the fair value of equity awards, on the grant date, recognized in the period using the Black-Scholes option pricing model. The Company recognizes expense for awards with graded vesting schedules over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is deemed probable. The Company recognizes forfeitures for all awards as such forfeitures occur.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000195">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.&lt;/p&gt;
</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000196">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segment Reporting&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment in the United States.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_0001260990_20210101_20210331"
      decimals="INF"
      id="F_000213"
      unitRef="U_onctsegment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000197">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities and adjusted for the weighted-average number of common shares outstanding that are subject to repurchase. The Company has excluded weighted-average shares subject to repurchase of 13,000 shares and 32,000 shares from the weighted-average number of common shares outstanding for the three months ended March 31, 2021 and 2020, respectively. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares; in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,278&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;841&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,069&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,168&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock subject to repurchase&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,357&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,039&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="C_0001260990_20210101_20210331"
      decimals="INF"
      id="F_000214"
      unitRef="U_xbrlishares">13000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="C_0001260990_20200101_20200331"
      decimals="INF"
      id="F_000215"
      unitRef="U_xbrlishares">32000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000199">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares; in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase common stock&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,278&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;841&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,069&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,168&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock subject to repurchase&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,357&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,039&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20210101_20210331"
      decimals="INF"
      id="F_000216"
      unitRef="U_xbrlishares">4278</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockWarrantsMember_20200101_20200331"
      decimals="INF"
      id="F_000217"
      unitRef="U_xbrlishares">841</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      decimals="INF"
      id="F_000218"
      unitRef="U_xbrlishares">4069</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaapEmployeeStockOptionMember_20200101_20200331"
      decimals="INF"
      id="F_000219"
      unitRef="U_xbrlishares">2168</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockSubjectToRepurchaseMember_20210101_20210331"
      decimals="INF"
      id="F_000220"
      unitRef="U_xbrlishares">10</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_onctCommonStockSubjectToRepurchaseMember_20200101_20200331"
      decimals="INF"
      id="F_000221"
      unitRef="U_xbrlishares">30</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_20210101_20210331"
      decimals="INF"
      id="F_000222"
      unitRef="U_xbrlishares">8357</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0001260990_20200101_20200331"
      decimals="INF"
      id="F_000223"
      unitRef="U_xbrlishares">3039</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000198">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recently Adopted Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2020, the FASB issued ASU 2020-06, &lt;span style="font-style:italic;"&gt;Debt&#x2014;Debt with Conversion and Other Options&lt;/span&gt; (Subtopic 470-20) and &lt;span style="font-style:italic;"&gt;Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity&lt;/span&gt; (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#x2019;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company adopted this standard effective January 1, 2021, and the adoption had no impact on the consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000178">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.17%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Balance Sheet Details&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;605&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;412&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical trials&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,138&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;980&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Legal fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;308&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;699&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,528&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,773&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,042&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000200">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued liabilities consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;605&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;412&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Clinical trials&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,138&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;980&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Legal fees&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;308&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;699&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,528&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,773&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,042&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <onct:AccruedResearchAndDevelopmentExpenses
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000224"
      unitRef="U_iso4217USD">605000</onct:AccruedResearchAndDevelopmentExpenses>
    <onct:AccruedResearchAndDevelopmentExpenses
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000225"
      unitRef="U_iso4217USD">412000</onct:AccruedResearchAndDevelopmentExpenses>
    <onct:AccruedClinicalTrials
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000226"
      unitRef="U_iso4217USD">1138000</onct:AccruedClinicalTrials>
    <onct:AccruedClinicalTrials
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000227"
      unitRef="U_iso4217USD">980000</onct:AccruedClinicalTrials>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000228"
      unitRef="U_iso4217USD">308000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000229"
      unitRef="U_iso4217USD">77000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000230"
      unitRef="U_iso4217USD">699000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000231"
      unitRef="U_iso4217USD">1528000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000232"
      unitRef="U_iso4217USD">23000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000233"
      unitRef="U_iso4217USD">45000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000234"
      unitRef="U_iso4217USD">2773000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_0001260990_20201231"
      decimals="-3"
      id="F_000235"
      unitRef="U_iso4217USD">3042000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000179">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.17%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Commitments, Contingencies and Related Party Transactions&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Rent expense was $41,000 for &lt;span style="color:#000000;"&gt;each of &lt;/span&gt;the three months ended March&#160;31, 2021 and 2020. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May 22, 2019, the Company entered into a sublease agreement for office space of 4,677 square feet in San Diego, California which expired on March 31, 2021. On March 17, 2021, the Company entered into a lease directly with the landlord for the same facility (the &#x201c;San Diego Lease&#x201d;) which expires on May 31, 2022. Base rent under the San Diego Lease is approximately $184,000 annually and the monthly rent expense is being recognized on a straight-line basis over the term of the lease. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The San Diego Lease is included in the accompanying condensed consolidated balance sheet at the present value of the lease payments. As the San Diego Lease does not have an implicit interest rate, the present value reflects a 10.0% discount rate which is the estimated rate of interest that the Company would have to pay in order to borrow an amount equal to the lease payments on a collateralized basis over a similar term and in a similar economic environment. The Company recognized a net operating lease right-of-use asset and an aggregate lease liability of $&lt;span style="color:#000000;"&gt;204,000&lt;/span&gt; as of March&#160;31, 2021, in the accompanying condensed consolidated balance sheets. The weighted average remaining lease term was 1.2 years.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturities of the lease liability due under this lease agreement as of March&#160;31, 2021, are as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturity of lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;138&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;215&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;204&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less current portion of lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(173&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.26%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Related Party Transactions&lt;span style="font-weight:normal;font-style:normal;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Effective in September 2019, the Company and Shanghai Pharmaceutical (USA) Inc. (&#x201c;SPH USA&#x201d;), the Company&#x2019;s largest stockholder and an affiliate of two of the Company&#x2019;s directors entered into a Materials and Supply and Services Agreement (&#x201c;SPH USA Services Agreement&#x201d;). Pursuant to the SPH USA Services Agreement, the Company and SPH USA will execute various statements of work for the transfer to SPH USA of key reagents and other materials, and for the supply of certain services by the Company to SPH USA, as contemplated under and in furtherance of a license and distribution agreement between the parties (see Note 4). The Company recorded amounts receivable from SPH USA related to statements of work totaling $0.3 million as of March 31, 2021 and December 31, 2020. The Company has an agreement with SPH USA for certain rights to the greater China area (see Note 4).&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the securities purchase agreements and underwritten offerings described in Note 5, other investors included individuals or entities affiliated with David F. Hale, SPH USA, Daniel L. Kisner, Hazel M. Aker, and Michael G. Carter.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LeaseAndRentalExpense
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210101_20210331"
      decimals="0"
      id="F_000236"
      unitRef="U_iso4217USD">41000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20200101_20200331"
      decimals="0"
      id="F_000237"
      unitRef="U_iso4217USD">41000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:NetRentableArea
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190522"
      decimals="0"
      id="F_000238"
      unitRef="U_utrsqft">4677</us-gaap:NetRentableArea>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190423_20190522"
      id="F_000239">2021-03-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210317_20210317"
      id="F_000240">2022-05-31</us-gaap:LeaseExpirationDate1>
    <onct:AnnualBaseRent
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20190423_20190522"
      decimals="0"
      id="F_000241"
      unitRef="U_iso4217USD">184000</onct:AnnualBaseRent>
    <onct:AnnualBaseRent
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210317_20210317"
      decimals="0"
      id="F_000242"
      unitRef="U_iso4217USD">184000</onct:AnnualBaseRent>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210331"
      decimals="3"
      id="F_000243"
      unitRef="U_xbrlipure">0.100</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210331"
      decimals="0"
      id="F_000244"
      unitRef="U_iso4217USD">204000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_0001260990_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_onctOfficeSpaceMember_20210331"
      id="F_000245">P1Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000201">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturities of the lease liability due under this lease agreement as of March&#160;31, 2021, are as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Maturity of lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;138&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total lease payments&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;215&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less imputed interest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total operating lease liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;204&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.26%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less current portion of lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(173&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.26%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lease liability&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000246"
      unitRef="U_iso4217USD">138000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000247"
      unitRef="U_iso4217USD">77000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000248"
      unitRef="U_iso4217USD">215000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000249"
      unitRef="U_iso4217USD">11000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000250"
      unitRef="U_iso4217USD">204000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000251"
      unitRef="U_iso4217USD">173000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000252"
      unitRef="U_iso4217USD">31000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="C_0001260990_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_onctShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_20210331"
      decimals="-5"
      id="F_000253"
      unitRef="U_iso4217USD">300000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:AccountsReceivableRelatedParties
      contextRef="C_0001260990_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_onctShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_20201231"
      decimals="-5"
      id="F_000254"
      unitRef="U_iso4217USD">300000</us-gaap:AccountsReceivableRelatedParties>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000180">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.17%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;License, Collaboration and Research Subaward Agreements&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Georgetown University (&#x201c;Georgetown&#x201d;)&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2014, the Company entered into an Exclusive License Agreement (the &#x201c;Georgetown License Agreement&#x201d;) with Georgetown, pursuant to which the Company: (i) licensed the exclusive worldwide right to patents and technologies for the development and commercialization of certain product candidates targeting EWS-FLI1 as an anti-tumor therapy for therapeutic, diagnostics, or research tool purposes, (ii) is solely responsible for all development and commercialization activities and costs, and (iii) is responsible for all costs related to the filing, prosecution and maintenance of the licensed patent rights.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the Georgetown License Agreement, commencing in 2015, the Company: (i) shall pay and has paid an annual license maintenance fee of $10,000 until the first commercial sale occurs, (ii) is required to make up to $0.2 million in aggregate milestone payments upon the achievement of certain regulatory milestones, and (iii) will be required to pay low single digit royalties based on annual net product sales. The Company accounted for the licensed technology as an asset acquisition because it did not meet the definition of a business. All milestone payments under the Georgetown License Agreement will be recognized as research and development expense upon completion of the required events, as the triggering events are not considered to be probable until they are achieved. As of March&#160;31, 2021, the Company had &lt;span style="color:#000000;"&gt;not&lt;/span&gt; triggered or made any milestone payments under the Georgetown License Agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Georgetown License Agreement may be terminated by either party upon material breach or may be terminated by the Company as to one or more countries with 90 days written notice of termination. The term of the Georgetown License Agreement will continue until the expiration of the last valid claim within the patent rights covering the product. Georgetown may terminate the agreement in the event: (i) the Company fails to pay any amount and fails to cure such failure within 30 days after receipt of notice, (ii) the Company defaults in its obligation to obtain and maintain insurance and fails to remedy such breach within 60 days after receipt of notice, or (iii) the Company declares insolvency or bankruptcy. The Company may terminate the Georgetown License Agreement at any time upon at least 60 days&#x2019; written notice.&#160;&#160;&#160;&#160;&#160;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;The University of Texas MD Anderson Cancer Center (&#x201c;MD Anderson&#x201d;)&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2014, the Company entered into a collaboration agreement (as amended, the &#x201c;Collaboration&#x201d;) with MD Anderson, which provides for the conduct of preclinical and clinical research for TK216 in exchange for certain program payments. If MD Anderson successfully completes all the requirements of the Collaboration in full and the program is successfully commercialized, the Company will be required to pay aggregate milestone payments of $1.0 million based on net product sales. In July 2020, the Company entered into a research agreement with MD Anderson for certain services up to an aggregate cost of $293,000. The &lt;span style="color:#000000;"&gt;Company&lt;/span&gt; recorded research and development expense &lt;span style="color:#000000;"&gt;of $0.1 million and a nominal amount &lt;/span&gt;for each of the three months ended March&#160;31, 2021 and 2020, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Agreements with the Regents of the University of California (the &#x201c;Regents&#x201d;)&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2016, and as amended and restated in August 2018, and as amended in March and May 2019, the Company entered into a license agreement (as amended, the &#x201c;Regents License Agreement&#x201d;) for the development, manufacturing and distribution rights related to the development and commercialization of ROR1 related naked antibodies, antibody fragments or synthetic antibodies, and genetically engineered cellular therapy. The Regents License Agreement provides for the following: (i) in May 2016, an upfront license fee of $0.5 million was paid and 107,108 shares of common stock were issued, (ii) $25,000 in annual license maintenance fees commencing in 2017, (iii) reimbursement of certain annual patent costs, (iv) certain development and regulatory milestones aggregating from $10.0 million to $12.5 million, on a per product basis, (v) certain worldwide sales milestones based on achievement of tiered revenue levels aggregating $75.0 million, (vi) low single-digit royalties, including potential future minimum annual royalties, on net sales of each target, and (vii) minimum diligence to advance licensed assets consisting of at least $1.0 million in development spend annually through 2021. Under the Regents License Agreement, the Company recorded:&#160;&lt;span style="color:#000000;"&gt;(i) $25,000 and none in license maintenance fees as research and development expense for each of the three months ended March 31, 2021 and 2020, (ii) $0.2 million and $25,000 in patent costs as general and administrative expense for the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021, the Company believes it has met its obligations under the Regents License Agreement.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2016, and as modified by the amended and restated Regents License Agreement in August 2018, the Company entered into a Research Agreement (the &#x201c;Research Agreement&#x201d;) with the Regents for further research on a ROR1 therapeutic development program. Under this &lt;span style="-sec-ix-hidden:F_000276"&gt;five-year&lt;/span&gt; agreement, the Regents will have an aggregate budget of $3.6 million, with $125,000 payable quarterly. The Company recorded $0.1 million in research and development expense under this agreement&#160;for each of the three months ended March 2021 and 2020, respectively. Such costs are includable as part of the Company&#x2019;s annual diligence obligations under the Regents License Agreement. The Regents License Agreement will expire upon the later of the expiration date of the longest-lived patent rights or the fifteenth anniversary of the first commercial sale of a licensed product. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Regents may terminate the Regents License Agreement if: (i) a material breach by the Company is not cured within a reasonable time, (ii) the Company files a claim asserting the Regents licensed patent rights are invalid or unenforceable and (iii) the Company files for bankruptcy. The Company may terminate the agreement at any time upon at least 60 days&#x2019; written notice.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;The University of Tennessee Research Foundation (&#x201c;UTRF&#x201d;)&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2015, the Company and UTRF entered into a license agreement (the &#x201c;SARD License Agreement&#x201d;) pursuant to which the Company was granted exclusive worldwide rights in all existing selective androgen receptor degrader (&#x201c;SARD&#x201d;) technologies owned or controlled by UTRF, including all improvements thereto.&#160; Under the SARD License Agreement, the Company is obligated to employ active, diligent efforts to conduct preclinical research and development activities for the SARD program to advance one or more lead compounds into clinical development.&#160; The Company is also obligated to pay UTRF annual license maintenance fees, low single-digit royalties on net sales of products and additional royalties on sublicense revenues, depending on the state of development of a clinical product candidate at the time it is sublicensed. The Company recorded research and development expense under this agreement of $35,000 and &lt;span style="color:#000000;"&gt;$0.1 million&lt;/span&gt; for each of the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021, the Company believes it has met its obligations under the SARD License Agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;The California Institute for Regenerative Medicine (&#x201c;CIRM&#x201d;) Awards&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2017, &lt;span style="color:#000000;"&gt;and as amended and restated in December 2020,&lt;/span&gt; CIRM awarded an $18.3 million grant to&lt;span style="color:#000000;"&gt; researchers at UC San Diego&lt;/span&gt; to advance the Company&#x2019;s Phase 1/2 clinical trial evaluating cirmtuzumab in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma. The Company: (i) is conducting this study in collaboration with UC San Diego, (ii) estimates it will receive approximately $14.0 million in development milestones under research subaward agreements during the award project period, estimated to be from October 1, 2017 to March 31, 2022, (iii) is committed to certain co-funding requirements, (iv) received &lt;span style="color:#000000;"&gt;no&lt;/span&gt; subaward payments in the three months ended March 31, 2021 and 2020, and (v) is required to provide UC San Diego progress and financial update reports throughout the award period. The subaward does not bear a royalty payment commitment, nor is the subaward otherwise refundable. For the three months ended March 31, 2021 and 2020, the Company recorded revenue of $0.7 million and $0.6 million, respectively. Related qualifying subaward costs for the three months ended March 31, 2021 and 2020 were $1.5 million and $1.3 million, respectively. As of March 31,2021, the Company believes it has met its obligations under the CIRM award and UC San Diego subawards.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2017, CIRM awarded a $5.8 million grant to the researchers at UC San Diego to develop a novel anti-cancer stem cell targeted therapy for patients with advanced solid and hematological malignancies. In connection with such CIRM award, the Company agreed to provide up to $1.0 million in contingency funds if required during the grant period, which expired in April 2020. The Company recorded no research and development expense, and no contingency funds have been provided under such CIRM award for each of the three months ended March 31, 2021 and 2020.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Clinical Trial and Supply Agreement&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April 2018, the Company entered into a Clinical Trial and Supply Agreement with Pharmacyclics, LLC, an AbbVie Company (&#x201c;Pharmacyclics&#x201d;) to supply ibrutinib for the Company&#x2019;s Phase 1/2 clinical trial evaluating cirmtuzumab in combination with ibrutinib, which agreement was amended in August 2019. Such agreement does not bear any upfront costs, inventory purchase costs, milestone or royalty payment commitments or other financial obligations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;SPH USA, a Related Party&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;License and Development Agreement (&#x201c;LDA&#x201d;)&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2018&lt;span style="color:#000000;"&gt;, and as amended in August 2020&lt;/span&gt;, the Company entered into the LDA with SPH USA for: (i) the territory of the People&#x2019;s Republic of China, Hong Kong, Macau, and Taiwan (&#x201c;Greater China&#x201d;), and (ii) rights to manufacture, develop, market, distribute and sell all of the Company&#x2019;s product candidates under the Georgetown License Agreement and the Regents License Agreement (exclusive to Greater China only). Under the LDA, SPH USA is solely responsible for: (a) all preclinical and clinical development activities required in order to obtain regulatory approval in Greater China for such product candidates, (b) any third-party license milestone or royalty payments owed under the Georgetown License Agreement and the Regents License Agreement, and (c) paying the Company a low single digit royalty on net sales in the territory.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The LDA will expire upon the expiration of the last royalty term for the last licensed product. The LDA may be terminated by: (i) SPH USA on a country by country or product by product basis with 180 days written notice, (ii) either party upon material breach that is not cured within 90 days, and (iii) either party in the event the other party declares insolvency or bankruptcy.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <onct:LicenseMaintenanceFeeToBePaidAndPaymentMade
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20150101_20151231"
      decimals="0"
      id="F_000255"
      unitRef="U_iso4217USD">10000</onct:LicenseMaintenanceFeeToBePaidAndPaymentMade>
    <onct:CollaborativeArrangementPotentialMilestonePayments
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_srtRangeAxis_srtMaximumMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20151231"
      decimals="INF"
      id="F_000256"
      unitRef="U_iso4217USD">200000</onct:CollaborativeArrangementPotentialMilestonePayments>
    <onct:NumberOfDaysInWrittenNoticeOfTermination
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210101_20210331"
      id="F_000258">P90D</onct:NumberOfDaysInWrittenNoticeOfTermination>
    <onct:NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210101_20210331"
      id="F_000259">P30D</onct:NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount>
    <onct:NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210101_20210331"
      id="F_000260">P60D</onct:NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment>
    <onct:MinimumPeriodOfWrittenNoticeToTerminateAgreement
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctGeorgetownUniversityMember_us-gaapTypeOfArrangementAxis_onctExclusiveLicenseAgreementMember_20210101_20210331"
      id="F_000261">P60D</onct:MinimumPeriodOfWrittenNoticeToTerminateAgreement>
    <onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_us-gaapTypeOfArrangementAxis_us-gaapCollaborativeArrangementMember_20141231"
      decimals="-5"
      id="F_000262"
      unitRef="U_iso4217USD">1000000.0</onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20200731"
      decimals="-3"
      id="F_000264"
      unitRef="U_iso4217USD">293000000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctMDAndersonCancerCenterMember_20210101_20210331"
      decimals="-5"
      id="F_000263"
      unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <onct:UpfrontLicenseFeesPaid
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531"
      decimals="-5"
      id="F_000265"
      unitRef="U_iso4217USD">500000</onct:UpfrontLicenseFeesPaid>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531"
      decimals="INF"
      id="F_000266"
      unitRef="U_xbrlishares">107108</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <onct:AnnualLicenseMaintenanceFees
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20170101_20171231"
      decimals="0"
      id="F_000267"
      unitRef="U_iso4217USD">25000</onct:AnnualLicenseMaintenanceFees>
    <onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMinimumMember_20160531"
      decimals="INF"
      id="F_000268"
      unitRef="U_iso4217USD">10000000.0</onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments>
    <onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMaximumMember_20160531"
      decimals="INF"
      id="F_000269"
      unitRef="U_iso4217USD">12500000</onct:CollaborativeArrangementPotentialRegulatoryMilestonePayments>
    <onct:SalesMilestonesBasedOnAchievementOfTieredRevenueLevels
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20160501_20160531"
      decimals="-5"
      id="F_000270"
      unitRef="U_iso4217USD">75000000.0</onct:SalesMilestonesBasedOnAchievementOfTieredRevenueLevels>
    <onct:AdvanceLicensedAssets
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_srtRangeAxis_srtMinimumMember_20160531"
      decimals="INF"
      id="F_000271"
      unitRef="U_iso4217USD">1000000.0</onct:AdvanceLicensedAssets>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20210101_20210331"
      decimals="0"
      id="F_000274"
      unitRef="U_iso4217USD">25000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20200101_20200331"
      decimals="0"
      id="F_000275"
      unitRef="U_iso4217USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20210101_20210331"
      decimals="-5"
      id="F_000272"
      unitRef="U_iso4217USD">200000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_20200101_20200331"
      decimals="0"
      id="F_000273"
      unitRef="U_iso4217USD">25000</us-gaap:GeneralAndAdministrativeExpense>
    <onct:ResearchAgreementResearchFundingAmount
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20210101_20210331"
      decimals="-5"
      id="F_000277"
      unitRef="U_iso4217USD">3600000</onct:ResearchAgreementResearchFundingAmount>
    <onct:ResearchAgreementResearchFundingAmountPayable
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20210101_20210331"
      decimals="0"
      id="F_000278"
      unitRef="U_iso4217USD">125000</onct:ResearchAgreementResearchFundingAmountPayable>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20210101_20210331"
      decimals="-5"
      id="F_000279"
      unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctResearchAgreementMember_20200101_20200331"
      decimals="-5"
      id="F_000280"
      unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <onct:NumberOfDaysInWrittenNoticeOfTermination
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctReagentsMember_us-gaapTypeOfArrangementAxis_onctRegentsLicenseAgreementMember_20210101_20210331"
      id="F_000281">P60D</onct:NumberOfDaysInWrittenNoticeOfTermination>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20210101_20210331"
      decimals="0"
      id="F_000282"
      unitRef="U_iso4217USD">35000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfTennesseeResearchFoundationMember_us-gaapTypeOfArrangementAxis_onctLicenseAgreementMember_20200101_20200331"
      decimals="-5"
      id="F_000283"
      unitRef="U_iso4217USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <onct:ResearchAndDevelopmentGrants
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20170801_20170831"
      decimals="-5"
      id="F_000284"
      unitRef="U_iso4217USD">18300000</onct:ResearchAndDevelopmentGrants>
    <onct:DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20170801_20170831"
      decimals="-5"
      id="F_000285"
      unitRef="U_iso4217USD">14000000.0</onct:DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod>
    <onct:SubawardPaymentsReceived
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20210101_20210331"
      decimals="-6"
      id="F_000286"
      unitRef="U_iso4217USD">0</onct:SubawardPaymentsReceived>
    <onct:SubawardPaymentsReceived
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20200331"
      decimals="-6"
      id="F_000287"
      unitRef="U_iso4217USD">0</onct:SubawardPaymentsReceived>
    <us-gaap:Revenues
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20210101_20210331"
      decimals="-5"
      id="F_000288"
      unitRef="U_iso4217USD">700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20200331"
      decimals="-5"
      id="F_000289"
      unitRef="U_iso4217USD">600000</us-gaap:Revenues>
    <onct:RelatedQualifyingSubawardCosts
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20210101_20210331"
      decimals="-5"
      id="F_000290"
      unitRef="U_iso4217USD">1500000</onct:RelatedQualifyingSubawardCosts>
    <onct:RelatedQualifyingSubawardCosts
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20200331"
      decimals="-5"
      id="F_000291"
      unitRef="U_iso4217USD">1300000</onct:RelatedQualifyingSubawardCosts>
    <onct:ResearchAndDevelopmentGrants
      contextRef="C_0001260990_srtCounterpartyNameAxis_onctUniversityOfCaliforniaSanDiegoMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031"
      decimals="-5"
      id="F_000292"
      unitRef="U_iso4217USD">5800000</onct:ResearchAndDevelopmentGrants>
    <onct:AmountAgreedToBeProvidedInContingencyFunds
      contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20171001_20171031"
      decimals="INF"
      id="F_000293"
      unitRef="U_iso4217USD">1000000.0</onct:AmountAgreedToBeProvidedInContingencyFunds>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_20210101_20210331"
      decimals="-6"
      id="F_000295"
      unitRef="U_iso4217USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_0001260990_20200101_20200331"
      decimals="-6"
      id="F_000296"
      unitRef="U_iso4217USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <onct:AmountAgreedToBeProvidedInContingencyFunds
      contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_onctCaliforniaInstituteForRegenerativeMedicineAwardMember_20200101_20200331"
      decimals="-6"
      id="F_000294"
      unitRef="U_iso4217USD">0</onct:AmountAgreedToBeProvidedInContingencyFunds>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000181">
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;text-indent:-4.17%;font-size:9pt;"&gt;&#160;&lt;/p&gt;
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.17%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/span&gt;&lt;span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Stockholders&#x2019; Equity&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Securities Purchase &lt;span style="color:#000000;"&gt;Agreements and Underwritten Offering&lt;/span&gt;&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2020, the Company entered into a Securities Purchase Agreement (the &#x201c;May Purchase Agreement&#x201d;) with several institutional and individual investors (including an entity affiliated with David F. Hale, the chairman of the Company&#x2019;s board of directors) for the concurrent sale of: (i) 1,943,636 shares of the Company&#x2019;s common stock in a registered direct offering, resulting in net proceeds of $4.4 million, after deducting the placement agent&#x2019;s cash commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the warrants, and (ii) unregistered warrants to purchase up to an aggregate of 971,818 shares of common stock. The combined purchase price for one share and one warrant to purchase half of a share of common stock was $2.5725. &lt;span style="color:#000000;"&gt;In addition, the Company issued warrants to purchase 116,618 shares of common stock at an exercise price of $3.2156 per share to the placement agent, H.C. Wainwright &amp;amp; Co., LLC (&#x201c;Wainwright&#x201d; or the &#x201c;placement agent&#x201d;) as part of its compensation, which warrants were immediately exercisable and expire on May 21, 2025.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2020, the Company entered into a Securities Purchase Agreement (the &#x201c;July Purchase Agreement&#x201d;) with several institutional and individual investors for the concurrent sale of: (i) 2,581,867 shares of the Company&#x2019;s common stock in a registered direct offering, resulting in net proceeds of $5.7 million, after deducting the placement agent&#x2019;s cash commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the warrants, and (ii) unregistered warrants to purchase up to an aggregate of 1,290,933 shares of common stock.&#160;The combined purchase price for one share and one warrant to purchase half of a share of common stock was $2.3825. The warrants issued to investors were, subject to certain ownership limitations, immediately exercisable at an exercise price equal to $2.32 per share and expire on January 21, 2026. In addition, the Company issued warrants to purchase 154,912 shares of common stock at an exercise price of $2.9781 per share to the placement agent as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on July 21, 2025. Other investors participating in the July Purchase Agreement included an entity affiliated with SPH USA, the Company&#x2019;s largest stockholder, Daniel L. Kisner, a member of the Company&#x2019;s board of directors, and Hazel M. Aker, the Company&#x2019;s then General Counsel.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020, the Company &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;entered into&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; an underwriting agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; (as amended and restated, the &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;August &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;w&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;riting Agreement&#x201d;) with Wainwright&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; for the sale of &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,428,886&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; shares of the Company&#x2019;s common stock at a price &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;to the public &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;of $&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.10&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; per share, resulting in net proceeds of $&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.4&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; million, after deducting the &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;underwriter&#x2019;s discounts,&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;commissions&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; and other offering expenses.&#160; In addition, the Company issued warrants to purchase &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;145,733&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; shares of common stock at an exercise price of $&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.625&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; per share to &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Wainwright&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; as part of its compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;, which &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;warrants were immediately exercisable upon issuance and terminate on &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;August 27, 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;An&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; i&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;nvestor&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; participating&lt;/span&gt;&lt;span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; in the transaction included Michael G. Carter, a member of the Company&#x2019;s board of directors.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2020, the Company entered into an underwriting agreement (as amended and restated, the &#x201c;November Underwriting Agreement&#x201d;) with Wainwright for the sale of 7,258,065 shares of the Company&#x2019;s common stock at a price to the public of $3.10 per share, resulting in net proceeds of $20.4 million, after deducting the underwriter&#x2019;s discounts, commissions and other offering expenses. In addition, the Company issued warrants to purchase 435,484 shares of common stock at an exercise price of $3.875 per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on November 17, 2025. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2020, the Company entered into an underwriting agreement (as amended and restated, the &#x201c;December Underwriting Agreement&#x201d;) with Wainwright for the sale of 19,161,667 shares of the Company&#x2019;s common stock at a price to the public of $4.50 per share, resulting in net proceeds of $79.0 million, after deducting the underwriter&#x2019;s discounts, commissions and other offering expenses In addition, the Company issued warrants to purchase 1,149,700 shares of common stock at an exercise price of $5.625 per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on December 9, 2025. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the May Purchase Agreement and July Purchase Agreement, the Company also agreed, on a best-efforts basis, to: (i) maintain its listing on The Nasdaq Capital Market to provide for the resale of the shares of common stock issuable upon the exercise of the warrants, and (ii) not enter into any agreement for the issuance of any shares of common stock involving a variable rate transaction before July 21, 2021, &lt;span style="color:#000000;"&gt;other than pursuant to a new at-the-market offering facility with the placement &lt;/span&gt;agent. Variable rate&#160;transaction means a transaction in which the Company issues or sells, or agrees to issue or sell, common stock or convertible securities in which the applicable sale, conversion, exercise or exchange price or&#160;rate&#160;may directly or indirectly effectively be reduced. The&lt;span style="color:#000000;"&gt; Company does not currently have an active at-the-market offering facility. &lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Common Stock Warrants&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-size:6pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of warrant activity and changes in warrants outstanding is presented below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of Shares Underlying Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average Exercise Price Per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average Remaining Contractual Term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,031,841&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000337"&gt;4.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.56%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(754,255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.57&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000338"&gt;4.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.56%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,277,586&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.42&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000339"&gt;4.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March 31, 2021, all warrants met the criteria for classification in stockholders&#x2019; equity.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.67%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Equity Incentive Plans&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contemporaneous with the Merger closing: (i) Private Oncternal&#x2019;s 2015 Equity Incentive Plan, as amended (the &#x201c;2015 Plan&#x201d;) was assumed by the Company, and (ii) the Company adopted the 2019 Incentive Award Plan (&#x201c;2019 Plan&#x201d;) under which the sum of: (a) 1,678,571&#160;shares of common stock, (b)&#160; up to 275,579 shares of common stock which were subject to outstanding awards under the GTx 2013 Equity Incentive Plan (the &#x201c;2013 Plan&#x201d;) as of June 7, 2019, that upon cancellation will become available for issuance under the 2019 Plan, and (c)&#160;an annual increase on the first day of each calendar year beginning January&#160;1, 2020, and ending on and including January&#160;1, 2029, equal to the lesser of (A) 5% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (B)&#160;such smaller number of shares of common stock as is determined by the Board, are reserved for issuance. At March 31, 2021, 2,143,999 shares remain available for future issuance under the 2019 Plan and Inducement Plan.&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,977,826&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.46&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000350"&gt;8.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,378,589&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options vested and expected to vest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,977,826&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.46&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000351"&gt;8.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,378,589&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,075,315&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.51&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000352"&gt;7.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,170,595&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March 31, 2021, under the 2013 Plan, there were: (i) &lt;span style="color:#000000;"&gt;87,133&lt;/span&gt; outstanding and fully vested and exercisable options with a weighted average exercise price of $&lt;span style="color:#000000;"&gt;62.48&lt;/span&gt; per share that expire in the second quarter of 2021, and (ii) &lt;span style="color:#000000;"&gt;24,282&lt;/span&gt; options cancelled during the three months ended March 31, 2021 were added to the 2019 Plan. As of March 31, 2021, the remaining former GTx stock option plans had an aggregate of &lt;span style="color:#000000;"&gt;4,582&lt;/span&gt; outstanding and fully vested and exercisable options with a weighted average exercise price of $&lt;span style="color:#000000;"&gt;270.00&lt;/span&gt; per share that expire in the second quarter of 2021.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2015, Private Oncternal adopted the 2015 Plan which provided for the issuance of up to 631,120 shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants.&#160;&#160;In general, the options issued under the 2015 Plan expire ten years from the date of grant and vest over a &lt;span style="-sec-ix-hidden:F_000363"&gt;four-year&lt;/span&gt; period. Certain grants vest based on the achievement of development or regulatory milestones. No further awards will be made under the 2015 Plan, which was terminated as to new grants in June 2019. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The 2019 Plan provides for the issuance of shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants.&#160;&#160;In general, the options issued under the 2019 Plan expire ten years from the date of grant and vest over a &lt;span style="-sec-ix-hidden:F_000365"&gt;four-year&lt;/span&gt; period. Certain grants vest based on the achievement of development or regulatory milestones. The 2019 Plan allows for the early exercise of all stock option grants if authorized by the board of directors at the time of grant. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On February 11, 2021, the Company&#x2019;s board of directors adopted the 2021 Employment Inducement Incentive Award Plan (the &#x201c;Inducement Plan&#x201d;) and initially reserved 700,000 shares of common stock for issuance. The Inducement Plan is a non-shareholder approved stock plan adopted pursuant to the &#x201c;inducement exception&#x201d; provided under Nasdaq listing rules. The Inducement Plan will be used exclusively for the issuance of non-statutory stock options to certain new hires who satisfied the requirements to be granted inducement grants under Nasdaq rules as an inducement material to the individual&#x2019;s entry into employment with the Company. The terms of the Inducement Plan are substantially similar to the terms of our 2019 Plan. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the Company&#x2019;s stock option activity under the 2019 Plan, Inducement Plan and 2015 Plan is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,107,625&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.08&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,127,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.78&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(168,750&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.47&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(88,049&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.06&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,977,826&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.46&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Information about the Company&#x2019;s outstanding stock options under the 2019 Plan and 2015 Plan is as follows (in thousands, except share and per share data and expected term):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted average grant date fair value per share of option grants for the three months ended March 31, 2021 was $&lt;span style="color:#000000;"&gt;5.06&lt;/span&gt; per share.&#160;&#160;The aggregate intrinsic value of stock options exercised during the three months ended March 31, 2021 was $365,000. The intrinsic value is calculated as the difference between the fair value of the Company&#x2019;s common stock at the time of the option exercise and the exercise price of that stock option.&lt;/p&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation Expense&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants, were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000383"&gt;6.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000384"&gt;5.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.17%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility. &lt;span style="font-style:normal;"&gt;Prior to the Merger, Private Oncternal did not have a trading history for its common stock.&#160;&#160;Accordingly, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the life sciences industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected term. &lt;span style="font-style:normal;"&gt;The expected term represents the period of time that options are expected to be outstanding. Because Private Oncternal did not have historical exercise behavior, it determined the expected life assumption using the simplified method for employees, which is an average of the contractual term of the option and its vesting period. The expected term for nonemployee options is generally the remaining contractual term.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate. &lt;span style="font-style:normal;"&gt;The risk-free interest rate is based on the implied yield on the U.S. Treasury securities with a maturity date similar to the expected term of the associated stock option award.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield. &lt;span style="font-style:normal;"&gt;The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero.&lt;/span&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense recognized for all equity awards has been reported in the condensed consolidated statements of operations as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;473&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;139&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;365&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;260&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;838&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;399&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of March 31, 2021, the total compensation cost related to non-vested awards not yet recognized was $12.4 million and the weighted-average period over which it is expected to be recognized was 3.6 years. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Common Stock Reserved for Future Issuance&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock reserved for future issuance is as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,278&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock options issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,069&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock available for issuance under the Inducement Plan and 2019 Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,491&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531"
      decimals="INF"
      id="F_000297"
      unitRef="U_xbrlishares">1943636</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531"
      decimals="-5"
      id="F_000298"
      unitRef="U_iso4217USD">4400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531"
      decimals="INF"
      id="F_000299"
      unitRef="U_xbrlishares">971818</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <onct:CombinedPurchasePriceOfShareAndWarrantPerUnit
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531"
      decimals="4"
      id="F_000300"
      unitRef="U_iso4217USD_xbrlishares">2.5725</onct:CombinedPurchasePriceOfShareAndWarrantPerUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531"
      decimals="INF"
      id="F_000301"
      unitRef="U_xbrlishares">116618</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531"
      decimals="4"
      id="F_000302"
      unitRef="U_iso4217USD_xbrlishares">3.2156</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200501_20200531"
      id="F_000303">2025-05-21</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731"
      decimals="INF"
      id="F_000304"
      unitRef="U_xbrlishares">2581867</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731"
      decimals="-5"
      id="F_000305"
      unitRef="U_iso4217USD">5700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731"
      decimals="INF"
      id="F_000306"
      unitRef="U_xbrlishares">1290933</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <onct:CombinedPurchasePriceOfShareAndWarrantPerUnit
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731"
      decimals="4"
      id="F_000307"
      unitRef="U_iso4217USD_xbrlishares">2.3825</onct:CombinedPurchasePriceOfShareAndWarrantPerUnit>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731"
      decimals="2"
      id="F_000308"
      unitRef="U_iso4217USD_xbrlishares">2.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <onct:CommonStockWarrantsExpirationDate
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731"
      id="F_000309">2026-01-21</onct:CommonStockWarrantsExpirationDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731"
      decimals="INF"
      id="F_000310"
      unitRef="U_xbrlishares">154912</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200731"
      decimals="4"
      id="F_000311"
      unitRef="U_iso4217USD_xbrlishares">2.9781</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_0001260990_srtTitleOfIndividualAxis_onctPlacementAgentMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctJulyPurchaseAgreementMember_20200701_20200731"
      id="F_000312">2025-07-21</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831"
      decimals="INF"
      id="F_000313"
      unitRef="U_xbrlishares">2428886</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <onct:CombinedPurchasePriceOfShareAndWarrantPerUnit
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831"
      decimals="2"
      id="F_000316"
      unitRef="U_iso4217USD_xbrlishares">2.10</onct:CombinedPurchasePriceOfShareAndWarrantPerUnit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831"
      decimals="-5"
      id="F_000314"
      unitRef="U_iso4217USD">4400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831"
      decimals="INF"
      id="F_000315"
      unitRef="U_xbrlishares">145733</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200831"
      decimals="3"
      id="F_000317"
      unitRef="U_iso4217USD_xbrlishares">2.625</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctAugustUnderwritingAgreementMember_20200801_20200831"
      id="F_000318">2025-08-27</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130"
      decimals="INF"
      id="F_000319"
      unitRef="U_xbrlishares">7258065</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <onct:CombinedPurchasePriceOfShareAndWarrantPerUnit
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130"
      decimals="2"
      id="F_000322"
      unitRef="U_iso4217USD_xbrlishares">3.10</onct:CombinedPurchasePriceOfShareAndWarrantPerUnit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130"
      decimals="-5"
      id="F_000320"
      unitRef="U_iso4217USD">20400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130"
      decimals="INF"
      id="F_000321"
      unitRef="U_xbrlishares">435484</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201130"
      decimals="3"
      id="F_000323"
      unitRef="U_iso4217USD_xbrlishares">3.875</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctNovemberUnderwritingAgreementMember_20201101_20201130"
      id="F_000324">2025-11-17</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231"
      decimals="INF"
      id="F_000325"
      unitRef="U_xbrlishares">19161667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <onct:CombinedPurchasePriceOfShareAndWarrantPerUnit
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231"
      decimals="2"
      id="F_000328"
      unitRef="U_iso4217USD_xbrlishares">4.50</onct:CombinedPurchasePriceOfShareAndWarrantPerUnit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_0001260990_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231"
      decimals="-5"
      id="F_000326"
      unitRef="U_iso4217USD">79000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_srtRangeAxis_srtMaximumMember_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231"
      decimals="INF"
      id="F_000327"
      unitRef="U_xbrlishares">1149700</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201231"
      decimals="3"
      id="F_000329"
      unitRef="U_iso4217USD_xbrlishares">5.625</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctDecemberUnderwritingAgreementMember_20201201_20201231"
      id="F_000330">2025-12-09</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <onct:ScheduleOfWarrantActivityTableTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000202">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of warrant activity and changes in warrants outstanding is presented below:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.56%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of Shares Underlying Warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average Exercise Price Per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.76%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-Average Remaining Contractual Term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,031,841&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.25&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000337"&gt;4.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.56%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.56%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(754,255&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.57&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000338"&gt;4.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.56%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,277,586&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.42&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000339"&gt;4.07&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</onct:ScheduleOfWarrantActivityTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000331"
      unitRef="U_xbrlishares">5031841</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000334"
      unitRef="U_iso4217USD_xbrlishares">9.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <onct:ExerciseOfWarrants
      contextRef="C_0001260990_20210101_20210331"
      decimals="INF"
      id="F_000332"
      unitRef="U_xbrlishares">754255</onct:ExerciseOfWarrants>
    <onct:WarrantExercisedPricePerShare
      contextRef="C_0001260990_20210101_20210331"
      decimals="INF"
      id="F_000335"
      unitRef="U_iso4217USD_xbrlishares">2.57</onct:WarrantExercisedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="C_0001260990_20210331"
      decimals="INF"
      id="F_000333"
      unitRef="U_xbrlishares">4277586</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0001260990_20210331"
      decimals="INF"
      id="F_000336"
      unitRef="U_iso4217USD_xbrlishares">10.42</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607"
      decimals="INF"
      id="F_000340"
      unitRef="U_xbrlishares">1678571</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607"
      decimals="INF"
      id="F_000341"
      unitRef="U_xbrlishares">275579</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <onct:SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20190607_20190607"
      decimals="2"
      id="F_000342"
      unitRef="U_xbrlipure">0.05</onct:SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember_20210331"
      decimals="INF"
      id="F_000343"
      unitRef="U_xbrlishares">2143999</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000203">
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.66%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Per Share&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,977,826&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.46&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000350"&gt;8.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,378,589&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options vested and expected to vest&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,977,826&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.46&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000351"&gt;8.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,378,589&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,075,315&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.51&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000352"&gt;7.30&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,170,595&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210331"
      decimals="INF"
      id="F_000344"
      unitRef="U_xbrlishares">3977826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210331"
      decimals="INF"
      id="F_000347"
      unitRef="U_iso4217USD_xbrlishares">5.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210331"
      decimals="-3"
      id="F_000353"
      unitRef="U_iso4217USD">11378589000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210331"
      decimals="INF"
      id="F_000345"
      unitRef="U_xbrlishares">3977826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210331"
      decimals="INF"
      id="F_000348"
      unitRef="U_iso4217USD_xbrlishares">5.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210331"
      decimals="-3"
      id="F_000354"
      unitRef="U_iso4217USD">11378589000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210331"
      decimals="INF"
      id="F_000346"
      unitRef="U_xbrlishares">1075315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210331"
      decimals="INF"
      id="F_000349"
      unitRef="U_iso4217USD_xbrlishares">3.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210331"
      decimals="-3"
      id="F_000355"
      unitRef="U_iso4217USD">5170595000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandThirteenPlanMember_20210331"
      decimals="INF"
      id="F_000356"
      unitRef="U_xbrlishares">87133</onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber>
    <onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice
      contextRef="C_0001260990_20210331"
      decimals="2"
      id="F_000357"
      unitRef="U_iso4217USD_xbrlishares">62.48</onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanMember_20210101_20210331"
      decimals="INF"
      id="F_000358"
      unitRef="U_xbrlishares">24282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctGTxStockOptionPlansMember_20210331"
      decimals="INF"
      id="F_000359"
      unitRef="U_xbrlishares">4582</onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber>
    <onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctGTxStockOptionPlansMember_20210331"
      decimals="2"
      id="F_000360"
      unitRef="U_iso4217USD_xbrlishares">270.00</onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001260990_srtConsolidatedEntitiesAxis_onctPrivateOncternalMember_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150731"
      decimals="INF"
      id="F_000361"
      unitRef="U_xbrlishares">631120</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandFifteenPlanMember_20150701_20150731"
      id="F_000362">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenPlanMember_20150701_20150731"
      id="F_000364">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctInducementPlanMember_20210211"
      decimals="INF"
      id="F_000366"
      unitRef="U_xbrlishares">700000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000204">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of the Company&#x2019;s stock option activity under the 2019 Plan, Inducement Plan and 2015 Plan is as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,107,625&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.08&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,127,000&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.78&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(168,750&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.47&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(88,049&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.06&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at March 31, 2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,977,826&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.46&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001260990_20201231"
      decimals="INF"
      id="F_000367"
      unitRef="U_xbrlishares">2107625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001260990_20201231"
      decimals="2"
      id="F_000372"
      unitRef="U_iso4217USD_xbrlishares">4.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_0001260990_20210101_20210331"
      decimals="INF"
      id="F_000368"
      unitRef="U_xbrlishares">2127000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_0001260990_20210101_20210331"
      decimals="2"
      id="F_000373"
      unitRef="U_iso4217USD_xbrlishares">6.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_0001260990_20210101_20210331"
      decimals="INF"
      id="F_000369"
      unitRef="U_xbrlishares">168750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_0001260990_20210101_20210331"
      decimals="2"
      id="F_000374"
      unitRef="U_iso4217USD_xbrlishares">5.47</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0001260990_20210101_20210331"
      decimals="INF"
      id="F_000370"
      unitRef="U_xbrlishares">88049</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_0001260990_20210101_20210331"
      decimals="2"
      id="F_000375"
      unitRef="U_iso4217USD_xbrlishares">4.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_0001260990_20210331"
      decimals="INF"
      id="F_000371"
      unitRef="U_xbrlishares">3977826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_0001260990_20210331"
      decimals="2"
      id="F_000376"
      unitRef="U_iso4217USD_xbrlishares">5.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20210101_20210331"
      decimals="2"
      id="F_000377"
      unitRef="U_iso4217USD_xbrlishares">5.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenAndTwoThousandFifteenPlanMember_20210101_20210331"
      decimals="-3"
      id="F_000378"
      unitRef="U_iso4217USD">365000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_0001260990_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20210101_20210331"
      id="F_000205">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants, were as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.6&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.0&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89.9&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;89.4&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000383"&gt;6.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="-sec-ix-hidden:F_000384"&gt;5.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001260990_20210101_20210331"
      decimals="3"
      id="F_000379"
      unitRef="U_xbrlipure">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_0001260990_20200101_20200331"
      decimals="3"
      id="F_000380"
      unitRef="U_xbrlipure">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001260990_20210101_20210331"
      decimals="3"
      id="F_000381"
      unitRef="U_xbrlipure">0.899</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_0001260990_20200101_20200331"
      decimals="3"
      id="F_000382"
      unitRef="U_xbrlipure">0.894</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000206">
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense recognized for all equity awards has been reported in the condensed consolidated statements of operations as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Three Months Ended&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;473&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;139&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;365&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;260&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;838&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;399&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20210101_20210331"
      decimals="-3"
      id="F_000385"
      unitRef="U_iso4217USD">473000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20200331"
      decimals="-3"
      id="F_000386"
      unitRef="U_iso4217USD">139000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20210101_20210331"
      decimals="-3"
      id="F_000387"
      unitRef="U_iso4217USD">365000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001260990_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20200331"
      decimals="-3"
      id="F_000388"
      unitRef="U_iso4217USD">260000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001260990_20210101_20210331"
      decimals="-3"
      id="F_000389"
      unitRef="U_iso4217USD">838000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_0001260990_20200101_20200331"
      decimals="-3"
      id="F_000390"
      unitRef="U_iso4217USD">399000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_0001260990_20210331"
      decimals="-5"
      id="F_000391"
      unitRef="U_iso4217USD">12400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_0001260990_20210101_20210331" id="F_000392">P3Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000207">
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock reserved for future issuance is as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;"&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;March&#160;31,&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock warrants&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,278&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock options issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,069&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock available for issuance under the Inducement Plan and 2019 Plan&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,144&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,491&lt;/p&gt;&lt;/td&gt;
&lt;td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <onct:CommonStockWarrantsReservedForFutureIssuance
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000393"
      unitRef="U_xbrlishares">4278000</onct:CommonStockWarrantsReservedForFutureIssuance>
    <onct:CommonStockOptionsIssuedAndOutstandingForFutureIssuance
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000394"
      unitRef="U_xbrlishares">4069000</onct:CommonStockOptionsIssuedAndOutstandingForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001260990_us-gaapPlanNameAxis_onctTwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember_20210331"
      decimals="-3"
      id="F_000395"
      unitRef="U_xbrlishares">2144000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0001260990_20210331"
      decimals="-3"
      id="F_000396"
      unitRef="U_xbrlishares">10491000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <onct:COVID19PandemicAndCARESActDisclosureTextBlock contextRef="C_0001260990_20210101_20210331" id="F_000182">
&lt;div style="align:left;"&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td style="width:4.17%;white-space:nowrap" valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;6&lt;/span&gt;&lt;span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;COVID-19 Pandemic and CARES Act&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A novel strain of coronavirus (SAR-CoV-2) causing a severe respiratory disease (&#x201c;COVID-19&#x201d;), was declared a global pandemic by the World Health Organization in March 2020. COVID-19 has presented substantial public health and economic challenges and is affecting economies, financial markets and business operations around the world. International and U.S. governmental authorities in impacted regions have taken actions in an effort to slow the spread of COVID-19, including issuing varying forms of &#x201c;stay-at-home&#x201d; orders, and restricting business functions outside of one&#x2019;s home. In response, the Company has put restrictions on employee travel and working from its executive offices with many employees continuing their work remotely. While the Company is currently continuing the clinical trials it has underway in sites across the U.S., COVID-19 precautions have directly or indirectly impacted the timeline for some of its clinical trials. Additionally, the Company&#x2019;s expectations for the timing of first-in-human dosing of its ROR1 CAR-T therapy has been delayed to the first half of 2022. The Company considered the impacts of COVID-19 on the assumptions and estimates used to prepare its condensed consolidated financial statements and determined that there were no material adverse impacts on the Company&#x2019;s results of operations and financial position at March 31, 2021. The full extent to which the COVID-19 pandemic will continue to directly or indirectly impact the Company&#x2019;s business results of operations and financial condition, will depend on future development that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, the success or failure of vaccination programs, the emergence of new variants of COVID-19, as well as the economic impact on local, regional, national and international markets.&#160; &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In response to the COVID-19 pandemic, the CARES Act was signed into law on March 27, 2020.&#160; The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#x2019;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property, and authorized the Paycheck Protection Program. The CARES Act had no material impact on the Company&#x2019;s income tax provision for the three months ended March&#160;31, 2021.&#160;&#160;&lt;span style="color:#000000;"&gt;The Company continues to monitor changes and revisions to the CARES Act and its impact on the Company&#x2019;s condensed consolidated financial position, results of operations and cash flows.&lt;/span&gt;&lt;/p&gt;
</onct:COVID19PandemicAndCARESActDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009170577416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Apr. 29, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Oncternal Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001260990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ONCT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,368,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-50549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">62-1715807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">12230 El Camino Real<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">434-1113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009170666696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 111,211<span></span>
</td>
<td class="nump">$ 116,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other</a></td>
<td class="nump">1,873<span></span>
</td>
<td class="nump">1,266<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">113,084<span></span>
</td>
<td class="nump">118,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">769<span></span>
</td>
<td class="nump">766<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">114,057<span></span>
</td>
<td class="nump">118,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,892<span></span>
</td>
<td class="nump">1,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">2,773<span></span>
</td>
<td class="nump">3,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred grant revenue</a></td>
<td class="nump">885<span></span>
</td>
<td class="nump">1,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease, current</a></td>
<td class="nump">173<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,723<span></span>
</td>
<td class="nump">5,858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease, net of current</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 3)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, authorized shares &#8211; 5,000; issued and outstanding shares &#8211; none</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; authorized shares &#8211; 60,000; issued and outstanding shares &#8211; 49,366 and 48,802 at March 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">196,999<span></span>
</td>
<td class="nump">195,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(88,745)<span></span>
</td>
<td class="num">(82,797)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">108,303<span></span>
</td>
<td class="nump">112,951<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 114,057<span></span>
</td>
<td class="nump">$ 118,809<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009097994200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">49,366,000<span></span>
</td>
<td class="nump">48,802,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">49,366,000<span></span>
</td>
<td class="nump">48,802,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009176937512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Grant revenue</a></td>
<td class="nump">$ 748<span></span>
</td>
<td class="nump">$ 578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">3,913<span></span>
</td>
<td class="nump">2,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,794<span></span>
</td>
<td class="nump">2,633<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">6,707<span></span>
</td>
<td class="nump">5,329<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(5,959)<span></span>
</td>
<td class="num">(4,751)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,948)<span></span>
</td>
<td class="num">$ (4,738)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding, basic and diluted</a></td>
<td class="nump">49,094<span></span>
</td>
<td class="nump">15,355<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009097621784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (5,948)<span></span>
</td>
<td class="num">$ (4,738)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">838<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_NoncashLeaseExpense', window );">Noncash lease expense</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other</a></td>
<td class="num">(609)<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">749<span></span>
</td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(267)<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_IncreaseDecreaseInOperatingLeaseLiability', window );">Change in lease liability</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred grant revenue</a></td>
<td class="num">(748)<span></span>
</td>
<td class="num">(578)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,985)<span></span>
</td>
<td class="num">(4,036)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">358<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of common stock warrants</a></td>
<td class="nump">101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">459<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(5,526)<span></span>
</td>
<td class="num">(4,032)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">116,737<span></span>
</td>
<td class="nump">20,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">111,211<span></span>
</td>
<td class="nump">16,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="nump">$ 1,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Payment of 2019 bonus awards with stock options in lieu of cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Deferred financing costs included in accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cashless exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009170457576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 14,312<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 79,869<span></span>
</td>
<td class="num">$ (65,572)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,387,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options for cash</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability', window );">Vesting related to unvested share liability</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash', window );">Issuance of 2019 bonus award with stock options in lieu of cash</a></td>
<td class="nump">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(4,738)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,738)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">10,395<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">80,690<span></span>
</td>
<td class="num">(70,310)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,392,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 112,951<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">195,699<span></span>
</td>
<td class="num">(82,797)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">48,802,000<span></span>
</td>
<td class="nump">48,802,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options for cash</a></td>
<td class="nump">$ 358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options for cash (in shares)</a></td>
<td class="nump">88,049<span></span>
</td>
<td class="nump">88,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash', window );">Exercise of warrants for cash</a></td>
<td class="nump">$ 101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares', window );">Exercise of warrants for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ExerciseOfCashlessWarrantShares', window );">Cashless exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">459,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability', window );">Vesting related to unvested share liability</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,948)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,948)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="nump">$ 108,303<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 196,999<span></span>
</td>
<td class="num">$ (88,745)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Mar. 31, 2021</a></td>
<td class="nump">49,366,000<span></span>
</td>
<td class="nump">49,366,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital exercise of warrants to purchase common stock for cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital exercise of warrants to purchase common stock for cash shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital vesting related to unvested share liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ExerciseOfCashlessWarrantShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cashless exercise of warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ExerciseOfCashlessWarrantShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of bonus awards with stock option in lieu of cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009093653912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.17%;white-space:nowrap" valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Description of Business</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Oncternal Therapeutics, Inc. (&#8220;Oncternal&#8221; or the &#8220;Company&#8221;), formerly known as GTx, Inc., was incorporated in Tennessee in September 1997 and reincorporated in Delaware in 2003 and is based in San Diego, California.  Oncternal is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The Company&#8217;s clinical pipeline includes cirmtuzumab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and TK216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Merger</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 7, 2019, the Company, then operating as GTx, Inc. (&#8220;GTx&#8221;), completed the merger contemplated by its Agreement and Plan of Merger and Reorganization, as amended (the &#8220;Merger Agreement&#8221;), with privately-held Oncternal Therapeutics, Inc. (&#8220;Private Oncternal&#8221;) and Grizzly Merger Sub, Inc., a wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;), dated March 6, 2019. Under the Merger Agreement, Merger Sub merged with and into Private Oncternal, with Private Oncternal surviving as a wholly-owned subsidiary of the Company (the &#8220;Merger&#8221;). GTx changed its name to Oncternal Therapeutics, Inc., and Private Oncternal, which remains as a wholly-owned subsidiary of the Company, changed its name to Oncternal Oncology, Inc. On June 10, 2019, the Company&#8217;s common stock began trading on The Nasdaq Capital Market under the ticker symbol &#8220;ONCT.&#8221;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as otherwise indicated, references herein to &#8220;Oncternal,&#8221;and &#8220;the Company,&#8221; refer to Oncternal Therapeutics, Inc. on a post-Merger basis, and the term &#8220;Private Oncternal&#8221; refers to the business of privately-held Oncternal Therapeutics, Inc., prior to completion of the Merger.&#160;&#160;References to GTx refer to GTx, Inc. prior to completion of the Merger.&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oncternal Oncology, Inc. and Oncternal, Inc. All intercompany accounts and transactions have been eliminated in the preparation of the condensed consolidated financial statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Going Concern</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows Accounting Standards Codification (ASC) <span style="font-style:italic;">Topic 205-40, Presentation of Financial Statements&#8212;Going Concern</span>, which requires that management evaluate whether there are relevant conditions and events that in the aggregate raise substantial doubt about the entity&#8217;s ability to continue as a going concern and to meet its obligations as they become due within one year after the date that the financial statements are issued.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.&#160;&#160;As of March 31, 2021, the Company had $111.2 million in cash and cash equivalents. The Company believes it has sufficient cash to fund its projected operating requirements for at least twelve months from the filing date of this Quarterly Report. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.&#160;&#160;The Company has experienced net losses and negative cash flows from operating activities since its inception and has an accumulated deficit of $88.7 million as of March 31, 2021. The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.&#160;</p>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unaudited condensed consolidated financial statements at March&#160;31, 2021, and for the three months ended March&#160;31, 2021 and 2020, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). These unaudited condensed consolidated financial statements have been prepared on the same basis as the audited, consolidated financial statements and include all adjustments, consisting of only normal recurring accruals, which in the opinion of management are necessary to present fairly the Company&#8217;s financial position as of the interim date and results of operations for the interim periods presented. Interim results are not necessarily indicative of results for a full year or future periods. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements for the year ended December 31, 2020, filed with the SEC on its Annual Report on Form 10-K/A for the year ended December 31, 2020, filed with the SEC on March 12, 2021. The results presented in these unaudited condensed consolidated financial statements are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company&#8217;s condensed consolidated financial statements and accompanying notes requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities. Significant estimates consist of those used to determine the fair value of the Company&#8217;s stock-based awards and those used to determine grant revenue and accruals for research and development costs. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market accounts.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent Costs</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses and Accruals</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of costs incurred for the Company&#8217;s own and for sponsored and collaborative research and development activities. Research and development costs are expensed as incurred and include manufacturing process development costs, manufacturing costs, costs associated with preclinical studies and clinical trials, regulatory and medical affairs activities, quality assurance activities, salaries and benefits, including stock-based compensation, fees paid to third-party consultants, license fees and overhead.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:4.17%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying consolidated balance sheets as prepaid expenses and other assets or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities and all clinical trial expenses are included in research and development expenses. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. As of March 31, 2021, the Company&#8217;s clinical trial accrual balance of $1.1&#160;million is included in accrued liabilities and other liabilities.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1: Observable inputs such as quoted prices in active markets.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company&#8217;s current financial assets and liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company has no current financial assets or liabilities measured at fair value on a recurring basis and no transfers between levels have occurred during the periods presented.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently generates revenue from the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) pursuant to a research subaward agreement (see Note 4), which provides the Company with payments in return for certain research and development activities over a contractually defined period. Revenue from such subaward is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the subaward agreement have been met.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The subaward agreement is on a best-effort basis and does not require scientific achievement as a performance obligation. All fees received under the agreement are non-refundable. The costs associated with the agreement are expensed as incurred and reflected as a component of research and development expense in the accompanying condensed consolidated statements of operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Funds received from the subaward agreement are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the subaward are part of the Company&#8217;s development programs. In those instances where the Company first receives consideration in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company records a grant receivable. At March 31, 2021, and December 31, 2020, the Company had deferred grant revenue of $0.9 million and $1.6 million, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense represents the fair value of equity awards, on the grant date, recognized in the period using the Black-Scholes option pricing model. The Company recognizes expense for awards with graded vesting schedules over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is deemed probable. The Company recognizes forfeitures for all awards as such forfeitures occur.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</p>

<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment in the United States.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities and adjusted for the weighted-average number of common shares outstanding that are subject to repurchase. The Company has excluded weighted-average shares subject to repurchase of 13,000 shares and 32,000 shares from the weighted-average number of common shares outstanding for the three months ended March 31, 2021 and 2020, respectively. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares; in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,278</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">841</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,069</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,168</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,357</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,039</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the FASB issued ASU 2020-06, <span style="font-style:italic;">Debt&#8212;Debt with Conversion and Other Options</span> (Subtopic 470-20) and <span style="font-style:italic;">Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity</span> (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company adopted this standard effective January 1, 2021, and the adoption had no impact on the consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009194068584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Details</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.17%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Balance Sheet Details</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">605</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,138</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">980</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">308</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">699</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,528</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,773</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,042</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009092115128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingencies and Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments, Contingencies and Related Party Transactions</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.17%;white-space:nowrap" valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">3.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commitments, Contingencies and Related Party Transactions</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Lease</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent expense was $41,000 for <span style="color:#000000;">each of </span>the three months ended March&#160;31, 2021 and 2020. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 22, 2019, the Company entered into a sublease agreement for office space of 4,677 square feet in San Diego, California which expired on March 31, 2021. On March 17, 2021, the Company entered into a lease directly with the landlord for the same facility (the &#8220;San Diego Lease&#8221;) which expires on May 31, 2022. Base rent under the San Diego Lease is approximately $184,000 annually and the monthly rent expense is being recognized on a straight-line basis over the term of the lease. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The San Diego Lease is included in the accompanying condensed consolidated balance sheet at the present value of the lease payments. As the San Diego Lease does not have an implicit interest rate, the present value reflects a 10.0% discount rate which is the estimated rate of interest that the Company would have to pay in order to borrow an amount equal to the lease payments on a collateralized basis over a similar term and in a similar economic environment. The Company recognized a net operating lease right-of-use asset and an aggregate lease liability of $<span style="color:#000000;">204,000</span> as of March&#160;31, 2021, in the accompanying condensed consolidated balance sheets. The weighted average remaining lease term was 1.2 years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of the lease liability due under this lease agreement as of March&#160;31, 2021, are as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity of lease liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less current portion of lease liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(173</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.26%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Related Party Transactions<span style="font-weight:normal;font-style:normal;">&#160;</span></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective in September 2019, the Company and Shanghai Pharmaceutical (USA) Inc. (&#8220;SPH USA&#8221;), the Company&#8217;s largest stockholder and an affiliate of two of the Company&#8217;s directors entered into a Materials and Supply and Services Agreement (&#8220;SPH USA Services Agreement&#8221;). Pursuant to the SPH USA Services Agreement, the Company and SPH USA will execute various statements of work for the transfer to SPH USA of key reagents and other materials, and for the supply of certain services by the Company to SPH USA, as contemplated under and in furtherance of a license and distribution agreement between the parties (see Note 4). The Company recorded amounts receivable from SPH USA related to statements of work totaling $0.3 million as of March 31, 2021 and December 31, 2020. The Company has an agreement with SPH USA for certain rights to the greater China area (see Note 4).</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the securities purchase agreements and underwritten offerings described in Note 5, other investors included individuals or entities affiliated with David F. Hale, SPH USA, Daniel L. Kisner, Hazel M. Aker, and Michael G. Carter.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009179625128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration and Research Subaward Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License, Collaboration and Research Subaward Agreements</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.17%;white-space:nowrap" valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">4.</span></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">License, Collaboration and Research Subaward Agreements</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Georgetown University (&#8220;Georgetown&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2014, the Company entered into an Exclusive License Agreement (the &#8220;Georgetown License Agreement&#8221;) with Georgetown, pursuant to which the Company: (i) licensed the exclusive worldwide right to patents and technologies for the development and commercialization of certain product candidates targeting EWS-FLI1 as an anti-tumor therapy for therapeutic, diagnostics, or research tool purposes, (ii) is solely responsible for all development and commercialization activities and costs, and (iii) is responsible for all costs related to the filing, prosecution and maintenance of the licensed patent rights.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Georgetown License Agreement, commencing in 2015, the Company: (i) shall pay and has paid an annual license maintenance fee of $10,000 until the first commercial sale occurs, (ii) is required to make up to $0.2 million in aggregate milestone payments upon the achievement of certain regulatory milestones, and (iii) will be required to pay low single digit royalties based on annual net product sales. The Company accounted for the licensed technology as an asset acquisition because it did not meet the definition of a business. All milestone payments under the Georgetown License Agreement will be recognized as research and development expense upon completion of the required events, as the triggering events are not considered to be probable until they are achieved. As of March&#160;31, 2021, the Company had <span style="color:#000000;">not</span> triggered or made any milestone payments under the Georgetown License Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Georgetown License Agreement may be terminated by either party upon material breach or may be terminated by the Company as to one or more countries with 90 days written notice of termination. The term of the Georgetown License Agreement will continue until the expiration of the last valid claim within the patent rights covering the product. Georgetown may terminate the agreement in the event: (i) the Company fails to pay any amount and fails to cure such failure within 30 days after receipt of notice, (ii) the Company defaults in its obligation to obtain and maintain insurance and fails to remedy such breach within 60 days after receipt of notice, or (iii) the Company declares insolvency or bankruptcy. The Company may terminate the Georgetown License Agreement at any time upon at least 60 days&#8217; written notice.&#160;&#160;&#160;&#160;&#160;&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The University of Texas MD Anderson Cancer Center (&#8220;MD Anderson&#8221;)</span></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2014, the Company entered into a collaboration agreement (as amended, the &#8220;Collaboration&#8221;) with MD Anderson, which provides for the conduct of preclinical and clinical research for TK216 in exchange for certain program payments. If MD Anderson successfully completes all the requirements of the Collaboration in full and the program is successfully commercialized, the Company will be required to pay aggregate milestone payments of $1.0 million based on net product sales. In July 2020, the Company entered into a research agreement with MD Anderson for certain services up to an aggregate cost of $293,000. The <span style="color:#000000;">Company</span> recorded research and development expense <span style="color:#000000;">of $0.1 million and a nominal amount </span>for each of the three months ended March&#160;31, 2021 and 2020, respectively.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Agreements with the Regents of the University of California (the &#8220;Regents&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016, and as amended and restated in August 2018, and as amended in March and May 2019, the Company entered into a license agreement (as amended, the &#8220;Regents License Agreement&#8221;) for the development, manufacturing and distribution rights related to the development and commercialization of ROR1 related naked antibodies, antibody fragments or synthetic antibodies, and genetically engineered cellular therapy. The Regents License Agreement provides for the following: (i) in May 2016, an upfront license fee of $0.5 million was paid and 107,108 shares of common stock were issued, (ii) $25,000 in annual license maintenance fees commencing in 2017, (iii) reimbursement of certain annual patent costs, (iv) certain development and regulatory milestones aggregating from $10.0 million to $12.5 million, on a per product basis, (v) certain worldwide sales milestones based on achievement of tiered revenue levels aggregating $75.0 million, (vi) low single-digit royalties, including potential future minimum annual royalties, on net sales of each target, and (vii) minimum diligence to advance licensed assets consisting of at least $1.0 million in development spend annually through 2021. Under the Regents License Agreement, the Company recorded:&#160;<span style="color:#000000;">(i) $25,000 and none in license maintenance fees as research and development expense for each of the three months ended March 31, 2021 and 2020, (ii) $0.2 million and $25,000 in patent costs as general and administrative expense for the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021, the Company believes it has met its obligations under the Regents License Agreement.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2016, and as modified by the amended and restated Regents License Agreement in August 2018, the Company entered into a Research Agreement (the &#8220;Research Agreement&#8221;) with the Regents for further research on a ROR1 therapeutic development program. Under this <span style="-sec-ix-hidden:F_000276">five-year</span> agreement, the Regents will have an aggregate budget of $3.6 million, with $125,000 payable quarterly. The Company recorded $0.1 million in research and development expense under this agreement&#160;for each of the three months ended March 2021 and 2020, respectively. Such costs are includable as part of the Company&#8217;s annual diligence obligations under the Regents License Agreement. The Regents License Agreement will expire upon the later of the expiration date of the longest-lived patent rights or the fifteenth anniversary of the first commercial sale of a licensed product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Regents may terminate the Regents License Agreement if: (i) a material breach by the Company is not cured within a reasonable time, (ii) the Company files a claim asserting the Regents licensed patent rights are invalid or unenforceable and (iii) the Company files for bankruptcy. The Company may terminate the agreement at any time upon at least 60 days&#8217; written notice.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The University of Tennessee Research Foundation (&#8220;UTRF&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2015, the Company and UTRF entered into a license agreement (the &#8220;SARD License Agreement&#8221;) pursuant to which the Company was granted exclusive worldwide rights in all existing selective androgen receptor degrader (&#8220;SARD&#8221;) technologies owned or controlled by UTRF, including all improvements thereto.&#160; Under the SARD License Agreement, the Company is obligated to employ active, diligent efforts to conduct preclinical research and development activities for the SARD program to advance one or more lead compounds into clinical development.&#160; The Company is also obligated to pay UTRF annual license maintenance fees, low single-digit royalties on net sales of products and additional royalties on sublicense revenues, depending on the state of development of a clinical product candidate at the time it is sublicensed. The Company recorded research and development expense under this agreement of $35,000 and <span style="color:#000000;">$0.1 million</span> for each of the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021, the Company believes it has met its obligations under the SARD License Agreement.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) Awards</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2017, <span style="color:#000000;">and as amended and restated in December 2020,</span> CIRM awarded an $18.3 million grant to<span style="color:#000000;"> researchers at UC San Diego</span> to advance the Company&#8217;s Phase 1/2 clinical trial evaluating cirmtuzumab in combination with ibrutinib for the treatment of patients with B-cell lymphoid malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma. The Company: (i) is conducting this study in collaboration with UC San Diego, (ii) estimates it will receive approximately $14.0 million in development milestones under research subaward agreements during the award project period, estimated to be from October 1, 2017 to March 31, 2022, (iii) is committed to certain co-funding requirements, (iv) received <span style="color:#000000;">no</span> subaward payments in the three months ended March 31, 2021 and 2020, and (v) is required to provide UC San Diego progress and financial update reports throughout the award period. The subaward does not bear a royalty payment commitment, nor is the subaward otherwise refundable. For the three months ended March 31, 2021 and 2020, the Company recorded revenue of $0.7 million and $0.6 million, respectively. Related qualifying subaward costs for the three months ended March 31, 2021 and 2020 were $1.5 million and $1.3 million, respectively. As of March 31,2021, the Company believes it has met its obligations under the CIRM award and UC San Diego subawards.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2017, CIRM awarded a $5.8 million grant to the researchers at UC San Diego to develop a novel anti-cancer stem cell targeted therapy for patients with advanced solid and hematological malignancies. In connection with such CIRM award, the Company agreed to provide up to $1.0 million in contingency funds if required during the grant period, which expired in April 2020. The Company recorded no research and development expense, and no contingency funds have been provided under such CIRM award for each of the three months ended March 31, 2021 and 2020.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical Trial and Supply Agreement</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April 2018, the Company entered into a Clinical Trial and Supply Agreement with Pharmacyclics, LLC, an AbbVie Company (&#8220;Pharmacyclics&#8221;) to supply ibrutinib for the Company&#8217;s Phase 1/2 clinical trial evaluating cirmtuzumab in combination with ibrutinib, which agreement was amended in August 2019. Such agreement does not bear any upfront costs, inventory purchase costs, milestone or royalty payment commitments or other financial obligations.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">SPH USA, a Related Party</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">License and Development Agreement (&#8220;LDA&#8221;)</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018<span style="color:#000000;">, and as amended in August 2020</span>, the Company entered into the LDA with SPH USA for: (i) the territory of the People&#8217;s Republic of China, Hong Kong, Macau, and Taiwan (&#8220;Greater China&#8221;), and (ii) rights to manufacture, develop, market, distribute and sell all of the Company&#8217;s product candidates under the Georgetown License Agreement and the Regents License Agreement (exclusive to Greater China only). Under the LDA, SPH USA is solely responsible for: (a) all preclinical and clinical development activities required in order to obtain regulatory approval in Greater China for such product candidates, (b) any third-party license milestone or royalty payments owed under the Georgetown License Agreement and the Regents License Agreement, and (c) paying the Company a low single digit royalty on net sales in the territory.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The LDA will expire upon the expiration of the last royalty term for the last licensed product. The LDA may be terminated by: (i) SPH USA on a country by country or product by product basis with 180 days written notice, (ii) either party upon material breach that is not cured within 90 days, and (iii) either party in the event the other party declares insolvency or bankruptcy.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009091952072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.17%;text-indent:-4.17%;font-size:9pt;">&#160;</p>
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.17%;white-space:nowrap" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">5</span><span style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stockholders&#8217; Equity</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Securities Purchase <span style="color:#000000;">Agreements and Underwritten Offering</span></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2020, the Company entered into a Securities Purchase Agreement (the &#8220;May Purchase Agreement&#8221;) with several institutional and individual investors (including an entity affiliated with David F. Hale, the chairman of the Company&#8217;s board of directors) for the concurrent sale of: (i) 1,943,636 shares of the Company&#8217;s common stock in a registered direct offering, resulting in net proceeds of $4.4 million, after deducting the placement agent&#8217;s cash commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the warrants, and (ii) unregistered warrants to purchase up to an aggregate of 971,818 shares of common stock. The combined purchase price for one share and one warrant to purchase half of a share of common stock was $2.5725. <span style="color:#000000;">In addition, the Company issued warrants to purchase 116,618 shares of common stock at an exercise price of $3.2156 per share to the placement agent, H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221; or the &#8220;placement agent&#8221;) as part of its compensation, which warrants were immediately exercisable and expire on May 21, 2025.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company entered into a Securities Purchase Agreement (the &#8220;July Purchase Agreement&#8221;) with several institutional and individual investors for the concurrent sale of: (i) 2,581,867 shares of the Company&#8217;s common stock in a registered direct offering, resulting in net proceeds of $5.7 million, after deducting the placement agent&#8217;s cash commissions and other offering expenses, and excluding the proceeds, if any, from the exercise of the warrants, and (ii) unregistered warrants to purchase up to an aggregate of 1,290,933 shares of common stock.&#160;The combined purchase price for one share and one warrant to purchase half of a share of common stock was $2.3825. The warrants issued to investors were, subject to certain ownership limitations, immediately exercisable at an exercise price equal to $2.32 per share and expire on January 21, 2026. In addition, the Company issued warrants to purchase 154,912 shares of common stock at an exercise price of $2.9781 per share to the placement agent as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on July 21, 2025. Other investors participating in the July Purchase Agreement included an entity affiliated with SPH USA, the Company&#8217;s largest stockholder, Daniel L. Kisner, a member of the Company&#8217;s board of directors, and Hazel M. Aker, the Company&#8217;s then General Counsel.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020, the Company </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">entered into</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> an underwriting agreement</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (as amended and restated, the &#8220;</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">w</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">riting Agreement&#8221;) with Wainwright</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the sale of </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,428,886</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of the Company&#8217;s common stock at a price </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to the public </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.10</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per share, resulting in net proceeds of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million, after deducting the </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">underwriter&#8217;s discounts,</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commissions</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and other offering expenses.&#160; In addition, the Company issued warrants to purchase </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145,733</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of common stock at an exercise price of $</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.625</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per share to </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wainwright</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as part of its compensation</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">warrants were immediately exercisable upon issuance and terminate on </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 27, 2025</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> i</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nvestor</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> participating</span><span style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in the transaction included Michael G. Carter, a member of the Company&#8217;s board of directors.</span></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2020, the Company entered into an underwriting agreement (as amended and restated, the &#8220;November Underwriting Agreement&#8221;) with Wainwright for the sale of 7,258,065 shares of the Company&#8217;s common stock at a price to the public of $3.10 per share, resulting in net proceeds of $20.4 million, after deducting the underwriter&#8217;s discounts, commissions and other offering expenses. In addition, the Company issued warrants to purchase 435,484 shares of common stock at an exercise price of $3.875 per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on November 17, 2025. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the Company entered into an underwriting agreement (as amended and restated, the &#8220;December Underwriting Agreement&#8221;) with Wainwright for the sale of 19,161,667 shares of the Company&#8217;s common stock at a price to the public of $4.50 per share, resulting in net proceeds of $79.0 million, after deducting the underwriter&#8217;s discounts, commissions and other offering expenses In addition, the Company issued warrants to purchase 1,149,700 shares of common stock at an exercise price of $5.625 per share to Wainwright as part of its compensation, which warrants were immediately exercisable upon issuance and terminate on December 9, 2025. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the May Purchase Agreement and July Purchase Agreement, the Company also agreed, on a best-efforts basis, to: (i) maintain its listing on The Nasdaq Capital Market to provide for the resale of the shares of common stock issuable upon the exercise of the warrants, and (ii) not enter into any agreement for the issuance of any shares of common stock involving a variable rate transaction before July 21, 2021, <span style="color:#000000;">other than pursuant to a new at-the-market offering facility with the placement </span>agent. Variable rate&#160;transaction means a transaction in which the Company issues or sells, or agrees to issue or sell, common stock or convertible securities in which the applicable sale, conversion, exercise or exchange price or&#160;rate&#160;may directly or indirectly effectively be reduced. The<span style="color:#000000;"> Company does not currently have an active at-the-market offering facility. </span></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock Warrants</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-size:6pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of warrant activity and changes in warrants outstanding is presented below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares Underlying Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Exercise Price Per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Remaining Contractual Term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,031,841</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.25</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000337">4.40</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.56%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(754,255</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.57</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000338">4.59</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.56%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,277,586</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.42</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000339">4.07</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, all warrants met the criteria for classification in stockholders&#8217; equity.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:1.67%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Equity Incentive Plans</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contemporaneous with the Merger closing: (i) Private Oncternal&#8217;s 2015 Equity Incentive Plan, as amended (the &#8220;2015 Plan&#8221;) was assumed by the Company, and (ii) the Company adopted the 2019 Incentive Award Plan (&#8220;2019 Plan&#8221;) under which the sum of: (a) 1,678,571&#160;shares of common stock, (b)&#160; up to 275,579 shares of common stock which were subject to outstanding awards under the GTx 2013 Equity Incentive Plan (the &#8220;2013 Plan&#8221;) as of June 7, 2019, that upon cancellation will become available for issuance under the 2019 Plan, and (c)&#160;an annual increase on the first day of each calendar year beginning January&#160;1, 2020, and ending on and including January&#160;1, 2029, equal to the lesser of (A) 5% of the aggregate number of shares of common stock outstanding on the final day of the immediately preceding calendar year and (B)&#160;such smaller number of shares of common stock as is determined by the Board, are reserved for issuance. At March 31, 2021, 2,143,999 shares remain available for future issuance under the 2019 Plan and Inducement Plan.</p>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,977,826</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.46</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000350">8.90</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,378,589</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,977,826</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.46</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000351">8.90</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,378,589</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,075,315</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.51</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000352">7.30</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,170,595</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, under the 2013 Plan, there were: (i) <span style="color:#000000;">87,133</span> outstanding and fully vested and exercisable options with a weighted average exercise price of $<span style="color:#000000;">62.48</span> per share that expire in the second quarter of 2021, and (ii) <span style="color:#000000;">24,282</span> options cancelled during the three months ended March 31, 2021 were added to the 2019 Plan. As of March 31, 2021, the remaining former GTx stock option plans had an aggregate of <span style="color:#000000;">4,582</span> outstanding and fully vested and exercisable options with a weighted average exercise price of $<span style="color:#000000;">270.00</span> per share that expire in the second quarter of 2021.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2015, Private Oncternal adopted the 2015 Plan which provided for the issuance of up to 631,120 shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants.&#160;&#160;In general, the options issued under the 2015 Plan expire ten years from the date of grant and vest over a <span style="-sec-ix-hidden:F_000363">four-year</span> period. Certain grants vest based on the achievement of development or regulatory milestones. No further awards will be made under the 2015 Plan, which was terminated as to new grants in June 2019. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2019 Plan provides for the issuance of shares of common stock for incentive stock options, non-statutory stock options, restricted stock awards, restricted stock unit awards and other stock awards to its employees, members of its board of directors and consultants.&#160;&#160;In general, the options issued under the 2019 Plan expire ten years from the date of grant and vest over a <span style="-sec-ix-hidden:F_000365">four-year</span> period. Certain grants vest based on the achievement of development or regulatory milestones. The 2019 Plan allows for the early exercise of all stock option grants if authorized by the board of directors at the time of grant. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 11, 2021, the Company&#8217;s board of directors adopted the 2021 Employment Inducement Incentive Award Plan (the &#8220;Inducement Plan&#8221;) and initially reserved 700,000 shares of common stock for issuance. The Inducement Plan is a non-shareholder approved stock plan adopted pursuant to the &#8220;inducement exception&#8221; provided under Nasdaq listing rules. The Inducement Plan will be used exclusively for the issuance of non-statutory stock options to certain new hires who satisfied the requirements to be granted inducement grants under Nasdaq rules as an inducement material to the individual&#8217;s entry into employment with the Company. The terms of the Inducement Plan are substantially similar to the terms of our 2019 Plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the Company&#8217;s stock option activity under the 2019 Plan, Inducement Plan and 2015 Plan is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,107,625</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.08</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,127,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.78</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(168,750</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.47</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(88,049</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.06</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,977,826</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.46</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Information about the Company&#8217;s outstanding stock options under the 2019 Plan and 2015 Plan is as follows (in thousands, except share and per share data and expected term):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average grant date fair value per share of option grants for the three months ended March 31, 2021 was $<span style="color:#000000;">5.06</span> per share.&#160;&#160;The aggregate intrinsic value of stock options exercised during the three months ended March 31, 2021 was $365,000. The intrinsic value is calculated as the difference between the fair value of the Company&#8217;s common stock at the time of the option exercise and the exercise price of that stock option.</p>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation Expense</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants, were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89.4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000383">6.4</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000384">5.4</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.17%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected volatility. <span style="font-style:normal;">Prior to the Merger, Private Oncternal did not have a trading history for its common stock.&#160;&#160;Accordingly, the expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the life sciences industry. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected term. <span style="font-style:normal;">The expected term represents the period of time that options are expected to be outstanding. Because Private Oncternal did not have historical exercise behavior, it determined the expected life assumption using the simplified method for employees, which is an average of the contractual term of the option and its vesting period. The expected term for nonemployee options is generally the remaining contractual term.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-free interest rate. <span style="font-style:normal;">The risk-free interest rate is based on the implied yield on the U.S. Treasury securities with a maturity date similar to the expected term of the associated stock option award.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected dividend yield. <span style="font-style:normal;">The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends and, therefore, used an expected dividend yield of zero.</span></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense recognized for all equity awards has been reported in the condensed consolidated statements of operations as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">473</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">365</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">260</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">838</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2021, the total compensation cost related to non-vested awards not yet recognized was $12.4 million and the weighted-average period over which it is expected to be recognized was 3.6 years. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock Reserved for Future Issuance</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for future issuance is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,278</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options issued and outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,069</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock available for issuance under the Inducement Plan and 2019 Plan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,144</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,491</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009092180296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COVID-19 Pandemic and CARES Act<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_COVID19PandemicAndCARESActAbstract', window );"><strong>C O V I D19 Pandemic And C A R E S Act [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_COVID19PandemicAndCARESActDisclosureTextBlock', window );">COVID-19 Pandemic and CARES Act</a></td>
<td class="text">
<div style="align:left;">
<table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;">
<tr>
<td style="width:4.17%;white-space:nowrap" valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">6</span><span style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">.</span></p></td>
<td valign="top">
<p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;color:#000000;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">COVID-19 Pandemic and CARES Act</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A novel strain of coronavirus (SAR-CoV-2) causing a severe respiratory disease (&#8220;COVID-19&#8221;), was declared a global pandemic by the World Health Organization in March 2020. COVID-19 has presented substantial public health and economic challenges and is affecting economies, financial markets and business operations around the world. International and U.S. governmental authorities in impacted regions have taken actions in an effort to slow the spread of COVID-19, including issuing varying forms of &#8220;stay-at-home&#8221; orders, and restricting business functions outside of one&#8217;s home. In response, the Company has put restrictions on employee travel and working from its executive offices with many employees continuing their work remotely. While the Company is currently continuing the clinical trials it has underway in sites across the U.S., COVID-19 precautions have directly or indirectly impacted the timeline for some of its clinical trials. Additionally, the Company&#8217;s expectations for the timing of first-in-human dosing of its ROR1 CAR-T therapy has been delayed to the first half of 2022. The Company considered the impacts of COVID-19 on the assumptions and estimates used to prepare its condensed consolidated financial statements and determined that there were no material adverse impacts on the Company&#8217;s results of operations and financial position at March 31, 2021. The full extent to which the COVID-19 pandemic will continue to directly or indirectly impact the Company&#8217;s business results of operations and financial condition, will depend on future development that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, the success or failure of vaccination programs, the emergence of new variants of COVID-19, as well as the economic impact on local, regional, national and international markets.&#160; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the COVID-19 pandemic, the CARES Act was signed into law on March 27, 2020.&#160; The CARES Act, among other things, includes tax provisions relating to refundable payroll tax credits, deferment of employer&#8217;s social security payments, net operating loss utilization and carryback periods, modifications to the net interest deduction limitations and technical corrections to tax depreciation methods for qualified improvement property, and authorized the Paycheck Protection Program. The CARES Act had no material impact on the Company&#8217;s income tax provision for the three months ended March&#160;31, 2021.&#160;&#160;<span style="color:#000000;">The Company continues to monitor changes and revisions to the CARES Act and its impact on the Company&#8217;s condensed consolidated financial position, results of operations and cash flows.</span></p>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_COVID19PandemicAndCARESActAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>COVID-19 Pandemic and CARES Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_COVID19PandemicAndCARESActAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_COVID19PandemicAndCARESActDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>COVID-19 Pandemic and CARES Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_COVID19PandemicAndCARESActDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009180509288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Merger</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Merger</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 7, 2019, the Company, then operating as GTx, Inc. (&#8220;GTx&#8221;), completed the merger contemplated by its Agreement and Plan of Merger and Reorganization, as amended (the &#8220;Merger Agreement&#8221;), with privately-held Oncternal Therapeutics, Inc. (&#8220;Private Oncternal&#8221;) and Grizzly Merger Sub, Inc., a wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;), dated March 6, 2019. Under the Merger Agreement, Merger Sub merged with and into Private Oncternal, with Private Oncternal surviving as a wholly-owned subsidiary of the Company (the &#8220;Merger&#8221;). GTx changed its name to Oncternal Therapeutics, Inc., and Private Oncternal, which remains as a wholly-owned subsidiary of the Company, changed its name to Oncternal Oncology, Inc. On June 10, 2019, the Company&#8217;s common stock began trading on The Nasdaq Capital Market under the ticker symbol &#8220;ONCT.&#8221;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Except as otherwise indicated, references herein to &#8220;Oncternal,&#8221;and &#8220;the Company,&#8221; refer to Oncternal Therapeutics, Inc. on a post-Merger basis, and the term &#8220;Private Oncternal&#8221; refers to the business of privately-held Oncternal Therapeutics, Inc., prior to completion of the Merger.&#160;&#160;References to GTx refer to GTx, Inc. prior to completion of the Merger.&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Oncternal Oncology, Inc. and Oncternal, Inc. All intercompany accounts and transactions have been eliminated in the preparation of the condensed consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_LiquidityAndGoingConcernPolicyTextBlock', window );">Liquidity and Going Concern</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Liquidity and Going Concern</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company follows Accounting Standards Codification (ASC) <span style="font-style:italic;">Topic 205-40, Presentation of Financial Statements&#8212;Going Concern</span>, which requires that management evaluate whether there are relevant conditions and events that in the aggregate raise substantial doubt about the entity&#8217;s ability to continue as a going concern and to meet its obligations as they become due within one year after the date that the financial statements are issued.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.13%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.&#160;&#160;As of March 31, 2021, the Company had $111.2 million in cash and cash equivalents. The Company believes it has sufficient cash to fund its projected operating requirements for at least twelve months from the filing date of this Quarterly Report. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From inception, the Company has devoted substantially all of its efforts to drug discovery and development and conducting preclinical studies and clinical trials. The Company has a limited operating history and the sales and income potential of the Company&#8217;s business and market are unproven. Successful transition to attaining profitable operations is dependent upon achieving a level of revenues adequate to support the Company&#8217;s cost structure.&#160;&#160;The Company has experienced net losses and negative cash flows from operating activities since its inception and has an accumulated deficit of $88.7 million as of March 31, 2021. The Company expects to continue to incur net losses for the foreseeable future and believes it will need to raise substantial additional capital to accomplish its business plan over the next several years. The Company plans to continue to fund its losses from operations and capital funding needs through a combination of equity offerings, debt financings or other sources, including potential collaborations, licenses and other similar arrangements. If the Company is unable to secure adequate additional funding, the Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, or suspend or curtail planned programs. Any of these actions could materially harm the Company&#8217;s business, results of operations and future prospects. There can be no assurance as to the availability or terms upon which such financing and capital might be available in the future.&#160;</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_UnauditedInterimFinancialInformationPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Presentation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unaudited condensed consolidated financial statements at March&#160;31, 2021, and for the three months ended March&#160;31, 2021 and 2020, have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and with generally accepted accounting principles in the United States of America (&#8220;GAAP&#8221;). These unaudited condensed consolidated financial statements have been prepared on the same basis as the audited, consolidated financial statements and include all adjustments, consisting of only normal recurring accruals, which in the opinion of management are necessary to present fairly the Company&#8217;s financial position as of the interim date and results of operations for the interim periods presented. Interim results are not necessarily indicative of results for a full year or future periods. The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. These unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements for the year ended December 31, 2020, filed with the SEC on its Annual Report on Form 10-K/A for the year ended December 31, 2020, filed with the SEC on March 12, 2021. The results presented in these unaudited condensed consolidated financial statements are not necessarily indicative of the results expected for the full fiscal year or any other interim period or any future year or period.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s condensed consolidated financial statements are prepared in accordance with GAAP. The preparation of the Company&#8217;s condensed consolidated financial statements and accompanying notes requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities. Significant estimates consist of those used to determine the fair value of the Company&#8217;s stock-based awards and those used to determine grant revenue and accruals for research and development costs. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking accounts and money market accounts.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ConcentrationRiskCreditRiskPolicyTextBlock', window );">Concentration of Credit Risk</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments, which are designed to maintain safety and liquidity.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Patent Costs</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses and Accruals</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses and Accruals</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist of costs incurred for the Company&#8217;s own and for sponsored and collaborative research and development activities. Research and development costs are expensed as incurred and include manufacturing process development costs, manufacturing costs, costs associated with preclinical studies and clinical trials, regulatory and medical affairs activities, quality assurance activities, salaries and benefits, including stock-based compensation, fees paid to third-party consultants, license fees and overhead.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:10pt;text-indent:4.17%;color:#212529;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has entered into various research and development contracts with research institutions, clinical research organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of performance are reflected in the accompanying consolidated balance sheets as prepaid expenses and other assets or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities and all clinical trial expenses are included in research and development expenses. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances at the end of any reporting period. Actual results could differ from the Company&#8217;s estimates. As of March 31, 2021, the Company&#8217;s clinical trial accrual balance of $1.1&#160;million is included in accrued liabilities and other liabilities.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value Measurements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or non-recurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1: Observable inputs such as quoted prices in active markets.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2: Inputs, other than the quoted prices in active markets that are observable either directly or indirectly.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts of the Company&#8217;s current financial assets and liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. The Company has no current financial assets or liabilities measured at fair value on a recurring basis and no transfers between levels have occurred during the periods presented.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently generates revenue from the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) pursuant to a research subaward agreement (see Note 4), which provides the Company with payments in return for certain research and development activities over a contractually defined period. Revenue from such subaward is recognized in the period during which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the subaward agreement have been met.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The subaward agreement is on a best-effort basis and does not require scientific achievement as a performance obligation. All fees received under the agreement are non-refundable. The costs associated with the agreement are expensed as incurred and reflected as a component of research and development expense in the accompanying condensed consolidated statements of operations.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Funds received from the subaward agreement are recorded as revenue as the Company is the principal participant in the arrangement because the activities under the subaward are part of the Company&#8217;s development programs. In those instances where the Company first receives consideration in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt of consideration, the Company records a grant receivable. At March 31, 2021, and December 31, 2020, the Company had deferred grant revenue of $0.9 million and $1.6 million, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense represents the fair value of equity awards, on the grant date, recognized in the period using the Black-Scholes option pricing model. The Company recognizes expense for awards with graded vesting schedules over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For equity awards for which vesting is subject to performance-based milestones, the expense is recorded over the remaining service period after the point when the achievement of the milestone is deemed probable. The Company recognizes forfeitures for all awards as such forfeitures occur.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes net deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes.</p>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business in one operating segment in the United States.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for potentially dilutive securities and adjusted for the weighted-average number of common shares outstanding that are subject to repurchase. The Company has excluded weighted-average shares subject to repurchase of 13,000 shares and 32,000 shares from the weighted-average number of common shares outstanding for the three months ended March 31, 2021 and 2020, respectively. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and dilutive common stock equivalents outstanding for the period determined using the treasury-stock and if-converted methods. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares; in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,278</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">841</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,069</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,168</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,357</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,039</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recently Adopted Accounting Pronouncements</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2020, the FASB issued ASU 2020-06, <span style="font-style:italic;">Debt&#8212;Debt with Conversion and Other Options</span> (Subtopic 470-20) and <span style="font-style:italic;">Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity</span> (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity&#8217;s own equity. Specifically, ASU 2020-06 simplifies accounting for the issuance of convertible instruments by removing major separation models required under current GAAP. In addition, the ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and simplifies the diluted earnings per share (EPS) calculation in certain areas. ASU 2020-06 will be effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, beginning in fiscal years which begin after December 15, 2020. The FASB has specified that an entity should adopt the guidance as of the beginning of its annual fiscal year. The Company adopted this standard effective January 1, 2021, and the adoption had no impact on the consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ConcentrationRiskCreditRiskPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration risk credit risk policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ConcentrationRiskCreditRiskPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liquidity and going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patent costs policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_UnauditedInterimFinancialInformationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unaudited interim financial information policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_UnauditedInterimFinancialInformationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009171039560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Potentially dilutive securities not included in the calculation of diluted net loss per share, because to do so would be anti-dilutive, are as follows (in common stock equivalent shares; in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase common stock</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,278</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">841</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,069</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,168</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,357</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,039</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009179625128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued Liabilities</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued liabilities consist of the following (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">605</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">412</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,138</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">980</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legal fees</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">308</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">699</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,528</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,773</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,042</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009093804168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingencies and Related Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities of Lease Liabilities</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of the lease liability due under this lease agreement as of March&#160;31, 2021, are as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity of lease liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.8%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total lease payments</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">215</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less imputed interest</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.26%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating lease liabilities</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.92%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.26%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less current portion of lease liability</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(173</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.26%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liability</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.92%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009090441432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ScheduleOfWarrantActivityTableTextBlock', window );">Summary Of Warrant Activity And Changes In Warrants Outstanding</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of warrant activity and changes in warrants outstanding is presented below:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:80%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.56%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.42%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of Shares Underlying Warrants</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.72%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Exercise Price Per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.76%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-Average Remaining Contractual Term (in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,031,841</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.25</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000337">4.40</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.56%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.78%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.56%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(754,255</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.38%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.57</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000338">4.59</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:39.56%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,277,586</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.38%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.42</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000339">4.07</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Summary of Stock Option Outstanding, Vested and Expected to Vest and Exercisable</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.66%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Per Share</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in years)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.24%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,977,826</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.46</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000350">8.90</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,378,589</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,977,826</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.46</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000351">8.90</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,378,589</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.66%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,075,315</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.51</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000352">7.30</span></p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.24%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,170,595</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of the Company&#8217;s stock option activity under the 2019 Plan, Inducement Plan and 2015 Plan is as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:70%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at December 31, 2020</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,107,625</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.08</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,127,000</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.78</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(168,750</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.47</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(88,049</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.06</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance at March 31, 2021</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,977,826</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.88%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.46</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Share-Based Compensation Expense</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense recognized for all equity awards has been reported in the condensed consolidated statements of operations as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">473</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">365</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">260</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">838</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">399</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Common Stock Reserved for Future Issuance</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for future issuance is as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:60%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.82%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,278</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options issued and outstanding</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,069</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock available for issuance under the Inducement Plan and 2019 Plan</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,144</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,491</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option Grants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Determine Fair Value</a></td>
<td class="text">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of stock option grants, were as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&#160;</p>
<div>
<table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:90%;">
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.0</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89.9</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89.4</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000383">6.4</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000384">5.4</span></p></td>
<td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
</tr>
<tr>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;" valign="bottom">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ScheduleOfWarrantActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of warrant activity table text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ScheduleOfWarrantActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009170445496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>segment </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (88,745)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (82,797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">111,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AccruedClinicalTrials', window );">Accrued Clinical Trials</a></td>
<td class="nump">1,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred grant revenue</a></td>
<td class="nump">$ 885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Weighted-average shares subject to repurchase | shares</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AccruedClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AccruedClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009097255320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">8,357<span></span>
</td>
<td class="nump">3,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onct_CommonStockWarrantsMember', window );">Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">4,278<span></span>
</td>
<td class="nump">841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">4,069<span></span>
</td>
<td class="nump">2,168<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onct_CommonStockSubjectToRepurchaseMember', window );">Common Stock Subject to Repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onct_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onct_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onct_CommonStockSubjectToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=onct_CommonStockSubjectToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009170745736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AccruedResearchAndDevelopmentExpenses', window );">Research and development</a></td>
<td class="nump">$ 605<span></span>
</td>
<td class="nump">$ 412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AccruedClinicalTrials', window );">Accrued Clinical Trials</a></td>
<td class="nump">1,138<span></span>
</td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Legal fees</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation</a></td>
<td class="nump">699<span></span>
</td>
<td class="nump">1,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 2,773<span></span>
</td>
<td class="nump">$ 3,042<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AccruedClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AccruedClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009170676392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments, Contingencies and Related Party Transactions - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 17, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 22, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember', window );">Shanghai Pharmaceutical (USA) Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedParties', window );">Amounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">San Diego, California | Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetRentableArea', window );">Rentable area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">May 31,  2022<span></span>
</td>
<td class="text">Mar. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AnnualBaseRent', window );">Annual base rent</a></td>
<td class="nump">$ 184,000<span></span>
</td>
<td class="nump">$ 184,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Lease discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AnnualBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual base rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AnnualBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amount of receivables arising from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetRentableArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area for properties owned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetRentableArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=onct_OfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=onct_OfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009179322040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments, Contingencies and Related Party Transactions - Summary of Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Liabilities Payments Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021</a></td>
<td class="nump">$ 138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less current portion of lease liability</a></td>
<td class="num">(173)<span></span>
</td>
<td class="num">$ (40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liability</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009085836808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License, Collaboration and Research Subaward Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Patent costs as general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,794,000<span></span>
</td>
<td class="nump">2,633,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">748,000<span></span>
</td>
<td class="nump">578,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=onct_MDAndersonCancerCenterMember', window );">MD Anderson Cancer Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Aggregate cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 293,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=onct_ReagentsMember', window );">Regents of the University of California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_UpfrontLicenseFeesPaid', window );">Upfront license fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AnnualLicenseMaintenanceFees', window );">Annual license maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels', window );">Worldwide sales milestones based on achievement of tiered revenue levels</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Patent costs as general and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=onct_UniversityOfCaliforniaSanDiegoMember', window );">University of California San Diego School of Medicine | The California Institute for Regenerative Medicine ("CIRM") Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ResearchAndDevelopmentGrants', window );">Grants awarded to researchers</a></td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="nump">$ 18,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod', window );">Development milestones to be received under research subaward agreements throughout award project period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_SubawardPaymentsReceived', window );">Subaward payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_RelatedQualifyingSubawardCosts', window );">Related qualifying subaward costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | The California Institute for Regenerative Medicine ("CIRM") Award</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AmountAgreedToBeProvidedInContingencyFunds', window );">Amount agreed to be provided in contingency funds</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Regents of the University of California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments', window );">Potential regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Regents of the University of California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments', window );">Potential regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_AdvanceLicensedAssets', window );">Advance licensed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=onct_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement | Georgetown University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_LicenseMaintenanceFeeToBePaidAndPaymentMade', window );">Annual license maintenance fee to be paid and payment made</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CollaborativeArrangementPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_NumberOfDaysInWrittenNoticeOfTermination', window );">Written notice of termination, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount', window );">Days after receipt of notice, to pay failure amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment', window );">Days after receipt of notice for default in payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement', window );">Minimum period in days of written notice to terminate license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=onct_ExclusiveLicenseAgreementMember', window );">Exclusive License Agreement | Maximum | Georgetown University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CollaborativeArrangementPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaboration Agreement | MD Anderson Cancer Center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments', window );">Potential regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=onct_ResearchAgreementMember', window );">Research Agreement | Regents of the University of California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ResearchAgreementTerm', window );">Research agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ResearchAgreementResearchFundingAmount', window );">Aggregate research agreement budget</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ResearchAgreementResearchFundingAmountPayable', window );">Research amount payable quarterly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=onct_RegentsLicenseAgreementMember', window );">Regents License Agreement | Regents of the University of California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_NumberOfDaysInWrittenNoticeOfTermination', window );">Written notice of termination, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=onct_LicenseAgreementMember', window );">License Agreement | University of Tennessee Research Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AdvanceLicensedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Advance licensed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AdvanceLicensedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AmountAgreedToBeProvidedInContingencyFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount agreed to be provided in contingency funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AmountAgreedToBeProvidedInContingencyFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_AnnualLicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual license maintenance fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_AnnualLicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CollaborativeArrangementPotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement, potential milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CollaborativeArrangementPotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement, potential regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development milestones to be received under research subaward agreements throughout award project period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_LicenseMaintenanceFeeToBePaidAndPaymentMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License maintenance fee to be paid and payment made.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_LicenseMaintenanceFeeToBePaidAndPaymentMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum period of written notice to terminate agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days after receipt of notice for default in payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days after receipt of notice in fails to pay amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_NumberOfDaysInWrittenNoticeOfTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days in written notice of termination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_NumberOfDaysInWrittenNoticeOfTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_RelatedQualifyingSubawardCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related qualifying subaward costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_RelatedQualifyingSubawardCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ResearchAgreementResearchFundingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research agreement research funding amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ResearchAgreementResearchFundingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ResearchAgreementResearchFundingAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research agreement research funding amount payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ResearchAgreementResearchFundingAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ResearchAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research agreement term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ResearchAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ResearchAndDevelopmentGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ResearchAndDevelopmentGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Worldwide sales milestones based on achievement of tiered revenue levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_SubawardPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subaward payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_SubawardPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_UpfrontLicenseFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront license fees paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_UpfrontLicenseFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=onct_MDAndersonCancerCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=onct_MDAndersonCancerCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=onct_ReagentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=onct_ReagentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=onct_UniversityOfCaliforniaSanDiegoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=onct_UniversityOfCaliforniaSanDiegoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=onct_CaliforniaInstituteForRegenerativeMedicineAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=onct_CaliforniaInstituteForRegenerativeMedicineAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=onct_ExclusiveLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=onct_ExclusiveLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=onct_GeorgetownUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=onct_GeorgetownUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=onct_ResearchAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=onct_ResearchAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=onct_RegentsLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=onct_RegentsLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=onct_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=onct_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=onct_UniversityOfTennesseeResearchFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=onct_UniversityOfTennesseeResearchFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009088818696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Securities Purchase Agreements and Underwritten Offering (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="nump">5,031,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,277,586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="nump">$ 9.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_PurchaseAgreementMember', window );">Purchase Agreement | Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CombinedPurchasePriceOfShareAndWarrantPerUnit', window );">Combined purchase price of share and warrant per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_PurchaseAgreementMember', window );">Purchase Agreement | Warrants to purchase common stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">971,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_PurchaseAgreementMember', window );">Purchase Agreement | Warrants to purchase common stock | Placement Agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Common stock warrants exercisable and expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_PurchaseAgreementMember', window );">Purchase Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,943,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and common stock warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_JulyPurchaseAgreementMember', window );">July Purchase Agreement | Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CombinedPurchasePriceOfShareAndWarrantPerUnit', window );">Combined purchase price of share and warrant per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CommonStockWarrantsExpirationDate', window );">Common stock warrants expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 21,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_JulyPurchaseAgreementMember', window );">July Purchase Agreement | Warrants to purchase common stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,290,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_JulyPurchaseAgreementMember', window );">July Purchase Agreement | Warrants to purchase common stock | Placement Agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Common stock warrants exercisable and expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 21,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_JulyPurchaseAgreementMember', window );">July Purchase Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,581,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and common stock warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_AugustUnderwritingAgreementMember', window );">August Underwriting Agreement | Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CombinedPurchasePriceOfShareAndWarrantPerUnit', window );">Combined purchase price of share and warrant per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Common stock warrants exercisable and expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 27,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_AugustUnderwritingAgreementMember', window );">August Underwriting Agreement | Warrants to purchase common stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_AugustUnderwritingAgreementMember', window );">August Underwriting Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,428,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and common stock warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_NovemberUnderwritingAgreementMember', window );">November Underwriting Agreement | Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CombinedPurchasePriceOfShareAndWarrantPerUnit', window );">Combined purchase price of share and warrant per unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Common stock warrants exercisable and expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 17,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_NovemberUnderwritingAgreementMember', window );">November Underwriting Agreement | Warrants to purchase common stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_NovemberUnderwritingAgreementMember', window );">November Underwriting Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares, issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,258,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and common stock warrants, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_DecemberUnderwritingAgreementMember', window );">December Underwriting Agreement | Warrants to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CombinedPurchasePriceOfShareAndWarrantPerUnit', window );">Combined purchase price of share and warrant per unit</a></td>
<td class="nump">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="nump">$ 5.625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Common stock warrants exercisable and expiration date</a></td>
<td class="text">Dec.  09,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_DecemberUnderwritingAgreementMember', window );">December Underwriting Agreement | Warrants to purchase common stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued</a></td>
<td class="nump">1,149,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=onct_DecemberUnderwritingAgreementMember', window );">December Underwriting Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCapitalizationEquityLineItems', window );"><strong>Schedule Of Capitalization Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock, shares, issued</a></td>
<td class="nump">19,161,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock and common stock warrants, net</a></td>
<td class="nump">$ 79.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CombinedPurchasePriceOfShareAndWarrantPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Combined purchase price of share and warrant per unit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CombinedPurchasePriceOfShareAndWarrantPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CommonStockWarrantsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CommonStockWarrantsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCapitalizationEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCapitalizationEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onct_PurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onct_PurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=onct_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=onct_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=onct_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=onct_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onct_JulyPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onct_JulyPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onct_AugustUnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onct_AugustUnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onct_NovemberUnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onct_NovemberUnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=onct_DecemberUnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=onct_DecemberUnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009170738968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Options outstanding, Number of Warrant</a></td>
<td class="nump">5,031,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ExerciseOfWarrants', window );">Number of Shares Underlying Warrants Exercised</a></td>
<td class="num">(754,255)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Options outstanding, Number of Warrant</a></td>
<td class="nump">4,277,586<span></span>
</td>
<td class="nump">5,031,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted-Average Exercise Price</a></td>
<td class="nump">$ 9.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_WarrantExercisedPricePerShare', window );">Exercised</a></td>
<td class="nump">2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted-Average Exercise Price</a></td>
<td class="nump">$ 10.42<span></span>
</td>
<td class="nump">$ 9.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ClassOfWarrantWeightedAverageRemainingContractualTerm', window );">Weighted-Average Remaining Contractual Term</a></td>
<td class="text">4 years 26 days<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_WarrantWeightedAverageRemainingContractualTermExercised', window );">Weighted-Average Remaining Contractual Term, Exercised</a></td>
<td class="text">4 years 7 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ClassOfWarrantWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant weighted-average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ClassOfWarrantWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_WarrantExercisedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant exercised price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_WarrantExercisedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_WarrantWeightedAverageRemainingContractualTermExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant weighted average remaining contractual term exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_WarrantWeightedAverageRemainingContractualTermExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009085775528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Equity Incentive Plans (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 07, 2019</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Feb. 11, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock shares provided for issuance of stock awards to its employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,491,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price of options outstanding and fully vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanMember', window );">2019 incentive award plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares of common stock reserved for issuance</a></td>
<td class="nump">1,678,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Maximum number of shares of common stock a participant may receive</a></td>
<td class="nump">275,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance', window );">Percentage of annual increase in shares reserved for issuance</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember', window );">2019 incentive award plan and inducement plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock shares provided for issuance of stock awards to its employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,143,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandThirteenPlanMember', window );">2013 plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber', window );">Number of options outstanding and fully vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandFifteenPlanMember', window );">2015 plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandFifteenPlanMember', window );">2015 plan | Private Oncternal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock shares provided for issuance of stock awards to its employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">631,120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_GTxStockOptionPlansMember', window );">GTx Stock Option Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber', window );">Number of options outstanding and fully vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price of options outstanding and fully vested and exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenPlanMember', window );">2019 plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_InducementPlanMember', window );">Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of common stock shares provided for issuance of stock awards to its employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember', window );">2019 and 2015 plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share of option grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 365,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The annual percentage increase in shares reserved for issuance under sharebased compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_TwoThousandThirteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_TwoThousandThirteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_TwoThousandFifteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_TwoThousandFifteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=onct_PrivateOncternalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=onct_PrivateOncternalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_GTxStockOptionPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_GTxStockOptionPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_TwoThousandNineteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009097980280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Option Outstanding, Vested and Expected to Vest and Exercisable (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, Number of Shares</a></td>
<td class="nump">3,977,826<span></span>
</td>
<td class="nump">2,107,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.46<span></span>
</td>
<td class="nump">$ 4.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_EquityIncentivePlanMember', window );">Equity incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, Number of Shares</a></td>
<td class="nump">3,977,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest, Number of Shares</a></td>
<td class="nump">3,977,826<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, Number of Shares</a></td>
<td class="nump">1,075,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">5.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 10 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 10 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options outstanding, Weighted Average Remaining Contractual Term</a></td>
<td class="text">7 years 3 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 11,378,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">11,378,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 5,170,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009170479928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Option Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, beginning balance | shares</a></td>
<td class="nump">2,107,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, granted | shares</a></td>
<td class="nump">2,127,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of options, cancelled | shares</a></td>
<td class="num">(168,750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, exercised | shares</a></td>
<td class="num">(88,049)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, ending balance | shares</a></td>
<td class="nump">3,977,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance | $ / shares</a></td>
<td class="nump">$ 4.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, granted | $ / shares</a></td>
<td class="nump">6.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, cancelled | $ / shares</a></td>
<td class="nump">5.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, exercised | $ / shares</a></td>
<td class="nump">4.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance | $ / shares</a></td>
<td class="nump">$ 5.46<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009093675736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">89.90%<span></span>
</td>
<td class="nump">89.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009179306776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 838<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 365<span></span>
</td>
<td class="nump">$ 260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009092219544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock-Based Compensation Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Compensation cost related to non-vested awards not yet recognized</a></td>
<td class="nump">$ 12.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Remaining weighted-average period</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.1</span><table class="report" border="0" cellspacing="2" id="idm140009092009112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CommonStockWarrantsReservedForFutureIssuance', window );">Common stock warrants</a></td>
<td class="nump">4,278,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance', window );">Common stock options issued and outstanding</a></td>
<td class="nump">4,069,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for future issuance</a></td>
<td class="nump">10,491,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember', window );">2019 incentive award plan and inducement plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock available for future issuance</a></td>
<td class="nump">2,143,999<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock options issued and outstanding for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_onct_CommonStockWarrantsReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock warrants reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">onct_CommonStockWarrantsReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>onct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>49
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M2/!0:'L#_+Y2RNQ/[ /JO>#I?U!+ P04    "  BB:92$I(%@,\$   P$@
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M:NAZI>09*6L-WNR%X\:MAFRXL&5\,@K^RV&=66^DR*$H+$=PI67!<VK@YLG
M#U3+:"1W:$/U 7V%BFMTA7X\/:!?OOR*OB NT-\'66DJ<KV:&D!C?4ZS)O)]
M'9F,1([1-RG,0:/? 4'^?OT4LFA3(6^IW).@PV]47:,8_X9(1+ 'S^;SRZ,
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M<*GZ.T9]8^31?0K82F-DZ2X/C.9,60/X_TY*\W9C [1?D];_ U!+ P04
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M4PSY=82W3.M]K25\!=0':X7^L"?1JI<@IN5P4M@.YY4N!T*V8M(I=F89P9J
MPX@PF$B$MZ[M"M(2+PEOMA:';4EQS<9"?CB4#I@#WKM-3*'RVU$Q@?2V 1=,
M_59DB=DK1EUZJ);,1#5'UT ;U[J9 4_DB)MNV542($JV,_"MVA8)6'@R2Z2V
M!0"QIXTB2$EBW!!0@Q2Z#3=:UC & ;&5YGIB"0WCF([(+J!KQJ@&<M^0HO8D
M7&@?93($VEF]*RC]!324%.T+U!@P%P-_$08;I&?J]8CM+3FXL.4DR%9P.ZG%
MD8&PMJ.E\"ZL#>(F[^I.L&RAR:JY]/G;LV>SI]%3U(A[#4DF<G.QI!@;\#>.
M[&Q*?ZBS\#_BFF9I+SL2 1.5.AH'&BJO:".K""TDA@Q!%ZQ$B@@>DY Z<\Y[
M)01#+$?#V# BO_98I=%?('P<9/'4K59VRU)I]0XOT<,#*XG(R5(DC @EM);T
M0.13]+.F6ZVIC#7U@K*0#W(4%KBX0AK'<B3"0B_:$)_Q!A7P#)8RAZB74ZJ4
MC,L&&]T"*;-2"^,IF<#'<@K[0I-_'FY7*40>:PD\^ASV;IBI8>Q=PSHAZT5Q
M2&H)!IT(W+,WC#BUHD!)FLU%9[6ZHJC/,8-="?B2/(F?A ;P9[91MQQ?"&KY
M0IN\!E9@F0]*L7RX9(L;0H8$V5P)*B<D'M?QIO0GZ(4S5ZP^PACPZ)55->6'
M)J!HI[, #I!(*@H7.%LB(W44OAE?"*2ZKA*(LZ5Z;\4XT[$KL$59<M*&Q-(8
M3J>66@KD3QXOJFL0+)GNEKLU+ >.,Y)&78=_HD$,C*RFCBSM[3?A2EZ\JY.@
M,MZ1(DN'FF%$K2"#>V,$I*WM',NLA^;)&F5<R&52VPZ7\VK\ 5PS C=*CD;&
M%BPCM@7&#5U(!U:O*%*QR'TFN"0CE4!'*U!B<&U$&JQ+QZWU4)Y>OCT;5+Y\
MP$HW% 0J!I'4SRH"FI24$)&RE^RGAH7&V(N)..7NA>K;!Z>GYWW%^)$-[L\)
M>T1"OJGEJ.;C6H4MB<Q(]I_<1X>25QFU$Q10Q>?.<<O+R>/(QESVP<(;R,6C
M+DN"MI);<MLAN0>@YR5#?1T?UFK5J)7OAEB*MI1ZJ9"%T6_$$K.E*@G*C'E;
M3S8<71*UB@IGX%_6 HW$*,8\,IAD6$[)U!0N'$\]NW?^H[ !DVK:2"XUNGQY
M2LF6D[RL9 0')ZLD>9#?!N^78R2;;!48H]KPR-"E,@NA4T,1-=L9\<E@?"/<
M<?]+(6ODK8?6A#/(=NM8@27X.L72#.P \Y#$.BLF+$ENQ>K:\Y <T\-1O=^V
M]M%#"(%S4M'94%/(.O8T%AP"-> 06YM(6D(T2B2J<Y-([8&R<8F4_IJWN34?
MM> ZA6,1GOG<-5*0Q&"T;:O)47<<$"R2+4:"XQM8&O?/?7Q$6 3P#RTO#F]O
MS\CIN</8-"09P?[T)MW:9?.CZ3\.3__2YA*BY\<IK ORC^[BO?Q/B_=NYVJ3
M8P5-ZCZSL*\M8;:J=SG"'()MADX>/O,N&98'"_LDM>/;Z%RCO?OO9.U;.8PR
MPFA &"\+ON/@IO!X%SLPVC3$3PPIY;U#28DM[@PEDS0D3)**!SM&YPX1H \Q
M]XHPL\&]6$^MST<B+?)VOMNA<E434J*+#S8/)),,E7NG]\F5&YM3N72B^Z@B
MD#J^*6 CZ/ L!D%SUF.3)*]@K]DNDZFJ([A986-"_.(RB?2M]C=?/I5OTTD7
M<7#2E8@-&9=V)3*BOCV6;AEO<_NU)0T/D-^$UJ5QE-=60D5UFT92'UM#Y\%]
MPU9FV5EHE_ ?;_MVR:!Z8J45U!0E?+$&2L4Y N5!)JH[01OB'3@I #A678(@
M(>B*:K<;NK79H/Q9*Z^HA1YIV)SMZ^5$N,,?E U'> I /6[.USJ_\N"F;R6"
M#GT;^PG^DYETV)JV=^0S>#X4<E&ZJZ0_5S94W@NK[&6Q7L/1J&0_A^P=Y$8U
M5^(%>7J,)&HYQ](YP3, 46L)IWQA>:]V%ETYM'SM4&B&6 QOE[KP4!B?='80
M=8B7LNUB':>_Y+[)O?L4-WA&6C\4_M.N!KWO2VFJ#*G.&4@_[064\7'C32"5
M% O$ITGF?*$JQ7WR0DKW(6")J-+'"B\$:D$E?!)1 G E2$11D0]30Q]N'BOB
MZG98"\/&85>E6X/8%>R>[W\I-*\0>MC.-MR9&CJ$=*]2?T@^#7";CB\TL1^J
M;%$FJH*E]LWH*K2F9]FY(J,#80A,_E^KI=U#/0WI,](S<##7,123)Q15X7DH
M<"UE!LIKW!8.99-$B (ALW1LJ$CE/A6D:8$?X580V8<TI&@WZK^$TG<I%L!/
M@'+&IMR.R"G E0U=?R1!]TT2=-^FR><TQ.F+?3$ZYJHDN7#<[DD,L&,[.O.0
MA"]XW882-+?)N3<:.S#7>G]^Z/MRL_T$"C$D\E'YI04<JH:.FN8"J6%2[)8[
MFTVV%OHW_4'.&?A%&Z#A/7N[DU".A]9MF(A 78)T[!)>)]D?4 G?E/0MD.13
M!W>UX9@%3&M9MH-.5YJ]">] */X:?:GQV$:5A;AY:8LI(%8K20@93S5MWP^3
MU=P3@^FMD05&^JZ$);6_;+X&6:9SW\KW#4\Z^606UZ7Q<M)++GZ>S@*D"X9J
M&JQ*>GD"^=B(SJ5_%LL+ETIV%VY(>RF6T@46%H035+B CV&&$,,6-J#(0!=Q
MNPXC;:!-H*56!0,255RSKNDN5%N>L&35<S!95@+Q/7 9 -D!]O7!/.,A0.YX
M,(XNMU"GB,;#2RH!*!#H+929:EOBF1LBNP!^BK&08!JYZ;J'>TMDI)NR@=<D
M)-LX#U0()KDC7,VRWPD':8*Y*L[J2'<VCS,"(UP/,Y-"MKK]JITT1WT2YZ:2
MMM?E5H>9E4ZHB[NK@PMEP:2T^-K08SRW4U['<"A^$>0XQ/>?NV+59[P>;_H.
M<C"? ,<C)5[MB7)CHO<="FX$+S-1[_?T%J*-;X?\I+UPYR7C[NB7*-U;6+1D
MNE^9S^;]1:0;F,*(#A,+']CSSU3X_),+G_=:$?ZJ(QQ/^I@$0?ADNN$A(-(7
M3),$J_"@G21%;M%956L:.F;CKWE_VBVIMGR25S2<EI1\[$F*H\AGXYUR4/(A
M/D.F*TH=LB_933NHXV#JI;ATTGO$9HUIIOT;W 7U<I '^<*.N.2LJ0BKE@R3
M<TTIRW<THO]PE2OX_*;O 'E3YEL0ZI$VG@?J(X1D0]>(2Z:OYXJT!_< 3+)A
M3,Y?:2]T>T.]7%]-4)(J\W*C&)R?.D8_DU0 //8HJWWFJWL-"\%]SRI6KD4?
M[W>J_)&C/<\=3^*PD 0.]NQ&WIA*Y=O.2XX'4N9Q@F;TWA\X20="!A8XM#:N
M]Z:P99NROL9K\K+;D(QXJ 4F_]6/$I3-I@/QG1\A'3=-%R8O7F2_\C7M_$7V
M84%ASE^5\!Z><B 4OBIG.W'BA0SE1&@T[L%['+_(WO&#$^^.+4U:$DUW;.![
MMM0/Z6GP%EZ4L+BVX@L@2LKR*AQY\B+[U)@=PI/RA*Z9H!1HJ:VT^$A0-E*H
MZF?-N#&TU7DE9VAOI?W!68?+*!D'3DI_'B=1UG)^3GI#H^'/]RWZDFM?7]GJ
M:$:QLH\^FK8&2VZZ4%>0WNO5[/!$KCH7&S_P"=M.>7*K4:WO/TD%EQ3D8]7I
M?K+-(.I^(V*EH<K?S]!]?1\L7(P#/#G@+WE,[D%&TAH?N;"X\.VH"P 7)--X
MEQ?[+D(_[$C*,VD&RC-]?HLSUC!D :D2KR^T?XH$_)ZP/#7"PK76V;N+]_'V
MC$M%)3<5JD<NKEMP:ZU'D]E#&A7_#8Z1/7[4.[,!ZO2>W$\54>41 "3C(2BO
MD4 C%>"]8!=?\:N(/SKI<?E\$(# 12H4#@"1])*!#(GW:S(I)GUEKYWH=;&0
MYNIFR9X14)0'N8T8MD"B4-7UJ-F+HO #S10RI>KFGI1II+W@DBG+$1GW]X2U
M;L6P1U;1/3 9Z (!>"IS/XF)%D9+AR7$",?33038_+R+O\ZCH)UB>8-8ON("
M1>;RN,**^;.GNR=$;@(HA],4 7'J@\MH,;K[[-Z:N"\IE "9&A6ZG^2_"UWO
MJT+&>O%)!WYPYP@4TA$.BMQ'GQM1QW9#);::AVY1.H]\^1Z:>E=]\HXT]Q,=
M,1@*+]$KQNR';BV4;??%\%1(_1S%NR:)I8*\920C)7J)ZK\-8G QP*O054O+
M0G8 $C:36 U\:%BXY!5L P:I?<X>;LO3;@BP9 Q!E@0]JNPA ]!'@[T&(6CD
MY.]B]*[-^I'<LO76L?%-IX2#(;.Q-HTW$21,<9;3\2&,D?N^X3Q@T4MH>+U!
MY<C1['D_[=70J.3L27ACDJ1>@B67W(UYS3CS+.G&^ ]VVS31RV)J=R/7-GX8
M2FYG)J%C(:22YTWV1V8:SY&T^;I2(.$R7QL>;Y9QMX!K:U/H:K<)P%NZ2"3?
M[LL5D8R(6$5.2HU85FN^U@6/I,1Q,@Z:KFQC$1UO(GU1+KL][)SD(WHO;"<K
M'TEPIB8J#?5,^>M"H;:A8BJ5#5,H62CL4KK^1L&D 3J4#B4(;A$.O5/%L.?Z
M*)2P4_N1R"UVU++U2S:FA%;X8D9"39\B/,_Q1"G(\!G/8RWZ@#^B E"]U+[Y
MRVJ@VLO?UGFW3Y<P;B)?Y2G1C^K+\#:WOTY8,K#F52VO2A+32&V*/+HVQ19L
M#D/,/?8"I]&CL.T^D!N:R?VEMEQ,TR,4 K"]#/7'KHK @3ZOI\V!?;,7_;=J
M2A<9N ]Y<I\0RT?O=HLP.2:7N<OXS8. 7[\] X+CX@Y[SA6?U8UTB>@)0:QT
MNR23+8.AAK3<&1 4,$'NKS0HJEGG;<SO1%3X;\VP#.-AIKF7C'90H3>F8122
MJ_3P'3]I1X$[]@H*8'O-GN9CQ\CP-U<\*MGV&'%G*MWW?3WMEBY0\0]]%9"#
M#0I4@G:ANJ(I?)E_HMF OGJ/5N#S43*1-+S1[:]-Y2;M6@_'DC6EPX;:+7TG
MT=N\*(>:K3P1Y$?-P+(,G>J:OCEJ;U,%3Y*)^MYS?"5,6IC0ZRG/?,I= :EV
MQ8W/K?DPRJ(4H1+(]FXPK1;]P.U*.W:'PGRLER1G]3'M#6[DAY>F4M"2VGL,
MR"7U0.HW?C[U2G-')L[I!;O8/33SS6%*)M3Z4*P%\1O9C<=QM0>5P"T\(;D=
M'I'B-3=H_;01B?5#G"UW.C1OB:U"R@1!L1%SB^,W<IN"]$OFN3!=&X9:90Y&
MQD10Z>G!5;/\%(-OC/;&QDW%GL&%Y%'*/,MD\KW0.3,U);EQV/!&'CY(;V%A
M&SQ6S=+*^^]KDS"=\^DYI-*A^U[3[R=(JV0X!RP*=,/Q<Y!!J=!L"W%TK'26
M_095_FKPW#E]%7)-@J91WCQ.TA-=F>,/2A%[Y[^,RE<Z 0W%Y5Y8-_PC#KJ8
M*KIZ13!L.H:,#$;E"X"T)WCJ6H*]XKH^#$N4DZ];DBJ' )Q6I0,.15EU' W<
M<$)7S#BY8_U3-,5F6H)Z "[]C,C8MRE\!MTYS6\^N@_1,#^9'!T=A67$P<EQ
M^DXL\OZ2;+]G<GH(QM^0G'7Q;[2,0';/!W])5 9)O9('GZ2C-_L-*04=/7ZG
M[]^[SMY.^T/*Y12F!K):[H$3LO&HF)+13I]LTC=$&Y,DDO@MLFW&PO17KJJ<
MOPC#T"7O&:2:?U=URE_:N&22Y"X'Z',(5H4%L^S\CL<H>V]CP$!M *)[S6#2
M-P4@#I,Y,R1C&DZ<L$/U;?/L(0_!CBK6"^1'H<9TCFZ 'KTXB$9[0$9+_QP=
M_,X-"H$ST;/2?0\>3XZ?/CMX]GA^<)8>)]6;P\='3YX?'$_F3YX-%XPZ[<'\
MZ.#DZ.#9Y.2'IP=PWI/G!Q><]R'<T\+PB'_ZPQO6-(:F3"2G 12==BM$J*2$
M_OGT\C7,R=&=W.GE)_YD>O1D@I)[T?KO7M*?4BZ>L:VZD$H^<(?_@[^'>:/Y
M.\'<%Z%/_ZZ+%:CPFYS%:0*(]2WWY6,_YL--PP-W[>W8CZH<)K^0PU^;I]\!
MXBO.II4?RXGOQI\:.I5?V.F7R^\4084K&@VK]!*/'LV>_O @L_+;/_*B-1O^
MO9V%:5M3\Y\T2J$M+<#G2P-S]B_H@/@#3*_^'U!+ P04    "  BB:92?"3?
MQX0"  !%!0  &    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;*5436_;, R]
MZU<(Q@X;$,2?:=(B"9"D&S9@Q8(6VP[##K)-VT)ER9/DI?WWH^3$RX VEUTL
MD>)[?*1%+0]*/YH&P-*G5DBS"AIKNYLP-$4#+3-3U8'$DTKIEEDT=1V:3@,K
M/:@581)%5V'+N S62^_;Z_52]59P"7M-3=^V3#]O0:C#*HB#D^.>UXUUCG"]
M[%@-#V"_=GN-5CBRE+P%:;B25$.U"C;QS39S\3[@&X>#.=M35TFNU*,S/I6K
M('*"0$!A'0/#Y3?L0 A'A#)^'3F#,:4#GN]/[!]\[5A+S@SLE/C.2]NL@D5
M2ZA8+^R].GR$8STSQU<H8?R7'H;8- UHT1NKVB,8%;1<#BM[.O;A#+"(7@$D
M1T#B=0^)O,I;9MEZJ=6!:A>-;&[C2_5H%,>E^RD/5N,I1YQ=;YE@L@#ZX&_
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MG95,ED([:32S(C_O7R:OKF:T/BSX78J5VWAF%,G<F$=Z>9^=]\<$2"B1>K+
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MU.B8Z&3'%)/(6U59\R0QH03P'22GLY 0KG7-%2245U(MJ?OP;C=3"/VY0 U
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M@36/@AH2YV72(?L&BRTKV\@'0=CM29$"Z*7">IS1F6LAS]=;4+]Z&5#/8"@
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ML6TVU.MD,>-@ 0$_[?,!-1RE[3@8Z/;+!P_]41:]&1!F=Q+0T=]V(N(A<="
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M^0NHEK-3O8::%=M89;L"ZZBBJ1P(4JC+:)&BPED8H,#9W5"LO,ICJ)'+M,L
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M"7;PN='7(@P9450HIQE.!,)9H;S?KE1Q35BG78E=C2LU!D)?P#UC I7XA7K
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M4FE/&WFYDMBX)' ++G1+3D[G4 ;&8A B6$14&7R /8"" K(FL6%MVRU)4%M
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MH."."7EN8$QR7]2"OVTP4M)<>EH6JF!@JXH5RYJF,K3A84\6/7N\:27IJ@/
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M/FD:*596@A:X")W,8?;'-N)LA/2F5[K_6H@F@%!3*2S6G)W.BW"H+,]SD&[
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M26E#-^#ZM(&]N3]H@_ [;V__#U!+ P04    "  BB:92?V3;.BD#  ".!@
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MT!P*U@K[J'9?89_/R/%E2AC_I;O.-DD"FK7&JGH/Q@AJ+KN3O>SK< 281"<
M\1X0^[@[1S[*.V;9?*K5CFIGC6SNXE/U: R.2_=3-E;C*T><G2^98#(#NO$=
M< >6<6'HQ0^V%6 NIZ%%'\XRS/9\RXXO/L&7T <E;67H9YE#_C\^Q-CZ .-#
M@,OX+.$#TU<T&0YH',7#,WQ)GW#B^9(3?&OVZG.C"YG319;IEF'"?Q9;8S6V
MR-\S+M+>1>I=I"=<;+H&IZKH'$!.[SG;<L$M!_-13<_S'4C$.PG-%,Z%L<Z'
MK8 62N!X<5G2"RY1HUK#9&XN;PG6+ZM< <D=9%!O07O!5=-](O((!KP- K"?
MGW%.&YPZ2SZ1ZVB$WW08DQ7&Q#,FJ-4<ZT6&@V$R(3>3B-Q#B>H"P) DFI#Q
MF*Q4C2O#,#=UY/KF!HU'\81\QS@UB1.2.M)X,!XG>":#*(T_JGEXU-,UZ-)/
MKLN[E;9K[U[;+X=%-Q/OYMUFP1*47!HJH$!H=#4>!51WT]H)5C5^0K;*XKSY
M:X4+#K0SP/="*7L0G(-^9<[? %!+ P04    "  BB:926WY0S[D"  #S!0
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M#_="OJH<0).W@I=JY.1:;^Y<5Z4Y%%3=B@V4N+(2LJ :IW+MJHT$FEE1P=W
M\_IN05GIC(?VVUR.AV*K.2MA+HG:%@65[_? Q7[D^,[APQ-;Y]I\<,?##5W#
M O3+9BYQYC9>,E9 J9@HB835R)GX=]/$V%N#'PSVZFA,3"9+(5[-Y%LV<CP#
M!!Q2;3Q0?.U@"IP;1XCQI_;I-"&-\'A\\/[%YHZY+*F"J> _6:;SD9,X)(,5
MW7+])/9?H<XG,OY2P95]DGUE&P\<DFZ5%D4M1H*"E=6;OM5U.!+XO3."H!8$
M_RL(:T%H$ZW(;%HSJNEX*,6>2&.-WLS UL:J,1M6FK^XT!)7&>KT^)YR6J9
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ME0F8#9#_KZ)(/!QD!LKMQ>?_ U!+ P04    "  BB:92E)QNJ3$#   '"@
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M;,V86V_;-A3'OPIA=%@+=)9(2KX4CH$U2;<,ZVHT[?HP[(&1Z)@H1:HD92?
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MR+SES"=:K$S7=B<T]8!FN*0V'66V@;[/A="[21:@;/S'_P%02P,$%     @
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M!JUO=#2J;-GEQ,BMZWHK::B'NF%*MQPJNX"^)U*:P\1N4-^;H[]02P,$%
M  @ (HFF4IP6I6'C @  Q@@  !D   !X;"]W;W)K<VAE971S+W-H965T,S N
M>&ULS5;?;]HP$/Y7K&C26FEM0L*O5H!4*-LJK1J"=7N8]F"2@UAU[-0VT.ZO
MW]D)*:40[:$/?4G\X[[/W]TY=^EMI+K7*8 ACQD7NN^EQN27OJ_C%#*JSV4.
M G<64F74X%0M?9TKH(D#9=P/@Z#M9Y0);]!S:Q,UZ,F5X4S 1!&]RC*JGH;
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ML>3'#JT/X/N5,;0W?('N^9S^!5!+ P04    "  BB:92O^.(59P"  #@!@
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MINV]B3<H^9,R7Q9V.K+N0ZVP.\TROJS[RZP5@+%W<79:EF+U6?!<%LQ-_N"
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M$D7U/KBS'X7K?2K<_$LV_@U02P,$%     @ (HFF4I>*NQS     $P(   L
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M +T-ZFW>J;?SC]JZN>>YQO/?2;4?G[7S\=/RN;EX+Q/.&O[3'7\!4$L#!!0
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M@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M (:M (:M (:M (:M (:M
M(6N*0M84A:SI?Y+U0^OE7__Q:M>DEJHY^+/NM^+L"U!+ 0(4 Q0    ( "*)
MIE('04UB@0   +$    0              "  0    !D;V-0<F]P<R]A<' N
M>&UL4$L! A0#%     @ (HFF4HL(=<#O    *P(  !$              ( !
MKP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ (HFF4IE<G",0!@
MG"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    "  BB:92=IPI=E@%   7%@  &               @($."   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ (HFF4A*2!8#/!
M,!(  !@              ("!G T  'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;%!+ 0(4 Q0    ( "*)IE+OMR DQ0(  $T)   8              " @:$2
M  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  BB:92-G)Z
MCGP#  "R"@  &               @(&<%0  >&PO=V]R:W-H965T<R]S:&5E
M=#0N>&UL4$L! A0#%     @ (HFF4KIGIAD*!0  61(  !@
M ("!3AD  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( "*)
MIE+RECHML 0   L4   8              " @8X>  !X;"]W;W)K<VAE971S
M+W-H965T-BYX;6Q02P$"% ,4    "  BB:92$TF]Y^H8  ",20  &
M        @(%T(P  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%
M  @ (HFF4GPDW\>$ @  104  !@              ("!E#P  'AL+W=O<FMS
M:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( "*)IE)?O-&ZBP8  #$/   8
M              " @4X_  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"
M% ,4    "  BB:92:"(J@]P,  !=)0  &0              @($/1@  >&PO
M=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( "*)IE+\86K2%!
M "TT   9              " @2)3  !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL4$L! A0#%     @ (HFF4G-S&LN^!@  8@\  !D              ("!
M;6,  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  BB:92
MG;9"IF\8  #S30  &0              @(%B:@  >&PO=V]R:W-H965T<R]S
M:&5E=#$S+GAM;%!+ 0(4 Q0    ( "*)IE)_9-LZ*0,  (X&   9
M      " @0B#  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%
M  @ (HFF4K#KT<^0 @  /@4  !D              ("!:(8  'AL+W=O<FMS
M:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    "  BB:926WY0S[D"  #S!0
M&0              @($OB0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+
M 0(4 Q0    ( "*)IE)&2.A4[ 4  &P/   9              " @1^,  !X
M;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ (HFF4A\SQ5=7
M P  -0D  !D              ("!0I(  'AL+W=O<FMS:&5E=',O<VAE970Q
M."YX;6Q02P$"% ,4    "  BB:92JR/Q8E<#  #P"@  &0
M@('0E0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( "*)
MIE*7_A[AN0(  (0'   9              " @5Z9  !X;"]W;W)K<VAE971S
M+W-H965T,C N>&UL4$L! A0#%     @ (HFF4B7O$/^] P  J P  !D
M         ("!3IP  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
M    "  BB:927)5,"<("  "H!P  &0              @(%"H   >&PO=V]R
M:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( "*)IE(>HGVM5@@  'XK
M   9              " @3NC  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL
M4$L! A0#%     @ (HFF4D2:S2\S!P  :BP  !D              ("!R*L
M 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  BB:92E)QN
MJ3$#   '"@  &0              @($RLP  >&PO=V]R:W-H965T<R]S:&5E
M=#(U+GAM;%!+ 0(4 Q0    ( "*)IE+I'FBS-P4  ,L7   9
M  " @9JV  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @
M(HFF4CQ]Z=8%!   !!   !D              ("!"+P  'AL+W=O<FMS:&5E
M=',O<VAE970R-RYX;6Q02P$"% ,4    "  BB:92RJF,_BT#  !/"@  &0
M            @(%$P   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4
M Q0    ( "*)IE(/^[1:O (  $,'   9              " @:C#  !X;"]W
M;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ (HFF4IP6I6'C @
MQ@@  !D              ("!F\8  'AL+W=O<FMS:&5E=',O<VAE970S,"YX
M;6Q02P$"% ,4    "  BB:922*_B%&D"  !*!0  &0              @(&U
MR0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( "*)IE*_
MXXA5G (  . &   9              " @57,  !X;"]W;W)K<VAE971S+W-H
M965T,S(N>&UL4$L! A0#%     @ (HFF4H<F;ZLG P  ,A,   T
M     ( !*,\  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  BB:92EXJ[',
M   3 @  "P              @ %ZT@  7W)E;',O+G)E;'-02P$"% ,4
M"  BB:92O VU@3(#  !-%@  #P              @ %CTP  >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ (HFF4HH3@V1C 0  MQ,  !H
M ( !PM8  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M(HFF4E4IDH^) 0  7A0  !,              ( !7=@  %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     "@ * #/"@  %]H

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>105</ContextCount>
  <ElementCount>274</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>42</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Commitments, Contingencies and Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactions</Role>
      <ShortName>Commitments, Contingencies and Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - License, Collaboration and Research Subaward Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreements</Role>
      <ShortName>License, Collaboration and Research Subaward Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - COVID-19 Pandemic and CARES Act</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct</Role>
      <ShortName>COVID-19 Pandemic and CARES Act</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetails</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Commitments, Contingencies and Related Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsTables</Role>
      <ShortName>Commitments, Contingencies and Related Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactions</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquity</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail</Role>
      <ShortName>Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Balance Sheet Details - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Details - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Commitments, Contingencies and Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Commitments, Contingencies and Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Commitments, Contingencies and Related Party Transactions - Summary of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments, Contingencies and Related Party Transactions - Summary of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100230 - Disclosure - License, Collaboration and Research Subaward Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails</Role>
      <ShortName>License, Collaboration and Research Subaward Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Stockholders' Equity - Securities Purchase Agreements and Underwritten Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails</Role>
      <ShortName>Stockholders' Equity - Securities Purchase Agreements and Underwritten Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Stockholders' Equity - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Stockholders' Equity - Equity Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails</Role>
      <ShortName>Stockholders' Equity - Equity Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Stockholders' Equity - Summary of Stock Option Outstanding, Vested and Expected to Vest and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Option Outstanding, Vested and Expected to Vest and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Stockholders' Equity - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Stockholders' Equity - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Stockholders' Equity - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="onct-10q_20210331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="onct-10q_20210331.htm">onct-10q_20210331.htm</File>
    <File>onct-20210331.xsd</File>
    <File>onct-20210331_cal.xml</File>
    <File>onct-20210331_def.xml</File>
    <File>onct-20210331_lab.xml</File>
    <File>onct-20210331_pre.xml</File>
    <File>onct-ex101_249.htm</File>
    <File>onct-ex102_247.htm</File>
    <File>onct-ex103_248.htm</File>
    <File>onct-ex311_8.htm</File>
    <File>onct-ex312_9.htm</File>
    <File>onct-ex321_7.htm</File>
    <File>onct-ex322_6.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>55
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "onct-10q_20210331.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "contextCount": 105,
   "dts": {
    "calculationLink": {
     "local": [
      "onct-20210331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "onct-20210331_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "onct-10q_20210331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "onct-20210331_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "onct-20210331_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "onct-20210331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 338,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 11,
    "http://www.oncternal.com/20210331": 5,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 20
   },
   "keyCustom": 47,
   "keyStandard": 227,
   "memberCustom": 30,
   "memberStandard": 10,
   "nsprefix": "onct",
   "nsuri": "http://www.oncternal.com/20210331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - License, Collaboration and Research Subaward Agreements",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreements",
     "shortName": "License, Collaboration and Research Subaward Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Stockholders' Equity",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "onct:COVID19PandemicAndCARESActDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - COVID-19 Pandemic and CARES Act",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct",
     "shortName": "COVID-19 Pandemic and CARES Act",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "onct:COVID19PandemicAndCARESActDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Balance Sheet Details (Tables)",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsTables",
     "shortName": "Balance Sheet Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Commitments, Contingencies and Related Party Transactions (Tables)",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsTables",
     "shortName": "Commitments, Contingencies and Related Party Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "onct:ScheduleOfWarrantActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "onct:ScheduleOfWarrantActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_onctsegment",
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail)",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail",
     "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "onct:AccruedResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Balance Sheet Details - Accrued Liabilities (Details)",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails",
     "shortName": "Balance Sheet Details - Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "onct:AccruedResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiability",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Commitments, Contingencies and Related Party Transactions - Additional Information (Details)",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Commitments, Contingencies and Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_onctShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember_20210331",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:AccountsReceivableRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Commitments, Contingencies and Related Party Transactions - Summary of Maturities of Lease Liabilities (Details)",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails",
     "shortName": "Commitments, Contingencies and Related Party Transactions - Summary of Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - License, Collaboration and Research Subaward Agreements - Additional Information (Details)",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
     "shortName": "License, Collaboration and Research Subaward Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "onct:ScheduleOfWarrantActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Stockholders' Equity - Securities Purchase Agreements and Underwritten Offering (Details)",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails",
     "shortName": "Stockholders' Equity - Securities Purchase Agreements and Underwritten Offering (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_us-gaapClassOfWarrantOrRightAxis_onctCommonStockWarrantsMember_us-gaapSubsidiarySaleOfStockAxis_onctPurchaseAgreementMember_20200531",
      "decimals": "4",
      "lang": null,
      "name": "onct:CombinedPurchasePriceOfShareAndWarrantPerUnit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "onct:ScheduleOfWarrantActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Stockholders' Equity - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details)",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails",
     "shortName": "Stockholders' Equity - Summary Of Warrant Activity And Changes In Warrants Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "onct:ScheduleOfWarrantActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": "INF",
      "lang": null,
      "name": "onct:ExerciseOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Stockholders' Equity - Equity Incentive Plans (Details)",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails",
     "shortName": "Stockholders' Equity - Equity Incentive Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210331",
      "decimals": "2",
      "lang": null,
      "name": "onct:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Stockholders' Equity - Summary of Stock Option Outstanding, Vested and Expected to Vest and Exercisable (Details)",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails",
     "shortName": "Stockholders' Equity - Summary of Stock Option Outstanding, Vested and Expected to Vest and Exercisable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_us-gaapPlanNameAxis_onctEquityIncentivePlanMember_20210331",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20201231",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Details)",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
     "shortName": "Stockholders' Equity - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Stockholders' Equity - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails",
     "shortName": "Stockholders' Equity - Schedule of Assumptions Used to Estimate Fair Value of Stock Option Grants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlipure",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210331",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Stockholders' Equity - Share-Based Compensation Expense (Details)",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails",
     "shortName": "Stockholders' Equity - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Stockholders' Equity - Stock-Based Compensation Expense (Details)",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails",
     "shortName": "Stockholders' Equity - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210331",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "onct:CommonStockWarrantsReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails",
     "shortName": "Stockholders' Equity - Common Stock Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "onct:CommonStockWarrantsReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_xbrlishares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20191231",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_iso4217USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100060 - Disclosure - Description of Business, Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Balance Sheet Details",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetails",
     "shortName": "Balance Sheet Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Commitments, Contingencies and Related Party Transactions",
     "role": "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactions",
     "shortName": "Commitments, Contingencies and Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "onct-10q_20210331.htm",
      "contextRef": "C_0001260990_20210101_20210331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 42,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address Address Line2",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "verboseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "onct_AccruedClinicalTrials": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued clinical trials.",
        "label": "Accrued Clinical Trials",
        "terseLabel": "Accrued Clinical Trials"
       }
      }
     },
     "localname": "AccruedClinicalTrials",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development.",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital exercise of warrants to purchase common stock for cash.",
        "label": "Adjustments To Additional Paid In Capital Exercise Of Warrants To Purchase Common Stock For Cash",
        "terseLabel": "Exercise of warrants for cash"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCash",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital exercise of warrants to purchase common stock for cash shares.",
        "label": "Adjustments To Additional Paid In Capital Exercise Of Warrants To Purchase Common Stock For Cash Shares",
        "terseLabel": "Exercise of warrants for cash (in shares)"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalExerciseOfWarrantsToPurchaseCommonStockForCashShares",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital vesting related to unvested share liability.",
        "label": "Adjustments To Additional Paid In Capital Vesting Related To Unvested Share Liability",
        "terseLabel": "Vesting related to unvested share liability"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalVestingRelatedToUnvestedShareLiability",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AdvanceLicensedAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advance licensed assets.",
        "label": "Advance Licensed Assets",
        "terseLabel": "Advance licensed assets"
       }
      }
     },
     "localname": "AdvanceLicensedAssets",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AmountAgreedToBeProvidedInContingencyFunds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount agreed to be provided in contingency funds.",
        "label": "Amount Agreed To Be Provided In Contingency Funds",
        "terseLabel": "Amount agreed to be provided in contingency funds"
       }
      }
     },
     "localname": "AmountAgreedToBeProvidedInContingencyFunds",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AnnualBaseRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual base rent.",
        "label": "Annual Base Rent",
        "terseLabel": "Annual base rent"
       }
      }
     },
     "localname": "AnnualBaseRent",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AnnualLicenseMaintenanceFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual license maintenance fees.",
        "label": "Annual License Maintenance Fees",
        "terseLabel": "Annual license maintenance fees"
       }
      }
     },
     "localname": "AnnualLicenseMaintenanceFees",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_AugustUnderwritingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "August underwriting agreement.",
        "label": "August Underwriting Agreement [Member]",
        "terseLabel": "August Underwriting Agreement"
       }
      }
     },
     "localname": "AugustUnderwritingAgreementMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_COVID19PandemicAndCARESActAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Pandemic and CARES Act.",
        "label": "C O V I D19 Pandemic And C A R E S Act [Abstract]"
       }
      }
     },
     "localname": "COVID19PandemicAndCARESActAbstract",
     "nsuri": "http://www.oncternal.com/20210331",
     "xbrltype": "stringItemType"
    },
    "onct_COVID19PandemicAndCARESActDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19 Pandemic and CARES Act.",
        "label": "C O V I D19 Pandemic And C A R E S Act Disclosure [Text Block]",
        "terseLabel": "COVID-19 Pandemic and CARES Act"
       }
      }
     },
     "localname": "COVID19PandemicAndCARESActDisclosureTextBlock",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCOVID19PandemicAndCARESAct"
     ],
     "xbrltype": "textBlockItemType"
    },
    "onct_CaliforniaInstituteForRegenerativeMedicineAwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California Institute for Regenerative Medicine Award.",
        "label": "California Institute For Regenerative Medicine Award [Member]",
        "terseLabel": "The California Institute for Regenerative Medicine (\"CIRM\") Award"
       }
      }
     },
     "localname": "CaliforniaInstituteForRegenerativeMedicineAwardMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_CashlessExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cashless exercise of warrants.",
        "label": "Cashless Exercise Of Warrants",
        "terseLabel": "Cashless exercise of warrants"
       }
      }
     },
     "localname": "CashlessExerciseOfWarrants",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_ClassOfWarrantWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of warrant weighted-average remaining contractual term.",
        "label": "Class Of Warrant Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term"
       }
      }
     },
     "localname": "ClassOfWarrantWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_CollaborativeArrangementPotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement, potential milestone payments.",
        "label": "Collaborative Arrangement Potential Milestone Payments",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialMilestonePayments",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_CollaborativeArrangementPotentialRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement, potential regulatory milestone payments.",
        "label": "Collaborative Arrangement Potential Regulatory Milestone Payments",
        "terseLabel": "Potential regulatory milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialRegulatoryMilestonePayments",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_CombinedPurchasePriceOfShareAndWarrantPerUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Combined purchase price of share and warrant per unit.",
        "label": "Combined Purchase Price Of Share And Warrant Per Unit",
        "terseLabel": "Combined purchase price of share and warrant per unit"
       }
      }
     },
     "localname": "CombinedPurchasePriceOfShareAndWarrantPerUnit",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "onct_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "onct_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "onct_CommonStockOptionsIssuedAndOutstandingForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock options issued and outstanding for future issuance.",
        "label": "Common Stock Options Issued And Outstanding For Future Issuance",
        "terseLabel": "Common stock options issued and outstanding"
       }
      }
     },
     "localname": "CommonStockOptionsIssuedAndOutstandingForFutureIssuance",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_CommonStockSubjectToRepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock subject to repurchase.",
        "label": "Common Stock Subject To Repurchase [Member]",
        "terseLabel": "Common Stock Subject to Repurchase"
       }
      }
     },
     "localname": "CommonStockSubjectToRepurchaseMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_CommonStockWarrantsExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants expiration date.",
        "label": "Common Stock Warrants Expiration Date",
        "terseLabel": "Common stock warrants expiration date"
       }
      }
     },
     "localname": "CommonStockWarrantsExpirationDate",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "onct_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants.",
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Warrants to purchase common stock"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_CommonStockWarrantsReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants reserved for future issuance.",
        "label": "Common Stock Warrants Reserved For Future Issuance",
        "terseLabel": "Common stock warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsReservedForFutureIssuance",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_ConcentrationRiskCreditRiskPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration risk credit risk policy.",
        "label": "Concentration Risk Credit Risk Policy [Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRiskPolicyTextBlock",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "onct_DecemberUnderwritingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December underwriting agreement.",
        "label": "December Underwriting Agreement [Member]",
        "terseLabel": "December Underwriting Agreement"
       }
      }
     },
     "localname": "DecemberUnderwritingAgreementMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development milestones to be received under research subaward agreements throughout award project period.",
        "label": "Development Milestones To Be Received Under Research Subaward Agreements Throughout Award Project Period",
        "terseLabel": "Development milestones to be received under research subaward agreements throughout award project period"
       }
      }
     },
     "localname": "DevelopmentMilestonesToBeReceivedUnderResearchSubawardAgreementsThroughoutAwardProjectPeriod",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity incentive plan.",
        "label": "Equity Incentive Plan [Member]",
        "terseLabel": "Equity incentive plan"
       }
      }
     },
     "localname": "EquityIncentivePlanMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ExclusiveLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive license agreement.",
        "label": "Exclusive License Agreement [Member]",
        "terseLabel": "Exclusive License Agreement"
       }
      }
     },
     "localname": "ExclusiveLicenseAgreementMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ExerciseOfCashlessWarrantShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cashless exercise of warrants",
        "label": "Exercise Of Cashless Warrant Shares",
        "verboseLabel": "Cashless exercise of warrants"
       }
      }
     },
     "localname": "ExerciseOfCashlessWarrantShares",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_ExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of warrants.",
        "label": "Exercise Of Warrants",
        "negatedLabel": "Number of Shares Underlying Warrants Exercised"
       }
      }
     },
     "localname": "ExerciseOfWarrants",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_GTxStockOptionPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gtx stock option plans.",
        "label": "G Tx Stock Option Plans [Member]",
        "terseLabel": "GTx Stock Option Plans"
       }
      }
     },
     "localname": "GTxStockOptionPlansMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_GeorgetownUniversityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Georgetown University.",
        "label": "Georgetown University [Member]",
        "terseLabel": "Georgetown University"
       }
      }
     },
     "localname": "GeorgetownUniversityMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10120.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liability.",
        "label": "Increase Decrease In Operating Lease Liability",
        "terseLabel": "Change in lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_InducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement plan member.",
        "label": "Inducement Plan [Member]",
        "terseLabel": "Inducement Plan"
       }
      }
     },
     "localname": "InducementPlanMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_IssuanceOfBonusAwardsWithStockOptionInLieuOfCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of bonus awards with stock option in lieu of cash.",
        "label": "Issuance Of Bonus Awards With Stock Option In Lieu Of Cash",
        "terseLabel": "Issuance of 2019 bonus award with stock options in lieu of cash"
       }
      }
     },
     "localname": "IssuanceOfBonusAwardsWithStockOptionInLieuOfCash",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_JulyPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "July purchase agreement member",
        "label": "July Purchase Agreement [Member]",
        "terseLabel": "July Purchase Agreement"
       }
      }
     },
     "localname": "JulyPurchaseAgreementMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement.",
        "label": "License Agreement [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_LicenseMaintenanceFeeToBePaidAndPaymentMade": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License maintenance fee to be paid and payment made.",
        "label": "License Maintenance Fee To Be Paid And Payment Made",
        "terseLabel": "Annual license maintenance fee to be paid and payment made"
       }
      }
     },
     "localname": "LicenseMaintenanceFeeToBePaidAndPaymentMade",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_LiquidityAndGoingConcernPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liquidity and going concern.",
        "label": "Liquidity And Going Concern Policy [Text Block]",
        "terseLabel": "Liquidity and Going Concern"
       }
      }
     },
     "localname": "LiquidityAndGoingConcernPolicyTextBlock",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "onct_MDAndersonCancerCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MD Anderson Cancer Center.",
        "label": "M D Anderson Cancer Center [Member]",
        "terseLabel": "MD Anderson Cancer Center"
       }
      }
     },
     "localname": "MDAndersonCancerCenterMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_MinimumPeriodOfWrittenNoticeToTerminateAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum period of written notice to terminate agreement.",
        "label": "Minimum Period Of Written Notice To Terminate Agreement",
        "terseLabel": "Minimum period in days of written notice to terminate license agreement"
       }
      }
     },
     "localname": "MinimumPeriodOfWrittenNoticeToTerminateAgreement",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10080.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash lease expense.",
        "label": "Noncash Lease Expense",
        "terseLabel": "Noncash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_NovemberUnderwritingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "November underwriting agreement.",
        "label": "November Underwriting Agreement [Member]",
        "terseLabel": "November Underwriting Agreement"
       }
      }
     },
     "localname": "NovemberUnderwritingAgreementMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days after receipt of notice for default in payment.",
        "label": "Number Of Days After Receipt Of Notice For Default In Payment",
        "terseLabel": "Days after receipt of notice for default in payment"
       }
      }
     },
     "localname": "NumberOfDaysAfterReceiptOfNoticeForDefaultInPayment",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days after receipt of notice in fails to pay amount.",
        "label": "Number Of Days After Receipt Of Notice To Pay Failure Amount",
        "terseLabel": "Days after receipt of notice, to pay failure amount"
       }
      }
     },
     "localname": "NumberOfDaysAfterReceiptOfNoticeToPayFailureAmount",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_NumberOfDaysInWrittenNoticeOfTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days in written notice of termination.",
        "label": "Number Of Days In Written Notice Of Termination",
        "terseLabel": "Written notice of termination, period"
       }
      }
     },
     "localname": "NumberOfDaysInWrittenNoticeOfTermination",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_OfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office space.",
        "label": "Office Space [Member]",
        "terseLabel": "Office Space"
       }
      }
     },
     "localname": "OfficeSpaceMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_OwnershipPercentageOfStockholdersUponClosingOfMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ownership percentage of stockholders upon closing of merger.",
        "label": "Ownership Percentage Of Stockholders Upon Closing Of Merger",
        "terseLabel": "Ownership percentage of stockholders upon closing of merger"
       }
      }
     },
     "localname": "OwnershipPercentageOfStockholdersUponClosingOfMerger",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "onct_PatentCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent costs policy.",
        "label": "Patent Costs Policy [Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "PatentCostsPolicyTextBlock",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "onct_PlacementAgentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Placement agent member.",
        "label": "Placement Agent [Member]",
        "terseLabel": "Placement Agent"
       }
      }
     },
     "localname": "PlacementAgentMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_PreferredStockWarrantLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock warrant liability.",
        "label": "Preferred Stock Warrant Liability",
        "terseLabel": "Preferred stock warrant liability"
       }
      }
     },
     "localname": "PreferredStockWarrantLiability",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_PrivateOncternalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Private Oncternal.",
        "label": "Private Oncternal [Member]",
        "terseLabel": "Private Oncternal"
       }
      }
     },
     "localname": "PrivateOncternalMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_PurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase agreement member.",
        "label": "Purchase Agreement [Member]",
        "terseLabel": "Purchase Agreement"
       }
      }
     },
     "localname": "PurchaseAgreementMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ReagentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reagents.",
        "label": "Reagents [Member]",
        "terseLabel": "Regents of the University of California"
       }
      }
     },
     "localname": "ReagentsMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_RegentsLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regents license agreement.",
        "label": "Regents License Agreement [Member]",
        "terseLabel": "Regents License Agreement"
       }
      }
     },
     "localname": "RegentsLicenseAgreementMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_RelatedQualifyingSubawardCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related qualifying subaward costs.",
        "label": "Related Qualifying Subaward Costs",
        "terseLabel": "Related qualifying subaward costs"
       }
      }
     },
     "localname": "RelatedQualifyingSubawardCosts",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_ResearchAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement.",
        "label": "Research Agreement [Member]",
        "terseLabel": "Research Agreement"
       }
      }
     },
     "localname": "ResearchAgreementMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ResearchAgreementResearchFundingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement research funding amount.",
        "label": "Research Agreement Research Funding Amount",
        "terseLabel": "Aggregate research agreement budget"
       }
      }
     },
     "localname": "ResearchAgreementResearchFundingAmount",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_ResearchAgreementResearchFundingAmountPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement research funding amount payable.",
        "label": "Research Agreement Research Funding Amount Payable",
        "terseLabel": "Research amount payable quarterly"
       }
      }
     },
     "localname": "ResearchAgreementResearchFundingAmountPayable",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_ResearchAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research agreement term.",
        "label": "Research Agreement Term",
        "terseLabel": "Research agreement term"
       }
      }
     },
     "localname": "ResearchAgreementTerm",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_ResearchAndDevelopmentGrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development grants.",
        "label": "Research And Development Grants",
        "terseLabel": "Grants awarded to researchers"
       }
      }
     },
     "localname": "ResearchAndDevelopmentGrants",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_SalesMilestonesBasedOnAchievementOfTieredRevenueLevels": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Worldwide sales milestones based on achievement of tiered revenue levels.",
        "label": "Sales Milestones Based On Achievement Of Tiered Revenue Levels",
        "terseLabel": "Worldwide sales milestones based on achievement of tiered revenue levels"
       }
      }
     },
     "localname": "SalesMilestonesBasedOnAchievementOfTieredRevenueLevels",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_ScheduleOfWarrantActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of warrant activity table text block.",
        "label": "Schedule Of Warrant Activity Table [Text Block]",
        "terseLabel": "Summary Of Warrant Activity And Changes In Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfWarrantActivityTableTextBlock",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "onct_ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shanghai Pharmaceutical United States of America Inc.",
        "label": "Shanghai Pharmaceutical United States Of America Inc [Member]",
        "terseLabel": "Shanghai Pharmaceutical (USA) Inc."
       }
      }
     },
     "localname": "ShanghaiPharmaceuticalUnitedStatesOfAmericaIncMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Number",
        "verboseLabel": "Number of options outstanding and fully vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableNumber",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options vested and expected to vest outstanding and exercisable weighted average exercise price.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Weighted Average Exercise Price",
        "verboseLabel": "Weighted average exercise price of options outstanding and fully vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableWeightedAverageExercisePrice",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "onct_SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The annual percentage increase in shares reserved for issuance under sharebased compensation arrangement.",
        "label": "Sharebased Compensation Arrangement Percentage Of Annual Increase In Shares Reserved For Issuance",
        "terseLabel": "Percentage of annual increase in shares reserved for issuance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementPercentageOfAnnualIncreaseInSharesReservedForIssuance",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "onct_StockExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock exchange ratio.",
        "label": "Stock Exchange Ratio",
        "terseLabel": "Common stock and preferred stock exchange ratio"
       }
      }
     },
     "localname": "StockExchangeRatio",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "onct_SubawardPaymentsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Subaward payments received.",
        "label": "Subaward Payments Received",
        "terseLabel": "Subaward payments received"
       }
      }
     },
     "localname": "SubawardPaymentsReceived",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_TwoThousandFifteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fifteen plan.",
        "label": "Two Thousand Fifteen Plan [Member]",
        "terseLabel": "2015 plan"
       }
      }
     },
     "localname": "TwoThousandFifteenPlanMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_TwoThousandNineteenAndTwoThousandFifteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen and two thousand fifteen plan.",
        "label": "Two Thousand Nineteen And Two Thousand Fifteen Plan [Member]",
        "terseLabel": "2019 and 2015 plan"
       }
      }
     },
     "localname": "TwoThousandNineteenAndTwoThousandFifteenPlanMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen incentive award plan and inducement plan.",
        "label": "Two Thousand Nineteen Incentive Award Plan And Inducement Plan [Member]",
        "terseLabel": "2019 incentive award plan and inducement plan"
       }
      }
     },
     "localname": "TwoThousandNineteenIncentiveAwardPlanAndInducementPlanMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_TwoThousandNineteenIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen incentive award plan.",
        "label": "Two Thousand Nineteen Incentive Award Plan [Member]",
        "terseLabel": "2019 incentive award plan"
       }
      }
     },
     "localname": "TwoThousandNineteenIncentiveAwardPlanMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_TwoThousandNineteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen plan.",
        "label": "Two Thousand Nineteen Plan [Member]",
        "terseLabel": "2019 plan"
       }
      }
     },
     "localname": "TwoThousandNineteenPlanMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_TwoThousandThirteenPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand thirteen plan.",
        "label": "Two Thousand Thirteen Plan [Member]",
        "terseLabel": "2013 plan"
       }
      }
     },
     "localname": "TwoThousandThirteenPlanMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_UnauditedInterimFinancialInformationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unaudited interim financial information policy.",
        "label": "Unaudited Interim Financial Information Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "UnauditedInterimFinancialInformationPolicyTextBlock",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "onct_UniversityOfCaliforniaSanDiegoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of California San Diego.",
        "label": "University Of California San Diego [Member]",
        "terseLabel": "University of California San Diego School of Medicine"
       }
      }
     },
     "localname": "UniversityOfCaliforniaSanDiegoMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_UniversityOfTennesseeResearchFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of Tennessee Research Foundation.",
        "label": "University Of Tennessee Research Foundation [Member]",
        "terseLabel": "University of Tennessee Research Foundation"
       }
      }
     },
     "localname": "UniversityOfTennesseeResearchFoundationMember",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "onct_UpfrontLicenseFeesPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront license fees paid.",
        "label": "Upfront License Fees Paid",
        "terseLabel": "Upfront license fees paid"
       }
      }
     },
     "localname": "UpfrontLicenseFeesPaid",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "onct_WarrantExercisedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant exercised price per share.",
        "label": "Warrant Exercised Price Per Share",
        "terseLabel": "Exercised"
       }
      }
     },
     "localname": "WarrantExercisedPricePerShare",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "onct_WarrantWeightedAverageRemainingContractualTermExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant weighted average remaining contractual term exercised.",
        "label": "Warrant Weighted Average Remaining Contractual Term Exercised",
        "terseLabel": "Weighted-Average Remaining Contractual Term, Exercised"
       }
      }
     },
     "localname": "WarrantWeightedAverageRemainingContractualTermExercised",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "onct_WarrantsCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants cancelled.",
        "label": "Warrants Cancelled",
        "terseLabel": "Cancelled"
       }
      }
     },
     "localname": "WarrantsCancelled",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "onct_WarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants granted.",
        "label": "Warrants Granted",
        "terseLabel": "Granted"
       }
      }
     },
     "localname": "WarrantsGranted",
     "nsuri": "http://www.oncternal.com/20210331",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r212",
      "r213",
      "r217",
      "r218",
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r212",
      "r213",
      "r217",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r37",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r156",
      "r157",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r274",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r156",
      "r157",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r274",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r154",
      "r156",
      "r157",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r274",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r154",
      "r156",
      "r157",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r274",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r117",
      "r118",
      "r152",
      "r153",
      "r275",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r117",
      "r118",
      "r152",
      "r153",
      "r275",
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r120",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title Of Individual With Relationship To Entity [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CALIFORNIA",
        "terseLabel": "San Diego, California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10090.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedParties": {
     "auth_ref": [
      "r15",
      "r65",
      "r238",
      "r240",
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amount of receivables arising from transactions with related parties.",
        "label": "Accounts Receivable Related Parties",
        "terseLabel": "Amounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10100.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r29"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Legal fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r16",
      "r192"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10070.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid In Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r189",
      "r190",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r158",
      "r160",
      "r195",
      "r196"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r160",
      "r185",
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Potentially dilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r64",
      "r100",
      "r109",
      "r114",
      "r122",
      "r212",
      "r217",
      "r223",
      "r263",
      "r268"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r36",
      "r64",
      "r122",
      "r212",
      "r217",
      "r223"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10130.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r161",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r59",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy",
        "terseLabel": "Merger"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r1",
      "r67",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description And Basis Of Presentation [Text Block]",
        "terseLabel": "Description of Business, Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r24",
      "r53"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10160.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r54",
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash And Cash Equivalents Policy [Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r49",
      "r53",
      "r58"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r49",
      "r224"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class Of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in CCYY-MM-DD format.",
        "label": "Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable",
        "terseLabel": "Common stock warrants exercisable and expiration date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r150",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class Of Warrant Or Right [Axis]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class Of Warrant Or Right [Domain]",
        "terseLabel": "Class of Warrant or Right"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1",
        "periodEndLabel": "Weighted-Average Exercise Price",
        "periodStartLabel": "Weighted-Average Exercise Price",
        "terseLabel": "Warrant exercise price per share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights",
        "periodEndLabel": "Options outstanding, Number of Warrant",
        "periodStartLabel": "Options outstanding, Number of Warrant",
        "terseLabel": "Warrants issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfWarrantActivityAndChangesInWarrantsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r207",
      "r208",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "License, Collaboration and Research Subaward Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r31",
      "r135",
      "r265",
      "r272"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10030.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 3)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments, Contingencies and Related Party Transactions"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock Capital Shares Reserved For Future Issuance",
        "positiveLabel": "Common stock available for future issuance",
        "terseLabel": "Number of common stock shares provided for issuance of stock awards to its employees"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r68",
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10060.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "terseLabel": "Common stock, $0.001 par value; authorized shares \u2013 60,000; issued and outstanding shares \u2013 49,366 and 48,802 at March 31, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation Policy [Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [
      "r55",
      "r56",
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.",
        "label": "Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction",
        "terseLabel": "Deferred financing costs included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10110.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred grant revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r83",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share Policy [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee Related Liabilities Current",
        "terseLabel": "Compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Service Share Based Compensation Aggregate Disclosures [Abstract]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]",
        "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r186"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Compensation cost related to non-vested awards not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Option Grants"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r72",
      "r77",
      "r79",
      "r85",
      "r123",
      "r141",
      "r148",
      "r189",
      "r190",
      "r191",
      "r204",
      "r205",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r277",
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment Aggregate Cost",
        "terseLabel": "Aggregate cost"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r59",
      "r221",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value Of Financial Instruments Policy",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r124",
      "r125",
      "r127",
      "r128",
      "r249",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite Lived Intangible Assets By Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r124",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite Lived Intangible Assets Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 10060.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General And Administrative Expense",
        "terseLabel": "General and administrative",
        "verboseLabel": "Patent costs as general and administrative expense"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Grants receivable"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r41",
      "r59",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax Policy [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10100.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10110.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase Decrease In Accrued Liabilities",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10130.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Deferred Revenue",
        "terseLabel": "Deferred grant revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10090.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r46",
      "r99"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 10020.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Lease And Rental Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in CCYY-MM-DD format.",
        "label": "Lease Expiration Date1",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments.",
        "label": "Lessee Operating Lease Discount Rate",
        "terseLabel": "Lease discount rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Summary of Maturities of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r235"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r235"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 10040.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r235"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 10030.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee Operating Lease Liability Payments Remainder Of Fiscal Year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r235"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 10010.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r64",
      "r122",
      "r223",
      "r264",
      "r270"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r64",
      "r122",
      "r213",
      "r217",
      "r218",
      "r223"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10010.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10030.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10020.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "terseLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r49",
      "r50",
      "r52"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10010.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r39",
      "r40",
      "r43",
      "r52",
      "r64",
      "r71",
      "r73",
      "r74",
      "r75",
      "r76",
      "r78",
      "r79",
      "r81",
      "r100",
      "r108",
      "r110",
      "r113",
      "r115",
      "r122",
      "r223",
      "r266",
      "r273"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetRentableArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net rentable area for properties owned.",
        "label": "Net Rentable Area",
        "terseLabel": "Rentable area"
       }
      }
     },
     "localname": "NetRentableArea",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements Policy Policy [Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number Of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 10040.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r100",
      "r108",
      "r110",
      "r113",
      "r115"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 10010.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Liabilities Payments Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails2": {
       "order": 10020.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "terseLabel": "Operating lease liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 10010.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10120.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "negatedLabel": "Less current portion of lease liability",
        "terseLabel": "Lease, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails": {
       "order": 10020.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10020.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Lease, net of current",
        "verboseLabel": "Lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsSummaryOfMaturitiesOfLeaseLiabilitiesDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r231"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10140.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r234",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease Weighted Average Remaining Lease Term1",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r7",
      "r29"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails": {
       "order": 10050.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10150.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables And Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r161",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10050.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "terseLabel": "Preferred stock, $0.001 par value, authorized shares \u2013 5,000; issued and outstanding shares \u2013 none"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r22",
      "r23"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10170.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock and common stock warrants, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r47",
      "r188"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10040.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10050.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds From Warrant Exercises",
        "terseLabel": "Proceeds from exercise of common stock warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r39",
      "r40",
      "r48",
      "r64",
      "r71",
      "r78",
      "r79",
      "r100",
      "r108",
      "r110",
      "r113",
      "r115",
      "r122",
      "r211",
      "r215",
      "r216",
      "r219",
      "r220",
      "r223",
      "r267"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10060.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r26",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r10",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r155",
      "r237",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r155",
      "r237",
      "r240",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party Transactions By Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureCommitmentsContingenciesAndRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r197",
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 10050.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research And Development Expense Excluding Acquired In Process Cost",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r59",
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research And Development Expense Policy",
        "terseLabel": "Research and Development Expenses and Accruals"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r148",
      "r192",
      "r269",
      "r280",
      "r281"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10080.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r72",
      "r77",
      "r79",
      "r123",
      "r189",
      "r190",
      "r191",
      "r204",
      "r205",
      "r277",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r42",
      "r64",
      "r97",
      "r98",
      "r107",
      "r111",
      "r112",
      "r116",
      "r117",
      "r119",
      "r122",
      "r223",
      "r267"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "order": 10030.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Grant revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule Of Accrued Liabilities Table [Text Block]",
        "terseLabel": "Summary of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesScheduleOfPotentiallyDilutiveSecuritiesExcludedFromCalculationOfDilutedNetLossPerShareWouldBeAntiDilutiveDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss per Share Would Be Anti-dilutive"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCapitalizationEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule Of Capitalization Equity [Line Items]",
        "terseLabel": "Schedule Of Capitalization Equity [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfCapitalizationEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCapitalizationEquityTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning the equity component of the capitalization of the entity. The table may be detailed by subsidiary (legal entity) (if applicable) and include information by component of equity as may be included in the Statement of Changes in Shareholders' Equity.",
        "label": "Schedule Of Capitalization Equity [Table]",
        "terseLabel": "Schedule Of Capitalization Equity [Table]"
       }
      }
     },
     "localname": "ScheduleOfCapitalizationEquityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r160",
      "r184",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]",
        "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r160",
      "r184",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]",
        "terseLabel": "Summary of Share-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r161",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r167",
      "r173",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Schedule of Assumptions Used to Determine Fair Value"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r32",
      "r62",
      "r86",
      "r87",
      "r137",
      "r139",
      "r140",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule Of Stock By Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r138",
      "r139",
      "r140",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information.  Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule Of Stock By Class [Text Block]",
        "terseLabel": "Common Stock Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting Policy Policy [Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "order": 10070.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1",
        "terseLabel": "Options vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized",
        "terseLabel": "Shares of common stock reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant",
        "terseLabel": "Maximum number of shares of common stock a participant may receive"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number",
        "terseLabel": "Options exercisable, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price",
        "terseLabel": "Options outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value",
        "terseLabel": "Intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Number of options, cancelled",
        "terseLabel": "Number of options cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Number of options, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per share of option grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Options outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r169",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of options, ending balance",
        "periodStartLabel": "Number of options, beginning balance",
        "terseLabel": "Options outstanding, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, ending balance",
        "periodStartLabel": "Weighted average exercise price, beginning balance",
        "terseLabel": "Options outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r176"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value",
        "terseLabel": "Options outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Table [Text Block]",
        "terseLabel": "Summary of Stock Option Outstanding, Vested and Expected to Vest and Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number",
        "terseLabel": "Options vested and expected to vest, Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "terseLabel": "Options outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r159",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r59",
      "r161",
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share Based Compensation Option And Incentive Plans Policy",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period",
        "terseLabel": "Options expiration term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityEquityIncentivePlansDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r179",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityScheduleOfAssumptionsUsedToEstimateFairValueOfStockOptionGrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r187"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1",
        "terseLabel": "Options outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Options outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Options outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Remaining weighted-average period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityStockBasedCompensationExpenseDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1",
        "terseLabel": "Options outstanding, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionOutstandingVestedAndExpectedToVestAndExercisableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r34",
      "r68",
      "r69",
      "r70",
      "r72",
      "r77",
      "r79",
      "r85",
      "r123",
      "r141",
      "r148",
      "r189",
      "r190",
      "r191",
      "r204",
      "r205",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r277",
      "r278",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityTables",
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r85",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquityTables",
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r55",
      "r56",
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued1",
        "terseLabel": "Payment of 2019 bonus awards with stock options in lieu of cash"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r141",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "terseLabel": "Common stock, shares, issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r141",
      "r148",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of options, exercised",
        "terseLabel": "Exercise of stock options for cash (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetails",
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r34",
      "r141",
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of stock options for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r18",
      "r19",
      "r64",
      "r121",
      "r122",
      "r223"
     ],
     "calculation": {
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets": {
       "order": 10040.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r63",
      "r148",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders Equity Note Stock Split Conversion Ratio1",
        "terseLabel": "Reverse stock split of common stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureStockholdersEquitySecuritiesPurchaseAgreementsAndUnderwrittenOfferingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Details"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureBalanceSheetDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Liquidation Preference",
        "terseLabel": "Convertible preferred stock, liquidation preference"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r8",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity Par Or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock, par value"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Authorized",
        "terseLabel": "Convertible preferred stock, shares authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Issued",
        "terseLabel": "Convertible preferred stock, shares issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity Shares Outstanding",
        "terseLabel": "Convertible preferred stock, shares outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureLicenseCollaborationAndResearchSubawardAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted-average shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).",
        "label": "Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation",
        "terseLabel": "Weighted-average shares subject to repurchase"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.oncternal.com/20210331/taxonomy/role/DisclosureDescriptionOfBusinessBasisOfPresentationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r295": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r296": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r297": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r298": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r299": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2646-109256"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>56
<FILENAME>0001564590-21-025109-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-025109-xbrl.zip
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M1/*S"H5(Q#8@8@?;,>HX16PWG:7V=W*2WH@2:WKC4 5OYO0C&7N' .LC,WH
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MN76A583DP?NJ0AJB'%P<:!)A!YUG2&5(94B@-R[0Y"X=O60?BK^D8*1/@'"
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MGF@.0X@VN076T@@1N1[?1OQ$B_#@GO>GZZ@G_4^]4OZ'0(CQ6[Z\;P+5%P-
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MU9.YFTVFV@9O*=Z=<YI#(C];Z8')M(&';LE?[KKWCS^N?UQ=WW1OSJ^[7W^
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M:GX?X>$1W+%<+Y<B9\X%)"TF+:95CV57/;Y=WUP"(%]= A3'RYGY5CZ^P3\
MPWT.Z)M:P"2M):U=6VL;I+4SM+:10SMO1=>L:T?V X)?22])+]?6RR;IY0R]
M;/ZX_)^_7_]VG6LCZ.7KP.I95,J;5S65KN6E%3VJ%%##,#U<_W[3?<SITC\
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MO&V=@:)WFJ5.9W,N""GZL2LZ 1W)?Y'Y0$"W"M UI]895P*ZU0\RT3N-4I.
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MS-Y96$W K-;I$)BI)C,%V-FJ?L!\XSIB4=3FH'D:?T7%X^KEDLC!H Q>8=E
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M SUC8>!^CK9O 3S;;.3SL_C#9RUR#RJ5*!3;RWDB]<IIN[['?M=C/K3W[J@
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MV=]A%0;CS62-)S,T_K*] =)=%, $%Q"]^'#3%:UJ5\C9,(CN(B :I*E?F?\
MTF6"C7N&/YWPCS":!5?#/\2SOP7^C %A?7-A'_"*3W_&#C7$_3"_G\\8_0)[
M -V.QX[%[E!>?:'!C67"/#5UZJLLG1ULLMZI@*0N05+?#B3M1@566V+S+5S
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M ;MC5)+H(I" 6!C!">N68AHYS1/?7+PN!4;1<..#5V'S/#I'*)HGJ ;--@Z
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MD'+5!)L J;E"3E8HZ6[,,*$H'"_PQARDT0R)I@5CY)5EZ3+-W.>K!2*'5%R
MR:,89XX#D>>I>'O<]/+9A3M<2P+U\ .NY-8;INNX'=_3*K[S17RF-;RXFNIU
M5A IPAD+]9+2B.I":41%5*$CQ&:2Z(QQ'&$N;<H91@J9S(^$,\W1!>@@!X'7
MX(E2C4<46_(!MN,ZL#V0<VBYV8\D\I*:"BJA"'D-04BXP]H(F378 8_Y=,*0
MOT^H"WM(;U-%PJP2, O"&[PH.J6&N' QVQ[X\<.$O*V:D1;"+;7O\L:T])S?
MBIS!*O?X]4Y*NU>(53R'?UQ@G!4>\6Z*>XV%MV3SG>-LOBXW7U^]>4I! 0!
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M2O2%+*O'4V:9Q>"KTLO-1H:57BC-B99E<%1BE1X(5'G9KY>T)\W-%5=Z"Z?
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MZ/+)[/Q&+L!G:/N(@5+KFWUL-ND*/^>QAA>.2<@9N5"<9_1"&&G4^OU=$7(
M\!=D_[+!._U-YNX<%!&P$M1O&'IZ.:3(2Q]2F H\=6OMYFI$I5K^V;E&#;3Q
MP QJ 1Z?Y@%TE^999M7Y\;BK7AOTR^;0710C:8FF""(4DVC]6D]+M(73$K0
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M;=<7G3ZJC?I@ALS&%3,O)"8=(C\_, !)]&&>WO+-G.,E6G@2?Z67#.-HX@=
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MFO5.P^ISNH.','L8+3Z@UQ@!F?3&U<YX8%7;XWZC.FB/!]5QJSX:M2W3[H+
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M%:_KXWF=WE%1O&/$KPR%X'5UF[5V?RF29L _! !@&S/"0^X._.UXQ%3@R/F
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MG/2Y[*?%B*\$^E+_@0OCKV9HFW\:@)X('>L@=B4/+RY.6@(Q"@AXK!N'0#Q
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MU@?FP3M=HGP&()^:CH</6WSWF5#EDM8,&])G4/[KG#Q$,!+.F8C0R8N_U>X
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M* U*L>ZI[_F6*[(UD3/R[3E7F X6-HA$!<5*)L[(B4"(HCQ!JV(>8!:5&2
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MQ&5&Q"Z?,NS\7&'G3PW)"L-!F-ESGFB;UR#FLMBF\FUN$NH=DUTN:[Z9[7:
MR8V]."DT5J:&QJ5.I=KJ(W2DG0CMDBS*"U-AA(]8Y[U8HE7T-:55#Z%?>O=
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MN2E448,O[RCC1SO)MG5&-^ E.EMHR6:,3!1RPIL :'35$45YA$(GB4DYR1P
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M&]47ENHU\24_R4P'EQ_F"8I!H&.BY&ZE$S0O%:B!/%XX/U7-/E533*5)2G=
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MM3(KL1J55=B-DF>L;!3OO7^GGNLEV@/7VU3](:R)_9T,01JAT_+#&,T3SJ<
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M*3PMHD:%U J,^G_)"(RZ<J%?F5*;+HAB?!".?"NVN%(1$TPMQXN<=(K=MI!
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MJ5J8>:UB0KG,N,@/EWH^N :@6.&V47FV3]$Y1.&=[4M\5\H0R[QA_@;Y"FV
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M77Z]^/CNT^6'T^N+3Q_W7N/7UL6%W'7K_6)]NO[]_-(J7/*TA>8BJN<&GL[
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MUG6Q="3?@O V4&>9](*BU/S$%6!;O&GF$M#QV7X<ZGS/>7>%Y"@T1V\$9/H
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MW=#Y=>5LZEY_V#LZ/G#[O<'@Q#W^MF$N]1?\[C;R8%XMRJ-^((>:NLS"59@
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M@!0&3K(O?G0[W:^]P<F:"-"G\=ASA/5>8$\.C<&<A3>![5AOA6]]L"/KTVT
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ML=X&''VV :XV>V6ID^N)B(55XBNH6!B]^E.'_@>7.")*O+'GT$Y(;-D1Z+$
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MZ=$_?OO/__CU;YT.&EP/[U#?\>DC&5#I>%P&@GQXN/T)_?/R_@8]. NRQ&C
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MFJJ U%F#\_RJ3'79T7TBNU,4]7H RNZ HI[L""AUFJH"2G:EOQ0HJNP E+<
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MAR7K:R5U6HA42X#(SHI=;6?+LG7D;U;]'541WIDHG05D_+_]'U!+ P04
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MGO?W1,K\ S"3]VQ/Y)6(9\0@O-MS$'(C60R%IEV3LBC4%N*,(;HX0)0;#V=
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M-B:=P)C@:P3GV)4)$HYLIMOK.]\V!-ZC*D!2ZFHA7#G_!SNJ.5T#P0@GVM:
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MOIIFV&UO'2K>#+O%!;^2S; [4-,@<5S.S;AALK=7/TO(SI$)%3<%ZX!3*8$
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MEW4QZ>?IC$I^HJLGF)Q\O%4E]G=TWS"/%&9XG[+I5EFC>>F^?^-L@. #&"-
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MP1Q2,X[V_5+*<1)P05H2-;QUU)%V@>V@L4P;0'7X@9 !<"' >B-\OR+'B#A
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M+UPR?9_IHF".1SM%)Z7!]]L]/P,_AYLXC#U9#@V @M54Y2< PA,D"R!YS.4
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MA]LXI(O)U<V[VU5HNE8RH6I8C%*+BYM"PE2"D],W0,K UDE,"MKAR8=RDV8
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MXOJG2E1&P(3TY!C3NJW9V_8W\'PN=F5Y0Z]F4C[&J=66ML^:,$A)AK-9$A?
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M)6'C]FN\&SJ_WIO@OD[Z]"J);%\%*).V%[\'6$TXV;*[OX5<*.C:0,_4K 3
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M.8CJ,RF+L:@3JV=H/M8G1"YI>08%F+"C;D#\/<U[PY68L/S0J-L+%0^$5?5
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M?W%%?B*_E+\B_Z#;RK_]?U!+ P04    "  BB:9261B>GK8N  ":<0, %0
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M ,+Z\YATYV!!UEVRQGPQ14OOX)X\%/NS&$R']@^&T[@#N4Q<#+!Q_[5B!\T
M?J]!ZSWNIQ#VK'2/268[4(;=[55U)+SESB(W><2C/T7V-Q3>X2"+A_^!(]>^
M0"2J/J45F_&[?EWI:+BF/MCHAE.'C:99)HC)BD D9,Y1TZ$6^U4S5N]DPA74
M]2E9^J+JX.$/8! @9GXP1CW6R:4ED =XGT)W^T,NU*.>UA'L^(MM,0'A() V
MV= ;!-DTTY!P2(KBGL=WDB[,8HHG<3!A,^UL.ZQ),@WF]4;#*5,[9T,,[^%6
M6'"]@C64.!T1S$3"FPP/X&FRU"HN2PR^\23K]"2[*XI)>V_TG"@WAZB;C=0J
MI/5UM.MLI(?Y$N5\^F5(]\3"*\2ZGIO<7N>7D4_VE>!%KHR(EKS-X1+Y2@92
M1TFGY2_)"MEL0!S$--D+"*3W/IZC(*#2[ 8U66JEE([%P[B:D\J23,*<U5$;
M$PGK320L,C=#N>A*0%?J(&KX14TP776=Q!S*94 0-HZ3DR%GMD%%$+DZ)8K%
MYYMM$9#;I]6(J3\$<&BY1Y5%7F%L>$N]]^2JJ7IT^MX5<]ZK.4X=/LV7GY:6
MN^E.1O0]%\H'1 RKZ9=/R%\)Q;**T]8_8J$(Y%H2.O@ORF1/-A593 ^P?D0&
M4D]+[I;H>7":D-PM#YS7Y\)F>M"$[N ZX\3UK*]@T$)KO+B]ECP**"0P$<$Q
M\9$EPO1!4VU(4]D./;O)#5(8ZD,"TIYB)?4D#JWJ/$YC]<3DXMM)Z-S2<NZ7
M%IQV,Q2%Y$;YW7-"$IP#BRV8SB<KY,.GM]Y,T-E-CKB>Z&UV_HM[OA6UULUU
M7FNYV.:_$75=$Z$JEPMB/B?IMM:P @074$%++;8Z'\.)%6Y)5M"0Y ;\9^10
MLQ3)%BJ^7+C(=3JNBZU,XFLN<O7C"M*!!6CV9H$W;X-P[<.@SGZA_WI-_I4;
M#/GLC\L)#Z/93R7 #?PP!RS\USZH\%%:#?H+P@O?6B^)=.-?'C4$6N,Y3>:6
M[Y1WZFL(J#XJN7U).0F-);4TFG^D2VIQ3J;I+J)BFP/7;D[3?37YA!NN%;RF
MOSCQ'5PX=WR:[C@IO-.$-*#=?7=N''HRVB4/AGGM>"A.E"(W#UQ^23+]25-Z
MPXK<=7?W[7OC0&Q@52A!]&"W?C#SO."P(N%&)K ,P(]F>G(([U\!,RC#SLRC
M0MR\C&M-W PS,Z\&C3 [>,S(T/HTS-U9O\(.WJL89,-42 HA*WR39$B9>78V
M7%QUS\D9?+^8F>JK$7RE;@4,-3-S9BI$C<?+A,%I9OJT1G#6NR5E\'W6<%CT
MW=LO2W/UU0J3&+OI?&?_2D>1:>+F>+T!A4;;G6?9-T!"(M2KGEB'WG(RL6LU
ME$;?/SG?OXR%[YZ=Z%K(OGZ9P4_%<\E)=M#YV)-Z?,&56,$*?II]&N$WD+U/
M/Y&[05]!4BZ%G$+D^^@- K%.9Y/<KC>P'BWW[\@22CO7I)?NI!2<9;GYD?%0
M$*/;N?E6"H::VRCO- ^EF(,6C O%R5#J0.A".(^H^FOM0126J8B6ZSCLT5:=
M$?YS#*^'%C2&TQ" Z^U8+223,6F%UEV5&([J9.>@EF+^%MUB,9,-\I]QEP:M
M.V=&7A OL0NJ(/;3W.QI4H?'Z-DB%<PG"Q^AV%2H+GBUE;Y[8JQ2.S:I$#MZ
M*M$.["=\@>Y]O'%@A+<>LYYM;R+/%LC&(D!2RI,\L>/]5V2YSIS4F$MQHH7;
MN?FL(Z,GU(?6^!$,Y$G;R(6"):-D-Q=BH&=KNC[<JY2 %#^Y=#!?'1<%(?90
M0-9-2O<[N5:5;XFGI8^CQ1)'X81RY6.2HO$>@?3E'U.[3$BN\J*,.7'5(X$U
M7D6D&5_IX-,/R):&711O_R0IA#BC?%1;Y%PQRZIX)6^.\JS%K;64-$<>J$HN
M209BKQS/(3H5R1TI$:A;2THNJ-S>D,R$R=%K3^ 2)["A2EK+26(+) T3-\0Y
MQ)YZ$U!C8:N269O.GQS$*L'=D1W,SZHL^0:A^@DL7RT'[KT> 8JD8.('MY*(
MMI+LMT$0(?LJ\DE2?"K"X]I?W]!/^I70:<U+40KU[VNXYI"2BA0Q M.]Y?"?
M>F7-M:1_I$4UOZ)PB4$SW, B)4MRL@")16Z.1 <3@9F+G!Z-KB+1G9B:5TE(
M,@8SNVALT(2D35]029 5S7I "U(3"_O;3'"D:A[WJFK6B=2XOL+IL(I6\=::
MSG_ M1OZ^H9#6-E/F!Q^C@>K(#L.N<<B3EB*_[3&X)6U#2;SD&B:H':N04+'
M7=U@_PK-K<@-;[T$*NXA2-%N911/&.C?P%4U$BE/)DVZ\1ANO9WYAN,RF6\'
M<T5^"Q)L9T>WN(]5[=[" Y]:#N T O&7D/]JV?SW"2&:>N+%B]$DCDG$C%CR
M==Y/Z4ZF;)W:?N6T%,^AM;+#[71^28PMV/<<Z]'RKARTP(*Y0OB(R>VEC-RM
M%X1.&(5$.,)I1>\A!*"OR'9F@ :]Y(N6A).CKF-MWC@D4.F.V#ENO1"6@$."
M(.C5YJOU#^Q?NE8@63U.F'3'X[W8,K9$$Z4(D6V\DYZ0Y]$7R,SL ,>>;>5+
MNDAL*0ZJ361\IB@)LEC67-*VLB "L"%+-5346'V$>2II+\F-18<HS,1N,SF-
M_FI"+*X!]FA%;?\2*")?D)-J(EV>^N(U3NLH2:'\!<&H4(A_>DP&"&)<1:*M
MW$:L^E*VT"^IJX6_)K[=8B>5(,&VQK3?GTBJIN*V;7&:W(GYUTE!H]9XLUXD
M>-MMU-JJ)5M6C+.=)JWR);+<<@VDI XM'A6 L&AX M?2T5+RY>!*917?HL1%
MOC!I'>,E&4JF\QQKHEIR"0&]Q8\5W(H;%$!6U[L6-W)_87G.7_0.< E=8]>Q
M4T^5^YRW#/%\)I86QW*S_%Q2Q6\4==B]TYE2X JK,*M;2::GV=,@ W"MD#,]
M-Q_?(8$;''&F9^UKJE9@7MW(]&1_>O;[GCIL>@[ XNL"+KBLF)Z:KNQ"APNO
ME P-,Z56'1J[E_^AU!-K7_04&WY,SVA8:R[#PE8]TVNUR5E-,8>-ER%GIJ!7
MH)#QFO!9/DV#3PGI15C]F&-Z.LAFV.T_R;',56:BI>H65?J>F@)X=CI*O6H
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MH[('U]KT!YLBV\]?[MY4FSX+M &+VO0.->CC45X/SZK<_T6M2@:Y=]*TBI(
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MO$94E=E]O=+.UK6QO!^_H-_S2C?RK5KUQ^L6_;'W_/DK^/]MW^SO[S]_OKU
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MJTF83I*#.RH=3I2.EIJ-8(*(?'K@LR;15[(1W:B.V1^%#C6TI.K:O/JP'H*
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M<5+Q0_,G5NJXC[2(9#E,$G6)EZ&2IH(N!KE83C>" Q4PZ57)E^7J L&2=.#
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MH2^"# #\%XP Z\L(!H#_M%Z -?'!]M*^UC#&:D=0,C@L5%DX7&O<DVE.1]D
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M-_:UV2IA6\0T6&J817T*[A64 2AM^,5"F#F@EYB*W);1_/B9V@H\E5P#+^@
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M+D4$Z2 0M@,-)!28 19RFR.*PI'_KQ&;W+>-<^WZR0[?/J7F(R92&%6,@EV
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M7ZR^'>YL6WLQJM(F4_)\;(4^U!PD=@W!J>G]-6+&L+@[6+60BZ9:V3SP3>&
MT)0>>FDC2S5,]6#8:Y'):86ME1HT\,(1NPK\"P?J^>XU/TH;$+66)LW"E[OO
MIOQBJ0:,:P?I%@Z2^H$J3%([5Z2BI/#,"I'F*$$D?:PPG?)79OEQKLT2W+J
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M+-DCQJAAFG/]S#K-]1R:\>L4K2X*1WY1ZAEG:L+*/'M:^WA.C$(''\3TNI5
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M%V\)$TBA&3:7$RX8D)O93#?=2V^*W(%/\9%& 0@Q=,J9YD"09]#^B?OL6]5
MOYX+X?CF*BK'\E"YB]Z0/\]ZK@WXAT7)5(?<49T> V^4)[2:@EZS9HB95>N_
MA.<"1:)LHR4V8]Q.*\QSP9$#$@WM+6CD#(83,,@S<VD+%C8FY_%'!1)/8OBA
MK^ #"F*054#&!'G1+5:O82*I-((;2]6&L3[;A8&'.C"/(HV@(F_&H;ZA'R(8
MIE")BT LX)6*$9VD'K_36\,H$EK"3N[#E+8/TP'DF.(H0Y*9"71/\R"* M3-
M)V-20H*GFIEQBCV27:72D$"3^NB[PA=MS4GJ!:J:YL%:<T3X@' >7??=2FT*
M:V]44>C6>_@OI:'F:%=PM;G%-IIW<"PXAZ(%1:DPU>?<*#MJ[Y909#8'V-#8
M,")^6X<5()[TJ]SO#.41>/EMN6R#L-1"[$UH<,B-!6>:!XLI3Z^BPK"PF/%4
M6-':^OA08QZI](8.%WFF8:\1,AN\)XS#:8 FP"8\)L7.1U>L& H%@+-A%=\6
M)*QLJ_.,"TV8U4)6Y>]S,ZJ[RRO<ZD S26;=/-V2H&"L 9;"G'!]E:H1RIOA
MZ2)OP=)8Z<HF]H7 N=.>I'<GC 139T;#G,+WM2%B$AQCD.N;N)>MS])[)N%9
M7CQ[6CR68NQ<MPQY+)U_779:![?J]$NTH,S:>1H&7Y6B@AP\)]&7$%-#2LE,
M$W?"GN;$%B#\EHZ+XN@=TJ4<T );@GA@B-K:24LP 8L$ZOH9F#@F-RC ;HYW
MV. 8^R0VN$3&!!Y:8<OO382!M6<H'^ILQ]16[6G<^S.JPE 4%++5J<R@I\TR
M"D-45+8F[^4$[W2Y:BW($Y>%XYFYIL&*F[>\6KJ5U%T?>=@V9E[+V6LRZ60U
M1C\G:.?E&K2S2M#.3]4]#G$#R,0(/TC$&L2=\K>=$*[ _R/Z,:??(A,2I[HB
MJ=G2DF*^J;(IX"QW]'$8_&W7W/J#Z/;.Q04&FJ3-N'/!@5&5)U95FJM#J8$
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M<2O ^C9?(A<[3@6!J6DZB,&*1R4]-P25Q7&A>=&R/?JP4]\OW67_->Z6@47
M!10\*%2^*4C/8%&GX.F# )8;-(XXOTS#^F[/G=+";5>0.'FTC- )DW6DBTA?
M_8774N)B-,)R8P[/^BD6MO]^1K*@9+9H":3U1233GS[=KGI$;@;2&S]E7K>
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MC&4\V[VT \$"8>"6Q( _,H]]"3@50?K;05M1O>^7RER&09(_FXSTS-;\9F-
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M)$J]-_%F"/<%\2BL<,3-7?EP4:&NB19_,;Q9D,3N-E1>@TX35)N(]F0K166
M&[K![08^ZXB)"*& @N$GZ-X4-Q(1HM.;^R?7)'))?$E?HG\=1'G<RUMX@A62
M!F*66'/D[Y:%L<4>$<<A7&C@2!2E3 >@F(4?04UA%H<8]T4UB\O9F@K!1O5B
MW7I>GK!Z>L7,GU3'-,;PG)BP?:\U%J/KND0I%N*F-G<$>X&J(FD<"1T'F'Y3
M/=)F U\;CZ]1\%[NH<S0%G>!UCH IAZB3\-.23BY7(C(:9?(6C";*Q$CD_*
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MJK\QJJTT+\O5G0<X)K:W?!:!* U\:L<ZHE_<]GT"$EF /XK%LEN=!%LW"QU
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MA#>!1<>MC\"7D1LAX#UG?IAODQCAAQW$8T>,D-C)J&#LO&2LJ*5J-DB:Z&9
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MJC(06Z*^^<0IV0W)+FQ+6_TU8FI^W&%J=K0I#T&;\O$QC.JKIO[H[,?]2ZT
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M$-#L6LJ#I=I",D-+BQEW&EG6>\6^NP)>U*M*M 2OH5P9D45<$N;F4K[!ES/
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M]B$F'-NYA?=Q"__U./6O:ZQF+II[9'O/.F657&^!9PR#01'M+Z_@,A#%K,9
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M<O*Q&G\<.9O7>L?8C1J#,&&PYDO4<L?H*FVED;#7RECM#I.'.DP>[S1Y[]H
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M<E<.9,*E<4[@("#'TKDF\9^$WWEFE#8W((-3Y?.PU0O,0D2^G4#FAZFU933
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MWH5'PH_@),!B> 2GLZ'E.VI\C]OQ/8*M^AXEDS59I'&83<NNB)=?PH-8OIC
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M =H&NL3?.Y?L+_TMKT*BNMKZX,91RRL:ZLQXO^,P50%AP0F]7>B(X;Q_O?I
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M,3Q&_.T52L XF>=N)MYIC=9=1T15$I)53M+E"NDS#?15P^YG.!4.I\-E-0W
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MM ^'N\).]O#13Q5&5)?1D0=2$DK<="LA2J ]4VD8P-=[?^#;CL+,'VE"O79
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MB,['?K>+'\X^[9]YFJG1U8K'_:7]YEWSB>>=0T-#'^1&V#08JU1T)],POIK
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M?A1_;G&&G,K(9T)J)!_8*_0ZW99;:XDJHN;3TK=_,2G#.E!6*XMS7J?'#F'
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MP&^QW.\B#O,H@V5"7<^;3[EJC,2"SV7 Q,7ILRD&,3PJP5VE7'VC4*<BE.<
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MMF?"9K7[O:\8 70^AU->*HW.)^$-[H&@Z[XG&QPCX'.-&03&&=>LY)45L>G
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MZV'S;2)SZ+<_R@W]]L>_?P!02P,$%     @ (HFF4HLL$T*O!0  I!P  !
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ML<F-]6X/$PJ*RN]OALW*.-GYUDFWNLLTO^7U_>8WPW\!4$L! A0#%     @
M(HFF4M&^P-[)(0$ %5,4 !4              ( !     &]N8W0M,3!Q7S(P
M,C$P,S,Q+FAT;5!+ 0(4 Q0    ( "*)IE)5Z@+VQ1$  (2R   1
M      "  ?PA 0!O;F-T+3(P,C$P,S,Q+GAS9%!+ 0(4 Q0    ( "*)IE)/
MXYL6I@@  %ML   5              "  ? S 0!O;F-T+3(P,C$P,S,Q7V-A
M;"YX;6Q02P$"% ,4    "  BB:92 $X+&1,:   5G@$ %0
M@ ')/ $ ;VYC="TR,#(Q,#,S,5]D968N>&UL4$L! A0#%     @ (HFF4A;/
M.63T4P  ^@D% !4              ( !#U<! &]N8W0M,C R,3 S,S%?;&%B
M+GAM;%!+ 0(4 Q0    ( "*)IE)9&)Z>MBX  )IQ P 5              "
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M>#,Q,5\X+FAT;5!+ 0(4 Q0    ( "*)IE*>A<Z29 @  *I1   0
M      "  19E P!O;F-T+65X,S$R7SDN:'1M4$L! A0#%     @ (HFF4E%0
MO-FU!0  ;1P  !               ( !J&T# &]N8W0M97@S,C%?-RYH=&U0
M2P$"% ,4    "  BB:92BRP30J\%  "D'   $               @ &+<P,
F;VYC="UE>#,R,E\V+FAT;5!+!08     #0 - $8#  !H>0,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
